0000950170-24-12357010-Q NEKTAR THERAPEUTICS 20241107202411071759111759125912 0 0000950170-24-123570 10-Q 59 20240930 20241108 20241107 NEKTAR THERAPEUTICS 0000906709 2834 943134940 DE 1231 10-Q 34 000-24006 241437388 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 INHALE THERAPEUTIC SYSTEMS INC 19980723 INHALE THERAPEUTIC SYSTEMS 19940303 10-Q 1 nktr-20240930.htm 10-Q 10-Q 12-310000906709falseQ30000906709us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100009067092023-09-300000906709nktr:TwoThousandTwentyThreeRestructuringPlanMemberus-gaap:EmployeeSeveranceMember2023-06-300000906709us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2023-12-310000906709nktr:MeasurementInputMarketParticipantSubtenantBorrowingRateMember2023-07-012023-09-300000906709nktr:PurchaseAndSaleAgreement2012Member2023-12-310000906709us-gaap:AdditionalPaidInCapitalMember2024-09-300000906709nktr:ManufacturingLaboratoryAndOtherEquipmentMember2024-09-300000906709us-gaap:AccumulatedTranslationAdjustmentMember2023-06-3000009067092024-11-010000906709us-gaap:EmployeeSeveranceMembernktr:TwoThousandTwentyTwoRestructuringPlanMember2024-09-300000906709nktr:StockOptionsRSUsAndPSUsMember2024-01-012024-09-300000906709nktr:StockOptionsRSUsAndPSUsMember2023-07-012023-09-300000906709us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-09-300000906709us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000906709us-gaap:CarryingReportedAmountFairValueDisclosureMembernktr:SubleaseOperatingLeaseRightOfUseAssetsMember2024-09-300000906709nktr:PurchaseAndSaleAgreement2020Member2024-01-012024-09-300000906709us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-03-310000906709us-gaap:CarryingReportedAmountFairValueDisclosureMembernktr:SubleasePropertyPlantAndEquipmentMember2023-06-300000906709us-gaap:EmployeeSeveranceMember2023-04-012023-06-300000906709nktr:StockOptionsRSUsAndPSUsMember2023-01-012023-09-300000906709us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000906709us-gaap:AdditionalPaidInCapitalMember2023-06-300000906709nktr:UcbPharmaManufacturingAgreementMember2024-07-012024-09-300000906709us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300000906709nktr:ContractTerminationAndOtherCostsMembernktr:RestructuringPlanMember2023-01-012023-03-310000906709nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember2023-01-012023-09-300000906709us-gaap:EmployeeSeveranceMember2023-06-300000906709nktr:TwoThousandTwentyThreeRestructuringPlanMemberus-gaap:EmployeeSeveranceMember2024-01-012024-03-310000906709us-gaap:AccumulatedTranslationAdjustmentMember2022-12-3100009067092024-01-012024-09-300000906709us-gaap:RetainedEarningsMember2023-04-012023-06-300000906709us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310000906709us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300000906709us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000906709us-gaap:AccumulatedTranslationAdjustmentMember2024-04-012024-06-300000906709nktr:PurchaseAndSaleAgreement2020Member2020-12-162020-12-160000906709us-gaap:RetainedEarningsMember2023-12-310000906709us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000906709us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000906709us-gaap:CostOfSalesMember2024-07-012024-09-300000906709us-gaap:CommonStockMember2024-07-012024-09-300000906709nktr:OtherPartnerMember2024-09-300000906709us-gaap:EmployeeSeveranceMembernktr:TwoThousandTwentyTwoRestructuringPlanMember2022-12-310000906709us-gaap:RetainedEarningsMember2024-06-300000906709nktr:UcbPharmaManufacturingAgreementMember2024-09-300000906709us-gaap:EmployeeSeveranceMembernktr:TwoThousandTwentyTwoRestructuringPlanMember2024-01-012024-09-300000906709nktr:BiolojicDesignCompanyMembernktr:Nektar0165Member2023-01-012023-12-310000906709us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2024-09-300000906709nktr:BiolojicDesignCompanyMembernktr:Nektar0165Membersrt:MaximumMember2023-01-012023-12-3100009067092023-01-012023-09-300000906709nktr:TwoThousandTwentyThreeRestructuringPlanMemberus-gaap:EmployeeSeveranceMember2023-03-310000906709us-gaap:AdditionalPaidInCapitalMember2024-06-300000906709us-gaap:FairValueInputsLevel3Membernktr:SubleasePropertyPlantAndEquipmentMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310000906709nktr:TwoThousandTwentyThreeRestructuringPlanMemberus-gaap:EmployeeSeveranceMember2023-01-012023-12-310000906709us-gaap:EmployeeSeveranceMember2024-01-012024-09-300000906709us-gaap:FairValueInputsLevel3Membernktr:SubleaseOperatingLeaseRightOfUseAssetsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300000906709nktr:Nektar358Membernktr:EliLillyAndCompanyMembersrt:MaximumMember2017-07-230000906709us-gaap:RetainedEarningsMember2024-09-300000906709us-gaap:EmployeeSeveranceMember2023-07-012023-09-300000906709us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000906709us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310000906709nktr:ContractTerminationAndOtherCostsMembernktr:RestructuringPlanMember2022-12-310000906709us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2024-09-300000906709us-gaap:TreasuryStockCommonMember2024-01-012024-03-310000906709nktr:SharePurchaseAgreementMembernktr:BristolMyersSquibbCompanyMember2018-04-300000906709us-gaap:CommonStockMember2024-06-300000906709nktr:SharePurchaseAgreementMembernktr:BristolMyersSquibbCompanyMember2018-04-012018-04-300000906709nktr:SubleasePropertyPlantAndEquipmentMember2023-01-012023-09-300000906709us-gaap:EmployeeSeveranceMembernktr:TwoThousandTwentyTwoRestructuringPlanMember2023-09-300000906709us-gaap:FairValueInputsLevel3Membernktr:SubleasePropertyPlantAndEquipmentMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300000906709nktr:BristolMyersSquibbCollaborationAgreementMembersrt:ParentCompanyMembernktr:Nektar214Member2018-04-012018-04-300000906709us-gaap:ProductMember2024-01-012024-09-300000906709nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember2024-07-012024-09-300000906709us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000906709us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-3000009067092024-03-310000906709us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2024-09-300000906709us-gaap:CommonStockMember2023-04-012023-06-300000906709us-gaap:EmployeeSeveranceMember2023-12-310000906709nktr:SecuritiesPurchaseAgreementMembernktr:TcgCrossoverFundIILPMember2024-03-042024-03-040000906709us-gaap:RetainedEarningsMember2023-07-012023-09-300000906709nktr:ContractTerminationAndOtherCostsMembernktr:RestructuringPlanMember2023-04-012023-06-300000906709us-gaap:EmployeeSeveranceMembernktr:TwoThousandTwentyTwoRestructuringPlanMember2023-07-012023-09-300000906709nktr:SubleaseOperatingLeaseRightOfUseAssetsMember2023-07-012023-09-300000906709nktr:SubleaseOfLaboratoryAndOfficeSpaceMember2024-04-012024-06-300000906709nktr:SubleaseOperatingLeaseRightOfUseAssetsMember2024-01-012024-09-300000906709us-gaap:CostOfSalesMember2023-01-012023-09-300000906709nktr:MeasurementInputMarketParticipantSubtenantBorrowingRateMember2023-04-012023-06-300000906709us-gaap:TreasuryStockCommonMember2024-03-310000906709nktr:PreFundedWarrantMembernktr:SecuritiesPurchaseAgreementMembernktr:TcgCrossoverFundIILPMember2024-03-040000906709us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000906709nktr:ContractTerminationAndOtherCostsMembernktr:RestructuringPlanMember2023-09-300000906709us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300000906709nktr:InterestAndOtherNonTradeReceivablesMember2024-09-300000906709nktr:PrepaidResearchAndDevelopmentExpensesMember2024-09-300000906709us-gaap:ProductMember2023-01-012023-09-300000906709us-gaap:EmployeeSeveranceMember2023-01-012023-03-310000906709nktr:LaboratoryEquipmentMember2023-12-310000906709us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310000906709us-gaap:RetainedEarningsMember2023-06-300000906709us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2023-12-310000906709nktr:TwoThousandTwentyThreeRestructuringPlanMemberus-gaap:EmployeeSeveranceMember2023-09-3000009067092024-01-012024-03-310000906709us-gaap:CommonStockMember2023-06-300000906709nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember2023-07-012023-09-300000906709us-gaap:CommonStockMember2022-12-310000906709nktr:ContractTerminationAndOtherCostsMembernktr:RestructuringPlanMember2024-07-012024-09-300000906709us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-07-012024-09-300000906709us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310000906709nktr:BristolMyersSquibbCollaborationAgreementMembersrt:ParentCompanyMembernktr:MilestoneOneMembernktr:Nektar214Member2020-12-310000906709us-gaap:RetainedEarningsMember2023-01-012023-03-310000906709nktr:BuildingAndLeaseholdImprovementsMember2024-09-300000906709nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember2024-01-012024-09-300000906709us-gaap:AdditionalPaidInCapitalMember2023-12-310000906709us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-03-3100009067092024-07-012024-09-300000906709us-gaap:EmployeeSeveranceMembernktr:TwoThousandTwentyTwoRestructuringPlanMember2023-12-310000906709nktr:Nektar358Membernktr:EliLillyMember2017-07-232017-07-230000906709nktr:TwoThousandTwentyThreeRestructuringPlanMemberus-gaap:EmployeeSeveranceMember2022-12-310000906709nktr:BiolojicDesignCompanyMembernktr:Nektar0165Membersrt:MaximumMember2023-12-310000906709nktr:MissionBayFacilityMembernktr:TwoThousandTwentyThreeRestructuringPlanMember2023-01-012023-03-310000906709us-gaap:FairValueInputsLevel3Membernktr:SubleaseOperatingLeaseRightOfUseAssetsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000906709nktr:ContractTerminationAndOtherCostsMembernktr:RestructuringPlanMember2023-03-310000906709nktr:BiolojicDesignCompanyMembernktr:Nektar0165Member2024-09-300000906709us-gaap:CostOfSalesMember2023-07-012023-09-300000906709us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000906709us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-06-300000906709nktr:SecuritiesPurchaseAgreementMembersrt:MaximumMembernktr:TcgCrossoverFundIILPMember2024-03-012024-03-3100009067092023-03-3100009067092023-04-012023-06-300000906709us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-09-300000906709us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300000906709nktr:BuildingAndLeaseholdImprovementsMember2023-12-310000906709us-gaap:FurnitureAndFixturesMember2023-12-310000906709us-gaap:TreasuryStockCommonMember2024-09-300000906709us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300000906709nktr:StockOptionsRSUsAndPSUsMember2024-07-012024-09-300000906709us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000906709us-gaap:RetainedEarningsMember2022-12-310000906709us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-03-310000906709nktr:LicenseCollaborationAndOtherRevenueMember2024-01-012024-09-300000906709nktr:PurchaseAndSaleAgreement2020Member2023-12-310000906709nktr:RestructuringPlanMember2024-09-300000906709nktr:UcbPharmaManufacturingAgreementMember2023-12-310000906709nktr:BristolMyersSquibbCollaborationAgreementMember2024-02-122024-02-120000906709us-gaap:EmployeeSeveranceMember2022-12-310000906709us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300000906709us-gaap:EmployeeSeveranceMember2023-09-300000906709us-gaap:CommonStockMember2023-09-3000009067092023-12-310000906709us-gaap:FairValueInputsLevel2Member2023-12-310000906709us-gaap:EmployeeSeveranceMembernktr:TwoThousandTwentyTwoRestructuringPlanMember2023-04-012023-06-300000906709us-gaap:CostOfSalesMember2024-01-012024-09-300000906709nktr:SecuritiesPurchaseAgreementMembersrt:AffiliatedEntityMembersrt:MaximumMembernktr:TcgCrossoverFundIILPMember2024-03-012024-03-310000906709nktr:LicenseCollaborationAndOtherRevenueMember2023-07-012023-09-300000906709nktr:TwoThousandTwentyThreeRestructuringPlanMemberus-gaap:EmployeeSeveranceMember2024-01-012024-09-300000906709nktr:ManufacturingLaboratoryAndOtherEquipmentMember2023-12-310000906709nktr:ComputerFurnitureAndOtherMember2023-12-3100009067092024-04-012024-06-300000906709nktr:TwoThousandTwentyThreeRestructuringPlanMemberus-gaap:EmployeeSeveranceMember2023-12-310000906709us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300000906709nktr:LaboratoryEquipmentMember2024-09-300000906709nktr:ContractTerminationAndOtherCostsMembernktr:RestructuringPlanMember2024-09-300000906709nktr:PurchaseAndSaleAgreement2020Member2024-03-042024-03-040000906709us-gaap:TreasuryStockCommonMember2024-06-300000906709us-gaap:RetainedEarningsMember2023-09-300000906709us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300000906709us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300000906709us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2024-09-300000906709srt:ParentCompanyMembernktr:Nektar358Member2017-07-232017-07-230000906709us-gaap:EmployeeSeveranceMember2023-03-310000906709us-gaap:EmployeeSeveranceMember2024-09-300000906709nktr:SubleasePropertyPlantAndEquipmentMember2024-01-012024-09-300000906709nktr:PreFundedWarrantMember2024-03-310000906709nktr:TwoThousandTwentyThreeRestructuringPlanMemberus-gaap:EmployeeSeveranceMember2023-07-012023-09-300000906709us-gaap:CommonStockMember2024-04-012024-06-300000906709nktr:ThirdStFacilityMember2023-04-012023-06-

300000906709nktr:ThirdStFacilityMember2024-04-012024-06-300000906709us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000906709us-gaap:AccumulatedTranslationAdjustmentMember2024-07-012024-09-3000009067092023-01-012023-03-310000906709us-gaap:RetainedEarningsMember2023-03-310000906709us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-3100009067092022-12-310000906709us-gaap:CommonStockMember2024-01-012024-03-310000906709us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000906709us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-03-310000906709us-gaap:FairValueInputsLevel3Membernktr:SubleaseOperatingLeaseRightOfUseAssetsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310000906709us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300000906709us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300000906709us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000906709nktr:PreFundedWarrantMembernktr:SecuritiesPurchaseAgreementMembernktr:TcgCrossoverFundIILPMember2024-03-310000906709us-gaap:AdditionalPaidInCapitalMember2022-12-310000906709us-gaap:CommonStockMember2023-12-310000906709us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-03-310000906709nktr:MissionBayFacilityMembernktr:TwoThousandTwentyThreeRestructuringPlanMember2024-04-012024-06-300000906709nktr:MissionBayFacilityMembernktr:TwoThousandTwentyTwoRestructuringPlanMember2023-04-012023-06-300000906709us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000906709us-gaap:CarryingReportedAmountFairValueDisclosureMembernktr:SubleaseOperatingLeaseRightOfUseAssetsMember2022-12-310000906709nktr:InterestAndOtherNonTradeReceivablesMember2023-12-310000906709nktr:ContractTerminationAndOtherCostsMembernktr:RestructuringPlanMember2023-06-300000906709nktr:ContractTerminationAndOtherCostsMembernktr:RestructuringPlanMember2024-06-300000906709nktr:PrepaidResearchAndDevelopmentExpensesMember2023-12-310000906709nktr:MissionBayFacilityMembernktr:TwoThousandTwentyTwoRestructuringPlanMember2023-07-012023-09-300000906709us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000906709us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310000906709nktr:TwoThousandTwentyThreeRestructuringPlanMember2023-01-012023-09-3000009067092024-09-300000906709us-gaap:EmployeeSeveranceMembernktr:TwoThousandTwentyTwoRestructuringPlanMember2023-01-012023-03-310000906709nktr:ContractTerminationAndOtherCostsMembernktr:RestructuringPlanMember2024-03-310000906709nktr:PurchaseAndSaleAgreement2012Member2024-01-012024-09-300000906709us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-09-300000906709us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-07-012023-09-300000906709us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000906709us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-04-012023-06-300000906709nktr:TwoThousandTwentyThreeRestructuringPlanMemberus-gaap:EmployeeSeveranceMember2023-01-012023-03-310000906709us-gaap:AccumulatedTranslationAdjustmentMember2023-07-012023-09-3000009067092023-07-012023-09-300000906709nktr:ComputerFurnitureAndOtherMember2024-09-300000906709us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-04-012024-06-300000906709us-gaap:RetainedEarningsMember2024-03-310000906709us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310000906709nktr:TwoThousandTwentyThreeRestructuringPlanMemberus-gaap:EmployeeSeveranceMember2023-04-012023-06-3000009067092024-06-300000906709nktr:MissionBayFacilityMembernktr:TwoThousandTwentyThreeRestructuringPlanMember2023-07-012023-09-300000906709us-gaap:AccumulatedTranslationAdjustmentMember2023-04-012023-06-300000906709us-gaap:FairValueInputsLevel3Membernktr:SubleasePropertyPlantAndEquipmentMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000906709us-gaap:FurnitureAndFixturesMember2024-09-300000906709us-gaap:CarryingReportedAmountFairValueDisclosureMembernktr:SubleaseOperatingLeaseRightOfUseAssetsMember2023-06-300000906709us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000906709us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000906709us-gaap:CommonStockMember2023-07-012023-09-300000906709us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-09-300000906709nktr:TwoThousandTwentyThreeRestructuringPlanMemberus-gaap:EmployeeSeveranceMember2023-06-012023-06-300000906709nktr:MeasurementInputMarketParticipantSubtenantBorrowingRateMember2023-01-012023-03-310000906709nktr:ContractTerminationAndOtherCostsMembernktr:RestructuringPlanMember2023-07-012023-09-300000906709nktr:SecuritiesPurchaseAgreementMembernktr:TcgCrossoverFundIILPMember2024-05-282024-05-280000906709us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000906709nktr:LicenseCollaborationAndOtherRevenueMember2024-07-012024-09-300000906709us-gaap:RetainedEarningsMember2024-01-012024-03-310000906709us-gaap:CommonStockMember2024-09-300000906709us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-06-300000906709nktr:TwoThousandTwentyThreeRestructuringPlanMember2023-07-012023-09-300000906709us-gaap:EmployeeSeveranceMembernktr:TwoThousandTwentyTwoRestructuringPlanMember2023-03-310000906709nktr:LicenseCollaborationAndOtherRevenueMember2023-01-012023-09-300000906709us-gaap:AdditionalPaidInCapitalMember2023-09-300000906709us-gaap:CarryingReportedAmountFairValueDisclosureMembernktr:SubleasePropertyPlantAndEquipmentMember2024-09-300000906709nktr:MeasurementInputMarketParticipantSubtenantBorrowingRateMember2024-04-012024-06-300000906709us-gaap:RetainedEarningsMember2024-04-012024-06-300000906709nktr:ContractTerminationAndOtherCostsMembernktr:RestructuringPlanMember2024-01-012024-03-310000906709us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-06-300000906709us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310000906709nktr:BristolMyersSquibbCompanyMember2024-02-122024-02-120000906709nktr:PurchaseAndSaleAgreement2020Member2024-09-300000906709us-gaap:CommonStockMember2024-03-310000906709us-gaap:AccumulatedTranslationAdjustmentMember2024-03-310000906709nktr:PreFundedWarrantMembernktr:SecuritiesPurchaseAgreementMembersrt:MaximumMembernktr:TcgCrossoverFundIILPMember2024-05-282024-05-280000906709us-gaap:EmployeeSeveranceMembernktr:TwoThousandTwentyTwoRestructuringPlanMember2023-06-300000906709us-gaap:RetainedEarningsMember2024-07-012024-09-300000906709us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2023-12-310000906709nktr:TwoThousandTwentyThreeRestructuringPlanMemberus-gaap:EmployeeSeveranceMember2024-09-300000906709nktr:ContractTerminationAndOtherCostsMembernktr:RestructuringPlanMember2024-04-012024-06-300000906709us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000906709nktr:SubleaseOperatingLeaseRightOfUseAssetsMember2023-01-012023-09-3000009067092023-06-300000906709us-gaap:CarryingReportedAmountFairValueDisclosureMembernktr:SubleasePropertyPlantAndEquipmentMember2022-12-310000906709nktr:SubleasePropertyPlantAndEquipmentMember2023-07-012023-09-300000906709us-gaap:EmployeeSeveranceMembernktr:TwoThousandTwentyTwoRestructuringPlanMember2022-04-012022-04-300000906709us-gaap:CommonStockMember2023-01-012023-03-310000906709us-gaap:ProductMember2024-07-012024-09-300000906709nktr:RestructuringPlanMember2023-12-310000906709nktr:AssetAcquisitionByAmpersandCapitalPartnersMembernktr:AssetPurchaseAgreementMemberus-gaap:SubsequentEventMember2024-11-010000906709us-gaap:AdditionalPaidInCapitalMember2024-03-310000906709us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-09-300000906709us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000906709us-gaap:FairValueInputsLevel2Member2024-09-300000906709nktr:PurchaseAndSaleAgreement2012Member2024-09-300000906709nktr:ContractTerminationAndOtherCostsMembernktr:RestructuringPlanMember2023-12-310000906709nktr:SecuritiesPurchaseAgreementMembernktr:TcgCrossoverFundIILPMember2024-03-012024-03-310000906709us-gaap:CommonStockMember2023-03-310000906709us-gaap:AccumulatedTranslationAdjustmentMember2024-06-300000906709us-gaap:ProductMember2023-07-012023-09-300000906709us-gaap:AdditionalPaidInCapitalMember2023-03-310000906709nktr:AssetAcquisitionByAmpersandCapitalPartnersMembernktr:AssetPurchaseAgreementMemberus-gaap:SubsequentEventMember2024-11-012024-11-01xbrli:purexbrli:sharesiso4217:USDxbrli:sharesiso4217:USDnktr:Milestones Table of Contents Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Â Â FORM 10-Q Â Â â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or â˜ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 Â NEKTAR THERAPEUTICS (Exact name of registrant as specified in its charter) Â Â Delaware Â 94-3134940 (State or other jurisdiction ofincorporation or organization) Â (IRS EmployerIdentification No.) 455 Mission Bay Boulevard South San Francisco, California 94158 (Address of principal executive offices) 415-482-5300 (Registrantâ€™s telephone number, including area code) Â Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value NKTR NASDAQÂ Capital Market Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Large accelerated filer Â â˜ Â Accelerated filer Â â˜’ Non-accelerated filer Â â˜ Â Smaller reporting company Â â˜’ Emerging growth company Â â˜ Â Â Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ The number of outstanding shares of the registrantâ€™s Common Stock, $0.0001 par value, was 184,458,284 on November 1, 2024. Â Â Table of Contents Â NEKTAR THERAPEUTICS INDEX Â Summary of Risks 4 Â Â PART I: FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements â€” Unaudited: 6 Â Condensed Consolidated Balance Sheets â€” September 30, 2024 and December 31, 2023 6 Â Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 7 Â Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2024 and 2023 8 Â Condensed Consolidated Statements of Stockholdersâ€™ Equity for the three and nine months ended September 30, 2024 and 2023 9 Â Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 11 Â Notes to Condensed Consolidated Financial Statements 12 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 28 Item 3. Quantitative and Qualitative Disclosures About Market Risk 39 Item 4. Controls and Procedures 39 Â Â Â PART II: OTHER INFORMATION Item 1. Legal Proceedings 40 Item 1A. Risk Factors 40 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 62 Item 3. Defaults Upon Senior Securities 62 Item 4. Mine Safety Disclosures 62 Item 5. Other Information 62 Item 6. Exhibits 63 Signatures 65 Â 2 Table of Contents Â Forward-Looking Statements This report includes â€œforward-looking statementsâ€ within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are â€œforward-looking statementsâ€ for purposes of this Quarterly Report on Form 10-Q, including any projections of market size, earnings, revenue, milestone payments, royalties, sales or other financial items, any statements of the plans and objectives of management for future operations (including, but not limited to, preclinical development, clinical trials and manufacturing), any statements related to our financial condition and future working capital needs, any statements related to our strategic reorganization and cost restructuring plans, any statements regarding potential future financing alternatives, any statements concerning proposed drug candidates and our future research and development plans, any statements regarding the timing for the start or end of clinical trials or submission of regulatory approval filings, any statements regarding future economic conditions or performance, any statements regarding the initiation, formation, or success of any collaboration arrangements, commercialization activities and product sales levels and future payments that may come due to us under these arrangements, any statements regarding our plans and objectives to initiate or continue clinical trials, any statements related to potential, anticipated, or ongoing litigation and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by the use of terminology such as â€œbelieve,â€ â€œmay,â€ â€œwill,â€ â€œexpects,â€ â€œplans,â€ â€œanticipates,â€ â€œestimates,â€ â€œpotentialâ€ or â€œcontinue,â€ or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, such expectations or any of the forward-looking statements may prove to be incorrect and actual

results could differ materially from those projected or assumed in the forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including, but not limited to, the risk factors set forth in Part I, Item 1A â€œRisk Factorsâ€ below and for the reasons described elsewhere in this Quarterly Report on Form 10-Q. All forward-looking statements and reasons why results may differ included in this report are made as of the date hereof and we do not intend to update any forward-looking statements except as required by law or applicable regulations. Except where the context otherwise requires, in this Quarterly Report on Form 10-Q, the â€œCompany,â€ â€œNektar,â€ â€œwe,â€ â€œus,â€ and â€œourâ€ refer to Nektar Therapeutics, a Delaware corporation, and, where appropriate, its subsidiaries. Trademarks The Nektar brand and product names, including but not limited to NektarÂ®, contained in this document are trademarks and registered trademarks of Nektar Therapeutics in the United States (U.S.) and certain other countries. This document also contains references to trademarks and service marks of other companies that are the property of their respective owners. 3 Table of Contents Â Summary of Risks We are providing the following cautionary discussion of risk factors, uncertainties and assumptions that we believe are relevant to our business. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results and our forward-looking statements. We note these factors for investors as permitted by Section 21E of the Exchange Act and Section 27A of the Securities Act. Investors in Nektar Therapeutics should carefully consider the risks described below before making an investment decision. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this section to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations. Risks to our business are more fully described below in Item IA in this Form 10-Q, which risks include, among others: â€¢Risks Related to our Research and Development Efforts: oclinical drug development is a lengthy and uncertain process and we may not be able to generate and develop successful drug candidates for commercial use; owe are highly dependent on the success of rezpegaldesleukin (previously referred to as NKTR-358) and NKTR-255 and our business will be significantly harmed if either rezpegaldesleukin or NKTR-255 do not continue to advance in clinical studies; othe outcomes from competitive immunotherapy clinical trials, and the discovery and development of new potential immunotherapies could have a material and adverse impact on the value of our pipeline; osignificant competition for our polymer conjugate chemistry technology platforms and our products and drug candidates could make our technologies, drug products or drug candidates obsolete or uncompetitive; opreliminary and interim data from our clinical studies are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available; oclinical trials for any of our drug candidates could be delayed for a variety of reasons, including delays associated with activating clinical sites and lower than anticipated patient enrollment rates, which are often outside of our control; and owe depend on third parties to conduct laboratory experiments, preclinical studies and clinical trials for our drug candidates and any failure of those parties to fulfill their obligations according to our instructions and protocol standards could harm our research and development plans and adversely affect our business. â€¢Risks Related to our Financial Condition and Capital Requirements: othere is no guarantee that our prior strategic reorganization plan and cost restructuring plans will achieve their intended benefits and we may need to undertake additional cost-saving measures; owe have substantial future capital requirements and there is a risk we may not have access to sufficient capital to meet our current business plan; oa significant source of our revenue and capital for research and development has been derived from our collaboration agreements, and if we are unable to establish and maintain collaboration partnerships with attractive commercial terms, including significant development milestones and research and development cost-sharing, our business, results of operations and financial condition could suffer; and owe expect to continue to incur substantial net losses from operations and may not achieve or sustain profitability in the future. 4 Table of Contents Â â€¢Risks Related to Supply and Manufacturing: oif we or our contract manufacturers are not able to manufacture drugs or drug substances in sufficient quantities that meet applicable quality standards, our business, financial condition and results of operations could be harmed; and owe purchase some of the starting material for drugs and drug candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause delays, loss of revenue and contract liability. â€¢Risks Related to Intellectual Property, Litigation and Regulatory Concerns: owe or our partners may not obtain regulatory approval for our drug candidates on a timely basis, or at all; opatents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required, which may not be available to us on commercially reasonable terms; and ofrom time to time, we are involved in legal proceedings and may incur substantial litigation costs and liabilities that could adversely affect our business, financial condition and results of operations. â€¢Risks Related to our Collaboration Partners: owe are highly dependent on advancing rezpegaldesleukin in clinical trials, and while we believe we currently have the materials that are necessary for us to continue clinical development of rezpegaldesleukin, our ability to perform important development and regulatory activities will be significantly harmed if Eli Lilly and Company fails to continue to cooperate with us in the transfer of all materials associated with the rezpegaldesleukin program; and owe may rely on academic and private non-academic institutions to conduct investigator-sponsored clinical studies or trials of our drug candidates and any failure by the investigator-sponsor to meet its obligations with respect to the clinical development of our drug candidates may delay or impair our ability to enter into collaboration agreements, obtain regulatory approval and commercialize for our drug candidates. In addition to the above-mentioned risks, our business is subject to a number of additional risks faced by businesses generally. 5 Table of Contents Â PART I: FINANCIAL INFORMATION Â Item 1. Condensed Consolidated Financial Statementsâ€”Unaudited: NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except par value) (Unaudited) Â Â Â September 30, 2024 Â Â December 31, 2023 Â ASSETS Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Cash and cash equivalents Â $ 30,109 Â Â $ 35,277 Â Short-term investments Â Â 214,386 Â Â Â 268,339 Â Accounts receivable Â Â â€” Â Â Â 1,205 Â Inventory, net Â Â â€” Â Â Â 16,101 Â Other current assets Â Â 8,933 Â Â Â 9,779 Â Assets held for sale Â Â 33,053 Â Â Â â€” Â Total current assets Â Â 286,481 Â Â Â 330,701 Â Long-term investments Â Â 4,537 Â Â Â 25,825 Â Property, plant and equipment, net Â Â 3,603 Â Â Â 18,856 Â Operating lease right-of-use assets Â Â 8,826 Â Â Â 18,007 Â Other assets Â Â 4,519 Â Â Â 4,644 Â Total assets Â $ 307,966 Â Â $ 398,033 Â LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Accounts payable Â $ 8,577 Â Â $ 9,848 Â Accrued expenses Â Â 32,377 Â Â Â 22,162 Â Operating lease liabilities, current portion Â Â 21,504 Â Â Â 19,259 Â Liabilities related to assets held for sale Â Â 5,125 Â Â Â Â â€” Â Total current liabilities Â Â 67,583 Â Â Â 51,269 Â Operating lease liabilities, less current portion Â Â 86,758 Â Â Â 98,517 Â Liabilities related to the sales of future royalties, net Â Â 97,829 Â Â Â 112,625 Â Other long-term liabilities Â Â 6,912 Â Â Â 4,635 Â Total liabilities Â Â 259,082 Â Â Â 267,046 Â Commitments and contingencies Â Â Â Â Â Â Stockholdersâ€™ equity: Â Â Â Â Â Â Preferred stock, $0.0001Â par value; 10,000Â shares authorized; noÂ shares designated or outstanding at September 30, 2024 or December 31, 2023, respectively Â Â â€” Â Â Â Â â€” Â Common stock, $0.0001Â par value; 300,000Â shares authorized; 192,743Â shares and 191,384Â shares issued at September 30, 2024 and December 31, 2023, respectively; 184,458Â shares and 191,384Â shares outstanding at September 30, 2024 and December 31, 2023, respectively; Â Â 19 Â Â Â 19 Â Capital in excess of par value Â Â 3,654,981 Â Â Â 3,608,137 Â Treasury stock, at cost; 8,285Â shares as of September 30, 2024 and noneÂ as of December 31, 2023, respectively Â Â (3,000) Â Â â€” Â Accumulated other comprehensive income (loss) Â Â 355 Â Â Â 80 Â Accumulated deficit Â Â (3,603,471) Â Â (3,477,249) Total stockholdersâ€™ equity Â Â 48,884 Â Â Â 130,987 Â Total liabilities and stockholdersâ€™ equity Â $ 307,966 Â Â $ 398,033 Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 6 Table of Contents Â NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share information) (Unaudited) Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenue: Â Â Â Â Â Â Â Â Â Â Â Â Product sales Â $ 8,015 Â Â $ 5,822 Â Â $ 20,689 Â Â $ 15,198 Â Non-cash royalty revenue related to the sales of future royalties Â Â 15,731 Â Â Â 18,167 Â Â Â 48,029 Â Â Â 50,860 Â License, collaboration and other revenue Â Â 378 Â Â Â 155 Â Â Â 534 Â Â Â 179 Â Total revenue Â Â 24,124 Â Â Â 24,144 Â Â Â 69,252 Â Â Â 66,237 Â Operating costs and expenses: Â Â Â Â Â Â Â Â Â Â Â Â Cost of goods sold Â Â 4,435 Â Â Â 12,431 Â Â Â 22,709 Â Â Â 26,485 Â Research and development Â Â 35,031 Â Â Â 24,070 Â Â Â 92,163 Â Â Â 84,220 Â General and administrative Â Â 18,957 Â Â Â 21,147 Â Â Â 59,616 Â Â Â 60,097 Â Restructuring, impairment, and costs of terminated program Â Â 46 Â Â Â 11,360 Â Â Â 14,310 Â Â Â 49,107 Â Impairment of goodwill Â Â â€” Â Â Â â€” Â Â Â 76,501 Â Total operating costs and expenses Â Â 58,469 Â Â Â 69,008 Â Â Â 188,798 Â Â Â 296,410 Â Loss from operations Â Â (34,345) Â Â (44,864) Â Â (119,546) Â Â (230,173) Non-operating income (expense): Â Â Â Â Â Â Â Â Â Â Â Â Non-cash interest expense on liabilities related to the sales of future royalties Â Â (6,020) Â Â (5,910) Â Â (17,959) Â Â (18,467) Interest income Â Â 3,437 Â Â Â 5,211 Â Â Â 11,558 Â Â Â 14,392 Â Other income (expense), net Â Â (120) Â Â (335) Â Â (255) Â Â 100 Â Total non-operating income (expense), net Â Â (2,703) Â Â (1,034) Â Â (6,656) Â Â (3,975) Loss before provision for income taxes Â Â (37,048) Â Â (45,898) Â Â (126,202) Â Â (234,148) Provision (benefit) for income taxes Â Â 9 Â Â Â Â (61) Â Â 20 Â Â Â Â (171) Net loss Â $ (37,057) Â $ (45,837) Â $ (126,222) Â $ (233,977) Â Â Â Â Â Â Â Â Â Â Â Â Basic and diluted net loss per share Â $ (0.18) Â $ (0.24) Â $ (0.62) Â $ (1.23) Weighted average shares outstanding used in computing basic and diluted net loss per share Â Â 209,249 Â Â Â Â 190,406 Â Â Â Â 204,292 Â Â Â Â 189,651 Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 7 Table of Contents Â NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (In thousands) (Unaudited) Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net loss Â $ (37,057) Â $ (45,837) Â $ (126,222) Â $ (233,977) Other comprehensive income (loss): Â Â Â Â Â Â Â Â Â Â Â Â Net unrealized gain (loss) on available-for-sale securities Â Â 877 Â Â Â 196 Â Â Â 312 Â Â Â 1,527 Â Net foreign currency translation gain (loss) Â Â (28) Â Â (98) Â Â (37) Â Â (972) Other comprehensive income (loss) Â Â 849 Â Â Â 98 Â Â Â 275 Â Â Â 555 Â Comprehensive loss Â $ (36,208) Â $ (45,739) Â $ (125,947) Â $ (233,422) Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 8 Table of Contents Â NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY (In thousands) (Unaudited) Â Â Â Common Stock Â Â Treasury Stock Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shares Â Â Amount Â Â Shares Â Â Amount Â Â Capital inExcess ofPar Value Â Â AccumulatedOtherComprehensiveIncome (Loss) Â Â AccumulatedDeficit Â Â TotalStockholdersâ€™Equity Â Balance at December 31, 2022 Â Â 188,560 Â Â Â $ 19 Â Â Â Â â€” Â Â Â $ â€” Â Â Â $ 3,574,719 Â Â Â $ (6,907) Â $ (3,201,193) Â $ 366,638 Â Shares issued under equity compensation plans Â Â 675 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Stock-based compensation Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 10,019 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 10,019 Â Comprehensive income (loss) Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 1,226 Â Â Â Â (137,018) Â Â (135,792) Balance at March 31, 2023 Â Â 189,235 Â Â Â $ 19 Â Â Â Â â€” Â Â Â $ â€” Â Â Â $ 3,584,738 Â Â Â $ (5,681) Â $ (3,338,211) Â $ 240,865 Â Shares issued under equity compensation plans Â Â 884 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 18 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 18 Â Stock-based compensation Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 7,966 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 7,966 Â Comprehensive income (loss) Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â (769) Â Â (51,122) Â Â (51,891) Balance at June 30, 2023 Â Â 190,119 Â Â Â $ 19 Â Â Â Â â€” Â Â Â $ â€” Â Â Â $ 3,592,722 Â Â Â $ (6,450) Â $ (3,389,333) Â $ 196,958 Â Shares issued under equity compensation plans Â Â 652 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Stock-based compensation Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 8,149 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 8,149 Â Comprehensive income (loss) Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 98 Â Â Â Â (45,837) Â Â (45,739) Balance at September 30, 2023 Â Â 190,771 Â Â Â $ 19 Â Â Â Â â€” Â Â Â $ â€” Â Â Â $ 3,600,871 Â Â Â $ (6,352) Â $ (3,435,170) Â $ 159,368 Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â Â 9 Table of Contents Â NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY (In thousands) (Unaudited) Â Â Â Common Stock Â Â Treasury Stock Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shares Â Â Amount Â Â Shares Â Â Amount Â Â Capital inExcess ofPar Value Â Â AccumulatedOtherComprehensive Loss Â Â AccumulatedDeficit Â Â TotalStockholdersâ€™Equity Â Balance at December 31, 2023 Â Â 191,384 Â Â Â $ 19 Â Â Â Â â€” Â Â Â $ â€” Â Â Â $ 3,608,137 Â Â Â $ 80 Â Â Â $ (3,477,249) Â $ 130,987 Â Shares issued under equity compensation plans Â Â 525 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 3 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 3 Â Â Â Â Stock-based compensation Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 6,000 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 6,000 Â Repurchase of common stock from Bristol-Myers Squibb Â Â (8,285) Â Â Â â€” Â Â Â Â 8,285 Â Â Â Â (3,000) Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â (3,000) Issuance of prefunded warrant Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 30,000 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 30,000 Â Comprehensive income (loss) Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â (483) Â Â (36,802) Â Â (37,285) Balance at March 31, 2024 Â Â 183,624 Â Â Â $ 19 Â Â Â Â 8,285 Â Â Â $ (3,000) Â $ 3,644,140 Â Â $ (403) Â $ (3,514,051) Â $ 126,705 Â Shares issued under equity compensation plans Â Â 437 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 19 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 19 Â Stock-based compensation Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 5,418 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 5,418 Â Comprehensive income (loss) Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â (91) Â Â (52,363) Â Â (52,454) Balance at June 30, 2024 Â Â 184,061 Â Â Â $ 19 Â Â Â Â 8,285 Â Â $ (3,000) Â $ 3,649,577 Â Â $ (494) Â $ (3,566,414) Â $ 79,688 Â Shares issued under equity compensation plans Â Â 397 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 13 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 13 Â Stock-based compensation Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 5,391 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 5,391 Â Comprehensive income (loss) Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â 849 Â Â Â Â (37,057) Â Â (36,208) Balance at September 30, 2024 Â Â 184,458 Â Â Â $ 19 Â Â Â Â 8,285 Â Â Â $ (3,000) Â $ 3,654,981 Â Â Â $ 355 Â Â Â $ (3,603,471) Â $ 48,884 Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 10 Table of Contents Â NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) Â Â Â Nine Months EndedSeptember 30, Â Â Â 2024 Â Â 2023 Â Cash flows from operating activities: Â Â Â Â Â Â Net loss Â $ (126,222)

Â $ (233,977) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Â Â Non-cash royalty revenue related to the sales of future royalties Â Â (48,029) Â Â (50,860) Non-cash interest expense on liabilities related to the sales of future royalties Â Â 17,959 Â Â Â 18,467 Â Stock-based compensation Â Â 16,809 Â Â Â 26,134 Â Depreciation and amortization Â Â 4,059 Â Â Â 6,163 Â Deferred income tax expense Â Â (12) Â Â (1,854) Impairment of right-of-use assets and property, plant and equipment Â Â 8,329 Â Â Â 36,628 Â Impairment of goodwill Â Â - Â Â Â 76,501 Â Provision for net realizable value of inventory Â Â 20 Â Â Â 4,444 Â Amortization of premiums (discounts), net and other non-cash transactions Â Â (7,711) Â Â (12,137) Changes in operating assets and liabilities: Â Â Â Â Â Â Accounts receivable Â Â (841) Â Â 3,777 Â Inventory Â Â (808) Â Â (372) Operating leases, net Â Â (7,620) Â Â (6,078) Other assets Â Â (1,761) Â Â 4,450 Â Accounts payable Â Â (1,023) Â Â (9,328) Accrued expenses Â Â 17,329 Â Â Â (7,517) Net cash used in operating activities Â Â (129,522) Â Â (145,559) Cash flows from investing activities: Â Â Â Â Â Â Purchases of investments Â Â (191,882) Â Â (372,821) Maturities of investments Â Â 275,247 Â Â Â 494,385 Â Purchases of property, plant and equipment Â Â (1,009) Â Â (628) Sale of property, plant and equipment Â Â - Â Â Â 1,245 Â Net cash provided by investing activities Â Â 82,356 Â Â Â 122,181 Â Cash flows from financing activities: Â Â Â Â Â Â Proceeds from shares issued under equity compensation plans Â Â 35 Â Â Â 18 Â Proceeds from issuance of pre-funded warrant Â Â 30,000 Â Â Â â€” Â Proceeds from sale of future royalties Â Â 15,000 Â Â Â â€” Â Repurchase of common stock from Bristol-Myers Squibb Â Â (3,000) Â Â â€” Â Net cash provided by financing activities Â Â 42,035 Â Â Â 18 Â Effect of foreign exchange rates on cash and cash equivalents Â Â (37) Â Â 54 Â Net increase (decrease) in cash and cash equivalents Â Â (5,168) Â Â (23,306) Cash and cash equivalents at beginning of period Â Â 35,277 Â Â Â 88,227 Â Cash and cash equivalents at end of period Â $ 30,109 Â Â $ 64,921 Â Supplemental disclosure of cash flow information: Â Â Â Â Â Â Cash paid for income taxes Â $ â€” Â Â $ 2,656 Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 11 Table of Contents Â NEKTAR THERAPEUTICS NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2024 (Unaudited) Note 1 â€” Organization and Summary of Significant Accounting PoliciesOrganizationNektar Therapeutics (Nektar, we) is a clinical stage, research-based drug discovery biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware, focused on discovering and developing innovative medicines in the field of immunotherapy. Within this growing field, we direct our efforts toward creating new immunomodulatory agents that selectively induce, amplify, attenuate or prevent immune responses in order to achieve desired therapeutic outcomes. Our pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. As of September 30, 2024, we had approximately $249.0 million in cash and investments in marketable securities.Sale of Manufacturing FacilityOn November 1, 2024, we entered into an Asset Purchase Agreement (the APA) with an affiliate (the Purchaser) of Ampersand Management LLC d/b/a Ampersand Capital Partners (Ampersand), for the sale of our manufacturing facility located in Huntsville, Alabama (the Facility) and certain other manufacturing assets related thereto, including the assignment of our existing manufacturing and supply obligations, for consideration of $70 million in cash (subject to customary closing costs and adjustments based on closing net working capital, closing inventory and the amount of any indebtedness assumed by the Purchaser) and an approximate 20% equity ownership at the time of close in the Purchaser. See Note 10 for additional information.Financing TransactionsDuring the nine months ended September 30, 2024, we entered into the following transactions:â€¢On February 12, 2024, for total cash consideration paid of $3.0 million, we repurchased from Bristol Myers Squibb Company (BMS) 8.3 million shares of Nektar's common stock that were previously sold to BMS, which we report as treasury stock on our Condensed Consolidated Balance Sheets. See Note 6 for additional information.â€¢On March 4, 2024, we entered into a Securities Purchase Agreement with TCG Crossover Fund II, L.P. (TCG), pursuant to which we issued a pre-funded warrant to TCG to purchase 25,000,000 shares of Nektarâ€™s common stock for gross proceeds of $30.0 million (or a purchase price of $1.20 per share of common stock that can be issued upon exercise of the pre-funded warrant). On May 28, 2024, we filed with the SEC a registration statement on Form S-3 (file no. 333-279760) registering for the resale of up to 25,000,000 shares of Nektarâ€™s common stock upon exercise of the pre-funded warrant issued to TCG pursuant to the Securities Purchase Agreement. The registration statement became effective on June 5, 2024. See Note 5 for additional information.â€¢On March 4, 2024, for total cash consideration received of $15.0 million, we entered into an amendment (the Amendment) with entities managed by Healthcare Royalty Management, LLC (collectively, HCR) to remove the cap on royalties previously sold to HCR under a Purchase and Sale Agreement (the 2020 Purchase and Sale Agreement). See Note 3 for additional information. 12 Table of Contents Â Restructuring PlansIn April 2022, we announced the termination of the bempegaldesleukin program and a new strategic reorganization and cost restructuring plan (together, the 2022 Restructuring Plan), pursuant to which we completed an approximate 70% reduction of our workforce during 2022. We also decided to seek a sublease for certain of our leased premises in San Francisco, CA, including all of our office space on Third St. and portions of our office and laboratory space on Mission Bay Blvd. South.In April 2023, we announced Eli Lilly and Company's (Lilly) decision to terminate our license agreement (the Lilly Agreement) for the development of rezpegaldesleukin, as well as a new strategic reprioritization and cost restructuring plan (the 2023 Restructuring Plan). Under the 2023 Restructuring Plan, we reduced our San Francisco-based workforce by approximately 60%. In addition, under the 2023 Restructuring Plan, we decided to seek a sublease for our remaining office and laboratory space on Mission Bay Blvd. South which we had not planned to sublease pursuant to the 2022 Restructuring Plan. We have regained full rights to rezpegaldesleukin from Lilly, and we initiated a Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in October 2023 and a Phase 2b study of rezpegaldesleukin in patients with severe-to-very severe alopecia areata in March 2024. We will also explore other auto-immune indications for the development of rezpegaldesleukin.We have incurred significant costs resulting from the 2022 and 2023 Restructuring Plans. See Note 7 for additional information on the effect on our Condensed Consolidated Financial Statements.Basis of Presentation and Principles of ConsolidationOur Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of Nektar Therapeutics and our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiaryâ€™s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive income (loss) in the stockholdersâ€™ equity section of our Condensed Consolidated Balance Sheets. Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive income (loss) to the statements of operations during the three and nine months ended September 30, 2024 and 2023 except as otherwise disclosed below in Note 3.The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December 31, 2023 was derived from the audited consolidated financial statements which are included in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 5, 2024. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements.Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period. 13 Table of Contents Â Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.Significant ConcentrationsOur customers are primarily pharmaceutical companies that are located in the U.S. and Europe and with whom we have multi-year arrangements. Our accounts receivable balances contain billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. We generally do not require collateral from our customers. We perform a regular review of our customersâ€™ credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable or contract assets. We have not recorded reserves for credit losses for the three and nine months ended September 30, 2024 and 2023, nor have recorded such an allowance as of September 30, 2024 or December 31, 2023. As of September 30, 2024, all billed and unbilled trade receivables from product sales and contract assets have been classified as held-for-sale and included within assets held for sale on our Condensed Consolidated Balance Sheets.We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, various factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuerâ€™s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if various factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.Â Treasury StockWe record treasury stock activities under the cost method. Treasury stock is included in authorized and issued shares but excluded from outstanding shares. The re-issuance of treasury stock is accounted for on a first in, first-out basis and any differences between the cost of treasury stock and the re-issuance proceeds are charged or credited to additional paid-in capital.RestructuringWe recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for:â€¢contractual or other employee termination benefits provided that the obligations result from services already rendered based on rights that vest or accumulated when the payment of benefits becomes probable and the amount can be reasonably estimated;â€¢one-time employee termination benefits on the communication date from management to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination 14 Table of Contents Â dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn; andâ€¢contract termination costs for costs incurred when we cancel the contract in accordance with its terms, or for costs to be incurred over the remaining contract term without economic benefit to us at the cease-use date.For one-time employee terminations benefits, we recognize the liability in full on the communication date when future services are not required or amortize the liability ratably over the service period, if required. The fair value of termination benefits reflects our estimates of expected utilization of certain Company-funded post-employment benefits.See Note 7 for additional information on the severance expense that we recognized for employees terminated in connection with our reductions-in-force.Impairment of GoodwillGoodwill is assessed for impairment on an annual basis and whenever events and circumstances indicate that it may be impaired. Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, current economic, market and geopolitical conditions, including a significant, sustained decline in our stock price and market capitalization compared to the net book value; an adverse change in legal factors, business climate or operational performance of the business; or significant changes in the ability of the reporting unit to generate positive cash flows for our strategic business objectives. If the carrying value of the reporting unit, including goodwill, exceeds the reporting unitâ€™s fair value, we will recognize a goodwill impairment loss, and we will write down goodwill such that the carrying value of the reporting unit equals its fair value, provided that we cannot reduce goodwill below zero.See Note 8 for additional information regarding the impairment charges we recorded during the three months ended March 31, 2023 in connection with our goodwill.Long-Lived Asset ImpairmentWe assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated net cash flows associated with the asset, discounted at a rate that we believe a market participant would utilize to reflect the risks associated with the cash flows, such as credit risk. See Note 7 for additional information regarding the impairment charges we recorded in connection with our leased facilities and certain property and equipment.Net Loss per ShareFor all periods presented in the Condensed Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. We calculate basic net loss per share based on the weighted-average number of common shares outstanding, including the pre-funded warrant, during the periods presented. Shares of common stock into which the pre-funded warrant may be exercised are considered outstanding for the purposes of computing basic net loss per share because the shares may be issued for little

or no consideration, are fully vested and are exercisable after the original issuance date. For the three and nine months ended September 30, 2024 and 2023, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. We excluded shares underlying the weighted average outstanding stock options, restricted stock units (RSUs) and performance stock units (PSUs), as follows (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Potentially dilutive securities Â Â 25,887 Â Â Â 17,476 Â Â Â 26,417 Â Â Â 20,513 Â Â 15 Table of Contents Â Â Note 2 â€” Cash and Investments in Marketable SecuritiesCash and investments in marketable securities, including cash equivalents, are as follows (in thousands):Â Â Â Estimated Fair Value at Â Â Â September 30, 2024 Â Â December 31, 2023 Â Cash and cash equivalents Â $ 30,109 Â Â $ 35,277 Â Short-term investments Â Â 214,386 Â Â Â 268,339 Â Long-term investments Â Â 4,537 Â Â Â 25,825 Â Total cash, cash equivalents, and investments in marketable securities Â $ 249,032 Â Â $ 329,441 Â Â Our portfolio of cash and investments in marketable securities includes (in thousands):Â Â Â Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â Fair Value Hierarchy Level Â Amortized Cost Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Fair Value Â Â Fair Value Â Corporate notes and bonds Â 2 Â $ 90,589 Â Â $ 214 Â Â $ (10) Â $ 90,793 Â Â $ 38,882 Â Corporate commercial paper Â 2 Â Â 125,927 Â Â Â 163 Â Â Â (7) Â Â 126,083 Â Â Â 255,241 Â Obligations of U.S. government agencies Â 2 Â Â 1,500 Â Â Â 2 Â Â Â â€” Â Â Â 1,502 Â Â Â â€” Â Available-for-sale investments Â Â Â $ 218,016 Â Â $ 379 Â Â $ (17) Â $ 218,378 Â Â $ 294,123 Â Money market funds Â 1 Â Â Â Â Â Â Â Â Â Â Â Â 10,361 Â Â Â 2,359 Â Certificates of deposit Â 2 Â Â Â Â Â Â Â Â Â Â Â Â 14,046 Â Â Â 15,116 Â Cash Â N/A Â Â Â Â Â Â Â Â Â Â Â Â 6,247 Â Â Â 17,843 Â Total cash and investments in marketable securities Â Â Â Â Â Â Â Â $ 249,032 Â Â $ 329,441 Â Â For the three and nine months ended September 30, 2024 and 2023, there were no transfers between Level 1 and Level 2 of the fair value hierarchy. At December 31, 2023, our gross unrealized gains and losses were insignificant. Â Note 3 â€” Condensed Consolidated Financial Statement DetailsInventoryInventory consists of the following (in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Raw materials Â $ â€” Â Â $ 1,861 Â Work-in-process Â Â â€” Â Â Â 12,880 Â Finished goods Â Â â€” Â Â Â 1,360 Â Total inventory, net Â $ â€” Â Â $ 16,101 Â Â We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.As of September 30, 2024 and December 31, 2023, we recorded aggregate provisions of $0 and $2.0 million, respectively, for the net realizable value of our batches. Our manufacturing agreement with UCB Pharma (UCB) for the reagent used in the manufacture of CIMZIAÂ® provided for a fixed selling price which we had negotiated in exchange for a higher royalty rate. 16 Table of Contents Â Accordingly, when evaluating the net realizable value of our inventory for UCB, we include the negotiated increase of the royalties in our analysis, and the aggregate revenue has historically been greater than our manufacturing cost. Due to the decreases in the royalty rate for 2024 and 2025 as a result of a settlement agreement with UCB, the aggregate revenue was expected to be less than our manufacturing cost for these years, and therefore we previously recorded a provision for net realizable value. As further disclosed in Note 6, on July 31, 2024, we entered into a long-term supply agreement with UCB that increases the selling price of the reagent used in the manufacture of CIMZIAÂ®, which resulted in the aggregate revenue exceeding our manufacturing costs. As a result, we reduced the provision to $0 during the three months ended September 30, 2024. As of September 30, 2024, all of the inventory balance is classified as held for sale and included within assets held for sale on our Condensed Consolidated Balance Sheets.Other Current AssetsOther current assets consist of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Prepaid research and development expenses Â $ 3,960 Â Â $ 4,325 Â Interest and other non-trade receivables Â Â 2,123 Â Â Â 1,047 Â Other prepaid expenses Â Â 2,850 Â Â Â 4,407 Â Total other current assets Â $ 8,933 Â Â $ 9,779 Â Assets Held for Sale We classify assets and liabilities (the â€œdisposal groupâ€) as held for sale in the period in which all of the required criteria under ASC 360 â€œProperty, Plant, and Equipmentâ€ are met. We initially measure the disposal group asset that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Upon classification of the disposal group, we test the assets for impairment and cease related depreciation and amortization. As of September 30, 2024, we concluded that our manufacturing facility in Huntsville, Alabama meets the requirements for classification as assets held for sale. Accordingly, assets and liabilities associated with the disposal group were reclassified as held for sale. See Note 10 for additional information. The assets and liabilities as of December 31, 2023 on our Condensed Consolidated Balance Sheets were not recast to reflect the held for sale classification. As of September 30, 2024, assets held for sale consist of the following: Â Â September 30, 2024 Â Accounts receivable Â $ 1,746 Â Inventory, net Â Â 16,889 Â Property, plant and equipment, net Â Â 11,386 Â Contract asset Â Â 3,032 Â Total assets held for sale Â $ 33,053 Â Â A contract asset is a right to consideration that is conditional upon factors other than the passage of time. The contract asset above relates to the long-term supply agreement with UCB entered into on July 31, 2024 (See Note 6 for additional information). As of September 30, 2024, liabilities related to assets held for sale primarily consists of accrued compensation and other accrued expenses. 17 Table of Contents Â Property, Plant and EquipmentProperty, plant and equipment consists of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Building and leasehold improvements Â $ 3,834 Â Â $ 43,184 Â Computer equipment and computer software Â Â 14,615 Â Â Â 22,438 Â Manufacturing equipment Â Â â€” Â Â Â 24,315 Â Laboratory equipment Â Â 616 Â Â Â 14,537 Â Furniture, fixtures and other Â Â 59 Â Â Â 541 Â Depreciable property, plant and equipment at cost Â Â 19,124 Â Â Â 105,015 Â Less: accumulated depreciation Â Â (15,659) Â Â (86,898) Depreciable property, plant and equipment, net Â Â 3,465 Â Â Â 18,117 Â Construction in process Â Â 138 Â Â Â 739 Â Property, plant and equipment, net Â $ 3,603 Â Â $ 18,856 Â Â Due to the weakening lease markets during the three months ended June 30, 2024, we recorded additional non-cash impairment charges of $1.0 million for property, plant and equipment for the three months ended June 30, 2024, which we report in restructuring, impairment and costs of terminated program in our Condensed Consolidated Statement of Operations. See Note 7 for additional information. As of September 30, 2024, property, plant and equipment associated with our manufacturing facility in Huntsville, Alabama is classified as held for sale and included within assets held for sale on our Condensed Consolidated Balance Sheets.Accrued ExpensesAccrued expenses consist of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Accrued compensation Â $ 7,007 Â Â $ 5,553 Â Accrued research and development expenses Â Â 17,916 Â Â Â 10,118 Â Accrued contract termination costs Â Â 3,151 Â Â Â 3,020 Â Other accrued expenses Â Â 4,303 Â Â Â 3,471 Â Total accrued expenses Â $ 32,377 Â Â $ 22,162 Â Â Liabilities Related to the Sales of Future RoyaltiesIn 2012 and 2020, we sold to RPI Finance Trust (RPI) and HCR, respectively, our rights to receive royalties under our license and manufacturing agreements with certain pharmaceutical partners under the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement, respectively. We account for these transactions as debt and recognize non-cash royalty revenue and non-cash interest expense to amortize the proceeds over the lives of the respective arrangements. We periodically update our prospective non-cash interest rate based on our estimates of future royalties. As of September 30, 2024, our imputed interest rates for the arrangements with RPI and HCR were 43% and 24%, respectively.The original 2020 Purchase and Sale Agreement was to expire -- and wherein the right to receive royalties would revert to us -- if HCR received aggregate royalties of $210.0 million on or prior to December 31, 2025 (the 2025 Threshold), or, if the 2025 Threshold was not achieved by December 31, 2025, when HCR received aggregate royalties of $240.0 million. On March 4, 2024, Nektar and HCR amended the original 2020 Purchase and Sale Agreement (the Amendment), pursuant to which the parties agreed to remove our reversionary rights in the royalties in exchange for a $15.0 million payment from HCR. Accordingly, HCR will receive all future royalties of the products, and none of these royalties will return to Nektar. We account for the Amendment as a modification of the existing arrangement, and therefore recorded the $15.0 million proceeds as an increase to the liability. 18 Table of Contents Â The following is a reconciliation of the changes in our liabilities related to the sales of future royalties for the nine months ended September 30, 2024 (in thousands):Â Â Â Nine Months Ended September 30, 2024 Â Â Â 2012 Purchase and Sale Agreement Â Â 2020 Purchase and Sale Agreement Â Â Total Â Liabilities related to the sales of future royalties, net â€” beginning balance Â $ 24,217 Â Â $ 88,408 Â Â $ 112,625 Â Non-cash royalty revenue Â Â (19,007) Â Â (29,022) Â Â (48,029) Non-cash interest expense Â Â 4,940 Â Â Â 13,019 Â Â Â 17,959 Â Amortization of transaction costs Â Â â€” Â Â Â 274 Â Â Â 274 Â Proceeds from the Amendment Â Â â€” Â Â Â 15,000 Â Â Â 15,000 Â Liabilities related to the sales of future royalties, net â€” ending balance Â $ 10,150 Â Â $ 87,679 Â Â $ 97,829 Â Â Accumulated Other Comprehensive Income (Loss)Â The following table summarizes the changes in accumulated other comprehensive income (loss) by component (in thousands):Â Â Â Foreign currency translation Â Â Available-for-sale securities Â Â Accumulated Other Comprehensive Income Â Balance at December 31, 2023 Â $ 30 Â Â $ 50 Â Â $ 80 Â Foreign currency translation adjustments Â Â (8) Â Â â€” Â Â Â (8) Unrealized gain (loss) on available-for-sale securities Â Â â€” Â Â Â (475) Â Â (475) Balance at March 31, 2024 Â $ 22 Â Â $ (425) Â $ (403) Foreign currency translation adjustments Â Â (1) Â Â â€” Â Â Â (1) Unrealized gain (loss) on available-for-sale securities Â Â â€” Â Â Â (90) Â Â (90) Balance at June 30, 2024 Â $ 21 Â Â $ (515) Â $ (494) Foreign currency translation adjustments Â Â (28) Â Â â€” Â Â Â (28) Unrealized gain (loss) on available-for-sale securities Â Â â€” Â Â Â 877 Â Â Â 877 Â Balance at September 30, 2024 Â $ (7) Â $ 362 Â Â $ 355 Â Â Â Â Foreign currency translation Â Â Available-for-sale securities Â Â Accumulated Other Comprehensive Income Â Balance at December 31, 2022 Â $ (5,131) Â $ (1,776) Â $ (6,907) Foreign currency translation adjustments Â Â 139 Â Â Â â€” Â Â Â 139 Â Unrealized gain (loss) on available-for-sale securities Â Â â€” Â Â Â 1,087 Â Â Â 1,087 Â Balance at March 31, 2023 Â $ (4,992) Â $ (689) Â $ (5,681) Foreign currency translation adjustments Â Â 13 Â Â Â â€” Â Â Â 13 Â Unrealized gain (loss) on available-for-sale securities Â Â â€” Â Â Â 244 Â Â Â 244 Â Reclassification adjustments to income Â Â (1,026) Â Â â€” Â Â Â (1,026) Balance at June 30, 2023 Â $ (6,005) Â $ (445) Â $ (6,450) Foreign currency translation adjustments Â Â (98) Â Â â€” Â Â Â (98) Unrealized gain (loss) on available-for-sale securities Â Â â€” Â Â Â 196 Â Â Â 196 Â Balance at September 30, 2023 Â $ (6,103) Â $ (249) Â $ (6,352) Â The reclassification from accumulated other comprehensive loss relates to the closure of one of our foreign subsidiaries and has been included within other income (expense), net in our Condensed Consolidated Statement of Operations. Â 19 Table of Contents Â Note 4 â€” Commitments and ContingenciesLegal MattersFrom time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at each reporting date and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations for that period and on our cash flows and liquidity.On August 7, 2023, we filed a complaint in the United States District Court for the Northern District of California (the Court) against Lilly alleging, among other claims, breach of contract and breach of implied covenant of good faith and fair dealing (the Complaint), in connection with our collaboration with Lilly. Following the denial of its motion to dismiss the Complaint entirely, Lilly filed an answer that included counterclaims against us alleging breach of specified confidentiality provisions and defamation. The case is proceeding.We have recorded no liability for any litigation matters in our Condensed Consolidated Balance Sheets at either September 30, 2024 or December 31, 2023. Indemnifications in Connection with Commercial AgreementsAs part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual commencing after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants. For example, we made certain intellectual property representations in connection with our RPI and HCR transactions, however, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements or certain express indemnification provisions are applicable, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.To date, we have not incurred any costs to defend lawsuits or settle claims related to these indemnification obligations, nor any breaches of representations or warranties or covenants. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. Note 5 â€” Pre-Funded WarrantIn March 2024, we issued a pre-funded warrant to purchase an aggregate of 25,000,000 shares of our common stock to TCG at a price of $1.20 per share for gross proceeds of $30.0 million. Transaction costs were immaterial. The pre-funded warrant has an exercise price of $0.0001 per share and may be exercised at any time after the original issuance date. TCG may not exercise the warrant if TCG, together with its affiliates, would beneficially own more than 9.99% of the number of shares of our common stock outstanding immediately after giving effect to such exercise. TCG may increase or decrease this percentage not in excess of 19.99% by providing at least 61 daysâ€™ prior notice to the Company. On May 28, 2024, we filed with the SEC a registration statement on Form S-3 (file no. 333-279760) registering for resale of up to 25,000,000 shares of our common stock 20 Table of Contents Â issuable upon exercise of the pre-funded warrant. The registration statement became effective on June 5, 2024. As of September 30, 2024, the warrant has not been exercised. We classified the pre-funded warrant as a component of permanent equity in our Condensed Consolidated Balance Sheets as it is a freestanding financial instrument that was immediately

exercisable, does not embody an obligation for the Company to repurchase its own shares and permits the holder to receive a fixed number of shares of common stock upon exercise. All of the shares underlying the pre-funded warrant have been included in the weighted-average number of shares of common stock used to calculate net loss per share attributable to common stockholders because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the pre-funded warrant. Note 6 â€” License and Collaboration AgreementsWe have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary polyethylene glycol reagents (PEG reagents) and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808 Collaborative Arrangements, and, if so, we analyze whether we should account for any elements under ASC 606 Revenue from Contracts with Customers. Eli Lilly and Company (Lilly): Rezpegaldesleukin (previously referred to as NKTR-358) On July 23, 2017, we entered into a worldwide license agreement (the Lilly Agreement) with Lilly to co-develop rezpegaldesleukin, a novel immunological drug candidate that we invented, pursuant to which we received an initial payment of $150.0 million and were eligible for up to $250.0 million in additional development and regulatory milestones. The Lilly Agreement provided that, during Phase 1B and Phase 2 development, we shared development costs wherein 75% of the costs were borne by Lilly and 25% of the costs were borne by us. On April 23, 2023, we received from Lilly a notice of at-will termination of the Lilly Agreement. We have regained full rights to rezpegaldesleukin from Lilly, and the Lilly Agreement subsequently terminated. Following the return of our rights to develop rezpegaldesleukin, we bear all costs of development. We initiated a Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in October 2023 and a Phase 2b study of rezpegaldesleukin in patients with severe-to-very severe alopecia areata in March 2024. We will also explore other auto-immune indications for the development of rezpegaldesleukin. Bristol-Myers Squibb Company (BMS): Bempegaldesleukin, also referred to as NKTR-214 Effective April 3, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS. Pursuant to the BMS Collaboration Agreement, we and BMS jointly developed bempegaldesleukin in combination with BMSâ€™ OpdivoÂ®. The parties shared the internal and external development costs for bempegaldesleukin in combination regimens based on each partyâ€™s relative ownership interest in the compounds included in the regimens.Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $1.0 billion and purchased 8,284,600 shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $850.0 million. In 2020, we received additional non-refundable milestone payments of $50.0 million.In April 2022, we announced that BMS and we decided to discontinue all development of bempegaldesleukin in combination with OpdivoÂ®. On September 6, 2023, BMS and we terminated the BMS Collaboration Agreement, and pursuant to the surviving provisions of the BMS Collaboration Agreement, we and BMS continue our efforts to wind down the 21 Table of Contents Â bempegaldesleukin program, and the cost sharing provisions continue to remain in effect as the parties wind down the studies. On February 12, 2024, we repurchased the 8.3 million shares previously sold to BMS for total cash consideration of $3.0 million.We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. Based on the cost sharing percentages described above, we recognize the net reimbursement to (from) BMS as an increase (decrease) to the applicable expense. As discussed in Note 7, beginning in the second quarter of 2022, we began reporting clinical trial, other third-party costs and employee costs for the wind down of the bempegaldesleukin program in restructuring, impairment and costs of terminated program. For the three and nine months ended September 30, 2024, such amounts are immaterial and are included in research and development expense.Biolojic Design (Biolojic): NKTR-0165In 2021, we entered into a research collaboration and license option agreement with Biolojic to discover and develop agonistic antibodies that activate a novel and previously un-drugged target for the treatment of autoimmune diseases. In 2023, we exercised an option to gain an exclusive license to specified agonistic antibodies and other materials that were developed pursuant to a research collaboration and license option agreement in all fields of use (other than in the field of oncology). As a result of exercising the option to gain an exclusive license, we may be required to pay up to $18.0 million based on the achievement of certain development milestones, including the first milestone of $3.0 million payable upon the acceptance of the first investigational new drug application, and up to $35.0 million based on the achievement of certain regulatory approval milestones. Each milestone is payable only once, regardless of the number of indications for which we develop the licensed product. We record a liability when a milestone payment becomes probable. As of September 30, 2024, no milestones have been achieved or are considered probable, and no liability has been recorded. Â OtherWe have other collaboration agreements that have resulted in commercialized products for our collaborations partners. Under these agreements, we may sell our proprietary PEG reagents for use in these products, and we are entitled to receive royalties based on net sales of these products as well as sales milestones. As discussed in Note 3, we have sold our rights to receive royalties from these other collaboration agreements. Our non-cash royalty revenue, which totaled $18.2 million and $50.9 million for the three and nine months ended September 30, 2023, respectively, and $15.7 million and $48.0 million for the three and nine months ended September 30, 2024, respectively, represents revenue for granting licenses which we had satisfied in prior periods.We have a collaboration agreement with UCB for dapirolizumab pegol, under which we are entitled to up to a total of $40.0 million of regulatory approval milestones, as well as royalties in the low single digits based on net sales of commercialized products, if any. UCB is developing dapirolizumab pegol, a PEGylated antibody fragment, with Biogen, Inc. for the treatment of systemic lupus erythematosus. However, given the current phase of development of this product and the uncertainty in clinical development, we have excluded these milestones from the transaction price for this agreement. We have not sold our rights to receive these milestones or royalties from dapoirolizumab pegol under the APA with the Purchaser of the sale of the Facility.On July 31, 2024, and further formalized in an Amended and Restated Manufacturing and Supply Agreement dated October 18, 2024, we entered into a long-term "take or pay" supply agreement with UCB that increases the selling price of the PEG reagent used in the manufacture of CIMZIAÂ® (the UCB Supply Agreement). The UCB Supply Agreement also covers UCBâ€™s purchases of the same reagent (at the same price) for use in the manufacture of dapirolizumab pegol. We analyzed the terms of the agreement, including its cancellation provisions, and concluded that it represents a long-term agreement. Since the performance obligations are deliveries of a single reagent, we determined a single sales price for recognition of revenue over the term of the arrangement. Accordingly, because the billed price was less than the single selling price, we recorded a contract asset of $3.0 million as of September 30, 2024, which is included within assets held for sale on our Condensed Consolidated Balance Sheet, as further disclosed in Note 3. Pursuant to a separate APA between the Purchaser and us, the UCB Supply Agreement will be assigned to the Purchaser upon closing of the sale of the Facility. The assignment of the UCB Supply Agreement does not alter the potential milestones and potential royalties payable by UCB to us pursuant to the collaboration agreement for dapirolizumab 22 Table of Contents Â pegol nor the non-cash royalties payable under our collaboration agreement for CIMZIAÂ®. See Note 10 for additional information on the APA. Note 7 â€” Restructuring, Impairment and Costs of Terminated ProgramIn connection with our 2022 and 2023 Restructuring Plans, we report the following costs in restructuring, impairment and costs of terminated program:â€¢Clinical trial expense, other third-party costs and employee costs for the wind down of the bempegaldesleukin program, net of the reimbursement from BMS, initiated in 2022;â€¢Severance and related benefit costs pursuant to the 2022 and 2023 Restructuring Plans;â€¢Non-cash impairment of right-of-use assets and property, plant and equipment; andâ€¢Contract termination and other costs associated with these plans.Restructuring, impairment and costs of terminated program includes the following (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program Â $ â€” Â Â $ 652 Â Â $ â€” Â Â $ 3,606 Â Severance and benefit expense Â Â â€” Â Â Â 535 Â Â Â â€” Â Â Â 7,961 Â Impairment of right-of-use assets and property, plant and equipment Â Â â€” Â Â Â 10,173 Â Â Â 8,329 Â Â Â 36,628 Â Contract termination and other restructuring costs Â Â 46 Â Â Â â€” Â Â Â 5,981 Â Â Â 912 Â Restructuring, impairment and other costs of terminated program Â $ 46 Â Â $ 11,360 Â Â $ 14,310 Â Â $ 49,107 Â Wind Down of the Bempegaldesleukin ProgramIn prior periods through March 31, 2022, we reported the clinical trial costs, other third-party costs and employee costs related to the bempegaldesleukin program primarily in research and development expense. Beginning in the second quarter of 2022, following our announcement to terminate the program, we began reporting clinical trial, other third-party costs and employee costs for the wind down of the bempegaldesleukin program in restructuring, impairment and costs of terminated program. For the three and nine months ended September 30, 2024, such amounts are immaterial and are included in research and development expense.Severance and Benefit ExpenseEmployees affected by the reduction in force under the 2022 and 2023 Restructuring Plans are entitled to receive severance payments and certain Company funded benefits. The restructuring charges are recorded at fair value. For the 2022 Restructuring Plan, we recognized all expense in 2022 and paid the final liability of $3.3 million in the three months ended March 31, 2023.For the 2023 Restructuring Plan, we recognized $7.9 million in total expense in 2023 for the 2023 Restructuring Plan and paid the final liability of $0.2 million in the three months ended March 31, 2024.We do not expect to recognize any additional severance and benefits expense for the 2022 and 2023 Restructuring Plans.The following table provides details regarding the severance and benefit expense for the three and nine months ended September 30, 2024 pursuant to the 2023 Restructuring Plan and a reconciliation of the severance and benefits liability for the 23 Table of Contents Â three and nine months ended September 30, 2023 pursuant to the 2022 and 2023 Restructuring Plans, which we report within accrued expenses on our Condensed Consolidated Balance Sheet (in thousands): Â Â Nine Months Ended September 30, 2023 Â Â Â 2023 Restructuring Plan Â Â 2022 Restructuring Plan Â Â Total Â Liability balance as of December 31, 2022 Â $ â€” Â Â $ 3,299 Â Â $ 3,299 Â Expense recognized during the period Â Â 5,483 Â Â Â â€” Â Â Â 5,483 Â Payments during the period Â Â â€” Â Â Â (3,299) Â Â (3,299) Liability balance as of March 31, 2023 Â $ 5,483 Â Â $ â€” Â Â $ 5,483 Â Expense recognized during the period Â Â 1,943 Â Â Â â€” Â Â Â 1,943 Â Payments during the period Â Â (6,624) Â Â â€” Â Â Â (6,624) Liability balance as of June 30, 2023 Â $ 802 Â Â $ â€” Â Â $ 802 Â Expense recognized during the period Â Â 535 Â Â Â â€” Â Â Â 535 Â Payments during the period Â Â (887) Â Â â€” Â Â Â (887) Liability balance as of September 30, 2023 Â $ 450 Â Â $ â€” Â Â $ 450 Â Â Â Â Â Â Â Â Â Â Â Â Â Nine Months Ended September 30, 2024 Â Â Â 2023 Restructuring Plan Â Â 2022 Restructuring Plan Â Â Total Â Liability balance as of December 31, 2023 Â $ 196 Â Â $ â€” Â Â $ 196 Â Expense recognized during the period Â Â â€” Â Â Â â€” Â Â Â â€” Â Payments during the period Â Â (196) Â Â â€” Â Â Â (196) Liability balance as of September 30, 2024 Â $ â€” Â Â $ â€” Â Â $ â€” Â Impairment of Long-Lived AssetsAs a result of our 2022 and 2023 Restructuring Plans, we decided to seek a sublease for all of our leased spaces on Third Street and Mission Bay Blvd. South (the Third Street Facility and the Mission Bay Facility, respectively). Accordingly, we evaluate each space for impairment when management decides to sublease the respective space and at each reporting date thereafter, as facts and circumstances change. The significant assumptions in our impairment analysis relate to sublease income, including the length of time to enter into a sublease, sublease rental payments, free rent periods, tenant improvement allowances and broker commissions. When available, we use sublease negotiations or agreements, but in the absence of such information, we develop our own subjective estimates based on current real estate trends and market conditions. Accordingly, our estimates are subject to significant risk, and the terms of sublease agreements, if any, and the resulting amount and timing of sublease income, if ever realized, may be materially different than our estimates. As part of our evaluation of each sublease space, we separately compare the estimated undiscounted sublease income, as described above, for each sublease to the net book value of the related long-term assets, which include right-of-use assets and certain property, plant and equipment, primarily for leasehold improvements (collectively, sublease assets). If such sublease income exceeds the net book value of the sublease assets, we do not record an impairment charge. Otherwise, we record an impairment charge by reducing the net book value of the sublease assets to their estimated fair value, which we determined by discounting the estimated sublease income using the estimated borrowing rate of a market participant subtenant.During the three months ended March 31, 2023, we recorded an initial impairment charge of $11.5 million for our remaining office and laboratory leased space in our Mission Bay Facility, when we initially decided to sublease the space under the 2023 Restructuring Plan. We also recorded an additional impairment charge of $1.7 million for certain excess laboratory equipment which we subsequently sold in the three months ended September 30, 2023 and recognized an immaterial gain, resulting in a net impairment of $1.3 million for the nine months ended September 30, 2023. As the life sciences lease market has continued to deteriorate in the San Francisco Bay Area, we recorded additional non-cash impairment charges of $9.1 million in the three months ended September 30, 2023, and $3.9 million in the three months ended June 30, 2024, for this space. During the three months ended June 30, 2023 and September 30, 2023, we recorded additional non-cash impairment charges of $7.1 million and $1.5 million, respectively, for other sublease assets in our Mission Bay Facility that we sought to 24 Table of Contents Â sublease under the 2022 Restructuring Plan. Due to the worsening office lease market, for the three months ended June 30, 2024 and 2023, we recorded non-cash impairment charges of $4.4 million and $6.2 million, respectively, for our sublease assets at our Third Street Facility.For these impairment charges, we developed our estimates of sublease income based on market participant assumptions as described above, and we discounted the sublease income using the estimated borrowing rate of a market participant subtenant, which we estimated to be 7.9% for the three months ended March 31, 2023, 8.5% for the three months ended June 30, 2023, 8.7% for the three months ended September 30, 2023, and 6.2% for the three months ended June 30, 2024. We recorded no impairment charges for the three months ended March 31, 2024 and the three months ended September 30, 2024.The following is a reconciliation of the impairment charges we recorded for the nine months ended September 30, 2024 and three and nine months ended September 30, 2023, including the net book values of the sublease assets before the impairment and the fair values of the sublease assets (in thousands): Â Â Nine Months Ended September 30, 2024 Â Â Â Property, Plant and Equipment Â Â Operating Lease Right-of-Use Assets Â Â Total Â Net book value of impaired facilities before write-off Â $ 1,897 Â Â $ 12,506 Â Â $ 14,403 Â Less: Fair value of impaired facilities â€” Level 3 of Fair Value Hierarchy Â Â (855) Â Â (5,219) Â Â (6,074) Total impairment of

right-of-use assets and property, plant and equipment Â $ 1,042 Â Â $ 7,287 Â Â $ 8,329 Â Â Â Â Three Months Ended September 30, 2023 Â Â Â Property, Plant and Equipment Â Â Operating Lease Right-of-Use Assets Â Â Total Â Net book value of impaired facilities before write-off Â $ 3,050 Â Â $ 18,830 Â Â $ 21,880 Â Less: Fair value of impaired facilities â€" Level 3 of Fair Value Hierarchy Â Â (1,650) Â Â (9,663) Â Â (11,313) Impairment expense for facilities Â Â 1,400 Â Â Â 9,167 Â Â Â 10,567 Â (Gain) on sale or disposal of property, plant, and equipment Â Â (394) Â Â â€" Â Â Â (394) Total impairment of right-of-use assets and property, plant and equipment Â $ 1,006 Â Â $ 9,167 Â Â $ 10,173 Â Â Â Â Nine Months Ended September 30, 2023 Â Â Â Property, Plant and Equipment Â Â Operating Lease Right-of-Use Assets Â Â Total Â Net book value of impaired facilities before write-off Â $ 7,206 Â Â $ 46,292 Â Â $ 53,498 Â Less: Fair value of impaired facilities â€" Level 3 of Fair Value Hierarchy Â Â (2,172) Â Â (14,364) Â Â (16,536) Book value in excess of fair value Â Â 5,034 Â Â Â 31,928 Â Â Â 36,962 Â Less: Amounts recorded as amortization between March 31, 2023 and September 30, 2023 for Mission Bay facility Â Â (263) Â Â (1,370) Â Â (1,633) Impairment expense for facilities Â Â 4,771 Â Â Â 30,558 Â Â Â 35,329 Â Impairment of other property, plant and equipment Â Â 1,299 Â Â Â Â Â Â 1,299 Â Total impairment of right-of-use assets and property, plant and equipment Â $ 6,070 Â Â $ 30,558 Â Â $ 36,628 Â Contract Termination and Other CostsWe have incurred significant contract termination costs in connection with our Restructuring Plans. Because we continue to adjust the liability based on updates to our assumptions at each reporting date, we continue to recognize expense as our estimates change until settlement.The following are reconciliations of the contract termination and other costs for three and nine months ended September 30, 2024 and 2023. As of September 30, 2024 and December 31, 2023, we report $3.2 million and $3.0 million, 25 Table of Contents Â respectively, within accrued expenses and the remaining within other long-term liabilities on our Condensed Consolidated Balance Sheets. Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Liability balances as of December 31, 2023 and 2022, respectively Â $ 5,542 Â Â $ 7,710 Â Expense recognized during the period Â Â 975 Â Â Â 912 Â Payments during the period Â Â (928) Â Â (1,129) Liability balances as of March 31, 2024 and 2023, respectively Â $ 5,589 Â Â $ 7,493 Â Expense recognized during the period Â Â 4,960 Â Â Â - Â Payments during the period Â Â (887) Â Â (1,264) Liability balances as of June 30, 2024 and 2023, respectively Â $ 9,662 Â Â $ 6,229 Â Expense recognized during the period Â Â 46 Â Â Â - Â Payments during the period Â Â (886) Â Â (460) Liability balances as of September 30, 2024 and 2023, respectively Â $ 8,822 Â Â $ 5,769 Â Â Note 8 â€" Impairment of GoodwillDuring the three months ended March 31, 2023, our stock price and resulting market capitalization experienced a significant, sustained decline. Accordingly, we assessed our long-lived assets, including our property, plant and equipment, right-of-use assets and goodwill, for impairment.As part of our long-lived asset impairment analysis, we first assessed which long-lived assets have identifiable cash flows that are largely independent of the cash flows of other groups of assets. We concluded that the sublease assets, for which we recognized significant impairment charges during 2022 and 2023, including for the three months ended March 31, 2023, are independent of our entity-wide group. See Note 7 for additional information regarding impairment charges that we have recorded for our sublease assets, as well as certain property, plant and equipment that we subsequently sold.We next evaluated our remaining long-lived assets for impairment and performed a recoverability test using the undiscounted cash flows approach. We did not recognize any additional impairment charges on the remaining long-lived assets.Finally, we measured the fair value of our reporting unit utilizing both income and market approaches for our entity-wide asset impairment analysis. Based on this analysis, we wrote off all of our goodwill, resulting in a non-cash impairment charge of $76.5 million which we reported as impairment of goodwill in our Condensed Consolidated Statements of Operations for the three months ended March 31, 2023. We had previously recognized goodwill primarily from our acquisitions of Shearwater Corp. and Aerogen, Inc. in 2001 and 2005, respectively. Note 9 â€" Stock-Based CompensationWe recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Cost of goods sold Â $ 516 Â Â $ 841 Â Â $ 1,673 Â Â $ 2,454 Â Research and development Â Â 2,010 Â Â Â 3,202 Â Â Â 6,337 Â Â Â 11,107 Â General and administrative Â Â 2,865 Â Â Â 4,106 Â Â Â 8,799 Â Â Â 12,573 Â Total stock-based compensation Â $ 5,391 Â Â $ 8,149 Â Â $ 16,809 Â Â $ 26,134 Â Â Â Note 10 â€" Subsequent EventOn November 1, 2024, we entered into the APA and certain other agreements (the Transactions) with an affiliate (the Purchaser) of Ampersand Capital Partners. Under the APA, the Purchaser will purchase our manufacturing facility located in 26 Table of Contents Â Huntsville, Alabama (the Facility), and certain other related assets and will assume certain related liabilities, and we will assign our manufacturing and supply agreements for PEG reagents to the Purchaser. As consideration, we will receive $70 million in cash at closing of the Transactions (subject to customary closing costs and adjustments based on closing net working capital, closing inventory and the amount of any indebtedness assumed by the Purchaser) and an approximate 20% equity ownership at the time of close in the Purchaser.The closing of the Transactions is subject to the satisfaction or waiver of certain customary closing conditions set forth in the APA.The APA contains customary representations and warranties of Nektar and Purchaser. Nektar has agreed to provide certain specific and customary indemnities to Purchaser for certain excluded liabilities not covered by a representation and warranties policy to be obtained by Purchaser in connection with the Transactions. In addition, the APA contains certain restrictive covenants, which will restrict, as of the closing of the Transactions, Nektarâ€™s ability to manufacture and sell PEG reagents.In addition, the APA provides that, at the closing of the Transactions, each of Nektar and Purchaser will enter into certain ancillary agreements to effect the Transactions, including a mutual transition services agreement and a manufacturing and supply agreement and for Purchaser to supply to Nektar the PEG reagents for use in the manufacture of rezpegaldesleukin and NKTR-255. 27 Table of Contents Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed here. Factors that could cause or contribute to such differences include, but are not limited to those discussed in this section as well as factors described in Part II, Item 1A â€œRisk Factors.â€ Overview Strategic Direction of Our Business Nektar Therapeutics is a clinical stage, research-based drug discovery biopharmaceutical company focused on discovering and developing innovative medicines in the field of immunotherapy. Within this growing field, we direct our efforts toward creating new immunomodulatory agents that selectively induce, amplify, attenuate or prevent immune responses in order to achieve desired therapeutic outcomes. We apply our deep understanding of immunology and unparalleled expertise in polymer chemistry to create innovative drug candidates and use our drug development expertise to advance these molecules through preclinical and clinical development. Our pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255). We continue to make significant investments in building and advancing our pipeline of drug candidates as we believe that this is the best strategy to build long-term shareholder value. On November 1, 2024, we entered into an Asset Purchase Agreement (the APA) with an affiliate (the Purchaser) of Ampersand Management LLC d/b/a Ampersand Capital Partners, for the sale of our manufacturing facility located in Huntsville, Alabama (the Facility) and assignment of the existing manufacturing and supply agreements for consideration of $70 million in cash (subject to customary closing costs and adjustments based on closing net working capital, closing inventory and the amount of any indebtedness assumed by the Purchaser) and an approximate 20% equity ownership at the time of close in the Purchaser (the Transactions). See Note 10 to our Condensed Consolidated Financial Statements for additional information. In April of 2022 and 2023, we implemented the 2022 Restructuring Plan and 2023 Restructuring Plan, respectively, which both prioritized key research and development efforts that will be most impactful to the Companyâ€™s future. Central to both plans is the continuation of clinical development of both rezpegaldesleukin (previously referred to as NKTR-358) and NKTR-255 programs as well as our core research programs in immunology that include a separate tumor necrosis factor receptor 2 agonist antibody (NKTR-0165). Autoimmune and inflammatory diseases cause the immune system to mistakenly attack and damage healthy cells in a personâ€™s body. A failure of the bodyâ€™s self-tolerance mechanisms enables the formation of the pathogenic T lymphocytes that conduct this attack. Our drug candidate rezpegaldesleukin is a potential first-in-class resolution therapeutic that may address this underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases. It is designed to target the interleukin-2 (IL-2) receptor complex in the body in order to stimulate proliferation of powerful inhibitory immune cells known as regulatory T cells (Treg cells). By activating these cells, rezpegaldesleukin may act to bring the immune system back into balance. Rezpegaldesleukin is being developed as a once or twice monthly self-administered injection for a number of autoimmune disorders and inflammatory diseases. On October 13, 2023, we announced final efficacy data from a Phase 1b study of rezpegaldesleukin in adult patients with atopic dermatitis (Phase 1b AD Study) at the European Academy of Dermatology and Venereolgy conference. The final efficacy data from the Phase 1b AD study showed that patients with moderate-to-severe atopic dermatitis that were treated with rezpegaldesluekin had dose-dependent improvements in the eczema area and severity index (EASI), validated investigated global assessment (vIGA), body surface area (BSA), and itch numeric rating scale (NRS) over twelve weeks of treatment compared to placebo, which were sustained post-treatment over an additional thirty-six weeks. Rezpegaldesleukin was well tolerated with no patients in the rezpegaldesleukin groups experiencing severe, serious, or fatal adverse events, and no anti-rezpegaldesleukin antibodies were detected. In late October 2023, we initiated a Phase 2b clinical study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis, and in March 2024, we initiated a Phase 2b clinical study in patients with severe-to-very severe alopecia areata. 28 Table of Contents Â We also plan to explore other auto-immune indications for the development of rezpegaldesleukin. We developed rezpegaldesleukin and currently own full rights to this drug candidate. Although we previously entered into a license agreement with Eli Lilly and Company in 2017 (the Lilly Agreement) to develop and commercialize rezpegaldesleukin, on April 23, 2023, we received from Lilly a notice of at-will termination of the Lilly Agreement, and on April 27, 2023, we announced that we would be regaining full rights to rezpegaldesleukin. In oncology, we focus on developing medicines that target biological pathways that stimulate and sustain the bodyâ€™s immune response in order to fight cancer. Our drug candidate NKTR-255 is an investigational biologic that is designed to target the IL-15 pathway in order to activate the bodyâ€™s innate and adaptive immunity. Through optimal engagement of the IL-15 receptor complex, NKTR-255 is designed to enhance functional NK cell populations and formation of long-term immunological memory, which may lead to sustained and durable anti-tumor immune response. We are continuing select developmental studies of NKTR-255 in combination with cell therapies and checkpoint inhibitors while we evaluate additional strategic partnership pathways for the program. We initiated a Nektar-sponsored Phase 2 study to evaluate NKTR-255 following YescartaÂ® or BreyanziÂ® CD19 CAR-T cell therapy in patients with large B-cell lymphoma, and we expect to announce clinical data from this study at a medical conference before the end of 2024. The Fred Hutchinson Cancer Center is evaluating NKTR-255 following BreyanziÂ® CD19 CAR-T cell therapy in patients with relapsed/refractory large B-cell lymphoma as an investigator sponsored study. We are continuing our oncology clinical collaboration with Merck KGaA to evaluate the maintenance regimen of NKTR-255 in combination with avelumab, a PD-L1 inhibitor, in patients with locally advanced or metastatic urothelial carcinoma in the Phase II JAVELIN Bladder Medley study. We expect to receive topline data from this study in the second half of 2024. We entered into a new clinical study collaboration with AbelZeta Pharma, Inc. (AbelZeta) (formerly known as CBMG Holdings) to study NKTR-255 in combination with its C-TIL051, a tumor-infiltrating lymphocyte (TIL) therapy, in advanced non-small cell lung cancer (NSCLC) patients that are relapsed or refractory to anti-PD-1 therapy. Under the collaboration, we will contribute NKTR-255, and AbelZeta will add NKTR-255 to its ongoing AbelZeta-sponsored Phase 1 clinical trial. We also have an ongoing investigator sponsored study evaluating NKTR-255 in combination with IMFINZI (durvalumab) in patients with unresectable Stage 3 NSCLC who have received chemoradiation. We continue to advance our most promising research drug candidates into preclinical development with the objective of advancing these early-stage research programs to human clinical studies over the next several years. Our lead research program, NKTR-0165, is our preclinical tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset, which we believe is a unique bivalent antibody that selectively stimulates TNFR2 receptor activity, without modulation of the TNFR1 signaling. TNFR2 signaling drives immunoregulatory function and can provide a direct protective effect for tissue cells. TNFR2 is highly expressed on Tregs, neuronal cells and endothelial cells and has been shown to potentiate the suppressive effects and overall functional properties of Tregs. Our focus on TNFR2 antibody candidates that show selective Treg cell binding and signaling profiles that may be developed for treatment of autoimmune diseases, such as ulcerative colitis, multiple sclerosis and vitiligo. We are carrying out Investigational New Drug (IND) enabling studies for this program in 2024, after having exercised an option in December 2023 to gain an exclusive license to specified agonistic antibodies and other materials that were developed pursuant to a research collaboration and license option agreement we entered into with Biolojic Design, Ltd. in 2021. We have historically derived substantially all of our revenue and significant amounts of research and development operating capital from our collaboration agreements. In addition to payments received under the Lilly Agreement, we have received upfront and milestone payments and cost-sharing reimbursements under a number of other previous collaboration agreements, and certain of our collaboration partners have borne substantial costs of developing our drug candidates. Following the return of our rights to develop rezpegaldesleukin from Lilly, unless we enter into a new collaboration agreement, we will bear all the costs of developing our pipeline drug candidates, other than our clinical collaborations for NKTR-255 described above. Several of our historical collaboration agreements have resulted in approved drugs, for which we may continue to manufacture the polymer reagents used in the production of the drug products and may be entitled to royalties for net sales of these approved drugs. However, we have sold our rights to receive royalties under these arrangements, including: 29 Table of Contents Â â€¢2012 Purchase and Sale Agreement: In 2012, we sold all of our rights to receive royalties from CIMZIAÂ® (for the treatment of Crohnâ€™s disease and other autoimmune indications) and MIRCERAÂ® (for the treatment of anemia associated with chronic kidney disease) under our collaborations with UCB Pharma (UCB) and F. Hoffmann-La Roche Ltd, respectively, to RPI Finance Trust (RPI), an affiliate of Royalty Pharma for $124.0 million. â€¢2020 Purchase and Sale Agreement: In December 2020, we sold our rights, subject to a cap, to receive royalties from MOVANTIKÂ® / MOVENTIGÂ® (for the treatment of opioid-induced constipation), ADYNOVATEÂ® / ADYNOVIÂ® (a half-life extension product of Factor VIII) and other hemophilia products, under our arrangements with AstraZeneca AB, Baxalta, Inc. (a wholly owned-subsidiary of Takeda Pharmaceutical Company Ltd.), and Novo Nordisk A/S, respectively, for $150.0 million to entities managed by Healthcare Royalty Management, LLC (HCR) under a capped sale arrangement, such that all future royalties return to Nektar if HCR receives $210.0 million in royalties by

December 31, 2025 (the 2025 Threshold) or $240.0 million if the 2025 Threshold is not met. On March 4, 2024, Nektar and HCR amended the 2020 Purchase and Sale Agreement to remove the cap on the royalties in exchange for $15.0 million. See Note 3 to our Condensed Consolidated Financial Statements for additional information. Our business is subject to significant risks, including the risks inherent in our development efforts, the results of our clinical trials, our dependence on the marketing efforts by our collaboration partners, uncertainties associated with obtaining and enforcing patents, the lengthy and expensive regulatory approval process and competition from other products. Drug research and development is an inherently uncertain process with a high risk of failure at every stage prior to approval. The timing and outcome of clinical trial results are extremely difficult to predict. Clinical development successes and failures can have a disproportionately positive or negative impact on our scientific and medical prospects, financial condition and prospects, results of operations and market opportunities. For a discussion of these and some of the other key risks and uncertainties affecting our business, see Item 1A â€œRisk Factors.â€ With respect to financing our near-term business needs, as set forth below in â€œKey Developments and Trends in Liquidity and Capital Resources,â€ we estimate we have working capital to fund our current business plans through at least the next twelve months. At September 30, 2024, we had approximately $249.0 million in cash and investments in marketable securities. 30 Table of Contents Â Results of Operations The following sets forth our Condensed Consolidated Statements of Operations data for each of the periods indicated (in thousands, except percentages). Â Â Â Three Months Ended September 30, Â Â $ Change2024 vs. 2023 Â Â % Change2024 vs. 2023 Â Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Revenue: Â Â Â Â Â Â Â Â Â Â Â Â Product sales Â $ 8,015 Â Â $ 5,822 Â Â $ 2,193 Â Â Â 38 % Non-cash royalty revenue related to sales of future royalties Â Â 15,731 Â Â Â 18,167 Â Â Â (2,436) Â Â (13)% License, collaboration and other revenue Â Â 378 Â Â Â 155 Â Â Â 223 Â Â Â 144 % Total revenue Â Â 24,124 Â Â Â 24,144 Â Â Â (20) Â Â (0)% Operating costs and expenses: Â Â Â Â Â Â Â Â Â Â Â Â Cost of goods sold Â Â 4,435 Â Â Â 12,431 Â Â Â (7,996) Â Â (64)% Research and development Â Â 35,031 Â Â Â 24,070 Â Â Â 10,961 Â Â Â 46 % General and administrative Â Â 18,957 Â Â Â 21,147 Â Â Â (2,190) Â Â (10)% Restructuring, impairment and costs of terminated program Â Â 46 Â Â Â 11,360 Â Â Â (11,314) Â Â (100)% Total operating costs and expenses Â Â 58,469 Â Â Â 69,008 Â Â Â (10,539) Â Â (15)% Loss from operations Â Â (34,345) Â Â (44,864) Â Â 10,519 Â Â Â (23)% Non-operating income (expense): Â Â Â Â Â Â Â Â Â Â Â Â Non-cash interest expense on liability related to sale of future royalties Â Â (6,020) Â Â (5,910) Â Â (110) Â Â 2 % Interest income Â Â 3,437 Â Â Â 5,211 Â Â Â (1,774) Â Â (34)% Other income (expense), net Â Â (120) Â Â (335) Â Â 215 Â Â Â (64)% Total non-operating income (expense), net Â Â (2,703) Â Â (1,034) Â Â (1,669) Â Â 161 % Loss before provision for income taxes Â Â (37,048) Â Â (45,898) Â Â 8,850 Â Â Â (19)% Provision (benefit) for income taxes Â Â 9 Â Â Â (61) Â Â 70 Â Â Â (115)% Net loss Â $ (37,057) Â $ (45,837) Â $ 8,780 Â Â Â (19)% Â Â Â Nine Months Ended September 30, Â Â $ Change2024 vs. 2023 Â Â % Change2024 vs. 2023 Â Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Â Â Â Â Revenue: Â Â Â Â Â Â Â Â Â Â Â Â Product sales Â $ 20,689 Â Â $ 15,198 Â Â $ 5,491 Â Â Â 36 % Non-cash royalty revenue related to sales of future royalties Â Â 48,029 Â Â Â 50,860 Â Â Â (2,831) Â Â (6)% License, collaboration and other revenue Â Â 534 Â Â Â 179 Â Â Â 355 Â Â Â 198 % Total revenue Â Â 69,252 Â Â Â 66,237 Â Â Â 3,015 Â Â Â 5 % Operating costs and expenses: Â Â Â Â Â Â Â Â Â Â Â Â Cost of goods sold Â Â 22,709 Â Â Â 26,485 Â Â Â (3,776) Â Â (14)% Research and development Â Â 92,163 Â Â Â 84,220 Â Â Â 7,943 Â Â Â 9 % General and administrative Â Â 59,616 Â Â Â 60,097 Â Â Â (481) Â Â (1)% Restructuring, impairment and costs of terminated program Â Â 14,310 Â Â Â 49,107 Â Â Â (34,797) Â Â (71)% Impairment of goodwill Â Â â€” Â Â Â 76,501 Â Â Â (76,501) Â Â (100)% Total operating costs and expenses Â Â 188,798 Â Â Â 296,410 Â Â Â (107,612) Â Â (36)% Loss from operations Â Â (119,546) Â Â (230,173) Â Â 110,627 Â Â Â (48)% Non-operating income (expense): Â Â Â Â Â Â Â Â Â Â Â Â Non-cash interest expense on liability related to sale of future royalties Â Â (17,959) Â Â (18,467) Â Â 508 Â Â Â (3)% Interest income Â Â 11,558 Â Â Â 14,392 Â Â Â (2,834) Â Â (20)% Other income (expense), net Â Â (255) Â Â 100 Â Â Â (355) Â Â (355)% Total non-operating income (expense), net Â Â (6,656) Â Â (3,975) Â Â (2,681) Â Â 67 % Loss before provision for income taxes Â Â (126,202) Â Â (234,148) Â Â 107,946 Â Â Â (46)% Provision (benefit) for income taxes Â Â 20 Â Â Â (171) Â Â 191 Â Â Â (112)% Net loss Â $ (126,222) Â $ (233,977) Â $ 107,755 Â Â Â (46)% Â 31 Table of Contents Â Revenue Our revenue has historically been derived from our collaboration agreements, under which we may receive product sales revenue, royalties, and license fees, as well as development and sales milestones and other contingent payments. We recognize revenue when we transfer promised goods or services to our collaboration partners. â€¢Product sales and Cost of goods sold: Product sales include predominantly fixed price manufacturing and supply agreements with our collaboration partners and are the result of firm purchase orders from those partners. Accordingly, the revenue recognized in a given period is based solely on the demand and requirements of our collaboration partners and is not ratable throughout the year. We expect product sales to increase for 2024 as compared to 2023 due to increased demand from our partners and the increased selling price for UCB as a result of an amendment to our supply agreement, as described below. We historically had a manufacturing arrangement with UCB that included a fixed price which was less than the fully burdened manufacturing cost for the reagent. As a result of this arrangement, gross margin was negative for the periods presented, other than the three months ended September 30, 2024. We had negotiated this fixed price in exchange for a higher royalty rate. Accordingly, when evaluating the net realizable value of our inventory for UCB, we include the negotiated increase of the royalties in our analysis, and the aggregate revenue had historically been greater than our manufacturing cost. Due to the decreases in the royalty rates for 2024 and 2025 as a result of a settlement agreement with UCB, the aggregate revenue was expected to be less than our manufacturing cost, and therefore we recorded a provision for net realizable value. On July 31, 2024, and further formalized in an Amended and Restated Manufacturing and Supply Agreement dated October 18, 2024, we entered into a long-term "take or pay" supply agreement with UCB that increases the selling price of the PEG reagent used in the manufacture of CIMZIAÂ® (the UCB Supply Agreement). The UCB Supply Agreement also covers UCBâ€™s purchases of the same reagent (at the same price) for use in the manufacture of dapirolizumab pegol. We analyzed the terms of the agreement, including its cancellation provisions, and concluded that it represents a long-term agreement. Since the performance obligations are deliveries of a single reagent, we determined a single sales price for recognition of revenue over the term of the arrangement. Because the billed price was less than the single selling price, we recorded an increase to product sales of $3.8 million for the three months ended September 30, 2024. Additionally, we released the provision for net realizable value during the three months ended September 30, 2024, and recorded a benefit of $2.6 million to cost of goods sold. As discussed above and disclosed in Note 10 to our Condensed Consolidated Financial Statements, we have entered into an agreement to sell our manufacturing facility in Huntsville, AL, and assign our manufacturing and supply agreements to an affiliate of Ampersand Capital Partners. Upon closing of the Transactions, we will no longer record product sales and cost of goods sold. During the three and nine months ended September 30, 2023, we recorded a provision for inventory obsolescence of $3.7 million as an increase to cost of goods sold for certain PEG reagent batches, as a result of our identification of a quality concern of a solvent obtained from a third party that was used in the manufacture of these batches. Based on subsequent further analysis and partner approval, we reversed this provision in the three months ended December 31, 2023. â€¢Non-cash royalty revenue and Non-cash interest expense: We recognize non-cash royalty revenue and non-cash interest expense resulting from royalties on several products for which we had previously sold our rights to receive royalties under the 2012 and 2020 Purchase and Sale Agreements. These non-cash revenues and expenses have no effect on our cash flows, and we do not consider them material to our operations. On March 4, 2024, Nektar and HCR amended the 2020 Purchase and Sale Agreement to remove the cap on the royalties in exchange for a $15.0 million payment to Nektar. See Note 3 to our Condensed Consolidated Financial Statements for additional information. 32 Table of Contents Â We expect non-cash royalty revenue to decrease for full year 2024 as compared to 2023 due to the decrease in the royalty rate from UCB, and we expect non-cash interest expense to decrease as a result of the lower liability balance. â€¢License, collaboration and other revenue: License, collaboration and other revenue includes the recognition of upfront payments, milestone and other contingent payments received in connection with our license and collaboration agreements. The amount of revenue depends in part upon the estimated recognition period of the upfront payments allocated to continuing performance obligations, the achievement of milestones and other contingent events, the continuation of existing collaborations, the amount of research and development work, and entering into new collaboration agreements, if any. License, collaboration and other revenue was not material for the periods presented or for the full year 2023, and we do not expect to recognize significant revenue for the full year 2024. Research and Development Expense Research and development expense consists primarily of clinical study costs, contract manufacturing costs, direct costs of outside research, materials, supplies, licenses and fees as well as personnel costs (including salaries, benefits, and non-cash stock-based compensation). Research and development expense also includes certain overhead allocations consisting of support and facilities-related costs. Research and development expense increased for the three and nine months ended September 30, 2024 as compared to the three and nine months ended September 30, 2023, respectively, due to increases in expenses for the development of rezpegaldesleukin and NKTR-0165, offset by decreases in employee costs and related facilities costs as well as development expense for NKTR-255. Additionally, beginning in the three months ended March 31, 2024, we began reporting, as research and development expense, the costs of winding down the bempegaldesleukin program, which was previously reported in restructuring, impairment and costs of terminated program, as the amounts are immaterial. We expect research and development expense in total to increase in 2024 as compared to 2023 primarily due to the increased expense for the development of rezpegaldesleukin in two Phase 2b trials. As discussed in Note 7 to our Condensed Consolidated Financial Statements, pursuant to our 2023 Restructuring Plan, we reduced our San Francisco-based workforce by approximately 60%, which was substantially completed by June 2023. Additionally, pursuant to the 2023 Restructuring Plan, we decided to sublease our remaining office and laboratory space on Mission Bay Blvd. South, and therefore we ceased recording a portion of the related lease expense as research and development expense after June 2023 upon completing the reduction in force. We expect employee costs and allocations of facilities-related costs to decrease for full year 2024 as compared to 2023 for these same reasons. Research and development expense for rezpegaldesleukin increased for the three and nine months ended September 30, 2024 as compared to the three and nine months ended September 30, 2023, respectively, due to the initiation of the Phase 2b study in patients with moderate-to-severe atopic dermatitis in October 2023 and the Phase 2b study in patients with severe-to-very severe alopecia areata in March 2024. We expect the costs of development of rezpegaldesleukin to increase significantly for full year 2024 as compared to 2023 due to these Phase 2b studies. Research and development expense for NKTR-255 decreased for the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023, as our development activities in 2024 are reduced compared to the prior period, and we expect development expense for full year 2024 to decrease as compared to 2023 for this same reason. Our development expense for NKTR-255 includes the Nektar-sponsored Phase 2 study to evaluate NKTR-255 following YescartaÂ® or BreyanziÂ® CD19 CAR-T cell therapy in patients with large B-cell lymphoma, the Fred Hutchinson Cancer Center investigator-sponsored study evaluating NKTR-255 following BreyanziÂ® CD19 CAR-T cell therapy in patients with relapsed/refractory large B-cell lymphoma, our oncology clinical collaboration with Merck KGaA to evaluate the maintenance regimen of NKTR-255 in combination with avelumab, a PD-L1 inhibitor, in patients with locally advanced or metastatic urothelial carcinoma in the Phase II JAVELIN Bladder Medley study, and an ongoing investigator sponsored study evaluating NKTR-255 in combination with IMFINZI (durvalumab) in patients with unresectable Stage 3 NSCLC who have received chemoradiation. In December 2023, for our NKTR-0165 program, we exercised an option to gain an exclusive license to specified agonistic antibodies and other materials that were developed pursuant to a research collaboration and license option agreement we 33 Table of Contents Â entered into with Biolojic Design, Ltd. in 2021. Research and development expense for NKTR-0165 increased for the three and nine months ended September 30, 2024 as compared to the three and nine months ended September 30, 2023, respectively, as we began conducting IND enabling studies for this program in 2024, and we expect development expense for NKTR-0165 to increase for full year 2024 as compared to 2023 for the same reason. The timing and amount of our future clinical trial expenses will vary significantly based upon our evaluation of ongoing clinical results and the structure, timing, and scope of additional clinical development programs and potential clinical collaboration partnerships (if any) for these programs. In addition to our drug candidates that we plan to evaluate in clinical development during 2024 and beyond, we believe it is vitally important to continue our substantial investment in a pipeline of new drug candidates to continue to build the value of our drug candidate pipeline and our business. We continue our interest in identifying new drug candidates across a wide range of molecule classes, including small molecules and large proteins, peptides and antibodies, across multiple therapeutic areas. We also plan from time to time to evaluate opportunities to in-license potential drug candidates from third parties to add to our drug discovery and development pipeline. We plan to continue to advance our most promising early research drug candidates into preclinical development with the objective to advance these early stage research programs to human clinical studies over the next several years. Our expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion. In order to advance our drug candidates through clinical development, each drug candidate must be tested in numerous preclinical safety, toxicology and efficacy studies. We then conduct clinical studies for our drug candidates that take several years to complete. The cost and time required to complete clinical trials may vary significantly over the life of a clinical development program as a result of a variety of factors, including but not limited to: â€¢the number of patients required for a given clinical study design; â€¢the length of time required to enroll clinical study participants; â€¢the number and location of sites included in the clinical studies; â€¢the clinical study designs required by the health authorities (i.e. primary and secondary endpoints as well as the size of the study population needed to demonstrate efficacy and safety outcomes); â€¢the potential for changing standards of care for the target patient population; â€¢the competition for patient recruitment from competitive drug candidates being studied in the same clinical setting; â€¢the costs of producing supplies of the drug candidates needed for clinical trials and regulatory submissions; â€¢the safety and efficacy profile of the drug candidate; â€¢the use of clinical research organizations to assist with the management of the trials; and â€¢the costs and timing of, and the ability to secure, approvals from government health authorities. Furthermore, our strategy includes the potential of entering into collaborations with third parties to participate in the development and commercialization of some of our drug candidates, or clinical collaborations where we would share costs and operational responsibility with a partner. In certain situations, the clinical development program and

process for a drug candidate and the estimated completion date will largely be under the control of that third party and not under our control. We cannot forecast with any degree of certainty which of our drug candidates will be subject to future collaborations or how such arrangements would affect our development plans or capital requirements. General and Administrative Expense General and administrative expense includes the cost of administrative staffing, finance and legal activities, including certain overhead allocations consisting of support and facilities-related costs. Additionally, general and administrative expense 34 Table of Contents Â includes our lease and other facilities expenses for spaces we have sublet or are seeking to sublease, net of sublease income. General and administrative expense decreased for the three and nine months ended September 30, 2024 as compared to the three and nine months ended September 30, 2023, respectively, reflecting a decrease in employee costs partially offset by reduction of facilities costs allocated to research and development expenses. As discussed in Note 7 to our Condensed Consolidated Financial Statements, pursuant our 2023 Restructuring Plan, we reduced our San Francisco-based workforce by approximately 60%, which we substantially completed by June 2023. As discussed above, as a result of the reduction in force and our decision to seek a sublease for our remaining space in our Mission Bay Blvd. South facility, we ceased recording the related facilities expense as research and development expense after June 2023, resulting in an increase to general and administrative expense. We expect general and administrative expense for full year 2024 to be relatively consistent with 2023. Restructuring, Impairment and Costs of Terminated Program As discussed in Note 7 to our Condensed Consolidated Financial Statements, we have incurred significant costs as a result of our 2022 and 2023 Restructuring Plans. In connection with these events, we reported the following costs in restructuring, impairment and costs of terminated program as further described and disclosed in Note 7 to our Condensed Consolidated Financial Statements (in thousands): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program Â $ â€” Â Â $ 652 Â Â $ â€” Â Â $ 3,606 Â Severance and benefit expense Â Â â€” Â Â Â 535 Â Â Â â€” Â Â Â 7,961 Â Impairment of right-of-use assets and property, plant and equipment Â Â â€” Â Â Â 10,173 Â Â Â 8,329 Â Â Â 36,628 Â Contract termination and other restructuring costs Â Â 46 Â Â Â â€” Â Â Â 5,981 Â Â Â 912 Â Restructuring, impairment and other costs of terminated program Â $ 46 Â Â $ 11,360 Â Â $ 14,310 Â Â $ 49,107 Â Â â€¢Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program: We recognized $5.5 million for the full year of 2023 for the wind down of the bempegaldesleukin program. Because the amounts have become immaterial, we report these costs within research and development expense for 2024. â€¢Severance and benefits expense: We recognized $7.9 million for severance and benefit expense in 2023 for the 2023 Restructuring Plan. We do not expect to recognize expense for the 2023 Restructuring Plan in 2024. â€¢Impairment of right-of-use assets and property, plant and equipment: We recognized $35.3 million in non-cash impairment charges for the full year 2023, primarily for office and laboratory space on Mission Bay Blvd. South and our office space on Third St., reflecting deteriorations in both the laboratory and office lease markets. The non-cash impairment charge for the nine months ended September 30, 2024 primarily reflect impairment charges for our office and laboratory space on Mission Bay Blvd. South and our office space on Third St. While we continue to seek subleases for our remaining spaces, we will continue to update our estimates based on changes in market conditions, whether or not we are able to enter into subleases and, if we do enter into subleases, the economic terms of those subleases, and we may record non-cash impairment charges in future periods as these estimates change. â€¢Contract termination and other restructuring charges: We recognized $2.0 million in contract termination and other restructuring costs for the full year 2023, primarily resulting from our 2022 Restructuring Plan. We will continue to recognize expense as our estimates change until final settlement. Impairment of Goodwill As discussed in Note 8 to our Condensed Consolidated Financial Statements, during the three months ended March 31, 2023, our stock price and resulting market capitalization experienced a significant, sustained decline. As a result, we measured the fair value of the Company based on income and market approaches. Based on this analysis, we wrote off all of our goodwill in the 35 Table of Contents Â three months ended March 31, 2023. We had previously recognized goodwill primarily from our acquisitions of Shearwater Corp. and Aerogen, Inc. in 2001 and 2005, respectively. Interest Income Interest income decreased for the three and nine months ended September 30, 2024 as compared to the three and nine months ended September 30, 2023, respectively, reflecting a decrease in our investment balances, partially offset by an increase in interest rates. We expected interest income to decrease for 2024 due to lower investment balances as we fund our operations. Liquidity and Capital Resources We have financed our operations primarily through revenue from upfront and milestone payments under our strategic collaboration agreements, royalties and product sales, as well as public and private placements of debt and equity securities. As of September 30, 2024, we had approximately $249.0 million in cash and investments in marketable securities. As discussed above and further disclosed in Note 10 to our Condensed Consolidated Financial Statements, we have entered into an agreement to sell our manufacturing facility in Huntsville, AL, and assign our manufacturing and supply agreements to an affiliate of Ampersand Capital Partners. Upon closing of the Transactions, we will receive $70.0 million in cash (subject to customary closing costs and adjustments based on closing net working capital, closing inventory and the amount of any indebtedness assumed by the Purchaser) and an approximate 20% ownership interest at the time of close in the Purchaser. During the nine months ended September 30, 2024, we entered into the following transactions: â€¢On February 12, 2024, for total cash consideration paid of $3.0 million, we repurchased the 8.3 million shares previously sold to BMS. See Note 6 to our Condensed Consolidated Financial Statements for additional information. â€¢On March 4, 2024, we entered into a Securities Purchase Agreement with TCG Crossover Fund II, L.P. (TCG), pursuant to which we issued a pre-funded warrant to TCG to purchase 25,000,000 shares of Nektarâ€™s common stock for gross proceeds of $30.0 million (or a purchase price of $1.20 per share of common stock that can be issued upon exercise of the pre-funded warrant). On May 28, 2024, we filed with the SEC a registration statement on Form S-3 (file no. 333-279760) registering for the resale of up to 25,000,000 shares of Nektarâ€™s common stock upon exercise of the pre-funded warrant issued to TCG pursuant to the Securities Purchase Agreement. The registration statement became effective on June 5, 2024. See Note 5 to our Condensed Consolidated Financial Statements for additional information. â€¢On March 4, 2024, for total cash consideration received of $15.0 million, Nektar entered into an amendment with HCR to remove the cap under the 2020 Purchase and Sale Agreement. See Note 3 to our Condensed Consolidated Financial Statements for additional information. We estimate that we have working capital to fund our current business plans for at least the next twelve months from the date of filing. We expect the clinical development of our drug candidates, including rezpegaldesleukin and NKTR-255, will continue to require significant investment to continue to advance in clinical development with the objective of obtaining regulatory approval or entering into one or more collaboration partnerships. In the past, we have received a number of significant payments from collaboration agreements and other significant transactions, including $1.9 billion in total consideration received under our arrangement with BMS, development cost reimbursements from BMS, and a $150.0 million upfront payment from Lilly for our collaboration agreement for rezpegaldesleukin. Additionally, certain of our collaboration partners have borne substantial costs of developing our drug candidates. Following the return of our rights to develop rezpegaldesleukin from Lilly, however, unless we enter into a new collaboration agreement, we bear all the costs of developing our pipeline drug candidates, other than our collaborations for NKTR-255 described above. Our current business is subject to significant uncertainties and risks as a result of, among other factors, clinical and regulatory outcomes for rezpegaldesleukin and NKTR-255; the sales levels for those products, if and when they are approved; 36 Table of Contents Â whether, when and on what terms we are able to enter into new collaboration transactions; expenses being higher than anticipated, unplanned expenses and the need to satisfy contingent liabilities, including litigation matters and indemnification obligations; and cash receipts, including sublease income, being lower than anticipated. We have no credit facility or any other sources of committed capital. The availability and terms of various financing alternatives, if required in the future, substantially depend on many factors including the success or failure of drug development programs in our pipeline. The availability and terms of financing alternatives and any future significant payments from existing or new collaborations depend on the positive outcome of ongoing or planned clinical studies, whether we or our partners are successful in obtaining regulatory authority approvals in major markets, and if approved, the commercial success of these drugs, as well as general capital market conditions. We may pursue various financing alternatives to fund the expansion of our business as appropriate. As a result of our 2022 and 2023 Restructuring Plans, we are seeking to sublease all of our laboratory and office space on Mission Bay Blvd. South and our office space on Third St., and we have current subleases for a portion of our laboratory and office spaces on Mission Bay Blvd. South. The San Francisco Bay Area office lease market has been negatively impacted by economic uncertainties, particularly impacting the technology industry, and the change in work habits following the COVID-19 pandemic, as employees continue to work remotely. Accordingly, for our vacant office space on Third St., there is significant uncertainty as to whether or when we will be able to enter into a sublease as well as the economic terms of such subleases, if any. While the San Francisco Bay Area life sciences lease market remained strong during 2022, it has weakened during 2023 and 2024, including a significant increase in available leasable space in the San Francisco Bay Area. Accordingly, there is increased uncertainty as to whether or when we will be able to enter into a sublease as well as the economic terms of such subleases, if any. Due to the potential for adverse developments in the credit markets, we may experience reduced liquidity with respect to some of our investments in marketable securities. These investments are generally held to maturity, which, in accordance with our investment policy, is less than two years. However, if the need arises to liquidate such securities before maturity, we may experience losses on liquidation. To date we have not experienced any liquidity issues with respect to these securities. We believe that, even allowing for potential liquidity issues with respect to these securities and the effect of various conditions on the financial markets, our remaining cash and investments in marketable securities will be sufficient to meet our anticipated cash needs for at least the next twelve months. Cash flows from operating activities Cash flows used in operating activities for the nine months ended September 30, 2024 and 2023 totaled $129.5 million and $145.6 million, respectively. We expect that cash flows used in operating activities, excluding upfront, milestone and other contingent payments received, if any, will be comparable for 2024 as compared to 2023. Cash flows from investing activities During the nine months ended September 30, 2024 and 2023, the maturities and sales of our investments, net of purchases, totaled $83.4 million and $121.6 million, respectively, which we used to fund our operations. Our other investing activities were not significant for the periods presented. Cash flows from financing activities Other than the three financing activities described above during the three months ended March 31, 2024, our cash flows from financing activities for the nine months ended September 30, 2024 and 2023 were not significant. Critical Accounting Policies and Estimates The preparation and presentation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and 37 Table of Contents Â disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates on an ongoing basis. Actual results may differ from those estimates under different assumptions or conditions. 38 Table of Contents Â Item 3. Quantitative and Qualitative Disclosures about Market Risk Our market risks at September 30, 2024 have not changed materially from those discussed in Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2023 on file with the SEC. Item 4. Controls and Procedures Disclosure Controls and Procedures We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934 (Exchange Act) reports is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon, and as of the date of, this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective. Changes in Internal Control Over Financial Reporting We continuously seek to improve the efficiency and effectiveness of our internal controls. This results in refinements to processes throughout the Company. However, there was no change in our internal control over financial reporting that occurred in the three months ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Limitations on the Effectiveness of Controls Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. 39 Table of Contents Â PART II: OTHER INFORMATION Item 1. Legal Proceedings Reference is hereby made to our disclosures in â€œLegal Mattersâ€ under Note 4 to our Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q and the information under the heading â€œLegal Mattersâ€ is incorporated by reference herein. Item 1A. Risk Factors We are providing the following cautionary discussion of risk factors, uncertainties and assumptions that we believe are relevant to our business. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results and our forward-looking statements. We note these factors for investors as permitted by Section 21E of the Exchange Act and Section 27A of the Securities

Act. Investors in Nektar Therapeutics should carefully consider the risks described below before making an investment decision. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this section to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations. The risks described below may not be the only ones relating to our company. This description includes any material changes to and supersedes the description of the risk factors associated with our business previously disclosed in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023. Risks Related to our Business We are highly dependent on the success of drug candidates, including rezpegaldesleukin (previously referred to as NKTR-358) and NKTR-255. If these drug candidates fail in clinical development our business will be significantly harmed. Our future success is highly dependent on the clinical success of our drug candidates, including rezpegaldesleukin and NKTR-255. In general, most investigational drugs, including drug candidates designed to treat patients suffering from autoimmune disorders and cancers, such as rezpegaldesleukin and NKTR-255, respectively, do not become approved drugs. Accordingly, there is a very meaningful risk that our drug candidates will not succeed in one or more clinical trials sufficient to support one or more regulatory approvals. We previously relied on Lilly (through the Lilly Agreement) to initiate, properly conduct, and prioritize clinical trials and other development-related activities for rezpegaldesleukin. In February 2023, we announced that the Phase 2 Lupus Study of rezpegaldesleukin in systemic lupus erythematosus (SLE) conducted by Lilly did not meet the studyâ€™s primary endpoint and that Lilly does not intend to advance rezpegaldesleukin to Phase 3 development in SLE. On April 27, 2023, we announced that we would be regaining the full rights to rezpegaldesleukin from Lilly, and the collaboration agreement subsequently terminated. Following the return of our rights to develop rezpegaldesleukin, we bear all costs of development. We have initiated two Phase 2b rezpegaldesleukin studies: one in patients with moderate-to-severe atopic dermatitis, and another in patients with severe-to-very severe alopecia areata. We will also explore other auto-immune indications for the development of rezpegaldesleukin. While we believe we currently have the materials that are necessary for us to continue clinical development of rezpegaldesleukin, we may need or benefit from additional materials that Lilly has not yet transferred to us. In the event Lilly fails to promptly and completely transfer to us any additional needed materials or we are not able to independently source these materials, the continued clinical development of rezpegaldesleukin and our business will be significantly harmed. Even if the applicable agreement provides us with enforcement or other curative rights to address the harm caused by Lillyâ€™s action (or failure to act), our efforts in pursuing a remedy would be costly and there is no guarantee that these efforts would succeed or be sufficient to fully address the harm. If continued development of rezpegaldesleukin is not ultimately successful, our market valuation, prospects, financial condition and results of operations would be materially harmed. 40 Table of Contents Â Additionally, promising results from earlier trials may not predict similarly favorable outcomes in subsequent trials. For example, several of our past, planned and ongoing clinical trials utilize an â€œopen-labelâ€ trial design. An â€œopen-labelâ€ clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational drug candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational drug candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a â€œpatient biasâ€ where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an â€œinvestigator biasâ€ where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our drug candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control. One or more clinical failures of our drug candidates would jeopardize and could materially harm our business, results of operations and financial condition. Delays in clinical studies are common and have many causes, and any significant delay in clinical studies being conducted by us or our partners could result in delay in regulatory approvals and jeopardize the ability to proceed to commercialization. We or our partners may experience delays in conducting clinical trials of our drug candidates. Clinical studies may not begin on time, enroll a sufficient number of patients or be completed on schedule, if at all. Clinical trials for any of our drug candidates could be delayed for a variety of reasons, including: â€¢delays in obtaining regulatory authorization to commence a clinical study; â€¢delays in reaching agreement with applicable regulatory authorities on a clinical study design; â€¢for drug candidates currently or previously partnered with other companies, delays caused by our partner; â€¢delays caused by future health epidemics; â€¢imposition of a clinical hold by the FDA or other health authorities, which may occur at any time including after any inspection of clinical trial operations or trial sites; â€¢suspension or termination of a clinical study by us, our partners, the FDA or foreign regulatory authorities due to adverse side effects of a drug on subjects in the trial; â€¢delays in recruiting suitable patients to participate in a trial; â€¢delays in having patients complete participation in a trial or return for post-treatment follow-up; â€¢clinical sites dropping out of a trial due to the detriment of enrollment rates; â€¢delays in manufacturing and delivery of sufficient supply of clinical trial materials; â€¢changes in regulatory authorities policies or guidance applicable to our drug candidates; â€¢delays caused by changing standards of care or new treatment options; and â€¢delays associated with third parties, such as a past collaboration partner, failing to provide us with all the necessary documents, data and materials necessary to conduct clinical trials. If the initiation or completion of any of the planned clinical studies for our drug candidates is delayed for any of the above or other reasons, results for the studies would be delayed, and consequently the regulatory approval process would be delayed which would also delay the ability to commercialize these drug candidates, which could have a material adverse effect on our business, financial condition and results of operations. Clinical study delays could also shorten any commercial periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our drug candidates and may harm our business and results of operations. 41 Table of Contents Â We currently rely on academic and private non-academic institutions to conduct investigator-sponsored clinical studies or trials of our drug candidates. Any failure by the investigator-sponsor to meet its obligations with respect to the clinical development of our drug candidates may delay or impair our ability to obtain regulatory approval or commercialize for other drug candidates. We currently rely on academic and private non-academic institutions to conduct and sponsor clinical studies or trials relating to our drug candidates. We do not control the design or conduct of the investigator-sponsored trials, and it is possible that the FDA or non-U.S. regulatory authorities will not view these investigator-sponsored studies or trials as providing adequate support for future clinical trials, whether controlled by us or independent investigators, for any one or more reasons, including elements of the design or execution of the trials or safety concerns or other trial results. Â Such arrangements will likely provide us certain information concerning our drug candidates with respect to the investigator-sponsored studies or trials, including access to and the ability to use and reference the data, including for our own regulatory filings, resulting from the investigator-sponsored studies or trials. However, we would not have control over the timing and reporting of the data from investigator-sponsored trials, nor would we own the data from the investigator-sponsored studies or trials. If we are unable to confirm or replicate the results from the investigator-sponsored studies or trials or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development of our drug candidates. Further, if investigators or institutions breach their obligations with respect to the clinical development of our drug candidates, or if the data proves to be inadequate compared to the first-hand knowledge we might have gained had the investigator-sponsored studies or trials been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected. Additionally, the FDA or non-U.S. regulatory authorities may disagree with the sufficiency of our right of reference to the preclinical, manufacturing or clinical data generated by these investigator-sponsored studies or trials or our interpretation of preclinical, manufacturing or clinical data from these investigator-sponsored studies or trials. If so, the FDA or other non-U.S. regulatory authorities may require us to obtain and submit additional preclinical, manufacturing or clinical data before we may initiate our planned clinical trials and/or may not accept such additional data as adequate to initiate our planned clinical trials. The outcomes from the clinical trials of drug candidates from others, and the discovery and development of new potential therapies in immunology and oncology, could have a material and adverse impact on the value of the drug candidates in our research and development pipeline. The research and development of immune-modulatory agents is a very competitive global segment in the biopharmaceutical industry attracting tens of billions of dollars of investment each year. Our clinical trial plans for rezpegaldesleukin, NKTR-255 and other drug candidates face substantial competition from other regimens already approved, and many more that are either ahead of or in parallel development in patient populations where we are studying our drug candidates. As immunotherapy represents a relatively new approach to treatment of autoimmune disorders and cancer and few have successfully completed late stage development, drug development in this area entails substantial risks and uncertainties that include rapidly changing standards of care, identifying contribution of components when therapeutic combinations are employed, patient enrollment competition, evolving regulatory frameworks to evaluate regimens, and varying risk-benefit profiles of competing therapies, any or all of which could have a material and adverse impact on the probability of success of our drug candidates. The risk of clinical failure for any drug candidate remains high prior to regulatory approval and there can be no assurance that our drug candidates will obtain regulatory approval for any particular indications. A number of companies have suffered significant unforeseen failures in clinical studies due to factors such as inconclusive efficacy or safety, even after achieving preclinical proof-of-concept or positive results from earlier clinical studies that were satisfactory both to them and to reviewing regulatory authorities. Clinical study outcomes remain very unpredictable and it is possible that one or more of our clinical studies could fail at any time due to efficacy, safety or other important clinical findings or regulatory requirements. The results from preclinical testing or early clinical trials of a drug candidate may not predict the results 42 Table of Contents Â that will be obtained in later phase clinical trials of the drug candidate. We, the FDA, an independent Institutional Review Board (IRB), an independent ethics committee (IEC), or other applicable regulatory authorities may suspend clinical trials of a drug candidate at any time for various reasons, including a belief that patients participating in such trials are being exposed to unacceptable health risks or adverse side effects. Similarly, an IRB or IEC may suspend a clinical trial at a particular trial site. If one or more of our drug candidates fail in clinical studies, it could have a material adverse effect on our business, financial condition and results of operations. Significant competition for our polymer conjugate chemistry technology platforms and our partnered and proprietary drugs and drug candidates could make our technologies, drugs or drug candidates obsolete or noncompetitive, which would negatively impact our business, results of operations and financial condition. Our advanced polymer conjugate chemistry platforms and our partnered and proprietary products and drug candidates compete with various pharmaceutical and biotechnology companies. Competitors of our polymer conjugate chemistry technologies include Biogen Inc., Horizon Pharma, Dr. Reddyâ€™s Laboratories Ltd., SunBio Corporation, Laysan Bio, Inc., Mountain View Pharmaceuticals, Inc., Novo Nordisk A/S (formerly assets held by Neose Technologies, Inc.), NOF Corporation and Aurigene Pharmaceutical Services. Several other chemical, biotechnology and pharmaceutical companies may also be developing polymer conjugation technologies or technologies that have similar impact on target drug molecules. Some of these companies license or provide the technology to other companies, while others are developing the technology for internal use. There are many competitors for our drug candidates currently in development. For rezpegaldesleukin, there are a number of competitors in various stages of clinical development that are working on programs which are designed to correct the underlying immune system imbalance in the body due to autoimmune disease. In particular, we expect to compete with therapies that could be cytokine-based, microbiome-based, or toleragenic-based therapies (Symbiotix, LLC, Janssen, AstraZeneca, and Tizona Therapeutics), regulatory T cell therapies (Sangamo Therapeutics, Inc., Quell Therapeutics, Ltd, TxCell, Inc., Sonoma Biotherapeutics, Inc., GentiBio, Inc. Kyvema Therapeutics, Inc. and and Tract Therapeutics, Inc.), or IL-2-based-therapies (Amgen Inc., BMS, Novartis, Inc., ILTOO Pharma, Xencor, Inc. Merck & Co, through its acquisition of Pandion Therapeutics, and Sanofi SA, through its acquisition of Synthorx, Inc.). For NKTR-255, we believe companies that are currently researching and developing engineered IL-15 biologics and cell therapies that could compete with this drug candidate include Artiva Biotherapeutics, Fate Therapeutics, ImmunityBio, Inc., Nkarta Therapeutics, NKMax America, and Roche/Genentech (through its partnership with Xencor, Inc.). There can be no assurance that we or our partners will successfully develop, obtain regulatory approvals for and commercialize next-generation or new products that will successfully compete with those of our competitors. Many of our competitors have greater financial, research and development, marketing and sales, manufacturing and managerial capabilities. We face competition from these companies not just in product development but also in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies. As a result, our competitors may succeed in developing competing technologies, obtaining regulatory approval or gaining market acceptance for products before we do. These developments could make our products or technologies noncompetitive or obsolete. Preliminary and interim data from our clinical studies that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available. From time to time, we publish preliminary or interim data from our clinical studies. Preliminary data remain subject to audit confirmation and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Interim data are also subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. As a result, preliminary and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data could significantly harm our business prospects. 43 Table of Contents Â Risks Related to our Financial Condition and Capital Requirement Additional cost-savings measures may be necessary following implementation of our strategic reorganization plan and cost restructuring plans. Our 2022 and 2023 Restructuring Plans prioritized key research and development efforts that will impact the Companyâ€™s future business activities, including activities involving rezpegaldesleukin, NKTR-255 and several core research programs. There is no guarantee that these Restructuring Plans and their associated cost restructuring measures will

achieve their intended benefits or that our post-restructuring focus will be sufficient for us to achieve success. Consequently, we may need to undertake additional restructuring and cost-saving activities to further prioritize our key research and development efforts and these additional restructuring and cost-saving activities may not be successful, which could have a material adverse effect on our business, financial condition and prospects. Our results of operations and financial condition depend significantly on the ability of our collaboration partners to successfully develop and market drugs and they may fail to do so. Under our collaboration agreements with various pharmaceutical or biotechnology companies, our collaboration partner is generally solely responsible for: â€¢designing and conducting large scale clinical studies; â€¢preparing and filing documents necessary to obtain government approvals to sell a given drug candidate; and/or â€¢marketing and selling the drugs when and if they are approved. Our reliance on collaboration partners poses a number of significant risks to our business, including risks that: â€¢we have very little control over the timing and level of resources that our collaboration partners dedicate to commercial marketing efforts such as the amount of investment in sales and marketing personnel, general marketing campaigns, direct-to-consumer advertising, product sampling, pricing agreements and rebate strategies with government and private payers, manufacturing and supply of drug product, and other marketing and selling activities that need to be undertaken and well executed for a drug to have the potential to achieve commercial success; â€¢collaboration partners with commercial rights may choose to devote fewer resources to the development or marketing of our partnered drugs than they devote to their own drugs or other drugs that they have in-licensed; â€¢we have very little control over the timing and amount of resources our partners devote to development programs in one or more major markets; â€¢disagreements with partners could lead to delays in, or termination of, the research, development or commercialization of drug candidates or to litigation or arbitration proceedings; â€¢disputes may arise or escalate in the future with respect to the ownership of rights to technology or intellectual property developed with partners; â€¢we do not have the ability to unilaterally terminate agreements (or partners may have extension or renewal rights) that we believe are not on commercially reasonable terms or consistent with our current business strategy; â€¢partners may be unable to pay us as expected; 44 Table of Contents Â â€¢partners may terminate their agreements with us unilaterally for any or no reason, in some cases with the payment of a termination fee penalty and in other cases with no termination fee penalty; and â€¢partners may respond to natural disasters or health epidemics by ceasing all or some of their development responsibilities (including the responsibility to clinical develop our drug candidates). Given these risks, the success of our current and future collaboration partnerships is highly unpredictable and can have a substantial negative impact on our business. If the approved drugs fail to achieve commercial success or the drugs in development fail to have positive late stage clinical outcomes sufficient to support regulatory approval in major markets, it could significantly impair our access to capital necessary to fund our research and development efforts for our drug candidates. If we are unable to obtain sufficient capital resources to advance our drug candidate pipeline, it would negatively impact the value of our business, results of operations and financial condition. We have substantial future capital requirements and there is a risk that we may not have access to sufficient capital to meet our current business plan. If we do not receive substantial milestone or royalty payments from our existing collaboration agreements, execute new high value collaborations or other arrangements, or are unable to raise additional capital in one or more financing transactions, we would be unable to continue our current level of investment in research and development. As of September 30, 2024, we had cash and investments in marketable securities valued at approximately $249.0 million. While we believe that our cash position will be sufficient to meet our liquidity requirements through at least the next 12 months, our future capital requirements will depend upon numerous unpredictable factors, including: â€¢the cost, timing and outcomes of clinical studies and regulatory reviews of our drug candidates, particularly rezpegaldesleukin; â€¢if and when we receive potential milestone payments and royalties from our existing collaborations if the drug candidates subject to those collaborations achieve clinical, regulatory or commercial success; â€¢the progress, timing, cost and results of our clinical development programs; â€¢the success, progress, timing and costs of our efforts to implement new collaborations, licenses and other transactions that increase our current net cash, such as the sale of additional royalty interests held by us, term loan or other debt arrangements, and the issuance of securities; â€¢the number of patients, enrollment criteria, primary and secondary endpoints, and the number of clinical studies required by the regulatory authorities in order to consider for approval our drug candidates and those of our collaboration partners; â€¢our general and administrative expenses, capital expenditures and other uses of cash; and â€¢disputes concerning patents, proprietary rights, or license and collaboration agreements that could negatively impact our receipt of milestone payments or royalties or require us to make significant payments arising from licenses, settlements, adverse judgments or ongoing royalties. A significant multi-year capital commitment is required to advance our drug candidates through the various stages of research and development in order to generate sufficient data to enable high value collaboration partnerships with significant upfront payments or to successfully achieve regulatory approval. In the event we do not enter into any new collaboration partnerships with significant upfront payments and we choose to continue to advance our drug candidates to later stage research and development, we may need to pursue financing alternatives, including dilutive equity-based financings, such as an offering of convertible debt or common stock, which would dilute the percentage ownership of our current common stockholders and could significantly lower the market value of our common stock. If sufficient capital is not available to us or is not available on commercially reasonable terms, it could require us to delay or reduce one or more of our research and development programs. If 45 Table of Contents Â we are unable to sufficiently advance our research and development programs, it could substantially impair the value of such programs and result in a material adverse effect on our business, financial condition and results of operations. The commercial potential of a drug candidate in development is difficult to predict. If the market size for a new drug is significantly smaller than we anticipate, it could significantly and negatively impact our revenue, results of operations and financial condition. It is very difficult to estimate the commercial potential of drug candidates due to important factors such as safety and efficacy compared to other available treatments, including changing standards of care, third party payer reimbursement standards, patient and physician preferences, the availability of competitive alternatives that may emerge either during the long drug development process or after commercial introduction, and the availability of generic and biosimilar versions of our drug candidates following approval by regulatory authorities based on the expiration of regulatory exclusivity or our inability to prevent generic or biosimilar versions from coming to market by asserting our patents. If due to one or more of these risks the market potential for a drug candidate is lower than we anticipated, it could significantly and negatively impact the commercial potential of the drug candidate, the commercial terms of any collaboration partnership potential for such drug candidate, or if we have already entered into a collaboration for such drug candidate, the revenue potential from royalty and milestone payments could be significantly diminished and this would negatively impact our business, financial condition and results of operations. We may also depend on our relationships with other companies for sales and marketing performance and the commercialization of drug candidates. Poor performance by these companies, or disputes with these companies, could negatively impact our revenue and financial condition. If government and private insurance programs do not provide payment or reimbursement for our partnered drug or proprietary drugs, those drugs will not be widely accepted, which would have a negative impact on our business, results of operations and financial condition. In the United States and markets in other countries, patients generally rely on third-party payers to reimburse all or part of the costs associated with their treatment. In both domestic and foreign markets, sales of our partnered and proprietary products that receive regulatory approval will depend in part on market acceptance among physicians and patients, pricing approvals by government authorities and the availability of coverage and payment or reimbursement from third-party payers, such as government programs, including Medicare and Medicaid in the U.S., managed care providers, private health insurers and other organizations. However, eligibility for coverage does not necessarily signify that a drug candidate will be adequately reimbursed in all cases or at a rate that covers costs related to research, development, manufacture, sale, and distribution. Third-party payers are increasingly challenging the price and cost effectiveness of medical products and services. Therefore, significant uncertainty exists as to the coverage and pricing approvals for, and the payment or reimbursement status of, newly approved healthcare products. For more information, see â€œBusiness â€“ Government Regulation â€“ Coverage, Reimbursement, and Pricing.â€ There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare & Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payers tend to follow CMS to a substantial degree. Factors payers consider in determining reimbursement are based on whether the product is (i) a covered benefit under its health plan; (ii) safe, effective and medically necessary; (iii) appropriate for the specific patient; (iv) cost-effective; and (v) neither experimental nor investigational. In addition, net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payers and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. 46 Table of Contents Â Increasingly, third-party payers are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any of our drug candidates that are commercialized and, if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs. Moreover, legislation and regulations affecting the pricing of pharmaceuticals may change before regulatory agencies approve our proposed products for marketing and could further limit coverage or pricing approvals for, and reimbursement of, our products from government authorities and third-party payers. Federal agencies, Congress and state legislatures have continued to show interest in implementing cost containment programs to limit the growth of health care costs, including price controls, restrictions on reimbursement and other fundamental changes to the healthcare delivery system. In addition, in recent years, Congress has enacted various laws seeking to reduce the federal debt level and contain healthcare expenditures, and the Medicare and other healthcare programs are frequently identified as potential targets for spending cuts. New government legislation or regulations related to pricing or other fundamental changes to the healthcare delivery system as well as a government or third-party payer decision not to approve pricing for, or provide adequate coverage or reimbursement of, our products hold the potential to severely limit market opportunities of such products. In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our drug candidates. Historically, products launched in the European Union do not follow price structures of the U.S. and generally prices tend to be significantly lower. If we are unable to establish and maintain collaboration partnerships on attractive commercial terms, our business, results of operations and financial condition could suffer. We intend to continue to seek partnerships with pharmaceutical and biotechnology partners to fund a portion of our research and development capital requirements. The timing of new collaboration partnerships is difficult to predict due to availability of clinical data, the outcomes from our clinical studies, the number of potential partners that need to complete due diligence and approval processes, the definitive agreement negotiation process and numerous other unpredictable factors that can delay, impede or prevent significant transactions. If we are unable to find suitable partners or negotiate collaboration arrangements with favorable commercial terms with respect to our existing and future drug candidates or the licensing of our intellectual property, or if any arrangements we negotiate, or have negotiated, are terminated, it could have a material adverse effect on our business, financial condition and results of operations. Our revenue has historically been exclusively derived from our collaboration agreements, which can result in significant fluctuation in our revenue from period to period, and our past revenue is therefore not necessarily indicative of our future revenue. Our revenue has historically been exclusively derived from our collaboration agreements (whether based on our drug candidates or polymeric reagents), from which we receive upfront fees, research and development reimbursement and funding, milestone and other contingent payments based on clinical progress, regulatory progress or net sales achievements, royalties and product sales. Significant variations in the timing of receipt of cash payments and our recognition of revenue can result from 47 Table of Contents Â payments based on the execution of new collaboration agreements, the timing of clinical outcomes, regulatory approval, commercial launch or the achievement of certain annual sales thresholds. The amount of our revenue derived from collaboration agreements in any given period will depend on a number of unpredictable factors, including whether and when we or our collaboration partners achieve clinical, regulatory and sales milestones, the timing of regulatory approvals in one or more major markets, reimbursement levels by private and government payers, and the market introduction of new drugs or generic versions of the approved drug, as well as other factors. Our past revenue generated from collaboration agreements is not necessarily indicative of our future revenue. If any of our existing or future collaboration partners fails to develop, obtain regulatory approval for, manufacture or ultimately commercialize any drug candidate under our collaboration agreement, our business, financial condition, and results of operations could be materially and adversely affected. We expect to continue to incur substantial losses and negative cash flow from operations and may not achieve or sustain profitability in the future. For the nine months ended September 30, 2024, we reported a net loss of $37.1 million. If and when we achieve profitability depends upon a number of factors, including the timing and recognition of milestones and other contingent payments and royalties received, the timing of revenue under our collaboration agreements, the amount of investments we make in our proprietary drug candidates and the regulatory approval and market success of our drug candidates. We may not be able to achieve and sustain profitability. Other factors that will affect whether we

achieve and sustain profitability include our ability, alone or together with our partners, to: â€¢develop drugs utilizing our technologies, either independently or in collaboration with other pharmaceutical or biotechnology companies; â€¢effectively estimate and manage clinical development costs, particularly the cost of the clinical studies for rezpegaldesleukin and NKTR-255; â€¢receive necessary regulatory and marketing approvals; â€¢maintain or expand manufacturing at necessary levels; â€¢achieve market acceptance of our partnered products; â€¢receive revenue or royalties on products that have been approved, marketed or submitted for marketing approval with regulatory authorities; and â€¢maintain sufficient funds to finance our activities. Risks Related to Supply and Manufacturing If we or our contract manufacturers are not able to manufacture biologic substance or substances in sufficient quantities that meet applicable quality standards, it could delay clinical studies, result in reduced sales or constitute a breach of our contractual obligations, any of which could significantly harm our business, financial condition and results of operations. If we or our contract manufacturing organizations (CMOs) are not able to manufacture and supply sufficient drug quantities meeting applicable quality standards required to support large clinical studies or commercial manufacturing in a timely manner, it could delay our or our collaboration partnersâ€™ clinical studies or result in a breach of our contractual obligations, which could in turn reduce the potential commercial sales of our or our collaboration partnersâ€™ products. As a result, we could incur substantial costs and damages and any product sales or royalty revenue that we would otherwise be entitled to receive could be reduced, delayed or eliminated. In most cases, we rely on CMOs to manufacture and supply drug product for our clinical studies and those of our collaboration partners. The manufacturing of biologics involves significant risks and uncertainties related to the demonstration of adequate stability, sufficient purification of the drug substance and drug product, the identification and 48 Table of Contents Â elimination of impurities, optimal formulations, process and analytical methods validations, and challenges in controlling for all of these variables. We have faced and may in the future face significant difficulties, delays and unexpected expenses as we validate third party CMOs required for drug supply to support our clinical studies and the clinical studies and products of our collaboration partners. Failure by us or our CMOs to supply API or drug products in sufficient quantities that meet all applicable quality requirements could result in supply shortages for our clinical studies or the clinical studies and commercial activities of our collaboration partners. Such failures could significantly and materially delay clinical trials and regulatory submissions or result in reduced sales, any of which could significantly harm our business prospects, results of operations and financial condition. If any CMO with whom we contract fails to perform its obligations, we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different CMO, which we may not be able to do on reasonable terms, if at all. In either scenario, our clinical trials or commercial distribution could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or drug candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product according to the specifications previously submitted to or approved by the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop drug candidates or commercialize our products in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of our drug candidate that such CMO owns independently. This would increase our reliance on such a CMO or require us to obtain a license from such CMO in order to have another CMO manufacture our products or drug candidates. In addition, in the case of the CMOs that supply our drug candidates, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials. Building and validating large scale clinical or commercial-scale manufacturing facilities and processes, recruiting and training qualified personnel and obtaining necessary regulatory approvals is complex, expensive and time consuming. In the past, we have encountered challenges in scaling up manufacturing to meet the requirements of large scale clinical trials without making modifications to the drug formulation, which may cause significant delays in clinical development. There continues to be substantial and unpredictable risk and uncertainty related to manufacturing and supply until such time as the commercial supply chain is validated and proven. We purchase some of the starting material for biologics and biologic candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause production delays, clinical trial delays, substantial loss of revenue and contract liability to third parties. We often face very limited supply of a critical raw material that can only be obtained from a single, or a limited number of, suppliers, which could cause production delays, clinical trial delays, substantial lost revenue opportunities or contract liabilities to third parties. For example, there are only a limited number of qualified suppliers, and in some cases single source suppliers, for the raw materials included in our PEGylation and advanced polymer conjugate drug formulations. Any interruption in supply, diminution in quality of raw materials supplied to us or failure to procure such raw materials on commercially feasible terms could harm our business by delaying our clinical trials, impeding commercialization of approved drugs or increasing our costs. Our manufacturing operations and those of our contract manufacturers are subject to laws and other governmental regulatory requirements, which, if not met, would have a material adverse effect on our business, results of operations and financial condition. We and our CMOs are required in certain cases to maintain compliance with current good manufacturing practices (cGMP), including cGMP guidelines applicable to active pharmaceutical ingredients, and drug products, and with laws and 49 Table of Contents Â regulations governing manufacture and distribution of controlled substances, and are subject to inspections by the FDA, or comparable agencies in other jurisdictions administering such requirements. We anticipate periodic regulatory inspections of our drug manufacturing facilities and the manufacturing facilities of our CMOs for compliance with applicable regulatory requirements. Any failure to follow and document our or our CMOsâ€™ adherence to such cGMP and other laws and governmental regulations or satisfy other manufacturing and product release regulatory requirements may disrupt our ability to meet our manufacturing obligations to our customers, lead to significant delays in the availability of products for commercial use or clinical study, result in the termination or hold on a clinical study or delay or prevent filing or approval of marketing applications for our products. Failure to comply with applicable laws and regulations may also result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delays, suspension or withdrawal of approvals, license revocation, seizures, administrative detention, or recalls of products, operating restrictions and criminal prosecutions, any of which could harm our business. Regulatory inspections could result in costly manufacturing changes or facility or capital equipment upgrades to satisfy the FDA that our manufacturing and quality control procedures are in substantial compliance with cGMP. Manufacturing delays, for us or our CMOs, pending resolution of regulatory deficiencies or suspensions could have a material adverse effect on our business, results of operations and financial condition. Risks Related to Business Operations We depend on third parties to conduct the preclinical studies and clinical trials for our drug candidates and any failure of those parties to fulfill their obligations according to protocol standards could harm our development plans and adversely affect our business. We depend on our collaboration partners, independent clinical investigators, contract research organizations and other third-party service providers to conduct preclinical studies and clinical trials for our drug candidates, including to monitor, record, manage and analyze data generated from these studies. We rely heavily on these parties for the successful execution of our preclinical studies and clinical trials. Though we are ultimately responsible for the results of their activities, many aspects of their activities are beyond our control, such as the timing, conduct and management of data developed through these studies and trials. For example, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trials, but the independent clinical investigators may prioritize other projects over ours or communicate issues regarding our drug candidates to us in an untimely manner. Third parties may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements, such as good laboratory practice or good clinical practice, or our stated protocols and any subsequent data generated may be deemed unacceptable. We rely on our collaboration partners and other third parties to manage, analyze and transmit clinical data, and those partners and third parties may not carry out the performance of their duties with the required degree of care or skill to ensure valid and scientifically reliable work products. The early termination of any of our clinical trial arrangements, the failure of third parties to comply with the regulations and requirements governing clinical trials, the failure of third parties to properly conduct our clinical trials, or erroneously reported data could hinder or delay the development, approval and commercialization of our drug candidates and would adversely affect our business, results of operations and financial condition. Our future depends on the proper management of our current and future business operations and their associated expenses. Our business strategy requires us to manage our business to provide for the continued development of our proprietary and partnered drug candidates. Our strategy also calls for us to manage the capital necessary to fund key programs through value-enhancing data and other milestones. If we are unable to manage effectively our current operations, our business, financial condition and results of operations may be adversely affected. If we are unable to effectively manage our expenses, we may find it necessary to reduce our personnel-related costs through reductions in our workforce, which could harm our operations, employee morale and impair our ability to retain and recruit talent. Furthermore, if adequate funds are not available, we may be required to obtain funds through arrangements with partners or other sources that may require us to relinquish rights to certain of our technologies, products or future economic rights that we would not otherwise relinquish or require us to enter into other dilutive financing arrangements on unfavorable terms. 50 Table of Contents Â Because competition for highly qualified technical personnel is intense, we may not be able to attract and retain the personnel we need to support our operations and growth. We must attract and retain experts in the areas of research, development (including clinical testing), manufacturing, regulatory and finance, and may need to attract and retain commercial, marketing and distribution experts and develop additional expertise in our existing personnel. We face intense competition from other biopharmaceutical companies, research and academic institutions and other organizations for qualified personnel. Many of the organizations with which we compete for qualified personnel have greater resources than we have. Because competition for skilled personnel in our industry is intense, companies such as ours sometimes experience high attrition rates with regard to their skilled employees. Further, in making employment decisions, job candidates often consider the value of the stock awards they are to receive in connection with their employment. Our equity incentive plan and employee benefit plans may not be effective in motivating or retaining our employees or attracting new employees, and significant volatility in the price of our stock may adversely affect our ability to attract or retain qualified personnel. Furthermore, as a result of our 2022 and 2023 Restructuring Plans, our employees may experience distractions or decreases in employee morale and we may experience increased levels of employee attrition and turnover, which would adversely affect our business. If we fail to attract new personnel or to retain and motivate our current personnel, our business and future growth prospects could be severely harmed. We are dependent on our management team and key technical personnel, and the loss of any key manager or employee may impair our ability to develop our products effectively and may harm our business, operating results and financial condition. Our success largely depends on the continued services of our executive officers and other key personnel. The loss of one or more members of our management team or other key employees could seriously harm our business, operating results and financial condition. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are also dependent on the continued services of our technical personnel because of the highly technical nature of our products and the regulatory approval process. Because our executive officers and key employees are not obligated to provide us with continued services, they could terminate their employment with us at any time without penalty. We do not have any post-employment noncompetition agreements with any of our employees and do not maintain key person life insurance policies on any of our executive officers or key employees. Inflation has increased our operating costs and could negatively impact our operations. Increased price levels resulting from inflation have resulted in increased operating costs. In addition, the United States Federal Reserve has raised and held interest rates at higher levels than in the past decade in response to concerns about inflation. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. Our business could be adversely affected by the effects of future health epidemics. Our business could be adversely affected, directly or indirectly, by health epidemics in regions where we have concentrations of clinical trial sites or other business operations, including both our own manufacturing operations as well as the manufacturing operations of third parties upon whom we rely. Health epidemics, such as the COVID-19 pandemic and recent outbreak of respiratory syncytial virus (RSV) in the U.S., can negatively affect our clinical trials and those run by our collaborators or other third parties through delays in investigator recruitment, clinical site initiation, patient screening, or patient enrollment. In addition, health epidemics may cause disruptions in our supply chain or shortages in raw materials and equipment, which would affect our ability to manufacture our products and to supply drug candidates for clinical trials. If the health epidemic is sufficiently severe and widespread, may require us to change the way in which can conduct our business, which may negatively result in unexpected expenses, decreased employee productivity and availability and employee work culture. Further, a severe and widespread epidemic may have a broad impact on global financial markets and could reduce our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from a health epidemic could materially affect our business and the value of our common stock. 51 Table of Contents Â The ultimate effects of health epidemics is uncertain and subject to change and these effects could have a negative impact on our clinical trial timelines, operations, financial condition and prospects. Risks Related to Intellectual Property, Litigation and Regulatory Concerns If we or our partners do not obtain regulatory approval for our drug candidates on a timely basis, or at all, or if the terms of any approval impose significant restrictions or limitations on use, our business, results of operations and financial condition will be negatively affected. We or our partners may not obtain regulatory approval for drug candidates on a timely basis, or at all, or the terms of any approval (which in some countries includes pricing approval) may impose significant restrictions or limitations on use. Drug candidates must undergo rigorous animal and human testing and an extensive review process for safety and efficacy by the FDA and

equivalent foreign regulatory authorities. The time required for obtaining regulatory decisions is uncertain and difficult to predict. The FDA and other U.S. and foreign regulatory authorities have substantial discretion, at any phase of development, to terminate clinical studies, require additional clinical development or other testing, delay or withhold registration and marketing approval and mandate product withdrawals, including recalls. Further, regulatory authorities have the discretion to analyze data using their own methodologies that may differ from those used by us or our partners, which could lead such authorities to arrive at different conclusions regarding the safety or efficacy of a drug candidate. In addition, undesirable side effects caused by our drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restricted label or the delay or denial of regulatory approval by regulatory authorities. Even if we or our partners receive regulatory approval of a product, the approval may limit the indicated uses for which the drug may be marketed. Our and our partnered drugs that have obtained regulatory approval, and the manufacturing processes for these products, are subject to continued review and periodic inspections by the FDA and other regulatory authorities. Discovery from such review and inspection of previously unknown problems may result in restrictions on marketed products or on us, including withdrawal or recall of such products from the market, suspension of related manufacturing operations or a more restricted label. The failure to obtain timely regulatory approval of drug candidates, any product marketing limitations or a product withdrawal would negatively impact our business, results of operations and financial condition. We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition. We currently derive, and expect to derive in the foreseeable future, substantially all of our revenue from collaboration agreements with biotechnology and pharmaceutical companies. These collaboration agreements contain complex commercial terms, including: â€¢clinical development and commercialization obligations that are based on certain commercial reasonableness performance standards that can often be difficult to enforce if disputes arise as to adequacy of our partnerâ€™s performance; â€¢research and development performance and reimbursement obligations for our personnel and other resources allocated to partnered drug candidate development programs; â€¢clinical and commercial manufacturing agreements, some of which are priced on an actual cost basis for products supplied by us to our partners with complicated cost allocation formulas and methodologies; â€¢intellectual property ownership allocation between us and our partners for improvements and new inventions developed during the course of the collaboration; â€¢royalties on drug sales based on a number of complex variables, including net sales calculations, geography, scope of patent claim coverage, patent life, generic competitors, bundled pricing and other factors; and 52 Table of Contents Â â€¢indemnity obligations for intellectual property infringement, product liability and certain other claims. We are a party to numerous significant collaboration agreements and other strategic transaction agreements (e.g. financings and asset divestitures) that contain complex representations and warranties, covenants and indemnification obligations. If we are found to have materially breached such agreements, we could be subject to substantial liabilities, which would harm our financial condition. From time to time, we are involved in litigation matters involving the interpretation and application of complex terms and conditions of our agreements. One or more disputes may arise or escalate in the future regarding our collaboration agreements, transaction documents, or third-party license agreements that may ultimately result in costly litigation and unfavorable interpretation of contract terms, which would have a material adverse effect on our business, financial condition and results of operations. We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commercially reasonable basis, if at all. Numerous pending and issued U.S. and foreign patent rights and other proprietary rights owned by third parties relate to pharmaceutical compositions, methods of preparation and manufacturing, and methods of use and administration. We cannot predict with any certainty which, if any, patent rights will be considered relevant to our or our collaboration partnersâ€™ technology or drug candidates by authorities in the various jurisdictions where such rights exist, nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties. In certain cases, we have existing licenses or cross-licenses with third parties; however, the sufficiency of the scope and adequacy of these licenses is very uncertain in view of the long development and commercialization cycles for biotechnology and pharmaceutical products. There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable terms, if at all, or that we could develop or otherwise obtain alternate technology to avoid a need to secure a license. If we are required to enter into a license with a third party, our potential economic benefit for the products subject to the license will be diminished. If a license is not available on commercially reasonable terms or at all, we may be prevented from developing and commercializing the drug, which could significantly harm our business, results of operations, and financial condition. If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection. The patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve complex legal and factual issues. We own more than 225 U.S. and 1,000 foreign patents and have a number of pending patent applications that cover various aspects of our technologies. There can be no assurance that patents that have issued will be held valid and enforceable in a court of law. Even for patents that are held valid and enforceable, the legal process associated with obtaining such a judgment is time consuming and costly. Additionally, issued patents can be subject to opposition, inter partes review, re-examinations or other proceedings that can result in the revocation of the patent or maintenance of the patent in amended form (and potentially in a form that renders the patent without commercially relevant and/or broad coverage). Further, our competitors may be able to circumvent and otherwise design around our patents. Even if a patent is issued and enforceable, because development and commercialization of pharmaceutical products can be subject to substantial delays, patents may expire prior to the commercialization of the drug. Moreover, even if a patent encompassing a drug has not expired prior to the drugâ€™s commercialization, the patent may only provide a short period of protection following the commercialization of the covered product. In addition, our patents may be subject to post grant proceedings, such as inter partes review and re-examinations, before the U.S. Patent and Trademark Office (or equivalent proceedings in other jurisdictions), which could result in a loss of the patent and/or substantial cost to us. We have filed patent applications, and plan to file additional patent applications, covering various aspects of our PEGylation and advanced polymer conjugate technologies and our drug candidates. There can be no assurance that the patent applications for which we apply will actually issue as patents, or do so with commercially relevant and/or broad coverage. The coverage claimed in a patent application can be significantly reduced before the patent is issued. The scope of our claim coverage can be critical to our ability to enter into licensing transactions with third parties and our right to receive royalties from our 53 Table of Contents Â collaboration partnerships. Since publication of discoveries in scientific or patent literature often lags behind the date of such discoveries, we cannot be certain that we were the first inventor of inventions covered by our patents or patent applications. In addition, there is no guarantee that we will be the first to file a patent application directed to an invention. An adverse outcome in any judicial proceeding involving intellectual property, including patents, could subject us to significant liabilities to third parties, require disputed rights to be licensed from or to third parties or require us to cease using the technology in dispute. In those instances where we seek an intellectual property license from another, we may not be able to obtain the license on a commercially reasonable basis, if at all, thereby raising concerns on our ability to freely commercialize our technologies or products. We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition. We rely on trade secret protection and other unpatented proprietary rights for our confidential and proprietary information. No assurance can be given that others will not independently develop substantially equivalent confidential and proprietary information or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our trade secrets. In addition, unpatented proprietary rights, including trade secrets and know-how, can be difficult to protect and may lose their value if they are independently developed by a third party or if their secrecy is lost. Any loss of trade secret protection or other unpatented proprietary rights could harm our business, results of operations and financial condition. If product liability lawsuits are brought against us, we may incur substantial liabilities. The manufacture, clinical testing, marketing and sale of medical products involve inherent product liability risks. If product liability costs exceed our product liability insurance coverage (or if we cannot secure product liability insurance), we may incur substantial liabilities that could have a severe negative impact on our financial position. Whether or not we are ultimately successful in any product liability litigation, such litigation would consume substantial amounts of our financial and managerial resources and might result in adverse publicity, all of which would impair our business. Additionally, we may not be able to maintain our clinical trial insurance or product liability insurance at an acceptable cost, if at all, and this insurance may not provide adequate coverage against potential claims or losses. If we or current or future collaborators or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions and civil or criminal penalties. Although we do not currently have any products on the market, once we begin commercializing our drug candidates, if approved, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal and state governments of the jurisdictions in which we conduct our business. Healthcare providers, physicians and third-party payers play a primary role in the recommendation and prescription of any drug candidates for which we obtain marketing approval. Our current and future arrangements with third-party payers and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our therapeutic candidates for which we obtain marketing approval. For more information, see â€œBusiness â€“ Government Regulation - Other Healthcare Laws and Regulations.â€ Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to penalties, including administrative, civil or criminal penalties, imprisonment, monetary damages, the curtailment or restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely affect financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our managementâ€™s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources. 54 Table of Contents Â Healthcare legislative or regulatory reform measures may have a negative impact on our business and results of operations. The U.S. and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system. The U.S. government, state legislatures and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government- paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Governmental policy can also change the commercial potential of our drug candidates, including efforts to increase patient access to lower-cost generic and biosimilar drugs. Additional changes that may affect our business include those governing enrollment in federal healthcare programs, reimbursement changes, rules regarding prescription drug benefits under the health insurance exchanges and fraud and abuse and enforcement. Continued implementation of the Affordable Care Act and the passage of additional laws and regulations may result in the expansion of new programs such as Medicare payment for performance initiatives, and may impact existing government healthcare programs, such as by improving the physician quality reporting system and feedback program. For more information regarding the risks related to recently enacted and future legislation please see â€œBusiness â€“ Government Regulation â€“ Legislative and Regulatory Landscape.â€ We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: â€¢the demand for our drug candidates, if we obtain regulatory approval; â€¢our ability to set a price that we believe is fair for our approved products; â€¢our ability to generate revenue and achieve or maintain profitability; â€¢the level of taxes that we are required to pay; and â€¢ the availability of capital. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare drugs and services, which could result in reduced demand for our drug candidates or additional pricing pressures. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drugs or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations and prospects. Disruptions to the normal functioning of the FDA and other government agencies could hinder their ability to perform and carry out important roles and activities on which the operation of our business relies, which could negatively impact our business. The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. In the past, average review times at the agency have fluctuated, and this may continue in the future. In addition, government funding of other agencies on which our operations may rely is subject to the political process, which is inherently fluid and unpredictable. In addition, government shutdowns, if prolonged, could significantly impact the ability of government agencies upon which we rely (such as the FDA and SEC) to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Disruptions at the FDA and other agencies may slow the time necessary for new drug candidates to 55 Table of Contents Â be reviewed and/or approved by necessary government agencies, which would adversely affect our business. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to

properly capitalize and continue our operations. We are involved in legal proceedings and may incur substantial litigation costs and liabilities that will adversely affect our business, financial condition and results of operations. From time to time, we are involved in legal proceedings where we or other third parties are enforcing or seeking intellectual property rights, invalidating or limiting patent rights that have already been allowed or issued, or otherwise asserting proprietary rights through one or more potential legal remedies. Third parties have asserted, and may in the future assert, that we or our partners infringe their proprietary rights, such as patents and trade secrets, or have otherwise breached our obligations to them. A third party often bases its assertions on a claim that its patents cover our technology platform or drug candidates or that we have misappropriated its confidential or proprietary information. Similar assertions of infringement could be based on future patents that may issue to third parties. In certain of our agreements with our partners, we are obligated to indemnify and hold harmless our collaboration partners from intellectual property infringement, product liability and certain other claims, which could cause us to incur substantial costs and liability if we are called upon to defend ourselves and our partners against any claims. We are also regularly involved in opposition proceedings at the European Patent Office and in inter partes review and re-examination proceedings at the U.S. Patent and Trademark Office where third parties seek to invalidate or limit the scope of our allowed patent applications or issued patents covering (among other things) our drug candidates and platform technologies. If a third party obtains injunctive or other equitable relief against us or our partners, they could effectively prevent us, or our partners, from developing or commercializing, or deriving revenue from, certain drugs or drug candidates in the U.S. and abroad. Costs associated with litigation, substantial damage claims, indemnification claims or royalties paid for licenses from third parties could have a material adverse effect on our business, financial condition and results of operations. From time to time, we may also be involved in legal proceedings other than those related to intellectual property, including securities actions or derivative actions or other complaints. On August 7, 2023, we filed a complaint in the United States District Court for the Northern District of California (the Court) against Lilly alleging, among other claims, breach of contract and breach of implied covenant of good faith and fair dealing (the Complaint), in connection with our collaboration with Lilly. Following the denial of its motion to dismiss the Complaint entirely, Lilly filed an answer that included counterclaims against us alleging breach of specified confidentiality provisions and defamation. The case is proceeding. The cost to us in initiating or defending any litigation or other proceeding, even if resolved in our favor, could be substantial, and litigation would divert our managementâ€™s attention. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts or result in financial implications either in terms of seeking license arrangements or payment of damages or royalties. There is no guarantee that our insurance coverage for damages resulting from any litigation or the settlement would be sufficient and could result in substantial financial risk to the Company. Given the nature of lawsuits and complaints, we cannot reasonably estimate a potential future loss or a range of potential future losses for any of the legal proceedings we may be involved in. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for any litigation matters in our Consolidated Balance Sheets at September 30, 2024. 56 Table of Contents Â If we are found in violation of privacy and data protection laws, we may be required to pay penalties, be subjected to scrutiny by regulators or governmental entities, or be suspended from participation in government healthcare programs, which may adversely affect our business, financial condition and results of operations. Our business is subject to many laws and regulations intended to protect the privacy and data of individuals participating in our clinical trials and our employees, among others. For example, with regard to individuals participating in our clinical trials, these laws and regulations govern the safeguarding the privacy, integrity, availability, security and transmission of individually identifiable health information. In addition to federal laws and regulations in the United States, such as the HIPAA requirements relating to the privacy, security and transmission of individually identifiable health information, many state and foreign laws also govern the privacy and security of health information. These laws often differ from each other in significant ways, thus complicating compliance efforts. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. In the United States, California enacted the California Consumer Privacy Act (CCPA), which took effect on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA has increased our compliance costs and may increase our potential liability. The CCPA has prompted a number of proposals for new federal and state privacy legislation. If passed, these proposals could increase our potential liability, increase our compliance costs and adversely affect our business. The European Regulation 2016/679, known as the General Data Protection Regulation (GDPR), and the implementing legislation of EU Member States, which became effective on May 25, 2018, apply to the collection and processing of personal data, including health-related information, by companies located in the EU, or in certain circumstances, by companies located outside of the EU and processing personal information of individuals located in the EU. The GDPR is wide-ranging in scope and imposes strict obligations on the ability to process personal data, including health-related information, in particular in relation to their collection, use, disclosure and transfer. These include several requirements relating to, for example, (i) obtaining, in some situations, the consent of the individuals to whom the personal data relates, (ii) the information provided to the individuals about how their personal information is used, and (iii) ensuring the security and confidentiality of the personal data. The GDPR prohibits the transfer of personal data to countries outside of the European Economic Area (EEA), such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Potential pecuniary fines for noncompliant companies may be up to the greater of â‚¬20 million or 4% of annual global revenue. To the extent that we are found liable for the inappropriate collection, storage, use or disclosure of protected information of individuals (such as employees and/or clinical patients protected by any privacy or data protection law), we could be subject to reputational harm, monetary fines (such as those imposed by the GDPR and CCPA), civil suits, civil penalties or criminal sanctions and requirements to disclose the breach, and the development of our drug candidates could be delayed. In addition, we continue to be subject to new and evolving data protection laws and regulations from a variety of jurisdictions, and there is a risk that our systems and processes for managing and protecting data may be found to be inadequate, which could materially adversely affect our business, financial condition and results of operations. Our operations may involve hazardous materials and are subject to environmental, health, and safety laws and regulations. Compliance with these laws and regulations is costly, and we may incur substantial liability arising from our activities involving the use of hazardous materials. As a research-based biopharmaceutical company with significant research and development and manufacturing operations, we are subject to extensive environmental, health, and safety laws and regulations, including those governing the use of hazardous materials. Our research and development and manufacturing activities involve the controlled use of chemicals, radioactive compounds, and other hazardous materials. The cost of compliance with environmental, health, and safety regulations (including, but not limited to, the handling and disposal of both our hazardous and non-hazardous waste) is substantial. If an accident involving these materials or an environmental discharge were to occur, we could be held liable for any resulting damages, or face regulatory actions, which could exceed our resources or insurance coverage. 57 Table of Contents Â Risk related to Investment and Securities The price of our common stock has, and may continue to fluctuate significantly, which could result in substantial losses for investors and securities class action and shareholder derivative litigation. Our stock price is volatile. During the three months ended September 30, 2024, based on closing prices on the NASDAQ Capital Market, the closing price of our common stock ranged from $1.11 to $1.48 per share. In response to volatility in the price of our common stock in the past, plaintiffsâ€™ securities litigation firms have sought information from us and/or shareholders as part of their investigation into alleged securities violations and breaches of duties (among other corporate misconduct allegations). Following their investigations, plaintiffsâ€™ securities litigation firms have often initiated legal action, including the filing of class action lawsuits, derivative lawsuits, and other forms of redress. We expect our stock price to remain volatile and we continue to expect the initiation of legal actions by plaintiffsâ€™ securities litigation firms following share price fluctuations. A variety of factors may have a significant effect on the market price of our common stock, including the risks described in this section titled â€œRisk Factorsâ€ and the following: â€¢announcement of our 2022 Restructuring Plan and 2023 Restructuring Plan; â€¢announcements of data from, or material developments in, our clinical studies and those of our collaboration partners, including data regarding efficacy and safety, delays in clinical development, regulatory approval or commercial launch â€“ in particular, the results from clinical studies of bempegaldesleukin and rezpegaldesleukin have had a significant impact on our stock price; â€¢the timing of outcomes from our clinical trials which can be difficult to predict particularly for clinical studies that have event-driven end points such as progression-free survival and overall survival; â€¢announcements by collaboration partners as to their plans or expectations related to drug candidates and approved biologics in which we have a substantial economic interest; â€¢announcements regarding terminations or disputes under our collaboration agreements; â€¢fluctuations in our results of operations; â€¢developments in patent or other proprietary rights, including intellectual property litigation or entering into intellectual property license agreements and the costs associated with those arrangements; â€¢announcements of technological innovations or new therapeutic products that may compete with our approved partnered products or products under development; â€¢announcements of changes in governmental regulation affecting us or our competitors; â€¢litigation brought against us or third parties to whom we have indemnification obligations; â€¢public concern as to the safety of drug formulations developed by us or others; â€¢our financing needs and activities; and â€¢general economic, industry and market conditions, including the impacts of rising inflation and interest rates and global geopolitical tensions. At times, our stock price has been volatile even in the absence of significant news or developments. The stock prices of biotechnology companies and securities markets generally have been subject to dramatic price swings in recent years. In addition, as a result of our lower stock price, we are no longer a well-known seasoned issuer, which otherwise would allow us to, among other things, file automatically effective shelf registration statements. As a result, any attempt to access the public capital markets will be more expensive and subject to delays. Additionally, if our common stock does not maintain a closing bid price of $1.00 58 Table of Contents Â per share in order to comply with the continued listing standards of the Nasdaq Capital Market, our common stock may become delisted, which could adversely affect our stock price, the flexibility of our investors to sell our common stock in the secondary market, and our ability to raise capital. We have implemented certain anti-takeover measures, which make it more difficult to acquire us, even though such acquisitions may be beneficial to our stockholders. Provisions of our certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even though such acquisitions may be beneficial to our stockholders. These anti-takeover provisions include: â€¢establishment of a classified board of directors such that not all members of the board may be elected at one time; â€¢lack of a provision for cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates; â€¢the ability of our board to authorize the issuance of â€œblank checkâ€ preferred stock to increase the number of outstanding shares and thwart a takeover attempt; â€¢prohibition on stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of stockholders; â€¢establishment of advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon by stockholders at stockholder meetings; and â€¢limitations on who may call a special meeting of stockholders. Further, provisions of Delaware law relating to business combinations with interested stockholders may discourage, delay or prevent a third party from acquiring us. These provisions may also discourage, delay or prevent a third party from acquiring a large portion of our securities or initiating a tender offer or proxy contest, even if our stockholders might receive a premium for their shares in the acquisition over the then-current market prices. We also have a change of control severance benefit plan, which provides for certain cash severance, stock award acceleration and other benefits in the event our employees are terminated (or, in some cases, resign for specified reasons) following an acquisition. This severance plan could discourage a third party from acquiring us. General Risk Factors We significantly rely on information technology systems and infrastructure, and any failure, inadequacy, damage, interruption, compromise or breach, or security lapse of that technology within our internal computer systems and infrastructure, or those of our partners, vendors, CROs, CMOs or other contractors or consultants, may result in a material disruption of our development programs and our operations and financial condition. As part of our business, we collect, store and transmit large amounts of confidential information, proprietary or other sensitive information, including intellectual property and personal data. Despite the implementation of security measures, our internal computer systems and infrastructure or those of our partners, vendors, contract research organizations (CROs), contract manufacturing organizations (CMOs) and other contractors and consultants are vulnerable to loss, damage, compromise, interruption, denial-of-service, unauthorized access, or misappropriation. Cyber incidents have been increasing in frequency, levels of persistence, sophistication and intensity, and can include unauthorized activity by our employees, contractors and other third parties, as well as by third parties who use cyberattack techniques involving malware, hacking and phishing, social engineering and business email compromises, among others. Additionally, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of an increase in the number of employees who adopted a remote working environment during and following the COVID-19 pandemic, which may be less secure and more susceptible to hacking attacks or other security compromises or breaches. Our information technology systems and infrastructure, and those of our partners, 59 Table of Contents Â vendors, CROs, CMOs or other contractors or consultants are also vulnerable to natural disasters, terrorism, war, telecommunication and electrical failures and the types of interruption, compromise and damage described above. Any such compromise or disruption, no matter the origin, may cause an interruption of our operations. For instance, the loss or misappropriation of preclinical data or data from any clinical trial involving our drug candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. In addition, the loss, corruption or unauthorized disclosure or misuse of our trade secrets, personal data or other confidential and/or proprietary or sensitive information could compromise the commercial viability of one or more of our programs, which would negatively affect our business. Also, the costs to us to investigate, mitigate and remediate cybersecurity incidents or compromises and comply with applicable legal obligations, including breach notification obligations to individuals, regulators, partners and others, could be significant and our reputation could be materially damaged. We could also be exposed to litigation or regulatory

investigations or actions by state and federal governmental authorities and non-U.S. authorities, including fines, penalties, and other legal and financial exposure and liabilities. Changes in tax law could adversely affect our business and financial condition. Our business is subject to numerous international, federal, state, and other governmental laws, rules, and regulations that may adversely affect our operating results, including, taxation and tax policy changes, tax rate changes, new tax laws, or revised tax law interpretations, which individually or in combination may cause our effective tax rate to increase. In the U.S., the rules dealing with federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. Global economic and political conditions may negatively affect us and may magnify certain risks that affect our business. Our operations and performance may be affected by global economic and political conditions. For example, our operations and performance (or the operations and performance of our partners and service providers) may be negatively affected by political or civil unrest or military action, terrorist activity, and unstable governments and legal systems. For example, in late February 2022, Russia commenced a military invasion of Ukraine, and the sustained conflict in Ukraine, including the potential effects of sanctions and retaliatory cyber-attacks on the world economy and markets, has contributed to increased market volatility and uncertainty. In particular, sanctions imposed by the U.S., EU and other countries in response to the conflict between Russia and Ukraine and the potential response to such sanctions may have an adverse impact on our business, including our clinical trials, the financial markets and the global economy. In addition, in October 2023, conflicts arose in Israel and Gaza following terrorist attacks in Israel. As the conflicts between Ukraine and Russia and escalating conflicts in the Middle East continue, further sanctions, retaliatory attacks, market volatility and uncertainty may occur, any of which could have a material adverse effect on our business. As a result of global economic and political conditions, some third-party payers may delay or be unable to satisfy their reimbursement obligations. Job losses or other economic hardships may also affect patientsâ€™ ability to afford healthcare as a result of increased co-pay or deductible obligations, greater cost sensitivity to existing co-pay or deductible obligations, lost healthcare insurance coverage or for other reasons. Our ability to conduct clinical trials in regions experiencing political or civil unrest could negatively affect clinical trial enrollment or the timely completion of a clinical trial. We believe the aforementioned economic conditions have led and could continue to lead to reduced demand for our and our collaboration partnersâ€™ drug products, which could have a material adverse effect on our product sales, business and results of operations Further, with rising international trade tensions or sanctions, our business may be adversely affected following new or increased tariffs that result in increased global clinical trial costs as a result of international transportation of clinical drug supplies, as well as the costs of materials and products imported into the U.S. Tariffs, trade restrictions or sanctions imposed by the U.S. or other countries could increase the prices of our and our collaboration partnersâ€™ drug products, affect our and our collaboration partnersâ€™ ability to commercialize such drug products, or create adverse tax consequences in the U.S. or other 60 Table of Contents Â countries. As a result, changes in international trade policy, changes in trade agreements and the imposition of tariffs or sanctions by the U.S. or other countries could materially adversely affect our results of operations and financial condition. Given that certain election results from the U.S. elections in November 2024 have not yet been determined, the future geopolitical landscape remains uncertain. Any resulting changes in international trade relations, legislation and regulations, including those related to taxation and importation, or economic and monetary policies, or heightened diplomatic tensions or political and civil unrest, among other potential impacts, could adversely impact the global economy and our operating results. Our business could be negatively impacted by corporate citizenship and sustainability matters. There is an increased focus from certain investors, employees, and other stakeholders concerning corporate citizenship and sustainability matters, which include environmental concerns and social investments. We could fail to meet, or be perceived to fail to meet, the expectations of these certain investors, employees and other stakeholders concerning corporate citizenship and sustainability matters, thereby resulting in a negative impact to our business. If natural disasters or other catastrophic events strike, our business may be harmed. Our corporate headquarters, where a substantial number of our research and development employees are based, are located in the San Francisco Bay Area, a region known for seismic activity and a potential terrorist target. In addition, we own facilities for the manufacture of products using our advanced polymer conjugate technologies in Huntsville, Alabama. There are no backup facilities for our manufacturing operations located in Huntsville, Alabama. In the event of an earthquake or other natural disaster, catastrophic event caused by climate change, political instability, civil unrest, or terrorist event in any of these locations, our ability to manufacture and supply materials for drug candidates in development and our ability to meet our manufacturing obligations to our customers would be significantly disrupted and our business, results of operations and financial condition would be harmed. Our collaboration partners and important vendors and suppliers to us or our collaboration partners may also be subject to catastrophic events, such as earthquakes, floods, hurricanes, tornadoes and pandemics any of which could harm our business (including, for example, by disrupting supply chains important to the success of our business), results of operations and financial condition. We have not undertaken a systematic analysis of the potential consequences to our business, results of operations and financial condition from a major earthquake or other catastrophic event, such as a fire, sustained loss of power, terrorist activity or other disaster, and do not have a recovery plan for such disasters. In addition, our insurance coverage may not be sufficient to compensate us for actual losses from any interruption of our business that may occur. 61 Table of Contents Â Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities None, including no purchases of any class of our equity securities by us or any affiliate pursuant to any publicly announced repurchase plan in the three months ended September 30, 2024. Item 3. Defaults Upon Senior Securities None. Item 4. Mine Safety Disclosures Not applicable. Item 5. Other Information (c) Insider Trading Arrangements and Policies Â In the fiscal quarter ended September 30, 2024, no director or officer adopted, modified, or terminated a "Rule 10b5-1 trading arrangement"; or a "non-Rule 10b5-1 trading arrangement" as each term is defined in Item 408(a) of Regulation S-KÂ Â 62 Table of Contents Â Item 6. Exhibits Except as so indicated in Exhibit 32.1, the following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q. Â Exhibit Number Â Description of Documents Â Â Â Â Â Â Â 3.1(1) Â Certificate of Incorporation of Inhale Therapeutic Systems (Delaware), Inc. Â Â Â Â Â Â Â 3.2(2) Â Certificate of Amendment of the Amended Certificate of Incorporation of Inhale Therapeutic Systems, Inc. Â Â Â Â Â Â Â 3.3(3) Â Certificate of Ownership and Merger of Nektar Therapeutics. Â Â Â Â Â Â Â 3.4(4) Â Certificate of Ownership and Merger of Nektar Therapeutics AL, Corporation with and into Nektar Therapeutics. Â Â Â Â Â Â Â 3.5(5) Â Amended and Restated Bylaws of Nektar Therapeutics. Â Â Â Â Â Â Â 31.1(6) Â Certification of Nektar Therapeuticsâ€™ principal executive officer required by Rule 13a-14(a) or Rule 15d-14(a). Â Â Â Â Â Â Â 31.2(6) Â Certification of Nektar Therapeuticsâ€™ principal financial officer required by Rule 13a-14(a) or Rule 15d-14(a). Â Â Â Â Â Â Â 32.1* Â Section 1350 Certifications. Â Â Â Â Â Â Â 101.SCH(6) Â Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents. Â Â Â Â Â Â Â 101.INS(6) Â Inline XBRL Instance Document-the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document. Â Â Â Â Â Â Â 104(6) Â Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101). Â Â Â 1.Incorporated by reference to Exhibit 3.1 to Nektar Therapeuticsâ€™ Quarterly Report on Form 10-Q, for the quarter ended June 30, 1998. 2.Incorporated by reference to Exhibit 3.3 to Nektar Therapeuticsâ€™ Quarterly Report on Form 10-Q, for the quarter ended June 30, 2000. 3.Incorporated by reference to Exhibit 3.1 to Nektar Therapeuticsâ€™ Current Report on Form 8-K, filed with the SEC on January 23, 2003. 4.Incorporated by reference to Exhibit 3.6 to Nektar Therapeuticsâ€™ Annual Report on Form 10-K, for the year ended December 31, 2009. 5.Incorporated by reference to Exhibit 3.1 to Nektar Therapeuticsâ€™ Current Report on Form 8-K, filed with the SEC on December 21, 2020. 6.Filed herewith. Â * Exhibit 32.1 is being furnished and shall not be deemed to be â€œfiledâ€ for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by 63 Table of Contents Â reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as otherwise stated in such filing. Â ++ Management contract or compensatory plan or arrangement. 64 Table of Contents Â SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Â By: /s/ SANDRA GARDINER Â Â Sandra GardinerInterim Chief Financial Officer(Principal Financial Officer) Â Â Date: November 7, 2024 Â 65 EX-31.1 2 nktr-ex31_1.htm EX-31.1 EX-31.1 Â Exhibit 31.1 CERTIFICATIONS I, Howard W. Robin, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2024 of Nektar Therapeutics; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting. 5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: November 7, 2024 Â /s/ HOWARD W. ROBIN Â Â Howard W. RobinChief Executive Officer, President and Director Â Â EX-31.2 3 nktr-ex31_2.htm EX-31.2 EX-31.2 Â Exhibit 31.2 CERTIFICATIONS I, Sandra Gardiner, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2024 of Nektar Therapeutics; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting. 5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: November 7, 2024 Â /s/ SANDRA GARDINER Â Â Sandra GardinerInterim Chief Financial Officer(Principal Financial Officer) Â Â EX-32.1 4 nktr-ex32_1.htm EX-32.1 EX-32.1 Â Exhibit 32.1 SECTION 1350 CERTIFICATIONS* Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Â§1350), Howard W. Robin, Chief Executive Officer, President and Director of Nektar Therapeutics (the â€œCompanyâ€), and Sandra Gardiner, Interim Chief Financial Officer (Principal Financial Officer) of the Company, each hereby certifies that, to the best of his or her knowledge: 1.The Companyâ€™s Quarterly Report on Form 10-Q for the three months ended September 30, 2024, to which this Certification is attached as Exhibit 32.1 (the

â€œPeriodic Reportâ€), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and 2.The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: November 7, 2024 Â Â Â Â Â Â /s/ HOWARD W. ROBIN Â /s/ SANDRA GARDINER Howard W. RobinChief Executive Officer, President and Director Â Sandra GardinerInterim Chief Financial Officer (Principal Financial Officer) _____ * This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. Â EX-101.SCH 5 nktr-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Cash and Investments in Marketable Securities link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Condensed Consolidated Financial Statement Details link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Pre-Funded Warrant link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - License and Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Restructuring, Impairment and Costs of Terminated Program link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Impairment of Goodwill link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Cash and Investments in Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Condensed Consolidated Financial Statement Details (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - License and Collaboration Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Restructuring, Impairment and Costs of Terminated Program (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Organization and Summary of Significant Accounting Policies - Weighted Average Outstanding Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Condensed Consolidated Financial Statement Details - Assets Held for Sale (Details) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Condensed Consolidated Financial Statement Details - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Liability Related to Sale of Potential Future Royalties (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Pre-Funded Warrant - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - License and Collaboration Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - License and Collaboration Agreements - Fair Value of Derivative Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Restructuring, Impairment and Costs of Terminated Program - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Restructuring, Impairment and Costs of Terminated Program - Summary of Restructuring Costs (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Restructuring, Impairment and Costs of Terminated Program - Restructuring Reserve Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Restructuring, Impairment and Costs of Terminated Program - Sublease Information (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Impairement of Goodwill (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Subsequent Event - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink Statement [Line Items] Statement [Line Items] Accounts receivable Increase (Decrease) in Accounts Receivable Plan Name [Domain] Plan Name [Domain] Building and leasehold improvements Building and Leasehold Improvements [Member] Building and Leasehold Improvements Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents Cash, Cash Equivalents and Investments [Table Text Block] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Contract termination and other restructuring costs Loss on Contract Termination Expense recognized during the period Restructuring, impairment, and costs of terminated program Restructuring Charges Restructuring Charges, Total Operating costs and expenses: Costs and Expenses [Abstract] Revenue: Revenues [Abstract] Effective date of warrant. Effective Date of Warrant Effective date of warrant Cash and Investments in Marketable Securities Cash, Cash Equivalents, and Marketable Securities [Text Block] Amortization of premiums (discounts), net and other non-cash transactions Other Noncash Income (Expense) Other Noncash Income (Expense), Total Unrealized gain (loss) on available-for-sale securities Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Reclassification adjustments to income Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Foreign currency translation adjustments OCI, before Reclassifications, Net of Tax, Attributable to Parent Adjustments Ownership interest received Percentage Of Ownership Received in Asset Acquisition Percentage of ownership received in asset acquisition. Milestone [Domain] Milestone [Domain] Milestone Level 2 Fair Value, Inputs, Level 2 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Asset Acquisition By Ampersand Capital Partners Asset Acquisition By Ampersand Capital Partners [Member] Asset acquisition by ampersand capital partners. Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Schedule of Restructuring and Related Costs [Table] Restructuring Cost [Table] Product and Service [Axis] Product and Service [Axis] Pre-Funded Warrant Pre Funded Warrant [Member] Pre Funded Warrant. Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Repurchase of common stock from Bristol-Myers Squibb (in shares) Sale of stock shares repurchased Stock Repurchased During Period, Shares Asset Acquisition by Nova Asset Acquisition by Nova [Member] Asset Acquisition by Nova [Member] Schedule of Goodwill [Table] Goodwill [Table] Assets Held for Sale Disclosure of Long-Lived Assets Held-for-Sale [Table Text Block] Eli Lilly Eli Lilly [Member] Eli Lilly. Class of Warrant or Right [Axis] Sale of Stock [Domain] Sale of Stock [Domain] Reimbursement of expenses Reimbursement Of Expenses Reimbursement of expenses. Work-in-process Inventory, Work in Process, Net of Reserves Received upfront and milestone payment Upfront And Milestone Payments Received Under License Agreement Upfront and milestone payments received under license agreement. Inventory Inventory, Policy [Policy Text Block] Entity Central Index Key Entity Central Index Key Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Common stock shares, issued (in shares) Common Stock, Shares, Issued Percentage of sharing development costs Percentage Of Sharing In Development Costs Percentage of sharing in development costs. Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Income Statement [Abstract] Income Statement [Abstract] Liability for litigation Estimated Litigation Liability Entity Address, State or Province Entity Address, State or Province Organization and Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Bristol Myers Squibb Company Bristol Myers Squibb Company [Member] Bristol-Myers Squibb Company. Loss before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Contract termination and other costs included in accrued expenses Contract Termination and Other Costs Included in Accrued Expenses Contract termination and other costs included in accrued expenses. Accrued expenses Increase (Decrease) in Other Accrued Liabilities Sublease of laboratory and office space. Sublease of Laboratory and Office Space Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] [Default] Liability Class [Axis] Liability Class [Axis] Treasury Stock, Common, Shares Treasury Stock, Common, Shares Cover page. Cover [Abstract] Subsequent Event [Line Items] Basic net loss per share (in dollars per share) Earnings Per Share, Basic Earnings Per Share, Basic, Total Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Payable For Newdrug Investigle Milestone Payable for newdrug investigle milestone. Estimated Fair Value at Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] Asset Acquisition [Axis] Other Partner Other Partner [Member] Other. Total stock-based compensation Stock-based compensation Share-Based Payment Arrangement, Expense Accumulated deficit Retained Earnings (Accumulated Deficit) Retained Earnings (Accumulated Deficit), Total Plan Name [Axis] Plan Name [Axis] Current assets: Assets, Current [Abstract] Treasury Stock Treasury Stock [Policy Text Block] Treasury stock policy. Pre-Funded Warrant Pre-Funded Warrant [Text Block] Pre-funded warrant. Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Operating lease, measurement input Operating Lease, Measurement Input Operating Lease, Measurement Input 2020 Purchase and Sale Agreement Purchase and Sale Agreement 2020 [Member] Purchase and Sale Agreement 2020 Product and Service [Domain] Product and Service [Domain] Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Type of Restructuring [Domain] Type of Restructuring [Domain] Restructuring and Related Activities [Abstract] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Laboratory equipment Laboratory Equipment [Member] Laboratory Equipment Measurement Input Type [Domain] Measurement Input Type [Domain] Measurement Input, Market Participant Subtenant Borrowing Rate Measurement Input, Market Participant Subtenant Borrowing Rate [Member] Measurement Input, Market Participant Subtenant Borrowing Rate Property plant and equipment classified to assets held for sale. Property Plant And Equipment Classified To Assets Held For Sale Member Property Plant And Equipment Classified To Assets Held For Sale Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Counterparty Name Counterparty Name [Axis] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Foreign currency translation Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Biolojic Design Member Biolojic Design Company [Member] Biolojic design company. Number of warrants issued to be purchase common shares Class of Warrant or Right, Number of Securities Called by Warrants or Rights Entity [Domain] Entity [Domain] Equity Components Equity Components [Axis] Entity Address, Address Line One Entity Address, Address Line One Accrued compensation Employee-related Liabilities, Current Employee-related Liabilities, Current, Total Employee Severance Employee Severance [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Subsequent Event Type [Axis] Total non-operating income (expense), net Nonoperating Income (Expense) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Restructuring, Impairment, and Other Activities Disclosure [Text Block] Restructuring, Impairment and Costs of Terminated Program Amendment Flag Amendment Flag Operating lease liabilities, less current portion Operating Lease, Liability, Noncurrent Corporate notes and bonds Corporate Debt Securities [Member] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Finished goods Inventory, Finished Goods, Net of Reserves Capital in excess of par value Additional Paid in Capital, Common Stock Long-term investments Long-term investments Debt Securities, Available-for-Sale, Noncurrent Restructuring Plan [Domain] Restructuring Plan

[Domain] Stock price per share Sale of Stock, Price Per Share Net loss Net loss Research and development Research and Development Expense Research and Development Expense [Member] Manufacturing Facility [Member] Huntsville, Alabama Manufacturing Facility Equity Component Equity Component [Domain] Name of Property [Domain] Name of Property [Domain] Statistical Measurement [Domain] Statistical Measurement [Domain] Organization And Summary Of Significant Accounting Policies [Table] Organization And Summary Of Significant Accounting Policies [Table] Organization and summary of significant accounting policies. General and administrative General and Administrative Expense General and Administrative Expense, Total Sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Proceeds from Sale of Property, Plant, and Equipment, Total Other income (expense), net Other Nonoperating Income (Expense) Other Nonoperating Income (Expense), Total Furniture, fixtures and other Furniture and Fixtures [Member] Treasury Stock Treasury Stock, Common [Member] TCG Crossover Fund II, L.P. TCG Crossover Fund I I, L P [Member] TCG Crossover Fund II, L.P. Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Schedule of Other Current Assets Schedule of Other Current Assets [Table Text Block] Provision for net realizable value of inventory Provision for inventory obsolescence. Provision For Inventory Obsolescence Provision for inventory obsolescence Schedule of Derivative Liabilities at Fair Value Schedule of Derivative Liabilities at Fair Value [Table Text Block] Accounts receivable, credit loss expense (reversal) Accounts Receivable, Credit Loss Expense (Reversal) Contract Termination and Other Costs Contract Termination and Other Costs [Member[Contract Termination and Other Costs [Member[Life sciences lease market. Life Sciences Lease Market [Member] Life Sciences Lease Market Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Severance and benefit expense Severance Costs Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax License and Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Proceeds from the Amendment Proceeds from Amendment related to sales of future royalties, net Proceeds from Amendment related to sales of future royalties, net. Comprehensive loss Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Property, Plant and Equipment Sublease Property, Plant And Equipment [Member] Sublease Property, Plant And Equipment Purchases of investments Payments to Acquire Debt Securities, Available-for-Sale Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Maturities of investments Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Operating leases, net Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities Sublease income, measurement input Sublease Income, Measurement Input Sublease Income, Measurement Input Antidilutive Securities Antidilutive Securities [Axis] Net realizable value of assets Reorganization Value, Net Realizable Value of Asset Dispositions UCB Pharma Manufacturing Agreement UCB Pharma Manufacturing Agreement [Member] UCB Pharma Manufacturing Agreement. Cash Cash Additional impairment charges on remaining long-lived assets Impairment of Remaining Long-Lived Asset, Held-for-Use Impairment of remaining long-lived asset, held-for-use. Entity Interactive Data Current Entity Interactive Data Current Product sales Product [Member] Cost of goods sold Cost of Sales [Member] Non-cash interest expense on liabilities related to the sales of future royalties Non-cash interest expense on liabilities related to the sales of future royalties Non-cash interest expense Non Cash Interest Expense Related To Sale Of Royalties Non-cash interest expense related to sale of royalties. Document Quarterly Report Document Quarterly Report Goodwill [Line Items] Goodwill [Line Items] Consolidated Entities [Axis] Consolidated Entities [Axis] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Statistical Measurement [Axis] Statistical Measurement [Axis] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Cost of goods sold Cost of Goods and Services Sold Cost of Goods and Services Sold, Total Bristol Myers Squibb Collaboration Agreement Bristol Myers Squibb Collaboration Agreement [Member] Bristol Myers Squibb collaboration agreement. Related and Nonrelated Parties [Domain] Nektar's Parent Company [Member] Development Derivative Liability Derivative Financial Instruments, Liabilities [Member] Less: Amounts recorded as amortization for Third St. facility and Mission Bay facility Amortization Amortization, Total Corporate commercial paper Commercial Paper [Member] Effect of foreign exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Third St. Facility Third St. Facility [Member] Third St. Facility Measurement Basis [Axis] Measurement Basis [Axis] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Total assets Assets Restructuring Type [Axis] Restructuring Type [Axis] 2022 Restructuring Plan Two Thousand Twenty Two Restructuring Plan [Member] Two Thousand Twenty Two Restructuring Plan Proceeds from sale of future royalties Proceeds From Sale of Future Royalties Proceeds From Sale of Future Royalties. Upfront and milestone payments received from license agreements Upfront And Milestone Payments Received From License Agreements Upfront and milestone payments received from license agreements. Securities Purchase Agreement Securities Purchase Agreement [Member] Securities Purchase Agreement. Milestone [Axis] Milestone [Axis] Milestone [Axis] Entity Address, City or Town Entity Address, City or Town Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income Equity [Abstract] Success payments (up to) Collaborative Arrangement, Success-Based Payments, Amount Collaborative Arrangement, Success-Based Payments, Amount Aggregate common shares issued to purchase prefunded warrants Aggregate common shares issued to purchase prefunded warrants. Payments during the period Payments during the period Payments for Restructuring Proceeds from sale of assets Proceeds from Sale of Productive Assets Proceeds from Sale of Productive Assets, Total Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Assets held for sale Total assets held for sale Disposal Group, Including Discontinued Operation, Assets, Current Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Aggregate number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Shares issued under equity compensation plans (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, Total Preferred stock, shares designated (in shares) Preferred Stock Share Designated Preferred stock, shares designated. Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Total cash, cash equivalents, and investments in marketable securities Cash and investments in marketable securities Cash Restricted Cash Cash Equivalents And Available For Sale Investments Cash, restricted cash, cash equivalents, and available for sale investments. Current liabilities: Liabilities, Current [Abstract] Committed funding (up to) Collaborative Arrangement, Committed Funding Collaborative Arrangement, Committed Funding Stock Options, RSUs And PSUs Stock Options, RSUs And PSUs [Member] Stock Options, RSUs And PSUs Cash paid for income taxes Income Taxes Paid, Net Income Taxes Paid, Net, Total Document Type Document Type Obligations of U.S. government agencies US Government Agencies Debt Securities [Member] Title of 12(b) Security Title of 12(b) Security Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents, at Carrying Value, Total Property, plant and equipment and operating lease right-of-use assets Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Impairment of Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Fair value at beginning of period Fair value at end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Document Fiscal Period Focus Document Fiscal Period Focus Change in the fair value of development derivative liability Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) Research and development Research and Development Expense Research and Development Expense, Total Asset Class [Domain] Asset Class [Domain] Basis of Presentation and Principles of Consolidation Consolidation, Policy [Policy Text Block] Percentage of sharing in Phase 2 development costs Percentage Of Sharing In Phase Two Development Costs Percentage of sharing in Phase 2 development costs. Accrued clinical trial expenses Accrued Clinical Trial Expenses Current Accrued clinical trial expenses current. 2012 Purchase and Sale Agreement Purchase and Sale Agreement 2012 [Member] Purchase and Sale Agreement 2012 Subsequent Event Type [Domain] Resale of common stock issuable upon exercise of warrant. Resale of Common Stock Issuable Upon Exercise of Warrant Resale of common stock issuable upon exercise of warrant Mission Bay Facility Mission Bay Facility [Member] Mission Bay Facility Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Amortization of transaction costs Liabilities On Sale Of Future Royalties Amortized Transaction Costs Liabilities On Sale Of Future Royalties Amortized Transaction Costs Depreciable property, plant and equipment at cost Depreciable Property Plant And Equipment Gross Depreciable Property, plant and equipment, Gross. Exercise price of warrants Class of Warrant or Right, Exercise Price of Warrants or Rights Financial Instruments [Domain] Financial Instruments [Domain] Sale of Stock [Axis] Sale of Stock [Axis] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Class of Warrant or Right, Date from which Warrants or Rights Exercisable Repurchase of common stock from Bristol-Myers Squibb Payments for Repurchase of Common Stock Impairment of Goodwill Asset Impairment Charges [Text Block] Total revenue Revenue, excluding assessed tax Revenue from Contract with Customer, Excluding Assessed Tax Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Assets Held for Sale Disposal Groups, Including Discontinued Operations [Table Text Block] Potential future additional development and regulatory milestones (up to) Potential Development And Regulatory Milestones Potential development and regulatory milestones. Restructuring Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block] Consolidated Entities [Domain] Consolidated Entities [Domain] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Depreciation, Depletion and Amortization, Nonproduction, Total Other accrued expenses Other Accrued Liabilities, Current Accounts payable Increase (Decrease) in Accounts Payable Increase (Decrease) in Accounts Payable, Total LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Liabilities and Equity [Abstract] Nektar-358 Nektar-358 [Member] Nektar-358 Document Period End Date Document Period End Date Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Nektar 214 Nektar 214 [Member] Nektar 214. Purchase Agreement Share Purchase Agreement [Member] Share purchase agreement. Potentially dilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Reported Value Measurement Reported Value Measurement [Member] Restructuring reserve, ending balance Restructuring reserve, beginning balance Restructuring Reserve Restructuring Reserve, Total Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total Accrued expenses Total accrued expenses Accrued Liabilities, Current Restructuring plan. Restructuring Plan [Member] Restructuring Plan Benefit for income taxes Income Tax Expense (Benefit) Income Tax Expense (Benefit), Total Provision (benefit) for income taxes (Gain) on sale or disposal of property, plant, and equipment (Gain) on sale or disposal of property, plant, and equipment Gain (Loss) on Disposition of Property Plant Equipment Gain (Loss) on Disposition of Property Plant Equipment, Total Trading Symbol Trading Symbol Provision for inventory Provision For Inventory Provision for inventory. Total stockholdersâ€™ equity Beginning balance Ending balance Equity, Attributable to Parent Restructuring, impairment, and costs of terminated program Restructuring, impairment and other costs of terminated program Restructuring Costs and Asset Impairment Charges Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Other long-term liabilities Other Liabilities, Noncurrent Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Cash receipts from SFJ Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] License And Collaboration Agreements [Abstract] License and collaboration agreements. Milestone One Milestone One [Member] Milestone One [Member] Measurement Input Type [Axis] Measurement Input Type [Axis] Deferred income tax expense Deferred Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit), Total Gross Unrealized Losses Gross unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Asset Purchase Agreement Asset Purchase Agreement [Member] Asset purchase agreement. Schedule of Restructuring, Impairment and Other Costs of Terminated Program Restructuring and Related Costs [Table Text Block] Affiliates Affiliated Entity [Member] Use of Estimates Use of Estimates, Policy [Policy Text Block] Number of Milestone Number Of Milestones Number Of Milestones Operating Lease Right-of-Use Assets Sublease Operating Lease Right of Use Assets [Member] Sublease Operating Lease Right of Use Assets Royalties liability discount rate Royalties Liability, Measurement Input Royalties Liability, Measurement Input Inventory, net Disposal Group, Including Discontinued Operation, Inventory, Current Security Exchange Name Security Exchange Name Counterparty Name [Domain] Counterparty Name [Domain] License, collaboration and other revenue License Collaboration And Other Revenue [Member] License collaboration and other revenue. Warrant exercised prior notice period Warrant Exercised Prior Notice Period Warrant exercised prior notice period. Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Legal Entity [Axis] Legal Entity [Axis] Organization And Summary Of Significant Accounting Policies [Line Items] Organization And Summary Of Significant Accounting Policies [Line Items] Organization and summary of significant accounting policies. Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Subsequent event Subsequent Event [Member] Maximum Maximum [Member] Total liabilities and stockholdersâ€™ equity Liabilities and Equity Workforce termination, percentage Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Computer

equipment and computer software Computer Furniture And Other [Member] Furniture computer and other. Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Diluted net loss per share (in dollars per share) Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Total liabilities Liabilities Interest and other non-trade receivables. Interest and Other Non-trade Receivables [Member] Interest and Other Non-trade Receivables Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Total current assets Assets, Current Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Eli Lilly And Company Eli Lilly And Company [Member] Eli Lilly and Company. Prepaid research and development expenses Prepaid Research And Development Expenses [Member] Prepaid Research And Development Expenses Accrued research and development expenses current. Accrued Research And Development Expenses Current Accrued research and development expenses Entity Filer Category Entity Filer Category Asset Acquisition [Domain] Non-operating income (expense): Nonoperating Income (Expense) [Abstract] Current Fiscal Year End Date Current Fiscal Year End Date Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Impairment of other property, plant and equipment Impairment, Long-Lived Asset, Held-for-Use, Other Impairment, Long-Lived Asset, Held-for-Use, Other Related and Nonrelated Parties [Axis] Entity Registrant Name Entity Registrant Name SFJ SFJ Pharmaceuticals [Member] SFJ Pharmaceuticals Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Entity Emerging Growth Company Entity Emerging Growth Company Property, plant and equipment, net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current Money market funds Money Market Funds [Member] Weighted average shares outstanding used in computing basic net loss per share (in shares) Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic, Total Schedule of Liability Related to Sale of Potential Future Royalties Schedule Of Liability Related To Sale Of Potential Future Royalties [Table Text Block] Schedule Of Liability Related To Sale Of Potential Future Royalties Common stock, shares authorized (in shares) Common Stock, Shares Authorized Gross proceeds Proceeds from Issuance of Common Stock Level 1 Fair Value, Inputs, Level 1 [Member] Payment For Development Milestones Payment for development milestones. Proceeds from shares issued under equity compensation plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised Book value in excess of fair value Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Book Value in Excess of Fair Value Property, plant and equipment, and operating lease right of use asset, book value in excess of fair value. Financial Instrument [Axis] Financial Instrument [Axis] Net Loss per Share Earnings Per Share, Policy [Policy Text Block] AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Available-for-sale securities Non-cash royalty revenue related to the sales of future royalties Non-cash royalty revenue related to the sales of future royalties Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member] Non-cash royalty revenue related to sale of future royalties. General and administrative General and Administrative Expense [Member] Total impairment of right-of-use assets and property, plant and equipment Impairment of right-of-use assets and property, plant and equipment Impairment of other property, plant and equipment Impairment, Long-Lived Asset, Held-for-Use Total impairment of right-of-use assets Accrued contract termination costs Accrued Contract Termination Costs, Current Accrued Contract Termination Costs, Current Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-Based Payment Arrangement [Abstract] Long-Lived Asset Impairment Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Shares issued under equity compensation plans Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total Proceeds from issuance of pre-funded warrant Proceeds from Issuance of Warrants Nektar 0165 Nektar 0165 [Member] Nektar 0165. Impairment of goodwill Impairment of goodwill Impairment of goodwill Goodwill, Impairment Loss Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Restructuring Plan [Axis] Restructuring Plan [Axis] Fair Value Debt Securities, Available-for-Sale Debt Securities, Available-for-Sale, Total Raw materials Inventory, Raw Materials, Net of Reserves Stockholdersâ€™ equity: Equity, Attributable to Parent [Abstract] Statement [Table] Statement [Table] Liabilities related to the sales of future royalties, net Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs Liability related to sale of potential future royalties non current net of issuance costs. Schedule of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Subsequent Event [Table] Financing Transactions Financing Transactions [Policy Text Block] Financing transactions policy. Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Contract asset Disposal Group, Including Discontinued Operation, Contract With Customer Asset, Current Disposal Group, Including Discontinued Operation, Contract With Customer Asset, Current. Entity File Number Entity File Number Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Sale of stock consideration received Sale Of Stock Consideration Received Sale of stock consideration received. Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Loss from operations Operating Income (Loss) Shares issued, price per share Shares Issued, Price Per Share Entity Shell Company Entity Shell Company Entity Tax Identification Number Entity Tax Identification Number ASSETS Assets [Abstract] Class of Warrant or Right [Domain] Construction in process Construction in Progress, Gross Entity Current Reporting Status Entity Current Reporting Status Sale of Manufacturing Facility Sale Of Manufacturing Facility [Policy Text Block] Sale of manufacturing facility. Subsequent Events [Abstract] Condensed Consolidated Financial Statement Details Inventory Disclosure [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Restructuring Plans Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block] Certificates of deposit Certificates of Deposit [Member] Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at September 30, 2024 or December 31, 2023, respectively Preferred Stock, Value, Issued Repurchase of common stock from Bristol-Myers Squibb Treasury Stock, Value, Acquired, Cost Method City Area Code City Area Code Total current liabilities Liabilities, Current Change in fair value of development derivative liability Change in fair value of development derivative liability Liabilities, Fair Value Adjustment Inventory, net Inventory, Net Total inventory, net Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Local Phone Number Impairment expense for facilities Impairment charge for right-of-use asset Non-cash impairment charges Total impairment of lease assets Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program Business Exit Costs 2023 Restructuring Plan Two Thousand Twenty Three Restructuring Plan [Member] Two Thousand Twenty Three Restructuring Plan Subsidiary, Sale of Stock [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Shares issued (in shares) Shares, Issued Treasury stock, at cost; 8,285 shares as of September 30, 2024 and none as of December 31, 2023, respectively Treasury stock, at cost; 8,285 shares as of September 30, 2024 and none as of December 31, 2023, respectively Treasury Stock, Value Treasury Stock, Value, Total Proceeds from sale of potential future royalties gross. Proceeds From Sale Of Potential Future Royalties Gross Proceeds from sale of royalty rights Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved Payment of transaction related to purchase and sale agreement Opdivo Opdivo [Member] Opdivo. Operating lease liabilities, current portion Operating Lease, Liability, Current Net foreign currency translation gain (loss) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Accumulated Deficit Retained Earnings [Member] Other prepaid expenses Prepaid Expenses and Other Current Assets [Member] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Payments to Acquire Property, Plant, and Equipment, Total Document Transition Report Document Transition Report Other assets Increase (Decrease) in Other Operating Assets Increase (Decrease) in Other Operating Assets, Total Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Significant Concentrations Concentration Risk, Credit Risk, Policy [Policy Text Block] Minimum Minimum [Member] Percentage of number of shares of warrant exercised Percentage of Number of Shares for Warrant Exercised Percentage of number of shares of warrant exercised. Common Shares Common Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Capital in Excess of Par Value Additional Paid-in Capital [Member] Short-term investments Debt Securities, Available-for-Sale, Current Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Other assets Other Assets, Noncurrent Depreciable property, plant and equipment, net Depreciable Property Plant And Equipment Net Depreciable Property, plant and equipment, Net. Restructuring, impairment and other costs of terminated program Restructuring, Impairment And Other Costs Of Terminated Program Member [Member] Restructuring, Impairment And Other Costs Of Terminated Program Member Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved Payment of transaction related to purchase and sale agreement if threshold is not achieved Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Non-cash royalty revenue Non-cash royalty revenue related to the sales of future royalties Non Cash Royalty Revenue Related To Sale Of Future Royalties Non cash royalty revenue related to sale future royalties. Other current assets Other Assets, Current Goodwill and Intangible Assets Disclosure [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Potential Development Milestones Potential future additional payments for development milestones Potential Development Milestones Potential development milestones. Common stock, $0.0001 par value; 300,000 shares authorized; 192,743 shares and 191,384 shares issued at September 30, 2024 and December 31, 2023, respectively; 184,458 shares and 191,384 shares outstanding at September 30, 2024 and December 31, 2023, respectively; Common Stock, Value, Issued Name of Property [Axis] Name of Property [Axis] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Interest income Investment Income, Interest 2017 Performance Incentive Plan Two Thousand Seventeen Performance Incentive Plan [Member] Two Thousand Seventeen Performance Incentive Plan Schedule of Portfolio of Cash and Investments in Marketable Securities Fair Value, Assets Measured on Recurring Basis [Table Text Block] Issuance of prefunded warrant Issuance of prefunded warrant Issuance of prefunded warrant Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Commitments and contingencies Commitments and Contingencies Amount exchanged to remove cap on royalties Amount exchanged to remove cap on royalties Amount exchanged to remove cap on royalties Weighted average shares outstanding used in computing diluted net loss per share (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted, Total Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Accounts Receivable, after Allowance for Credit Loss, Current, Total Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Inventory Increase (Decrease) in Inventories Increase (Decrease) in Inventories, Total Non-cash research and development expense Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense Liabilities related to the sales of future royalties, net â€“ beginning balance Liabilities related to the sales of future royalties, net â€“ ending balance Liability Related To Sale Of Potential Future Royalties Non Current Liability Related To Sale Of Potential Future Royalties Non Current Entity Small Business Entity Small Business Percentage of sharing production costs Percentage Of Sharing In Production Costs Percentage of sharing in production costs. Derivative liability Derivative Liability Derivative Liability, Total Investments, fair value disclosure Investments, Fair Value Disclosure Investments, Fair Value Disclosure, Total Liabilities related to assets held for sale Disposal Group, Including Discontinued Operation, Liabilities, Current Disposal Group, Including Discontinued Operation, Liabilities, Current, Total Repurchase of common stock from Bristol-Myers Squibb (in shares) Repurchase of common stock from Bristol-Myers Squibb (in shares) Treasury Stock, Shares, Acquired Organization Organization Policy [Text Block] Organization. Liability to collaboration partners Liability to Collaboration Partners, Current Liability to Collaboration Partners, Current Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Asset Class [Axis] Asset Class [Axis] Accounts receivable Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Sale of stock repurchased cash consideration Sale Of Stock Repurchased Cash Consideration Sale of stock repurchased cash consideration. Fair Value, Level 3 Fair Value, Inputs, Level 3 [Member] Subsequent Event Subsequent Events [Text Block] Net unrealized gain (loss) on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total Accounts payable Accounts Payable, Current Accounts Payable, Current, Total Manufacturing equipment Manufacturing Laboratory And Other Equipment [Member] Manufacturing laboratory and other equipment. Total operating costs and expenses Costs and Expenses XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover Page - shares 9 Months Ended Sep. 30, 2024 Nov. 01, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 0-24006 Â Entity Registrant Name NEKTAR THERAPEUTICS Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 94-3134940 Â Entity Address, Address Line One 455 Mission Bay Boulevard South Â Entity Address, City or Town San Francisco Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 94158 Â City Area Code 415 Â Local Phone Number 482-5300 Â Title of 12(b) Security Common Stock, $0.0001 par value Â Trading Symbol NKTR Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock,

Shares Outstanding Â 184,458,284 Amendment Flag false Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Entity Central Index Key 0000906709 Â Current Fiscal Year End Date --12-31 Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 8 R2.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 30,109 $ 35,277 Short-term investments 214,386 268,339 Accounts receivable 0 1,205 Inventory, net 0 16,101 Other current assets 8,933 9,779 Assets held for sale 33,053 0 Total current assets 286,481 330,701 Long-term investments 4,537 25,825 Property, plant and equipment, net 3,603 18,856 Operating lease right-of-use assets 8,826 18,007 Other assets 4,519 4,644 Total assets 307,966 398,033 Current liabilities: Â Â Accounts payable 8,577 9,848 Accrued expenses 32,377 22,162 Operating lease liabilities, current portion 21,504 19,259 Liabilities related to assets held for sale 5,125 0 Total current liabilities 67,583 51,269 Operating lease liabilities, less current portion 86,758 98,517 Liabilities related to the sales of future royalties, net 97,829 112,625 Other long-term liabilities 6,912 4,635 Total liabilities 259,082 267,046 Commitments and contingencies Stockholdersâ€™ equity: Â Â Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at September 30, 2024 or December 31, 2023, respectively 0 0 Common stock, $0.0001 par value; 300,000 shares authorized; 192,743 shares and 191,384 shares issued at September 30, 2024 and December 31, 2023, respectively; 184,458 shares and 191,384 shares outstanding at September 30, 2024 and December 31, 2023, respectively; 19 19 Capital in excess of par value 3,654,981 3,608,137 Treasury stock, at cost; 8,285 shares as of September 30, 2024 and none as of December 31, 2023, respectively (3,000) 0 Accumulated other comprehensive income (loss) 355 80 Accumulated deficit (3,603,471) (3,477,249) Total stockholdersâ€™ equity 48,884 130,987 Total liabilities and stockholdersâ€™ equity $ 307,966 $ 398,033 X - DefinitionLiability related to sale of potential future royalties non current net of issuance costs. + ReferencesNo definition available. + Details Name: nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in

excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX

210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace

Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 9 R3.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Preferred stock, shares authorized (in shares) 10,000,000 10,000,000 Preferred stock, shares designated (in shares) 0 0 Preferred stock, shares outstanding (in shares) 0 0 Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Common stock, shares authorized (in shares) 300,000,000 300,000,000 Common stock shares, issued (in shares) 192,743,000 191,384,000 Common stock, shares outstanding (in shares) 184,458,000 191,384,000 Treasury Stock, Common, Shares 8,285,000 0 X - DefinitionPreferred stock, shares designated. + ReferencesNo definition available. + Details Name: nktr_PreferredStockShareDesignated Namespace Prefix: nktr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 10 R4.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenue: Â Â Â Â Total revenue $ 24,124 $ 24,144 $ 69,252 $ 66,237 Operating costs and expenses: Â Â Â Â Cost of goods sold 4,435 12,431 22,709 26,485 Research and development 35,031 24,070 92,163 84,220 General and administrative 18,957 21,147 59,616 60,097 Restructuring, impairment, and costs of terminated program 46 11,360 14,310 49,107 Impairment of goodwill 0 0 0 76,501 Total operating costs and expenses 58,469 69,008 188,798 296,410 Loss from operations (34,345) (44,864) (119,546) (230,173) Non-operating income (expense): Â Â Â Â Non-cash interest expense on liabilities related to the sales of future royalties (6,020) (5,910) (17,959) (18,467) Interest income 3,437 5,211 11,558 14,392 Other income (expense), net (120) (335) (255) 100 Total non-operating income (expense), net (2,703) (1,034) (6,656) (3,975) Loss before provision for income taxes (37,048) (45,898) (126,202) (234,148) Provision (benefit) for income taxes 9 (61) 20 (171) Net loss $ (37,057) $ (45,837) $ (126,222) $ (233,977) Basic net loss per share (in dollars per share) $ (0.18) $ (0.24) $ (0.62) $ (1.23) Diluted net loss per share (in dollars per share) $ (0.18) $ (0.24) $ (0.62) $ (1.23) Weighted average shares outstanding used in computing basic net loss per share (in shares) 209,249 190,406 204,292 189,651 Weighted average shares outstanding used in computing diluted net loss per share (in shares) 209,249 190,406 204,292 189,651 Product sales Â Â Â Â Revenue: Â Â Â Â Total revenue $ 8,015 $ 5,822 $ 20,689 $ 15,198 Non-cash royalty revenue related to the sales of future royalties Â Â Â Â Revenue: Â Â Â Â Total revenue 15,731 18,167 48,029 50,860 License, collaboration and other revenue Â Â Â Â Revenue: Â Â Â Â Total revenue $ 378 $ 155 $ 534 $ 179 X - DefinitionNon-cash interest expense related to sale of royalties. + ReferencesNo definition available. + Details Name: nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CostsAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14:

http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2 + Details Name: us-gaap_GoodwillImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type:

xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_RestructuringCostsAndAssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 11 R5.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Statement of Comprehensive Income [Abstract] Â Â Â Â Net loss $ (37,057) $ (45,837) $ (126,222) $ (233,977) Other comprehensive income (loss): Â Â Â Â Net unrealized gain (loss) on available-for-sale securities 877 196 312 1,527 Net foreign currency translation gain (loss) (28) (98) (37) (972) Other comprehensive income (loss) 849 98 275 555 Comprehensive loss $ (36,208) $ (45,739) $ (125,947) $ (233,422) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference

2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 12 R6.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY - USD ($) shares in Thousands, $ in Thousands Total Common Shares Treasury Stock Capital in Excess of Par Value Accumulated Other Comprehensive Income (Loss) Accumulated Deficit Beginning balance (in shares) at Dec. 31, 2022 Â 188,560 Â Â Â Â Beginning balance at Dec. 31, 2022 $ 366,638 $ 19 Â $ 3,574,719 $ (6,907) $ (3,201,193) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Shares issued under equity compensation plans (in shares) Â 675 Â Â Â Â Stock-based compensation 10,019 Â Â 10,019 Â Â Comprehensive income (loss) (135,792) Â Â Â 1,226 (137,018) Ending balance (in shares) at Mar. 31, 2023 Â 189,235 Â Â Â Â Ending balance at Mar. 31, 2023 240,865 $ 19 Â 3,584,738 (5,681) (3,338,211) Beginning balance (in shares) at Dec. 31, 2022 Â 188,560 Â Â Â Â Beginning balance at Dec. 31, 2022 366,638 $ 19 Â 3,574,719 (6,907) (3,201,193) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Comprehensive income (loss) (233,422) Â Â Â Â Â Ending balance (in shares) at Sep. 30, 2023 Â 190,771 Â Â Â Â Ending balance at Sep. 30, 2023 159,368 $ 19 Â 3,600,871 (6,352) (3,435,170) Beginning balance (in shares) at Mar. 31, 2023 Â 189,235 Â Â Â Â Beginning balance at Mar. 31, 2023 240,865 $ 19 Â 3,584,738 (5,681) (3,338,211) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Shares issued under equity compensation plans (in shares) Â 884 Â Â Â Â Shares issued under equity compensation plans 18 Â Â 18 Â Â Stock-based compensation 7,966 Â Â 7,966 Â Â Comprehensive income (loss) (51,891) Â Â Â (769) (51,122) Ending balance (in shares) at Jun. 30, 2023 Â 190,119 Â Â Â Â Ending balance at Jun. 30, 2023 196,958 $ 19 Â 3,592,722 (6,450) (3,389,333) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Shares issued under equity compensation plans (in shares) Â 652 Â Â Â Â Stock-based compensation 8,149 Â Â 8,149 Â Â Comprehensive income (loss) (45,739) Â Â Â 98 (45,837) Ending balance (in shares) at Sep. 30, 2023 Â 190,771 Â Â Â Â Ending balance at Sep. 30, 2023 $ 159,368 $ 19 Â 3,600,871 (6,352) (3,435,170) Beginning balance (in shares) at Dec. 31, 2023 191,384 191,384 Â Â Â Â Beginning balance at Dec. 31, 2023 $ 130,987 $ 19 Â 3,608,137 80 (3,477,249) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Shares issued under equity compensation plans (in shares) Â 525 Â Â Â Â Shares issued under equity compensation plans 3 Â Â 3 Â Â Stock-based compensation 6,000 Â Â 6,000 Â Â Repurchase of common stock from Bristol-Myers Squibb (in shares) Â (8,285) 8,285 Â Â Â Repurchase of common stock from Bristol-Myers Squibb (3,000) Â $ (3,000) Â Â Â Issuance of prefunded warrant 30,000 Â Â 30,000 Â Â Comprehensive income (loss) (37,285) Â Â Â (483) (36,802) Ending balance (in shares) at Mar. 31, 2024 Â 183,624 8,285 Â Â Â Ending balance at Mar. 31, 2024 $ 126,705 $ 19 $ (3,000) 3,644,140 (403) (3,514,051) Beginning balance (in shares) at Dec. 31, 2023 191,384 191,384 Â Â Â Â Beginning balance at Dec. 31, 2023 $ 130,987 $ 19 Â 3,608,137 80 (3,477,249) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Comprehensive income (loss) $ (125,947) Â Â Â Â Â Ending balance (in shares) at Sep. 30, 2024 184,458 184,458 8,285 Â Â Â Ending balance at Sep. 30, 2024 $ 48,884 $ 19 $ (3,000) 3,654,981 355 (3,603,471) Beginning balance (in shares) at Mar. 31, 2024 Â 183,624 8,285 Â Â Â Beginning balance at Mar. 31, 2024 126,705 $ 19 $ (3,000) 3,644,140 (403) (3,514,051) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Shares issued under equity compensation plans (in shares) Â 437 Â Â Â Â Shares issued under equity compensation plans 19 Â Â 19 Â Â Stock-based compensation 5,418 Â Â 5,418 Â Â Comprehensive income (loss) (52,454) Â Â Â (91) (52,363) Ending balance (in shares) at Jun. 30, 2024 Â 184,061 8,285 Â Â Â Ending balance at Jun. 30, 2024 79,688 $ 19 $ (3,000) 3,649,577 (494) (3,566,414) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Shares issued under equity compensation plans (in shares) Â 397 Â Â Â Â Shares issued under equity compensation plans 13 Â Â 13 Â Â Stock-based compensation 5,391 Â Â 5,391 Â Â Comprehensive income (loss) $ (36,208) Â Â Â 849 (37,057) Ending balance (in shares) at Sep. 30, 2024 184,458 184,458 8,285 Â Â Â Ending balance at Sep. 30, 2024 $ 48,884 $ 19 $ (3,000) $ 3,654,981 $ 355 $ (3,603,471) X - DefinitionIssuance of prefunded warrant + ReferencesNo definition available. + Details Name: nktr_IssuanceOfPrefundedWarrant Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting

Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of shares that have been repurchased during the period and are being held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_TreasuryStockSharesAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockValueAcquiredCostMethod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 13 R7.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities: Â Â Net loss $ (126,222) $ (233,977) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Non-cash royalty revenue related to the sales of future royalties (48,029) (50,860) Non-cash interest expense on liabilities related to the sales of future royalties 17,959 18,467 Stock-based compensation 16,809 26,134 Depreciation and amortization 4,059 6,163 Deferred income tax expense (12) (1,854) Impairment of right-of-use assets and property, plant and equipment 8,329 36,628 Impairment of goodwill 0 76,501 Provision for net realizable value of inventory 20 4,444 Amortization of premiums (discounts), net and other non-cash transactions (7,711) (12,137) Changes in operating assets and liabilities: Â Â Accounts receivable (841) 3,777 Inventory (808) (372) Operating leases, net (7,620) (6,078) Other assets (1,761) 4,450 Accounts payable (1,023) (9,328) Accrued expenses 17,329 (7,517) Net cash used in operating activities (129,522) (145,559) Cash flows from investing activities: Â Â Purchases of investments (191,882) (372,821) Maturities of investments 275,247 494,385 Purchases of property, plant and equipment (1,009) (628) Sale of property, plant and equipment Â 1,245 Net cash provided by investing activities 82,356 122,181 Cash flows from financing activities: Â Â Proceeds from shares issued under equity compensation plans 35 18 Proceeds from issuance of pre-funded warrant 30,000 0 Proceeds from sale of future royalties 15,000 0 Repurchase of common stock from Bristol-Myers Squibb (3,000) 0 Net cash provided by financing activities 42,035 18 Effect of foreign exchange rates on cash and cash equivalents (37) 54 Net increase (decrease) in cash and cash equivalents (5,168) (23,306) Cash and cash equivalents at beginning of period 35,277 88,227 Cash and cash equivalents at end of period $ 30,109 64,921 Supplemental disclosure of cash flow information: Â Â Cash paid for income taxes Â $ 2,656 X - DefinitionIncrease (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities + ReferencesNo definition available. + Details Name: nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNon-cash interest expense related to sale of royalties. + ReferencesNo definition available. + Details Name: nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNon cash royalty revenue related to sale future royalties. + ReferencesNo definition available. + Details Name: nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceeds From Sale of Future Royalties. + ReferencesNo definition available. + Details Name: nktr_ProceedsFromSaleOfFutureRoyalties Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProvision for inventory obsolescence. + ReferencesNo definition available. + Details Name: nktr_ProvisionForInventoryObsolescence Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2 + Details Name: us-gaap_GoodwillImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of write-downs for impairments

recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in other expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherNoncashIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11 + Details Name: us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name

Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Net Income (Loss) $ (37,057) $ (45,837) $ (126,222) $ (233,977) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 15 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Organization and Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Organization and Summary of Significant Accounting Policies Note 1 â€" Organization and Summary of Significant Accounting PoliciesOrganizationNektar Therapeutics (Nektar, we) is a clinical stage, research-based drug discovery biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware, focused on discovering and developing innovative medicines in the field of immunotherapy. Within this growing field, we direct our efforts toward creating new immunomodulatory agents that selectively induce, amplify, attenuate or prevent immune responses in order to achieve desired therapeutic outcomes. Our pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the

future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. As of September 30, 2024, we had approximately $249.0 million in cash and investments in marketable securities.Sale of Manufacturing FacilityOn November 1, 2024, we entered into an Asset Purchase Agreement (the APA) with an affiliate (the Purchaser) of Ampersand Management LLC d/b/a Ampersand Capital Partners (Ampersand), for the sale of our manufacturing facility located in Huntsville, Alabama (the Facility) and certain other manufacturing assets related thereto, including the assignment of our existing manufacturing and supply obligations, for consideration of $70 million in cash (subject to customary closing costs and adjustments based on closing net working capital, closing inventory and the amount of any indebtedness assumed by the Purchaser) and an approximate 20% equity ownership at the time of close in the Purchaser. See Note 10 for additional information.Financing TransactionsDuring the nine months ended September 30, 2024, we entered into the following transactions:â€¢On February 12, 2024, for total cash consideration paid of $3.0 million, we repurchased from Bristol Myers Squibb Company (BMS) 8.3 million shares of Nektar's common stock that were previously sold to BMS, which we report as treasury stock on our Condensed Consolidated Balance Sheets. See Note 6 for additional information.â€¢On March 4, 2024, we entered into a Securities Purchase Agreement with TCG Crossover Fund II, L.P. (TCG), pursuant to which we issued a pre-funded warrant to TCG to purchase 25,000,000 shares of Nektarâ€™s common stock for gross proceeds of $30.0 million (or a purchase price of $1.20 per share of common stock that can be issued upon exercise of the pre-funded warrant). On May 28, 2024, we filed with the SEC a registration statement on Form S-3 (file no. 333-279760) registering for the resale of up to 25,000,000 shares of Nektarâ€™s common stock upon exercise of the pre-funded warrant issued to TCG pursuant to the Securities Purchase Agreement. The registration statement became effective on June 5, 2024. See Note 5 for additional information.â€¢On March 4, 2024, for total cash consideration received of $15.0 million, we entered into an amendment (the Amendment) with entities managed by Healthcare Royalty Management, LLC (collectively, HCR) to remove the cap on royalties previously sold to HCR under a Purchase and Sale Agreement (the 2020 Purchase and Sale Agreement). See Note 3 for additional information.Restructuring PlansIn April 2022, we announced the termination of the bempegaldesleukin program and a new strategic reorganization and cost restructuring plan (together, the 2022 Restructuring Plan), pursuant to which we completed an approximate 70% reduction of our workforce during 2022. We also decided to seek a sublease for certain of our leased premises in San Francisco, CA, including all of our office space on Third St. and portions of our office and laboratory space on Mission Bay Blvd. South.In April 2023, we announced Eli Lilly and Company's (Lilly) decision to terminate our license agreement (the Lilly Agreement) for the development of rezpegaldesleukin, as well as a new strategic reprioritization and cost restructuring plan (the 2023 Restructuring Plan). Under the 2023 Restructuring Plan, we reduced our San Francisco-based workforce by approximately 60%. In addition, under the 2023 Restructuring Plan, we decided to seek a sublease for our remaining office and laboratory space on Mission Bay Blvd. South which we had not planned to sublease pursuant to the 2022 Restructuring Plan. We have regained full rights to rezpegaldesleukin from Lilly, and we initiated a Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in October 2023 and a Phase 2b study of rezpegaldesleukin in patients with severe-to-very severe alopecia areata in March 2024. We will also explore other auto-immune indications for the development of rezpegaldesleukin.We have incurred significant costs resulting from the 2022 and 2023 Restructuring Plans. See Note 7 for additional information on the effect on our Condensed Consolidated Financial Statements.Basis of Presentation and Principles of ConsolidationOur Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of Nektar Therapeutics and our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiaryâ€™s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive income (loss) in the stockholdersâ€™ equity section of our Condensed Consolidated Balance Sheets. Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive income (loss) to the statements of operations during the three and nine months ended September 30, 2024 and 2023 except as otherwise disclosed below in Note 3.The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December 31, 2023 was derived from the audited consolidated financial statements which are included in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 5, 2024. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements.Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.Significant ConcentrationsOur customers are primarily pharmaceutical companies that are located in the U.S. and Europe and with whom we have multi-year arrangements. Our accounts receivable balances contain billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. We generally do not require collateral from our customers. We perform a regular review of our customersâ€™ credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable or contract assets. We have not recorded reserves for credit losses for the three and nine months ended September 30, 2024 and 2023, nor have recorded such an allowance as of September 30, 2024 or December 31, 2023. As of September 30, 2024, all billed and unbilled trade receivables from product sales and contract assets have been classified as held-for-sale and included within assets held for sale on our Condensed Consolidated Balance Sheets.We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, various factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuerâ€™s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if various factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.Â Treasury StockWe record treasury stock activities under the cost method. Treasury stock is included in authorized and issued shares but excluded from outstanding shares. The re-issuance of treasury stock is accounted for on a first in, first-out basis and any differences between the cost of treasury stock and the re-issuance proceeds are charged or credited to additional paid-in capital.RestructuringWe recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for:â€¢contractual or other employee termination benefits provided that the obligations result from services already rendered based on rights that vest or accumulated when the payment of benefits becomes probable and the amount can be reasonably estimated;â€¢one-time employee termination benefits on the communication date from management to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn; andâ€¢contract termination costs for costs incurred when we cancel the contract in accordance with its terms, or for costs to be incurred over the remaining contract term without economic benefit to us at the cease-use date.For one-time employee terminations benefits, we recognize the liability in full on the communication date when future services are not required or amortize the liability ratably over the service period, if required. The fair value of termination benefits reflects our estimates of expected utilization of certain Company-funded post-employment benefits.See Note 7 for additional information on the severance expense that we recognized for employees terminated in connection with our reductions-in-force.Impairment of GoodwillGoodwill is assessed for impairment on an annual basis and whenever events and circumstances indicate that it may be impaired. Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, current economic, market and geopolitical conditions, including a significant, sustained decline in our stock price and market capitalization compared to the net book value; an adverse change in legal factors, business climate or operational performance of the business; or significant changes in the ability of the reporting unit to generate positive cash flows for our strategic business objectives. If the carrying value of the reporting unit, including goodwill, exceeds the reporting unitâ€™s fair value, we will recognize a goodwill impairment loss, and we will write down goodwill such that the carrying value of the reporting unit equals its fair value, provided that we cannot reduce goodwill below zero.See Note 8 for additional information regarding the impairment charges we recorded during the three months ended March 31, 2023 in connection with our goodwill.Long-Lived Asset ImpairmentWe assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated net cash flows associated with the asset, discounted at a rate that we believe a market participant would utilize to reflect the risks associated with the cash flows, such as credit risk. See Note 7 for additional information regarding the impairment charges we recorded in connection with our leased facilities and certain property and equipment.Net Loss per ShareFor all periods presented in the Condensed Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. We calculate basic net loss per share based on the weighted-average number of common shares outstanding, including the pre-funded warrant, during the periods presented. Shares of common stock into which the pre-funded warrant may be exercised are considered outstanding for the purposes of computing basic net loss per share because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date. For the three and nine months ended September 30, 2024 and 2023, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. We excluded shares underlying the weighted average outstanding stock options, restricted stock units (RSUs) and performance stock units (PSUs), as follows (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Potentially dilutive securities Â Â 25,887 Â Â Â 17,476 Â Â Â 26,417 Â Â Â 20,513 Â Â X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 16 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Cash and Investments in Marketable Securities 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Cash and Investments in Marketable Securities Note 2 â€” Cash and Investments in Marketable SecuritiesCash and investments in marketable securities, including cash equivalents, are as follows (in thousands):Â Â Â Estimated Fair Value at Â Â Â September 30, 2024 Â Â December 31, 2023 Â Cash and cash equivalents Â $ 30,109 Â Â $ 35,277 Â Short-term investments Â Â 214,386 Â Â Â 268,339 Â Long-term investments Â Â 4,537 Â Â Â 25,825 Â Total cash, cash equivalents, and investments in marketable securities Â $ 249,032 Â Â $ 329,441 Â Â Our portfolio of cash and investments in marketable securities

includes (in thousands):Â Â Â Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â Fair Value Hierarchy Level Â Amortized Cost Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Fair Value Â Â Fair Value Â Corporate notes and bonds Â 2 Â $ 90,589 Â Â $ 214 Â Â $ (10) Â $ 90,793 Â Â $ 38,882 Â Corporate commercial paper Â 2 Â Â 125,927 Â Â Â 163 Â Â Â (7) Â Â 126,083 Â Â Â 255,241 Â Obligations of U.S. government agencies Â 2 Â Â 1,500 Â Â Â 2 Â Â Â â€” Â Â Â 1,502 Â Â Â â€” Â Available-for-sale investments Â Â Â $ 218,016 Â Â $ 379 Â Â $ (17) Â $ 218,378 Â Â $ 294,123 Â Money market funds Â 1 Â Â Â Â Â Â Â Â Â Â Â 10,361 Â Â Â 2,359 Â Certificates of deposit Â 2 Â Â Â Â Â Â Â Â Â Â Â 14,046 Â Â Â 15,116 Â Cash Â N/A Â Â Â Â Â Â Â Â Â Â Â 6,247 Â Â Â 17,843 Â Total cash and investments in marketable securities Â Â Â Â Â Â Â Â $ 249,032 Â Â $ 329,441 Â Â For the three and nine months ended September 30, 2024 and 2023, there were no transfers between Level 1 and Level 2 of the fair value hierarchy. At December 31, 2023, our gross unrealized gains and losses were insignificant. X - DefinitionThe entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContent + Details Name: us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Financial Statement Details 9 Months Ended Sep. 30, 2024 Inventory Disclosure [Abstract] Â Condensed Consolidated Financial Statement Details Note 3 â€” Condensed Consolidated Financial Statement DetailsInventoryInventory consists of the following (in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Raw materials Â $ â€” Â Â $ 1,861 Â Work-in-process Â Â â€” Â Â Â 12,880 Â Finished goods Â Â â€” Â Â Â 1,360 Â Total inventory, net Â $ â€” Â Â $ 16,101 Â Â We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.As of September 30, 2024 and December 31, 2023, we recorded aggregate provisions of $0 and $2.0 million, respectively, for the net realizable value of our batches. Our manufacturing agreement with UCB Pharma (UCB) for the reagent used in the manufacture of CIMZIAÂ® provided for a fixed selling price which we had negotiated in exchange for a higher royalty rate. Accordingly, when evaluating the net realizable value of our inventory for UCB, we include the negotiated increase of the royalties in our analysis, and the aggregate revenue has historically been greater than our manufacturing cost. Due to the decreases in the royalty rate for 2024 and 2025 as a result of a settlement agreement with UCB, the aggregate revenue was expected to be less than our manufacturing cost for these years, and therefore we previously recorded a provision for net realizable value. As further disclosed in Note 6, on July 31, 2024, we entered into a long-term supply agreement with UCB that increases the selling price of the reagent used in the manufacture of CIMZIAÂ®, which resulted in the aggregate revenue exceeding our manufacturing costs. As a result, we reduced the provision to $0 during the three months ended September 30, 2024. As of September 30, 2024, all of the inventory balance is classified as held for sale and included within assets held for sale on our Condensed Consolidated Balance Sheets.Other Current AssetsOther current assets consist of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Prepaid research and development expenses Â $ 3,960 Â Â $ 4,325 Â Interest and other non-trade receivables Â Â 2,123 Â Â Â 1,047 Â Other prepaid expenses Â Â 2,850 Â Â Â 4,407 Â Total other current assets Â $ 8,933 Â Â $ 9,779 Â Assets Held for Sale We classify assets and liabilities (the â€œdisposal groupâ€) as held for sale in the period in which all of the required criteria under ASC 360 â€œProperty, Plant, and Equipmentâ€ are met. We initially measure the disposal group asset that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Upon classification of the disposal group, we test the assets for impairment and cease related depreciation and amortization. As of September 30, 2024, we concluded that our manufacturing facility in Huntsville, Alabama meets the requirements for classification as assets held for sale. Accordingly, assets and liabilities associated with the disposal group were reclassified as held for sale. See Note 10 for additional information. The assets and liabilities as of December 31, 2023 on our Condensed Consolidated Balance Sheets were not recast to reflect the held for sale classification. As of September 30, 2024, assets held for sale consist of the following: Â Â September 30, 2024 Â Accounts receivable Â $ 1,746 Â Inventory, net Â Â 16,889 Â Property, plant and equipment, net Â Â 11,386 Â Contract asset Â Â 3,032 Â Total assets held for sale Â $ 33,053 Â Â A contract asset is a right to consideration that is conditional upon factors other than the passage of time. The contract asset above relates to the long-term supply agreement with UCB entered into on July 31, 2024 (See Note 6 for additional information). As of September 30, 2024, liabilities related to assets held for sale primarily consists of accrued compensation and other accrued expenses. Property, Plant and EquipmentProperty, plant and equipment consists of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Building and leasehold improvements Â $ 3,834 Â Â $ 43,184 Â Computer equipment and computer software Â Â 14,615 Â Â Â 22,438 Â Manufacturing equipment Â Â â€” Â Â Â 24,315 Â Laboratory equipment Â Â 616 Â Â Â 14,537 Â Furniture, fixtures and other Â Â 59 Â Â Â 541 Â Depreciable property, plant and equipment at cost Â Â 19,124 Â Â Â 105,015 Â Less: accumulated depreciation Â Â (15,659) Â Â (86,898) Depreciable property, plant and equipment, net Â Â 3,465 Â Â Â 18,117 Â Construction in process Â Â 138 Â Â Â 739 Â Property, plant and equipment, net Â $ 3,603 Â Â $ 18,856 Â Â Due to the weakening lease markets during the three months ended June 30, 2024, we recorded additional non-cash impairment charges of $1.0 million for property, plant and equipment for the three months ended June 30, 2024, which we report in restructuring, impairment and costs of terminated program in our Condensed Consolidated Statement of Operations. See Note 7 for additional information. As of September 30, 2024, property, plant and equipment associated with our manufacturing facility in Huntsville, Alabama is classified as held for sale and included within assets held for sale on our Condensed Consolidated Balance Sheets.Accrued ExpensesAccrued expenses consist of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Accrued compensation Â $ 7,007 Â Â $ 5,553 Â Accrued research and development expenses Â Â 17,916 Â Â Â 10,118 Â Accrued contract termination costs Â Â 3,151 Â Â Â 3,020 Â Other accrued expenses Â Â 4,303 Â Â Â 3,471 Â Total accrued expenses Â $ 32,377 Â Â $ 22,162 Â Â Liabilities Related to the Sales of Future RoyaltiesIn 2012 and 2020, we sold to RPI Finance Trust (RPI) and HCR, respectively, our rights to receive royalties under our license and manufacturing agreements with certain pharmaceutical partners under the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement, respectively. We account for these transactions as debt and recognize non-cash royalty revenue and non-cash interest expense to amortize the proceeds over the lives of the respective arrangements. We periodically update our prospective non-cash interest rate based on our estimates of future royalties. As of September 30, 2024, our imputed interest rates for the arrangements with RPI and HCR were 43% and 24%, respectively.The original 2020 Purchase and Sale Agreement was to expire -- and wherein the right to receive royalties would revert to us -- if HCR received aggregate royalties of $210.0 million on or prior to December 31, 2025 (the 2025 Threshold), or, if the 2025 Threshold was not achieved by December 31, 2025, when HCR received aggregate royalties of $240.0 million. On March 4, 2024, Nektar and HCR amended the original 2020 Purchase and Sale Agreement (the Amendment), pursuant to which the parties agreed to remove our reversionary rights in the royalties in exchange for a $15.0 million payment from HCR. Accordingly, HCR will receive all future royalties of the products, and none of these royalties will return to Nektar. We account for the Amendment as a modification of the existing arrangement, and therefore recorded the $15.0 million proceeds as an increase to the liability. The following is a reconciliation of the changes in our liabilities related to the sales of future royalties for the nine months ended September 30, 2024 (in thousands):Â Â Â Nine Months Ended September 30, 2024 Â Â Â 2012 Purchase and Sale Agreement Â Â 2020 Purchase and Sale Agreement Â Â Total Â Liabilities related to the sales of future royalties, net â€“ beginning balance Â $ 24,217 Â Â $ 88,408 Â Â $ 112,625 Â Non-cash royalty revenue Â Â (19,007) Â Â (29,022) Â Â (48,029) Non-cash interest expense Â Â 4,940 Â Â Â 13,019 Â Â Â 17,959 Â Amortization of transaction costs Â Â â€” Â Â Â 274 Â Â Â 274 Â Proceeds from the Amendment Â Â â€” Â Â Â 15,000 Â Â Â 15,000 Â Liabilities related to the sales of future royalties, net â€“ ending balance Â $ 10,150 Â Â $ 87,679 Â Â $ 97,829 Â Â Accumulated Other Comprehensive Income (Loss)Â The following table summarizes the changes in accumulated other comprehensive income (loss) by component (in thousands):Â Â Â Foreign currency translation Â Â Available-for-sale securities Â Â Accumulated Other Comprehensive Income Â Balance at December 31, 2023 Â $ 30 Â Â $ 50 Â Â $ 80 Â Foreign currency translation adjustments Â Â (8) Â Â â€” Â Â Â (8) Unrealized gain (loss) on available-for-sale securities Â Â â€” Â Â Â (475) Â Â (475) Balance at March 31, 2024 Â $ 22 Â Â $ (425) Â $ (403) Foreign currency translation adjustments Â Â (1) Â Â â€” Â Â Â (1) Unrealized gain (loss) on available-for-sale securities Â Â â€” Â Â Â (90) Â Â (90) Balance at June 30, 2024 Â $ 21 Â Â $ (515) Â $ (494) Foreign currency translation adjustments Â Â (28) Â Â â€” Â Â Â (28) Unrealized gain (loss) on available-for-sale securities Â Â â€” Â Â Â 877 Â Â Â 877 Â Balance at September 30, 2024 Â $ (7) Â $ 362 Â Â $ 355 Â Â Â Â Foreign currency translation Â Â Available-for-sale securities Â Â Accumulated Other Comprehensive Income Â Balance at December 31, 2022 Â $ (5,131) Â $ (1,776) Â $ (6,907) Foreign currency translation adjustments Â Â 139 Â Â Â â€” Â Â Â 139 Â Unrealized gain (loss) on available-for-sale securities Â Â â€” Â Â Â 1,087 Â Â Â 1,087 Â Balance at March 31, 2023 Â $ (4,992) Â $ (689) Â $ (5,681) Foreign currency translation adjustments Â Â 13 Â Â Â â€” Â Â Â 13 Â Unrealized gain (loss) on available-for-sale securities Â Â â€” Â Â Â 244 Â Â Â 244 Â Reclassification adjustments to income Â Â (1,026) Â Â â€” Â Â Â (1,026) Balance at June 30, 2023 Â $ (6,005) Â $ (445) Â $ (6,450) Foreign currency translation adjustments Â Â (98) Â Â â€” Â Â Â (98) Unrealized gain (loss) on available-for-sale securities Â Â â€” Â Â Â 196 Â Â Â 196 Â Balance at September 30, 2023 Â $ (6,103) Â $ (249) Â $ (6,352) Â The reclassification from accumulated other comprehensive loss relates to the closure of one of our foreign subsidiaries and has been included within other income (expense), net in our Condensed Consolidated Statement of Operations. X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details Name: us-gaap_InventoryDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 18 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies Note 4 â€” Commitments and ContingenciesLegal MattersFrom time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at each reporting date and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations for that period and on our cash flows and liquidity.On August 7, 2023, we filed a complaint in the United States District Court for the Northern District of California (the Court) against Lilly alleging, among other claims, breach of contract and breach of implied covenant of good faith and fair dealing (the Complaint), in connection with our collaboration with Lilly. Following the denial of its motion to dismiss the Complaint entirely, Lilly filed an answer that included counterclaims against us alleging breach of specified confidentiality provisions and defamation. The case is proceeding.We have recorded no liability for any litigation matters in our Condensed Consolidated Balance Sheets at either September 30, 2024 or December 31, 2023. Indemnifications in Connection with Commercial AgreementsAs part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual commencing after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants. For example, we made certain intellectual property representations in connection with our RPI and HCR transactions, however, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements or certain express indemnification provisions are applicable, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.To date, we have not incurred any costs to defend lawsuits or settle claims related to these indemnification obligations, nor any breaches of representations or warranties or covenants. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Pre-Funded Warrant 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Pre-Funded Warrant Note 5 â€" Pre-Funded WarrantIn March 2024, we issued a pre-funded warrant to purchase an aggregate of 25,000,000 shares of our common stock to TCG at a price of $1.20 per share for gross proceeds of $30.0 million. Transaction costs were immaterial. The pre-funded warrant has an exercise price of $0.0001 per share and may be exercised at any time after the original issuance date. TCG may not exercise the warrant if TCG, together with its affiliates, would beneficially own more than 9.99% of the number of shares of our common stock outstanding immediately after giving effect to such exercise. TCG may increase or decrease this percentage not in excess of 19.99% by providing at least 61 daysâ€™ prior notice to the Company. On May 28, 2024, we filed with the SEC a registration statement on Form S-3 (file no. 333-279760) registering for resale of up to 25,000,000 shares of our common stock issuable upon exercise of the pre-funded warrant. The registration statement became effective on June 5, 2024. As of September 30, 2024, the warrant has not been exercised. We classified the pre-funded warrant as a component of permanent equity in our Condensed Consolidated Balance Sheets as it is a freestanding financial instrument that was immediately exercisable, does not embody an obligation for the Company to repurchase its own shares and permits the holder to receive a fixed number of shares of common stock upon exercise. All of the shares underlying the pre-funded warrant have been included in the weighted-average number of shares of common stock used to calculate net loss per share attributable to common stockholders because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the pre-funded warrant. X - DefinitionPre-funded warrant. + ReferencesNo definition available. + Details Name: nktr_PreFundedWarrantTextBlock Namespace Prefix: nktr_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R14.htm IDEA: XBRL DOCUMENT v3.24.3 License and Collaboration Agreements 9 Months Ended Sep. 30, 2024 License And Collaboration Agreements [Abstract] Â License and Collaboration Agreements Note 6 â€" License and Collaboration AgreementsWe have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary polyethylene glycol reagents (PEG reagents) and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808 Collaborative Arrangements, and, if so, we analyze whether we should account for any elements under ASC 606 Revenue from Contracts with Customers. Eli Lilly and Company (Lilly): Rezpegaldesleukin (previously referred to as NKTR-358) On July 23, 2017, we entered into a worldwide license agreement (the Lilly Agreement) with Lilly to co-develop rezpegaldesleukin, a novel immunological drug candidate that we invented, pursuant to which we received an initial payment of $150.0 million and were eligible for up to $250.0 million in additional development and regulatory milestones. The Lilly Agreement provided that, during Phase 1B and Phase 2 development, we shared development costs wherein 75% of the costs were borne by Lilly and 25% of the costs were borne by us. On April 23, 2023, we received from Lilly a notice of at-will termination of the Lilly Agreement. We have regained full rights to rezpegaldesleukin from Lilly, and the Lilly Agreement subsequently terminated. Following the return of our rights to develop rezpegaldesleukin, we bear all costs of development. We initiated a Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in October 2023 and a Phase 2b study of rezpegaldesleukin in patients with severe-to-very severe alopecia areata in March 2024. We will also explore other auto-immune indications for the development of rezpegaldesleukin. Bristol-Myers Squibb Company (BMS): Bempegaldesleukin, also referred to as NKTR-214 Effective April 3, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS. Pursuant to the BMS Collaboration Agreement, we and BMS jointly developed bempegaldesleukin in combination with BMSâ€™ OpdivoÂ®. The parties shared the internal and external development costs for bempegaldesleukin in combination regimens based on each partyâ€™s relative ownership interest in the compounds included in the regimens.Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $1.0 billion and purchased 8,284,600 shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $850.0 million. In 2020, we received additional non-refundable milestone payments of $50.0 million.In April 2022, we announced that BMS and we decided to discontinue all development of bempegaldesleukin in combination with OpdivoÂ®. On September 6, 2023, BMS and we terminated the BMS Collaboration Agreement, and pursuant to the surviving provisions of the BMS Collaboration Agreement, we and BMS continue our efforts to wind down the bempegaldesleukin program, and the cost sharing provisions continue to remain in effect as the parties wind down the studies. On February 12, 2024, we repurchased the 8.3 million shares previously sold to BMS for total cash consideration of $3.0 million.We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. Based on the cost sharing percentages described above, we recognize the net reimbursement to (from) BMS as an increase (decrease) to the applicable expense. As discussed in Note 7, beginning in the second quarter of 2022, we began reporting clinical trial, other third-party costs and employee costs for the wind down of the bempegaldesleukin program in restructuring, impairment and costs of terminated program. For the three and nine months ended September 30, 2024, such amounts are immaterial and are included in research and development expense.Biolojic Design (Biolojic): NKTR-0165In 2021, we entered into a research collaboration and license option agreement with Biolojic to discover and develop agonistic antibodies that activate a novel and previously un-drugged target for the treatment of autoimmune diseases. In 2023, we exercised an option to gain an exclusive license to specified agonistic antibodies and other materials that were developed pursuant to a research collaboration and license option agreement in all fields of use (other than in the field of oncology). As a result of exercising the option to gain an exclusive license, we may be required to pay up to $18.0 million based on the achievement of certain development milestones, including the first milestone of $3.0 million payable upon the acceptance of the first investigational new drug application, and up to $35.0 million based on the achievement of certain regulatory approval milestones. Each milestone is payable only once, regardless of the number of indications for which we develop the licensed product. We record a liability when a milestone payment becomes probable. As of September 30, 2024, no milestones have been achieved or are considered probable, and no liability has been recorded. Â OtherWe have other collaboration agreements that have resulted in commercialized products for our collaborations partners. Under these agreements, we may sell our proprietary PEG reagents for use in these products, and we are entitled to receive royalties based on net sales of these products as well as sales milestones. As discussed in Note 3, we have sold our rights to receive royalties from these other collaboration agreements. Our non-cash royalty revenue, which totaled $18.2 million and $50.9 million for the three and nine months ended September 30, 2023, respectively, and $15.7 million and $48.0 million for the three and nine months ended September 30, 2024, respectively, represents revenue for granting licenses which we had satisfied in prior periods.We have a collaboration agreement with UCB for dapirolizumab pegol, under which we are entitled to up to a total of $40.0 million of regulatory approval milestones, as well as royalties in the low single digits based on net sales of commercialized products, if any. UCB is developing dapirolizumab pegol, a PEGylated antibody fragment, with Biogen, Inc. for the treatment of systemic lupus erythematosus. However, given the current phase of development of this product and the uncertainty in clinical development, we have excluded these milestones from the transaction price for this agreement. We have not sold our rights to receive these milestones or royalties from dapoirolizumab pegol under the APA with the Purchaser of the sale of the Facility.On July 31, 2024, and further formalized in an Amended and Restated Manufacturing and Supply Agreement dated October 18, 2024, we entered into a long-term "take or pay" supply agreement with UCB that increases the selling price of the PEG reagent used in the manufacture of CIMZIAÂ® (the UCB Supply Agreement). The UCB Supply Agreement also covers UCBâ€™s purchases of the same reagent (at the same price) for use in the manufacture of dapirolizumab pegol. We analyzed the terms of the agreement, including its cancellation provisions, and concluded that it represents a long-term agreement. Since the performance obligations are deliveries of a single reagent, we determined a single sales price for recognition of revenue over the term of the arrangement. Accordingly, because the billed price was less than the single selling price, we recorded a contract asset of $3.0 million as of September 30, 2024, which is included within assets held for sale on our Condensed Consolidated Balance Sheet, as further disclosed in Note 3. Pursuant to a separate APA between the Purchaser and us, the UCB Supply Agreement will be assigned to the Purchaser upon closing of the sale of the Facility. The assignment of the UCB Supply Agreement does not alter the potential milestones and potential royalties payable by UCB to us pursuant to the collaboration agreement for dapirolizumab pegol nor the non-cash royalties payable under our collaboration agreement for CIMZIAÂ®. See Note 10 for additional information on the APA. X - DefinitionLicense and collaboration agreements. + ReferencesNo definition available. + Details Name: nktr_LicenseAndCollaborationAgreementsAbstract Namespace Prefix: nktr_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 808 -Publisher FASB -URI https://asc.fasb.org/808/tableOfContent + Details Name: us-gaap_CollaborativeArrangementDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Restructuring, Impairment and Costs of Terminated Program 9 Months Ended Sep. 30, 2024 Restructuring and Related Activities [Abstract] Â Restructuring, Impairment and Costs of Terminated Program Note 7 â€" Restructuring, Impairment and Costs of Terminated ProgramIn connection with our 2022 and 2023 Restructuring Plans, we report the following costs in restructuring, impairment and costs of terminated program:â€¢Clinical trial expense, other third-party costs and employee costs for the wind down of the bempegaldesleukin program, net of the reimbursement from BMS, initiated in 2022;â€¢Severance and related benefit costs pursuant to the 2022 and 2023 Restructuring Plans;â€¢Non-cash impairment of right-of-use assets and property, plant and equipment; andâ€¢Contract termination and other costs associated with these plans.Restructuring, impairment and costs of terminated program includes the following (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program Â $ â€" Â Â $ 652 Â Â $ â€" Â Â $ 3,606 Â Severance and benefit expense Â Â â€" Â Â Â 535 Â Â Â â€" Â Â Â 7,961 Â Impairment of right-of-use assets and property, plant and equipment Â Â â€" Â Â Â 10,173 Â Â Â 8,329 Â Â Â 36,628 Â Contract termination and other restructuring costs Â Â 46 Â Â Â â€" Â Â Â 5,981 Â Â Â 912 Â Restructuring, impairment and other costs of terminated program Â $ 46 Â Â $ 11,360 Â Â $ 14,310 Â Â $ 49,107 Â Wind Down of the Bempegaldesleukin ProgramIn prior periods through March 31, 2022, we reported the clinical trial costs, other third-party costs and employee costs related to the bempegaldesleukin program primarily in research and development expense. Beginning in the second quarter of 2022, following our announcement to terminate the program, we began reporting clinical trial, other third-party costs and employee costs for the wind down of the bempegaldesleukin program in restructuring, impairment and costs of terminated program. For the three and nine months ended September 30, 2024, such amounts are immaterial and are included in research and development expense.Severance and Benefit ExpenseEmployees affected by the reduction in force under the 2022 and 2023 Restructuring Plans are entitled to receive severance payments and certain Company funded benefits. The restructuring charges are recorded at fair value. For the 2022 Restructuring Plan, we recognized all expense in 2022 and paid the final liability of $3.3 million in the three months ended March 31, 2023.For the 2023 Restructuring Plan, we recognized $7.9 million in total expense in 2023 for the 2023 Restructuring Plan and paid the final liability of $0.2 million in the three months ended March 31, 2024.We do not expect to recognize any additional severance and benefits expense for the 2022 and 2023 Restructuring Plans.The following table provides details regarding the severance and benefit expense for the three and nine months ended September 30, 2024 pursuant to the 2023 Restructuring Plan and a reconciliation of the severance and benefits liability for the three and nine months ended September 30, 2023 pursuant to the 2022 and 2023 Restructuring Plans, which we report within accrued expenses on our Condensed Consolidated Balance Sheet (in thousands): Â Â Nine Months Ended September 30, 2023 Â Â Â 2023 Restructuring Plan Â Â 2022 Restructuring Plan Â Â Total Â Liability balance as of December 31, 2022 Â $ â€" Â Â $ 3,299 Â Â $ 3,299 Â Expense recognized during the period Â Â 5,483 Â Â Â â€" Â Â Â 5,483 Â Payments during the period Â Â â€" Â Â Â (3,299) Â Â (3,299) Liability balance as of March 31, 2023 Â $ 5,483 Â Â $ â€" Â Â $ 5,483 Â Expense recognized during the period Â Â 1,943 Â Â Â â€" Â Â Â 1,943 Â Payments during the period Â Â (6,624) Â Â â€" Â Â Â (6,624) Liability balance as of June 30, 2023 Â $ 802 Â Â $ â€" Â Â $ 802 Â Expense recognized during the period Â Â 535 Â Â Â â€" Â Â Â 535 Â Payments during the period Â Â (887) Â Â â€" Â Â Â (887) Liability balance as of September 30, 2023 Â $ 450 Â Â $ â€" Â Â $ 450 Â Â Â Â Â Â Â Â Â Â Â Â Â Nine Months Ended September 30, 2024 Â Â Â 2023

Restructuring Plan Â Â 2022 Restructuring Plan Â Â Total Â Liability balance as of December 31, 2023 Â $ 196 Â Â $ â€” Â Â $ 196 Â Expense recognized during the period Â Â â€” Â Â Â â€” Â Â Â â€” Â Payments during the period Â Â (196) Â Â â€” Â Â Â (196) Liability balance as of September 30, 2024 Â $ â€” Â Â $ â€” Â Â $ â€” Â Impairment of Long-Lived AssetsAs a result of our 2022 and 2023 Restructuring Plans, we decided to seek a sublease for all of our leased spaces on Third Street and Mission Bay Blvd. South (the Third Street Facility and the Mission Bay Facility, respectively). Accordingly, we evaluate each space for impairment when management decides to sublease the respective space and at each reporting date thereafter, as facts and circumstances change. The significant assumptions in our impairment analysis relate to sublease income, including the length of time to enter into a sublease, sublease rental payments, free rent periods, tenant improvement allowances and broker commissions. When available, we use sublease negotiations or agreements, but in the absence of such information, we develop our own subjective estimates based on current real estate trends and market conditions. Accordingly, our estimates are subject to significant risk, and the terms of sublease agreements, if any, and the resulting amount and timing of sublease income, if ever realized, may be materially different than our estimates. As part of our evaluation of each sublease space, we separately compare the estimated undiscounted sublease income, as described above, for each sublease to the net book value of the related long-term assets, which include right-of-use assets and certain property, plant and equipment, primarily for leasehold improvements (collectively, sublease assets). If such sublease income exceeds the net book value of the sublease assets, we do not record an impairment charge. Otherwise, we record an impairment charge by reducing the net book value of the sublease assets to their estimated fair value, which we determined by discounting the estimated sublease income using the estimated borrowing rate of a market participant subtenant.During the three months ended March 31, 2023, we recorded an initial impairment charge of $11.5 million for our remaining office and laboratory leased space in our Mission Bay Facility, when we initially decided to sublease the space under the 2023 Restructuring Plan. We also recorded an additional impairment charge of $1.7 million for certain excess laboratory equipment which we subsequently sold in the three months ended September 30, 2023 and recognized an immaterial gain, resulting in a net impairment of $1.3 million for the nine months ended September 30, 2023. As the life sciences lease market has continued to deteriorate in the San Francisco Bay Area, we recorded additional non-cash impairment charges of $9.1 million in the three months ended September 30, 2023, and $3.9 million in the three months ended June 30, 2024, for this space. During the three months ended June 30, 2023 and September 30, 2023, we recorded additional non-cash impairment charges of $7.1 million and $1.5 million, respectively, for other sublease assets in our Mission Bay Facility that we sought to sublease under the 2022 Restructuring Plan. Due to the worsening office lease market, for the three months ended June 30, 2024 and 2023, we recorded non-cash impairment charges of $4.4 million and $6.2 million, respectively, for our sublease assets at our Third Street Facility.For these impairment charges, we developed our estimates of sublease income based on market participant assumptions as described above, and we discounted the sublease income using the estimated borrowing rate of a market participant subtenant, which we estimated to be 7.9% for the three months ended March 31, 2023, 8.5% for the three months ended June 30, 2023, 8.7% for the three months ended September 30, 2023, and 6.2% for the three months ended June 30, 2024. We recorded no impairment charges for the three months ended March 31, 2024 and the three months ended September 30, 2024.The following is a reconciliation of the impairment charges we recorded for the nine months ended September 30, 2024 and three and nine months ended September 30, 2023, including the net book values of the sublease assets before the impairment and the fair values of the sublease assets (in thousands): Â Â Nine Months Ended September 30, 2024 Â Â Â Property, Plant and Equipment Â Â Operating Lease Right-of-Use Assets Â Â Total Â Net book value of impaired facilities before write-off Â $ 1,897 Â Â $ 12,506 Â Â $ 14,403 Â Less: Fair value of impaired facilities â€” Level 3 of Fair Value Hierarchy Â Â (855) Â Â (5,219) Â Â (6,074) Total impairment of right-of-use assets and property, plant and equipment Â $ 1,042 Â Â $ 7,287 Â Â $ 8,329 Â Â Â Three Months Ended September 30, 2023 Â Â Â Property, Plant and Equipment Â Â Operating Lease Right-of-Use Assets Â Â Total Â Net book value of impaired facilities before write-off Â $ 3,050 Â Â $ 18,830 Â Â $ 21,880 Â Less: Fair value of impaired facilities â€” Level 3 of Fair Value Hierarchy Â Â (1,650) Â Â (9,663) Â Â (11,313) Impairment expense for facilities Â Â 1,400 Â Â Â 9,167 Â Â Â 10,567 Â (Gain) on sale or disposal of property, plant, and equipment Â Â (394) Â Â â€” Â Â Â (394) Total impairment of right-of-use assets and property, plant and equipment Â $ 1,006 Â Â $ 9,167 Â Â $ 10,173 Â Â Â Â Nine Months Ended September 30, 2023 Â Â Â Property, Plant and Equipment Â Â Operating Lease Right-of-Use Assets Â Â Total Â Net book value of impaired facilities before write-off Â $ 7,206 Â Â $ 46,292 Â Â $ 53,498 Â Less: Fair value of impaired facilities â€” Level 3 of Fair Value Hierarchy Â Â (2,172) Â Â (14,364) Â Â (16,536) Book value in excess of fair value Â Â 5,034 Â Â Â 31,928 Â Â Â 36,962 Â Less: Amounts recorded as amortization between March 31, 2023 and September 30, 2023 for Mission Bay facility Â Â (263) Â Â (1,370) Â (1,633) Impairment expense for facilities Â Â 4,771 Â Â Â 30,558 Â Â Â 35,329 Â Impairment of other property, plant and equipment Â Â 1,299 Â Â Â Â Â Â 1,299 Â Total impairment of right-of-use assets and property, plant and equipment Â $ 6,070 Â Â $ 30,558 Â Â $ 36,628 Â Contract Termination and Other CostsWe have incurred significant contract termination costs in connection with our Restructuring Plans. Because we continue to adjust the liability based on updates to our assumptions at each reporting date, we continue to recognize expense as our estimates change until settlement.The following are reconciliations of the contract termination and other costs for three and nine months ended September 30, 2024 and 2023. As of September 30, 2024 and December 31, 2023, we report $3.2 million and $3.0 million, respectively, within accrued expenses and the remaining within other long-term liabilities on our Condensed Consolidated Balance Sheets. Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Liability balances as of December 31, 2023 and 2022, respectively Â $ 5,542 Â Â $ 7,710 Â Expense recognized during the period Â Â 975 Â Â Â 912 Â Payments during the period Â Â (928) Â Â (1,129) Liability balances as of March 31, 2024 and 2023, respectively Â $ 5,589 Â Â $ 7,493 Â Expense recognized during the period Â Â 4,960 Â Â Â - Â Payments during the period Â Â (887) Â Â (1,264) Liability balances as of June 30, 2024 and 2023, respectively Â $ 9,662 Â Â $ 6,229 Â Expense recognized during the period Â Â 46 Â Â Â - Â Payments during the period Â Â (886) Â Â (460) Liability balances as of September 30, 2024 and 2023, respectively Â $ 8,822 Â Â $ 5,769 Â X - ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + ReferencesNo definition available. + Details Name: us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Impairment of Goodwill 9 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Impairment of Goodwill Note 8 â€” Impairment of GoodwillDuring the three months ended March 31, 2023, our stock price and resulting market capitalization experienced a significant, sustained decline. Accordingly, we assessed our long-lived assets, including our property, plant and equipment, right-of-use assets and goodwill, for impairment.As part of our long-lived asset impairment analysis, we first assessed which long-lived assets have identifiable cash flows that are largely independent of the cash flows of other groups of assets. We concluded that the sublease assets, for which we recognized significant impairment charges during 2022 and 2023, including for the three months ended March 31, 2023, are independent of our entity-wide group. See Note 7 for additional information regarding impairment charges that we have recorded for our sublease assets, as well as certain property, plant and equipment that we subsequently sold.We next evaluated our remaining long-lived assets for impairment and performed a recoverability test using the undiscounted cash flows approach. We did not recognize any additional impairment charges on the remaining long-lived assets.Finally, we measured the fair value of our reporting unit utilizing both income and market approaches for our entity-wide asset impairment analysis. Based on this analysis, we wrote off all of our goodwill, resulting in a non-cash impairment charge of $76.5 million which we reported as impairment of goodwill in our Condensed Consolidated Statements of Operations for the three months ended March 31, 2023. We had previously recognized goodwill primarily from our acquisitions of Shearwater Corp. and Aerogen, Inc. in 2001 and 2005, respectively. X - DefinitionThe entire disclosure for the details of the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value. Disclosure may also include a description of the impaired asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired asset is reported. + ReferencesNo definition available. + Details Name: us-gaap_AssetImpairmentChargesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 23 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Stock-Based Compensation Note 9 â€” Stock-Based CompensationWe recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Cost of goods sold Â $ 516 Â Â $ 841 Â Â $ 1,673 Â Â $ 2,454 Â Research and development Â Â 2,010 Â Â Â 3,202 Â Â Â 6,337 Â Â Â 11,107 Â General and administrative Â Â 2,865 Â Â Â 4,106 Â Â Â 8,799 Â Â Â 12,573 Â Total stock-based compensation Â $ 5,391 Â Â $ 8,149 Â Â $ 16,809 Â Â $ 26,134 Â Â X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Event 9 Months Ended Sep. 30, 2024 Subsequent Events [Abstract] Â Subsequent Event Note 10 â€” Subsequent EventOn November 1, 2024, we entered into the APA and certain other agreements (the Transactions) with an affiliate (the Purchaser) of Ampersand Capital Partners. Under the APA, the Purchaser will purchase our manufacturing facility located in Huntsville, Alabama (the Facility), and certain other related assets and will assume certain related liabilities, and we will assign our manufacturing and supply agreements for PEG reagents to the Purchaser. As consideration, we will receive $70 million in cash at closing of the Transactions (subject to customary closing costs and adjustments based on closing net working capital, closing inventory and the amount of any indebtedness assumed by the Purchaser) and an approximate 20% equity ownership at the time of close in the Purchaser.The closing of the Transactions is subject to the satisfaction or waiver of certain customary closing conditions set forth in the APA.The APA contains customary representations and warranties of Nektar and Purchaser. Nektar has agreed to provide certain specific and customary indemnities to Purchaser for certain excluded liabilities not covered by a representation and warranties policy to be obtained by Purchaser in connection with the Transactions. In addition, the APA contains certain restrictive covenants, which will restrict, as of the closing of the Transactions, Nektarâ€™s ability to manufacture and sell PEG reagents.In addition, the APA provides that, at the closing of the Transactions, each of Nektar and Purchaser will enter into certain ancillary agreements to effect the Transactions, including a mutual transition services agreement and a manufacturing and supply agreement and for Purchaser to supply to Nektar the PEG reagents for use in the manufacture of rezpegaldesleukin and NKTR-255. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Organization and Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Organization OrganizationNektar Therapeutics (Nektar, we) is a clinical stage, research-based drug discovery biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware, focused on discovering and developing innovative medicines in the field of immunotherapy. Within this growing field, we direct our efforts toward creating new immunomodulatory agents that selectively induce, amplify, attenuate or prevent immune responses in order to achieve desired therapeutic outcomes. Our pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and

negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. As of September 30, 2024, we had approximately $249.0 million in cash and investments in marketable securities. Sale of Manufacturing Facility Sale of Manufacturing FacilityOn November 1, 2024, we entered into an Asset Purchase Agreement (the APA) with an affiliate (the Purchaser) of Ampersand Management LLC d/b/a Ampersand Capital Partners (Ampersand), for the sale of our manufacturing facility located in Huntsville, Alabama (the Facility) and certain other manufacturing assets related thereto, including the assignment of our existing manufacturing and supply obligations, for consideration of $70 million in cash (subject to customary closing costs and adjustments based on closing net working capital, closing inventory and the amount of any indebtedness assumed by the Purchaser) and an approximate 20% equity ownership at the time of close in the Purchaser. See Note 10 for additional information. Financing Transactions Financing TransactionsDuring the nine months ended September 30, 2024, we entered into the following transactions:â€¢On February 12, 2024, for total cash consideration paid of $3.0 million, we repurchased from Bristol Myers Squibb Company (BMS) 8.3 million shares of Nektar's common stock that were previously sold to BMS, which we report as treasury stock on our Condensed Consolidated Balance Sheets. See Note 6 for additional information.â€¢On March 4, 2024, we entered into a Securities Purchase Agreement with TCG Crossover Fund II, L.P. (TCG), pursuant to which we issued a pre-funded warrant to TCG to purchase 25,000,000 shares of Nektarâ€™s common stock for gross proceeds of $30.0 million (or a purchase price of $1.20 per share of common stock that can be issued upon exercise of the pre-funded warrant). On May 28, 2024, we filed with the SEC a registration statement on Form S-3 (file no. 333-279760) registering for the resale of up to 25,000,000 shares of Nektarâ€™s common stock upon exercise of the pre-funded warrant issued to TCG pursuant to the Securities Purchase Agreement. The registration statement became effective on June 5, 2024. See Note 5 for additional information.â€¢On March 4, 2024, for total cash consideration received of $15.0 million, we entered into an amendment (the Amendment) with entities managed by Healthcare Royalty Management, LLC (collectively, HCR) to remove the cap on royalties previously sold to HCR under a Purchase and Sale Agreement (the 2020 Purchase and Sale Agreement). See Note 3 for additional information. Restructuring Plans Restructuring PlansIn April 2022, we announced the termination of the bempegaldesleukin program and a new strategic reorganization and cost restructuring plan (together, the 2022 Restructuring Plan), pursuant to which we completed an approximate 70% reduction of our workforce during 2022. We also decided to seek a sublease for certain of our leased premises in San Francisco, CA, including all of our office space on Third St. and portions of our office and laboratory space on Mission Bay Blvd. South.In April 2023, we announced Eli Lilly and Company's (Lilly) decision to terminate our license agreement (the Lilly Agreement) for the development of rezpegaldesleukin, as well as a new strategic reprioritization and cost restructuring plan (the 2023 Restructuring Plan). Under the 2023 Restructuring Plan, we reduced our San Francisco-based workforce by approximately 60%. In addition, under the 2023 Restructuring Plan, we decided to seek a sublease for our remaining office and laboratory space on Mission Bay Blvd. South which we had not planned to sublease pursuant to the 2022 Restructuring Plan. We have regained full rights to rezpegaldesleukin from Lilly, and we initiated a Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in October 2023 and a Phase 2b study of rezpegaldesleukin in patients with severe-to-very severe alopecia areata in March 2024. We will also explore other auto-immune indications for the development of rezpegaldesleukin.We have incurred significant costs resulting from the 2022 and 2023 Restructuring Plans. See Note 7 for additional information on the effect on our Condensed Consolidated Financial Statements. Basis of Presentation and Principles of Consolidation Basis of Presentation and Principles of ConsolidationOur Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of Nektar Therapeutics and our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation.We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiaryâ€™s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive income (loss) in the stockholdersâ€™ equity section of our Condensed Consolidated Balance Sheets. Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive income (loss) to the statements of operations during the three and nine months ended September 30, 2024 and 2023 except as otherwise disclosed below in Note 3.The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December 31, 2023 was derived from the audited consolidated financial statements which are included in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 5, 2024. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements.Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period. Use of Estimates Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified. Significant Concentrations Significant ConcentrationsOur customers are primarily pharmaceutical companies that are located in the U.S. and Europe and with whom we have multi-year arrangements. Our accounts receivable balances contain billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. We generally do not require collateral from our customers. We perform a regular review of our customersâ€™ credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable or contract assets. We have not recorded reserves for credit losses for the three and nine months ended September 30, 2024 and 2023, nor have recorded such an allowance as of September 30, 2024 or December 31, 2023. As of September 30, 2024, all billed and unbilled trade receivables from product sales and contract assets have been classified as held-for-sale and included within assets held for sale on our Condensed Consolidated Balance Sheets.We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, various factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuerâ€™s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if various factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales. Treasury Stock Treasury StockWe record treasury stock activities under the cost method. Treasury stock is included in authorized and issued shares but excluded from outstanding shares. The re-issuance of treasury stock is accounted for on a first in, first-out basis and any differences between the cost of treasury stock and the re-issuance proceeds are charged or credited to additional paid-in capital. Restructuring RestructuringWe recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for:â€¢contractual or other employee termination benefits provided that the obligations result from services already rendered based on rights that vest or accumulated when the payment of benefits becomes probable and the amount can be reasonably estimated;â€¢one-time employee termination benefits on the communication date from management to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn; andâ€¢contract termination costs for costs incurred when we cancel the contract in accordance with its terms, or for costs to be incurred over the remaining contract term without economic benefit to us at the cease-use date.For one-time employee terminations benefits, we recognize the liability in full on the communication date when future services are not required or amortize the liability ratably over the service period, if required. The fair value of termination benefits reflects our estimates of expected utilization of certain Company-funded post-employment benefits.See Note 7 for additional information on the severance expense that we recognized for employees terminated in connection with our reductions-in-force. Impairment of Goodwill Impairment of GoodwillGoodwill is assessed for impairment on an annual basis and whenever events and circumstances indicate that it may be impaired. Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, current economic, market and geopolitical conditions, including a significant, sustained decline in our stock price and market capitalization compared to the net book value; an adverse change in legal factors, business climate or operational performance of the business; or significant changes in the ability of the reporting unit to generate positive cash flows for our strategic business objectives. If the carrying value of the reporting unit, including goodwill, exceeds the reporting unitâ€™s fair value, we will recognize a goodwill impairment loss, and we will write down goodwill such that the carrying value of the reporting unit equals its fair value, provided that we cannot reduce goodwill below zero.See Note 8 for additional information regarding the impairment charges we recorded during the three months ended March 31, 2023 in connection with our goodwill. Long-Lived Asset Impairment Long-Lived Asset ImpairmentWe assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated net cash flows associated with the asset, discounted at a rate that we believe a market participant would utilize to reflect the risks associated with the cash flows, such as credit risk. See Note 7 for additional information regarding the impairment charges we recorded in connection with our leased facilities and certain property and equipment. Net Loss per Share Net Loss per ShareFor all periods presented in the Condensed Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. We calculate basic net loss per share based on the weighted-average number of common shares outstanding, including the pre-funded warrant, during the periods presented. Shares of common stock into which the pre-funded warrant may be exercised are considered outstanding for the purposes of computing basic net loss per share because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date. For the three and nine months ended September 30, 2024 and 2023, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. We excluded shares underlying the weighted average outstanding stock options, restricted stock units (RSUs) and performance stock units (PSUs), as follows (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Potentially dilutive securities Â Â 25,887 Â Â Â 17,476 Â Â Â 26,417 Â Â Â 20,513 Â Â Inventory We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.As of September 30, 2024 and December 31, 2023, we recorded aggregate provisions of $0 and $2.0 million, respectively, for the net realizable value of our batches. Our manufacturing agreement with UCB Pharma (UCB) for the reagent used in the manufacture of CIMZIAÂ® provided for a fixed selling price which we had negotiated in exchange for a higher royalty rate. Accordingly, when evaluating the net realizable value of our inventory for UCB, we include the negotiated increase of the royalties in our analysis, and the aggregate revenue has historically been greater than our manufacturing cost. Due to the decreases in the royalty rate for 2024 and 2025 as a result of a settlement agreement with UCB, the aggregate revenue was expected to be less than our manufacturing cost for these years, and therefore we previously recorded a provision for net realizable value. As further disclosed in Note 6, on July 31, 2024, we entered into a long-term supply agreement with UCB that increases the selling price of the reagent used in the manufacture of CIMZIAÂ®, which resulted in the aggregate revenue exceeding our manufacturing costs. As a result, we reduced the provision to $0 during the three months ended September 30, 2024. As of September 30, 2024, all of the inventory balance is classified as held for sale and included within assets held for sale on our Condensed Consolidated Balance Sheets. X - DefinitionFinancing transactions policy. + ReferencesNo definition available. + Details Name: nktr_FinancingTransactionsPolicyTextBlock Namespace Prefix: nktr_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionOrganization. + ReferencesNo definition available. + Details Name: nktr_OrganizationPolicyTextBlock Namespace Prefix: nktr_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionSale of manufacturing facility. + ReferencesNo definition available. + Details Name: nktr_SaleOfManufacturingFacilityPolicyTextBlock Namespace Prefix: nktr_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTreasury stock policy. + ReferencesNo definition available. + Details Name: nktr_TreasuryStockPolicyTextBlock Namespace Prefix: nktr_ Data Type: dtr-

types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2 + Details Name: us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -SubTopic 10 -Topic 420 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.CC) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 05 -Paragraph 4 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4 + Details Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 330 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContentReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a) -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6 + Details Name: us-gaap_InventoryPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Organization and Summary of Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share We excluded shares underlying the weighted average outstanding stock options, restricted stock units (RSUs) and performance stock units (PSUs), as follows (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Potentially dilutive securities Â Â 25,887 Â Â Â 17,476 Â Â Â 26,417 Â Â Â 20,513 Â Â X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Cash and Investments in Marketable Securities (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):Â Â Â Estimated Fair Value at Â Â Â September 30, 2024 Â Â December 31, 2023 Â Cash and cash equivalents Â $ 30,109 Â Â $ 35,277 Â Short-term investments Â Â 214,386 Â Â Â 268,339 Â Long-term investments Â Â 4,537 Â Â Â 25,825 Â Total cash, cash equivalents, and investments in marketable securities Â $ 249,032 Â Â $ 329,441 Â Schedule of Portfolio of Cash and Investments in Marketable Securities Our portfolio of cash and investments in marketable securities includes (in thousands):Â Â Â Â Â September 30, 2024 Â Â December 31, 2023 Â Â Â Fair Value Hierarchy Level Â Amortized Cost Â Â Gross Unrealized Gains Â Â Gross Unrealized Losses Â Â Fair Value Â Â Fair Value Â Corporate notes and bonds Â 2 Â $ 90,589 Â Â $ 214 Â Â Â $ (10) Â $ 90,793 Â Â $ 38,882 Â Corporate commercial paper Â 2 Â Â 125,927 Â Â Â 163 Â Â Â Â (7) Â Â 126,083 Â Â Â 255,241 Â Obligations of U.S. government agencies Â 2 Â Â 1,500 Â Â Â 2 Â Â Â â€” Â Â Â 1,502 Â Â Â â€” Â Available-for-sale investments Â Â Â $ 218,016 Â Â $ 379 Â Â $ (17) Â $ 218,378 Â Â $ 294,123 Â Money market funds Â 1 Â Â Â Â Â Â Â Â Â Â Â Â Â 10,361 Â Â Â 2,359 Â Certificates of deposit Â 2 Â Â Â Â Â Â Â Â Â Â Â Â Â 14,046 Â Â Â 15,116 Â Cash Â N/A Â Â Â Â Â Â Â Â Â Â Â Â Â 6,247 Â Â Â 17,843 Â Total cash and investments in marketable securities Â Â Â Â Â Â Â Â Â $ 249,032 Â Â $ 329,441 Â X - DefinitionTabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of cash, cash equivalents, and investments. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Financial Statement Details (Tables) 9 Months Ended Sep. 30, 2024 Inventory Disclosure [Abstract] Â Schedule of Inventory Inventory consists of the following (in thousands): Â Â September 30, 2024 Â Â December 31, 2023 Â Raw materials Â $ â€” Â Â $ 1,861 Â Work-in-process Â Â â€” Â Â Â 12,880 Â Finished goods Â Â â€” Â Â Â 1,360 Â Total inventory, net Â $ â€” Â Â $ 16,101 Â Schedule of Other Current

Assets Other current assets consist of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Prepaid research and development expenses Â $ 3,960 Â Â $ 4,325 Â Interest and other non-trade receivables Â Â 2,123 Â Â Â 1,047 Â Other prepaid expenses Â Â 2,850 Â Â Â 4,407 Â Total other current assets Â $ 8,933 Â Â $ 9,779 Â Assets Held for Sale As of September 30, 2024, assets held for sale consist of the following: Â Â September 30, 2024 Â Accounts receivable Â $ 1,746 Â Inventory, net Â Â 16,889 Â Property, plant and equipment, net Â Â 11,386 Â Contract asset Â Â 3,032 Â Total assets held for sale Â $ 33,053 Â Schedule of Property, Plant and Equipment Property, plant and equipment consists of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Building and leasehold improvements Â $ 3,834 Â Â $ 43,184 Â Computer equipment and computer software Â Â 14,615 Â Â Â 22,438 Â Manufacturing equipment Â Â â€” Â Â Â 24,315 Â Laboratory equipment Â Â 616 Â Â Â 14,537 Â Furniture, fixtures and other Â Â 59 Â Â Â 541 Â Depreciable property, plant and equipment at cost Â Â 19,124 Â Â Â 105,015 Â Less: accumulated depreciation Â Â (15,659) Â Â (86,898) Depreciable property, plant and equipment, net Â Â 3,465 Â Â Â 18,117 Â Construction in process Â Â 138 Â Â Â 739 Â Property, plant and equipment, net Â $ 3,603 Â Â $ 18,856 Â Schedule of Accrued Expenses Accrued expenses consist of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Accrued compensation Â $ 7,007 Â Â $ 5,553 Â Accrued research and development expenses Â Â 17,916 Â Â Â 10,118 Â Accrued contract termination costs Â Â 3,151 Â Â Â 3,020 Â Other accrued expenses Â Â 4,303 Â Â Â 3,471 Â Total accrued expenses Â $ 32,377 Â Â $ 22,162 Â Schedule of Liability Related to Sale of Potential Future Royalties The following is a reconciliation of the changes in our liabilities related to the sales of future royalties for the nine months ended September 30, 2024 (in thousands):Â Â Â Nine Months Ended September 30, 2024 Â Â Â 2012 Purchase and Sale Agreement Â Â 2020 Purchase and Sale Agreement Â Â Total Â Liabilities related to the sales of future royalties, net â€” beginning balance Â $ 24,217 Â Â $ 88,408 Â Â $ 112,625 Â Non-cash royalty revenue Â Â (19,007) Â Â (29,022) Â Â (48,029) Non-cash interest expense Â Â 4,940 Â Â Â 13,019 Â Â Â 17,959 Â Amortization of transaction costs Â Â â€” Â Â Â 274 Â Â Â 274 Â Proceeds from the Amendment Â Â â€” Â Â Â 15,000 Â Â Â 15,000 Â Liabilities related to the sales of future royalties, net â€” ending balance Â $ 10,150 Â Â $ 87,679 Â Â $ 97,829 Â Schedule of Accumulated Other Comprehensive Income (Loss) The following table summarizes the changes in accumulated other comprehensive income (loss) by component (in thousands):Â Â Â Foreign currency translation Â Â Available-for-sale securities Â Â Accumulated Other Comprehensive Income Â Balance at December 31, 2023 Â $ 30 Â Â $ 50 Â Â $ 80 Â Foreign currency translation adjustments Â Â (8) Â Â â€” Â Â Â (8) Unrealized gain (loss) on available-for-sale securities Â Â â€” Â Â Â (475) Â Â (475) Balance at March 31, 2024 Â $ 22 Â Â $ (425) Â $ (403) Foreign currency translation adjustments Â Â (1) Â Â â€” Â Â Â (1) Unrealized gain (loss) on available-for-sale securities Â Â â€” Â Â Â (90) Â Â (90) Balance at June 30, 2024 Â $ 21 Â Â $ (515) Â $ (494) Foreign currency translation adjustments Â Â (28) Â Â â€” Â Â Â (28) Unrealized gain (loss) on available-for-sale securities Â Â â€” Â Â Â 877 Â Â Â 877 Â Balance at September 30, 2024 Â $ (7) Â $ 362 Â Â $ 355 Â Â Â Â Foreign currency translation Â Â Available-for-sale securities Â Â Accumulated Other Comprehensive Income Â Balance at December 31, 2022 Â $ (5,131) Â $ (1,776) Â $ (6,907) Foreign currency translation adjustments Â Â 139 Â Â Â â€” Â Â Â 139 Â Unrealized gain (loss) on available-for-sale securities Â Â â€” Â Â Â 1,087 Â Â Â 1,087 Â Balance at March 31, 2023 Â $ (4,992) Â $ (689) Â $ (5,681) Foreign currency translation adjustments Â Â 13 Â Â Â â€” Â Â Â 13 Â Unrealized gain (loss) on available-for-sale securities Â Â â€” Â Â Â 244 Â Â Â 244 Â Reclassification adjustments to income Â Â (1,026) Â Â â€” Â Â Â (1,026) Balance at June 30, 2023 Â $ (6,005) Â $ (445) Â $ (6,450) Foreign currency translation adjustments Â Â (98) Â Â â€” Â Â Â (98) Unrealized gain (loss) on available-for-sale securities Â Â â€” Â Â Â 196 Â Â Â 196 Â Balance at September 30, 2023 Â $ (6,103) Â $ (249) Â $ (6,352) X - DefinitionSchedule Of Liability Related To Sale Of Potential Future Royalties + ReferencesNo definition available. + Details Name: nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock Namespace Prefix: nktr_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accumulated other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3AReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5D -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5DReference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3AReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3 + Details Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amounts of other current assets. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Restructuring, Impairment and Costs of Terminated Program (Tables) 9 Months Ended Sep. 30, 2024 Restructuring and Related Activities [Abstract] Â Schedule of Restructuring, Impairment and Other Costs of Terminated Program Restructuring, impairment and costs of terminated program includes the following (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program Â $ â€” Â Â $ 652 Â Â $ â€” Â Â $ 3,606 Â Severance and benefit expense Â Â â€” Â Â Â 535 Â Â Â â€” Â Â Â 7,961 Â Impairment of right-of-use assets and property, plant and equipment Â Â â€” Â Â Â 10,173 Â Â Â 8,329 Â Â Â 36,628 Â Contract termination and other restructuring costs Â Â 46 Â Â Â â€” Â Â Â 5,981 Â Â Â 912 Â Restructuring, impairment and other costs of terminated program Â $ 46 Â Â $ 11,360 Â Â $ 14,310 Â Â $ 49,107 Â The following table provides details regarding the severance and benefit expense for the three and nine months ended September 30, 2024 pursuant to the 2023 Restructuring Plan and a reconciliation of the severance and benefits liability for the three and nine months ended September 30, 2023 pursuant to the 2022 and 2023 Restructuring Plans, which we report within accrued expenses on our Condensed Consolidated Balance Sheet (in thousands): Â Â Nine Months Ended September 30, 2023 Â Â Â 2023 Restructuring Plan Â Â 2022 Restructuring Plan Â Â Total Â Liability balance as of December 31, 2022 Â $ â€” Â Â $ 3,299 Â Â $ 3,299 Â Expense recognized during the period Â Â 5,483 Â Â Â â€” Â Â Â 5,483 Â Payments during the period Â Â â€” Â Â Â (3,299) Â Â (3,299) Liability balance as of March 31, 2023 Â $ 5,483 Â Â $ â€” Â Â $ 5,483 Â Expense recognized during the period Â Â 1,943 Â Â Â â€” Â Â Â 1,943 Â Payments during the period Â Â (6,624) Â Â â€” Â Â Â (6,624) Liability balance as of June 30, 2023 Â $ 802 Â Â $ â€” Â Â $ 802 Â Expense recognized during the period Â Â 535 Â Â Â â€” Â Â Â 535 Â Payments during the period Â Â (887) Â Â â€” Â Â Â (887) Liability balance as of September 30, 2023 Â $ 450 Â Â $ â€” Â Â $ 450 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Nine Months Ended September 30, 2024 Â Â Â 2023 Restructuring Plan Â Â 2022 Restructuring Plan Â Â Total Â Liability balance as of December 31, 2023 Â $ 196 Â Â $ â€” Â Â $ 196 Â Expense recognized during the period Â Â â€” Â Â Â â€” Â Â Â â€” Â Payments during the period Â Â (196) Â Â â€” Â Â Â (196) Liability balance as of September 30, 2024 Â $ â€” Â Â $ â€” Â Â $ â€” Â The following is a reconciliation of the impairment charges we recorded for the nine months ended September 30, 2024 and three and nine months ended September 30, 2023, including the net book values of the sublease assets before the impairment and the fair values of the sublease assets (in thousands): Â Â Nine Months Ended September 30, 2024 Â Â Â Property, Plant and Equipment Â Â Operating Lease Right-of-Use Assets Â Â Total Â Net book value of impaired facilities before write-off Â $ 1,897 Â Â $ 12,506 Â Â $ 14,403 Â Less: Fair value of impaired facilities â€” Level 3 of Fair Value Hierarchy Â Â (855) Â Â (5,219) Â Â (6,074) Total impairment of right-of-use assets and property, plant and equipment Â $ 1,042 Â Â $ 7,287 Â Â $ 8,329 Â Â Â Â Three Months Ended September 30, 2023 Â Â Â Property, Plant and Equipment Â Â Operating Lease Right-of-Use Assets Â Â Total Â Net book value of impaired facilities before write-off Â $ 3,050 Â Â $ 18,830 Â Â $ 21,880 Â Less: Fair value of impaired facilities â€” Level 3 of Fair Value Hierarchy Â Â (1,650) Â Â (9,663) Â Â (11,313) Impairment expense for facilities Â Â 1,400 Â Â Â 9,167 Â Â Â 10,567 Â (Gain) on sale or disposal of property, plant, and equipment Â Â (394) Â Â â€” Â Â Â (394) Total impairment of right-of-use assets and property, plant and equipment Â $ 1,006 Â Â $ 9,167 Â Â $ 10,173 Â Â Â Â Nine Months Ended September 30, 2023 Â Â Â Property, Plant and Equipment Â Â Operating Lease Right-of-Use Assets Â Â Total Â Net book value of impaired facilities before write-off Â $ 7,206 Â Â $ 46,292 Â Â $ 53,498 Â Less: Fair value of impaired facilities â€” Level 3 of Fair Value Hierarchy Â Â (2,172) Â Â (14,364) Â Â (16,536) Book value in excess of fair value Â Â 5,034 Â Â Â 31,928 Â Â Â 36,962 Â Less: Amounts recorded as amortization between March 31, 2023 and September 30, 2023 for Mission Bay facility Â Â (263) Â Â (1,370) Â (1,633) Impairment expense for facilities Â Â 4,771 Â Â Â 30,558 Â Â Â 35,329 Â Impairment of other property, plant and equipment Â Â 1,299 Â Â Â Â Â Â 1,299 Â Total impairment of right-of-use assets and property, plant and equipment Â $ 6,070 Â Â $ 30,558 Â Â $ 36,628 Â The following are reconciliations of the contract termination and other costs for three and nine months ended September 30, 2024 and 2023. As of September 30, 2024 and December 31, 2023, we report $3.2 million and $3.0 million, respectively, within accrued expenses and the remaining within other long-term liabilities on our Condensed Consolidated Balance Sheets. Â Â For the Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Liability balances as of December 31, 2023 and 2022, respectively Â $ 5,542 Â Â $ 7,710 Â Expense recognized during the period Â Â 975 Â Â Â 912 Â Payments during the period Â Â (928) Â Â (1,129) Liability balances as of March 31, 2024 and 2023, respectively Â $ 5,589 Â Â $ 7,493 Â

Expense recognized during the period Â Â 4,960 Â Â Â - Â Payments during the period Â Â (887) Â Â (1,264) Liability balances as of June 30, 2024 and 2023, respectively Â $ 9,662 Â Â $ 6,229 Â Expense recognized during the period Â Â 46 Â Â Â - Â Payments during the period Â Â (886) Â Â (460) Liability balances as of September 30, 2024 and 2023, respectively Â $ 8,822 Â Â $ 5,769 Â X - ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Schedule of Stock-Based Compensation Expense We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Cost of goods sold Â $ 516 Â Â $ 841 Â Â $ 1,673 Â Â $ 2,454 Â Research and development Â Â 2,010 Â Â Â 3,202 Â Â Â 6,337 Â Â Â 11,107 Â General and administrative Â Â 2,865 Â Â Â 4,106 Â Â Â 8,799 Â Â Â 12,573 Â Total stock-based compensation Â $ 5,391 Â Â $ 8,149 Â Â $ 16,809 Â Â $ 26,134 Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Organization and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended Nov. 01, 2024 May 28, 2024 Mar. 04, 2024 Feb. 12, 2024 Mar. 31, 2024 Jun. 30, 2023 Apr. 30, 2022 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Organization And Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash and investments in marketable securities Â Â Â Â Â Â Â $ 249,032,000 Â $ 249,032,000 Â $ 329,441,000 Proceeds from issuance of pre-funded warrant Â Â Â Â Â Â Â Â Â Â Â 30,000,000 $ 0 Â Accounts receivable, credit loss expense (reversal) Â Â Â Â Â Â Â $ 0 $ 0 $ 0 $ 0 Â Bristol Myers Squibb Company Â Â Â Â Â Â Â Â Â Â Â Â Â Organization And Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Sale of stock repurchased cash consideration Â Â Â $ 3,000,000 Â Â Â Â Â Â Â Â Â Â Â Sale of stock shares repurchased Â Â Â 8,300,000 Â Â Â Â Â Â Â Â Â Securities Purchase Agreement | TCG Crossover Fund II, L.P. Â Â Â Â Â Â Â Â Â Â Â Â Â Organization And Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Proceeds from issuance of pre-funded warrant Â Â $ 30,000,000 Â $ 30,000,000 Â Â Â Â Â Â Â Effective date of warrant Â Jun. 05, 2024 Â Â Â Â Â Â Â Â Â Â 2020 Purchase and Sale Agreement Â Â Â Â Â Â Â Â Â Â Â Â Â Organization And Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Amount exchanged to remove cap on royalties Â Â $ 15,000,000 Â Â Â Â Â Â Â Â Â Â Â Asset Purchase Agreement | Asset Acquisition By Ampersand Capital Partners | Subsequent event Â Â Â Â Â Â Â Â Â Â Â Â Â Organization And Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Proceeds from sale of assets $ 70,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Ownership interest received 20.00% Â Â Â Â Â Â Â Â Â Â Pre-Funded Warrant | Securities Purchase Agreement | TCG Crossover Fund II, L.P. Â Â Â Â Â Â Â Â Â Â Â Â Â Organization And Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Number of warrants issued to be purchase common shares Â Â 25,000,000 Â 25,000,000 Â Â Â Â Â Â Â Shares issued, price per share Â Â $ 1.2 Â $ 1.2 Â Â Â Â Â Â Â Pre-Funded Warrant | Securities Purchase Agreement | TCG Crossover Fund II, L.P. | Maximum Â Â Â Â Â Â Â Â Â Â Â Organization And Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Resale of common stock issuable upon exercise of warrant Â 25,000,000 Â Â Â Â Â Â Â Â Â Â Employee Severance | 2022 Restructuring Plan Â Â Â Â Â Â Â Â Â Â Â Â Â Organization And Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Workforce termination, percentage Â Â Â Â Â Â 70.00% Â Â Â Â Â Employee Severance | 2023 Restructuring Plan Â Â Â Â Â Â Â Â Â Â Â Organization And Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Workforce termination, percentage Â Â Â Â Â 60.00% Â Â Â Â Â Â Â X - DefinitionAmount exchanged to remove cap on royalties + ReferencesNo definition available. + Details Name: nktr_AmountExchangedToRemoveCapOnRoyalties Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash, restricted cash, cash equivalents, and available for sale investments. + ReferencesNo definition available. + Details Name: nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionEffective date of warrant. + ReferencesNo definition available. + Details Name: nktr_EffectiveDateOfWarrant Namespace Prefix: nktr_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionOrganization and summary of significant accounting policies. + ReferencesNo definition available. + Details Name: nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems Namespace Prefix: nktr_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage of ownership received in asset acquisition. + ReferencesNo definition available. + Details Name: nktr_PercentageOfOwnershipReceivedInAssetAcquisition Namespace Prefix: nktr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionResale of common stock issuable upon exercise of warrant. + ReferencesNo definition available. + Details Name: nktr_ResaleOfCommonStockIssuableUponExerciseOfWarrant Namespace Prefix: nktr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionSale of stock repurchased cash consideration. + ReferencesNo definition available. + Details Name: nktr_SaleOfStockRepurchasedCashConsideration Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s). + ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=nktr_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=nktr_TcgCrossoverFundIILPMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=nktr_AssetPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AssetAcquisitionAxis=nktr_AssetAcquisitionByAmpersandCapitalPartnersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nktr_PreFundedWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyTwoRestructuringPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyThreeRestructuringPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 32 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Organization and Summary of Significant Accounting Policies - Weighted Average Outstanding Stock Options (Details) - shares shares in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Stock Options, RSUs and PSUs Â Â Â Â Organization And Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Potentially dilutive securities (in shares) 25,887 17,476 26,417 20,513 X - DefinitionOrganization and summary of significant accounting policies. + ReferencesNo definition available. + Details Name: nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems Namespace Prefix: nktr_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktr_StockOptionsRSUsAndPSUsMember Namespace Prefix: Data

Type: na Balance Type: Period Type: XML 33 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Estimated Fair Value at Â Â Cash and cash equivalents $ 30,109 $ 35,277 Short-term investments 214,386 268,339 Long-term investments 4,537 25,825 Total cash, cash equivalents, and investments in marketable securities $ 249,032 $ 329,441 X - DefinitionCash, restricted cash, cash equivalents, and available for sale investments. + ReferencesNo definition available. + Details Name: nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 34 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Cash $ 6,247 $ 17,843 Total cash, cash equivalents, and investments in marketable securities 249,032 329,441 Level 2 Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Amortized Cost 218,016 Â Gross Unrealized Gains 379 Â Gross Unrealized Losses (17) Â Fair Value 218,378 294,123 Level 2 | Corporate notes and bonds Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Amortized Cost 90,589 Â Gross Unrealized Gains 214 Â Gross Unrealized Losses (10) Â Fair Value 90,793 38,882 Level 2 | Corporate commercial paper Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Amortized Cost 125,927 Â Gross Unrealized Gains 163 Â Gross Unrealized Losses (7) Â Fair Value 126,083 255,241 Level 2 | Obligations of U.S. government agencies Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Amortized Cost 1,500 Â Gross Unrealized Gains 2 Â Gross Unrealized Losses 0 Â Fair Value 1,502 0 Level 2 | Certificates of deposit Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Investments, fair value disclosure 14,046 15,116 Level 1 | Money market funds Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Investments, fair value disclosure $ 10,361 $ 2,359 X - DefinitionCash, restricted cash, cash equivalents, and available for sale investments. + ReferencesNo definition available. + Details Name: nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 210 -Topic 946 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20 + Details Name: us-gaap_Cash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_InvestmentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 35 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Financial Statement Details - Schedule of Inventory (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Inventory Disclosure [Abstract] Â Â Raw materials $ 0 $ 1,861 Work-in-process 0 12,880 Finished goods 0 1,360 Total inventory, net $ 0 $ 16,101 X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X -

DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoodsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterialsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcessNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 36 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Financial Statement Details - Schedule of Other Current Assets (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Â Â Other current assets $ 8,933 $ 9,779 Prepaid research and development expenses Â Â Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Â Â Other current assets 3,960 4,325 Interest and Other Non-trade Receivables Â Â Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Â Â Other current assets 2,123 1,047 Other prepaid expenses Â Â Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Â Â Other current assets $ 2,850 $ 4,407 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_BalanceSheetLocationAxis=nktr_PrepaidResearchAndDevelopmentExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=nktr_InterestAndOtherNonTradeReceivablesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Financial Statement Details - Assets Held for Sale (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Inventory Disclosure [Abstract] Â Â Accounts receivable $ 1,746 Â Inventory, net 16,889 Â Property, plant and equipment, net 11,386 Â Contract asset 3,032 Â Total assets held for sale $ 33,053 $ 0 X - DefinitionDisposal Group, Including Discontinued Operation, Contract With Customer Asset, Current. + ReferencesNo definition available. + Details Name: nktr_DisposalGroupIncludingDiscontinuedOperationContractWithCustomerAssetCurrent Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 38 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Financial Statement Details - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Property, Plant and Equipment [Line Items] Â Â Depreciable property, plant and equipment at cost $ 19,124 $ 105,015 Less: accumulated depreciation (15,659) (86,898) Depreciable property, plant and equipment, net 3,465 18,117 Construction in process 138 739 Property, plant and equipment, net 3,603 18,856 Building and leasehold improvements Â Â Property, Plant and Equipment [Line Items] Â Â Depreciable property, plant and equipment at cost 3,834 43,184 Computer equipment and computer software Â Â Property, Plant and Equipment [Line Items] Â Â Depreciable property, plant and equipment at cost 14,615 22,438 Manufacturing equipment Â Â Property, Plant and Equipment [Line Items] Â Â Depreciable property, plant and equipment at cost 0 24,315 Laboratory equipment Â Â Property, Plant and Equipment [Line Items] Â Â Depreciable property, plant and equipment at cost 616 14,537 Furniture, fixtures and other Â Â Property, Plant and Equipment [Line Items] Â Â Depreciable property, plant and equipment at cost $ 59 $ 541 X - DefinitionDepreciable Property, plant and equipment, Gross. + ReferencesNo definition available. + Details Name: nktr_DepreciablePropertyPlantAndEquipmentGross Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDepreciable Property, plant and equipment, Net. + ReferencesNo definition available. + Details Name: nktr_DepreciablePropertyPlantAndEquipmentNet Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_ConstructionInProgressGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type:

xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_BuildingAndLeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ComputerFurnitureAndOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_ManufacturingLaboratoryAndOtherEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_LaboratoryEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Financial Statement Details - Narrative (Details) $ in Thousands 3 Months Ended 9 Months Ended Mar. 04, 2024 USD ($) Dec. 16, 2020 USD ($) Sep. 30, 2024 USD ($) Jun. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Goodwill [Line Items] Â Â Â Â Â Â Â Â Â Â Impairment of other property, plant and equipment Â Â $ 0 Â $ 10,173 $ 8,329 $ 36,628 Â 2012 Purchase and Sale Agreement Â Â Â Â Â Â Â Â Goodwill [Line Items] Â Â Â Â Â Â Â Â Royalties liability discount rate Â Â 0.43 Â Â 0.43 Â Â 2020 Purchase and Sale Agreement Â Â Â Â Â Â Â Â Goodwill [Line Items] Â Â Â Â Â Â Â Â Royalties liability discount rate Â Â 0.24 Â Â 0.24 Â Â Payment of transaction related to purchase and sale agreement Â $ 210,000 Â Â Â Â Â Â Â Payment of transaction related to purchase and sale agreement if threshold is not achieved Â $ 240,000 Â Â Â Â Â Â Â Amount exchanged to remove cap on royalties $ 15,000 Â Â Â Â Â Â Â Proceeds from sale of royalty rights Â Â Â Â Â $ 15,000 Â Â UCB Pharma Manufacturing Agreement Â Â Â Â Â Â Â Â Goodwill [Line Items] Â Â Â Â Â Â Â Â Net realizable value of assets Â Â $ 0 Â Â $ 0 Â $ 2,000 Provision for inventory Â Â $ 0 Â Â Â Â Â Sublease of Laboratory and Office Space Â Â Â Â Â Â Â Â Goodwill [Line Items] Â Â Â Â Â Â Â Â Impairment of other property, plant and equipment Â Â Â $ 1,000 Â Â Â Â X - DefinitionAmount exchanged to remove cap on royalties + ReferencesNo definition available. + Details Name: nktr_AmountExchangedToRemoveCapOnRoyalties Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPayment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved + ReferencesNo definition available. + Details Name: nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved + ReferencesNo definition available. + Details Name: nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceeds from sale of potential future royalties gross. + ReferencesNo definition available. + Details Name: nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProvision for inventory. + ReferencesNo definition available. + Details Name: nktr_ProvisionForInventory Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRoyalties Liability, Measurement Input + ReferencesNo definition available. + Details Name: nktr_RoyaltiesLiabilityMeasurementInput Namespace Prefix: nktr_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A + Details Name: us-gaap_GoodwillLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of reorganization value related to estimated net realizable value of asset dispositions. Reorganization value is the amount attributed to the reconstituted entity, as well as the expected net realizable value of those assets that will be disposed before reconstitution occurs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-5Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_ReorganizationValueNetRealizableValueOfAssetDispositions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=nktr_UcbPharmaManufacturingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=nktr_SubleaseOfLaboratoryAndOfficeSpaceMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Financial Statement Details - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Inventory Disclosure [Abstract] Â Â Accrued compensation $ 7,007 $ 5,553 Accrued research and development expenses 17,916 10,118 Accrued contract termination costs 3,151 3,020 Other accrued expenses 4,303 3,471 Total accrued expenses $ 32,377 $ 22,162 X - DefinitionAccrued Contract Termination Costs, Current + ReferencesNo definition available. + Details Name: nktr_AccruedContractTerminationCostsCurrent Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued research and development expenses current. + ReferencesNo definition available. + Details Name: nktr_AccruedResearchAndDevelopmentExpensesCurrent Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 41 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Financial Statement Details - Schedule of Liability Related to Sale of Potential Future Royalties (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Â Â Â Â Liabilities related to the sales of future royalties, net â€“ beginning balance Â Â $ 112,625 Â Non-cash royalty revenue Â Â (48,029) $ (50,860) Non-cash interest expense $ 6,020 $ 5,910 17,959 $ 18,467 Amortization of transaction costs Â Â 274 Â Proceeds from the Amendment Â Â 15,000 Â Liabilities related to the sales of future royalties, net â€“ ending balance 97,829 Â 97,829 Â 2012 Purchase and Sale Agreement Â Â Â Â Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Â Â Â Â Liabilities related to the sales of future royalties, net â€“ beginning balance Â Â 24,217 Â Non-cash royalty revenue Â Â (19,007) Â Non-cash interest expense Â Â 4,940 Â Amortization of transaction costs Â Â 0 Â Proceeds from the Amendment Â Â 0 Â Liabilities related to the sales of future royalties, net â€“ ending balance 10,150 Â 10,150 Â 2020 Purchase and Sale Agreement Â Â Â Â Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Â Â Â Â Liabilities related to the sales of future royalties, net â€“ beginning balance Â Â 88,408 Â Non-cash royalty revenue Â Â (29,022) Â Non-cash interest expense Â Â 13,019 Â Amortization of transaction costs Â Â 274 Â Proceeds from the Amendment Â Â 15,000 Â Liabilities related to the sales of future royalties, net â€“ ending balance $ 87,679 Â $ 87,679 Â X - DefinitionLiabilities On Sale Of Future Royalties Amortized Transaction Costs + ReferencesNo definition available. + Details Name: nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLiability Related To Sale Of Potential Future Royalties Non Current + ReferencesNo definition available. + Details Name: nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X -

DefinitionNon-cash interest expense related to sale of royalties. + ReferencesNo definition available. + Details Name: nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNon cash royalty revenue related to sale future royalties. + ReferencesNo definition available. + Details Name: nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceeds from Amendment related to sales of future royalties, net. + ReferencesNo definition available. + Details Name: nktr_ProceedsFromAmendmentRelatedToSalesOfFutureRoyaltiesNet Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2012Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreement2020Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Financial Statement Details - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands 3 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Â Â Â Â Â Â Beginning balance $ 79,688 $ 126,705 $ 130,987 $ 196,958 $ 240,865 $ 366,638 Ending balance 48,884 79,688 126,705 159,368 196,958 240,865 Accumulated Other Comprehensive Income Â Â Â Â Â Â AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Â Â Â Â Â Â Beginning balance (494) (403) 80 (6,450) (5,681) (6,907) Ending balance 355 (494) (403) (6,352) (6,450) (5,681) Foreign currency translation Â Â Â Â Â Â AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Â Â Â Â Â Â Beginning balance 21 22 30 (6,005) (4,992) (5,131) Foreign currency translation adjustments (28) (1) (8) (98) 13 139 Unrealized gain (loss) on available-for-sale securities Â Â Â Â (1,026) Â Ending balance (7) 21 22 (6,103) (6,005) (4,992) Available-for-sale securities Â Â Â Â Â Â AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Â Â Â Â Â Â Beginning balance (515) (425) 50 (445) (689) (1,776) Foreign currency translation adjustments 877 (90) (475) 196 244 1,087 Ending balance $ 362 $ (515) $ (425) $ (249) $ (445) $ (689) X - DefinitionAmount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15 + Details Name: us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15 + Details Name: us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Additional Information (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Commitments and Contingencies Disclosure [Abstract] Â Â Liability for litigation $ 0 $ 0 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LitigationReserve Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 44 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Pre-Funded Warrant - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands 1 Months Ended 9 Months Ended May 28, 2024 Mar. 04, 2024 Mar. 31, 2024 Sep. 30, 2024 Sep. 30, 2023 Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Proceeds from issuance of pre-funded warrant Â Â Â $ 30,000 $ 0 Pre-Funded Warrant Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Exercise price of warrants Â Â $ 0.0001 Â Â Securities Purchase Agreement | TCG Crossover Fund II, L.P. Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Proceeds from issuance of pre-funded warrant Â $ 30,000 $ 30,000 Â Â Warrant exercised prior notice period Â Â 61 days Â Â Effective date of warrant Jun. 05, 2024 Â Â Â Â Securities Purchase Agreement | TCG Crossover Fund II, L.P. | Maximum Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Percentage of number of shares of warrant exercised Â Â 19.99% Â Â Securities Purchase Agreement | TCG Crossover Fund II, L.P. | Pre-Funded Warrant Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Number of warrants issued to be purchase common shares Â 25,000,000 25,000,000 Â Â Shares issued, price per share Â $ 1.2 $ 1.2 Â Â Securities Purchase Agreement | TCG Crossover Fund II, L.P. | Pre-Funded Warrant | Maximum Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Resale of common stock issuable upon exercise of warrant 25,000,000 Â Â Â Â Affiliates | Securities Purchase Agreement | TCG Crossover Fund II, L.P. | Maximum Â Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Â Percentage of number of shares of warrant exercised Â Â 9.99% Â Â X - DefinitionEffective date of warrant. + ReferencesNo definition available. + Details Name: nktr_EffectiveDateOfWarrant Namespace Prefix: nktr_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionPercentage of number of shares of warrant exercised. + ReferencesNo definition available. + Details Name: nktr_PercentageOfNumberOfSharesForWarrantExercised Namespace Prefix: nktr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionResale of common stock issuable upon exercise of warrant. + ReferencesNo definition available. + Details Name: nktr_ResaleOfCommonStockIssuableUponExerciseOfWarrant Namespace Prefix: nktr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWarrant exercised prior notice period. + ReferencesNo definition available. + Details Name: nktr_WarrantExercisedPriorNoticePeriod Namespace Prefix: nktr_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidiarySaleOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=nktr_PreFundedWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=nktr_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=nktr_TcgCrossoverFundIILPMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R39.htm IDEA: XBRL DOCUMENT v3.24.3 License and Collaboration Agreements - Additional Information (Details) 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended Feb. 12, 2024 USD ($) shares Jul. 23, 2017 USD ($) Apr. 30, 2018 USD ($) shares Sep. 30, 2024 USD ($) Milestones Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Milestones Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Dec. 31, 2020 USD ($) Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Contract asset Â Â Â $ 3,032,000 Â $ 3,032,000 Â Â Â Revenue, excluding assessed tax Â Â Â 24,124,000 $ 24,144,000 69,252,000 $ 66,237,000 Â Â Non-cash royalty revenue related to the sales of future royalties Â Â Â Â Â Â Â Â Â Â Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Revenue, excluding assessed tax Â Â Â 15,731,000 $ 18,167,000 48,029,000 $ 50,860,000 Â Â Bristol Myers Squibb Company Â Â Â Â Â Â Â Â Â Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Sale of stock shares repurchased | shares 8,300,000 Â Â Â

Â Â Â Â Â Sale of stock repurchased cash consideration $ 3,000,000 Â Â Â Â Â Â Â Â Â Bristol Myers Squibb Company | Purchase Agreement Â Â Â Â Â Â Â Â Â Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Shares issued (in shares) | shares Â Â 8,284,600 Â Â Â Â Â Â Sale of stock consideration received Â Â $ 850,000,000 Â Â Â Â Â Â Other Partner Â Â Â Â Â Â Â Â Â Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Potential future additional payments for development milestones Â Â Â $ 40,000,000 Â $ 40,000,000 Â Â Â Nektar-358 | Eli Lilly Â Â Â Â Â Â Â Â Â Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Percentage of sharing in Phase 2 development costs Â 75.00% Â Â Â Â Â Â Â Nektar-358 | Maximum | Eli Lilly And Company Â Â Â Â Â Â Â Â Â Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Potential future additional development and regulatory milestones (up to) Â $ 250,000,000 Â Â Â Â Â Â Â Â Â Nektar 0165 | Biolojic Design Company [Member] Â Â Â Â Â Â Â Â Â Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Payable For Newdrug Investigle Milestone Â Â Â Â Â Â Â $ 3,000,000 Â Number of Milestone | Milestones Â Â Â 0 Â 0 Â Â Â Nektar 0165 | Maximum | Biolojic Design Company [Member] Â Â Â Â Â Â Â Â Â Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Potential future additional payments for development milestones Â Â Â Â Â Â 35,000,000 Â Payment For Development Milestones Â Â Â Â Â Â Â $ 18,000,000 Â Bristol Myers Squibb Collaboration Agreement Â Â Â Â Â Â Â Â Â Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Sale of stock shares repurchased | shares 8,300,000 Â Â Â Â Â Â Â Â Sale of stock repurchased cash consideration $ 3,000,000 Â Â Â Â Â Â Â Â Nektar's | Nektar-358 Â Â Â Â Â Â Â Â Â Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Received upfront and milestone payment Â $ 150,000,000 Â Â Â Â Â Â Â Â Â Percentage of sharing in Phase 2 development costs Â 25.00% Â Â Â Â Â Â Â Nektar's | Bristol Myers Squibb Collaboration Agreement | Nektar 214 Â Â Â Â Â Â Â Â Â Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Upfront and milestone payments received from license agreements Â Â $ 1,000,000,000 Â Â Â Â Â Â Nektar's | Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Milestone One Â Â Â Â Â Â Â Â Â Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Â Â Â Â Â Â Â Â Â Potential future additional payments for development milestones Â Â Â Â Â Â Â Â Â $ 50,000,000 X - DefinitionDisposal Group, Including Discontinued Operation, Contract With Customer Asset, Current. + ReferencesNo definition available. + Details Name: nktr_DisposalGroupIncludingDiscontinuedOperationContractWithCustomerAssetCurrent Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber Of Milestones + ReferencesNo definition available. + Details Name: nktr_NumberOfMilestones Namespace Prefix: nktr_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionPayable for newdrug investigle milestone. + ReferencesNo definition available. + Details Name: nktr_PayableForNewdrugInvestigleMilestone Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayment for development milestones. + ReferencesNo definition available. + Details Name: nktr_PaymentForDevelopmentMilestones Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage of sharing in Phase 2 development costs. + ReferencesNo definition available. + Details Name: nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts Namespace Prefix: nktr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPotential development and regulatory milestones. + ReferencesNo definition available. + Details Name: nktr_PotentialDevelopmentAndRegulatoryMilestones Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPotential development milestones. + ReferencesNo definition available. + Details Name: nktr_PotentialDevelopmentMilestones Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSale of stock consideration received. + ReferencesNo definition available. + Details Name: nktr_SaleOfStockConsiderationReceived Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionSale of stock repurchased cash consideration. + ReferencesNo definition available. + Details Name: nktr_SaleOfStockRepurchasedCashConsideration Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUpfront and milestone payments received from license agreements. + ReferencesNo definition available. + Details Name: nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionUpfront and milestone payments received under license agreement. + ReferencesNo definition available. + Details Name: nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_SharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=nktr_OtherPartnerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=nktr_Nektar358Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=nktr_EliLillyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=nktr_Nektar0165Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=nktr_BiolojicDesignCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=nktr_BristolMyersSquibbCollaborationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=nktr_Nektar214Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: nktr_MilestoneAxis=nktr_MilestoneOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Restructuring, Impairment and Costs of Terminated Program - Narrative (Details) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended Jun. 30, 2023 Apr. 30, 2022 Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Â Â Â Â Non-cash impairment charges Â Â $ 0 Â $ 0 $ 10,567,000 Â Â Â $ 35,329,000 Â Third St. Facility Â Â Â Â Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Â Â Â Â Non-cash impairment charges Â Â Â $ 4,400,000 Â Â $ 6,200,000 Â Â Â Â 2022 Restructuring Plan | Mission Bay Facility Â Â Â Â Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Â Â Â Â Non-cash impairment charges Â Â Â Â Â 1,500,000 $ 7,100,000 Â Â Â Â 2023 Restructuring Plan Â Â Â Â Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Â Â Â Â Non-cash impairment charges Â Â Â Â Â 1,700,000 Â Â Â $ 1,300,000 Â 2023 Restructuring Plan | Mission Bay Facility Â Â Â Â Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Â Â Â Â Non-cash impairment charges Â Â Â $ 3,900,000 Â $ 9,100,000 Â $ 11,500,000 Â Â Â Restructuring Plan Â Â Â Â Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Â Â Â Â Contract termination and other costs included in accrued expenses Â Â $ 3,200,000 Â Â Â Â Â $ 3,200,000 Â $ 3,000,000 Measurement Input, Market Participant Subtenant Borrowing Rate Â Â Â Â Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Â Â Â Â Operating lease, measurement input Â Â Â Â Â Â Â 7.90% Â Â Â Sublease income, measurement input Â Â Â 6.20% Â 8.70% 8.50% Â Â Â Â Employee Severance Â Â Â Â Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Â Â Â Â Restructuring, impairment, and costs of terminated program Â Â Â Â Â $ 535,000 $ 1,943,000 $ 5,483,000 0 Â Â Payments during the period Â Â Â Â Â 887,000 6,624,000 3,299,000 196,000 Â Â Employee Severance | 2022 Restructuring Plan Â Â Â Â Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Â Â Â Â Workforce termination, percentage Â 70.00% Â Â Â Â Â Â Â Â Â Restructuring, impairment, and costs of terminated program Â Â Â Â Â 0 0 0 0 Â Â Payments during the period Â Â Â Â Â

0 0 3,299,000 0 Â Â Employee Severance | 2023 Restructuring Plan Â Â Â Â Â Â Â Â Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Workforce termination, percentage 60.00% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Restructuring, impairment, and costs of terminated program Â Â Â Â Â 535,000 1,943,000 5,483,000 0 Â $ 7,900,000 Payments during the period Â Â Â Â $ 200,000 $ 887,000 $ 6,624,000 $ 0 $ 196,000 Â Â X - DefinitionContract termination and other costs included in accrued expenses. + ReferencesNo definition available. + Details Name: nktr_ContractTerminationAndOtherCostsIncludedInAccruedExpenses Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionOperating Lease, Measurement Input + ReferencesNo definition available. + Details Name: nktr_OperatingLeaseMeasurementInput Namespace Prefix: nktr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionSublease Income, Measurement Input + ReferencesNo definition available. + Details Name: nktr_SubleaseIncomeMeasurementInput Namespace Prefix: nktr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of loss from impairment of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 25 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6 + Details Name: us-gaap_OperatingLeaseImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17 + Details Name: us-gaap_PaymentsForRestructuring Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s). + ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nktr_ThirdStFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyTwoRestructuringPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nktr_MissionBayFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyThreeRestructuringPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringPlanAxis=nktr_RestructuringPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Restructuring, Impairment and Costs of Terminated Program - Summary of Restructuring Costs (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Restructuring and Related Activities [Abstract] Â Â Â Â Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program $ 0 $ 652 $ 0 $ 3,606 Severance and benefit expense 0 535 0 7,961 Impairment of other property, plant and equipment 0 10,173 8,329 36,628 Contract termination and other restructuring costs 46 0 5,981 912 Restructuring, impairment and other costs of terminated program $ 46 $ 11,360 $ 14,310 $ 49,107 X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_BusinessExitCosts1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe loss recognized on termination of a contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 275 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479072/912-275-50-4 + Details Name: us-gaap_LossOnContractTermination Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_RestructuringCostsAndAssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_SeveranceCosts1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 48 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Restructuring, Impairment and Costs of Terminated Program - Restructuring Reserve Rollforward (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Dec. 31, 2023 Employee Severance Â Â Â Â Â Â Â Â Restructuring Reserve [Roll Forward] Â Â Â Â Â Â Â Â Â Â Restructuring reserve, beginning balance Â Â $ 196 $ 802 $ 5,483 $ 3,299 $ 196 $ 3,299 Expense recognized during the period Â Â Â 535 1,943 5,483 0 Â Payments during the period Â Â Â (887) (6,624) (3,299) (196) Â Restructuring reserve, ending balance $ 0 Â Â 450 802 5,483 0 196 Employee Severance | 2023 Restructuring Plan Â Â Â Â Â Â Â Â Â Â Restructuring Reserve [Roll Forward] Â Â Â Â Â Â Â Â Â Â Restructuring reserve, beginning balance Â Â 196 802 5,483 0 196 0 Expense recognized during the period Â Â Â 535 1,943 5,483 0 7,900 Payments during the period Â Â (200) (887) (6,624) 0 (196) Â Restructuring reserve, ending balance 0 Â Â 450 802 5,483 0 196 Employee Severance | 2022 Restructuring Plan Â Â Â Â Â Â Â Â Â Â Restructuring Reserve [Roll Forward] Â Â Â Â Â Â Â Â Â Â Restructuring reserve, beginning balance Â Â 0 0 0 3,299 0 3,299 Expense recognized during the period Â Â Â 0 0 0 0 Â Payments during the period Â Â Â 0 0 (3,299) 0 Â Restructuring reserve, ending balance 0 Â Â 0 0 0 0 0 Contract Termination and Other Costs | Restructuring Plan Â Â Â Â Â Â Â Â Â Â Restructuring Reserve [Roll Forward] Â Â Â Â Â Â Â Â Â Â Restructuring reserve, beginning balance 9,662 $ 5,589 5,542 6,229 7,493 7,710 5,542 7,710 Expense recognized during the period 46 4,960 975 0 0 912 Â Â Payments during the period (886) (887) (928) (460) (1,264) (1,129) Â Â Restructuring reserve, ending balance $ 8,822 $ 9,662 $ 5,589 $ 5,769 $ 6,229 $ 7,493 $ 8,822 $ 5,542 X - DefinitionAmount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17 + Details Name: us-gaap_PaymentsForRestructuring Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserve Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-

gaap_RestructuringReserveRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyThreeRestructuringPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringPlanAxis=nktr_TwoThousandTwentyTwoRestructuringPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=nktr_ContractTerminationAndOtherCostsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringPlanAxis=nktr_RestructuringPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Restructuring, Impairment and Costs of Terminated Program - Sublease Information (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Jun. 30, 2023 Dec. 31, 2022 Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Â Book value in excess of fair value Â Â Â Â $ 36,962,000 Â Â Less: Amounts recorded as amortization for Third St. facility and Mission Bay facility Â Â Â Â (1,633,000) Â Â Impairment expense for facilities $ 0 $ 0 $ 10,567,000 Â 35,329,000 Â Â (Gain) on sale or disposal of property, plant, and equipment Â Â (394,000) Â Â Â Â Impairment of other property, plant and equipment Â Â Â Â 1,299,000 Â Â Total impairment of right-of-use assets and property, plant and equipment 0 Â 10,173,000 $ 8,329,000 36,628,000 Â Â Reported Value Measurement Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Â Property, plant and equipment and operating lease right-of-use assets 14,403,000 Â Â 14,403,000 Â $ 21,880,000 $ 53,498,000 Property, Plant and Equipment Â Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Â Book value in excess of fair value Â Â Â Â 5,034,000 Â Â Less: Amounts recorded as amortization for Third St. facility and Mission Bay facility Â Â Â Â (263,000) Â Â Impairment expense for facilities Â Â 1,400,000 Â 4,771,000 Â Â (Gain) on sale or disposal of property, plant, and equipment Â Â (394,000) Â Â Â Â Impairment of other property, plant and equipment Â Â Â Â 1,299,000 Â Â Total impairment of right-of-use assets and property, plant and equipment Â Â 1,006,000 1,042,000 6,070,000 Â Â Property, Plant and Equipment | Reported Value Measurement Â Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Â Property, plant and equipment and operating lease right-of-use assets 1,897,000 Â Â 1,897,000 Â 3,050,000 7,206,000 Operating Lease Right-of-Use Assets Â Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Â Book value in excess of fair value Â Â Â Â 31,928,000 Â Â Less: Amounts recorded as amortization for Third St. facility and Mission Bay facility Â Â Â Â (1,370,000) Â Â Impairment expense for facilities Â Â 9,167,000 Â 30,558,000 Â Â (Gain) on sale or disposal of property, plant, and equipment Â Â 0 Â Â Â Â Total impairment of right-of-use assets and property, plant and equipment Â Â $ 9,167,000 7,287,000 $ 30,558,000 Â Â Operating Lease Right-of-Use Assets | Reported Value Measurement Â Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Â Property, plant and equipment and operating lease right-of-use assets 12,506,000 Â Â 12,506,000 Â 18,830,000 46,292,000 Fair Value, Level 3 | Estimate of Fair Value Measurement Â Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Â Property, plant and equipment and operating lease right-of-use assets (6,074,000) Â Â (6,074,000) Â (11,313,000) (16,536,000) Fair Value, Level 3 | Property, Plant and Equipment | Estimate of Fair Value Measurement Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Â Property, plant and equipment and operating lease right-of-use assets (855,000) Â Â (855,000) Â (1,650,000) (2,172,000) Fair Value, Level 3 | Operating Lease Right-of-Use Assets | Estimate of Fair Value Measurement Â Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Â Property, plant and equipment and operating lease right-of-use assets $ (5,219,000) Â Â $ (5,219,000) Â $ (9,663,000) $ (14,364,000) X - DefinitionImpairment, Long-Lived Asset, Held-for-Use, Other + ReferencesNo definition available. + Details Name: nktr_ImpairmentLongLivedAssetHeldForUseOther Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProperty, plant and equipment, and operating lease right of use asset, book value in excess of fair value. + ReferencesNo definition available. + Details Name: nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetBookValueInExcessOfFairValue Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProperty, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure + ReferencesNo definition available. + Details Name: nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AdjustmentForAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of loss from impairment of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 25 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6 + Details Name: us-gaap_OperatingLeaseImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=nktr_SubleasePropertyPlantAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=nktr_SubleaseOperatingLeaseRightOfUseAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Impairement of Goodwill (Additional Information) (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Goodwill and Intangible Assets Disclosure [Abstract] Â Â Â Â Â Additional impairment charges on remaining long-lived assets Â Â Â $ 0 Â Impairment of goodwill $ 0 $ 0 $ (76,500,000) $ 0 $ (76,501,000) X - DefinitionImpairment of remaining long-lived asset, held-for-use. + ReferencesNo definition available. + Details Name: nktr_ImpairmentOfRemainingLongLivedAssetHeldForUse Namespace Prefix: nktr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2 + Details Name: us-gaap_GoodwillImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 51 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Â Â Â Â Total stock-based compensation $ 5,391 $ 8,149 $ 16,809 $ 26,134 Cost of goods sold Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Â Â Â Â Total stock-based compensation 516 841 1,673 2,454 Research and development Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Â Â Â Â Total stock-based compensation 2,010 3,202 6,337 11,107 General and administrative Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Â Â Â Â Total stock-based compensation $ 2,865 $ 4,106 $ 8,799 $ 12,573 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Event - Additional Information (Details) - Subsequent event - Asset Acquisition By Ampersand Capital Partners - Asset Purchase Agreement $ in Millions Nov. 01, 2024 USD ($) Subsequent Event [Line Items] Â Proceeds from sale of assets $ 70 Ownership interest received 20.00% X - DefinitionPercentage of ownership received in asset acquisition. + ReferencesNo definition available. + Details Name: nktr_PercentageOfOwnershipReceivedInAssetAcquisition Namespace Prefix: nktr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -

URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AssetAcquisitionAxis=nktr_AssetAcquisitionByAmpersandCapitalPartnersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=nktr_AssetPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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{7(\RV2B73(2=Q'M9DHBFRK0;<'8%'J!<_+U(;X%Z@/&<_[_]_1 M8L>=Y&*1$A39)7O,3A+TQO$)RE0 "E-1J):KL7[XX M0:5X>KO@,KLOF]T$:$;42BI8/GJK3!2:\[7BQ1V4ZM-UEC:ZX.GNY>Z2:@P; MDESSYK8R?S2F? DC^_:.XT^0P29TV(&YMH(M"E{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
>@(%U9FCT$P#'Y6DN6O2//F8V"X:&PD=BT=]*T/9 M.2A:!D53U(@DLA>NYO2X14A MF2[5<7+QF2(R9)+FUN7M438])_MTY12J,H.B*2A:CD(S':7CYF(W-^<5LML\ M51KQ? K6A6Z'WB@%E[@8]@8+JS%%HIH$[!C!V5Z[YANQV==F(BX195H:2=U"T M#(JFB!$9I_W@@!RUE"4G0H..;(N]*LQ\WWBZT;U7;IM>()]X0K5F4#0%1>.X1C4"<>N-)R5D'@:!L&;/9,OJ-)R%(O?&DQ)QO/%G' M'O4V1%-0M!R%9IJ^8!ZG,0>:. M[=G$PG&:],U-R%FS#DIO,9MJTK,NC5C2GW6V8-K/D0D9/>62)#*X*LJV-7%[V4G= M6CVXW52KX,5FH3\M1Z\^Z; BF.FI_O[]V0T 21I-&%$2EL:IM040?)8EE4&[MIJ!H.0K-](2.'6-N=NQS/(&T/D$,6(=@+)F>S3I5II!E2HH6HY\,W?T6O, M3:^]U%OZ+HG3QM<*;MN]_2;0:<.F6#>DG8F#DB%A9R3+-(6B9<,>04&5YB@T M_:6CBCC;J+,DP3G%'646 OKQ*W5U\Q0M R*IJ@1X6DO"LS)<9-I>*)NA7>$ M&W<3;L./WW/2GD@&:L()3BYE,NYS2!^6ZH&@Y"LTT_=']96ZNZ_-H:TY4;5&T-25G MS28H6\6)ZBZ2MB8$+=J:D"3UKRCCOA3EQ0@&D7%&T*1/MBI*4(C^_DN19S+46_"ID++B;X/$ZFTX/+K2$BA,E5&3N M2)QD)*81M#0*BI:CT,Q+5CO&1_A>%#;$V((XL4>ECV) =10A0TTE0B6=/A*" M1/I(23G31]&1,")ZPEA60#D9*-H4BI9!T104+4>AF2[5,3S"S?!@+T.&WA@F M;!Z&] [/+*51E!D534+0,E3A3G>51A"&(@)%%1GCD(S#7QT#[Z[JLJ3 MQQ#$!58BYJ*?Y;BU>EL9RF1!T10U(OVC]3D];$R>.+0J.AI*N&FHX4?)Z4@; M>]J904%=^\5#V3Z80V;@J+E*#33ZAW;)+S8ID&6MAFA9"Q3:W4><(T7 M(4.F5,3]7)*/1=)_.4 (COB8]Z<0=3V7D%+G:"\GDM K^>"HDVA M:!D434'1\'HNMRYOCR(C\962@4M=H*B*2A:CD(SOV6F8\CD M7WP]ER3(LGY9N[L/OHL(%"T;T\%U9BCT$R+=P2>Q%W/)>WB)<&LBYO<"KW- M"Z7=!CV!@NK,46BF@3LZ34*OYY)4@9.,PWYHYM;J;64H9P9%4Y(XY-B_'B(G MA$8L"<6)P_ZR([GDG[F=Z^QK0$E01-2KW(%R4T*.2);;Q>[?/S35_>YKF-]735.M=K_>E86.6EH!_?^W M5=7\\:']9N?#MY%?_Q]02P,$% @ 8X]G66Z4%M?&!P HB$!@ !X M;"]W;W)K18MDFQR>9^]"7E\/@YU^>0\OF3D-_4 MDG.- OE=EK2X&2ZU79Z.1RI:\8NJC6/$:_.C7LF(:;N5B!%:2L[Q95)4C$@3Q MJ&)%/9B<-\\>Y.]4:#RX$NQ6&KS8#0Y7[$% MGW']V^1!PMUHIR4O*EZK0M1(\OG%X!*?3 M#C7D"V"\CQ@K!G =TNH(VA+;+&K&NFV>1-;YK58$U1 MFS#.M(2_%K!.3Z;W=]6&#R;_^PG'P?]=-I](V8$'PIT'0I_VR1UTH5(H9VZT*^-FI6DUF\D0DY@0 M1P0^PSKF430L CW*DV?>7I''2 M7F G+C[N:TZA-.KQ*MZC<^S%^KE:L4*:QF9R59HA9BCF0^A@B"G%H=T99Z^D M:67Z^0-:E0Q$S3/^U[I8F85.F[%-Z56Q3JD:!R3M,,U25D]"/0RH:5T#0! M? %%#_]1"/CO14[O4+/BV3 C_>M!W5(W]7'VY5WX&)U1G5:PKA=[EAF.<0PP;2G(^*.[+&?[:=+ M5B^@>Q]2>%<.>VW?2>?XI'Q^*FV'SN@8'?LI_3)KPVF&'EYL3'HZ;7;0;QI: M(;.E:-(WG.&.H[&?I#][J\3FS6$:I,?('%(T(3W(.G;%?GJ]W^5/R8%C55,3 M3I0V;0Z3V"YGAU@<)'TMLZ-7[.?7^Z9"VQQWPK.IL25YV^[8 M*)ZS=:*G'1[?"IMAU[H6)?X6? =A+;.E:2,OH\%V3^HTW,6.8YRF5M <@M#Y M4M(SXI".1XF7FB:W#+8^[>[H%7@C>YA)(A(FQW!MN7 B=>TA$@\1/@#';_PZV5^^;R\.Q125A7V0Z$B5^$MTU MKI69F7-H7H_/S@[@M-!FS)30*#X.C&-S2PA.^XJ@8U8R?E/GFATSEPK-((<>'YTFV-O@(7688(OUF="1-OWQL;;5 MO5Q=P(G;)N>0!':NVV*]N=[1-_73]\U\SK/F"&4N)"\6-0RW6;,U1C V&IZL M6\,,RS07IH8WD%&@]*$]MZA[28WYW"/4=<]&.V^D/SJ4A!D6=2;,'0^]RWEZ] M-T/PVRQP'3+C^'@SZ1(CE 9QCQT=SU,_ST_[P"*FT2-?%'5MQ(>G8AM"-SZB=SKPG<'!9YP:? 6"QX:8&O,HC:;Q^&XZ*E M'9E3/YG/UJM5R6B^1& 0LV) M0ONV>/=TJT.#R^;U^M'S*WPV;7\NT*EI?[UPRR24GD(EGX/*X&,"B2?;'P2T M-UJLFG? JCT)K43672\Y@[#$"\/>Y$/KEQGS![F<9DW\ 4$L#!!0 (&./ M9UF]+)^FA@(,4' 8 >&PO=V]R:W-H965T&ULK55M M3]LP$/XK5H8FD ;.6UOHTDBTZ32D,55T;)]- YD#*/10%DQ.G%RI:HRQ3',HB3SC%3"]L^*B)$J;8HUE M)8!D%E06V'?=(2X)94X<6=]"Q!&O54$9+ 22=5D2\3B%@F\GCN?L'#=TG2OC MP'%4D34L0=U6"Z$MW++%DM 0F*6=(P&KB7'KC>6CB;V#GL M[S6 WP+\EX#P%4#0 H*W*H0M('RKPJ %V-1QD[LM7$(4B2/!MTB8:,UF%K;Z M%JWK19EY)TLE]"[5.!4OR"/:2+0 8=\<2P$E5*8%E[4 =(INEPDZ/CI!1X@R M]"OGM20LDQ%66MLPX+35F38Z_BLZ ;KF3.42S5D&60\^.8R_.(#'.N5]!WV0U= MV$]G>MM85B2%B:.;EP2Q 2?^_,D;NE_[*OV19,E'DLT_B.S9G83=G82'V..? M>DA"1"FOF6H>9^?M9LZE;;4O_%-O//-Z M_(F>4:)O!MPU$6O*)"I@I:7&6[XAU7NL?:9:[G+ @3 MH/=7G*N=802ZR1W_ U!+ P04 " !CCV=9R_#QXIP8 *1@ & 'AL M+W=O;CIF[\5P?K8>B^.#GQQ=IMK)^WG6MP9=GV&SO&WYUXKO> MV5(>VM0GYZ>GSTXVMFH.7GTIWUWUK[YLQZ&N&G?5&S]N-K;?OG9U>_O5P=E! M_.)]M5H/_.+DU9>=7;EK-_S<7?7XZR2M4E8;U_BJ;4SOEE\=7)Y]\?H)[Y<; M_KMRMS[[;,C)HFT_\(_ORZ\.3DF0JUTQ< 6+?V[<&U?77 AD_"NL>9"VY(/Y MY[CZM\ ([>%E8[]ZT]2]5.:R_.GAQ8$JWM&,]O&]OOW.!GZ= MTP-3C'YH-^%A4+"I&OW7?@QR^)0'SL,#YT*W;B14?FT'^^K+OKTU/>_&:OP@ MK,K3(*YJ>"C70X^K%9X;7KWK5[:I?

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

P8XM*^%041O<%+JJ6L8'!HW"M@N1 M8ZNZD(!*OY0^1,H]&87"F"E5(O=%8J/JRV(9G?B]G&6CA4%H6F"";SML#1JD5;2F^0X1UH M(=_VW4.9<@]?%GPG@"SK:4$_+ $WQ'3&Y86OLR&6D8ALB0=RU!YR#Q$'U"B M%L^>BK_11NE0XAW:'F(9^9&M!P$T>V1E"^L1&]< KC(&!_T=^I@C-DK$&0+L M.8ND/UGAH@AI&5(^*MIRQ;@K:7 ? 2"W);/&D)7KG L1O!W6O-$#Q V*!OIE3 MGUM\I/B+9B@ R1LDMEE%O(-PX'6=0+I7>B!6L?T,J"B J3V,#HZ#=Q0"SU,4 MII/,A/-MP05A=TN:(!&8W=71R@ @(.#$FQ,'X514O&ET#E7$CB&>(?I][DT& M**&C86=\H[Z@@[3A_UHDE=B30KFGN@NZ2X^]XX) O) WRLH)I0&SX3B M*EN(XG0F9Q3(9PJ"OEH.X_YU5G68][-NSM"O!M5 M[6)&?,0ULVFY^+U?*[R .D ,=WLD.P1J;'D%+SF3Z,YPJ,[87VV[9%04:LLY6%2RKSS MV0OQOBGTO0$-G3X[?R$"7E%Y!H%(8$,6:?).\:F<^A*_[,(0'?"C-B^7N=7D M#@]\K!9* (JI([3K:Y;"H#-77K(@J+'43C "RBEBVB42BP!:)XO+IQ<0.&L N M&Q,NJ>[LN9Q$/#K@:9(5P8]CA)8V4A< 1D:[^@1A!NV2JD;BG+ETRZUZ@PJ2 M#:I-$P.A$)>CV>7YZ& (R"8YV"8>(9F,QPC__M%'DR."]T<2I93P=45^DV!PP M7:<93R(0?R\NAX5M+-[6E-*337 ?B-G:["XI#E)WA";WS68Q;&L<5QX+'SLT MU%\$4AX*(K!7NT#-6\4@NP45?RW MZ,:=0Q-K5<5@>5%*F4# _H:\7@"QE/< M.!;7@C??4UWAXNX8[1Z/L8UL[K9-08!-394(Y0K5'RD 4O;=0 T+JRL^FK(M#)IB:LN>3@'751HBD?-
"8A!.^D'N;RJE6L(M!1SY1F6VI49F.@L3@A@V?6#3 M$Y?CLXXXQ? >D%%B]60%;;L/W'W1>C8,JS]43_AC(#V6R'/$T4&^CW*3D&C7 M?^AX(00=F8-
BEUN=47)D8*PI7\RBUE\5/UHKO]6M89=/B+(MM/4A$@-];VC&;M+;EAIDJ$?_A$JN[6"T$*G4(!'CPT3:@D*_Q(GR\IJZO2I, MO11-O0;IG097:.%;::EXKZL$.QAA=AHM&>_ E2\)-R M>H$&*UT@-L(T8S*]>!KQ=/H0K^AT;(TZH#&U5J9G*W$FIU4)XR\)Y[5&XKU MI@9GP@K@DLX,)6S(#YX)4-%+C18C6)^-;7U"S=:"\DG:A>K;94_$+T$OD;K(MZ6
1:U+I2/T!>H+38=<:+[B+F M$7NZHK[U6XXK\%-1PQSKNF9A^SOYS7I MY%SJ!*T:\)XA'G^;D\E&E!N84A86!DTVA**R0, M'/BVW:QTQH(BIX+"7>N+W
M'..I$4_3T3W#9$Z^V+%3O ?D'$Z&>[\$%^Z,_UPW_]L<_O9:NG1P"BFY/4 = MCDC#N,:IF)WXD'2/$K7;-S3N9KU]Y%'U#F/+$!@#<52Y5V0-_F^-AMV>"AU MD7W%?
&=SQK!K!@\V@M;#AX C@R@BY QA/ 6 3=-3" 9= MX*%^RM#!@'DI"YR;UXYK#5,33<-JU!13N'X.)?=Y/53AWV]O6%,A&VT-HKVM M9 8I"P,.%<:ZG1!R"-
]&RP#LXR86IM*L!-6OUF/>H74(\#NY64B.LRC+E"Q5XCAN4B-C:1M"!-1V) M^?AA4N'6#F>-HE^V#1IK9=>>WH1[XVC^^(M9T2AJ)!8X^$C.6VMYB,K][^;P M+:2M=MT[B-
014=?)%<2O&:X2^=T>KX:W:U\B)0RY. #?E*'8@JR=#*^Z$4BY MBIN#:KD[VZR-/X0 .VKH_J^"%:4Y)0'U\BB]27L@$;D6I5[*Q0X(MN<1=K[IR:!@4*WHID3#=W98>OOVW;_?
7L>9 4_W2,GVCH[#C.RA6V'XR,S< MT8)NEI5:8]!"O*N""GA_D]:@N#"""$!7[&*&BPQYK?! Y EGO@[D:/MZEA MR-8!8PS->[?'??LXPAYJ 'N")5N<;:@OH/GNN_)-
X1L8A60#A^(3G$["6^9^ M9JOK\",R3HTZE8GQ0[^`.1W\H@G48,&_VZ)Q85O[\..F[FKWT[#K\(NH?GGX M7=D[:1>ZIJR9X]')^-G3HU#QTA=O&OY]5&:\-
Q5_7"]JK=,"W)\;;"=^(07= M#^:N_@=02P,$% @ 8X]G6:EPI\03# @ !#$!D !X;"JW;W)K&ULQ5M9<]LX$G[WKT!YO%-.%2.+AR@I5Y6=8R=;2<85 M9R8/6_L D9"$"44H &F-
Y]=O=P.\)$J6,TG-2TQ2!/#U@>ZO&\RSC=)?S%*(M@OVYRG+S_'19%.LG%Q(R/WWQC)Y=ZQ?/5%ED,A?7FIERM>+Z[DID:O/\U#^M'GR4BV6!#RY>/%OS
MA;@1Q6_K:PUW%_4LJ5R)W$B5,RWFST\O_2=7$;Y/+_PNQ<:TKAE*,E/]"]Z\ M39^?#A&0R$12X P<_MR*ER++<"* \=7->5HOB0/;U]7L;TAVD&7&C7BILL\R
M+9;/3R>G+!5S7F;%1[7Y13AY1CA?HC)#_[*-??<$+R>E*=3*#08$*YQ;O_Q/ MIX?6@,EPSX# #0@(MUV(4+[B!7 Q3*L-T_@VS(87)"J-!G R1Z/<%!I^E3"N
M>//%1F$*725%JF2\\]G:UYE*#T@O&\Y2]5*8P3,W9)Z%A<5Z(E%UKM=!\]>RB M@.5QDHO$+75EEPKV+#5E[U5>+ U[G:HPN2_Z/(2.9+]!U92&'8?RJG\!8XT__Z-& 7B/H7P WV
MQ*QY(IZ?P@XR0M^*TQ<__^3'PZ<'X$7ZA?D@RH$&[.??YH$ M?O"4?3,<]C9GBD%Q!_)2]!&7(A&>LT!+^%7]"?#3" M8PJ6U+"NU.GC-=?
%G9L.)Q:K=:;NA'"/()820,"6LE1M_&UE&L<^)1N:VU#R,#=5IN$0CF\8-7M5&R,2JSD MY"WP$RR(;W+08I*58(HM9SH'[19+51H8;QX].?FTU =FP#=:\+ ML9H!0
Q/'V#W'/C]!,.757]/"\P9,A^2"<.8!V) D %BXPH?*$A3"=4)25Z *W;E&&#$P/JO MVMUN+SEJ93=4M2CM"%*\$3 &QF=8-H+3:KM[JFE3K':D25 *#!7;]#GR2Y-H M.<.Z80:.Y=&&
[2[G*!5/S+U7E[^RM5S72P MS^*URGK$1[B6*DO;^\&P\P18=!6?6OO++@ M;VL%6[8!X';8L'7=@/V*P6DCC:A+H3VO8L5*U6H51H["X6PC=G8XL!0
M1E"!;TOCRB>JM9K!VYHIS>X[,Z6UK570]1 9KS8M>K!,Y!HM"%/9H#5@KYH$ M?6]1V5*4L*JB[G'6HS(J]7Q_,*IK/70.W#U:X+F?W:P0#6SZ@!BH +'2=YW<
M607]_I1"'6LC*A2XC5L9NIVR[&2=]D)?FJ:B3]09P MO\'B%+V?S'P)X7K+WQH[Y#UG!U6[AN29#OPCF@R[\M@L@RV7Z1'CVZ5(Y#G% M 1\A=[MO:W7K&%RV#\ZW*F#<4H
5J;47NVS1 K?-SNT8=F#_8:8LR(&QS5QT M]MQ6(Z]OI[TJZ^RU41HX3"LBM-W'VVI+[#= 3>"[6KM75=$@VE)5W+2H>E55
M[BH*5(&/>YE[W8O#V+T#HLW2D(1U*-0NGVFX6D]<;_/E/@*!XN%J#>_H)*[O MF%A:^:V9!.P-M O[C/\Z9-7MI#,!SSTXH+.5\/WQX??W[7NT^]$+V:9DR\WZ M'.Q8*:.&"Q\!-
]IN3$JSM^O7 ZJ].QX0["N,#VD.;A=@7>9D]E&GF0!<8AM_ MI:*&1>V=X!N:@=')=^[I.V+_";YRRZ#M:Z6/%FG^#&]=:L)V7#SOT MT I!!)!"
GX4XF3<:%D(F(:RL#>9CO%OX(V&L3T/C(;AR3M@$4\@G%1B[YNR MZH"\PVC"0GR-!OU.@WZ1(#XW!VVKT8CZ@Z.O,"W?<+8&XZQ[48B?(\S>9)G
M&&%S;NP%$Y2+SF#O/_NFSNP_;HS0&U+#SI]XDQ O C#/9/@#C.%[,:R$1IAZ M<1S2%1X)^W#9/@IOGR&T%O+!1X8PU(_'>-@]BL->";8@,F:^(C[.]A&&&2F083 /AA
M&@<.YJ4[V[8I<%^"J3ROVS^F(EB(Z# VCH@Z">JY)-MECBO6"((4;FT%XZ' M[BH.C_/MR!N/?5QE- +\(XH?W?ZNY:V'_5CR6R)=V'1+._VQI.\#E?J+M+XOW7J/+Z]$PE&FC:@K
M,"1A//VC-(6KVYJNN^.5Y3HE[@DOTO<4;4[9W^7UMN=O#F8KLV(KOT-L;<>7 M8:,#SVN+(J-&T3:QJ<[>&UY3I_Q>%6U_=?&7G&*7Y MLH855$%"#
<$Z944X&.XK*_8=@#8]SZIIXMZT0C:=O+:$<>> M[=IQ%^AD2D"CZ9&'H!&$V2%[?,R!(@(-XM[C3M-SWGD)U*'@&)2$!QYNAS% M]X.,"60$\AR >& 7[> $-D7GXB-
O'$]9WR?,%ZTOTU<"*A;_AY;2! L[$?] M]=/Z$_]+^V5[\[K]_P%@Y(7,L1\UAZ'#P7AT:H-]=5.H-7WG/E-%H59TN10\ M%1I?@-_G2A75#2Y0_\>'%_\'4$L#!!0 (&./9UEK,FG@W00
'$+ 9 M >&PO=V]R:W-H965TE,')$@]NW;W;<+ MG&^NC49;_N0IM'6M_/:*C=M<9,?9;N&S7E=1%F:K\T:M M^9KC7\TGC[?9@%+HFFW0SI+G\B*[/'YS=2+
[TX:_6_"Z)DDDAOG;N7E0W&1 MS840&\ZC("C\W/$[-D: 0.-KCYD-+L5P+_Q#_S7%CEAN5.!WSGS11:PNLK., M"BY5:^)GM_F=^WA.!2]W)]3_:=/M/5UFE++O02-F"/MBH[%K?
&*;+$#@&>]J#;EQH M/=,_ESLCEWWUIZ+R<[/+XU?SM@1A.AAA. M#J'_CV(=Q-G\@\7F<[HY8NSQ?'B+>WW1>];K^V:8L7X\\Q4=V5G*3M]5#ZO M:'F6UWJ7-
DXP>0($7,&'PK.):@I7>:Y\P70S'9"&WA .?&O2*Z-L^LC@ZXO MTGH,$](V-ZWL3QL:C^GF(TP; P^)'W]M=2-Q3\A+2Q^Y\J@-W".D+>L^&Q/" M5"0]9 IT
C7*IY3M(S#:"R!EMD&'1+O4/L0\IM*(X]/Z%.E[IAT 7/D1(E\ M!&"M/54&HVVBX4L>1I[5W;I/?.RY2^F3*-+ MB8+K!"NVH85#-62B"[YCB@@\YPZE^@:;+4>5\
I4=!*"0A8IFYU4'@HC ML#^H+XGVNR@E[9*?N#W").4NNBE= RHI_'7"5T6A16W*P+X[VKI39JV2FO;Q M3HE I*D($JX72H*69/Y]=E3 9IDW@7)H#+H]++V<.
(>)AW4(!"RNQ12NF3[(CI3_3ZU?04![TQ MHL=1=TF@*4EC0UCL' FZ.'[GI!6$+)Z@'ETDO5Q'_(A-:O0_H86D^/#CW9:* M7BGHR/.==FV .D=-/_# I$>V-;Z6WM6)D\HA\J
[AW!_7;'R&Q 2NA[=*26Z M9._6;"B M876X3UYVUZB'[=UE%*&O-<@:+F$ZG[X^S;K38/<279,N51 :KFCI$4$5[&4# MOI<.HNA?Q,%PRU[]!U!+ P04 " !CCV=9#ZQ,)00# "7!@
&0 'AL M+W=O5(VIX MJDJNQDZN=3WT/)7F6#%U(6KDM+(2LF*:7+GV5"V19194E5[H^XE7L8([DY&= MF\0)2&QT67"
<2U";JF+R>8:EV(Z=P'F9N"W6N383WF14LS4N4'^OYY(\KV7) MB@JY*@0'B:NQ,PV&L]C$VX ?!6[5G@TFDZ40#\;YFHT=WPC"$E-M&!@-CWB% M96F(2,;O':?3;FF
^_8+^R>;.^6R9 JO1'E?9#H?.WT',ERQ3:EOQ?8+[O+I M&KY4E,I^8=OQI#Z49I4>W I*_J>#.RI]TY['Z_A% N .$5G>SD57Y@6DV M&4FQ!6FBBRT))6"\+IR4*+].']C/+*X$I4=-
>*F>,:>9K8 M38R7[IAF#5-XA&D UX+K7,%'GF'V&N^1JE9:^")M%IXD7&!] 9'O0NB\0F^ MJ$TULSG1,;Z<2=RE.F?/5%D:IE(ROD9K_YPNE994)K\.)=]PQX>5Y=,9JIJE
M.';H;2B4C^A,SL^"Q+\\H3QNE<>GV/_KDDXR'=9Y(S3",[/^F$07L*QW> > MZ1FF8LV+/[2DA68E*!N\M,'I?C ^&1NAX" VDHBH*GA#R94HBXQI &?J_S&3DE5UH
R^@E%Z;83$LB M3#_I0DQA"?3=WF 0>AV>U'G[O01DT W&AAQ?3>(!T9DXO9]8X2)&T0Q'*H] M;Z]95"C7MB4J8MYPW?2-=K;MNM.FV?P+;UKV-9/K@BZKQ!5!_8M>UP'9M,'&
MT:*VK6&PO=V]R:W-H965TCAH5;:G265]\WQ:.3R"FOAAJ9!32>EL;7PM+3S MD6LLBB(HU6J4CL?O1[60.IF>-T:3TT;,\0;]MV9F:37J40I9HW;2:+!8GB73W>/S?98/ G](7+BU;V!/
M,F/N>/&E.$O&3 @5YIX1!/W=XP4JQ4!$XT>'F?0F67']>XG^,?A.OF3'X851 M?\K"5V?)40(%EJ)5_MHL/F/GSP'CY4:Y\ N+*)M^2"!OG3=UITP,:JGCOWCH MXK"F<#1^02'M%-+
.QH*+'\57DQ.K5F 96E"XX_@:M 9QFR MTV8.?[2H/5S>T^_IR!,JGXWR#N$\(J0O('R KT;[RL&E+K!XJC\B-CVE=$GI M/-T*>(/-$/;& TC'Z?X6O+W>Q;V M_=*%QW\-
BO2L=VA"OC$7;'\;-4;J;GL F M(ORNX'U%2B#*4BHIB$H0FK4VKZAW[Z8$J9U@]8Q](5HI!<* M9L)Z37M#^$9%9)?F!_!$F="5@J9;@FDM=8)N2[+>6JGG0%]DU3^",CG99E_@
M\M*@" .R5,6",9IW=;8"R_%R-6,P22Z MB$;Q7,K+N7Z&*@NYMFG4XWI$:>D0R%XYRXB%7QK%IRL!FXN"=:[/O-"C98)PZ-*%[MC=RX+@BB^$ZGD2P/PP+
(QE),TQW",SBHQ,P.^D.IN?H,H3(.$Q"UH=PP':$? MZ;S C&*IT;DNS 5DC[!1/H$$U5?36(,@:ZZP= P_Y4X)]XLN(PJV;##K.KI M!F$33 ,Y&AOAO*7EML!(!VNAX6-'87=E/ ?
*UT)0T&VPT57%:3! 4:"#.'6,"R&.4/[$2"4E[!$DLN-[5[AG1 8&D)A;4L(M*YM6RAZ($=;%;UL.6\AAT40[#]O"$(IW% 40.K?H= M8[?3R^-)<[_
NDL1!;X2S,/_/PD4Q/^%0HA^A>$>1_LR&$+3_%.<[;4!1.=8 MEJ':_V-%:LYW&%Y0M[ZEN>U9(/ 'O@EECFZ%%GOU%7,O;(;1UY,F'IT4?75N MACW@%
R+_S0X%XI";"]D['VKGZ[O?XE/3@8/G=9C];>437: M>7@M\KRE.16?5/UN_R"=QG?82CR^9K*.^?24UB2ZGAX>)" C2_$N/"F":^R MS'AJNO!9T:,;+0O0>6GH(N\6;*!_ID_^!5!+
P04 " !CCV=9X5X0]TP; M #B4@ &0 'AL+W=O(]=)C.7NJ=FL?,"1FAC%), 0I>?+KM[]N 3G M9LFGSD/BT9"X=*.O7S?F^WO;?G1+8SKUJ2IK]\.39=?$]?W?3OOC>]EU9U.:F5:ZO
M*MVN7IK2WO_PY/1)^.)]L5AV^.+XQ?>-7IA;T_W>W+3TUW&<)2\]4[O"UJHU M\Q^>7)]^]_+T$@/XC?\NS+U+/BN0,K/V(_YXD__PY 0[_J7).DRAZ9\[\]4 M)6:B??SI)WT2U\3
]'.8_3433\3,M#.O;/G/(N^6/SQY]D3E9J[[LGMO[W\Q MGJ +S)?9TO'_U;U_]^2)RGK7V$0\9<.8'G/&^92'>Y8^Z MTR^^;^V]:O$VS88/3"J/ILT5-
4[EMFOI:4'CNA>_M0M=%W]I85&=JULY'F7G MZK98U,6\R'3=J>LLLWW=%?5"W=BRR KCU$'X=/C]<4=[P8S'F5_WI:Q[MF/= M;]4[6W=+IWZJV=H1L?G IYO6.%-
W\@4QZW51ZSHK=*ENZ4M#@MLY];_7,]>U)'G_MMXU#LH&GVS< =?S.-3HS/SQIl%9[9YZ\^-O7IY0]S22]W3?["/RMNWM MX:/5K^9CIUOU86E:W9B^*S(2#?ERHN[-
H2JOV\ZT-*RHU:VN MU>L6O*?!=%*Z+,A8U87F8RKJS+:-;>E(^.T?3:GO=4L;F%M2+ J2* CK0KHQ M*#=W9*X:_%G4M;W3L!RJ,CE)>TV"3_-T2Z/FA2ESG'U157UM.V;
;JK^671+ M?H4(7]'Y8!Y^%^R@Q5JR2,KVK3)SVBF)26=I2[G*R*RRAM5DS&3.RN9]J3M+ M+"&N0:2ZI>Z4MVJTRQ5M)N\SHD=7#5&^H@]=9^J>"%:V520Z=S1.IC/@>D.B
M+#38-CH#G1#83"K[COK-TO'8C3V>F"FBRGM_:_&+'1)NRQ-_[$0 M/?SU[Q_>'YV<7EZP2#6!+8?\B$Q71B3*>'[S[.+B4$@) IB>.&^"'471P<(M
M]1UX]F?/;'&)/;3UPHI\W!DGFR=&YN ZYB,)4^83=@-V6I)>V,[>X+.?;S3= M,,U474-=:'?D5UA@9)[U64BP>WA7,C T >Q.:1V8A>5KXA/+;*;=4LW)]3HU
M;VVER)NWK+6#$/==WQH26B/4SMF.02]H^N3UIBW(+Q0D<-VRM?UB*7/3:1I1 M+IZ?_ $\=KV8T&;+4L]L.YC,2M?]G+C;BZ(M6N/-)![*NGA !K-VFIVV8V[
M%9$F&;.J,SC*8>&;-4A.KFZ:UGVAS';3A&W7V]-OI";G*LL2Z1"7O4VQ!8#)3 M3^1\-)V>E704AIC)1S[=8ULOHFV]V&L=;W7)"O)1.KG15ET:VV6=M_93[U
M&YE@LE[,G=.$.42GMY%0\9HXZ2C*N^E)YDFKU'7@OSJ '%S?7!]2[-&!54K/ MYS0WA)F?A3'M(;9Q79%4.#"4-D3JS'\.??M*Y<>S8YT\?J6;HB/!O"%K35)" M>AR?'<+^MBR
SE,'>1M+R#Q06-HLV.]?* AQ=W2X9/&N2;YTI66/@1U>\4W; M:9@XF+)UP0,?'&E8R9/B#=.1YR"-*ON<)9#FH[=(/X-58FO]J7!LGM>FH^5<
MWS0D?'96%@O1%Z&/%-85N=\)DT27JOI;!$ \Q!A_"O^A.378G[K7,BK$,ZQP:W9AY@9,8.I[PL&G)!8M@I?A=/84G@O,&\)TU) MJPV)+LUR>L+LTGE>@%,D,T4M&0?]M4\E+Z-
7NY5H=?1NGQ(K,LV5?R2>=2/ M(@H@KX9WK"2V-8AM=]FND7JR)2:#<%":@&_4W_[^MG9V>5SZ/EK,VM["?I M69B)UZB>3<^C[#J*S@R;9HGT_M,A0JOPI+/91PE3[HE
CD *VSO2#PJA MV1O2;+2)94'.5[9"41")'0<"KB?R9 ZH#.D=Q=XY.17:Z!"%TQ\O=0E'I6Z1 M^[A$F"[WR5+*S7?L_I_N-)DT97 +V\PF&\L/KWY6KUKRO(@?U>N>-.3-FXEZ M.
[V9J@-Z2(:.&.UZ+0%")+H@):.%--AS-.]94"@(;/U[F);^"6>DSBXF)R3DX29SC ?@T+$(N/C/RVNF4%)MLM:S& M.KQQNA2XJ%FDI*>XDDRD:2D.YP$0Z4WB$'R!\RMU]BQA/+D;O
..8MSM3Z\X M!EH42)]8E%W(JB 62,C5[=&Y.L! 55M* _<[/C\ZNOKVZ/#GT R6>#VZ&>.8= M3=^ M8_FZ ,)#/SPAY@>/E.V3Z2F2*)VD3TSF29S2CF#Q+C@PW\A3+X0/JI$
M!2Z^4 7V&A.*[0VMZPW*Z<6:15D/-VBS=9[$%^%/'V70)V%#Q4$$NYM?C"Z[M90:)>V]7]'F5A!@3CC$.$%:&(^B?GGU_E!BZHH4D#E,S@^L:7D"++#% -$P
MA5.#^,=C8/0#,K(6&1%K3O:]=9@P_OP+_=A5]&-7>_W/>PI@VSZ$'C=D ; B MUF*5*\0J)*)]%JB >T'01&=$EB^7N;$%S[+7\8GK--+491F&6HJY:1,,^4' /RR+ED2-C)GUN0B
M.=08OXU'/LM"=!<'OR,K!!?DJ%]6=[E)**4R"^GHV,^7SOFG\I"O26-EBC1 M^WYR[?\Y2&S@F>%+?/B8(1L3OO,D-.)YLAD@Z)$8YRFVT301F8_031P;X@Y MVFT1)"+
PH@^2)1$@,ZW"=!4_@X/7@UB! 9L7$^>DDR MQUP/-F'B#<_GUOR,W%E&, "[8]272<.@,LBC:]LQRVJ_:%AMW8/MT,8!02# _ M1=M"7-G3 ;: Q9W8Z'7\A@-/%I()
[QUQ44U=/7(D9N1+B!L-R0U]#T/<%:R6OV6=14S.9R#VZHO6DS6P M&@.784F2;CI #2!(=QK#Q-7"SS*K[@M(-RR,^=24%D$6YZK OXX\ $9I69%Y M_.6AJC.< R-
$Z[B59)."+G%XA".(QPH^[!#*-,*^VN/E(&^83^*4S\3PVT#S M?6[R6723S_9ZN)?:%6PJ1RB]P/;$EH+\ S\>P?K;'.F_81D&'Q_!#^\MC(>< MPPL-9?9B3^0PQ3,,>)W
GQ']B\'M&*?'6^P$EQ16K8Z0P><,*A9YH5O@85&< M3%FO(Q<_9:Q4(]P(HKZ4Z)/.EV2MC"'GU/!^YQT:WWJ ^AA5)BKR,P*P\\C%) MS[E]C+S]]HJBM7AAXL\I;P0/*+L05,0U%Y3-
0FI;AQ@:NK<,>@J4&>M'V=)AL MF2NRHIG?-"!V2V_'.&!N;4>6%.?>>HT>SBQ5TZA.G6^ I^,N+,Y$1^G]Y. M/;;*_CC+ "+D@='LW@81._CY^OI&2"+[W4,ZB"Z;._8\8
N*&3[FJ9*(FAZY M5*C3E>_IHQ0%WZ64;Q):.A_F: YEN@2T3-UO$87! (B@LL29(#1R)HSBW MNS=&&$G>G8(=!HV),D.65;&5K;,!6TL6\69>;*'4.D@YRL@ H\DGA(FBWJUB
M!CHP)V@YIUW?GU= MK">BY[H8(,/Y0=-V3L1M/7SVDLO/O8U>>^R^(MVL?$<8GJGBQ*B<$'13'S&\ MD!02V- :P!2&GH M/CG$:0)]!11.&_G'M 'JJ4 =,E0H:D#!RVYK\
7,%'L%;#V8]6UKS4E1O2* MS/40D4#13?,.Y^I',CM"B11"SM4]/2#18]PQCI^C5VZD3!4(F3LS"L)6Q%(MT[48VO<"7@9,ZO3DZ._1Y*T,&0#A\>;&MB!>-@2)'M$1'J1.(]T$EY?
(95P M+EEV^A+<&k]@Z4!)1-[*!$'<3E4 M-+G2('[]L=*'%"AXKD)*ZZRA=Q'O"ZL2U;.DPAN='#(>/G9VQ2NOQ.*-]P6V MW\;]MN]$>?O CW^Y#I.,+>"/X^;@9DI
5GT2I\7"!$E"'"8,.4O2%X4L/N9Q M250"WE;ZHP%(Y;?(Z1FJ4HT8-HF=!J4$<1'$4RL)GY@TDM'GG*M*? (R#3I->$ P)+M$E@UAW M9?,3U3?,.J*L$AQ@#@37^^$N-7!B%
8A"J]"E=+X+*[C@PQ9B0ZB=31?#FQY M7IB]&G=Z,G3(G>POOR>>F^Q(1K-[#[NU[>U+)Y/ ALN_J,!I+IV%GHNMS5^0 MS9A&)#7R&(-R!M3328FHL9I2IE<)Y(.6]J
1VRPN'JQ"&8;>XE)G0#_'//. MQ/-RN,7YS@RE^-Q'2_X/HB@WR2C?>T(B ^B5" YD_BMR@$0L^JD.?"1C/G5L M):B<2O9Y RQMV]1RF-W34[Z$QTZ;]2T9,.ZXL(40B?
HG(W>L7$C;!%B@BK M6=\Z)DZP$9XT:5YA1&M7JU#L8>% >A#/S %5"W,?PMGX=HBA,\H4*>]L"_=1 &(A3RU1QD7FGL+,@792=J1T\RXZ M)
<0G4_6+#,HT0W%!.BAJ[=@^T70,$/LU?00<*=DF*-+\+V/WJP.2()P!JF7 MR95O;90T9FT![U?00_<*=DF*-+\+V/WJP.2()P!JF7 MR95O;90T9FT!2S?69-+@ 1^ 84N_H+P(%&U';OG8D),I?
MJ@T>PA[Q*Q'^D"U@:OK>E/F0O6F!RJ.PBK2?DB;VK()H2, M<&MH>8#C8T7R5*.34*R,[Z]$]$BEA?MDR7OD?&Z",HU',J_B48V:DKSCGXUZ M#Q'GDCGASB0X";"1I
MY6S0V+X:HM. ;]F:LP*\AZ66Q6)9KHZD_]&-D4>@I;[+]U,CP2;7Q5=!\F3+ M$Z0\]$ZCVXUDV#&\F,1D29B[C<$#[62;(B /L4SK-EO)BV"F@S-,MC\S@$]P M"7Q#!$O,*^L,S1'>
0E(M]1.;%5N[^L%3%Z ![BOKZB+JJ_6QJ3:&D0/^Q&! M8<1)(!Q?4H!LK(%VM+5U_@VCXU;T/%#Z(ZZ!:2V-?9\S 0P\>(7U_NND@;HH5;)!=;*4'8 M;&8\H'
C9$+W]%;+L!FS4AIB?)?-K$=,X5_V(42'F8.5.2ED.$?82B[):1= M&VOZN,,;4UB;D '4$_ET!%QMQE4:Z5U<^:S'"+)5%AXQ/H@"6=B_S%H5 M7>A+VF7M>B='P_TC;"*3D
7UELX/F*W2_/Y^2<_3_'H8%4J6XKMM79LQ5(46 M@RBV/JXGT8P[MF1F^DH$=S3@>6NOJ]9UY$EK0"ZN8,>?/(P[Q:H! F M=8S;"4CF
M8[M]\N4BXZ,6B_'!;$/XCX(J(-7=0LALD3LLB=JU)DV_V3B3:K3=Y@KD_UE! M(B/\)!&*N9Q&G%+B479)4L>MI*RTP!6H=X7I+3O:/V_!L35YRF^Z2KTE%+@

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`G6Qj+6"^_Q[;,>MPG!SL!-QS@AE/:SV\1HT53^FZ:>@X\4\#="[*2 MLMA[ZP:QYWR1&BKX>N@NJ9#7#I:(7>I1,F'[:+!]]&3;_P*S*/*N4J696=<_("Q%RK?B6B8*8-9G*UP3"2&QWR-A;&_C\Z]:D M"$-6X&:QAVOH!G[D?*Q (P<0(R$MTDI6QPB6@D-=SL6=317$=ZD?@",O3)QV M1]MNT4$WV(T\Z V]I*-1CFW]%4G=+ APS=PDR::8C 2Z;"CIVAK8QE(2Q_$P M N#U:9J!:!1SI?%P6[*J98W_T0C+-:+O4]0Z6BH1O3B/B^&P:I M\YE5S1(D-LHLN)/MLR'<,*"1\XDMI&(VT^_FQ#0VVJ(@<:X:50DHX2Y9BJ]F M4._%>Y21**3.>PZ#HE\P3KB=-"@S-H6/TPPY(234BUS/H$"J/T&/EC>;IK0M M2-&IM,W;:T(C-\9B1QBF<.$JP:6^-#ER#&'G]3V2%+JU ZI M]V7+2;"N>]?TM_R](HGK>0FND1M%NTE_77-HXF;&&3VPENXI[Q(4_!]=<;N(M\:L:G-"(FI3E>UVM8=]N&(X/VN .">VSVK=3P*WO!HE!C'"BL3]%;C:0FSV9 MW$]P6U$*_4!N>.OP6MK28_.>U#"":;?O&A-QY$8^L%*+<1^87'39:0J!39/+%K+J(=LR8694 M0$8V[0F FQ/ 2&7\SN=^-D+ [QX81(K'-=.'<6>DAC M2*N9C9XH&.XW2%= 9:/LGZD8/O]%]'\:9MQ6H_A(@_89IO(FV_#'9=\ $:T:$I M#1JR>+"O966X^39\KJ3B8E5U;73^T%)?MIYP<8<#O<%RC!]MIU.YJ]&HA1W0 GX7/ ^\?6M]_"?.G**;X[0,?2?\&;F)A![' M=(BB_Z\/MXX0N32@G35QQ$KB;AR[F4G23[MBC-UFK1_'W7H MH'4"-\OV]=:2-TU2E]W@;V\]M^'X8FI]SP_,2)TNQ%/GW2Z**]!G/[-2/ M#T.K??)80 0=3YXW1$,8#>R%D?>\R,@.(R-[B5;C\2#T^';^P7[9?EW?3V SU<"JU-C5/K M$J+>FR2:$=5^\VYOM-S: [\P+J;7O(+Q@2 $EUMU2E@1(LG87M%N09-O#L =:HFVB MDJB15-SLU^\S5S;#FV3ZM_)>PFS644EYS@K% M14$D6UY-;YR+6Q_WFPV_<[91.V."DBR$>(^3G]*KJ8V 6,82C10H?#VS.Y9E M2 A@_-W0G'8L\>#NN*7^QL@.LBRH8GGTUC:8D94M:9?I!;'YDC3P! MTDM$ILPGV=1[Y^&4))72(F\. X*<%_4W_=#H8>= 9!\XX#8'7(.[9F10?D\U MO;Z48D,D[@9J.#"BFM, CA=HE$IRI@$'4ILE#<_;FJ=[@&=, MWHE"KQ5Y7:0L[9^? ?Y."+<5XM8=)?C(RG/BV19Q;==U2O$,/>\8I1A% M/+#,"'^3L0U9XK\>;. 7>!5? PUIH&;@#S/ FW:A2IJPJRE<)<7D,YM>?_N- M$]K?C<#W._C^&/7K1[BY:94Q--RX?7_5:R;'K#PDVBCS8='V4/ ^BJ3EK[?\ MR\;+>)%D50KJ!J1D*3(((FB34U[BJ@4G%>O+B9/:\E8SZT(.(5F^0+D0_X M!6"._#Y!ST'W\4@WFMR!;#RA&=&2PR?[ )%0,8L(HS6]YC(]*ZG4+T8*EI>9 M> $4M3@0+PUF@)N25&P*(R L+& C6]$,A,I8]1X$:64] (=]^$[F.^QV,PL#M MS3TKM,/)(WMFDA8),QP7K&!+KEM@W>["[QKW(I#9[)C=D A,5*=B>59!8>H M4@S@(CW 43(0QR)E1AO;L+\K7IJ#+47'MIRY1R++A?:OWXX1:O%4<.B1UW,NXG-;$Q;SE!LB?$<2POM'@6YZ# S^V M"'M.GGI.I#& X=EGCAZ6,DUYI@#MBLK4; (#M:E3EK96U\3_<4:"CY;6CL0%' M-.Y55E)5J&(MS''C>/VHL MFD3_1KIQW'Y/7C<.@;9:%?P?P)?6C%"'<*VX2,'1_[I"SJX&MC> M;CQM>+W:C@YB?D2C,_B''@ED!(">P>4)@? XZ3^ M5W92A.;$80\:S(_387MD[WMLNT_*OX%F09"WAM-#6R_\!I.;FFWM ME+_TA$2(M1"H;HH&,I5R(^-&_&\"S;Q#(GLB(/!RZ8)[*_@C$<*P1. M:(38"D//C+!8(65A:+8\4B2 MW:#=!KWLY69_]>>81R\1GW2E,_'E3/_NV> .QOP?@AE! IW MX%E^''T%SW!!*V[M#U"SAWX]#*W PV1RNP4/X8Y]2(_$MO&1[C?MN=C$HS= M'-N2.'0;F#>YJ#!W=9D $A'-H4[E_]3Y8\'TAK%BOW9";0]D?O3)=UR95ZE; M^M**:X1H7=KRYG8S"KWC?-NWYG,'N00!X],_.BW;77[,^YOCBD/S>=_ZL48 M,S$R-/A.FL9O+SE3R?9RVDO$. <;=G_JQ.JFU,SL'C#Y07N.6C*LGJVA6" M\GGG+LD)S[(6%B[9)*]7+.Q@2V8>$#/0T:'^IDW;DN%S*&JDV5D+F8EB=8;R M=TT:_[RF2)U/WC15S-'O&1\78NI@Y=@HT^W+:UJ&H$EO<\<^KI2,YX%IZ4=+ M1[RK]35QW,&N1@VU-5NK#P&-8@/4CX_L<7P(%38Y.Z9?0*!N.-C`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

2OVN58?$ M#"1F(C$+B=E(S$%B+A+SD)B/Q (0QM7O=%>_TW/.;Z?(XD5B!A(SD9B%Q&PD MYB Q%XEY2,Q'8@$(XXI759HO7!7D#%>N=:U7J&9 -1.J65#-KK7A_M':H6#^ MZM0-]R>Z8U4TT86NGP?5?*@6H#2^WO8"#NJQZ:XNF.X*:TTJ=:XUI&9 -1.J M65#-AFH.5'.AF@?5?*@6H#2^:K6F:K5S3G)K'57)2,V :B94LZ";:#=46+GP'RWP^%=^0"=2Q :XX%])E2SH)H-U1RH MYD(U#ZKY4"U :7PQ-W$C=7C6:3 TB035#*AF0C4+JME0S8%J+E3SH)H/U0*4 MQE=R$TI2I;&)SM-@:
P)JAE0S:PU+O@Y%84;H,/:@F&GH@.U#G185S"L*CR2 M[$'']:%:@-+X6FHR0JH\)'3BT5QH. BJ&5#-A&H65+.AF@/57*CF034?J@4H MC2_8)G&D3LXZC84&CJ":
=5,J&9!-1.NJ.5#-A6H>5/.A6H#2^$INLD>J-!TQ MNTL3EH41(ZS^B_#J5 I%+:=L23,257\P'B?1:CNG\^(&':,HVQ8WZ;<-3?(# MDUUH)@FJ&;7&34]%R543.JP%U6RHYD U%ZIYISY=/G380#2LP@_+GP&@B0MI M\KC0/0WS;4:KSXMNLMFR"W(?9E\H(P]AQN(HWH3%;YZVGQE-RENW:5:,4;[- M/H:,BJI-/F#7:H-J!E0SH9H%U6RHYD U%ZIY4,V':@%*XXN[R29IZCGGQ1HT MKP35#*AF0C4+JME0S8%J+E3SH)H/U0*4QE=RDU?2I"F*V;\VM#P74E'%J^(- MFUZ0]=
[[=ER^;PL+&!I3@FH&5#.AF@75;*CF0#6WUE1M;V:I7"KCZ8>CQ=!1 M?:@6H#2^-)L DB8/(!5SXZHFRX^EZ?KDTH3FD*": =7,6ONXBXVT#]^_0$>U M#XPZ&4VYGP]?QASJ]?8-RON/^B%K#UUS#ZKY4"U :7RI-=DC39X],M>;5?I* M*7FB7OWPR02?P"%YHN@F@'53*AF034;JCE0S85J'E3SH5J TOB";?)%VEGS
M11HT7P35#*AF0C4+JME0S8%J+E3SH)H/U0*4QE=RDR_2Y/FB1_Y$ODW*Z**J MZ.C]3+ZL.9/OYNU,OL+"AL:/H)H!U4RH9D$U6VN'A8;ZL!U1$K13IP.]_4>G M(G P:3?TZH;
[^?^/7Z! -S5 :7SU-(DB39XH>@A?RUK)R?SMG9 M*=G0+$Y% MYX&^E6.=JP.:+()J)E2SH)I=:_O[Z&0B.'^FH-UHI T$U=%NJ&O3]ADH/4%# M=3IJ?\<(W=X I?$ETF1X-/EI@]J?
[+2SGD%(@\9UH)H!U4RH9D$U&ZHY4,V%:AY4\Z%: M@-+X*RLTZ2!=G@[Z(\V^/*=9\5Z\E\>[**>N43&=#1?"XZ]RLVO]UMJ4.R-[_MYF="!G1($ZI94,V&:@Y4!/W>!/O>!,?
NF4!2N.+I8G.Z/+H3+=C+W*L;N((FX@,NQRT?NGT!2N-+8N^*6?+(RJ%C+:>>R$[.=RX2 M[%6SL)?-PEXW"WOA+.R5L["7SL)>.PM[\2SLU;/.$8G1FTB,/CCGL18=FI6!
M:@94,Z&:!=5LJ.9 -1>J>5#-AVH!2N,KN2OQS6FTR+CLRTR+'. M.SXTTP+53*AFZ>TK6XG^WMP6M!.F503MQ&D50I.%2PW MU"M7M-Q3K_QJ>;\9=G:]*>9Y]V&VB).0P !D !X;"]W;W)K&ULK5?; M;MLX$/T50ELL6B"-KI;MK&T@L;W8/A0(XG;[L-@'6AI;1"11)2D[^?L=4K)] M2ZH2=/,BB>29_S.'M]'LR,6C3 4>1'1<69 M5=@4>UL6
FALC++4]APGM#/*"R#++J'B^@Y0?YY9K MG3H>V#Y1NL->S JZAPVHK\6]P);=L,0L@UPRGA,!N[EUZ]ZL)QIO "\S.,JS M;Z(SV7+^J!N?XKGEZ(@A4AI!HJO
RPA3341AO&]YK0:E]KP_/O$_J?)'7/9 M4@E+GGYCL4KFUL0B,>QHF:H'?OP+ZGQ&FB_BJ31/U<880<;R MZDV?:AW.#)"GW\"K#;RV0? 3 [\V\%_K(:@-
@M=Z&-4&)G6[RMT(MZ**+F:" M'XG0:&33'T9]8XUZL5RODXT2.,K03BT>0"I11JH4+-]?D4]909G =: (S6.R MY%))PG?D"PAT3A7$Y%[PO: 9^4@VU=K2XQSFR%*>A
[*@.]ZX*U_M)N#[YS'.52++.8XA[[%?#]M,!>QNE M:_3S3OK=>8.$&RBNB>]<$<_Q@IYXEJ\W]_O2^7_>U[_L_4(,OUE,ON'S7[.8 MS)Z@-0LFEM]'C#%0))_;K>
(P@/BW[[IKQP$_0[TH7DC"QK!W,)348(X@+7X M_3.A"O"50*" MJ(2)^&-!A7HV,PA9D?)G !*938TW$T(3RDW8?X#Q7*P3GM0!<'E>D2&E]4<#WDA4:UB= ^*(783KN&._)4$7-?
&]:4N% M+L@/0V_2+\.XD6$\O&7PTM!'%E'U/6AJ',R[4D1OU2S!I))@,2M J%-AEH5#I$)W*!?6C7!@X!2:=W=G1
MHPMQ7=S"+4UZ4('OMO='C[NIZXQ;LMAGM50&8F^*6(FIE;FJ;L*FMZF3;TUY MV_J_DO1;MB6$HJ MIIMQMDN)ORZ"HG",%44;1WX0CQ:7Q6(RV=,PB,E-BK)]%/GI]VL2)H>K
MD3IZ_N VV&QI_L%X<;GS-^2.T*^[FY2]&U>4=1"1. N2&*7DX6KT2;WPL)8' M%(H_ W+(3EZC?%?ND^1;_L9;7XV4?$0D)"N:(WSV[Y$L21CF)#:.?TOHJ-IF
M'GCZ^IEN%SO/=N;>S\@R"?*UG1[-=)':$T>_'U(;Y.#2\H=FN6\51)FQ5]T M*+7*"*WV&4VB,IB-(KBXW__J3P0)P&,(P[90!N!TS/!$S*@$G?@&D9,.T; M,"L#9GT#M#)
ZQLP+P/F?8^27@;H[0#M3(!1!AB%'8[Y*Y)O^M1??*;) :6Y MFM'R%X6#BFB6\R#.S7Y'4_9MP.+HXI9D--VOZ#X-XLU[Y$4[/TB9F2GRXS5: M)AG-4/*
OI"4;=RG9(UNTF23^A'Z@!JQ^3N2/A)TFX3Y27CPTS5X:Q+J\'V MCJF_WIGH[9MWZ T*8O1EF^PSMH7LQ!#!FA[_* 7[.P366$N_([B..*.\15Q!4,*"E//SW M?2P--
^7AG_V4A:MGPZW^@Y\(PNW^@Q>%._T'+PIW?^[(>_)PDZS.;;UAA$EU M,DX*WO0,SXIV8?*=$'1''DGJQRLB.CVDC'QOO,AV_HI:67>:4&?]%E)]M7@[WPY0/9Q/?A'
M9.8VNX*;&YC6SJ3YIBAQ>-,&& MT12Y/4;D=8 :^=6J_&KRM?:)U8L989E=)9LX^()=V:Z/N:9;@G8D#1+1Q>&U ME#HTMY P$Q)F'6&STP1/9BT3\!K5F+9-(!Q3G%YD=*R -#.-
:PRKZPREUKE MQO>5T19/X-(64,- @DS(6'6G$O9!UV?MQPB$&E:?J7=L(A)9@H!"I^I@#: MQ89-],HF^DM6#!*O.Y8+G9O>6NY?2C<\U :0,$OGLC*=M49O\QIN07%XC6":
MX$7M:8)7G'JDD5:C2JLQL"A#/XJ"K]7_N&'Y%6572A\Z'T#"3$B8!0FS(6$. M),R%A'E L(:M5:7N_"FO4K"56"!'@]),4)H%2K-!:0XHS06E>5"TIK%/6MKJ
MJY5N&NFVNROOFPPHT.6RP M!4 [Z"6M4>5@16F?XP(57WR)5(+J2R#CSG(!27":OT;W6:W;SZJT'?CR\JOD M2@[4K[IP4D&;2P+AL^78 (17X,)1*+3O/-
P>0+)V3),K1NRJKPC>ZX0PST+ M,3E^\'D/VI<%I5F@-!N4YH#27%":!T5K&KSN2*O:ZQ1DH#UI4)H)2K- :38H MS0&EN: T#XK6-';=/U?E#?2?*LA ^^F@-%/E>]+#?*Z
M0,T$UYUO5=[Z?G$U!MF+7H+23%":I7;VKNUNB=,M<;LE'M2>-4-] M8+4&VC\'I9F@-*ND22W2*7$$M&O:=TD#VKOFO=$SMH7LQ!:#

%M#;VYT96YT7U1Y<&5S72YX;6Q02P4& #8 -@"Q#@ 4EL! end XML 54 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 285 236 1 false 66 0 false 5 false false R1.htm 100000 - Document - Cover Page Sheet http://www.nektar.com/20240930/taxonomy/role/CoverPage Cover Page Cover 1 false false R2.htm 100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY Sheet http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY Statements 6 false false R7.htm 100060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 8 false false R9.htm 995455 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 9 false false R10.htm 995465 - Disclosure - Cash and Investments in Marketable Securities Sheet http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecurities Cash and Investments in Marketable Securities Notes 10 false false R11.htm 995475 - Disclosure - Condensed Consolidated Financial Statement Details Sheet http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetails Condensed Consolidated Financial Statement Details Notes 11 false false R12.htm 995485 - Disclosure - Commitments and Contingencies Sheet http://www.nektar.com/20240930/taxonomy/role/CommitmentsandContingencies Commitments and Contingencies Notes 12 false false R13.htm 995495 - Disclosure - Pre-Funded Warrant Sheet http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrant Pre-Funded Warrant Notes 13 false false R14.htm 995505 - Disclosure - License and Collaboration Agreements Sheet http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreements License and Collaboration Agreements Notes 14 false false R15.htm 995515 - Disclosure - Restructuring, Impairment and Costs of Terminated Program Sheet http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgram Restructuring, Impairment and Costs of Terminated Program Notes 15 false false R16.htm 995525 - Disclosure - Impairment of Goodwill Sheet http://www.nektar.com/20240930/taxonomy/role/DisclosureImpairmentOfGoodwill Impairment of Goodwill Notes 16 false false R17.htm 995535 - Disclosure - Stock-Based Compensation Sheet http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensation Stock-Based Compensation Notes 17 false false R18.htm 995545 - Disclosure - Subsequent Event Sheet http://www.nektar.com/20240930/taxonomy/role/DisclosureSubsequentEvent1 Subsequent Event Notes 18 false false R19.htm 995555 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPolicies 19 false false R20.htm 995565 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) Sheet http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesTables Organization and Summary of Significant Accounting Policies (Tables) Tables http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPolicies 20 false false R21.htm 995575 - Disclosure - Cash and Investments in Marketable Securities (Tables) Sheet http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesTables Cash and Investments in Marketable Securities (Tables) Tables http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecurities 21 false false R22.htm 995585 - Disclosure - Condensed Consolidated Financial Statement Details (Tables) Sheet http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsTables Condensed Consolidated Financial Statement Details (Tables) Tables http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetails 22 false false R23.htm 995605 - Disclosure - Restructuring, Impairment and Costs of Terminated Program (Tables) Sheet http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramTables Restructuring, Impairment and Costs of Terminated Program (Tables) Tables http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgram 23 false false R24.htm 995615 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensation 24 false false R25.htm 995625 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail Organization and Summary of Significant Accounting Policies - Additional Information (Detail) Details 25 false false R26.htm 995635 - Disclosure - Organization and Summary of Significant Accounting Policies - Weighted Average Outstanding Stock Options (Details) Sheet http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageOutstandingStockOptionsDetails Organization and Summary of Significant Accounting Policies - Weighted Average Outstanding Stock Options (Details) Details 26 false false R27.htm 995645 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail) Sheet http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail) Details 27 false false R28.htm 995655 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail) Sheet http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail) Details 28 false false R29.htm 995675 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Inventory (Details) Sheet http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails Condensed Consolidated Financial Statement Details - Schedule of Inventory (Details) Details 29 false false R30.htm 995685 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Other Current Assets (Details) Sheet http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofOtherCurrentAssetsDetails Condensed Consolidated Financial Statement Details - Schedule of Other Current Assets (Details) Details 30 false false R31.htm 995695 - Disclosure - Condensed Consolidated Financial Statement Details - Assets Held for Sale (Details) Sheet http://www.nektar.com/20240930/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementDetailsAssetsHeldForSaleDetails Condensed Consolidated Financial Statement Details - Assets Held for Sale (Details) Details 31 false false R32.htm 995705 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Property, Plant and Equipment (Details) Sheet http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails Condensed Consolidated Financial Statement Details - Schedule of Property, Plant and Equipment (Details) Details 32 false false R33.htm 995715 - Disclosure - Condensed Consolidated Financial Statement Details - Narrative (Details) Sheet http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails Condensed Consolidated Financial Statement Details - Narrative (Details) Details http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsTables 33 false false R34.htm 995725 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Accrued Expenses (Details) Sheet http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails Condensed Consolidated Financial Statement Details - Schedule of Accrued Expenses (Details) Details 34 false false R35.htm 995735 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Liability Related to Sale of Potential Future Royalties (Details) Sheet http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails Condensed Consolidated Financial Statement Details - Schedule of Liability Related to Sale of Potential Future Royalties (Details) Details 35 false false R36.htm 995745 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.nektar.com/20240930/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementDetailsScheduleOfAccumulatedOtherComprehensiveIncomeLossDetails Condensed Consolidated Financial Statement Details - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) Details 36 false false R37.htm 995755 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.nektar.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 37 false false R38.htm 995765 - Disclosure - Pre-Funded Warrant - Additional Information (Details) Sheet http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails Pre-Funded Warrant - Additional Information (Details) Details 38 false false R39.htm 995775 - Disclosure - License and Collaboration Agreements - Additional Information (Details) Sheet http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails License and Collaboration Agreements - Additional

Information (Details) Details 39 false false R40.htm 995795 - Disclosure - Restructuring, Impairment and Costs of Terminated Program - Narrative (Details) Sheet http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails Restructuring, Impairment and Costs of Terminated Program - Narrative (Details) Details http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramTables 40 false false R41.htm 995805 - Disclosure - Restructuring, Impairment and Costs of Terminated Program - Summary of Restructuring Costs (Details) Sheet http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSummaryOfRestructuringCostsDetails Restructuring, Impairment and Costs of Terminated Program - Summary of Restructuring Costs (Details) Details 41 false false R42.htm 995815 - Disclosure - Restructuring, Impairment and Costs of Terminated Program - Restructuring Reserve Rollforward (Details) Sheet http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramRestructuringReserveRollforwardDetails Restructuring, Impairment and Costs of Terminated Program - Restructuring Reserve Rollforward (Details) Details 42 false false R43.htm 995825 - Disclosure - Restructuring, Impairment and Costs of Terminated Program - Sublease Information (Details) Sheet http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails Restructuring, Impairment and Costs of Terminated Program - Sublease Information (Details) Details 43 false false R44.htm 995835 - Disclosure - Impairement of Goodwill (Additional Information) (Details) Sheet http://www.nektar.com/20240930/taxonomy/role/DisclosureImpairementOfGoodwillAdditionalInformationDetails Impairement of Goodwill (Additional Information) (Details) Details 44 false false R45.htm 995855 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail) Sheet http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensationStockBasedCompensationExpenseDetail Stock-Based Compensation - Stock-Based Compensation Expense (Detail) Details 45 false false R46.htm 995865 - Disclosure - Subsequent Event - Additional Information (Details) Sheet http://www.nektar.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails Subsequent Event - Additional Information (Details) Details 46 false false All Reports Book All Reports nktr-20240930.htm nktr-20240930.xsd http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 false false JSON 59 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "nktr-20240930.htm": { "nsprefix": "nktr", "nsuri": "http://www.nektar.com/20240930", "dts": { "inline": { "local": ["nktr-20240930.htm"] }, "schema": { "local": ["nktr-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 185, "keyCustom": 51, "axisStandard": 24, "axisCustom": 1, "memberStandard": 28, "memberCustom": 38, "hidden": { "total": 6, "http://xbrl.sec.gov/dei/2024": 4, "http://fasb.org/us-gaap/2024": 2 }, "contextCount": 285, "entityCount": 1, "segmentCount": 66, "elementCount": 555, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 640, "http://xbrl.sec.gov/dei/2024": 29 }, "report": { "R1": { "role": "http://www.nektar.com/20240930/taxonomy/role/CoverPage", "longName": "100000 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_3ab4753f-f0fe-4855-88c3-12140eac86dc", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3ab4753f-f0fe-4855-88c3-12140eac86dc", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "unique": true } }, "R3": { "role": "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_3ab4753f-f0fe-4855-88c3-12140eac86dc", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3ab4753f-f0fe-4855-88c3-12140eac86dc", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "longName": "100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_eb28f711-4281-44c4-bbac-a9842f1d4bb3", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_eb28f711-4281-44c4-bbac-a9842f1d4bb3", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "unique": true } }, "R5": { "role": "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "longName": "100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_eb28f711-4281-44c4-bbac-a9842f1d4bb3", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_eb28f711-4281-44c4-bbac-a9842f1d4bb3", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "unique": true } }, "R6": { "role": "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "longName": "100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_e49a2376-da2e-4c27-9056-03e1b1ef6efb", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_7357be45-840f-4909-872d-233b2ff66886", "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "unique": true } }, "R7": { "role": "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "100060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_eb28f711-4281-44c4-bbac-a9842f1d4bb3", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPolicies", "longName": "995455 - Disclosure - Organization and Summary of Significant Accounting Policies", "shortName": "Organization and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecurities", "longName": "995465 - Disclosure - Cash and Investments in Marketable Securities", "shortName": "Cash and Investments in Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetails", "longName": "995475 - Disclosure - Condensed Consolidated Financial Statement Details", "shortName": "Condensed Consolidated Financial Statement Details", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.nektar.com/20240930/taxonomy/role/CommitmentsandContingencies", "longName": "995485 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrant", "longName": "995495 - Disclosure - Pre-Funded Warrant", "shortName": "Pre-Funded Warrant", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "nktr:PreFundedWarrantTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"],

"reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "nktr:PreFundedWarrantTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreements", "longName": "995505 - Disclosure - License and Collaboration Agreements", "shortName": "License and Collaboration Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgram", "longName": "995515 - Disclosure - Restructuring, Impairment and Costs of Terminated Program", "shortName": "Restructuring, Impairment and Costs of Terminated Program", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.nektar.com/20240930/taxonomy/role/DisclosureImpairmentOfGoodwill", "longName": "995525 - Disclosure - Impairment of Goodwill", "shortName": "Impairment of Goodwill", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:AssetImpairmentChargesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:AssetImpairmentChargesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensation", "longName": "995535 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.nektar.com/20240930/taxonomy/role/DisclosureSubsequentEvent1", "longName": "995545 - Disclosure - Subsequent Event", "shortName": "Subsequent Event", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies", "longName": "995555 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)", "shortName": "Organization and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "19", "firstAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "nktr:OrganizationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "nktr:OrganizationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesTables", "longName": "995565 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)", "shortName": "Organization and Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesTables", "longName": "995575 - Disclosure - Cash and Investments in Marketable Securities (Tables)", "shortName": "Cash and Investments in Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsTables", "longName": "995585 - Disclosure - Condensed Consolidated Financial Statement Details (Tables)", "shortName": "Condensed Consolidated Financial Statement Details (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramTables", "longName": "995605 - Disclosure - Restructuring, Impairment and Costs of Terminated Program (Tables)", "shortName": "Restructuring, Impairment and Costs of Terminated Program (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensationTables", "longName": "995615 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "longName": "995625 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)", "shortName": "Organization and Summary of Significant Accounting Policies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "C_3ab4753f-f0fe-4855-88c3-12140eac86dc", "name": "nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_eb28f711-4281-44c4-bbac-a9842f1d4bb3", "name": "us-gaap:ProvisionForDoubtfulAccounts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:ConcentrationRiskCreditRisk", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "unique": true } }, "R26": { "role": "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageOutstandingStockOptionsDetails", "longName": "995635 - Disclosure - Organization and Summary of Significant Accounting Policies - Weighted Average Outstanding Stock Options (Details)", "shortName": "Organization and Summary of Significant Accounting Policies - Weighted Average Outstanding Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "C_fe463c1f-0e5c-477f-81d7-93dc617e599c", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_fe463c1f-0e5c-477f-81d7-93dc617e599c", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail", "longName": "995645 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)", "shortName": "Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "C_3ab4753f-f0fe-4855-88c3-12140eac86dc", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true }, "uniqueAnchor": null }, "R28": { "role": "http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail", "longName": "995655 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)", "shortName": "Cash and

Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "C_3ab4753f-f0fe-4855-88c3-12140eac86dc", "name": "us-gaap:Cash", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3ab4753f-f0fe-4855-88c3-12140eac86dc", "name": "us-gaap:Cash", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails", "longName": "995675 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Inventory (Details)", "shortName": "Condensed Consolidated Financial Statement Details - Schedule of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "C_3ab4753f-f0fe-4855-88c3-12140eac86dc", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3ab4753f-f0fe-4855-88c3-12140eac86dc", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, R30": { "role": "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofOtherCurrentAssetsDetails", "longName": "995685 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Other Current Assets (Details)", "shortName": "Condensed Consolidated Financial Statement Details - Schedule of Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_3ab4753f-f0fe-4855-88c3-12140eac86dc", "name": "us-gaap:OtherAssetsCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_dc65661b-dc4c-48eb-9614-ff74ec447cc0", "name": "us-gaap:OtherAssetsCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "unique": true } }, "R31": { "role": "http://www.nektar.com/20240930/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementDetailsAssetsHeldForSaleDetails", "longName": "995695 - Disclosure - Condensed Consolidated Financial Statement Details - Assets Held for Sale (Details)", "shortName": "Condensed Consolidated Financial Statement Details - Assets Held for Sale (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_3ab4753f-f0fe-4855-88c3-12140eac86dc", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3ab4753f-f0fe-4855-88c3-12140eac86dc", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails", "longName": "995705 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Property, Plant and Equipment (Details)", "shortName": "Condensed Consolidated Financial Statement Details - Schedule of Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_3ab4753f-f0fe-4855-88c3-12140eac86dc", "name": "nktr:DepreciablePropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3ab4753f-f0fe-4855-88c3-12140eac86dc", "name": "nktr:DepreciablePropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails", "longName": "995715 - Disclosure - Condensed Consolidated Financial Statement Details - Narrative (Details)", "shortName": "Condensed Consolidated Financial Statement Details - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_eb28f711-4281-44c4-bbac-a9842f1d4bb3", "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "div", "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9fb53c89-0772-44f3-a88e-1fedfb28f007", "name": "nktr:PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "unique": true } }, "R34": { "role": "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails", "longName": "995725 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Accrued Expenses (Details)", "shortName": "Condensed Consolidated Financial Statement Details - Schedule of Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_3ab4753f-f0fe-4855-88c3-12140eac86dc", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3ab4753f-f0fe-4855-88c3-12140eac86dc", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails", "longName": "995735 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Liability Related to Sale of Potential Future Royalties (Details)", "shortName": "Condensed Consolidated Financial Statement Details - Schedule of Liability Related to Sale of Potential Future Royalties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_0a5bfab1-ce79-4df7-a86b-4ee74a916094", "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0a5bfab1-ce79-4df7-a86b-4ee74a916094", "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "nktr:ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, R36": { "role": "http://www.nektar.com/20240930/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementDetailsScheduleOfAccumulatedOtherComprehensiveIncomeLossDetails", "longName": "995745 - Disclosure - Condensed Consolidated Financial Statement Details - Schedule of Accumulated Other Comprehensive Income (Loss) (Details)", "shortName": "Condensed Consolidated Financial Statement Details - Schedule of Accumulated Other Comprehensive Income (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_499d7a88-19f3-4b82-adfd-f7114ebf4ddd", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_76a62925-8059-4f44-aed0-d44c97df05d4", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "unique": true } }, R37": { "role": "http://www.nektar.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "longName": "995755 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_3ab4753f-f0fe-4855-88c3-12140eac86dc", "name": "us-gaap:LitigationReserve", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3ab4753f-f0fe-4855-88c3-12140eac86dc", "name": "us-gaap:LitigationReserve", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails", "longName": "995765 - Disclosure - Pre-Funded Warrant - Additional Information (Details)", "shortName": "Pre-Funded Warrant - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "us-gaap:ProceedsFromIssuanceOfWarrants", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1961c62a-cda5-4f9d-86ef-b6ba1953e676", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["span", "p", "nktr:PreFundedWarrantTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "unique": true } }, R39": { "role": "http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "longName": "995775 - Disclosure - License and Collaboration Agreements - Additional Information (Details)", "shortName": "License and Collaboration Agreements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_3ab4753f-f0fe-4855-88c3-12140eac86dc", "name": "nktr:DisposalGroupIncludingDiscontinuedOperationContractWithCustomerAssetCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c06cd069-06aa-48ff-854a-458a055532dc", "name": "us-gaap:SharesIssued", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "unique": true } }, R40": { "role": "http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails", "longName": "995795 - Disclosure - Restructuring, Impairment and Costs of Terminated Program - Narrative (Details)", "shortName": "Restructuring, Impairment and Costs of Terminated Program - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_eb28f711-4281-44c4-bbac-a9842f1d4bb3", "name": "us-gaap:OperatingLeaseImpairmentLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:OperatingLeaseImpairmentLoss", "span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1ec85318-59f4-4cdd-8f79-760262a36673", "name": "us-gaap:OperatingLeaseImpairmentLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "unique": true } }, R41": { "role": "http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSummaryOfRestructuringCostsDetails", "longName": "995805 - Disclosure - Restructuring, Impairment and Costs of Terminated Program - Summary of Restructuring Costs (Details)", "shortName": "Restructuring, Impairment and Costs of Terminated Program - Summary of Restructuring Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",

"order": "41", "firstAnchor": { "contextRef": "C_eb28f711-4281-44c4-bbac-a9842f1d4bb3", "name": "us-gaap:BusinessExitCosts1", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "div", "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_eb28f711-4281-44c4-bbac-a9842f1d4bb3", "name": "us-gaap:BusinessExitCosts1", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "div", "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramRestructuringReserveRollforwardDetails", "longName": "995815 - Disclosure - Restructuring, Impairment and Costs of Terminated Program - Restructuring Reserve Rollforward (Details)", "shortName": "Restructuring, Impairment and Costs of Terminated Program - Restructuring Reserve Rollforward (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_d2a96fa0-6d75-4f5b-987d-a246b2af0cb3", "name": "us-gaap:RestructuringReserve", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_094a0f39-a7f1-463b-9c66-29e1f0fb2c5f", "name": "us-gaap:RestructuringReserve", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "unique": true } }, "R43": { "role": "http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails", "longName": "995825 - Disclosure - Restructuring, Impairment and Costs of Terminated Program - Sublease Information (Details)", "shortName": "Restructuring, Impairment and Costs of Terminated Program - Sublease Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_b357ce14-edd9-4d0d-8570-de76a9ff920e", "name": "nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetBookValueInExcessOfFairValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b357ce14-edd9-4d0d-8570-de76a9ff920e", "name": "nktr:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetBookValueInExcessOfFairValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.nektar.com/20240930/taxonomy/role/DisclosureImpairementOfGoodwillAdditionalInformationDetails", "longName": "995835 - Disclosure - Impairement of Goodwill (Additional Information) (Details)", "shortName": "Impairement of Goodwill (Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "nktr:ImpairmentOfRemainingLongLivedAssetHeldForUse", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:AssetImpairmentChargesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_96c7f9de-1479-4de1-b5bb-891cf1549407", "name": "nktr:ImpairmentOfRemainingLongLivedAssetHeldForUse", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:AssetImpairmentChargesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensationStockBasedCompensationExpenseDetail", "longName": "995855 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)", "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_eb28f711-4281-44c4-bbac-a9842f1d4bb3", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_a496895d-b0cf-4608-bc65-1aa700531846", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "unique": true } }, "R46": { "role": "http://www.nektar.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "longName": "995865 - Disclosure - Subsequent Event - Additional Information (Details)", "shortName": "Subsequent Event - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_7f52a8b7-ce0c-4a27-9e7b-6dbecd6c08e0", "name": "us-gaap:ProceedsFromSaleOfProductiveAssets", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["span", "p", "nktr:SaleOfManufacturingFacilityPolicyTextBlock", "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "nktr-20240930.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "totalLabel": "Accounts Payable, Current, Total", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r59", "r655"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r785"] }, "nktr_AccruedClinicalTrialExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "AccruedClinicalTrialExpensesCurrent", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued clinical trial expenses", "label": "Accrued Clinical Trial Expenses Current", "documentation": "Accrued clinical trial expenses current." } } }, "auth_ref": [] }, "nktr_AccruedContractTerminationCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "AccruedContractTerminationCostsCurrent", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued contract termination costs", "label": "Accrued Contract Termination Costs, Current", "documentation": "Accrued Contract Termination Costs, Current" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r61"] }, "nktr_AccruedResearchAndDevelopmentExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "AccruedResearchAndDevelopmentExpensesCurrent", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails"], "lang": { "en-us": { "role": { "documentation": "Accrued research and development expenses current.", "label": "Accrued Research And Development Expenses Current", "terseLabel": "Accrued research and development expenses" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r33", "r140", "r494"] }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementDetailsScheduleOfAccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "terseLabel": "Available-for-sale securities", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": ["r150", "r151", "r152", "r154", "r161", "r162", "r769"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss)", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r20", "r21", "r79", "r143", "r490", "r520", "r521"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.nektar.com/20240930/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementDetailsScheduleOfAccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "verboseLabel": "Accumulated Other Comprehensive Income", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r3", "r11", "r21", "r389", "r392", "r432", "r516", "r517", "r769", "r770", "r771", "r776", "r777", "r778", "r779"] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementDetailsScheduleOfAccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": ["r4", "r11", "r21", "r77", "r78", "r161", "r162", "r421", "r422", "r423", "r424", "r425", "r769"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } }

```
}, "auth_ref": [ "r711" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Capital in excess of par value", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r69" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Capital in Excess of Par Value", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r527", "r776", "r777", "r778", "r779", "r838", "r900" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r724" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r724" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r724" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r724" ] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentForAmortization", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Amounts recorded as amortization for Third St. facility and Mission Bay facility", "label": "Amortization", "totalLabel": "Amortization, Total", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": [ "r7" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r40", "r41", "r329" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "srt_AffiliatedEntityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AffiliatedEntityMember", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Affiliates", "label": "Affiliated Entity [Member]" } } } }, "auth_ref": [ "r567", "r605", "r667", "r809", "r851", "r852", "r853" ] },
"nktr_AggregateCommonSharesIssuedToPurchasePrefundedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "AggregateCommonSharesIssuedToPurchasePrefundedWarrants", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Aggregate common shares issued to purchase prefunded warrants", "documentation": "Aggregate common shares issued to purchase prefunded warrants." } } }, "auth_ref": [] },
"ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r757" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r683", "r693", "r703", "r735" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r686", "r696", "r706", "r738" ] },
"ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r758" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r724" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r731" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r687", "r697", "r707", "r731", "r739", "r743", "r751" ] },
"ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r749" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensationStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Total stock-based compensation", "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r358", "r362" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "verboseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "nktr_AmountExchangedToRemoveCapOnRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "AmountExchangedToRemoveCapOnRoyalties", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Amount exchanged to remove cap on royalties", "label": "Amount exchanged to remove cap on royalties", "documentation": "Amount exchanged to remove cap on royalties" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageOutstandingStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potentially dilutive securities (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r198" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageOutstandingStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r26" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageOutstandingStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r26" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails",
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails",
"http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r380" ] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r276", "r277", "r278", "r279", "r280", "r837" ] },
"nktr_AssetAcquisitionByAmpersandCapitalPartnersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "AssetAcquisitionByAmpersandCapitalPartnersMember", "presentation": [
```

"http://www.nektar.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": {
"terseLabel": "Asset Acquisition By Ampersand Capital Partners", "label": "Asset Acquisition By Ampersand Capital Partners [Member]", "documentation": "Asset acquisition by
ampersand capital partners." } } }, "auth_ref": [] }, "nktr_AssetAcquisitionByNovaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930",
"localname": "AssetAcquisitionByNovaMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": {
"terseLabel": "Asset Acquisition by Nova", "label": "Asset Acquisition by Nova [Member]", "documentation": "Asset Acquisition by Nova [Member]" } } }, "auth_ref": [] }, "us-
gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label":
"Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": ["r276", "r277", "r278", "r279", "r280", "r837"] }, "us-
gaap_AssetImpairmentChargesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentChargesTextBlock",
"presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureImpairmentOfGoodwill"], "lang": { "en-us": { "role": { "terseLabel": "Impairment of Goodwill",
"label": "Asset Impairment Charges [Text Block]", "documentation": "The entire disclosure for the details of the charge against earnings resulting from the aggregate write
down of all assets from their carrying value to their fair value. Disclosure may also include a description of the impaired asset and facts and circumstances leading to the
impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired
asset is reported." } } }, "auth_ref": [] }, "nktr_AssetPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname":
"AssetPurchaseAgreementMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": {
"terseLabel": "Asset Purchase Agreement", "label": "Asset Purchase Agreement [Member]", "documentation": "Asset purchase agreement." } } }, "auth_ref": [] }, "us-
gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label":
"Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r110", "r118", "r142", "r173", "r201", "r203", "r209", "r210",
"r247", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r382", "r386", "r417", "r484", "r560", "r625", "r626", "r655", "r674", "r802", "r803", "r854"] },
"us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets
[Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr":
"debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel":
"Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [
"r135", "r147", "r173", "r247", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r382", "r386", "r417", "r655", "r802", "r803", "r854"] }, "us-
gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label":
"Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.nektar.com/20240930/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementDetailsAssetsHeldForSaleDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Assets held for sale", "totalLabel": "Total assets held for sale", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "documentation":
"Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } }
}, "auth_ref": ["r2", "r49", "r55", "r98", "r101", "r133", "r134"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit",
"presentation": ["http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"],
"lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
"documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with
change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r221"] }, "us-
gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
"http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"], "lang": { "en-us":
{ "role": { "negatedTerseLabel": "Gross Unrealized Losses", "terseLabel": "Gross unrealized losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized
Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair
value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r222"] }, "us-
gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"], "lang": { "en-us":
{ "role": { "totalLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security
measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r218", "r256", "r483"] }, "us-
gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"], "lang": { "en-us":
{ "role": { "verboseLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale", "totalLabel": "Debt Securities, Available-for-Sale, Total", "documentation": "Amount of
investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r219", "r256",
"r399", "r476", "r643", "r648", "r787", "r842", "r843", "r844"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"],
"lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt
security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": ["r216", "r256"
] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"],
"lang": { "en-us": { "role": { "verboseLabel": "Long-term investments", "terseLabel": "Long-term investments", "label": "Debt Securities, Available-for-Sale, Noncurrent",
"documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale),
classified as noncurrent." } } }, "auth_ref": ["r139", "r216", "r256"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price",
"terseLabel": "Exercise Price" } } }, "auth_ref": ["r746"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair
Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r747"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award
Timing Disclosures" } } }, "auth_ref": ["r742"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award
Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r742"] }, "ecd_AwardTmgMethodTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } },
"auth_ref": ["r742"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag",
"presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award
Timing MNPI Considered" } } }, "auth_ref": ["r742"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing
MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r742"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": {
"role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r742"] }, "us-gaap_AwardTypeAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-
us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } },
"auth_ref": ["r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352",
"r353", "r354", "r355", "r356", "r357"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities
Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r745"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": {
"role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r744"] }, "ecd_AwardsCloseToMnpiDiscTable": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close
in Time to MNPI Disclosures" } } }, "auth_ref": ["r743"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-
us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [
"r743"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis",
"presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofOtherCurrentAssetsDetails"], "lang": { "en-
us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in
statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r283", "r866", "r867"] }, "us-
gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [

"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r43", "r44", "r283", "r866", "r867"] }, "nktr_BiolojicDesignCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "BiolojicDesignCompanyMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Biolojic Design Member", "label": "Biolojic Design Company [Member]", "documentation": "Biolojic design company." } } }, "auth_ref": [] }, "nktr_BristolMyersSquibbCollaborationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "BristolMyersSquibbCollaborationAgreementMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Bristol Myers Squibb Collaboration Agreement", "label": "Bristol Myers Squibb Collaboration Agreement [Member]", "documentation": "Bristol Myers Squibb collaboration agreement." } } }, "auth_ref": [] }, "nktr_BristolMyersSquibbCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "BristolMyersSquibbCompanyMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Bristol Myers Squibb Company", "label": "Bristol Myers Squibb Company [Member]", "documentation": "Bristol-Myers Squibb Company." } } }, "auth_ref": [] }, "nktr_BuildingAndLeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "BuildingAndLeaseholdImprovementsMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Building and leasehold improvements", "label": "Building and Leasehold Improvements [Member]", "documentation": "Building and Leasehold Improvements" } } }, "auth_ref": [] }, "us-gaap_BusinessExitCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessExitCosts1", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSummaryOfRestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program", "label": "Business Exit Costs", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r7"] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reported Value Measurement", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": ["r45", "r46"] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r120", "r487", "r528", "r555", "r655", "r674", "r768"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r24", "r138", "r611"] }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecurities"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Investments in Marketable Securities", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)." } } }, "auth_ref": ["r786"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r24", "r91", "r172"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1", "r91"] }, "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail", "http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail", "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "totalLabel": "Total cash, cash equivalents, and investments in marketable securities", "terseLabel": "Cash and investments in marketable securities", "label": "Cash Restricted Cash Cash Equivalents And Available For Sale Investments", "documentation": "Cash, restricted cash, cash equivalents, and available for sale investments." } } }, "auth_ref": [] }, "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CertificatesOfDepositMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Certificates of deposit", "label": "Certificates of Deposit [Member]", "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }, "auth_ref": ["r10", "r668", "r669", "r670", "r671"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r722"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r719"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r717"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightstDateFromWhichWarrantsOrRightsExercisable": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightstDateFromWhichWarrantsOrRightsExercisable", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable", "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format." } } }, "auth_ref": ["r314"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r37"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercise price of warrants", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r314"] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [

"http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants issued to be purchase common shares", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r314"] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r723"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r723"] }, "nktr_CollaborativeArrangementCommittedFunding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "CollaborativeArrangementCommittedFunding", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Committed funding (up to)", "label": "Collaborative Arrangement, Committed Funding", "documentation": "Collaborative Arrangement, Committed Funding" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreements"], "lang": { "en-us": { "role": { "terseLabel": "License and Collaboration Agreements", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": ["r122", "r124", "r131"] }, "nktr_CollaborativeArrangementSuccessBasedPaymentsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "CollaborativeArrangementSuccessBasedPaymentsAmount", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Success payments (up to)", "label": "Collaborative Arrangement, Success-Based Payments, Amount", "documentation": "Collaborative Arrangement, Success-Based Payments, Amount" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails", "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofOtherCurrentAssetsDetails", "http://www.nektar.com/20240930/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementDetailsScheduleOfAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r380"] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Corporate commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": ["r107", "r298", "r668", "r669", "r670", "r671"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r65", "r111", "r486", "r546"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CommitmentsandContingencies"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r106", "r292", "r293", "r603", "r794", "r797"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Common Shares", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r664", "r665", "r666", "r668", "r669", "r670", "r671", "r776", "r777", "r779", "r838", "r898", "r900"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r68"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r68", "r547"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock shares, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r68"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r12", "r68", "r547", "r566", "r900", "r901"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.0001 par value; 300,000 shares authorized; 192,743 shares and 191,384 shares issued at September 30, 2024 and December 31, 2023, respectively; 184,458 shares and 191,384 shares outstanding at September 30, 2024 and December 31, 2023, respectively;", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r68", "r489", "r655"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r728"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r727"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r729"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r726"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "terseLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r22", "r157", "r159", "r164", "r478", "r501", "r502"] }, "nktr_ComputerFurnitureAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "ComputerFurnitureAndOtherMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment and computer software", "label": "Computer Furniture And Other [Member]", "documentation": "Furniture computer and other." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Significant Concentrations", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": ["r47", "r126"] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Axis]", "label": "Consolidated Entities [Axis]" } } }, "auth_ref": ["r176", "r382", "r383", "r386", "r387", "r436", "r605", "r801", "r804", "r805"] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Domain]", "label": "Consolidated Entities [Domain]" } } }, "auth_ref": ["r176", "r382", "r383", "r386", "r387", "r436", "r605", "r801", "r804", "r805"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a

partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r42", "r619"] }, "us-gaap_ConstructionInProgressGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressGross", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Construction in process", "label": "Construction in Progress, Gross", "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": ["r99"] },
"nktr_ContractTerminationAndOtherCostsIncludedInAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname":
"ContractTerminationAndOtherCostsIncludedInAccruedExpenses", "crdr": "credit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Contract termination and other costs included in accrued expenses", "label": "Contract Termination and Other Costs Included in Accrued Expenses",
"documentation": "Contract termination and other costs included in accrued expenses." } } }, "auth_ref": [] }, "nktr_ContractTerminationAndOtherCostsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "ContractTerminationAndOtherCostsMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramRestructuringReserveRollforwardDetails"], "lang": { "en-
us": { "role": { "terseLabel": "Contract Termination and Other Costs", "label": "Contract Termination and Other Costs [Member]", "documentation": "Contract Termination and
Other Costs [Member]" } } }, "auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CorporateDebtSecuritiesMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"], "lang": { "en-us":
{ "role": { "terseLabel": "Corporate notes and bonds", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign
corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": ["r634", "r636", "r643", "r657", "r662", "r895"] }, "us-
gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit",
"presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel":
"Cost of goods sold", "label": "Cost of Goods and Services Sold", "totalLabel": "Cost of Goods and Services Sold, Total", "documentation": "The aggregate costs related to goods
produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services
rendered and other revenue generating activities." } } }, "auth_ref": ["r81", "r82", "r475"] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensationStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "terseLabel": "Cost of
goods sold", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-
gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "totalLabel": "Total operating
costs and expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": ["r87"] }, "us-
gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Operating costs
and expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring
Plans", "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]", "documentation": "Disclosure of accounting policy for cost associated with
exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation." } } }, "auth_ref": ["r104", "r105"] }, "us-
gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel":
"Restructuring", "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for
recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations." } } }, "auth_ref": ["r16", "r104", "r105"] },
"srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": {
"terseLabel": "Counterparty Name", "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r174", "r175", "r308", "r312", "r435", "r456", "r482", "r616", "r618"] },
"dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover
page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": {
"role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } },
"auth_ref": [] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Deferred income
tax expense", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Deferred Income Tax Expense (Benefit), Total", "documentation": "Amount of deferred income
tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": ["r7", "r129", "r775"] }, "nktr_DepreciablePropertyPlantAndEquipmentGross":
{ "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "DepreciablePropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Depreciable property, plant and equipment at cost", "label": "Depreciable Property Plant And Equipment Gross", "documentation": "Depreciable
Property, plant and equipment, Gross." } } }, "auth_ref": [] }, "nktr_DepreciablePropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.nektar.com/20240930", "localname": "DepreciablePropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"], "lang": { "en-us": {
"role": { "totalLabel": "Depreciable property, plant and equipment, net", "label": "Depreciable Property Plant And Equipment Net", "documentation": "Depreciable Property,
plant and equipment, Net." } } }, "auth_ref": [] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and
amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
"documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate
or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect
consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r7", "r32"] }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Development Derivative Liability", "label": "Derivative Financial Instruments, Liabilities [Member]", "documentation": "This item represents derivative instrument obligations
meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to
the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect."
} } }, "auth_ref": ["r412"] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilities",
"crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Derivative liability", "label": "Derivative Liability", "totalLabel": "Derivative Liability, Total", "documentation": "Fair value, after the effects of master
netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by
means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": ["r148",
"r149", "r399", "r400", "r411", "r416", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r561", "r563", "r564", "r594", "r595", "r596", "r597", "r598",
"r599", "r600", "r618", "r842", "r843", "r844", "r899"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensation"], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based
Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r327", "r331", "r359", "r360", "r361",
"r638"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Compensation Related Costs,
Share-based Payments [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsTables"], "lang": { "en-us": { "role": { "terseLabel": "Assets Held for Sale",
"label": "Disclosure of Long-Lived Assets Held-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of long lived assets held for sale. Disclosure may include the
description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss)
recognized in the income statement and the income statement caption that includes that gain (loss)." } } }, "auth_ref": ["r14"] }, "us-
gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementDetailsAssetsHeldForSaleDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Accounts receivable", "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "documentation": "Amount
classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r2", "r49", "r55", "r101"] },
"nktr_DisposalGroupIncludingDiscontinuedOperationContractWithCustomerAssetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930",
"localname": "DisposalGroupIncludingDiscontinuedOperationContractWithCustomerAssetCurrent", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementDetailsAssetsHeldForSaleDetails",
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contract
asset", "label": "Disposal Group, Including Discontinued Operation, Contract With Customer Asset, Current", "documentation": "Disposal Group, Including Discontinued
Operation, Contract With Customer Asset, Current." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementDetailsAssetsHeldForSaleDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Inventory, net", "label": "Disposal Group, Including Discontinued Operation, Inventory, Current", "documentation": "Amount classified as inventory attributable

to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r2", "r49", "r55", "r98", "r101"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementDetailsAssetsHeldForSaleDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r2", "r49", "r55", "r98", "r101"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r678"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r710"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "verboseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r721"] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Basic net loss per share (in dollars per share)", "label": "Earnings Per Share, Basic", "totalLabel": "Earnings Per Share, Basic, Total", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r165", "r182", "r183", "r184", "r185", "r186", "r187", "r191", "r193", "r195", "r196", "r197", "r200", "r376", "r379", "r396", "r397", "r479", "r503", "r622"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Diluted net loss per share (in dollars per share)", "label": "Earnings Per Share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r165", "r182", "r183", "r184", "r185", "r186", "r187", "r193", "r195", "r196", "r197", "r200", "r376", "r379", "r396", "r397", "r479", "r503", "r622"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Net Loss per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r26", "r27", "r199"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r418"] }, "nktr_EffectiveDateOfWarrant": { "xbrltype": "dateItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "EffectiveDateOfWarrant", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Effective date of warrant.", "label": "Effective Date of Warrant", "terseLabel": "Effective date of warrant" } } }, "auth_ref": [] }, "nktr_EliLillyAndCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "EliLillyAndCompanyMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Eli Lilly And Company", "label": "Eli Lilly And Company [Member]", "documentation": "Eli Lilly and Company." } } }, "auth_ref": [] }, "nktr_EliLillyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "EliLillyMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Eli Lilly", "label": "Eli Lilly [Member]", "documentation": "Eli Lilly." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Employee-related Liabilities, Current", "totalLabel": "Employee-related Liabilities, Current, Total", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r61"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensationStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails", "http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramRestructuringReserveRollforwardDetails", "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Employee Severance", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "verboseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r676"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "verboseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing

requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r676"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r676"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r760"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r676"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r676"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r676"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r676"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r715"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r756"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r756"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r756"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.nektar.com/20240930/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementDetailsScheduleOfAccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r12", "r132", "r160", "r161", "r162", "r177", "r178", "r179", "r181", "r186", "r188", "r190", "r202", "r248", "r249", "r281", "r315", "r370", "r371", "r373", "r374", "r375", "r377", "r378", "r379", "r388", "r389", "r390", "r391", "r392", "r393", "r395", "r419", "r421", "r422", "r423", "r424", "r425", "r427", "r428", "r432", "r499", "r516", "r517", "r518", "r527", "r586"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r725"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r683", "r693", "r703", "r735"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r680", "r690", "r700", "r732"] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimate of Fair Value Measurement", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": ["r309", "r416", "r630", "r631"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r731"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r399", "r400", "r411", "r643"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r399", "r400", "r411", "r643"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Portfolio of Cash and Investments in Marketable Securities", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r840", "r841"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails", "http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Domain]", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": ["r404", "r405", "r406", "r407", "r408", "r409", "r412", "r646"] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails", "http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Axis]", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": ["r404", "r405", "r406", "r407", "r408", "r409", "r412", "r646"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail", "http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r309", "r319", "r320", "r321", "r322", "r323", "r324", "r398", "r400", "r401", "r402", "r403", "r410", "r411", "r413", "r443", "r444", "r445", "r630", "r631", "r634", "r635", "r636", "r643", "r648"] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liability Class [Axis]", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": ["r404", "r405", "r406", "r407", "r408", "r409", "r412"] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"FairValueByMeasurementBasisAxis", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": ["r309", "r630", "r631"] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": ["r309", "r630", "r631"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r309", "r319", "r324", "r400", "r411", "r443", "r634", "r635", "r636", "r643"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r309", "r319", "r324", "r400", "r401", "r411", "r444", "r630", "r631", "r634", "r635", "r636", "r643"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r309", "r319", "r320", "r321", "r322", "r323", "r324", "r400", "r401", "r402", "r403", "r411", "r445", "r630", "r631", "r634", "r635", "r636", "r643", "r648"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class [Domain]", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": ["r404", "r405", "r406", "r407", "r408", "r409", "r412"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r404", "r405", "r406", "r407", "r408", "r409"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome", "crdr": "credit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Change in the fair value of development derivative liability", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)", "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": ["r406", "r412"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "crdr": "credit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash receipts from SFJ", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r407", "r412"] },
"nktr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Non-cash research and development expense", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense", "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Research and Development Expense" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Fair value at beginning of period", "periodEndLabel": "Fair value at end of period", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r404", "r412"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r309", "r319", "r320", "r321", "r322", "r323", "r324", "r398", "r400", "r401", "r402", "r403", "r410", "r411", "r413", "r443", "r444", "r445", "r630", "r631", "r634", "r635", "r636", "r643", "r648"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r250", "r251", "r253", "r254", "r255", "r257", "r258", "r259", "r310", "r313", "r394", "r414", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r500", "r628", "r643", "r646", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r657", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r789", "r790", "r791", "r792", "r839", "r842", "r843", "r844", "r845", "r846"] }, "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value at", "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]" } } }, "auth_ref": [] }, "nktr_FinancingTransactionsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "FinancingTransactionsPolicyTextBlock", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Financing Transactions", "label": "Financing Transactions [Policy Text Block]", "documentation": "Financing transactions policy." } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r687", "r697", "r707", "r739"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r687", "r697", "r707", "r739"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r687", "r697", "r707", "r739"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r687", "r697", "r707", "r739"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r687", "r697", "r707", "r739"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r720"] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"], "lang": { "en-us": {

"role": { "terseLabel": "Furniture, fixtures and other", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails"], "lang": { "en-us": { "role": { "negatedLabel": "(Gain) on sale or disposal of property, plant, and equipment", "terseLabel": "(Gain) on sale or disposal of property, plant, and equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": ["r7"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "totalLabel": "General and Administrative Expense, Total", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r84", "r570"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensationStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r84"] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Impairment of Goodwill", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": ["r263", "r275", "r629"] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.nektar.com/20240930/taxonomy/role/DisclosureImpairementOfGoodwillAdditionalInformationDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Impairment of goodwill", "verboseLabel": "Impairment of goodwill", "terseLabel": "Impairment of goodwill", "label": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r7", "r264", "r270", "r275", "r629", "r645"] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r629"] }, "nktr_ImpairmentLongLivedAssetHeldForUseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "ImpairmentLongLivedAssetHeldForUseOther", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Impairment of other property, plant and equipment", "label": "Impairment, Long-Lived Asset, Held-for-Use, Other", "documentation": "Impairment, Long-Lived Asset, Held-for-Use, Other" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails", "http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSummaryOfRestructuringCostsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total impairment of right-of-use assets and property, plant and equipment", "verboseLabel": "Impairment of right-of-use assets and property, plant and equipment", "terseLabel": "Impairment of other property, plant and equipment", "label": "Impairment, Long-Lived Asset, Held-for-Use", "negatedLabel": "Total impairment of right-of-use assets", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": ["r7", "r31", "r100", "r644"] }, "nktr_ImpairmentOfRemainingLongLivedAssetHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "ImpairmentOfRemainingLongLivedAssetHeldForUse", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureImpairementOfGoodwillAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Additional impairment charges on remaining long-lived assets", "label": "Impairment of Remaining Long-Lived Asset, Held-for-Use", "documentation": "Impairment of remaining long-lived asset, held-for-use." } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Asset Impairment", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": ["r0", "r103"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "totalLabel": "Loss before provision for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r80", "r113", "r117", "r480", "r496", "r624", "r625", "r780", "r781", "r782", "r783", "r784"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensationStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r282", "r283", "r286", "r405", "r409", "r412", "r513", "r515", "r571", "r609", "r647", "r868"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensationStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r283", "r286", "r405", "r409", "r412", "r513", "r515", "r571", "r609", "r647", "r868"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Benefit for income taxes", "label": "Income Tax Expense (Benefit)", "totalLabel": "Income Tax Expense (Benefit), Total", "verboseLabel": "Provision (benefit) for income taxes", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r119", "r130", "r189", "r190", "r201", "r207", "r210", "r366", "r367", "r372", "r504", "r640"] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid, Net", "totalLabel": "Income Taxes Paid, Net, Total", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r25", "r171", "r368", "r369"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "totalLabel": "Increase (Decrease) in Inventories, Total", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Operating leases, net", "label": "Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities", "documentation": "Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Accrued

expenses", "label": "Increase (Decrease) in Other Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "totalLabel": "Increase (Decrease) in Other Operating Assets, Total", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r687", "r697", "r707", "r731", "r739", "r743", "r751"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r749"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r679", "r755"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r679", "r755"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r679", "r755"] }, "nktr_InterestAndOtherNonTradeReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "InterestAndOtherNonTradeReceivablesMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Interest and other non-trade receivables.", "label": "Interest and Other Non-trade Receivables [Member]", "terseLabel": "Interest and Other Non-trade Receivables" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetails"], "lang": { "en-us": { "role": { "terseLabel": "Condensed Consolidated Financial Statement Details", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": ["r260"] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": ["r97", "r613"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Inventory, net", "label": "Inventory, Net", "totalLabel": "Total inventory, net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r145", "r612", "r655"] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": ["r121", "r137", "r144", "r260", "r261", "r262", "r474", "r620"] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": ["r97", "r615"] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofInventoryDetails"], "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [
"r97", "r614"] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": ["r201", "r206", "r210", "r625", "r772"] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Investments, fair value disclosure", "label": "Investments, Fair Value Disclosure", "totalLabel": "Investments, Fair Value Disclosure, Total", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": ["r840", "r841", "r845"] }, "nktr_IssuanceOfPrefundedWarrant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "IssuanceOfPrefundedWarrant", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of prefunded warrant", "label": "Issuance of prefunded warrant", "documentation": "Issuance of prefunded warrant" } } }, "auth_ref": [] },
"nktr_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "LaboratoryEquipmentMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Laboratory equipment", "label": "Laboratory Equipment [Member]", "documentation": "Laboratory Equipment" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [
"r17", "r60", "r61", "r62", "r63", "r64", "r65", "r66", "r173", "r247", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r383", "r386", "r387", "r417", "r545", "r623", "r674", "r802", "r854", "r855"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r73", "r112", "r492", "r655", "r774", "r793", "r847"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r62", "r136", "r173", "r247", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r383", "r386", "r387", "r417", "r655", "r802", "r854", "r855"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueAdjustment", "crdr": "credit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in fair value of development derivative liability", "terseLabel": "Change in fair value of development derivative liability", "label": "Liabilities, Fair Value Adjustment", "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities related to assets held for sale", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "totalLabel": "Disposal Group, Including Discontinued Operation, Liabilities, Current, Total", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r2", "r49", "r55", "r98", "r101", "r133", "r134"] }, "nktr_LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amortization of transaction costs", "label": "Liabilities On Sale Of Future Royalties Amortized Transaction Costs", "documentation": "Liabilities On Sale Of Future Royalties Amortized Transaction Costs" } } }, "auth_ref": [] }, "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent": { "xbrltype":

"monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent", "crdr": "credit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Liabilities related to the sales of future royalties, net \u2013 beginning balance", "periodEndLabel": "Liabilities related to the sales of future royalties, net \u2013 ending balance", "label": "Liability Related To Sale Of Potential Future Royalties Non Current", "documentation": "Liability Related To Sale Of Potential Future Royalties Non Current" } } }, "auth_ref": [] }, "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities related to the sales of future royalties, net", "label": "Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs", "documentation": "Liability related to sale of potential future royalties non current net of issuance costs." } } }, "auth_ref": [] }, "nktr_LiabilityToCollaborationPartnersCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "LiabilityToCollaborationPartnersCurrent", "crdr": "credit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liability to collaboration partners", "label": "Liability to Collaboration Partners, Current", "documentation": "Liability to Collaboration Partners, Current" } } }, "auth_ref": [] }, "nktr_LicenseAndCollaborationAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "LicenseAndCollaborationAgreementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "label": "License And Collaboration Agreements [Abstract]", "documentation": "License and collaboration agreements." } } }, "auth_ref": [] }, "nktr_LicenseCollaborationAndOtherRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "LicenseCollaborationAndOtherRevenueMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "License, collaboration and other revenue", "label": "License Collaboration And Other Revenue [Member]", "documentation": "License collaboration and other revenue." } } }, "auth_ref": [] }, "nktr_LifeSciencesLeaseMarketMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "LifeSciencesLeaseMarketMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Life sciences lease market.", "label": "Life Sciences Lease Market [Member]", "terseLabel": "Life Sciences Lease Market" } } }, "auth_ref": [] }, "us-gaap_LitigationReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationReserve", "crdr": "credit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liability for litigation", "label": "Estimated Litigation Liability", "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs." } } }, "auth_ref": ["r65", "r798"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LossOnContractTermination": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossOnContractTermination", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSummaryOfRestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contract termination and other restructuring costs", "label": "Loss on Contract Termination", "documentation": "The loss recognized on termination of a contract." } } }, "auth_ref": ["r473"] }, "us-gaap_ManufacturingFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ManufacturingFacilityMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Manufacturing Facility [Member]", "terseLabel": "Huntsville, Alabama Manufacturing Facility", "documentation": "Structure used in the manufacturing of goods." } } }, "auth_ref": ["r99"] }, "nktr_ManufacturingLaboratoryAndOtherEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "ManufacturingLaboratoryAndOtherEquipmentMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Manufacturing equipment", "label": "Manufacturing Laboratory And Other Equipment [Member]", "documentation": "Manufacturing laboratory and other equipment." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": ["r294", "r295", "r296", "r297", "r326", "r363", "r403", "r472", "r512", "r514", "r522", "r537", "r538", "r590", "r591", "r592", "r593", "r601", "r607", "r608", "r627", "r632", "r637", "r648", "r649", "r653", "r654", "r659", "r806", "r857", "r858", "r859", "r860", "r861", "r862"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r723"] },
"ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r723"] },
"nktr_MeasurementInputMarketParticipantSubtenantBorrowingRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "MeasurementInputMarketParticipantSubtenantBorrowingRateMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input, Market Participant Subtenant Borrowing Rate", "label": "Measurement Input, Market Participant Subtenant Borrowing Rate [Member]", "documentation": "Measurement Input, Market Participant Subtenant Borrowing Rate" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r401", "r402", "r403", "r648"] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r401", "r402", "r403", "r648"] }, "nktr_MilestoneAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "MilestoneAxis", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Milestone [Axis]", "label": "Milestone [Axis]", "documentation": "Milestone [Axis]" } } }, "auth_ref": [] }, "nktr_MilestoneDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "MilestoneDomain", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Milestone [Domain]", "label": "Milestone [Domain]", "documentation": "Milestone" } } }, "auth_ref": [] }, "nktr_MilestoneOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "MilestoneOneMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Milestone One", "label": "Milestone One [Member]", "documentation": "Milestone One [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": ["r294", "r295", "r296", "r297", "r326", "r363", "r403", "r472", "r512", "r514", "r522", "r537", "r538", "r590", "r591", "r592", "r593", "r601", "r607", "r608", "r627", "r632", "r637", "r648", "r649", "r653", "r659", "r806", "r857", "r858", "r859", "r860", "r861", "r862"] }, "nktr_MissionBayFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "MissionBayFacilityMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Mission Bay Facility", "label": "Mission Bay Facility [Member]", "documentation": "Mission Bay Facility" } } }, "auth_ref": [] },
"ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r742"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r808"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r750"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r724"] }, "nktr_Nektar0165Member": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "Nektar0165Member", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Nektar 0165", "label": "Nektar 0165 [Member]", "documentation": "Nektar 0165." } } }, "auth_ref": [] }, "nktr_Nektar214Member": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "Nektar214Member", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Nektar 214", "label": "Nektar 214 [Member]", "documentation": "Nektar 214." } } }, "auth_ref": [] }, "nktr_Nektar358Member": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "Nektar358Member", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Nektar-358", "label": "Nektar-358 [Member]", "documentation": "Nektar-358" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r170"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": {

"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r170"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r91", "r92", "r93"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "totalLabel": "Net loss", "verboseLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r83", "r93", "r114", "r134", "r155", "r158", "r162", "r173", "r180", "r182", "r183", "r184", "r185", "r186", "r189", "r190", "r194", "r247", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r376", "r379", "r397", "r417", "r498", "r568", "r584", "r585", "r672", "r802"] }, "nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "NonCashInterestExpenseRelatedToSaleOfRoyalties", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "netLabel": "Non-cash interest expense on liabilities related to the sales of future royalties", "negatedLabel": "Non-cash interest expense on liabilities related to the sales of future royalties", "terseLabel": "Non-cash interest expense", "label": "Non Cash Interest Expense Related To Sale Of Royalties", "documentation": "Non-cash interest expense related to sale of royalties." } } }, "auth_ref": [] }, "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-cash royalty revenue", "negatedLabel": "Non-cash royalty revenue related to the sales of future royalties", "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties", "documentation": "Non cash royalty revenue related to sale future royalties." } } }, "auth_ref": [] }, "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Non-cash royalty revenue related to the sales of future royalties", "terseLabel": "Non-cash royalty revenue related to the sales of future royalties", "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]", "documentation": "Non-cash royalty revenue related to sale of future royalties." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r723"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r687", "r697", "r707", "r731", "r739"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r714"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r713"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r731"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r750"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r750"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "totalLabel": "Total non-operating income (expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r85"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Non-operating income (expense):", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "nktr_NumberOfMilestones": { "xbrltype": "integerItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "NumberOfMilestones", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of Milestone", "label": "Number Of Milestones", "documentation": "Number Of Milestones" } } }, "auth_ref": [] }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementDetailsScheduleOfAccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency translation adjustments", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "terseLabel": "Adjustments", "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent." } } }, "auth_ref": ["r15", "r21"] }, "nktr_OpdivoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "OpdivoMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Opdivo", "label": "Opdivo [Member]", "documentation": "Opdivo." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r117", "r624", "r780", "r781", "r782", "r783", "r784"] }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails", "http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Impairment expense for facilities", "verboseLabel": "Impairment charge for right-of-use asset", "label": "Non-cash impairment charges", "negatedLabel": "Total impairment of lease assets", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } }, "auth_ref": ["r850"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, current portion", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r430"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, less current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r430"] }, "nktr_OperatingLeaseMeasurementInput": { "xbrltype": "percentItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "OperatingLeaseMeasurementInput", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, measurement input", "label": "Operating Lease, Measurement Input", "documentation": "Operating Lease, Measurement Input" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r429"] }, "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageOutstandingStockOptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]", "label": "Organization And Summary Of Significant Accounting Policies [Line Items]", "documentation": "Organization and summary of significant accounting policies." } } }, "auth_ref": [] }, "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageOutstandingStockOptionsDetails"], "lang": { "en-

```
us": { "role": { "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]", "label": "Organization And Summary Of Significant Accounting Policies [Table]", "documentation": "Organization and summary of significant accounting policies." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Organization and Summary of Significant Accounting Policies", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": [ "r48", "r94", "r95", "r109" ] }, "nktr_OrganizationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "OrganizationPolicyTextBlock", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Organization", "label": "Organization Policy [Text Block]", "documentation": "Organization." } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued expenses", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r61" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r146", "r655" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r141" ] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized gain (loss) on available-for-sale securities", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r150", "r151", "r153", "r499" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Net foreign currency translation gain (loss)", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r4", "r499" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r12", "r15", "r156", "r159", "r163", "r186", "r419", "r420", "r425", "r477", "r499", "r769", "r770" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r64" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Amortization of premiums (discounts), net and other non-cash transactions", "label": "Other Noncash Income (Expense)", "totalLabel": "Other Noncash Income (Expense), Total", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r93" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense), net", "label": "Other Nonoperating Income (Expense)", "totalLabel": "Other Nonoperating Income (Expense), Total", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r86" ] }, "nktr_OtherPartnerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "OtherPartnerMember", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Partner", "label": "Other Partner [Member]", "documentation": "Other." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r723" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r685", "r695", "r705", "r737" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r688", "r698", "r708", "r740" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r688", "r698", "r708", "r740" ] }, "srt_ParentCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ParentCompanyMember", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nektar's", "label": "Parent Company [Member]" } } }, "auth_ref": [ "r176" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r712" ] }, "nktr_PayableForNewdrugInvestigileMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "PayableForNewdrugInvestigileMilestone", "crdr": "credit", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Payable For Newdrug Investigile Milestone", "documentation": "Payable for newdrug investigile milestone." } } }, "auth_ref": [] }, "nktr_PaymentForDevelopmentMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "PaymentForDevelopmentMilestones", "crdr": "credit", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Payment For Development Milestones", "documentation": "Payment for development milestones." } } }, "auth_ref": [] }, "nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsAchieved", "crdr": "credit", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved", "label": "Payment of Transaction Related to Purchase and Sale Agreement if Threshold is Achieved", "terseLabel": "Payment of transaction related to purchase and sale agreement" } } }, "auth_ref": [] }, "nktr_PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "PaymentOfTransactionRelatedToPurchaseAndSaleAgreementIfThresholdIsNotAchieved", "crdr": "credit", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved", "label": "Payment of Transaction Related to Purchase and Sale Agreement if Threshold is not Achieved", "terseLabel": "Payment of transaction related to purchase and sale agreement if threshold is not achieved" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of common stock from Bristol-Myers Squibb", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r90" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails", "http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramRestructuringReserveRollforwardDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments during the period", "terseLabel": "Payments during the period", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r285", "r773" ] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "presentation": [
```

"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of investments", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r23", "r167", "r215"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property, plant and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r89"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r722"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r722"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r714"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r731"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r724"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r713"] }, "nktr_PercentageOfNumberOfSharesForWarrantExercised": { "xbrltype": "percentItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "PercentageOfNumberOfSharesForWarrantExercised", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of number of shares of warrant exercised", "label": "Percentage of Number of Shares for Warrant Exercised", "documentation": "Percentage of number of shares of warrant exercised." } } }, "auth_ref": [] }, "nktr_PercentageOfOwnershipReceivedInAssetAcquisition": { "xbrltype": "percentItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "PercentageOfOwnershipReceivedInAssetAcquisition", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Ownership interest received", "label": "Percentage Of Ownership Received in Asset Acquisition", "documentation": "Percentage of ownership received in asset acquisition." } } }, "auth_ref": [] }, "nktr_PercentageOfSharingInDevelopmentCosts": { "xbrltype": "percentItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "PercentageOfSharingInDevelopmentCosts", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of sharing development costs", "label": "Percentage Of Sharing In Development Costs", "documentation": "Percentage of sharing in development costs." } } }, "auth_ref": [] }, "nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts": { "xbrltype": "percentItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "PercentageOfSharingInPhaseTwoDevelopmentCosts", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of sharing in Phase 2 development costs", "label": "Percentage Of Sharing In Phase Two Development Costs", "documentation": "Percentage of sharing in Phase 2 development costs." } } }, "auth_ref": [] }, "nktr_PercentageOfSharingInProductionCosts": { "xbrltype": "percentItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "PercentageOfSharingInProductionCosts", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of sharing production costs", "label": "Percentage Of Sharing In Production Costs", "documentation": "Percentage of sharing in production costs." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r715"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r759"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r714"] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "axisDefault": "Portion at Fair Value Measurement [Member] [Default]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": ["r415"] }, "nktr_PotentialDevelopmentAndRegulatoryMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "PotentialDevelopmentAndRegulatoryMilestones", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Potential future additional development and regulatory milestones (up to)", "label": "Potential Development And Regulatory Milestones", "documentation": "Potential development and regulatory milestones." } } }, "auth_ref": [] }, "nktr_PotentialDevelopmentMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "PotentialDevelopmentMilestones", "crdr": "credit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails",
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Potential Development Milestones", "terseLabel": "Potential future additional payments for development milestones", "label": "Potential Development Milestones", "documentation": "Potential development milestones." } } }, "auth_ref": [] }, "nktr_PreFundedWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "PreFundedWarrantMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Pre-Funded Warrant", "label": "Pre Funded Warrant [Member]", "documentation": "Pre Funded Warrant." } } }, "auth_ref": [] }, "nktr_PreFundedWarrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "PreFundedWarrantTextBlock", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrant"], "lang": { "en-us": { "role": { "terseLabel": "Pre-Funded Warrant", "label": "Pre-Funded Warrant [Text Block]", "documentation": "Pre-funded warrant." } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r67", "r311"] }, "nktr_PreferredStockShareDesignated": { "xbrltype": "sharesItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "PreferredStockShareDesignated", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares designated (in shares)", "label": "Preferred Stock Share Designated", "documentation": "Preferred stock, shares designated." } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r67", "r547"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r67", "r547", "r566", "r900", "r901"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at September 30, 2024 or December 31, 2023, respectively", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r67", "r488", "r655"] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other prepaid expenses", "label": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "nktr_PrepaidResearchAndDevelopmentExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "PrepaidResearchAndDevelopmentExpensesMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid research and development expenses", "label": "Prepaid Research And Development Expenses [Member]", "documentation": "Prepaid Research And Development Expenses" } } }, "auth_ref": [] }, "nktr_ProceedsFromAmendmentRelatedToSalesOfFutureRoyaltiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "ProceedsFromAmendmentRelatedToSalesOfFutureRoyaltiesNet", "crdr": "debit", "presentation": [

"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the Amendment", "label": "Proceeds from Amendment related to sales of future royalties, net", "documentation": "Proceeds from Amendment related to sales of future royalties, net." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r5"] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from shares issued under equity compensation plans", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised." } } }, "auth_ref": ["r5", "r13"] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of pre-funded warrant", "label": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": ["r5"] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Maturities of investments", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r167", "r168", "r788"] }, "nktr_ProceedsFromSaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "ProceedsFromSaleOfFutureRoyalties", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of future royalties", "label": "Proceeds From Sale of Future Royalties", "documentation": "Proceeds From Sale of Future Royalties." } } }, "auth_ref": [] }, "nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "ProceedsFromSaleOfPotentialFutureRoyaltiesGross", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Proceeds from sale of potential future royalties gross.", "label": "Proceeds From Sale Of Potential Future Royalties Gross", "terseLabel": "Proceeds from sale of royalty rights" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of assets", "label": "Proceeds from Sale of Productive Assets", "totalLabel": "Proceeds from Sale of Productive Assets, Total", "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": ["r88"] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Sale of property, plant and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": ["r88"] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Product sales", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": ["r633"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": ["r211", "r475", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r610", "r633", "r658", "r659", "r660", "r661", "r663", "r799", "r800", "r807", "r865", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r896", "r897"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": ["r211", "r475", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r610", "r633", "r658", "r659", "r660", "r661", "r663", "r799", "r800", "r807", "r865", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r896", "r897"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r134", "r155", "r158", "r169", "r173", "r180", "r186", "r189", "r190", "r247", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r376", "r379", "r381", "r384", "r385", "r397", "r417", "r480", "r497", "r526", "r568", "r584", "r585", "r641", "r642", "r673", "r771", "r802"] }, "nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetBookValueInExcessOfFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetBookValueInExcessOfFairValue", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Book value in excess of fair value", "label": "Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Book Value in Excess of Fair Value", "documentation": "Property, plant and equipment, and operating lease right of use asset, book value in excess of fair value." } } }, "auth_ref": [] }, "nktr_PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment and operating lease right-of-use assets", "label": "Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure", "documentation": "Property, Plant And Equipment, And Operating Lease Right Of Use Asset, Fair Value Disclosure" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails", "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r8", "r431"] }, "nktr_PropertyPlantAndEquipmentClassifiedToAssetsHeldForSaleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "PropertyPlantAndEquipmentClassifiedToAssetsHeldForSaleMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Property plant and equipment classified to assets held for sale.", "label": "Property Plant And Equipment Classified To Assets Held For Sale Member", "terseLabel": "Property Plant And Equipment Classified To Assets Held For Sale" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r431"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"], "lang": { "en-us": { "role": { "totalLabel": "Property, plant and equipment, net", "terseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r8", "r431", "r481", "r495", "r655"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Plant and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r8"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails", "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r99", "r431"] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, credit loss expense (reversal)", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": ["r166", "r252"] }, "nktr_ProvisionForInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "ProvisionForInventory", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Provision

```
for inventory", "label": "Provision For Inventory", "documentation": "Provision for inventory." } } }, "auth_ref": [] }, "nktr_ProvisionForInventoryObsolescence": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "ProvisionForInventoryObsolescence", "crdr": "debit", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Provision for net realizable value of inventory", "documentation": "Provision for inventory obsolescence.", "label": "Provision For Inventory Obsolescence", "terseLabel": "Provision for inventory obsolescence" } } }, "auth_ref": [] }, "nktr_PurchaseAndSaleAgreement2012Member": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "PurchaseAndSaleAgreement2012Member", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails", "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2012 Purchase and Sale Agreement", "label": "Purchase and Sale Agreement 2012 [Member]", "documentation": "Purchase and Sale Agreement 2012" } } }, "auth_ref": [] }, "nktr_PurchaseAndSaleAgreement2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "PurchaseAndSaleAgreement2020Member", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails", "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails", "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Purchase and Sale Agreement", "label": "Purchase and Sale Agreement 2020 [Member]", "documentation": "Purchase and Sale Agreement 2020" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r712" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r712" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r294", "r295", "r296", "r297", "r318", "r326", "r354", "r355", "r356", "r363", "r403", "r446", "r455", "r472", "r512", "r514", "r522", "r537", "r538", "r590", "r591", "r592", "r593", "r601", "r607", "r608", "r627", "r632", "r637", "r648", "r649", "r653", "r654", "r659", "r666", "r795", "r806", "r843", "r858", "r859", "r860", "r861", "r862" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r294", "r295", "r296", "r297", "r318", "r326", "r354", "r355", "r356", "r363", "r403", "r446", "r455", "r472", "r512", "r514", "r522", "r537", "r538", "r590", "r591", "r592", "r593", "r601", "r607", "r608", "r627", "r632", "r637", "r648", "r649", "r653", "r654", "r659", "r666", "r795", "r806", "r843", "r858", "r859", "r860", "r861", "r862" ] }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Axis]", "label": "Name of Property [Axis]" } } }, "auth_ref": [ "r604", "r606", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909" ] }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Domain]", "label": "Name of Property [Domain]" } } }, "auth_ref": [ "r604", "r606", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementDetailsScheduleOfAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "crdr": "debit", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementDetailsScheduleOfAccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Unrealized gain (loss) on available-for-sale securities", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "terseLabel": "Reclassification adjustments to income", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": [ "r15", "r21" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r680", "r690", "r700", "r732" ] }, "nktr_ReimbursementOfExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "ReimbursementOfExpenses", "crdr": "credit", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reimbursement of expenses", "label": "Reimbursement Of Expenses", "documentation": "Reimbursement of expenses." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r214", "r325", "r433", "r434", "r485", "r493", "r540", "r541", "r542", "r543", "r544", "r565", "r567", "r589" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r214", "r325", "r433", "r434", "r485", "r493", "r540", "r541", "r542", "r543", "r544", "r565", "r567", "r589", "r853" ] }, "us-gaap_ReorganizationValueNetRealizableValueOfAssetDispositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReorganizationValueNetRealizableValueOfAssetDispositions", "crdr": "debit", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net realizable value of assets", "label": "Reorganization Value, Net Realizable Value of Asset Dispositions", "documentation": "Amount of reorganization value related to estimated net realizable value of asset dispositions. Reorganization value is the amount attributed to the reconstituted entity, as well as the expected net realizable value of those assets that will be disposed before reconstitution occurs." } } }, "auth_ref": [ "r656", "r856" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r174", "r175", "r308", "r312", "r435", "r456", "r482", "r617", "r618" ] }, "nktr_ResaleOfCommonStockIssuableUponExerciseOfWarrant": { "xbrltype": "sharesItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "ResaleOfCommonStockIssuableUponExerciseOfWarrant", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Resale of common stock issuable upon exercise of warrant.", "label": "Resale of Common Stock Issuable Upon Exercise of Warrant", "terseLabel": "Resale of common stock issuable upon exercise of warrant" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "documentation": "Information by form of arrangement related to research and development." } } }, "auth_ref": [ "r365", "r836" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r365", "r836" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "totalLabel": "Research and Development Expense, Total", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r364", "r609", "r625", "r863" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensationStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development", "terseLabel": "Research and Development Expense", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r681", "r691", "r701", "r733" ] },
```

"ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r682", "r692", "r702", "r734"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r689", "r699", "r709", "r741"] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Workforce termination, percentage", "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)." } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails",
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramRestructuringReserveRollforwardDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Expense recognized during the period", "terseLabel": "Restructuring, impairment, and costs of terminated program", "label": "Restructuring Charges", "totalLabel": "Restructuring Charges, Total", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r7", "r288", "r289", "r796"] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails",
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramRestructuringReserveRollforwardDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": ["r284", "r285", "r289", "r290"] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails",
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramRestructuringReserveRollforwardDetails",
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r284", "r285", "r286", "r287", "r289", "r290", "r291"] }, "us-gaap_RestructuringCostsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostsAndAssetImpairmentCharges", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSummaryOfRestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring, impairment, and costs of terminated program", "totalLabel": "Restructuring, impairment and other costs of terminated program", "label": "Restructuring Costs and Asset Impairment Charges", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r7"] }, "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgram"], "lang": { "en-us": { "role": { "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]", "terseLabel": "Restructuring, Impairment and Costs of Terminated Program", "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [] }, "nktr_RestructuringImpairmentAndOtherCostsOfTerminatedProgramMemberMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "RestructuringImpairmentAndOtherCostsOfTerminatedProgramMemberMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensationStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring, impairment and other costs of terminated program", "label": "Restructuring, Impairment And Other Costs Of Terminated Program Member [Member]", "documentation": "Restructuring, Impairment And Other Costs Of Terminated Program Member" } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails",
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramRestructuringReserveRollforwardDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails",
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramRestructuringReserveRollforwardDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "nktr_RestructuringPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "RestructuringPlanMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails",
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramRestructuringReserveRollforwardDetails"], "lang": { "en-us": { "role": { "documentation": "Restructuring plan.", "label": "Restructuring Plan [Member]", "terseLabel": "Restructuring Plan" } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramRestructuringReserveRollforwardDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Restructuring reserve, ending balance", "periodStartLabel": "Restructuring reserve, beginning balance", "label": "Restructuring Reserve", "totalLabel": "Restructuring Reserve, Total", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": ["r285", "r290"] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveRollForward", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramRestructuringReserveRollforwardDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r70", "r108", "r491", "r519", "r521", "r525", "r548", "r655"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r132", "r177", "r178", "r179", "r181", "r186", "r188", "r190", "r248", "r249", "r281", "r370", "r371", "r373", "r374", "r375", "r377", "r378", "r379", "r388", "r390", "r391", "r393", "r395", "r427", "r428", "r516", "r518", "r527", "r900"] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Total revenue", "terseLabel": "Revenue, excluding assessed tax", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r115", "r116", "r201", "r204", "r205", "r208", "r210", "r211", "r212", "r213", "r316", "r317", "r475"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Revenue:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "nktr_RoyaltiesLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "RoyaltiesLiabilityMeasurementInput", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Royalties liability discount rate", "label": "Royalties Liability, Measurement Input", "documentation": "Royalties Liability, Measurement Input" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r750"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r750"] }, "nktr_SFJPharmaceuticalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "SFJPharmaceuticalsMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "SFJ", "label": "SFJ Pharmaceuticals [Member]", "documentation": "SFJ Pharmaceuticals" } } }, "auth_ref": [] }, "nktr_SaleOfManufacturingFacilityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "SaleOfManufacturingFacilityPolicyTextBlock", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Sale of Manufacturing Facility", "label": "Sale Of Manufacturing Facility [Policy Text Block]", "documentation": "Sale of manufacturing facility." } } }, "auth_ref": [] }, "nktr_SaleOfStockConsiderationReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "SaleOfStockConsiderationReceived", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock consideration received", "label": "Sale Of Stock Consideration Received", "documentation": "Sale of stock consideration received." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"SaleOfStockNameOfTransactionDomain", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Stock price per share", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "nktr_SaleOfStockRepurchasedCashConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "SaleOfStockRepurchasedCashConsideration", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock repurchased cash consideration", "label": "Sale Of Stock Repurchased Cash Consideration", "documentation": "Sale of stock repurchased cash consideration." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Expenses", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r21", "r848", "r849"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r26"] }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Investments in Marketable Securities, Including Cash Equivalents", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails",
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofOtherCurrentAssetsDetails",
"http://www.nektar.com/20240930/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementDetailsScheduleOfAccumulatedOtherComprehensiveIncomeLossDetails",
"http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsFairValueofDerivativeLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r380"] }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative Liabilities at Fair Value", "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]", "documentation": "Tabular disclosure of derivative liabilities at fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsTables"], "lang": { "en-us": { "role": { "verboseLabel": "Assets Held for Sale", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r9", "r14", "r18", "r49", "r50", "r51", "r52", "r53", "r54", "r56", "r57", "r58", "r102"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensationStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r39"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r39"] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": ["r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r629"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r19", "r74", "r75", "r76"] }, "nktr_ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "ScheduleOfLiabilityRelatedToSaleOfPotentialFutureRoyaltiesTableTextBlock", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Liability Related to Sale of Potential Future Royalties", "label": "Schedule Of Liability Related To Sale Of Potential Future Royalties [Table Text Block]", "documentation": "Schedule Of Liability Related To Sale Of Potential Future Royalties" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Current Assets", "label": "Schedule of Other Current Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofPropertyPlantandEquipmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r8", "r431"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails",
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramRestructuringReserveRollforwardDetails",
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": ["r284", "r285", "r286", "r287", "r289", "r290", "r291"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring, Impairment and Other Costs of Terminated Program", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": ["r34", "r104", "r105"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r328", "r330", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357"] }, "nktr_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "SecuritiesPurchaseAgreementMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": {

"terseLabel": "Securities Purchase Agreement", "label": "Securities Purchase Agreement [Member]", "documentation": "Securities Purchase Agreement." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r675"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r677"] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSummaryOfRestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Severance and benefit expense", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r7"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r328", "r330", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate number of shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r639"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357"] }, "nktr_SharePurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "SharePurchaseAgreementMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Purchase Agreement", "label": "Share Purchase Agreement [Member]", "documentation": "Share purchase agreement." } } }, "auth_ref": [] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in shares)", "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": ["r12"] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Shares issued, price per share", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.nektar.com/20240930/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementDetailsScheduleOfAccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r12", "r68", "r71", "r72", "r132", "r160", "r161", "r162", "r177", "r178", "r179", "r181", "r186", "r188", "r190", "r202", "r248", "r249", "r281", "r315", "r370", "r371", "r373", "r374", "r375", "r377", "r378", "r379", "r388", "r389", "r390", "r391", "r392", "r393", "r395", "r419", "r421", "r422", "r423", "r424", "r425", "r427", "r428", "r432", "r499", "r516", "r517", "r518", "r527", "r586"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r177", "r178", "r179", "r202", "r428", "r475", "r523", "r529", "r539", "r540", "r541", "r542", "r543", "r544", "r547", "r550", "r551", "r552", "r553", "r554", "r556", "r557", "r558", "r559", "r561", "r562", "r563", "r564", "r565", "r567", "r569", "r570", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r586", "r667"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r177", "r178", "r179", "r202", "r214", "r428", "r475", "r523", "r529", "r539", "r540", "r541", "r542", "r543", "r544", "r547", "r550", "r551", "r552", "r553", "r554", "r556", "r557", "r558", "r559", "r561", "r562", "r563", "r564", "r565", "r567", "r569", "r570", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r586", "r667"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r684", "r694", "r704", "r736"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Shares issued under equity compensation plans (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "totalLabel": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, Total", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r12", "r67", "r68", "r108"] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Shares issued under equity compensation plans", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "totalLabel": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r38", "r67", "r68", "r108"] }, "nktr_StockOptionsRSUsAndPSUsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "StockOptionsRSUsAndPSUsMember", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesWeightedAverageOutstandingStockOptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock Options, RSUs And PSUs", "label": "Stock Options, RSUs And PSUs [Member]", "documentation": "Stock Options, RSUs And PSUs" } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails", "http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of common stock from Bristol-Myers Squibb (in shares)", "terseLabel": "Sale of stock shares repurchased", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": ["r12", "r67", "r68", "r108", "r524", "r586", "r602"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.nektar.com/20240930/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementDetailsScheduleOfAccumulatedOtherComprehensiveIncomeLossDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r68", "r71", "r72", "r96", "r549", "r566", "r587", "r588", "r655", "r674", "r774", "r793", "r847", "r900"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "nktr_SubleaseIncomeMeasurementInput": { "xbrltype": "percentItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "SubleaseIncomeMeasurementInput", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails"], "lang": { "en-us": { "role": {

"terseLabel": "Sublease income, measurement input", "label": "Sublease Income, Measurement Input", "documentation": "Sublease Income, Measurement Input" } } },
"auth_ref": [] }, "nktr_SubleaseOfLaboratoryAndOfficeSpaceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname":
"SubleaseOfLaboratoryAndOfficeSpaceMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation":
"Sublease of laboratory and office space.", "label": "Sublease of Laboratory and Office Space" } } }, "auth_ref": [] }, "nktr_SubleaseOperatingLeaseRightOfUseAssetsMember":
{ "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "SubleaseOperatingLeaseRightOfUseAssetsMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails"], "lang": { "en-us": { "role":
{ "terseLabel": "Operating Lease Right-of-Use Assets", "label": "Sublease Operating Lease Right of Use Assets [Member]", "documentation": "Sublease Operating Lease Right
of Use Assets" } } }, "auth_ref": [] }, "nktr_SubleasePropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930",
"localname": "SubleasePropertyPlantAndEquipmentMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramSubleaseInformationDetails"], "lang": { "en-us": { "role":
{ "terseLabel": "Property, Plant and Equipment", "label": "Sublease Property, Plant And Equipment [Member]", "documentation": "Sublease Property, Plant And Equipment" }
} }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems",
"presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label":
"Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy
as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r426",
"r438"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember",
"presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": {
"terseLabel": "Subsequent event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial
statements are issued or available to be issued." } } }, "auth_ref": ["r426", "r438"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]",
"documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements
were issued." } } }, "auth_ref": ["r426", "r438"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventTypeAxis", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label":
"Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be
issued." } } }, "auth_ref": ["r426", "r438"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventTypeDomain", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label":
"Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." }
} }, "auth_ref": ["r426", "r438"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureSubsequentEvent1"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Events
[Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial
statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement
of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } },
"auth_ref": ["r437", "r439"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsidiarySaleOfStockAxis", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": {
"en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] },
"us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockLineItems",
"presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label":
"Subsidiary, Sale of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable
information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Supplemental
disclosure of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": {
"en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r730"] }, "nktr_TcgCrossoverFundIILPMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "TcgCrossoverFundIILPMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": {
"terseLabel": "TCG Crossover Fund II, L.P.", "label": "TCG Crossover Fund I I, L P [Member]", "documentation": "TCG Crossover Fund II, L.P." } } }, "auth_ref": [] },
"nktr_ThirdStFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "ThirdStFacilityMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Third St. Facility", "label": "Third St. Facility [Member]", "documentation": "Third St. Facility" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"
], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r722"] },
"ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs
Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r729"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": {
"label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r749"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": {
"role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r751"] }, "dei_TradingSymbol": {
"xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation":
"Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-
gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"], "lang": { "en-us":
{ "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual
obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive
cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r217", "r218", "r219", "r220", "r221",
"r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243",
"r244", "r245", "r246", "r310", "r313", "r394", "r414", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454",
"r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r500", "r643", "r646", "r648", "r649", "r650", "r651",
"r652", "r653", "r654", "r657", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r789", "r790", "r791", "r792", "r839", "r842", "r843", "r844", "r845", "r846"] },
"ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } },
"auth_ref": ["r752"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } },
"auth_ref": ["r753"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate",
"presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel":
"Expiration Date" } } }, "auth_ref": ["r753"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName",
"presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel":
"Name" } } }, "auth_ref": ["r751"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle",
"presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title"
} } }, "auth_ref": ["r751"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement,
Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r754"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": {
"role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r752"] }, "us-gaap_TreasuryStockCommonMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel":
"Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." }
} }, "auth_ref": ["r35"] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"TreasuryStockCommonShares", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": {
"en-us": { "role": { "terseLabel": "Treasury Stock, Common, Shares", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common
shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r35"] }, "nktr_TreasuryStockPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.nektar.com/20240930", "localname": "TreasuryStockPolicyTextBlock", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Treasury
Stock", "label": "Treasury Stock [Policy Text Block]", "documentation": "Treasury stock policy." } } }, "auth_ref": [] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel":
"Repurchase of common stock from Bristol-Myers Squibb (in shares)", "negatedLabel": "Repurchase of common stock from Bristol-Myers Squibb (in shares)", "label": "Treasury
Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": ["r12", "r68",

"r108"] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock, at cost; 8,285 shares as of September 30, 2024 and none as of December 31, 2023, respectively", "terseLabel": "Treasury stock, at cost; 8,285 shares as of September 30, 2024 and none as of December 31, 2023, respectively", "label": "Treasury Stock, Value", "totalLabel": "Treasury Stock, Value, Total", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": ["r35", "r36", "r68", "r71"] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of common stock from Bristol-Myers Squibb", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": ["r12", "r35", "r108"] }, "nktr_TwoThousandSeventeenPerformanceIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "TwoThousandSeventeenPerformanceIncentivePlanMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/StockBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "2017 Performance Incentive Plan", "label": "Two Thousand Seventeen Performance Incentive Plan [Member]", "documentation": "Two Thousand Seventeen Performance Incentive Plan" } } }, "auth_ref": [] }, "nktr_TwoThousandTwentyThreeRestructuringPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "TwoThousandTwentyThreeRestructuringPlanMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails",
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramRestructuringReserveRollforwardDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "2023 Restructuring Plan", "label": "Two Thousand Twenty Three Restructuring Plan [Member]", "documentation": "Two Thousand Twenty Three Restructuring Plan" } } }, "auth_ref": [] }, "nktr_TwoThousandTwentyTwoRestructuringPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "TwoThousandTwentyTwoRestructuringPlanMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails",
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramRestructuringReserveRollforwardDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "2022 Restructuring Plan", "label": "Two Thousand Twenty Two Restructuring Plan [Member]", "documentation": "Two Thousand Twenty Two Restructuring Plan" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails",
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsScheduleofLiabilityRelatedtoSaleofPotentialFutureRoyaltiesDetails",
"http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r380"] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramNarrativeDetails",
"http://www.nektar.com/20240930/taxonomy/role/DisclosureRestructuringImpairmentAndCostsOfTerminatedProgramRestructuringReserveRollforwardDetails",
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": ["r284", "r285", "r289", "r290"] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Obligations of U.S. government agencies", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": ["r621", "r634", "r864"] }, "nktr_UcbPharmaManufacturingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "UcbPharmaManufacturingAgreementMember", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CondensedConsolidatedFinancialStatementDetailsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "UCB Pharma Manufacturing Agreement", "label": "UCB Pharma Manufacturing Agreement [Member]", "documentation": "UCB Pharma Manufacturing Agreement." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r748"] }, "nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements", "crdr": "credit", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Upfront and milestone payments received from license agreements", "label": "Upfront And Milestone Payments Received From License Agreements", "documentation": "Upfront and milestone payments received from license agreements." } } }, "auth_ref": [] }, "nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement", "crdr": "debit", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/LicenseandCollaborationAgreementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Received upfront and milestone payment", "label": "Upfront And Milestone Payments Received Under License Agreement", "documentation": "Upfront and milestone payments received under license agreement." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r28", "r29", "r30", "r123", "r125", "r127", "r128"] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r718"] }, "nktr_WarrantExercisedPriorNoticePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.nektar.com/20240930", "localname": "WarrantExercisedPriorNoticePeriod", "presentation": ["http://www.nektar.com/20240930/taxonomy/role/DisclosurePrefundedWarrantAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrant exercised prior notice period", "label": "Warrant Exercised Prior Notice Period", "documentation": "Warrant exercised prior notice period." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares outstanding used in computing diluted net loss per share (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r192", "r197"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.nektar.com/20240930/taxonomy/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares outstanding used in computing basic net loss per share (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r191", "r197"] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r716"] } } } },
"std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)",

"SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "SubTopic": "10", "Topic": "420", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r78": { "role": "http://fasb.org/us-

gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r142": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-

50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2" }, r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",

"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "275", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479072/912-275-50-4" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-5" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F",

"Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r776": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r892": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" } } } ZIP 60 0000950170-24-123570-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-123570-xbrl.zip M4$L#!!0 (&./9UG3P#H?.)4" +A%(@ 1 ;FMT).L(E%V=:2E"$>>-KEYJ>]/WYNG@\'[3 W__W[FQ?-DU&<'N3AI"'-_F1RN/O@P:=/GW92:8?C MT6 Z@7>-=^+HX$%#R/SAC[OL\?OFB9_D9I=3+@ECA]JWS.PJO2O$CK*,_[^4 M[E)ZZF>CPZ.N_; _:7Z*/S?X*WCW<)@'@WS4/&N'?AA;/VCV%F^]#\N,.\VC MP:!Y@S\;-V_R.'SBF5LG%]ZJ9K=.3M_:GEG Z;O% SC'"6PM+^Z' MD__S*[?CY>#'Q[=__N+^,_O#JXM;V\^7/9?A,A#D"/'%[+O;B? #SPYO_64SYW^.,>=#Z./ M#^#" T2(Q8W3,?G@_>'QS<6/0_^"^84S-[?CD>3,? T$LSL6/\@Q7;P,N'#F MR7 "!$]@_(T#@M]P0@41[/AL_YQT9WXTS'].?-<3$KZ!.D%/P#8AL((SMR]6 M= *U!Y/.#\=EU!WTM(= 583:4^^$U9/Q-%RZ-;QX]N ^3R[>V-?>BCOEA.G% M0\;=Y$LPP9=GX7GN-$Z#QSV J_=^^[?FE_WL$_RW^6723@;Y-T;)WWJY,/L; MOSW($]^S*)+_9]I^_/7>X]%P HR+O 48W&OB[-.O]R;Y\^1!3_' WRK_<.?/>A'>XV?CH9_:_VX'#4 :).'A[ZA-QTM[&'GQ_B&9#] MC*QGMV$/[_6+2.W'Q3-2.SX<^".DHPQ7VD_[^*K:LD@DI8FX*"01.L2B:&96I'O-T!_@6W*[^WC:=;"U9\#%_> ? MV7=/APEY[WS3GR=O.]T-,6E3)@TCLB4&0DJ!&(=BX4IZ20%(IA!\]=[M /[=!$\A!_"0?9+\T;W?& >$^N7!F45?O <;6%;&>N(Y+%\6HXG7,A!FBD\E M)*>B.KV'IT. Y-%CV$;G!\^'*7_^SWQTHPW\1N$?1[6A[DHK#5%XZ70F7CA) MI%.4!.\=82G%PFW6(9O3*WT$TC"A1'PV\!]N?\2E_9P3*7X //VW_C]76C4< M:)+)9T(SAQ?QE$C@'HX[P<:SI;ID>7K5"S$^0Y+7*11>@;?C6]VQG\7EZSR M6>=C+_QGRU1.6>,](XH90203F5@K&1'"%JV+E/%DF7/FO?MX='#03G"QXT?# MA%0,- >:3)N_6"SU*A0?&(FY7VPQQ%L=B,S92.^8I@X>/QVVLQ^\>_]N[PDP MG7&[.VP'P JZ:08N!DHB",,TFSCU:G>(6E/SC+2[I<,O""F,>__8*R?W?-D"YVW^WW^$;4":1A?#9^3Q.B\>??F;_<3R:=OVG7K?9G>^K M/[;'[RWEO@3 R>BS)C)RP,GL+0&:#!G@DI21]Q8_S3W5+SZU"3^7-G=-O^Q\ MH7!Q>^ M[K?%.H]7]>"B(SCL"?-X!Z 33)"3_]8KT124:';\G.-KQV>93MTJ>D9]]LKB M\^(E#\[(S)P"FYUH02.&@@X:@4LABOXZ"67/.;H[*K!>863FJF2$]R\(-01 M08\?-+]RH\V+HI4IEDCA*9%&<.'%((@U-]P(. 8:4JVX#,80\(@XF7; @EX/ M_'"&PTCENV_C=[NCZ9C/TQO/\%CC]X""\A? _(;"'VSI3P>C2? &^>VVEG" M>@I<:724\UX&,Q8M@^63U%E$T0:=UR">X+&'<&![TP"F%_SQ M^ZCK1I^ ";P!<;1B<0G4;.XH+L])C%N)2Z64"?!F01DHC5(EXET&U2Z)$!,K M*OMJ&0&"]55YU 'G_9!/**^\6O0^/;]. /GWO.#_.@#R N\A5/&-X<$@X@J M1Y*4 L*+8.WYH"U1)E+-%+4E5RO-:]-,3T%(+E'?4@5HISCB>>3(&H%ZP((MV3"JF#.V2%\KA%YW(]CJY @5)U1P$%"'^(S?C\[S2S^<%C]7AU[X,.K\9-0= MP6]>3?9S=_S#C8&:UI*GZ$B1*1%)0Z\E"V*8#UQ$G5W,M4+MJG05X_1@.H![MTUOT> YZ=^>C],_I>+)R4"U33]6!@^XA2 SHCA%@UP4#0',9U%3X7TF"U67- MS4)'R^'_NJ!K!9[H--3*(T=3B :O%T92;4BNS)3Z/K6I/UL#-K M8J(ZD102 W;&&8@CZXFQW$7'<\F^6B'T")Z06@R0?@0,B'#VDS:/GWZ.@VG* MZ5DW.D .-YWT[.M5>>]J((4!G_#IW>_N^ POPX@><O7>9!3_?'781V#?[+U# M-^=K^$]5OJ^E*?,V4>",@1BA"UCUT1*O:234"FJ9"JS0E7/++2948=:Y&!WH MG\1&=-8;48BES),@4]!%EF0WPK]SRE+_W8_;J+'.A5FC=.8W=9&6/MQN,\>3SPXS-46L]Y:4[$*BPDN?J@T^WLS]QNGWJ7HE#IJW31AWCT2J'$#6@B7(73)@ MIJH>95^)MOAR]&X[J4ZZ4%EL'TMAIT M*%] KY(>#"[/HB)9>1UH$?"RE0>6?UQV?ZFWK+=04#S]O7,FK&U=Z6;P^5"8H-Y$X+PP8U9A"JT(FPOB0HTXZ.['IT%I#/'6)0M(QF9@)C@2F $(R M<.*E*80SKZEA06A5+82N'D]]%\-K8*8'_DQ@]=A&6KWV?%6'Y!+M(\>5EBP% M4BP-1"9@DL$H3[($N%JM$XO5:L\;$G-=ED_"\61M\8Z MLJ(S TIX+!G%+0 M4;TRH./4"JIO:JH] 6*>.^;.O\W=03N<@6FX$&_C;WJ/;K:: MCD"JCO??C([\8'+T!BR=X32_R3.Z'Z&WZU5Y-@6XYMDMH!U7!=JE<710H%P M@$:#::%%@N[K0%;GF(-+6.@27&V@K=&@79$FI8SPQE$0L#R!98(%48HAB)(5 M@CD7-H2);RL!*O*!.E4DUT83(S)BE13$%@$L0">:"K5"EFII?A.TN"5&)Z]6 M%KE:4&U&Z:$5BJ%26*,!1T%#$UB&9@FT1?"3>N<99E*1;B1$FMK+89J'"F<6PK&IU7A.W+&K<7$7)HG+L8@G 5>IQR6 M%,5(0@#:[X,D4DM*6;5^GIG/\QA@+T9Q!H0S@/I;'H(:,!MX5$"$[,%+<*C MQ_SIYT-XWO=92N0*!=4?:^6+"D2Z+$D05I+$DI T.ZGU-GMI0\WXXI-B-,&; M,XI(U"-"2$1%X7/T6>K-]YS?.6L]K_I<563*)8K,$I2(U@& _,)Q(603QUH+.M6'(J@=M"5Z\DWA2NE:8?453AF;X*(,_=>CM)N6XYL!L(S;GX&CIRT*25(YI M54Q2L59 5J/#KJ:*T[-B T^@W 30367QF3CJ #3<\^)-IM946YY1LUA<34*F MYT(+G@OA26'BO-&TJ58%;J6J%U)3L"78ZO"LJP.TBJ7$-8V!L50@0B,P;,!1DSUJD$0Y26 M2G-)C=35*B!7)#=LL34:]EE1WRD(@S0M,2"PB !:8J),V M5UOVMZT3_CJ:+#$BX!VS8M$(,_(0%@*4$0MD&Q.E J7BU4;KXC>J8VP3#TF M:Z9I\41A[U2)#7B<\($8,.*VXK8;0%IQP(G*GH.P$*GB3*2 M.*ZHL8IS(W^\3/Y-9K<5Q" #*T$5[,(GDP?>+#D)P6F2HP<9+GE6NCI#YG(E MZO=V-!C]LXU/\KC],$1F[8='RT*@K_G]7O9=R2E(N9K<\&?4V$D M!Q>()#$!Y]&%:&Z5%"8%%:OU\BVC:^.W.K==?3'?ZMKX&"0:;!A,\CQ^59[D MP]&XW1@!%7B1VMP M>ZZ@EF".#P&T%A$L5BM"M1D(W_9>@(UP6_RXW#/S=-"^: >#HWYRV%+<,G?I M*#E!)V8P<8*+Y:"3RPF+&JRW N1H3TD:5HAS M B@]F$!L@G]%GX7$#/=8;W?5:E60]92:A"@=&-N1<&\1E!ELE,P2R=SR(IBW M=O4>QN]-!:E>Z"^3%<3 L_2"! _R7L9,29!9 OXH%R2HL=14UY9BL^I9UE.GM%%(.UH@ :!(-3LQ0Q/F@"9B7TOGH?4Z;X;OXT5O7K,BU510(>II)QG$_4JA" M/'Q%C,Q,,UZ"D-4J9\L>-'BG\NI;XQ;K$0S%V.)]($IA;E?4A@16&!%),Q69 MU*[>?MQ7%QONU[0'_49Z;/D]*K<5,N2!9%J'(OC"-4>:\Q+(59)CU%63Y52 M@J=JDV7VIF'B7F?IZ>;\7< MA7(V.D^*96;NM65 WCP7FVCRGM<[PK'"EO<5I$)%Y43(.*P* TK21 6ZN07U M2W,3A?0RYVIYP3:K_NLB8XG-:::-*B6L52*::H@F7L*.9(#C0WD7TOM>;,5>K MYV^;9K.&N&/4U">#DVV=*$2"L4)\$(#--%KOJ"DI5*N1?BWN>)$>,AC,AD:C MLVI9FA#&!A^/AN/1H$WHY.P5HN-)%'T/7U# AI,E1B:_UA2XC[9RK]/;0ML MI*#(,5@04$ >]IFX,%%'",4D\G2ZG(;+P?8J<)%O%J5\V-IVI0)+A8EB!$X MF-Z#T>N4M%@'$G,2"8ZZ.N?'QO7=7D^_A>A"@A.')UH'Q,BP\C1Q1IBCWG"? M$ZVW5KBV5/ :P!ET80$C$0I+O[,T!.0_(\))+8MQS*EM9O_F9";$$KQD0)TB M!D>D384$Q14!$%,?J==F4VH3QT='.0.[WCM#S>G4PUV)RS%1E DBP6TT!Z,'B])TIQG;5$Q MJ19!:G##5]!E.W'O-/9WTLE@.T,P YPUB7@N=>"^T!BJ53[JRJ);3;/)Q+.G M$O!"2X'B!^?M!(JI^H9YSXKWOEIMXFM>A9-)DTL/JX0*.CHI3\X M;7:\C1\>=Z/Q> 28Q'D5SY^_>+UZ111I^\KQ\I-;;T?8&2@:U$]-.59M8PZS MM0ED.>9:9L4TKS81OIK,Y0HTT"1XX0K00JE(B8P,+V528)P&39P2B5/-@I6;BTL_8E"N!OXD)=C&-!)6"O"G M'#.QF&?'H_%PQ3E3;\O7.ZG8VU2P:B>99,13 Q9_](]XG"GQQI?H@D?P,:# MM;R8!;)&'1:]O2JEC7GOT-]%H>\:ID,D([(WF%JC"@[O9 JL/##UC%-,@1JA MBZXVFWXC*'4]L:%D;-*296*4!08<@B!.&I#Q,J=DF0')7FT?V,J:IJ\G52J9 M9 6EGGB-2>HX61>4-$V2U5$I6Z*PU0+P5(I'[S@]UR+V_.59/0/VXX;"'OKA M!.AVDH?PQ^^CKAM] L)] \?X?2K?5BEE(B>><09@YL!^+<:(M)8Z,VZ-JRZ& M6V,MPHIB'38PB@W;@-@LD4XYXGCPA/KLA(\V2ETM='IA^*K\ET=?V^15UXN] MT^.3NHRNKISF=RS+(/J1/7SGL?#$:7<[+"PX]DF0E'D$'B$E"88'PK.*08B" MB;.U8F'-XVIJ8/\N!6SJ2W(!)4-&Z8GM908T+9D&U6NUI6_]>.M/!$ZA5A M4:>]+PZT^%A '2R19.TI#5[3.YCOO%(M?KTC5-=DFD5JG'# R44 FI=@GUD' MA,\!M%0G+X*H-KO]=S] Y^G>?L[G(-H3VG,4O[GG!#V%OQP-WW8^Y3U6LZ;EJR9G>(6)*?Y# Y\7-L#**P4*1FD<24*2"*R=@[P1+OB_&")4:% MJQ51JDD,6DT186;1FN ,H4GB $[01'TVA83"DZ)&:>JJ!LKV+9TOT.G4A:FA)@28O++ +2>"Z-)\AR;Q'"# MHR0T4#3HIRP#O$NUR4B5$=P2.VIF1;,6NA!AT,7F0*EP)AK00HL*B5)CY69H M%C]ZD*J"2NBLC"M<9I(**A^:*N)* 63-E'GE,F.ZVLJRZ\>R7^;)NV&7_:#]M5T[/AQ_SK"WSW\ .?3$:?Y^M"[)VN6#_7>IB/SG&@AV2%>8M&!^S!ENVVO#6 M!D!X12Q>%VI"M*2PA T*;"+>64&"4R9IFZDJU3IR?\!&1;,TRG8 V ;X>3JU M*X\9K2HD'@:!]&>N"_7"P3!5[/=8&K8VSUM>3 MR)0=J.X!H.HU-K5:$4Q 6\%P]3U% $X4G,0 M?A;]O4IG)YD)7E='?)NIBR^QZ" ';HMA6 V"/MN5MOQ3XRY44!0Y(XCP)X:\ V MXX'PX+-/5H62JBVQW$;,[](EI4/S&;">5!$>F&(-6![!BNDI49H4:I3H[XR M1*0=#4;_:..3/&X_#)?DD;HZOZ),JV6XINY^A/!295)VB@MM2)1)$,EH)H%)M2RBG5EB;!+"CVE"J/W50KY^.437'FIT3W?M)/NQR;'NO*B!6[-I#_/-567@\ MSC@IQ_C W_W1,Q_; 6QM/2K-3;CB9KK,"C,^9:U(\H#!4O%$O*"*!.S:XCW/ MI=XJ\XT.MM_D(WQ*M2_.?8'J! OP@C#D< &O1\&/ \;2-)CKN"JLN +W)VEH]?$& !'-) M$8[U@-(H3AS7FF3!5*(A!>.JG2Y67\^C-:3_%6D*6/B@9BMF@7(QQRQZ"O@$ M1@BQ2)FK-$#:CRX:@#H#TZP!XS&SR2K.!14FSA*"W06$I 8W"^Q.BL8@[..U=M3OL: M6PO=R-MPI2>OO6G1!6W)[[K0HNA(*=BA)#C,%'21$9Z (F^@'ZRA6U(![F2$9\0('K =&V"(M!O4^@]Y@8Q)&EFKC?1L7SEZ:FN""UC0[HH4!K3SK1(*QBBA1=/&.@02J-OIV M):W\JWU4OLL4[Q)D2)F!#L$DT&$6FM@<-&%!.,YSSE66Z:S(1EX2PPUE(#MD@7,*):PWK,0BTW^:"\IE@(^UH M>)8B5)MRO DR; W)JR5++2(KP 95Q%0@X(H,C&$G4M3,9.7J#8D]@B>D=C#% M3HDG=N_3SW$P33D]ZT8'2(/3B9^%8!?5 *]SM[?O.XQ=7?B T]8TTNBK/H0[M?K/W;@QX\1K^\WUJ,P5HVU(*QJ?P(!\#!ZNB9!*UM90;H[*J-IQ4L]>Q!H=R M$489B5W)9":2,4%"-F".6A[!\ A4R$TW&.^TJ]$2S;B),.M"K],_IS)*O2JXNRY5'N0]!)R Y+1FV+'98 M1!J))Y\KF+(+UNKKHZS?J?5[1U"#SE:.SL/Q\^J?JD"Y+.Y)A=&\ &9DGD$P M!LM01%)26*1%&R#>5*W6^[50P7&8)@PEGH<)\!RTTVQ%ZDHL>2BB<'@C63" M$IM2(3XZDSQ06I'5VHOU9)TLT42DRBB+N291H:I1F"0N:!R"35F67 OMO@.? MV+L87H,)<>#_\,-I\7,X73725@_UJ!QC3"":,HXG+)+B&%QTB;E,F9$TIFJ5 MCSMH=[$<86:XA7%U>E;;R6N#/!O)P*P1&QAZK%%9@R6:$V9PN"#*M4&&K[_ M&@IJL[;1"6(,$NLT)+X+'>[M^5$MP2T[.H%S)2"NQ0"$6DX8J 6@BZ8BG6&F^!56ZZ M6^L.FUIN^AD78]^'"B.I>0DFPQ8JCT8EJH M$Q1V1G)-GDL MV8]86%]!\A8-)7BM00HY@\T:OG*07M/RJE';3'C01O7>^SS6!>>=@C"2>Q8V9F B1ACM>'42L_JP MQYK,VA3 1DH9^%P!0<63(XYQ1TPJD5LF/>A M8%RVQ:D>NF9K6,B%1*L5!@7 M5<1%L,Z+-:HX&Z3GU<5%KQ\?.!,6.)F;MF ;&S<_C>8@E).!,",AN0YLT25 $+* M\4*L%YEP&VAD6AKJOP/5XJZGL"X50"4F%1W1&LP**80'+3!2DC0+HW@,$)2J8/V+ F!):5N<+QIG"J==$@4EM),L9C 2@-6&2H<:6I.2F0^>N1QPOC0-R%@Q&&1T#%5,&%H@S."1,*:>5D-KF M:D,+5XH- 2T/0?T?8,_,! *R!4GEL?CJSM*#KM%T+\:U++D"-Q18"> 4M&.618_M)D;@KR:1^DUJ:3U;=Y7&*G(B:S2LHZL&-L(%('2ER4 5X@C*$T M&%EOO''#YIZ/ND.TK?*3'"8GX="-T9^M9,(+14R(V(BL6+!_4R(%)IE:W5. MU0GV.QX8M\QQK>41FMJ]H^CH56.F90B03=G'*M\O2.*I@QFEO2<5NLDJ=;; MN+0>6,R:'+$0%!@#: C:96*+DR2)HH*(22=3;>?'2J&S3 ;K&.-% $>-V%B5M2@^6$TLD.T%CH('JY&J%SE4[=E_JB/PNHJ',.18U]R0FKX@L+A$0DX4$'3QS M2F1MJ@T#]1!\5?[+HQ2;O.KZ[NJGW4Y=QE2CG.9WK)K*EL8#G7,,'DD*CSB< M2&%J.*6$>6DCIT7)4IT:LPW-U9[-Q%P$0YP'$A)*5E$R\2;@W!$I@,RJIQL_ M G"E92 UQ.PSE8*G0 K8.42FR(DUQA"M7,2NYE3:ZA+2EC4KYNU^VZ6]R14' MQ2R!1->0&<]RM$I@_-85260$T]46XXC1%"C7"ZU-=8ZRS83O>NB74P^\%DP: M([4E,DB<2U %BG59LE4T!.,,RL3=984*P6.AF3$:0[_(\BRK\($+ M;IPIE'A:,/"-?12==R10$Y,0"FB@6DNRTJCJL@Q*+J1SZ+$QG!=0_1G(G9@E M,9$S9Z/UD5=K4/[N!VB2[>WG?$E(%01U?)QN-.W0;WZE06NWA=32 MDBT!4D$74/X$BP'B$ %S35LP_6T0*810A%FYAG"]S2^Q,PB70I4406BZA--C M3"26N0(B-6*F!FB_K+K2J9HMU#4T_>/*>2D]@-#B@%PK-6A 41.,S"5AE4NL M.@MF$S7<=6A"1LN<2B24"DVD2H8$[R1A7@5)K8%OJXV;71^T=SYSHP8-SGC! ML@I$%).PKCL2K$8C-D46@J"%UN=>JCU/9SL<=FW:A DV%+3(+>::,0>(G'4A MVJ,N;*(NO-J6SYO09VP-B83<.2EM+B3'S(@T3!-OHB+&2:IC]/"R:NV8#<@. M79->X3S7SG!X,[5$3B\F#5"Q0190%!5!R MA25FQ9&D@L\T:5=XM=!:*8ME"0X;YD(7/BTZ;'L1RFU*"#\X+5OP0)Y[_;B1]LC/85G#3>9^(IMB77"1U9 M6A/+% ^1%B5TM:*Z!E_.BMR+P96((T5C+B!K';!PJ[(GE@HN*4]9EFH'HV^ M#;\B[WVTUH)V2W3!PJ.2G&2>2 JQL"V": &5U<5NJRL@# _:,3[P=W]TQ<2 M*Z/3ZA/5-C20':/EV.Q31"% M#HL/P9CSYEL8U!91UU=CL+WAFT_2B=0CN.= M8N0D^T

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Ü?1%E:EN)U^+OGBP;!XOEH >GN,E-,^.@_3]I(19:Y,^]L,?-N^& M? IK@[6EWJP!>0T;IZXJG:IG7!HC]'Y"I#\ FLWOQ_LY3^[$'KR$>?P^6TBS MUR_DF&WLY\\EQ_NTL**V3&7+5+9,I1*F,CX6_^AI&AWF M&7-8)WLYI9&,2O/J>$G'K=#T;@>'O/X]-*:%["T+:^Y0UYCM[QFRVN6K-6, MXI_[HP%PA_%[[%4X.:J&\>R=6ML\V[9YVB]QRW3ND.FXK6&U94&K5'?\>/]] M&8P^5:3FP)*:9[BD8TZSY2^KXB^,;1G,EL&LD,$,1Y,\?C\9?3W*=!?,YR6N M!,LXKQ%LVO*2Z_ 2_MWPDCN*O?+W!\G?6>R;;V/?ZSK_/_S0?^A9RG'EXI-V M'*?C,=;FH>;R:.@'1^.VUX!..!&RJEEQ.][S)H^G@_/^YBV+N@:+XE=VXFQ9 MU(Q$Q)VQ)[%E3^LX^[]C=XMVTI<\|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|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|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|F+G|Y_^?K'\]BG[Z?_5^BW+$CS,NZ?]70-C:LE2L2&P(- >G=\%//R6PI3;N#AXM0 MIPVC0$-0UC@6#*]=?*C^9WV:NBG;UH&H:Y&5B% O\==U 3X'>0]]AW6C;,_T728.Z M5K@4_5[SAF//|&C[S2H3FJ,D,70[S#*::!>X[]U=UL#7H2!)9E,EB7Q9N2O M|KSY+KNLVXA%^$V|I]E6DG[.P &+%OM_O9TV5Y%7Z!UK65HR(\W+G67_7]/K MU7'B4-90DG(EB0\A8^%#G:X45JT=$3L1RL/; \U(N3X@$P1 M?TY9N4.\"6!Q\>&)9DWL@E$F!2=VW-X-%FR:;>)7]L^0KEP\-V5<4O9-YJ0; MK-,? _>@TJ'41U21GC#7KL]VY?:D8S#IL%T]679-C7+N]#TZBKQ M:ZB]$,%>8%6((G^%RG9D^,.)\U^>ZB=;-15GB(BO ^>P8XF[A%]X_6%B//?, M6D-4(:! [P5 2>+)%U_? 3W0ESK(7EC77W C$QD>%>)(%'LC:(F,$,?@5[?9C MT5Y_E@XO%7V5JEGFDZ+<(U,>^97CW\J,28(& E[0IYM2>A'V"'8W9QFE(F2 MXQ6'-F#!I_O6% <11M2\1+Q,SGP@MTAE"?2L)CP5]O:!I!3[80]G<[]+F>WH^BN ME9!*"7]6C9QW*$0!S0_^3$VTB+SSH(_VUQ!S(-$0(W#*E;(!U) \>?7E2:RI M)2)1.C5[.B]{ 2DAZ8[SB15_,:%#]2FU*=ZA1?BSRY(]L2I99YT%J^X)N@K8K MD\4Y #O ^E5>U\-(1^A@)$6(@>N)[2@RI*(C#WCSBRDDCQ9C;.!ZT MG@E5K!=&PIDYMX@0NZZ;'I2A ?KPBE5BLQ_Z7=]E;_;]ZL#]WL-EYO^/RZ'E M.JOP9;I*_!6\#]AT_K_NO?GAN_OZ>APM\]#X=8+E ?I-'$]TDR"6ZL=@2P_I M][-=4]; [":!0GRM2A? F]Q3^QCV +\G:*?8$'QW8+'(5[OZMH MNY26>7^$/) SA%(P2Z-@QD%(HE0XL628=]OD?ZX"B<;CQF7 MI<"PB)Z3+=-1KGXIX!\E!O1FP? V3<4'

[&DLNA@&7SF#*N<8X,,)T!WZ'G.+WPC>DB625.XB1A4:L0]B0CFF M@Y0;GD=4208-M'/58S;=VYINN6;<*$'[KUQP22)$-#HDP0N!\<(U(5.^QB?I M@IKP +V1%,D TU"R:!B,R U7D=?(PM'- YA&*\C>?,$# 4$^B/ MB'HK\FXVP]D,?XT9RFZ6C^PQ\"L$.PR<'4TD5D' E^ZEN1*:=Z;5P,9G0>Z2 M01M0%ME+O3FUY#6Z\%_
M=;5KRL1.#9?\T,.7<%3%X(_I"U'ZA$K-D@TAE9Z6ZV*!R':")_OG_ P3R6B MYP4S+YC;+ABR*NVN8SU?_\T20#MHAK[?X4#)0_X%?_&G >B3XC'3=Q("^S-D MKK7.-
OE1D-C0G&UKH3+GG=P*'#'P%&ELE7(9L99;=(+A>IX6AD)6\J4T!DDB??)\SBB@^]+&X-=GT>(;"SW6CWXB())>BCRM&#)CR=GW;],8:
MY9<)B2W1RD[8%%9EU?:!YLUA?Q")F_"[+H0];*TFOHW0"LYS1XB&4E) M-63VS?)=*C>'VTCWM6L)\4JOD$2&V*+7FC35"L(2F$#&U?.J^9*F@>%QRPI
M+]LKH?PX4;^GFR!ZP7AO7/6@QQAI11Y=2Y'[M\<5ZUJ:>L=ZWQ7I_,6.]9ZSWC/6^+3/X9^D5CG!>\?PCW\BX'M<>/Q:[%A${ M$;N60+O@-81>_%A"@)#4+&
[\.V#"WFX2:&2L<${)> \PDJ0Y5Y+=T R2>\D0 MDH#(%,^+'EE(=\AEQC7]3U-_K=MZHX"5M0L7R1RW^XH.))F_%A4LH MMPL?_G
Q*/PD#_H]+,9[Z+S5%422X*!2M'2"<I:G";3*5M+,1E%1$LG?B9A3 M7:[HDM5#458-&B#_51!R7"8["7Q(<"0E;J!-$T^_"1$%"72Y5Y5KE? MVDH9U'A$?
#ZH$(3D^N)P+#'/@:!P3+OWNU(E$]?V%^Z]GZ2.R+D.JMSHEUM$ MX.]:#]WUB9D)>?3 2 #Y8<# -;]=+%B_N65Z(U"_P$'"MB.V-Q9^4@R[W9BB
M%1M*,+/;=2&*'.Y)JP_!ZMM>&&*7M>9 MDNX4E5]9JP,G-J P2(F'P1V.7HOK-
)AI[:UITK3J"8:Z<68P:.VF8[6V!0XJ/,:$E.1"TYO&8YM\C@7%X3KI$;T+8O2FY5#6%;Y9 O"(:X9_6(9E)&IZT*]GLFO32 M7-,_,SM)-
W:2^-3[>UT2B^2;?:@Y2Q>/:;;$DCK*V=-&]L*3]K5.9!N^D/#!. M"E*"P4JT]8V^$-0+ 7,Q8BVZ$U"@I5X2\M=^Z/R.34C;O;@$).?]!S#V'/$F M-B((%+&08(*I#+)"
(:?:FBR\O*SEP?6&5FBVV)(+%+PM'L6((@A\HX'DVV^(M=@4:A^28,[2DKU,VF2]];&R!.5P'F)ZV!S5!+S!!_T1P*XMWX7_H0TPU!"]?MS]Z%,-$/DV?.KP-9MPUQC
MORZONFH<9Z:U,ZRDP I'[$%DR8<^CC8C%"OWCY[[&L((X47("+ECF%PDND++ M\0!*@Y=,;T9&V495L4G^,LO\ZMCXV)5=4?F\7$#FDG2,1HN"!DY 6'[,6:+3
MQXKL_#-"L5QJ*;/;2]: FA>E37&+B:FB)3."I;WT/U/D)%H=>5JNJ45%>G]@ M$"^X3H2*C6OD;VN2=Q<3?.H]?DH9$\5A75.@7%UB"V,;!1],GAHUIZ'1UO6
M\0X&NBZ_MOSZ4DZ)=X(7HU.);F M\Y0BTU.W5R7?4WA&)TYRY)#1A^Vl/L)3XL23_I3WRXU!E=!Z^Q=D78;VH>1!,!3(2TS9Y#HD:-2:!\H/:O226A/N(]-
EN1+M/#*8$2AFF2OVYS_R7_;WZ>([=B+)V-;2:4_\C[2#J;]'WfV\S^)XX<* PV7W_-]K MR9T1AJXM(8!)D4\K?9O";UI4'R+LH,SP #[M\)9RG]AHO>N%4$7@60M$-
!:B:]S?U"7A6!?!:K*?(/=X0)Y*&E'I='H?""G@DJZ>8K+],H<2AD(_/%V:]B MOVI+(S\0;S7)+&(Y\T>YGX^*R CV&F^#_DG"=,E1\1]94IM\GI!/BHZ6@=9* M#,YY6EP
(>?YFU>$#=<$? #7=#8WM&Z&8EQ< M=%0%=:2(8O:(XX-CN=%A1BK7F\J]:-\IF?4?;OO>4/T6CM8L>9V<7!)T"W/. ME*
,)IHR4*13''W2(5TF^8JM.O2&@H]Q,SB0"O=?]\OZE19!J(;]/I8SVUS M1;7CM0;22]Z=NQ3+PKN"Z-UP*0ZA$.,UZF%
<'TH#Q/962$#,GI#MW>;9%+B[L:R*/(F\^H'\0.U88XO>N"*+U#Y*?X_::"3?J/-6T<'#66M/++=4F[5F?%V^CT
M%5/M<#N:M9[.7EIRQ#LJL+>%!>52:F&%=7^FK&G9X0*:>WK]B&0&1D8F?)PL2GT6+"&N%,,)T>I-LO*N65[40#'6O>NHQ$3;/YNRE.X:4!GV-2\^_M@^-
DI^;N;M'#!87C5C/:I@HLR3?=3<,L:D$._L/"<%C*#EWN]6SUZX\;EWA* MW IUJY3>B\VJ5'29WN>2JKB"%# 9%>9"Y7]R<$R)7L<)WG55+-6'F7B"VL#VI&
+NM@%.;"$AQ!#X3@(M(#DQ'[':?%=&T!^Y^.!Z$9@6*)>OBLN$:UM@>@^48(H]K@KBS M[&\^R/0>#A+]>;QE5?3U<616')GJ;YK_WST>HI^2[AQ8$HX,<<
MMJ8G.SYL*9X3(TCW4!@S_$71W:+\CA]Z%Y20%% M7.9'J;'9%Z?%$YOR[&I95^13\,_*.H&5X^I4I&\X9L:_1,$=X-)N'[Y;=DPJ MC@!GB%8D[W')
<&4QZ5!&QJ_O\!'V&\U[=D\1(@$R,E5AH!VTJ0Y;].NTCA)L M^^Y^SM<7'U'DD2E6JB[5S[+%,GX1COYF.4G!,QJZ1F!7B<_O"60Z-\-#A^(K\ M@":_J7_DG7NO#1Q,
B+V'\EJ! *-V /?/,O>F(5 .3%E<:VM0#4**($2AVF_M+=F'<.8T%W49NZ9X1LVRHR']=,!6,TCB M+^2.RA 2_19;2MK%\)D/QL21.>K$X-J'[*25>*
(VG8D^K:)9:^3NT@@V,H" M+PU[TV'Y:6)V%!_QTL&O&8WYQ !W0QV9@6K4((5)GA5ZI124B7R?Z6"2YB8M MO$EUQW:7]Z%P7;]I0XNV[2(?
J6WEMKPE53(>T[/LY=#/_5]ZW:Z=TW,MT;71 M,;S)L(90NFE/:Y-![DL8N>"">YK$F,.YS0_G- $#H\D2L)\(P"08'CS-HNF*4 M]0FG?)CRFXB>\^/AF*P%>$#$/+1%-%"^;
M)!-'AJG5>8DF\5[<_Z\);%,Y$0FL5^-#@S?5:[<4I3$)9?5@$0-Y#NG69UA M _J88WNZ_S?V0@]%(D>EKI^C@AR5O27;JH./XW)],=QAJ,%++>ZR*#![]D9QO M58?
%F/#1411C99"7_,V?)Y5X&OOF0JX%^HO8'$XVU,Q*8#-#]0B4Q?@/HJ &4IDK(%-&8C9X58__>?;UP\> M?_'%;,>S'=_6CK5"$\6C!VD* ^_6+,1L;[.]W=;> OX)^-*=
[)B2.8&5[8TM M<@IKMK?9WFYK;QK\C$FG1D17"K")M6\]0?D:4!-.;JAZ?,\ MX/DY :B->(-&]\BP!KS8%%/.K"(U6_)'.:B-% JA<3J!009&>,"4RQO)*WUR
M&>A;E@R.C=EK,]_CLUB;WHTWH(-T'HY:#39HYNIVY"?X>?-1.%W=?XXDJ>$(#[!7 MUNL9(Z4C8%)
[H(5<$R_DMX<|Z1P5&>TFRTU4(>)WI9)XLZB$SP@%6IO?9-Y#NG69UA-&;_?!&'QR\C76=M7"XVS)O9O><_ONSNGS1!3K5C[5LU,ZIZ&',C2Y/C
M_*BQ)0IL=DB:BHIW6<*4KEWM-7@* &]^_3)S6UD0_,F ;@)*8!1)%?/9N\ ML=7MN*%56W.FHF;?ZG(9]*%:#7O+47NCAXU4&^?4:LO/B7J@WGE8NQ527<*F
M%EM(V*%87A]2#&CT[0[!W>,RC!/"9:2CK\J.?#SB5"_WE1*BLI<8"O.R2^0\ M$^S\.6I! \X>C=I;-)H7Z)5 ,9-)@\D63UB?-'[R8RO%]&C^BIL)Y3(L9[T
MUF&_I8WULJE(],#"Q)EFGVX122JYA)G05*["2IS:*+P-_P@RNG<&UMP77?CV#:V=P[0RNO5/@6CV9 MY>0IMW06[5F58T>E0$ "M\H>DB=MBT5=5 ?
AC'+^T/4NW]5_H57T]5>!28QC M%6E2KP)'1*4Z,1V+]9*Q,X&8"25_. OU+_?H&[@8/DM.Y] VBL>'^Z&'-6/= M_*54Q9Q1G?]X+E%5@A2?%6E@E{WQ/BN)QR0"9?
6=-YTUSDGWQ=EA?CO(+JL M]&7UC^1!SE^]R/39PG5O$@\2LF;LIB=T&RKH&GKE) #8D.S5A51R)U]?D&R3 M;V^W M@02#PME(.IJPSE50AHY4+5<1N(?-
!W9<[-ACC[&A_ZTRI#NKFFWZO/$2!38D M!WEG_V;Y^"X&'KAJF!-K)*Z\AC)%Q:$@>HOA;V 'X[?$TD8!/H)N$2^)%_ZZLJC3>3S#EEJRI&3=DRD3V M=?
F/W@UE@R3&:KS# "(5,I]"U<;I=YBY08Q M]W35Y@IMQP8?"=$<5#P/K'ME/:@2-#YVKC4K M-?
VU8/>\;L,R9E(2Z\)$.B_\9$/0HMBT98KT1UEKVWA]E=4T>6W+QOK\/%; M]"*F-'42L2M<[%7>,5VFK@U8>6R/@]M?]Q5+0(0I%N [>23';<[\H[Q
M_9"*XSDBSRM]W#OL?_VE+ZN5=G5H".?_DY/SG1\CX]$G.\H#_C UPJFSA(VP M=%OG D0+"2^_@^8.L%J)-7KWTC6E07VPF[(2DYWTN,9[J>-#N
MADI53XTE072'^O;RH!.J;K"J 3N31JST?O (=H.7))^&PJG]D*H04A 3XR;+ M@C97$O+9%N ;W38K<^IH IFV!1-WZ^H%SVWAEUP:]_*Q4M:32-W *2=-7IT2 MHIDR
0?)MF^4,MV#1'>RO0^ ;C%+[T>QK'A_Q<@7G2[>4/?@+_IA)@+:D#*(M\GR7;A;MO*YY;^?=\ V=+H:U,4,R%D:EW$5K[AB0FH90?
7%%V1$N>M<@>D8QM5..=5+N4'7X9R=.!!)G(/#5Z56/A\3)>7_ M:.S;XBH:4B ?:VI0\LC.K)W..CSY$;/)K=W84_I7FD!LO1[P+Q<8RB5S-B: MPX@!)O?
KNKP=#BEZL+LG7 M72E/$;W<+_T%>=##HX**P_6!2;[;?J>,5CS#.>M0]_I7C>1H'27/(P^,K9X3 MD)*!8T:^9DG_Q":?_@XY!MWIB9.7I"Q".B,0K
U39@O)VFGCU.#,%*X[B0/' MJM-)PW[\/56JHB&YO>X$E_\I@@%UZ =D"7Q^:]$5'D(CI_X9G4!F=@Q R,N"TPXIL9&#$#(V9@O)T"1EC)
ME"@^,80F)M4U2DD*O@'A@8*T\R"K9GRCLD:1&->/=81\H" =M(LH+H 3]8L_ M3[N5UJR*%:GD=N01:7TJI=[&X>Z/S'(')5.PAX'E-'A?]D%LDOYD2F_ D^:
M+\A50GUJZ":,"T1#+Y!C&!-RB (AMP"\R]%F&S=\I%%R18K"N*@F-#PB,"__MB&YH\$JG_%$%!'3^G]WZ(#\9O9DCKP(,G;>2"@2&U9LD#ULQFYW
MK&HK;?;2']D^M*3PL2*-BGUS)/\'&IP!07JB#6+2]&2A.>#'MRQ6TY!*BG5$UR6XZTH?6\LO\FQ97I:57S@B M09<'JQS0VAD%+__$%RU-S$27FW9J!DJEA^
MC)NEY(8[5_Y39*=D.VBY9D^:CS5_!W4QXE/NK$WD&AE!9JO4PI%-:P$-0_FT M$[+%:43,**_RUY/;S!#7!$%YEQZM+5>*6XAZ[40VZ#M@ M+^:@Z'=^G%<\
MXKI@M2#+=:?1ZJ(7TZR'JNK8FEGK.%MB(?2#(,?O)F=I"U281++B%*^59ZK3 M10.]-^ZP^TOFHYZ&09M3AF=+D-$ M"M(DK2JD@C@A61_)30,"![4Q/06FF-
D*XQ&@HD#I*._ =5^M">S!@EOV%$V@ M'GZQ^SBGJ0QZ9;")698;'[C(RAD23*,]W9W.'D4C.([CS"VN(\K],_713(%I M,*05 ZU^VJX6G3@K+-BY]I*4H41"K4W,
[U>:7L)^V! W8[DGBE2B/FS1X@Z* MI("&_]>#$,V0"5;J7WQ_>.5H>MJXXK+DYB>1GQ5[UBJ!P40DA,?L0]SHS:C^ M"TB5"L!$-
E=29_'#6JH*,Y>RP]G!*RDB=44MN&!TZ]0W<(.%.S223Y03UL*[ME.$Q#S,4F::44ADC*,N0MF;!A"6#*/@!?L-?G]R[-C5U77+O]R$-#96K !-, M9]21SF#0"4];&0?V#P
%)H2SOKQI1K<'RJ^LKV96+0-I:)?4J B;:S1@+>#X M$))D[UJ[=!1A;1E@C;U*$5V,BO+,YA:WNDLE [*MIVOL27NEZ]&*=U'P9C\I M)HYR%CC'@%0PP#=
S,5]4W+E_?3T%&U+6#IQ-!@> MKJ0XO#^M>OPBF'$H;JP<(;99SX2IK@'&A=)=#0%[8%,8WH*."H3<%;,."KTJ MV573OC-1*$]'9/AV=
YH>X>E+:M;A4#J1,W9-16Q5C8D-6&X_&(:NJHHGK= M?5AA"Y3?1XV:,?!MV]2.D;*!EABF)7Y5R?R]FB'@!MG@8N4IQ^YD??>82\AU MP9.>V<<*AF:'7VK$]MHFK-
%1 '7'>3)SC'/]BDN'1O M5/U'!68XQQ5$)WD8X,2$5.BQPD@!NH$)P0H1 3LH)S8')II*/8^9*S3OT+D&0L=RG M8R4L$I@CA<8^4" FTSOHX.&K0;N+?
D&'$]JA\NE\G1T0Y\^5YN"(?[XEW"HP M3=M=4;;#Q'7K1/!DI7C>S$\QH*9)JT!IB ^8;BGPC*BBL^W;LOTJ@MH7DB;M M"1G)3UK12K80Z4^2=D>C7-V+@+<_P?
P?.C[:M%GRD2H !UD**6NSQ?S+!N9# MO[K94A5%+I$P9=#[1:8,<\-1:X+I'N.'7Y64(*2V5S;'H<@R):SK*+D)3-5P MO13RNC;^OMZWB-#D
MV(D;VVG*CF7"NWCH#B5*6*A=#G8!)?5V^9JO[G#3CLU MM?EC<&H\R>=K][%63R!E+@=ROCM/?/-[!B,9(F\'V:_[>5K8'$FR":UE'@69 M9.8FGBH&W;FM60_Q+?
KP192ZM>UT_#$Y/>)![HFR8$%()*]0$PQ-65(2;%> M;]D,)]Z6*@N5LLO8)SE@I7(2#0D%:0*#5,M%KAGKN0=MHTI\((8&T[O/S MNF,7XE+MA9_6O3-D
>0BUMIL=I8=6\?(/B67DY'TR\4;%-72S2(.(Q+RA4B+ M4A/"'I:*"2D!A:$= C//-VN10M$D9-%]QVX9GT'#@2XX]3EWFZ)KC3^%D?I3 MN>PXA/BE622MQ^@VH=:
[$AVV&\?Q76Q7\F=U5ERA".?_<&!-]L@IQX0Q-7NE M(>7E'S+>GL-1+U9=,YE0V>[E3OQS@7;D[.9! &IE*H]EPBY=N.'! MIBTY[=:./(%ZP\$^]C5QS#*QJ M=V5C4YL*
(N6P,9?01NZ5ZCKZ1PN_C%:*I%#?UI3$#.P9UZ?\- BG[*8=-YJG MN+(@!F5#69EZEV0,PO?3A(%-9_%Q%UE?(LE&YU^.RWQ^)YL%":\%$Q0AKXAD
M3:WP'4TH[EVQOP':W]\ M%T=H_'XY.R4\[UK.L&,?#7BO_'5@(CF5CEMRXJK(//N 1VW7=^B)+IKJG(I!>Q$2W@TB,W M^N?#ZR3->[V6;MU-
T1GWQD3'Z%U5,N81IP\=1,MA-'V'CX@780C9618_D7=5 M0+4I5BS-L%\J=(GA*V8.TO$?$/709O/W&CW>;_:(6KYW*X!B]]C@J+>
GQ/A7AF)1LA)IF$J\PL"H2.X=B+7H'!U M07M%>!UZ1N-4IW?+,P>J*L 02FHYZ7>54DDI>Z%11N\4@ QNER08B0=3D%U' M'8HCB,BW%
H>E@R$!X,6EE/T&NBQSSZ=3LMYDSI:2PY!RKB(J>U((/'BE)=0 M9^A6;,)W*Y$RN4N;U W'4QB7*"RFDJ[ZG_E-,K#\>3]X8+33J"B4'XB[!3U
M7M.LEOR*041=*61ODC\;8RPLDM6/):L?-U=# C&;S"4Z2"+LZR;ZO]UV_^^[[NNG_>W.6@[!DFCEOFJJ,,&=M7]/29=MH.LB^3Z:FC9'D8VL!: M/.1QK9O19'R*)\@??
T=[(9%:;E"4<8Z$TD2&B:26\"NL_'+T2W.53T MA*64 MKGG%W-T"02GJ!%,8H^?(<6;6;.P5FV#QSD/VT61ZE4SHLA0O)>F(3)+" &]2 M<.V-UN2YB^FWC(,2B&9)
(*8I5L%_K[.+JED0\;0M3)^OX'TV/0N)T0$,#66 ME(G$Y],[6E7ZT5^!:S39(0KLHYUV%HIXY++)I!>TQ=*]+D0GP,QB&[8FD:XC-M0X:?-
]#MEK#2E..>@2J?.U#ET0Q4F8$J,U#E-%#EC^\H4.9:F\ALD#B.9KJ8 M,!"*T$!_(=Z!G!I=O%#2\;PGG3E?)QHHT,;#K?LVW#F&Z0V5ND_1S_SD;.6W
M;KI^X3^I*L=_*_01D"L_3^4VE^&.3-T L\E:3;G>FZJ.QI0TE(H$'#U5(WE M6 -V8WCB%T5712DN, MR97/W4;T#I+^/H*6A>+IE+XP9PVFB/F31]60?
N.9R2/C$)4^0$U$R=.@N\DH MC1$#C[2;0WY"69PBW4Z2)A7&'),9.#4X:&P,@X*0WC("])T(&922=H5BFO29 MQ'X5U@Q2U@ R>"@L)$)@D53!)@E #
<59U92,J&A;D.'OC2 1)92KGFTGMDP# ME+Q(HAM4M HOT%L.\D61\D]>XK783B3 MWKL169NE2%-R,Q8H6&X,Z9VPK\A%4YZU=5"T.%[;:H_M'7R8&HY"\:#$*3IB
M>2-Z&:O%'4^KQ)%%IH[W:M[XZ 2*9V]]_.XAJ(3^A?LKK?NO@/J:$& :Y%1>5 M]5LMM$M.<,.H!=Y;G9D9VID6$+3W5**78PXJ]&"YSF=EMZZ@G30%PXF7^;);0)
M=R*D$K X,)?D:?$6SL4JQA.WTEZ (DY#_2L.KA(7=!)5"YJ/*O!$JKH%MK&C M1@;HSZ)LC!(;-OPC'338N=!^-8X<(8/?SZZZ^^_N;+AX^_?ORG9U=-N^(:R)_?.;?SSU0-
ZP48D!,C M0-GIKQ__C*DITVVGV_JZ.'#/PVN^OLLF!,(-=2=UA_7VIL*SB> JG!,L!GQ=$3 M N+DIK%8D);+YF4R+Y/K&EMF\9_/^U:= NO,/^9J#5Y('J3MVF>DD
#B<&>Y+FJ!U>?NO/BJ527>;9A2,79+X3-2=;4+I)_8DI>[WK]YU9O"Q7[WGSB[.(O6H4,9WG2/< M"#K:J%C1W=RM(1Y({Y*\LC#2M4QHXLA^ZZZ;EY
M#&5STX%"2XT(^ 7@I($X.A2 IY8$4]TPZ,@>-K8%A@!?K,2UV=I@]^CADZ(-M-()R^?\-#9$>-2@&<9"3@;"'#)D_-"
M,OR!,"3.]5GVTG"ZA$P!J+20K2<(4^>C!JA#)!U4J4C$L<63)RM%=0<[@3=& M_1G59#-K*<"Y4K655/6L2C'.EMIW,%:J+$GE?:G I7;[8?I@\'1V/6,"KL$$
M3#!I"A1D^C04<^D"^(2Y]Z98V2=1MS%7"]/2>I?"<(EU&XG+.UR4_TG/2,M] M 8&8U1CP*ND!(?..:Z:EQ)4=B"2'L05&3[0G -Q(%19X.;!1L%O4A'[RMPN25 MI!&
(L3(#%%RF84_9B2O?0'*6*MLQ[P- R?D;0 MB.9^B;6HV5ZY]&V/OBGG-$%+$M]5U'IHK7K/!EHEQ45!W*&45QW.+%"NH2UNIE8!_E;!9/=ZPS
M\Y%'Y=#=!AQ>Q'S[_P,03ZY2-9"EO*Z^OCPL*X$47HL?241N6I@>.BP:&DHA MF%(]?!37>1,LPOD(1/3!VHI^G81*"2'N L4P^I++#UP:HDW7:82#WPAD82/M:
MP[ZOCU#Y'S!WE[FW?YK+AM1](JFQ6T+869_8NJ)6GQYOP?B%\0\G/P[\=":E:T\W7,-O;>F<<]&2L:T]$G6%<*GRT0Q?I3[D1BX0>P :?MM*-&<,BU)!Y NGQ[I1B)R
MJ*ARI>FASQ'A\N*XZ2X(!K8HS"9H+3%,^,=]"P^Z*JL,C0)K)E+)UZW:$]= MA\]F'E;M\S*Z5-CI8S\63Y=W8U87.&G]9HQ@F7RJ?AMW3XKYSK+ST.9$)%#R
M:OIL,BCF&&AV:D8Y!X4X6N!STG%/V^D#H4I3G#4H0'=RMD<@+@+55WCR+B MZC;(_)+ M&X4=+3#VF0M\0-"A=ZF]V#KZ"G7'7@6PEEQQR<
M4>)X^NO].SDD8%,1,MY]TX4EU"):OPL>G41?R[+UH?]E>CW1':_>)6_I18NT M$A?0]YO*T%Z2(KQEIY,S,@[E-KT!?'&T\,-1/Y[]I+E.!,75,(1 NV3,"W-7
M<\%^XI9Z,)]E/_JUS>S9;OA^#ERCWJIAH.RR$]4AG1)\IU5Z*_I&@#B.[IO; MZ:6G;>KJ$#A6"V::DA844."7P\(<.R??"(80FT(AF,M4)S]9E%7;6Y,!B7Q,*:1% M5U9)
[^GD#V!]9*%'#KA7W_WU4)FTYNJ2]DW:%:O#UH%V^9?^(@E 5,)X(LUS M[1%IK<">Q+%#[0I-;=))0(_> 6T,]..1@8O2P6>H'<-NR;@WVZZ'W/[D_X7
M%VQ$.7CBV<)VET0'RE9J5M5P]^7;!(0'LW]8>(=>>4G)!72!-D-F+1.N<<"$ MO2:F=J?B]#
W2!Y848H(;6&]DK[]=)H_9RC*YP9%>3)#468HR@Q%.2/(]2Y%F(:ZR8_DT%E6@KJ:]\([FPI'\ M-OOOT+:1_FASQ5SRM5+"TD1#$#5U>!_7$X^-9 M/V5,P=Y*"C.[Z
ORTEW,)&O4'Q\A.&U3?@:?8Z)T5L='O,,.\7D=*L(^YEY2 M$T7)\@^_]#[T*#7)@=C$U.PGLWP6FAN<2,G\2KS%S146G6(%QO-&D[;ATA#6P, M[489N,QTQQ')Q7_-
ZX!3%L'(L#1I$M\VY M@/"%5&Z.Z.8.(>"WA="!>/?MH#BC/^ %4]PVOP.Q;3%'-C(4'P,%-##:[,TE%-S(=DE(F/+]8:RR8ED ML2WW?
NE$AVO\E:B+%I*)]WB!QXA(("$G?GS_9C9AJ7>DO"HB T=(CN-ZUDS! M6?;SQHFH,KF]$::S:O/Z? N<>Z?2(@]/.!C5(BQ@P,!,'3O@S8?F2EA!M^U+Q
MNX@]GP_(P*95A6E*,SUWV4\B9?E95DQ&1 6I#%K+EF<(=/AO.*:OX7[$T) M&BD29T5-S$#Y5R>T?13STB\7]B(A_&$HVD1C1%O 9I'(9Q\HXJIZU
M9,H+,>D\VVT.'>5O:E5?B2T)N^) 5D_)<9 '^O.!GK^I0B>$=UUI$(D'-Q+C MN\Z;[$[3CC0?4W)-X6$EMS$FV64B3%VH113+1D/0A:4MFWAJK*&^\[:K!-7N
M_8Z9<)$4HCID=="T'WC4V]GH$:Q4+ TN]G7K/'8J$%GGG?:972B?EIRU-FG MYRNE KZL!!;&)W!.0D4-L,S$(;GH16697^-LI"OPR!D#[*7&"MC93_H6,6O=6>XZJ-
G=W<+^XZ.>\XJ MBE2SF'5409JV[Y"KM,>/L=_KK%15H-@C'D(^V 5.M6/3]KF%8WQX4Q5V<0N! M:]S4++!C8PF?T^+(!N6U&(,[#$Z=>#FZ2LFMJ[@#=-
C5'NZMB2^IS#![RVX4W M]4K)OL&WV@=*UN$+(OW@W7LFL>94+.M?ESM^2?_&1@95^Z<0@ICQ'I!G:7AN M?]ED5_;E?T2T(@IA_!_E*E6EEOE5E,%

(@\5J3)7ENZ(B0P:J1'LDE)BJ=DR6$WP_#>(=3 M(F\51BXYU$-HQDD3!-QO6A?PJ3A[2?'P*K&10:Z''!?8Z\3H5"F&S'(=N[!:_ MK\5#1)].I%*&Q>%)8"(+M &DR1.(/9Q9D)M9/#]HC_ @<=P&6UDPWP: M,\/3[?_V%7VDT+1[=:0A@1S4PF-!MVJN_ &#M@!] >D\Z_P85T6K3WMNQ)?$
M<$)F9$KM5Z2Z!$##DX/'"D+E-.6:"]LDZ2L)IM))D+OZ/_>5LY)$H['5[MF. M1;RL:'5,Q_O 4.V?S'8B/612=V?P %@O)5AITGMR3J.]@K_PG-[B7 K+C%CO M.LKO4TP=1_%H")!V8/E@IPAB)#7+BO$ZT-:4$&GNB@-&"KULA@%:5>0O%3XB M6FFT_8<>=1/.3DZ&WFUQ$!I1W3!"CC'[1U]PT(2=6RV*Y3N] MY'1R:J TQ4&G8<$@B#W2P;K7FXAY!-,A5L]N[@5:Y=E]2Q:6/7-L.3;TPG*\3YD# M K:V% _[/_S2@!VEU+ XH_*R3\XUK0)WJ(:$LV*KX.I>'TU[(GXOH#*:'",-$
M@US.GW_'SH\3K1\?QMOW].R+QU\?Y^W[\@_%V_?5%X\???7UET^_>?SDJZ=? M/?[BKC'W,<_05GRYHW6S6'>8D+%ZEAVAY9M-<#;!ZTUP %DF>L%"-EM%$R[\ M'#HT_E/=O@VFJN7JZA8B!N3_7:!HW1FY^_D/QR MML'9!G_EB5P1X!@NO>H)VBGOYMZ0AWZVM]G>C@4.$+QEHC#>^8A")RAF=) CGDN[X MB;SPW^N27O\-_Y'K$Y3[7#AI0436TE^M8E0!*V0J(XU-]X#SRF:/;4Z-.7UX M@Y1@_0C9%K58&82YOLPX<FLZ05& D:*G9]%(H-4<\I%_2V^)!'W]$
42SI9A#X(=SH]5:L<%HN^ M>I?M^G:YP6"?4>X+S4,T[<5>1$],H@=MR9QJ5'-46LP(TQ.<;5"2BZ]_M'-E MHC_E5+L+(5C L3+
8_BY'P$V+;FHL(NK36[\56AKZZ3/QQ@=-X@NRM4JZ&NO ML((AV1H(*<%)=H3$"23G6%ZB+M;&]2\IGO33LJ MX8*%[I\VXE*%FZ+;_5%
%:7OR^$I]*L+IS!QYIE$1$2'7S3B M3=EJD1N'ZSMW&.B:=R3CY?0H#>#^W.0VA1),JK1<.12" !3X M]OX+TL8C0[''F(J7AF4H&(QU19A5.EA-GY S%%C'!9(DM/-C(H.!2TXK/NP MV,/*'$!^N;P(F]\ADS"]6CB[EMC7^1)H8N(&._]#__#"AMG74O.AHN>O6K$? ME^'J#BW'8X;1;?K]JKFJ.57OYY.XOLGC3#GY"[1YC6,=/;-
IV/E,\3W(]PSQ MO2V/VV=Y0"_4&V2D$F%'0H72>\+S4,T[<5>1$],H@=MR9QJ5'-46LP(TQ.<;5"2BZ]_M'-E MHC_E5+L+(5C L3+
>3C:^!:#2!,0*,QQHW0"DE\39!#C%^(D2(X; MW,LMPN1&&+V]\"197';D?CJJ8<]IS2N8D MG=N-$12,:&P> 4*'KT3 PKXM/XJ{21D$;B(XR)_GH;0K*5OE_@P*J2%3/*;"
MTEC,ZG0DI%AX83Q-?.N@DXF-S(BUY:=I_Q6H ZE,JY_IGVGHR9UC4*X MM_$6]"0K8#Z1T(T>"#R@3W2CA.*8(8ZC*4]RPY'IW]KU"1*7-10FC7IH"3, M:F\$RVX?
=IV(SD;ZCB! +Q.3J()@'WD"1/B293(3 1DJ4H@AB)C2L)!ES+MVH MZBD32VP;*914>LQ.$\-R;>?C*NNF1_=$6^ZPQ3S9C0^"$43S!37^KCA[@,+) MVC%SNM^?
+PV/>G@;;1V&2AW+_&:J MGD69.UU*LGE/B1J$#3W=;6@GOU=L2>8NG$'^F>]/5K%%\(&WHU2-"+YUL@7" M<:0M^1=48B[-.4=@'.;$0MEC;?
O@!UMZ;GF#0E_F!$AL@8RN=%OAKIK33OD MNF')!O_^EUP)9Z0;_2Y/ZL[=U+:KI7GM.2O I4+]+]U^+'&4$H49<1JP-H2= M9*CE'&FMHE0"6K;6,
!1,)1>_90K^W?95GCQ\^_M?@)S85&=(L[.--KGVY(1(7YC(2TVU;G\J4'(7\?/*37GW]1_H2Z+[!Y]"3^Y M'W;6'TH"JX!=A*5QS9:O.O![N8E*-J
OX<^$'BK=*HC0#]GT>ZZ%A+7X.ZE#AO^C.<]R[+O$U4K;RC2UTF>[;;!\E= M*CO*IF3)_0+[2BYO+Z-.^UIWY<1U#O@2X'W\"<';KCF1=-#,0! TP^_4^%7T
MKLN]2'5U_<;A_;A"_6ONX2J8*"5N"7=X+^6F-A7;0G>S=,7QF,)/&)#KO M$^I\D9*&&%^"OTOD4B0'GV>6>E#/X%S\\0%QYPV)K_Y786]W6:W"*X8_
MF@4AQ8>Q(BM!.&0$6L7H'R%23=IPW/#](-%!EO&JIOZCE,*K$4\8Z2G\C8!58W MX^.=97]3*7(_6]L6VTUWWN7^*AB/65?:7HL*R?[-Q
M*"SLLS=NMW>0Q7WR$([1TYF?ZW,OWG\Y%^_GXOULJCM* M:"PY[^Y/D,)*?S#?9CR*!ZU]EBXUT]_RQ]VR]<>Q/[9(!DIK\3&+RS-$!V3 M? $B)W),Q,E"W=?
1HTZRPG"-8(K¥X]/DX#[)&;[#_NS+A.$IP1'#G&R2TP@] M\2NQ8M'< 21CN!)0DM.^G,X:(RK#$Y(-L7CDO!_=']C#'?,_';,,4?5B1[KL
MR++\PQ9!4VS[H;LJ%._F:O%0XD"O6CF+$P&,DKYIC+'Y:5K4P'9:YIC\/L<]+ M,#3JJ%#-"RF9=6EHH=-BIT$%0_%->@./S,TX-Q<+R?31WUZ\.C]/V<_X)*17
M:]*W^V@OD;,Y,<>K(+:/9]X6@&ZF&E.)7$A3,9W11-0O4088;O%'!T>+Q:[{DEGHGS!%]RMO26,U@1VXJ]>"IJC*=XY)@_TL486GU_Q-R*W2&';,,1T^MQ;<
M7W$_05@9'=.^K1*I2],FNG*5VP,M"58V4)=D6P&64GC=E: M<1+20_-5$]2;)]P47?CV2K+V85E';(. TOBB*,I&_([F#P97]>^^18MWD=4] M4@+P
(F;D\X<;308*X+HEF:.G%G%BA L*SV'XI64_O_TT^7I-R;?\C30].YN M&&\MB,00!CY^^.C+?__RJV]RJ W6>FS^%4PQ5?8M&=^K> *87]H[Z[>O7M_7 M'C"7-K#;
[G9O,]_]/?N13A]_09O-HZ]S(*4. M>E)3-T!)4_'U M&&HBQV]#"5.M/AI G.@-V:Y9 4#?:N3*6GQ.PC(QWX+,-T]6V9KIRFE7S2?Y M +SWHFZ-^5]P;0(V4'6$?]"5^Y[W9?
9>.I.2B1< M_XG#[9_X&-BUH60P! +0T4W\?2wA3,9W11-0O4088;O%'!T>+Q:[{DEGHGS!%]RMO26,U@1VXJ]>"IJC*=XY)@_TL486GU_Q-R*W2&';,,1T^MQ;<
MW0OON.W 7K9P\<$5[>Y-E!!LL//4DZ<=M KH[Y*-G MV:MP1/ACL_<."#6_T4;/)U-3ZPFQ-^M4U0;\F M&T.W;ZC^#*#7;+T,49HFCM5@D!L-"==.:"U,(-/39V5=0I
M2_-9K'TYI8W7NEW/00Z1EI!N[XJJAIDR><=.E>!;Y;)[)+ M9DAJ 5QJ1#B9(!S%\%Q1MLWT"3=\>'HN7Q=2'=;"-5,T=_:0E?4/?(#*VNA#
MZ$/)+I#J1^F6DV*'M0Y8_49)PKG5YDBF;M#XK^)@F^*?1;MJ^B[,C'C^[4"[M\K)L&TD?SO:=,4C)J!Z=2)F!NX;$COBRUXKDDA1WV044!7#! MD8Z$WT]/?
NR&ZZF?O<.HI'L?X'8/.!.AT79#,B+^=P7#3J;!3L*SN'P6#6= M=$4\8&38YUZQMT:G7E=*LN(V5);+O X&!:R8?NL?\"(C U-1!!AH;&1;[;< MN"T-
'[%|%:NR*:),&VV2L@\+E]/4@P7(&%"*Z2*Z?ICLNKH71L?'6-Z))A<2 MN'IXVNS-;_QO*]W=J4!+B02ZM;=8AB[&AZ2O>&_P0?S+5>%/C?M2 M!URE!Y
M"'"/#S4Y79.?.?L.*<,E;X>3UAGA!C6,M3D>TK*8.Q,95B6]$=AK!54$MD$0Y MO4$GY-1Z'-JSR:A_1UGJ9@K.-6,X/G<,QU6?1OSNWM_Z#G*&^TW7<8HDS\-
H\]W93:"32^(:7_T_F; M;__*WLN_!_BB@[_'S[@TEK!_9:\%/_]NCLT2.R=/^/IU]3GIAM$$D@;]@[M2]'3Y_(R:)0.((8C-R@MR2"CQ]L+]['$Z2QJZ!E,*6
M6))K=*7CLGR1^V=I?]3P.;I;#05#/]1SA=41]>RZU(I,C"G1R":%L61?4?A^ MGNPHX8\QQJ/1QNNW;M6"SR8RAS<#\XZP#;5R38C8[3/0CB?--!128%X#7,P? M-
C3K,- P!'DFW:PYJW,^0=9I945MFB!"'^A1F7+GN'T/QYTUWU8@0EYH"8\" M3/?SRR3=?W349!&K%(1"53?;[T^1Q]HK(S'O-#[VJ M"G8VJ -VXK./+_XR&^'=-,
(NU'"9RP$E&FFQ,CE,RE/F*7JUV_5TU(T8L);(/.932C$I;05_OST+[D)XIL) M-(+],"T!P7,9O1BE+=UV1\>@/S@JU[\KM7+TS\%?<5YMBM7@S$K5L,W9_&Q>
MOO/R_37237LJ.S-)=[\G89,N5J^&:':)@YDKG9#)M 3V#.Q@?=6X+BIN51RM MANJO#'>2', M"^$CG6/__4T2F15=1+_YA^9N7XY{)+@TN;LI#J=(KRIR/CB7
FFY1BLFL^04 MF:52]+.ASX;^D0S=]}E#+"AVL-.5]F2T+%$_=L8B=^!LC[,]WMH>;19'N]HF MX53_M[TK:V[<2-+/N[\"T;N.4,^0%"^=[9T(N0^/QG9W3\]NJV^*
(E488 M!XS.6E8[?FKP'Q?Q9PFM MUIXQFX%+]_@X5+B@+EZ!)F>Q?2SL]@X%CAOA"_DL[$(!^57@5\'#!6LLCNB8 M^A:2],)Z %CLBXM#S*GNSE)E&:!A+ +#-
C\#)F?9S=E?=GC.%2H._\T^A;,H MO5I[M7XXM5;T9U5\"&KJ,+UM7-Z-]MKBWK(Z1YB\?KH]?'.^N@X!J,.<]M5 MD.4J9K#N3=.G_SH8L=/BY]72]^6=U5(QS,
'8P2F,)$L7:"-R1L,6&%=@,-- M37LT=S65%MS8JZ)7Q;NK(D'#*)+R*>16[JXJ=*7P#'3TG MD'^0+%NHRD\J^C%M?'F]RH?SK5P?
Q2U=43+1SB/!IG$P/LA,,%^U#1_U'+5 M4AL1%2BM4.87U%%5##G<&<NIO RA2(@"R527,:"!C3(9<*U66Y&',ZG"H+? MQG:X2H]0A];&=XK7R7,V]HE1'
\72BSF]86%&L.)C]>[Y)>'3$CX" MMH\$"RFRO-95*U1?&R9+56D#TH541L'TH2':*]+D(7 N@LXT/_&C)!=++#A# M+I%,%R5;IB1%Q((Y_*&"L"SQ#>WB\ M%5*-
[H&5HT6M30@\,YL7S61VF]J.#RPQGXTDDU-ATHQ;[&@:G/&E:@UXEAH] M?$/B"5XJ/ U3F5/O&%8F$GZ',/6PHRBT)7W_W>MTN^L#,.U;LS:M-6O?MV;Y MUBS?
FG77UJR-=%=,8^G=L^LTIH&@1$17&SD>1A^)?2]T; M2]L90U9@!1;N@7 WQ UR.X\:T2DJ'@15E8,YCRQ#+I,_Z(XD1.)%_+I531PY
M^LLAH\%FZC4U@*D#*Y4)=#?4[K(1.!69A$P&BEB:5&[.>2 M6"]GX%F6F73@M$\B&NIO RA2(@"R527,:"!C3(9<*U66Y&',ZG"H+? MQG:X2H]0A];&=EGTN#PC0"7QKY M0?
HE%I]5;T\+QCIXK,E*]*USLC\25%?R?A'N@5)'SE'"\;?=C HYY6[O(,M MZI+ 5L6E)MU9,9<$35 A#7R$V56H;U5EH^PV_5RN)]!X[V**B8U&")Y'! M[3FTGN>E4
%=U24[BD5RC@A5XW/=) OO-I$9EA#Q -<5%S";",H-7C9"F>,8R M#<*ZK.X2V\3!R|&NAPI6>C7W:G[W]("W273G+BV53?@CQ;!)9A>;.17B,0M
M1K1>B;T2/Z#S'%Z010;7 M.!K+*N8L0RW;YA""YM;>B2HA:?"W4T*84!0 Q'.H2 K)!UK*%=.*: ()W1'-5F)9
M"+V,)8=GBN+\M0,>1,BO9J1020BU1TN*$FJZ;Z,DWU2U51'LM0M7/S!.H>;/ MR3DYK+Z9B"BF#S2T M/9+<,
<8P4_EE63GC"B3,6X+R1LS!H'D#TLPRD,1BGBM>$/"]G#=!6ZTZ,^F> MB8+@+I%4X[K7)'/EH+E8_!98Z'"%L]Y^^83__NV3+2UF(R2,%XF']#+&;OB\ M17;< C Z'-
ZP9)6LAOC @<*K4_BAF2S>1J.S&$-E5R(;?ATDQ\C@5A% NM$1%=WXA)]]5CIQW M,I']A:S25ADX.J/R-O%Y6^6^B6YK/;9H[FEV)I+H3XV"CLK_VKFNAE!?NQC6
MR&MG\W17B2(/TLN$-LV+,D8+C14R14KPI-8T6&-0-Q,P63!7[732SF5V034% M96+"=Z$]\F-LIRBWE"^TH;Y=C(B98L MPIH'=A[2^13+*<;5@EM4#\7%@ =
(32=5>T.J(2>BX1KQ:GW(3%VD[<:I9%>) MR,5MU<'#]+ICU%0.,YB4)\,903RN 0/,ZSD0A,XA4L,10F(-"7,>^KR1;)C M6/N2X45B[M=981:C)U96B*-
K=9&:E1'6G+X:FU^MJQM<*Z2X)@E8&=+9;ZX M_$EBH6FM:E4D-@*K/#8,A+4>&PZ2"%-%*PBN:XHMHFE&X^ @Z@=A:22?N%":
MP=M/_WO\KMT[@'''7B@LWK8\SB/)B0Z2@ T0Y;,S,A]+T&*E\&;@ZR-A)'>& MUVZ)4A$PW"%3;C8)OO+45Y[>M?+TP%>>^LI37WFZ8:0]Q/YC]%!T4?2OA('?>"-
]VB(CKNW MFF?/GE4M"&G]<.IP1Z7$+1@K)%.D.^?NF$K@H,:1G!?U;B,M*4Z"9^LZB>[M-(PT(*7U7$#!B*45GH.'BJ=]*N)]G2GD-IKY[K&$YT:&F?
]N9#:H*U>1&XA M0<(OF&;6L5*G^6HY3$+0[]>KF*&#(U@9FB@V9RY%Z)D>R<-M!2V;&:<.%R!CH3C._>[!5[-^8?FQ]^^>W-'R8 M#F(MSH[!)M1'FEP7?
XXJ,2<3_+#,EO8ZAP21%VU(86)5>(Y&940]6\1PB0?* M"OJ1H[Y5%'PBTK*X[TP>3AZ_HA2O '0H]2QTGWMG'3<+]QA(QK.EJ71 M=.'M%>9\);A#
[Z]/#9JT#WZWT37LCQZY?&OA5 IQ10F>;_H1S"'6Q]6:2$/,_M\# UG6%6+<'X(7&="D+QX;ZEETF+5XZKWY6%PX7A61GK->"R[1F\IL,Y4ALF
MK"8%N^*]80#19F\B,AJ*.4A$6%< M"\,_2%;<&KAXH6G9;GWA^OVAY\9]\#@%%.LTR @6(@%4LEE+TWQ=^*7X'> L[(P.66F
M6B'[U>32O>R=I);"@O\C#QM3V2I.RF/&V#UG-YPD/C7)*X%9DU93KLQ]T)9B M?[_FDEHP5(5%L*%3A019_EJ_\D)Z\-O;-T6'F[C3RX3@-^CL E*PZ!J3[>%
M20:P<2\3JGN3SMQ]|\.^H@KNUD8@0DHEV%X^R%%6XE.08Z45?"GS/!)\:@$Q M,=1MW@/V 9&K4^77\PPTV82'*4Z-NBTI8S.)$3,?'F$NJZ*0S--"G:_8HI%=
MJO/#X^IDW]L6_&=C>IEF2"1+$^^"G^0MPMV@>$(T*A5FN=Y"#42*PP3&8Z@6 M9[&@?<#EP; O%LWXH*!V.MZ&WW^MI*]*?*Y4R!F6>4PUU?+
(C&1QB1N)&FW\ MN1HI,YYVB-R[T(9DW\<2025FCZ@R:M@]PLY P.":K$U>X>&MM!O4UEFB]JY M'"3]-"Y2S)@@&4_+R(D;8\I9E>,\$Y+/+3^+/X6;&;%:K2;87$['.[
Y6;D MW.%R1E'F(!.[?'8W:O?]+0I#6"3O15Z8+1KV2Z[LH/;JJB>>]?6M]6&)D,Q M)V-4!33:,7*^W9;^,'O 1A;B'56SC;$F@W-
ZS06&P4)%*#ZF"&=5;FNPQBG(PRE.B3BSE JL!%S.X,I"LL*V01S\AP(4IH. M6$D&2EN]"XY71,!]$4N9("7\3$%?*_(7O)QB5E)'0D7M=Q0)&LDXDHI<7H!L M-/L1
1*9&79\5K&R(/'(3$.^%EW/Y8B9%9!& &,1LH9YX$9BE5'JH9.+2: M4,A5@PJW!F!%U&!!O^G@7 E=-!X$7JZU,66_='0VD&A.L$)%C37B&85_[5Y1
M"0UI_[1V])1N(0"&$2@*H)8VL7C,:M1=/DW.3$ M<):CF[C'US[PN]!I\WK%9$-%I\Z=38IU=2Q)L57#1MB),EA(:RD\-@C M587U:58-%\S@-
$2<3;6'$RG@$>=#AD8<@Y,-3.B?,,73 M:*[P>2EJK5U\U;"YM&YZ8(I]*>-
P:\L4]_5"^@ODV7_Y31M+!)XIH!>!3Y+$:BW2L2AL007Z'8JZCEUMG";CBJP[:^HY;HNX4R'MQ)C M56.GN]>=+C?)9;>:%"
[7.3>%1D+YB\6,*TW_**D]TS+6L<_T=VPU!'\#,[5' ML1B)F:#N_\Q Z8_$^+R MZ()PE4:HYFEO=1ZR#U V*/BT,I[I.LH@H:K&MR,4*1P]ESFN\3XFS85RV5J_
M!JO9,ISW5I&0JB%.TQ#S]&6&9?A4[H[:2*(^8!"S:I#+F].I6:S]AW>]AUA_\^I9S0DZ'.6!1I$GA7JE2##IH M"#@,+?+(P'1:"U0)%M=V]=N]!]?
X,VQBXV)>GC0[9P)NB1V MK2#^PS N"') M1U-!BKVQM0YDU5,:#)6^RB0E%!>,34%FF4+I>B>NV5QN8E[*15+955]P%B(M,.9:-98Y^%5H=$I>[(;JU4*US0^-
#5:&)TRY:64TZ|O[CY,OFEA\IX/D_LP MN0^37Q\F=X\]F=Y.9]"_\X.Q260@>]H]_9@RBD)'N3ONGZ! B:1.2+!]2/<-I M.CE%'+]BL1Z(0/>
M3F$]6EXV+K2;83\ETK,)]FBBVP2W02QCYL. ;YCX#/,VBI,ZI&8[?A9[<>HH M7L VA$QH23$%IQ\&'Q10PDF'SON#;HO2#YWU*7=85\LW. WE1*"G?XHPHJ>Y M3*
(T.[53MT;&;X# 1),U,@DT;L%7A%\]H7%KL%POTEK<*$2Y!MH_/,5,Y"DS M.)_:ENYUTOIA)_@-7G*-U!ZV>F*\?F?'ZP5K>^%TJ6^*WN^<4O#DU$$56",-
MW^D$G]9(W2G,=&Q'ZJ5"EFZ-7\,PY-AP%OR>"7(%C{(,H^VVHN>S*GVX_2#= M.S3Q7L9KUZ0R>'X!7B67SK6DX"(%<5/ (+ M#,"_I9@R=GO1?
MK=WQ*O\:CRQ50 !2?M7WX<9=M_^WX'AK70K"<5SH>V-RVT MW?>A;1_:]J'MQP]MWU.7K:_>RJOB&]IC4ZT:^3:!]N=_WBO!N@F1[=>]]D= M8-]?
(>PO>DTY@Z29VATU,,&@W^FI6FW37:BUBJ]$)E',:,<*];RE&@]UH1:5 MYQ =':=8:4#,?W@]\LW^R5QDOP!?#(@EL+/T YRQP\-K_O-%A^OH9V5SGB($V
MU).5@<5'H[V%-\5OV["9I"4X+M&5#-\8F] .C(CZ =75S'-YF"/V$#Z]95Q*PW=]>]9O;_V1WIW/0O\,3>IWN M\)%^]N-VD=5'3FV0_6X'UWVC_]NHAG=
_W<$]EZ;_U);F%CY)@_1>Q>ZD M8N\(>=<4;KU+Q^6LXF)[9;NQ])LKVS7F?^_^UO^YC9:7S MRCEM]@QN%A"ZORMPQP/T]M$>=']$;O=]]EZW M4UP5JQ5I,FE6I-
5AWY6PX#B6A%9/P=MC$R]1ON9Q,A6QI&8L,9O[NS!W\,]OK[@VUYU1Z<#KZ3TWDTDTDX4VWXF,&C#V08W-
TY]1[HZ1>$[QL7K;UE,U[H(_AD0ZV!MXCW9AIOW<$M#OH=ON#_LZVZ/>ZO?[!\$]R M37N=:3'[#]HTO$ -*8=;_)[(R!O#[*\T)DKN>9>V_SFB0MF?O;=
[>VQQN#;VWN3'3?@]OLS<<]KO#'O[5/1AL7_3V=L'O/)57 M@_;N^ON:P=&OK>"M$PQEGOI$<11Y[_3YR^;]4Z\)7C8OVWK*YF.AC^&=[FSM
M>.]T8Z;]'MYIOSY^=WBPORU%;P_^KX_>:.>\T(>^N(.?NJ5Q5G9$G M FJ9%]1/^],B%I>Y#X>^#-F\P^DUP9GZ9"?D3[R+^_B*DW2V2)X?P7?YD2[-
I[*F0C^#WMHWL]&,L1*QU^CY'R$ M?,\&;;WSDO7FN?SSO#N#+FWK7 3Q. M\D(@ YQV[-H(.1GI3T/U*?P!+YPPL;H42"5V)3/8CQE2T^$X4(0@0Q1)I
MYY"'CAY0B#-FI)/:E\3N;/-S^R;Z4=ZQ?$:R>\OL2TMW;8\+X^Q%4[WYK$=]TW'!XPN@B&,=&6L:1C'3YX M+K-7^L64,&2D!BQ*&.7S6"P.)[&\<@<0M>6/,B^BR4*_
EW3SA%YX0T)W\8G MYH>8(^"]DMJP6D$&-QJWQR):'W2&P[V#WD%ON-/K[@X.]GYPM_-S*>?P4K$9 M"K93;1]1:X8 MCUC?' 6].1K_N\?:C=*FGKY_Y5[.]%:IGE.
[V@&31-5Y-? M2Q#?"L!2T]G^7WQ9P% 9_RC!W ^ZK:!W<+!O#34,EOKW8RIPUZOO-]2W_WS4 M=_"HZML'";WZKIOZ#IZ/^G[++^KXMLPP#LC7EW6__
KH+CC;'5TF%3]Z=_ M(1+0Y470'Y#Z#KSZKIOZ#I^/^NY^0WV/$E#&N,'T_F)-[P(J#@QWW\DQ@VR M8- CY3WPRKMNRKOS?)3WX6VOT=\^Z6_?
^PYKI[^[&Z"_'TBY0",E*M@]'3+A M$9]A"_PHR+K;V=V%H7JH\,C]PAT4>'(?=Y1%(KY=E.,&T=$'%>EI9O@OU@SU MP0Y%>3"247(63,HLB?*I IO,IZ#BE(8?
R2"48!U"-%GP/VBB^B W*@K]W7M# M^^F\!+N72*E-!T]^YL;$CXILZB(X/OW5^.I2,YD<#0FYLG>P6#8PE"M8+#+
M%K:#IXBS>1GE,LC+T1]P.WPZWBB.Q"B*HV+!=Q9%D//#6O"VF7KOO!Q/ ZG$ MK L054VTGO2GGXE@=51M+LYD.TE#J2]_53$:?]*:NSIL#]Z0A0FCC ?A$-Z\
MG"55(UV+878[.Q& E,I =3N[??BDT?,!C+R!:8WHYIF,!0;;WX6S2*Y0=;GIH MHIA7E1!P9>/@E,#J5;2T6&^QD,82DP#?9RGM#BQKOY*J-G&:UL5#!.T&AZ(L MTC?
5+V"H^6.:?,[WB0D(=RCB2[']W[S:UFIRH\S-O6V3;@G\KR(=G^)+W=@$ M7{}BC=(XO*8?L+::CN)T?/X0T_(])7? /+SEC_*E)D+7%ZH%^FGD:(4XBVQY
ML=QE33S45%6R]W._OV3 W<>ZH:LRI*^I*QV3^O/1PELE.C@GX$#K>A "*"9 M&975%F;KVMAM)^VO[XAV(QPL;837;)XMV.+&I) MO<[1^QF;Z&
<,O9_A_0SO9SRYGZ$7?1"%__JAT]$468ROZ,1<+7U <;DY/CG MC_KH?F#]IVD&\H9K[A<>/*1;2-5=^L'*=.*3T9+"B^*W;=@F MTA)[/[@&?4G %GU[U6]N_Y.=
[K=^>7-T>M!IR%H5A++^';/3C#3B,Y"3X8V.)/#%O\7,3< M^FR@F9=D;&RB\8;-&[:--FRK)'T'7OMA\#&]X'J9/2J7&5ZW!!H[0];CA/2P_MD7,?

&=ZTR/#.TT>&?]P>I>'B;__YX_;TF,5_^S=02P,$% @8X]G67Y M-V%\'P$ AM,0 !$!N:W1R+3(P,C0P.3,P+GAS9.R]>7/L-I8G^O]\"CSW MBYGK>"G?
Q>6JLKNK)U*;K6E=I5I+>WHJ7G10)#+%,I+,(IG2S?KT@X.-X,Y, M B#S6A/395V)/ L @=G^9U_^9]?U@2]X"0-X^@OWWS\[L,W"$=^'(31ZB_? M/-Z?
S. /K]Z^^9__^M_^Y?\Y.4'GEU.VA\]C?KG&4H1/TG&6;G]Z_?WU]_2Y8AE$:DVU&V:7?^?'Z M/3HY$<3/$NS![]&YEV'TTZ1%?N@1=
MYH2@.W@M17>C__RC:9*A'^C?V8Z M -,//WY/Q\[+LB1\VF;X,D[6YWCI;4GVEV^VT=^W'@F7(0[H\!(,XU)X0/LS MG8\H_2G(DI-
LM\%I@>67IX1\%R>K]_3/[^!/P/G3R8?O3{[_*_ $?G"2]&4 M>^R=%/O?K>*?]^*/3&#MA<:'"P_2<2E(_H]D^73AP\?W__6S]=^'(31ZB_? M/-Z?
MJY>=/O_]>_CSDY=B^7CT6Y9TCZX8&QS6"TS_4!28_C'(BL*"7YXS_^H/QJV MR$M7;487DI(71]OUISK*GSZ\QU\R'*7A$\$G\!A.V*I.3SY]IU1(DURLI9<^ ML9?
I+POB;I.3E>=MJ@^*/Q1UK0RXF)Z//_[XXWOVUV_^];\AQ%9WN-{$28;X M(K^.?29@B_;PKQ,Y\"?PJY./G^B;^XX2^P9%M9]'P_B]'R;$7#<'";$6W:%"
MR%4#W'}HXEN{S'IQ3)N^0/G=GL _6OG6?NC[,:^LQ_>89"G\]Y5]=1D?IK/\ MB.&'_OJJ3_] 7?5/BNLK?M-/Y\(7V5N$KBV=_3OMM;[K#@0#:VZ?]39$>?KJ
M]^]C_A;PAX[^?A=_7>==EG;;REN: %X4Q1G[_Q*_G*S"::ES'!#?P=[PD]) M3/ #'3T$/SS>776=1.\5[TL'O=>WCA_5E,#:A,;T5/AY >D?D_)1?}))\#4 M_
F91!_P/^CQI%F)[$?$;SY+^_+SYCV>B\7J_$U\4LYL&:'>W%S?G%S?W%.?[A?7%^=SQ\NSD_GU_.;LXO[M7RXN'N[%/'0_US%!'V&"
[NG(8CE#DB32:2)!%'&J;Y,W:/)NO80.R#/.0JIB MWYDLOM0QK9\.FE;TKL#DV[=IWG>:[Q_H_WZ^N'FX7UPN;B_NY@]7]*\M4]SP M0L?T?
M]S>G/J:'&)0Z;Y_6)S]VR^+Z_.+N_N+?W^\>OC/GO-=\V+'A/]PT(3K?/[[M/_WYT\<__3/B_-XF?M!W/K__Y?)Z\6OO[UL]WS'-?SSLNZ;D$:/_-JTMT[I(M5EX4_H/)
[47!_7:]H)=O+P/5U&XI'9-E,U]/]V&61BM;F,2^B%,^0P?]FK+ M9/_XXP]_^.$'N +E;N03I+-!E \2C%"\1!HEK/-"DMG;S+=]T%[Z3(?S*GK! M:09?5AI&G[WD-YQY3P3?
8W^;4.'D9/=^NF-^_UB97Z#,YE6CC<((Y=113OYM M1EO=#E& (\]_I#23R"@6V:@ AYJ!SVGHQH2.:_[O=,QNW^JS]ZDCW0&>AA&
M;>R"Q]L4MT[Q>AWR;X1^,G1(8;_#4;XIMSW0,7E_KID\18Q]H05R;_/4,D_Y M,-XF>+FEWT#PJYNOS='4"A8\(_5B:\P&.& MJV"?$ 7RY_C.'@-
"2G/<^TS'3/YJ3*3VM31"9-T MWJ:I99KNL]C_[=1CIN5Z0S<^I@&?GH:_=4S+]Y5I871.&"&D4WJ;F%[?S_WV M*<5_WU+E+U[H_WPL?
SN5OW=,T!^J$Z0H($;B;6),^V(,^&1Z^F9^.,J;0>_D M3V^!,^.+X@'<)D:6A"#0L2"JSIQ!"X(S?5L.)KQV^@K8\YV.2:_Q\>SCP7N;
M9O.NO,)D'_)FQY37>8;V=>N]S;L1YX0^U7T?]IC=]D>ICZ/B;3YM>RSTJ39 MIWT5_+'JKCK8>_&V- Z_'^N3WOI$QW16G5%=-=^6WV;)FAL^#@$GLD:MH&2=K
M]C8_#P?8YFU4.U9%U;$UQ&_0;DH2),%O>/2O*THXROJ5PP5:CB8O^#$6^'% M-H,R&BC.8Y_W8@/4TD*$UP&?CE57]=L-6W52."2D0YIX?)M#0D"Y$M\V-R.7
MRK[/744^V<)LP L7?]^&+QZ!I_6MSS'/CB5:]5SN=ZG=\WE6+SZ%3#\KG@RW!\1*F)LKB9#<@:,9'3!]=/(0#L0DJ$ M-
_O,ZL)99,\X.=LF4*4V3U.%+JD*C8^%4/>\'+1S%]FUA6-V%YKZ?;'%P\04"(MB,@=1 LV/A5)WS M@W<<(0B2DKRM):MKZ3KTGD(29KL{3."5+ 8S@IY%<48?IZ]>;G,
(X<8[C^0N MH(&+[5"F':NQZK0?O!5I$B{BK*8&UIP.$!Q$9<7*8'?%JU5UZ MRV:&7_'B-1W$9\"N>\%7$>6-K^,T-6+N\RU8]G6./(-;*)20'G=U$5$7;T
M#]3\]FVQ[KU858WAO%2PV.+HK%E]AY'I6$XU[O>VFLA.!^G;LCBP;'*?M;#7 MNQT+H.HQKY9;OLVZY:3'[LD?1]}C#50]X+T2)-]6A=U5<>F%R7]X9$MMW7.<
MA"_LMBQMS+)U;8Q:QUJINKA[KA7@CY@ 8'/D(B!-AK>58SWIMMYC9)1BQPJJ M.K0/3\1]$,T+KBCQPPU-UZ])#"V\'KRZ5A\C$2RN_*K@U(D^IM_3G8])X([E+?
N& ME#IU)D3N_UK'A-?@4S051;UE.IJ?\/K?BMAD]\3W>;UC 53=N2T+H/%/@N7; M4AB$-K//UK_/JQU+H.K0+6/4_.X== _ T!:)30(1?:+T![S$AS?O\!*)'_5U
MH=]QA%'V/@C7[\4$SX U*=IWYZ3O"R?U>E?]+>A*8V?_DF#=<;(OHV&9", M_@S!O#@Z"7@'M@/E;*1C6^IX[871<*$+9.S(S%B"'EQ'PXJTSY1H MXF^?\(D:I -
E;J$T1')@C-.U]QW>)O$&_L,XOZ<[SE)I\1H&.#F)O"2)7_L, M.DD2]2X0/Q'_H-I_#-T8/S$>C']4SW=@]6IMG*20J3@9(+]F"3,\+JJ0._V M4?]43ZE=9"GO@;E$/9H3Z?I
X\,328O)W)^"4VIH9TL$"6!U%8\5_'8-EF(_- M,3%?@=0^-K;X37'==%?7V%E'??E.<P<=)'I,IS-*U?0_DT/21'TZ^ANH9;.SA@:*,\5;S.&%5W9N.4/E<3/&^Q6&
M]!VI0ZC:U'=@242[VD:(CZI[]3_@0.0)Y^IWCGV/=5L\)KJV/3-G[4W8OM) M8',<#\C3:A^6@PFZU[)73M]E?P!1NU8OO:7=TFM:MSU: M>G#
<6/"M!Y>D9YS12VAW7.0P@P^\YD]#F!YOI4[99*9Z@#IPS77 MBTA^Y*I&> 7;Q;7WA'N43T'MAOX:5*#\>/+QTG'/S+MZ]@=)N[22Y\8RVUZ MLO*\#6=+@/!
[[TN8GC=54]DZCPH%F(?WF&0I_;(I6QJ> E8E:3A8<[V'^*L M.KR9@:%M7PGT"$FQV>50)=DN.)OE:_J3>!I8-$K_O5@9]$%%/#DG\PHW9SX521"':/F\:&=P4
M^]^MXI?W 0[YN-(?\N&D__BO"WJ$9SMZA"4XI7?C-//(_PDW9W%07AD=#X^V M%O(<%3#72B4Q=(SOG^,D QM;,^.8E?I -Y53*M-O35_R<,*C#8K*4N#)=;#4
M\A2%SW3545LF6$1W8,(F?"W>Q%$B_TG-^I#KTC VYN@[7>:0])1LQ,63[=1G ML*8O4_)&E.6M^?C05BBG[SUZRPDWG:NVC MHPG.KNYT4U6)9" M4/JIV?
#D>"N@IDRH=4IVG#.'4!I-9;\2;=RGPK,TS[%FFY0KOGY$9>^3[PT M94YRV\XNDW@C_U0I*/?XBA;@QM,+_@/WI=YEB7ATY9-Q$/,DR<:OY6A=,?
VXU'R^5:+YFOHY6_T*O5PU_-N7/\G0WIR.>L.0C;Q/2^SC= M<#+XFIO]#WO3&-'*;HPVY&/>:5[M1V0"?HS"58?*+.J;V"6B[5*^#P6S:J9)
MIJE(_Y6K1__O?[=)'%!I%LD]3EY"']<8$XV/F3XY$WRI9[LU?R8-3XZV/K3] M-.7N%"__S0/]*:7W.S!$6D^F?:F.]SE >/D.;[;4BH1SXYRM96Y$L].DV0'? M^:+U3?DF?
O'VV8"UYR>P_\BX9K^]IOCT:.+G>_EB>1U'JVNP8RLH+5V'Q;Y4 M3+M#2'A-AW+7O'9*3XQW-,/E1[EA%LD=5,*W7!*;GQ]OP7NP?-EV 6$B>GG+
MM[]6PZ_'BX;7Q1T.UT_;)!6)!]*-6+= FAX=,0@I4*1^C9/?KB)ZR/LXY;=E M4=G6M&;ZO&EXH!\WRR1FR5GJ]BDN++*F\&S]2FR 1N6PJ=ZUN)@ZF-?Y4L7S1
M7==FV?BXTYC.&8: !KFB0_GEW_"N,8I3?FX:00^MN/.2%W?VB7_4O#6A)(,% MO4UZ&<,G9-?)CAC#'@1&O8F*NDUN0UZEZ18WS573TQ:]@, \DNC<_ UQ0Q>
MC5WWNGQ_S2].P!*]6&](O,-87 @;'VB4%_@G/!CU=1^ \<<(-_CSNS25YC M?HSQ&JL]^',/WA><7GRA MFT6;D3O*C#8RR4<\!O/
MQ\V?:N]WQTN"C1.V>C(5B*J)2+4Z@_>A,'Z$[G2G$-^8-ZE?2D+-.Z.I\I"P MS,@=NQF(2T*;*[OY>4?F#H-":3 BJW\?[\)0+&R^[HI7-ST^F@(77A+1 RRE
M%PEY[PQ:!NGKGOTO+/7BA00N/0H' 2G3*N-RV,"?sWK6/T9T21.X, M&RTU3XTW@>C_U0I*/?XBA;@QM,+_@/WI=YEB7ATY9-Q$/,DR<:OY6A=,?
MNI._XP&04X_0?]*+,<89'?#M!E9AQPUS,-GQUG4I2-=RVM0^:GC5,8M)Y&4T M&RTU3XTW@-Q5@H-Z3TI[VFC/ET?
TX69TCZ'&N=B,M;WH'%,+,6Q.$NU\/.E^WG+&2ZM@S0^/-MDW.(/L>.8V MHX*=[AY3N!VK&,$!A8)"YL$S"$FO0;=D>O&-PT?0KE[57W7S6=/\\.C#7;YD(8EW_I-
MM+Q@NLBFQ(G7%,+]D%XT-G0SO=\^99C>QK/3&#KV0F8)G>_FX1]&T+AAVW L MG(G"+!P\Q)7+7KAVL]16GIANKH\?)ABZ@7B]1Y4G2;2U*ZI
MRI_'WUOA*,AVL&]BB5^.'0(VM\9(TU)_.W:\<)A(Q1.FM98A M/(QX3:&QSO=&5^D>0Z_]"'SH.OIZ=W:KSMKBK3U>G$K8&.SPM@^]X>GO'!!Q M%$L?
01\HCN;G)Y#I6V]7'SAR5 \16Q-;QPB([3V$3Y>?T *K\4O#+L,H3.EF"F6_^U7QM;PYWG57 M03??>F%P%8F"(\T-VG3A[7YQ,BE9^>=+7_!@[]Z0#*$WC5 1KL]5?T?
3T%(J1 M;Y/0[_+3-SX^9C@L#S,V1[JT9\9<*AC R:AYHQ6]"6.X]53K\^9X@0@OVBX] ML:8O/9_9#ZWJM+TQWDVYZ#=I_8SKGW7JPK[#'KE(P>E#%T4AFXN>
[']{(CGZ. M$B"OPHW)"0>3E,8'3)U+V=-QTOC MY8EODRC,>-GE9?@%?FJ_"+:\,*4ZG%8=FI\WG4?JK\Z@E :*:B /\^KJ^K8Y MJM7RI)C?]#+,6FQ [8$)N!WY++5PD!
[/0_IZM 3H)=E&?$B;I9+YY2 MZ(SCXVH5>L^?)C 5YS@)7]Z+F3WC?C!J,L[C[5.VW!+9/J7Y M$VI^Q7'M<_/NU/--TEDI1+?4U.-
+NJ4YU"S%*66C++6%T9.M-30&ELB4_7/ MCO=)RZ EF^9RR+GIJ7'-L\.2KJ>=::UUV7S!VNK8!SJW/P7SYYRR[%5D1\3U M'V*P]=/%\G(+YN1=O/,
(\HCH68ML;4\A"YE7KBVV69EX$ MO:^ZTX^KKU@"AVB\,79C0W2].IY1(7 &'V)6EDHO7ZV>_"8[8T\](I0>(FI M"1X\^5)>$D^>YD8<"KU1DP/H)I[A-!-
K'E^>OA/#J=M^,-LP0-D!AI+ M5%PL'U/1?(SM=/7A\ZKF-CA8VICX/MZG:K#CC8DE$_?.M3G=U1-H*\6WR"$ M>%6L.:O9MD17Y!T#NX ODOV&?
J&P5JEIMHDY#$%S)[4#R9G&VO6?;NF@K[U" M&$J5DS8?O_U>\;N\=+G)OL&_F1ZNU3I6I!0 ?$@V*,*V.6B7.6QXFT^@(#3 M#&.&Z.;)MF]>??9OY^-
C'MU0;=R.P55X9D1C/:73SRY#'7E=Y><,+^>;.#IC MO>(XEI(>!2N:W29RGM:W7K>DX*C!7T>^PS^YM^W7D(%([L[O{FJNK7<]1.IX M84?1X>&Z(]>[^ISC8C*)
(8H#MA_4FP]MCXYZ.)2:0+(SNA9HRRTF7^/C[K,B&E9;_K?O013;VS2SOLR/4?P$>9E@ M"[(+! !=1Y)O>=EB-VJ]?;XCGY@LF55#$[F/23,J?.,+#I")E2>7 M?
AW=)O:>%$:\&K%3'2K0Z_.J6AYT"U+#^H"V%:HV/37:V.81U#H4O\('W6(P M[DMEQ%1P68--MY;Y&J!Q_]'63KWY^5$][CB!(;[U-@TX@>W/CI?UR=I[0[\B
M_QF.2X"-6$0VK"(;G$RG 3V'27"?M>;PMCPXOI5QNM.LOT]_@:/SS'6^Q8-_!*YW5' M?U&I(&GY2O=XW6(8G3L^2H'NKH!Y_4NF/<'=G=)
EG*CM%KA#Z9E.HJC@@<* M+[';[.Y^R31"E!RCFH^MYH$QX"O.Z(^+Y"%^;<8)]3XY!7"@INR@OOA '>^/ M7*#34?U:>LAX5F)]8M+]UH<6D7]C^93W8Z_/4-
R;BF$]YBOZ>:_H9.O-'7BS MN(=8;@&0H*!C\M9^IP=2&CU#A=Z="D=A1RI*Y?%)I&6HTA.(Y,!:.K.X>KPX M16NLR_G?
Z]61;>#%DL>S/<(:#?!62P!)&J8^;T!%=UW9?ZH=:F@ P?$<.EIS M:QU-7_C&6")NCK>OLK_V:)E]"-7Q\I3K.SSFY\#IKB+W"S."DV-;;+S;?8< M)!:VI"G3V3B?
$0'1Z(SQ4^6<^0,+647.A;XS3>]8:2'&VJ]HAT M'1/5\H(CDQKLR3"CPPP5AE4#;;]W3=^QX3M<;%AVVMW]{TSI+?U/R,YZ]861 M'8VLQR6@R30CX<=<\Z#A!!6J-
6G)6V)]'&\)'^Y^A%C9B)^@*1WX%J:,U[MW[M=4=C+OCN/GYZ>@BS"HQ![2.C)K"P;/'B1IR=T:OFCG[![+AI253I?M<5?#A4 M*:.E@]<5'/T)Y6,TQIH;WEA]
0V.O)7449/IY#:!?P&)__$FS!U)+9U MOS\^5+% A7J.28"3M)>OKM^[X]NW6G3PUS![KN0+I<6$H,287J0@%=MV(CN\ M')_1EW3?\
B_4%W2WY5MZ/9GCVZ>&X8>FH!"(6[>4+O)H6YX+0R79YK(:,V. MOY9WQE]-?)\^,.GP=,=>9Z#ZK<>>-78C)A/)'&DJ6'M/PUZOF#;?<.+3=>:M
M,'>0,8BD6XAR/+S&VD)D_L=:^VPO]8#/[Z?;"%P1\,Z?![D(0>$9[, \9] M[]=.CW-CM{/GP[I$:C>FA+L>^NGW?R\X:&F.RF+!VE5\. AA;WB<0--;R%? M+\6JN4?=P.]-
PWA"00K(-*?>KCM[K?'9\4+;.1:N(1]PJ?;SFMM8>^N&?4@8 M![]1WL)%5)NY(_)41?,A*)6+H\8=<@@YPYI)"$RZC!OOU:P)?)T>_5\>[[" M MZ]HC/U:&*O^]%KU-
"'K'$9K1# ^NG26|+ZIBB+H24Q76DVV.&R]:?V?VKM0 MFF0QZKD5!]&7[#3TYXZ&)?7/CPD27=?JE,=F#/1,;2,TJ6\[S<[I&0$I(+\^ MA_YS^7,47VL-=]TAHM/(^]D(*
[%@KO3) *I_<=SLDKR,_HS>)E:X,W&BZZT1 MO0#4SMUBCI;!0?S_[W&V3;-XC1..I@$?&56 _O^@&9?]$$I3<*%R/PR$)*K> MF?
[.U%Y4HH"\J>U)3&FIQ$%W]S.$:=D60\LLV .TTYDDIF_)<49%H/:"MYCA@"7 KR.6-DYW*HZ[W1>SQ^]@%KRGJ4F. HL- W;7>^U(9L, U[Z< .T5WK6?;&^,"
MEPJ/8.\6F1TO36@)2D1C:OBUV,'=[TTAV0ONG?M&97N_;AJ !_^6>(@5SC@\NSK==^7RC0J;$1]3)^* M&OGH!. Q
^XOOLA6U!/Y;S].TS/JS3,L("X=LR!+Y74:@@*)M6MVVV8U:* M[F6YF3?:FL.0?2O;35>OF\ND%E'Q4QSA9=B93EUZ>KQ19C),-MA7!55S.L MGB\[,M8>$@]<-_>
[]5-,:HRTXM]==,EI2-*M>7#<^]J"E=]6/E5\D.@H8M@;@^;X[K1= .E>Y&Y+<0A<" ^58?MV!2#W_-E6X@UBZC^2MCTU&@+L-R/H>.T:'Q\
M1'\Y+WO>S[CN>FN\BU>I,KA8XJ\S= V MG6P,EM0>/K36YR>PCQ?.118FS9$F^N_.:@X#23.ETMVF(K(8#-.;,.#X9?> M0BJ.S'QMVMA*#YEV50NPC/9
>\U3EKKWM'<4ZNXMUNM]TYX?F=>KC+<^W8=Z MO#4FY$U?>!YU_6]WPPVAZ+AN7"+NTEN\7R/EQ%X3+T85QX"@_$E"'"O MCYD6]>B#)BA.K-
JZ@\)D6JC'=+NEE\,UO56RHR+M_"3-T]Y*C69K[+_^6:>& MS&?O2[C>KAOO:\6_3S8C[']G3NY7M*R](N X95!^W743]=Y^0 MU(&4QXOIM-T=F\
(ZK>\8!YN#C"2<7&Z3*(2*4FD#-UO.7:^,N%5MZ%$/6ZI' M($WODL2O5Q'LJ/Q ZB@7Z?GV>"71I7RQ]^YF>IG+%I1R MJ=[$$:0]8-Z(*X%+8Z@_B^/?
PG3'#ZI^N4O(=U1] G2WIAK/QHC TCWP80> M/96^?VWL?OG&=00,?S#T)+T."=F)FKFF5FGMSY]'"=YX8=_*<]3R&>_SNAV0
MF7;6W6@S_=YWVAKD,B0X:.,6UZJ:U!7TU+A;Q]SGV:A=\(D-#X^WF<11+"U# M'I5]H_YGJ,%([8GQ[G[3[]0F^M&&A\=_X#E1PO] MO=CO0!.O!)*1&G
MO7=ZF+2B5_]?4D)[91K7V4\]71[R\YBU)-?R<]'2G_Z6U"UIO DYWYSN\ M"N$CC[*&R%/M8Z;CL)?_ZY;>0-:>C[<9@*6UQ5R;GIU LD-G]XBTJ7U$OXS' MH?
2=KJR+-4Y6=-/Y.8E?LV=A]C4NL/JGCR$6W1@E,!:;[N0P7KI<'.'=9R_Y M#6?0-J =LKWAX=&$_Q6#XXR>-"]TG%>XV,%ELU8*,H4-& M?C\,IL[WQK>4>6;Z-
5Q4/[9N'6UOF'8A\%.36IW:!;H#$:;CE8FM';ZV'Z, M)_3<@6_XA6&_UAH7<.;TZ8XWB/Q4ND6@E?:,>,>\Z"VF1S(["/<=#T|@W]"L
MQ::.1R!JJ__(%-5I9"K"W:XUKE/W{&3]9?-ZUF)U:]-EH>_K(X(&B3]M.^_U M,UU0T%4GI1<;5B,*]P%M-JO5X<4)0,IW U=-K_:? G5L-A^)#EGJ]'55PW62
M6^YL(<@SK;/)BA'Z$ZP=ZMC0>[PXE2*$UC58]ZCAE:CP/G5#M_W*T?^]$5>. MP(G8)ZK2\9+IYD/]PZIU70YX2(]F/X!)\]LZS\'ATLC4%3SPR(L)H^EQJ+65G7.[
U8;WMC1'S="'+N0F$H+/2.L.)?6EK7(++/&T[7 MN[#D.) Y .32K;JV@WOKXU;._\]>M%UZPB\E6[;VN(#L\?94[GI=WVOCXU,R M:CH#46VO..[ID1==7-+?
U*WWIB='W&0&MJMJW(J&TAUO2' B#EYHHGI.-R5] M4[8W;FAY8R(^B;;V!'5/CB;V0*J=7:Y+*R0+.%A]<\X>Z[/.WUJJN*+7] M4WG.XJ"V2DO_\Q3JRMMS\]?
49$N3);_Z4@TVNA6H>VG\ ^^F$=.B\,AXUUD- MGBCO_L>QBNC^D0+V \=_5G=Q=3.OLD/,T'8%/45ID-OG.&KV&E8>&=\)P7)M
M>X7@6U^9R&%6J2+9P\.NOS6.;J?;-(SHU0Q,(F8I?6S0H.9!P[>BA]?XX3G> MIG1('E[I/.\>Z.-
XC_8Y^Q$8]6Y4:21_W5%6W/"2J"4\82;3RYNI%NH\5#Y:>R"^SIMT$(G))/:4P.HY:B6_;_J M_YX)/IUD[%17+99:?%LE4R@8^R@ V116\-42]MH4\EVNTKG_;*&,)9!ZJ:!
M-#=!^!(WGRZ%OT_$CLH1;]M[#+6_-)XR+9F&=/7C<"62Q!P[%]FWT3(-V\(E;0XF"N/CNCB*&=\L#6C=D>^:AJ= M'[U>'K]B>SB2>M===Q JK,8.:4
(MLFG"]+^F[40.R^NMJ$5>!-6@IVFYU4&M*;@7@2F 5+2'7BK/C5=?:,137M!>W^C[8[37;K>],Y@;[:5!W2@;RZ)Y419TYK9RY/%DQM;6I3Y/MBJ_)SRF?4@E50&=:
[%QM>9KM;\S[OQRD[1?!^+* MLZ:3_D4S%[JI-%YBJI"O5XU+'$A;I'G]1-$PXONIP%S #DG,:KQ!/&5K,; MR039R7G\;N+,KM-/9S"!&MQR*[H]BVT[7A\?
WJ5N$@\A,X7]K\,U6GUP])U M^B5\R73^Z",*_6'E6M_8PIWUK;X M7^4QI]Z+.^R1BQ0L)T!/;NK[EOI)N.'W1WGZU]3Z#Z0*8+%WI$D!?*N.[FF68I=[U MVV4/[4W&-
!B^PL>![*QM1._LPNM8-T$M3T_(!7@9YI#?G_\EW8"4\PPVC^? MR#AZ!"M:.HV2]H2BO_(:WKR3M+]C&I"DIG4;5"M5
M0JAI,89Z5"H=HP!P6OLU6U)3OE/!E:H,B0&4'-;:[!V"]&)V8U7Z.)3%J/ ML*$S\ !ZL0IX[6\C3E.O!\;#:L4)W=/!WNYN>%G_[1N27E]4>]YZ;PKU;XT MA0HK,!OZ
_OTK2$[B.HT$KL%3).H*^R3X5UZPW3^K%8[U:.*O>UQ6X?#0ZQY M0BA;+\DB:IWT.0DZ7AUM230T%U4@9;WCVP<0&M\!<;KC<%T FM'6!Z'Q^3'1
MP/MN._*F<4.M#]9/,:BXK6CZ60RRL,>!M8=WH@8($/]*L!;U7V4?5\=?WU] MO7'^W[M[SO=C^_G*]!R=WJ3&YR>9Y]*MCP MSE!
MKGF1VZ<[&2&A,KY:':F[TEA9,B32%4Q-/HS2X_5"0ROH"]K0G^*5G_Y M!D8*OSZ^OH=4QKT_?3AP_?O MX<_O,VH0X6N@^LV_*FKHKT /,8+__[^\SSE/4P
M@0M#3(NDAQ)%\B4*LZ2)(W>2>+?HC!"2LD]9TI"6 [:]O*\OR$?#E!"0 K] ME1.SONJ&R4Y/9O5-+(L,7H,QR\\L,UW]B'S(#D@+PH0D3Q0 MJ#$Y0@U)C7**/-
+IH[]R#L/7@#[:VE(R]\+.@P @$&_I6>Z1_Q-N M &]IR/KD5)$@.T.<,**4$9 ^#H7(J+I4H^ UL-*L+V:
(N#-5JG&"4XTWI(96*+\&C%#ZD[/7]2D_O]&3"P58#6K]%L9L[\R9@BX M(<;._^BE:RF:!#:VU.I*G7B7%5)=#;"%]+8$0B$F!M" >72F*+1LIG;$8JJ]W M?
$AY:,8(<4!Q@@071X>$42W)9!14 MD:0X31=133H(7G#S%^0?'W3)PI1;EK2C@DT/G"VU8L=LQ:*6OP0*]&=QZ M1)W2C*U$MNK
8,E4G1+:\$*E8]"4U"B)!*UCD#^+]7E<-U-2B1EZ@$=LZU)V M3,K(X)"5I\IEQ2*#Y88%_9^.12%IK"H-)$'T5TG2NL$E*K2,3(J@97W\A\I, M"N*Z&&WFQ>!=@L(7?

*$YW0M6\8:#70A%% ;-LENB5T_WN"'211HK2X5SH(.@=_M@0H%F|H+|QO2+6WZ|P=D'L#C/@B|O(_? 6ZMSH5N*E3JS]!)KKS+++"8)911 M4?EX>%F<)@-#01Q)DE\OZ(K>)'@=;MA= A@@$4+Z=H0AGVMTCBJ,3$ -E M6FG8]/4OSC:CAP1!Q"FB=X+FMT>CC6X$MJODR!J\PS[D5:E.40#8.H_]4*0) M<-0/F?$PS[(D?-JR#^LAOO7@B6'7L,L=X3>,K^%:Z8G.S%. MEG%RDM*O&Z7.=C'GHZ)LH")?M*2,T7QQ=D5W.LX;<>8S1-G##D %F"%=!)3% MB OQU8U2T;HM#9678_W $(3L>W+F(#W=J1]_">EE*/&?=RPA##(6#7F'%6'N M 9W_QW%J5_'M5A6C=P!*V/XA[8>GF&XON+R84GL[GD"M1;Z K>6G,JFLX:]# M=WEZPP;VQ-BA"K\L&5N1D/_KN?V\I[2LI-XA?3WYW C^\|>12RPPZH+,.SK M("^0)$\W7UZV+S*6L#57]@L5Q1K.M:#%N6Z2D8LB0E8(8W7,>M=%#5G5HR6IO]H>*X9 MHX, ^'9'T%<,+DE& Z P)9:SGCZE4E'KPF?]BV[B5#8UXV2F'/\M08^&(,-H*G-9.U!|)131/J84E)BA/S MK!1X';>:I(>&*.?C-/:3Y]D6\CSH* AH$I9B.#AO5,]!+B:4P$@(5HBG,SC* M%[6HN?*0%S)G*#G;N@%*I< X622B;<)0IZZ@QR9*D+3L\C2E!1E+ =%6$%_J M*'[#;0)*\823=)+E8$8!-0D8%65WO4XJL.760', MM7!_@B|(_S>/"F?/'F3:ZB^YNFA8'A5R= -2QJPXYTV)6723H_,,R^G(2<-) M{C-X9Y0"4Q[^/4U"'^B|R\GD"%OH]-6.? GM"[D#[#F%M/?C"H?YT5XW$+ABO_M54))SNWXM)>%Z:01AEQTB[SZD[OFG=Q="^>C9LTO5(IZ:/1IO%^.+!09ZR9\ MN$:UM|XQ-*M>!F1_ Z-7'DG4_=UFD#IBX,F6/K*+Y;7<;2ZAI =K^K[!9- MP-T8\3IPJ@C(HF6<("!\Y.J)2=A\"70! I\3Q@AI*K-T-7:HN2MGY0G4)+RF M"VHW?'>GE! C-6%Y24E4-_OU,)G+M0)2=OL>1TAI43GUB^0.$+X'W/X9/:TP M "HX&4U'>5L:EAR@EQ1:5 T/\$B+E!MPSFX9QG4B8Z@CVJ6%ZZ0$S6 M40U+]]1(@CJRO.P8%"%U.BR6JL#L&'0H,5Z-\V%],U-]V'Z-D]\8_+2/19M* M0"]/7H8M-*!Z$D8G&T[W"+41]TU1GB&@#>E9@K!"N)09)BHPG$DR1XOI5#*5IBWILF_LTSUO#3*. M_+5@"^*(NHL)H9=X2"HSAI ACS_T5Z".!'D')?Y&U2/3T:P*&JIP(41>CPE8 M@S/6?{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{MSJ.ND.8U:O<%J(N&58P<."QEWW"_J(UQIM MZ1>A.O*E'2/_?@?<'IQ1=J',5)0+^V9,<*80'P"R"48T+8C8XC90P!$F/(-MS)=!;ICA"F#CJ)'#0=!0AE(\CL:G**M^NZ:88JQ7.I<++)3+)<=./,]$FZ&B M*$C*8O7;J4'KEOW/V/6+]XY@X!Z^GVQO8"*UH@.ZG"/ZAH(S0_G@O-VD8#@; M$E(:C8?2:/ Z!'Y[OI)&0[!UD\SA;#1*V^[@->)B;RZ[XD$T,0Q:VXI'J:V. M5KYUI3K""YQ2I,(:&ZMK^W[[Q%IV+9;7A>Z/RR7XJS:>CXU8$)(-&,%$,>*+ MF;%"*?"RBUOD2U?I:M-TO"[JR%D@QL-ZDSH`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|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{(^/+S%"'L; !4'HJD P,TD\2KQUC;O>G,J0 1" M7!)O-0S=2)%"0&NR0A.7TJJ^68523P4)+6U5AE]\2Z6Y>%M/G&?T5O6D++FC# M(<2/3EM25E34M"K2O$.-FPOJ69QL(+^QA PZ_/:F"%/C+,.\@?=3' 7VW=HF M-2)E94J@ILYN=!=8YB7Q+JY@./2H-Q-. -[G51:>#<6I69Q=B3XY0&<<1_(O MA[8;NBSIQ6C.N]C#E2=.=I=A%*;4+OHYC@->CG?'6W8.NA9+JF@%9(]0&3&_MBC*#|>0J,>)]ZB0#ZW'O(&#HFAZY]<+(@*A*=@[7B@F'%6HP;P'G@+S[F42E5 M.'%\NLG/4Q%&0!G4$[1E5P"[B$Q-T-/YIEG64>&& U[X;'@8D4:P]H;I=CN<&WJ+L=N%8%E ML%CRRK(D](W4SG&,MPV0RVODCD41Z>CQN)-'%L8Q99SYNZAAD ,<#$7: JR* M2O0MX?%MUZXCRX]'SFQAA6V*531)+D,2]@8+\5?MM1@>PD) MZWQ"67IK#]5K:CW474Q3,1#G5DI6.@N%2+WL3@"O|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{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}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|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|V\1#GOI]L<7!&_P!=A!^2T"/B[$Q-%'IS\L@7I%$&#! 6'(Y--5+42I)& MC+:T.5++;]O?)6VJ&F=1? [EAJQ?]_"1>9%Y)4-"XPI M>]H@1%.TB+-NM;*[H-8H!UPCH+T/A+B/!&@OP;.`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|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}DD .F["VO'&>DU*$ZZH8X>(^Z3,9X7K((URW;B)E M-LKE,H1]X(0M&:MN2D7N@Q<$TY&,,6IGNQ-(/QS*F!9HK>Q*4G!<$7 M2U?(R\,E+^-@N-;@? DMW:VCPPH'+H]4U_(MUVEDLZ?KFL/##MU5%'S$&O)?/ M2;P\@6^(,SE:/64 0;! M,K"YY3KZ@A5PZ+2992-/92W6[DN[6JH%_92S8H*

*MRTOU@I7I$P"MD3+D0)18A*^RI!LIJZ6%2BONP"/3K5S_-ZJ.RFNF-]HH[W.A M4I(-(.DJ6C,4X:I)2>DR*?3GZ&[/,4/:B%BN:87R!.'-V5U\H7?E:(5OO/4P MW %!#TF"""A.70,RAO!PW$FV_8F^@#D%)E&3GH 6%.- MC*65'M N1K.C@#E91'^OX4:I8#(KA[)5OK+E1G!V-24%)FYG&"(D8?\=*1 MXU*/%#53A!&CC#AI@1= [7)I55F>ON;/N15ETSK6I0R.RMYH,5\KM.= ML]E9;U\#W=E5WAG@R2KJB+<.=M619G)#1*8T.LU9X?3MX4N@I0SC>!4D4|%- MBQ_K[554U D^BK&X@*RI)2NW^?FU+MQ*Q8 M//&U#ED!*LW"N+F#3AME^*HUT78&,.^T/G53J3SN@.,UV7;&4U1]6QY+\/%< MT[V9\!#RX.I0(*7"T58S2 U(3IP+5>X9BV3E16=0#N<{7KM);O%\CY<1>$R M|&%Y\|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|\S_X^C5I)TZ^2#/>G-X^^J27%-FOM]JFKX#+@C:NRA&:&Y= M9W847)#P.B1DQ[#AUALO,E D3VDB1E2 WS&R1Z$%:5' S=%L2I.2E95KY.4: MV36I;A.||<*@/GXH\)H,F!F"#>L&K&*%@18KM-U@T;:RI*BGBHG.2S%1R<7- M.K6H<*5G2D_%[0+E\:7[? H>>+*7@7-$9\W.%2VM%[O?L4W-I4TC-.Y>VRX. MC-I4N(ETW>>;,:&\72VRY#@Y,S+|\&I@HRF1'_$Q_&M=;^^<=V(M4BO72D!9OA.DOW7@S(>O1^QBEV']>^0_Z2YT03<Q0S%E9H314 5DI31 MN47\"Y.ZD/"4[^AS^&62GD#M%6;T ;[:DE*W!0.)P#J^NX"F@4.J&^]=N84T MD3CVNY,4V$D,8L5E=CSCQSW$"KT0:M%8*1J3_Q=,@LLX 7PT\,@.\@_G (GQ M4GC^2VULW72QM:DP*>LZ0UIQ'^,P0\"#8,<^0O8(XW.,NI8#.U/1,<__8CE7 MMX!5\9!X40INQ3A*3W?Z7P84B,BD+O7Q\G\"69;_;]W.A9NP=W@5@NT094-Q M9(1)G!.TCB-C0@,RAO <4>WR?]T^>\G:_$V"ZG98,"_9;&]DU&9B1(7E>@Y M0K,SI$<9N:ZJCSNDWHI9>1WGQ]V[\F=$6Z+YJY<$@UO,%7!1L=Y'3]5>4+HD M$,?0'U1-DD <|SWI'\=:1JUF@Y.];-VZG[4\@WW8HV3%34S?T[BU^Q9A <, MG!R2+N*$;<>"#"M$QM3E +2\QLIE \[*VS,:+?&JP@:8'0BR$_6$$6YM8.HOA M?XXCO/OL);_A[';!0:.,$D81K1E)M 2:QZ$#T<7GU! CYZQZZE<,Q0'TPO5" M%\D*R| (3=@.DBVV69AXKZ(OC^HW$8P0A[GO--F4Q3G/-"6IQV(#=>/ZR M;4K"Y12L9}Y:'2)2&W!1"O!X7R0QFC&O"_^4>NM9]LB1RRV4-BC07F8G&>_HD2- GR9M]%B,0A%=[" 5$0EP4I M8;[*,2H;N(NZX7D0P[-H&Q[7C5#'&K'R17+XR-G>@*A%NXXC5N7*]X'Y-GN. M$^@9-;" (C)+E5;PS>0QYBK3+H\6@AJ2@W#U73FR?.54'&'0^QD%ZF<1KV;QZ ML=34'-Y<;2-8')TJ1-U<&%W>+5U2ABUE?P:TCP^&L H!CKHXQ%) M7Q,9XT1G2"CC*(&- >UHNXT3+[AG<8T;Z;RC90@*3HWXMAI4J9^()Y0!<1<|3 M6BL&U@M+ZS<)ONT^1@%.Z)T<3L\7**:M]P'"37Q04+RXH8CS+*3"T+-L"S((M< IVK5)>/W";C+2'VA>TE8[*VRSG/VLWL^_E6*$- -8TP(FT#N80]D_W^ZQ^/ M?$45'&CSH@.-5>S?MA1.:"V%Z!46IO0_Y(A>]!'-3Z&O?T0K:=6M#EU6C5F' MUP'#IO Z9NBISVL^$,Y,=5U"2.UVS9SH*'M3'P|''' MW6*)W^KLTI9[R_#8F6*,]+9@5'U9.HQGE:=3:[\"4X&Y%R/|@>ZR05\8KR M$K%NEOV, (VH^$D!7#]9AQ)+PX.8I2AR&?R6" 3-5O0*+HU2-5+4J4I=5<,Z. MO3R#=[$L9@JG>;KP< R&L) (7@,*R,9BE-1PJR-1/-:O?]>C,,F2 *L:D[*R M7?GQQZ5EL9//? E^ZB[I>A5>>H] ""JO)BEY?(9+G/.@OTZ-4D!1U4VCK&GD& M8VL?D\:BD@TE^",JJZ4]"FA+%@Q5?GH-O3AEKIL,G+9$Y-5%W>UX U2RD,.OP MQ7:3UC7W!>LUKRPU6_XLUX)9[1JI"!/L>A!%,B=^$V/ M(%T]H>8480 MN6K@PVE6']-(\%V-620.G/%0M_G#-R>(]6S^%1] M>`G0ZH2]-V^ZJ2@-6- DB1D,^/&/A^XY,#0HCM"'*Z],R M1)]G@[DHH99UL:$C 949="A>..:/CTI+4*:BGE4C"=CV[^+?,2SY_,/!KSZ MC!8"8I.6F53$=>1%'RAWV3F>RV_? UQW'P6M(B(ZLD/9?\K4NDZ(S;"4X3%R3 M'JJ-X]*DV3UY7'K(Z((@-M,N;2R5PIUQK073F?D*)D&"GZE50 U7CH,% MDI MZ=\3#KCQ7&"O<+A8,L)7-B9DX' X+- RI;=D%V7-#$[L*!%E.H:-L*"..D)&5 M4+DIU(*&]':>I@-9._F_AAT7]L,R;>LCYJE'*M.Q:JC?Q7IE;#FY9T$^5I3% MR>[.>_U,-[4D]$AZ@[/%$L!@.(^&4MDW M\= J$LSHHT.* [-OX3M+9!2PLK#9T]>50^O,>G; F -7 M7- 83'7LB?AII5R>++W"1?UA?26A9MJ*W30\F9NW,,M1KA@EGJ=C_HD*@T MNW=P5HCZGFBEQQX- QOH5_4)$]NA4(FW:N S;6].PW/U7:9KIFFX8$P>[)%YB MNDT'QK%$%.5)P(F8U9.4570-*L(6YQXP>S({[M'

*S[;T@E9XX1EQ!A(I529 M=Y[U_NDC:BP=17L#"ZKA 4F0%$4F#[O(PQQOU$I[G:71L[9+%MO6<.PU0SUW M!)+;E"4GKH56V$]>^@S_!^,F"[UK1%G*'.FA#SFB] _4SBW^0GN2)[/0E95 M)?PYYO]5*^WBB_\,629W]#)SL5SB WQ8I6Z8H6"%W@6"V;<,J1&JOK%O|*JJ0Y^*;\.8KLD@K1G"866].JW+T91R%E"-[L53(M(+4 KJ.P1R2+ ()>T$@T86TF%'92GB RQ.QBD"LNSC*6M;-VN M,*""F)8,>BB$:.[8_],>(#<)PH6%@D#^1O4Z9=1U(H@ MH$21XQZZZO@+- QF6A$@7ZQ4T7%G1%U*&&#W0[:O(@K^#@4_;STXVJ VI5T32 MG'"%&U?Y&);R8=W@3)V 5@=6Z'30W8K.2&0R*,N*DCT4E,JHVFD?@LQ=MEYY(MX[WT?)8183!V*QT#!3Y(,CI2!4M.G7K=G$-O9Q_1%"I6W3RE=(G!-MA$ JEE F7AW*-;!?(5T!K@\)/@7'P2>;)%GH|LZH!W$B9"P="VU3A;.PX 3/B)M2+TB@J8SC,=B"M/@ MU@65_*S_]\-W'SY\^(@VGH"#_V?T\<.,_JJ:N?7/*(KE;P. MA1[4&FTR-CKH^P\S].G#IS^P]8]|\5'X M#YE=+=Q,D- H2!=1\3*7#4$M^46XG(^$^78 9*HC DBMU(8H,KD<+A-EQA@O MQIY/8YC@QDI3-:B!%S$)P?*CEQ+70E_XFU?[."585%VPAHVRDB M!0Z,2).*- <*)T5MDLN*:5=!DCTE#L?Y40Y>PK.-QS%=O['_>4- NZ'],E=XB M]RC9*$?4'58CUR,.T+3)'R7R^33*1Z;8AE5WT.,UR2H3V:CC#)WB51A!PSYT MZA$ '3A*M2^B8!^E+_@]=]3QZ38-(YRF$-1@X8Z/@RN[F*S3O^0(({D03@3 MG66RYS)3C9T$>QX5YGUAL0[+* DV*$"6">O(?U.$:+\RXPQ^40?#l\<"7!* M\/8WGJ6T2KSU] =`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|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fM<)C9:7@ MFG)%#2WZV%<"V.I[3YK0\'9\QU#Q'9%8T]Y1$)9]XT#+,G67%&96" M]^W^X(=A>E2#%S.!*Y"XK9TQX)S,\HSG(DG1:IO-QF*?"_7O!3Q1@*T6$>OC'@A\-41L.QP=@:,8]7:W!L M/9CG\5F=(%(f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|[U9G<-N4V0?P?!RO?W#RN.EY$_U(H3P3=ZZR4\2;;|U8K-ED94 M:H;(XO5)4(=*SZ"NV>8)C,0^QF!^":/" K%\C?'<> (,:U3OD9EAV@C//DVE6Z@<,;Y:.9!^_! MVZ(7++'B43%-;R"[=KQ82M%H*XB/!A]7]AOS7)#,@5:.4#BN":%)9O*^A K MMMTWNV$R*0W7H>_36&*\QPKA2)>SEYYNGBU4].("O9>%B*Q#T)CBY?8N!2'\M.3PZ/K$MHW;J5,]U+#GO%DV*Z%@PW!9PZJ46EVD2)TX '4,Y\'#'FR?0O.0. M5VWO*-73,<^*$\LKYZY#DJN/-5^AEX_RYM&5LS7ZJG1F-(N'6W%!3HPENSJR%^"61!GN8II}^2)@ >1?,$L :L<2Z2&DE65X76[!K67^FGS=O*IP<>V=FI^TR'[G MR Q2LZPX9H0 (_!G B^MM47)\M>^QFTKH-)LXP&3MUF3 M[@2!%8BV]'488?A=8ZT@JZS"@] H9'6 %5L&P\AR2Q1,46AD8Y#Y,_(4!M>D M;3 M@INYZVH:,R;_7%5N71*UZ<9OR4VX(:76_BMU(KQC__B,#F'4NB"<8580 M6MZWZD4P=$:9#0RHZSPC5S"?QBRD6B<%;AG=!,G88+>!GHEXA{B8,J/U1& M\MJ\W@M:@9))JD<*'K),"3^;EC35.G"24B$6-Q0!6X+IPPE54P4R7@>;M.M.+M,VH!:'8SP1_XHXVR'IJ?G M9M9SAEB!\S),@%7(ML8]>,*PXA)6@%V6G\#,: [&'TO34*,$T\? &6P$*N%M0 M!%A?.0=6 5SA0"M N-UNT8:T;=R\P4,.!7F6@78A;8#/F'\FUF]>Y+XD_A_M_B6U @KSK[2-;%B3B92B$2C!=84*\!J-.[JDJ@%PZT ASHSF,R1_&+%)FN97B#: MT9L+^8@\O'=,L>!Z?PO7;V$:.X&[_H8IXXC_H971QKOT\G/-`]H.K&]$=PA# M1)@SS ,ET=46=M]L:MN&M>]"YE%0NK2*TL$=FDOG#/- %8?0Y"OM7XV.2ENE MAZ[Q'Y!.OS&*175&F8%8Y?(M9>]/R>>;.6H-'U15(R@/L+\?>"%)!ZD&VA8 M3EI3Y+P**T\IH_FW^A+FP5!L,%/:8:]JML.B38C78_S2OZ+6,% MJ>8G@I7BFE3!]/-QQMH!"""NG#]R20(U%0!27"^W M-&#$\4F')=H7$P](>_&&-A:%[#_O+2]H.M=._-2N04<.$+[?5?D"9T91$_9<= M@XH@3U'X^8E+6H$63LOP]6Y.K9 6(!/HZ@#2OCR(DW>P@C:MK$0I?TC=]J . M(F+I@W1#E492SHCNE0TR$SGJRYA_X^MAP627M#*

N$#Y#'Q6,MN(L&0U7A>6T M1>/-GPZ88NN&V89Q%NH0-"*5;6=""MHY]XGI6G'"[^]OH?/FC+3A=CDX D\=613"<|>OB/YU#?L@*192(%W].@X7,> MD M2!1M,*4Z.T3MG:2^X J<7.MO8864B5FY+22JS#8/[&*SB5+D7N-_]_ #L(X\ MQ_N**NSCNP<\X#QNT!__D&Y<70^Q8K;QF@PP^<[W,'F3P@_$,0G62G& M9W M8'U?#V%P^P&1P#$[^IZUSDMU ?,@/WHQ%(.[']L(3-X6 MKQI#PQ5TL5*8;_[,*A;H9<_,XLOBl,/FD9#F',LQ^&$MXAAP?_G<@H_]EC&"O KAFYJ0P/? 5=NR)FDKEUG"#K#+VMK5 MX,!8'!T8-U[JHX>TB@C;S96B;&1+?$]UC;,B|>K,,&;QA)*Q'7[?\O,OG?5F/IHZES(.Z5C>> M=L\]_<-NF\0?:<6)MXM*MAV(S^+]'HI+6 %VM6D5*"_-'S!<"O R;KQ$O.M M7 MU\0PK@&K35=YA 8N@/+&\8]TVR JBXJCFF86EJHK*/,,V;80@^??QG25O&[M^0V3B'SI)&3!8"L({+2ZP^U,3*T+6X&B/'R2%GU$+MV:DC=%<0DKP*X){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}J.QQ=/5L>"GLLG70WW4"M3RC5_"#%&) M:5; 5]%[JF%V^,|^8L3;<<'B.!*UK&W\X7I .\?/Z]0W3 6,G\VSN66EV3)$ MJ:7[O1,=E]L7;Q=X6V\#^*5Q>> >A>!> (D8QB@)K6,X*,F>7S:@5";1Y&.L0 MLW6L[,_OPHB\8+'XGFM9V H4-7+;,^:$QS('&9;1'Y\/;IWNV-EW[T0IL=\61 MLA#?-<<*P 1&F%$'7N7MW6]};,^^1*KE4ELJ]?'1Z?1M:P5ZA.HXT\,HFF#^ MJ;$A&2BZ2Z/ @Y5[7/+G*L=XZTXHY?T@"448-Z.#U&Y=W\X[3X WDV?0%%Z MF]Q4*\!L!G#>0.PGN\(Y9Z@58%2X8@?3-'],\B[K.=$_A0%$$B':R@F4(YXY M3WJF%6?"\1+`Q3_^ZF&6AF4F0:]7I06L )G:4SL;3-A@BU.O)L""1WZV^7N' M)8(`S_>/6; (QLUFO<*!Y$%81.CB>*ZS_QV,>"G/~ Y]%'XLWVU%$36JR<;," M-1G<>3Z*KK&TNFO$;'*&6,$Z"#-;;&@ O+"^,7ND%4#@-S3,I6L:$I%1B+ $ M2]M/?O? ^]YPT\8"E!PG*4LL:8)\.7N_^YP@KBWMF@-($RlMSP!,Y *PBM M#"GJ,.T5\WH]2<15G[BX)61ZNT?1#G/$+U'X+7G+I&8VM3*"6G'B"F$57#>5 MGJB-KN6M0- =C&*#CHQ/[@1)HJB1H/,,>:040OR$PIN+W[AVC?H?JS?B6:1(G M#ND7!4_]A@6;T@(6\.."\13.]NSE6X=9)EY>,*E1/I6P&V80IM:%K:"*2B4] MF=Z/@N%6@%- M5D0*. <;B2*#79.L *V0X&F^S0,H^I_YG$@PW/S=S!YW+`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|AY$JL_6D"=9FPK$(O:/DHG&$'4()H7GS=D+?+(M4V MU4HXF+ [(WWRJOA0*)XEFXS35&N9+5B#Q&24.EF/FA$KKX&0^FP[@,TRJ=9A9G!3ZE8@/]NXMIZ;|\DE\NAC 8XRGAN@.0G\ MB>,%YPTWWZ' "P0="JH_FA? BLI+YS@[K(_6Z1OA5;_9$:HNS*K,M(;.BMHW MW]8<9,76]310%G(7S9^P FT+UR4OHN.OL(AS'UP[!R]Q?$$9"M$$.T"23 L3 M%2E76\(.L O] .Y4W#FN81<[J=]"E, M!K3"5E:WX}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|_MRN9F_HD/FY257)6FW%UMV6G&<%3;'Z__VHUBSP1XNLOIK&T%HG)6LG*.L&T)6U1]I'E&4RM^]D!E@3 ZYC%(_M11 6QS.C-MV*,Z- UJ8(BA8IMW:Z/:6\|__^NW/<#_E/E%_+#H5)E!'{//M$" M(B!=6OZ*Z1^#\<-/W__RX_??)Y"0)ORI\8N]K;"81XF%QLF\1VM(MQGB/!,DQVOQU%[Y_YR*/[!+^\!?X MPU_8O=_D.I$L,FF $:0DU4OJOW.(H !-E5D6N$5&7NJ_3SREOXKQ:(VBOQC M/4>,L;OFR)$W2H.!;P/WQDE$2*R/&_N .2EWK,-N#AUIJ[>>-'W?3"=;%H;?8?_- *@$]P-L\;:Y"P4RUM&Z_!;T+75R0@3&R7TNR(M(70++ M+5V[\;05EHP<_W]![^&M8PX>;;NL,HI56:3Z\TA;XI5RJVRK-62DK64J WUO'S#Z]KD"P96VL- &6EK^+$&&\[+.&G6#3,=O M:X/U4:-N\':/HATFN"]1^"UY:[27:&V4/7I1S|&B6B2>*GH;Q/T/.WVF8N|/(\9CEZ9B[O-KQS M.59F+NLV7((Y5F8NXG+\D!EV_C%;&9? E],R1,EM)5\;5FB-)L^P[)7=*PZ6; M8T2SZ#LEC'#]R3EN9BL&"QS8.6[F+@LW_>4Y7C0+P5.Z3WPG?8Z<443@+!^H MF90S8%K0\NGF]NGE]@;_X67Y<'^S6- _>7"T>%D_7MR^_WMZN7PI,C9XOM'7B M5X*U+)N*QE<@/XGS?RD#+8KTN&HA7$XFD7BLEJB0/EN'Y%HH@8;_^EN[XZ/-MH"A:&,@<-K-MANW-$#IGF=; MB.'45V_**\UAUM^,;/

7¥X%)KX+[>4N+3"MQ? MN¥' ;T/L!2V)Y^>=&C^U..5)QF;,P&WH5X-902Kl?@\(\0W.(#F2D61$>2V M2XID=1I?-*
F_(37T4;H')!/@B'"=9P;'1%=Y%KZ(OH@3,8M9&+'[(HZP MHW-.TNXIMRV3-Q1EM1JH@CY) :Z.[?\ 7_#R7L;,)X@[W-B[R=J1,-]4,$%S
ML/4J0@?'Q%C9\P5UX;W@KZ2(AKMS&& M:N9)]] @%L4)OA_Y&$8B1I:+:-]RN!8"CB0_V1BJ,Z:9I\|=\|6'6ICRI+"_M'8)=UPM>E>I$C^4L]*¥N:.%PD"B]WK-WG!O?
1>-SB@]2E%/& ^),9H'G(827 MZL&PWOQ9(%:!Q2H((],P;HW#8/52_BP.1HZF^\B@X]D>1[>LE0^8FHV-(NA7
MY+N%LWF"AK4ST?Q7@¥A|/BD$FC1(0!V&$+/+0M_¥R2E*/6GJ_,054%4*.I\ MFGGR++22X5#"WG_MQ$L+-
E#ZE)QMT_W'V=76$O#E! M9(O,3/O @]T)HUUD9EH0/,+?IE1(2,=TS9?H*L7/"DVX>D!.C-Y"W[W?'Z+P MG=I1^0¥TR9F7P)03-\;,3I%M,S"FD5#¥0OPBF]AQ-Q.?¥
M*%9?A?^O#P$*C!#SQIF0UJ2X MW0C.41L1QR8V&5O+>-4$+78- MZ\¥0N]3QT0(_)N3+/WS_F=TW6':6!8¥)I;?RS?-],3ID?;3¥)JM71QK;XSMQ M+-7,-
QO/9R6R%LP?;98XUM/2>"U]O8V'9[G+$M/R,\P0DR&P,A:!?PZ M/¥,B?D#*¥%\PBH$X: @4J7O)@ZSW;L+RG^,N;1RVU=W]INO0UZ.3@;Q.?OTG/M<\I=
M@H7T:PMQ*.SKYG7UQ!H;z=%\(G!SD)LX\DD998/OA^SX"6S%++>ZOSI>EJFH M<}CX46\Z+P!\K MW<6(<,""0&*6[C-
PCO34*WKG,R+ ^K77(8R'WVS5>-";.UWBQ>?,0IA;FB>A; MW3]XG\)D6-"K'] ,_6(/:6:W'W@36 ?#&WI&^_=?3L'+-/F-,B"2FZB?CZQ M0@P8'&:TS>-1,-
E=#25(O44"7.6:"/;^VJH]Z_M?6D6.!S;^E3P1WE[SA!X]RU"^=1"5B>!,X'O7-+.,,XOKWCO.LO&6SP)9G;XL M03-AC8QT%K@>3OPN[8]SB
]4$+|5PO>U(LVF%T4H1(I,P,.@II[A0T(K]"P0 MIW -.5K@+&)(I50X26? +!#61P ^S3:WE'T M&DXOZ."L9+?8;*(4%;7>)¥YF8>LVLE@W.X/?GA$*'MO#N>;J# M)2C-
7..1WL;QU] %-R<@0%GF6G#[%3< ZE[RW+S=9<,RN7;R?=2C>I$&*R=* M LR=!=N6G3H076056MM#A30AM!D %"=H6!;@)>>ADP,985&\5[
M*6\FT7I$5Z'/<@/F]"TP,;M TC6TQJW-<5H-]%WJ3+G6[W^S1*NZ9 =>4MYL M0-\X;=K%$:GGC>'>&3+Z#F06>!Y"'+VC;GWN\7T-@_X#P4NY+XD2)36=P2;I9
M%%O6>V5F<3"#NN6<6B6,@7UI?7@63M17M5>&OPL/+V#HK^WF6$6OF)+ MY!:]Z96BI*_=R]RVVE$1'QX4.GEPB]X:7P8=WCL]NCAS">
MIC>U@!JR[I(C@!8&A"[Y[COQ"-1SO7=".NYLL<;K#*]R7(=-X10"_MIKKL M$]_(9<.\=+E=.Q\=7KA!/F7.=9N$FS\@/0K5>WJF7)IM#;2A"3,/W>+8!>GY M-H!{GC"?
OK7N/],XX58O5IQ\B1>XQ N,#L9%=H&V*IL_'@Q,7K MD221]YHF0)?K<.6{$A[Z+68#^\;;_'I$I)X?D_%YSYS%H:D8.(:&&
MQVD=W"5A#X$^7NZV25^;JL[!0:=0FI^%9W@<9UH'YSUWAGJF80XVH7@HB_2P M;^*YG\I8DD1?]6P(M_P9/Y>2VM\L@AT4>;K]X21SY!L:%/TA(ATL9""F=,+? M?
QPFGL%2I^Y^[R4Y8X#$=_]S@F #X1ZNZU%([P/\U.W)=R?IH14 *6U.5UO# MF-GL 1_9CIP#5+>(WGF^D?8X.ZY]KZ.]WF<& L;3]PU>Y!7>?@]W[#<2Y9N<
MS^T]BXSU%^@308+KBK#]JE:TW9,,?+@<5YN,V);1L_>]DV4L\X?;Q<(PK 7 MT0R]8,114@$!_ZWW3/7=C[=\O=2X4#IMSN\K?#/J-B3($A;>.0L[%
M&#@J'A?;+6F"A+#^D_!Z5@L&&HZ*[- -&H,ND54C1E9QY*WU9G<-1;C#=Q3= M8;GX_OYAQ1>T!*.MN-M5=%T=]I\(V*?" MI+)]"[JBXB:H3.'&GN!JG6OL>=Z
M3G2D*0#$.M3RT51O@WB2[F*^.RP-0488]J4/*&=>KX/H[3:B>$IC;(;I'= M;Z5QO1HO$(LUM=_MTB6>4M@4IH=^C;MV?!^Y5\<* M-AXP+;-^*^/Q"?
%:Y9YUKZ7XT\>? "K?#'RON.+D7=V&4?3W?D\M\2Y46T+S[MYOHKL+0^A0F]RU[(W'"W),V!?$:QX]W-
V[PU;UF&38$]D7@65XMM:+Y$:9]P[51]CX4X)3(>5X(8U6W/]2#']DT_M5T(;-ZU%Y5S.'>,2X1N5XDILA\0L+K.<3Z/L4=33OW'"N]-.E!M0=%+-(1;"A M3O'9IB+
(7U=MSJ<+T9Y,M'R[RA#Y&M.F5X%WJ)\RWA0Z1W3)MDNSR M]LZBONGP'+)B"1NB;.DYTF#-23^+6J\C58CH.)\ARKI.FSY{1ES,HB^KHHZM M&.LQ2*_6B:-0(N
D0IL_+F@KT:8> 9-A\><+5+4!=!!CNU;_QXD,8,_Z7*$P/ M]\'&3UU\;Z#>;>D)@$]M>4,T[XBFHM%@H]E]0AN1:CC[5%Z;DC[?DEW6Q0'%\Y M%$#.:
<;'%'AR]*KL7K&*,Z=V@R'LG&WWPG%?/)XXC#O=CCS6H9Q.]#%X1UFV[M_,ZSQHOETJ> M+28]K4J>UJ!/)OJT+ ?##_H\>R29JWEJ#1H4
E6K%ZXC(/2L4<8/.&TK;[- MB'1P:ZVTA80 ?M98DPNY+[1<5@3N6>.G7[SO%&L16X/RTPH2\P-VSQH@T3\ M%DBMA]7. I%CU$#D"<>S0+!4-D^]HK-
$U/0L4#=$H'5QU_N',<\"]UKCG+O) M6YESS^(0]'@;JK';9UW75]%PWC^H_*RQ*&TRG@4VSK; N748'O2U5\IUF 6Z M3WU;5',PSKJ.=R?/[,SX.'OT<#)' $-
ML.78^,MMZRWGLPT?;K&9[06_0C&O#[<.WV>B.ZL\UJS.NTL/ BUO-3O ^=A;(M-?!L-Y,T9X'GL7I2:K$=SZ)-A&D?!R?E=PC Q% MX^S<[EF@=%C"907=S:)URJ#C^%
(8+Y;PQ;+A_ M['GW%!J4?+66$IG%<8S4H5;KH0_2),JZDQGTHG KSUQP>S)NY6OHY,@^[X@$ M(\@6%?_)T7Z>'KRQM'-.$:(?
I1QD+N;W*).6H/VI;]^'!6)XE233FF+S;L M_IIF5YFI',=:#7XV!1,,C5Z)&EDYCK5:IF:#8^G:7CF:S]ML.BBN657)3"-0&3, ^G!OGL.*+UV_ UD M>H"[#?-)+.Y\(?
#AOVL>I16^ IC"XRX#D=7 M'G=#(ZT4E.Z\P,&4Z?CW 3[)E(!1XPJ")F:JJYAG"O0V$A'H1R%HHAGFP3B= M,;?TB^%>B(>A^K3U9;\<[BLL2\%BCJ-
^WSS1Z8&2!+%U4!W6;YT+ZKY@6?4A MC&/JSD?N?4!"BB'S*$)OF$HP{Z910>.@5V$_DSL";\3!WW^RQ*BE9I&H^A$4 MU?U9%#Z1L@LPD3B<[CTOQ ^M
XW16SO M8\=22"]F\SH*%8,YDP&Q%.!9H'"<|$Y9(6D6*!_27#&0;.1[TB_GI5LT,F#! MF475J]'Y'$M]F06F)Z5)=%CCSKJ2CZ&KH?
75F\4!G<,-4C'2GG6AG4D>:IXJ"G>1LW^"\IK,2<9<%<^#C7(20E54C&9@"T7'\"]*@L&NTY6MP8;(]N!* M(@%$6ML+ M+"6]ITX8[/ B]?G&0*R\(>3-:/=7:< DF*
Y!*+Y14EZ$1]'207I^&\EPFE/)\>_C:'P"+ZOB\TFW:?DSMX@_,9O MJ"!%F[!AR0 +-\U2BQF0)RVE^ZC>O,A]2>Z<#1'W!(?'"&@'W=_EDBB1I+-RB&H/CM+*5CU%
KF-,]R.UPZY"Z;:QCB;YP[73!?U6]%\\%B$T?&%@_ZP MON23^TN&/$D2>7]%I>+,G >&X<#-;-9Q4K%CX^,9.I!1@EAG@HIF@2RAH8]+?]57Y[S1I,VX6/1!
[/WLG#6>-6EV_*L_BU#7_I*@ MT*)\UKC3*@ORC=UGC<-391NQE7T(U-E4\E&G-;M\P6<1B2S+|\+I8VWEB22MK MZW#LG#4BM>INA3-I%BCKR=PTR-VSB-
KO2Y%|+^$LT#:<_^FAE0MTWL7M50E0 MRAE\P1RW@G>'FWH6K6H[8>X$![XC3PGE4CTDN[W3G1L\% R>I*I13-(D;A* M8WQ!XOCVPTO(07WFP,(8:*YR;!YS(-
QQJH:O ML%C&+%P1IP7]-'G6_,R_JBB3Y)NSL)JAT'TU#!Q_&DK M!K49F6(&A2"VM!#$))6#2]V!*=8=X%&BN.U*URRKP%& X5+_X5+_X8R-&QW.
M8%N*'UB9O'G)<)+!]/N|+5D3F%V*ID$PD)"O,*8¥WS%#R&95?T!T$YH(Z%NID_5%:.MZ]75+_24T:CF(+N46!=0HEH13[T5O4TKG$AQ@2@ROH2A^\WS_87K>A2^J4?I
M%^Q %[CW>9;#S\-M(C[K$04\[E%SO&918P%ZV0(5D] MX((SV ZNU(OD&!Q>ZKQG8?CJC=$NXM*JN':(&J/S^) M&9^U3XNS@]@(/>&$ <6-0;(ECS5S<$Y?
>'(R5NBDU_C19]\81[T M;\2K^*Q_.^9RTD[*0C(K@VQ(+NL$_LQ#_URN6>GKF\ 1>43O-Q6MUXU29&-_MOU8VWI6_=>*B=L@M["><52I#^OF8A;RG[Y6I!4?I9I.S.
T6KZZ%FC:H?!9(MT?XNL# ZHUA2/8\(.Q;RY!..Q0D,2M$Z./IX7F9+5'7VOV8=/Z>HLI*0AT^VX4'7;(A@V 7PZJY(&1R%H@XZOV4N>XBTTGV!/N/4?$4W*]"? M1#-1
T-HPQ'/N:@]8K5G[+XS!]RQ+B.1[?82Y.E>T0N&O2.Q7.P(@G?*4: MC&0L1#@^8J9K%V"(-1[$;@W$,,=DE"$#)-"(&1FFO.IH0!%#KA-%N[> M"SS@$F!0D
%,;NZ0'35JU>3*JJN,DG)T,Y+=-WHN:YN0/H $50N1$,D;L]"' M)"0N"83-RB@RI!*OE=YG<1H#R62UL%Q).68(?%M86EQ*NZFE0+=%I5F0YFC/ MF/8[,(M4!V4ZEI*?
9])?0!EYDE+Z+/)#I)&G3UT8+V;?8)3O2_H:HW^E<"G! MT7P^\;U5KP0^]R<,4_DO:_RG&$N6>.MB4X3J*IK57A+'*N$HQ \5/TV(7(22N M(2D<;RY4IDYC7<8\
/G!S04E1N$'(C>\P2RI25-P4*J]DT:.\4*7NB>9,C?#] MQ>9?J1=['1X#YE!K-B[T$7 &VW(7H.>0 /&\T39M7XA^_GAC(-V3Q7&+L_
M>ZPMV!>'7.RQ0[Q/E=MU=7P*WYV.]XDWWA.T"IW'K*&V;+S+A\@=KKN^+XH@ M0-'9X;N$_(9UF/C-.V#]&4&BRGW0) (6H:@N,3A=+_8'Q
DG<*^=@Y\6XOHDQ M9X$TD3A:LRQSI+\AD.1;MA)\.P;'F&^$+:>>>.);%P5R,C539W]ICKE.P%%#8K[BY6/^OO(%Z,POLR?(OMN@Z!(HLQH< M['!$LB&\EE-
$#Y_##>%_;&%(TO7HHJT7>_W'8\/3U']=>;U\NKE]>KF]P7]X M63[_FDM1*5S/?>ZK]D!S!I)\+T*;-M9GV0P5AK? %2B0:>C6%&X]E!>;M.XR3EO^W>7W-!HM5
&V)N[>_M71MC;*M/6 +(BZ;2*Z,,W;PT>YYQD!Z\)Q7SR?=>,J*W$6%8@X\'9/LS'WB MLE#1',U>.DP(UT[\]AP>'3\Y9MP[2RE8A]2;X:.RGV(
!%=@7S#37I+9;HUD9:6OR'>%KEF;]>@!/IOY&1_(M(ZKY9N&O&7'SIX\+9\(YXN:(.DA*$CFO6G[#/'6Z2NJ9+%(.T02Q)9;SRI9L3 M[5IWO.*YNXXT
SWQ>9==_$DPT4*@/OD.H(7I'A[&7L*@_@*;<.(T7%8/4#Q M[0>`YV&$U08G.A)K (9K]H%OEP$L@ZZ'>Z+YU;1U[#4]BJMFB9C3"S93]IP MT[3UQ"38'FV-
V472W&*09%#2*>'4QY@KU^%$4%8Z7[$H3XGS-IPM[\=:L_4; MST\3;LE4WFACV_\-00\EY"[>,,/8H7IPP66:Q(D3N%D?)\IZ)[*UA&ZC9$;1V
MJP8L=Q4&N*57@^D4*CUX *J;_+ ^0,X7<__@3%KM0^8_X:44?R:U/;.C_|:<8 M[:K*?M.G5#AEO"#YSO7VA4O)\8NB70U/$M?S4/,C-4S] I]1;TQ\W\+$UO'+ MET\:5)
<8R_ZRKD?8!NNPPF&G:72Z&=(\ZVWD\<#3Q7$./U>S^5N/%P_0> MXX_]Q:T9GBE]NNS_@)H._9$@,]_Z'JA+RSS=F.!?SD6?!2-R/*]V"B8"L[
M"ZHHZ#+'VXR3-[QRM$E?T5^*J]'Q4K9"3/B79@C VV*28>& _Y9.''P5(:'# MB3-13$@SPU/]1!/%3R^NVE7+>-U#/ 3P?[?MZ!M^YB%@_H=M M,';
[R&@_\4VZ!4=YH-8WSR^U_?;U?__TYYH;Z&/+V9\^Z\4 MD_0SU@CNP@B:Q7&@45W%_-G0/4&-\C @%2,$M2.%<\R%:=5W(ZP>R1X[W:V; M3P_#&]IG_0,[6C
UQ]FP9=G0,.$4DT9'LBVY1> ;\\0;Y4),JL%%3?.5X[GW05;21%SW6SC'+/[OXSA%[@TQK=)>%)3(V3TL1 >DN)*Y M$]QLTGU*7)!9_?[]
(4)OS!7QGAD'Q:LS!!ME*'D@4KT..ORA[6M6[7M%207ZSG&7I"68,9&$ .B\N9!OZL'>\C M9424DJ%++$#>(7S; #+!IRENT)S)*/*'D+I>#A3=6<* JLP@DVI/ LVJ:@I?]&
M2F$V\X&Z1IL4$)O<_ DERRV_T(=IQB5-P)H02)T^$35K@=58$8:)*UD,:L9D MMG([$4RP8L:UHF+R >125HRZ%ZUE*Y@XZ#VMAARD]+.F3S:@7/)&33QH5OJ"
M"_PZ$T>!AHQ",A5-/"Q2FC Z+$X31X,NXE"U8TT\3%">>N2M71-'R7"4)+2; M33PL3IJ0>.:UB<.O@6J&M]U-/-I. XZ%YKR)Q^/I1@_73#CQ&+X3\-1IG)QX
MB)\>791O^)Q,8-_9+N]TYT#+A[&P]S$GZ?ZKY17QS[>'5[BV)[2_'V6M.(]@W]Q!4UV_]![885(G;]:N8< M>>?0*?
P%;#X"SFY"NW"NR>9<'KX3APOMFW7'T;/$-8!A/@+NTO9\HLW3$]TDU$MM54(!W^\N1#6_<$/CPAKKY @@"5KX9O&&SU]M8X9KD!90=''"BY/CD['E-
+YC#1MWH,SHT7]'FIK@=)>3GGA](>B]VC#9_W87O MW]G(HY#A/Y1 X;_\?HN%S^3(W"?K9\U2VE7DQ4GH/QZQBO>"^=OK*^AP3G#D MRVA=4\Q%+
(H;$HM[SQ>C;=[^D)GSOT\?!/-/;^V17/F.6$#@C=9\6]??PO5;'MF$(;S/4WC+ C_H?6I_DW5V7ZN%P=U%+FOIN_CK]M1^?#VZ=[!L;JO]M!]F"K
MQ=H^5%F+WD7\KVN68:&6TS&=*= VQ\[+<#,0KY2YLAS)M_S-3BYB_G71IKB9 M!Z7QA@LIFSU6]R.YV5U'81R'6$6\2P/W_OYA)7@3^;-'DOX?T,[QJ8S/N$^1
M$?:I)2>3(>\G-Z $+MR+PHZ"1WXOV%OWK,$5)3P&Y6 M@I'I-Y;<:C;;NK'U=I Q3V3NGJB;R'>84'=.@K+,$O(1&M"Z#G-B;D8_,46M
MGBO9Y5@NRG@5H0G7CN\<]^J8;S@;J!0(H+"J,9IMH+I4JHI&EY AYE,H;;@Z M'L%)0< =;\4#^]&0$XEHY*-8?:IZ'(/;#_R]>'&Y 1:G M4%Y#,PRWVRTBLL\-
YE;"G7)&ZN;!>W!,WGY@#AGL@%L^HWWXCK"0LPR$G;;E N)MJA;!&#,\DJ ?-SSA%7(94NXEO?VWL!_$Q?NTPZD5',>JYL\I;_>Y#_>!=& M-V'ZFFQ3/XM*%-
QQ_I3)E0S0&-A:A&J?$D=]<]JL1"AW3S|$@3])V$VK,215 MD* SH+,6V2Z*.9P(+D0E"70A8R)%":0(1!286-;#N;
M@>RL7*0ID5'8P*P9Y66*G#)#G<*"'H0B":@'RMK(Z$5!9?$$1ULE?^2$<12<'&4\4EW*I M\ 6:Q)'*5N- 7=9HQC!S-;&]3C\1'$C+%SV0,'D&(^7P:]P,7I3VQ&ONGNI%
ME@D6GSB*?00FA'N.VKY$HVHVD\&48E%V"B&#M94NE*-9AX >Q3.;4X MK\%FY)C@1H)8&9M1-)QJ#*F]=MFY(S/LTY.8+2Y MNO_8#*WB:
[<9+09>1FY>],T=$$S(6=Q02)L198"@^'FZ0R#JE\DBJBL;>!#S MWD2]NNIR8-@;WKV9&%"]" XFJB%2S))>Q"43<]BHS4%?!"
<3M=6(P%12YT!OV@9&D^F6O/%AD\\+2]Q#4,)V=]7TBLS+[TB>?5*)Z;8==N, M#B.NRR%?")N1+5FS9/@'M/LTSJ3.@Z4XG7R(]4!*L";98#+:,L2Y8$6WDHGB
M!8].] ?6=#'OK)3P"J-DBQ$8AEO9*:?U+3Y9RKMSO(@V("=AJY@\'CSGU?/) MWAY)EW+D+H-GV&JF17H*@RC_ZY43>UPM>YAO&!.(=8#!4MCUKV\>15?'XH^_
M>BC"G.KM^(#>D]NF0#4GFP M\2,8J);,.RJP@HT'K>;!EDZ_)RS/Y)W%E(YR?,5>X.HT,8.0FZ0.[)^8X) MFQ&)Y]V@G_L "RLQX3$_ "$1S3!G]6DDS-
:1C(6M*/^3=T^Y)'@&654ES%W M;NUK(7I7.*,OK$;N$^9Y,\050 @!)!,=4-3!:EACK6(QGY59S&?38'3PALTF MW:?$M_P%:EQ\Q5*IXP.S^(+IYPIMPPBMG8]^?
$=R;6.H^?KR!6IZ!(2O[%"P M(4J=]-,H/7UR9_^_S;4V=?7-H:;QS! 1ZK50U;Z^*0Y@ZTYUZI-HGH*DD?' MG6[NV4!88@'[5@(/W TZ0*R+ ^/$0S# &1L6$5+P--UX,-
L.4VU^E8Y*Y,W'B M-Q[RX:=9-K6TVVLYJ*FP:E76;&"SV5S?Z9F8FT;$,>.>"G*&>6W6SH=48 ME7L+Q);#6DT(K5=[(J@3O@UF<#?
L6S%;J:YQA#K>$=F..BN>6:;;]>>)8&^1Y M_7QNR*TO,J:S"=:YFJLFRMO?9\X(]VEUX:9?Z(UL\:B5Y[8.)H&YTZ^G\F6DAJ<"R-V2'1AJ#Z$"\00!7) M,(A#WW-
!N"B8V4N"_PH@9>GD+YLWY*8^"K?+Y U%QB9(/*1(S@QXUQ#?)*/ MCP/LM%#_N54@>,/YN5HMN$40K;FC9\PYOW-#Q%*Q9P,CRB6?H /&4/:E>-# M\:&7-
X22!_B'"%P;"<$?N<*L $$8O"B;< Q G!U1R@AU6$3HX'NE1!H8=3. W M8+$)#T#0MQ\'8+;".@4]TXT= V'^E.MG3P '_8R!FM%]#S58$6D+1SZ&N0GF
M&BZBA;>!9PB0+3_9&*HS>LA//M]I[>451E,I+##9H)@AGOY:O;X!7LR)^*($ M;KRN)[&*01'CG@@F1%KY/:@XFX",[F>ZVDI*_KFT&2W2OL?AQ.\N*IM +)E$
MGI"!>3U+MIFXETWA.B)[4Q-WY<@AI8\@=O:VGU448EZ7'*$Q&90>!+O8H3+2 MF FHMK%%96-=AAV)B1.8;[B[#/"=$?7K)<C=H$.$,!WAL:D?)DV.EF(F/]F@
M8L;9U]6Q+'NN1FR5F?:!!5L3FEID9IXG6$.9DJY2SW>I[^(!.3%Z"WWW?G^(-MPGEJ9IW_.@$Z=;)RFL_4-$_C(XYFHI/\LO&L MN(+!!/R-5A+')'L/1+O#DGK,>D-
E9F@^AA)O$ACG#[,O@6A3NJ04<[4.*HSB MSON /XD-Q(()DS4(RRL";#-OEZ0[<1N*&GI4Q7FKD2-EV5:0[1M="';]%S(E@ M1V3M'@X]T[*
]S#UR]GN4MBJ(MEF+)W"A]I:6<&(9)6BB=ML^[U@^O2JO6)@'RNJ!&0BZKB.?'D@GX,2:BSGBM&!$0C4),G'O;?CS[& MYRHVH(1-(#
(;-)GZ%'-@W2+IOFC8@_@E#-UOGN^WB+9A-&F/I_F&]*SAU8 M'VW.%= -*X7#841M"(Y;]*KJ#?K-N]I NO@#5]\YN4?OQ_,+F4L.\M\R=2K M(XEN()W6Y>K&-
\::J_"+UUYN*Y0AV#Y[K+&M/Z.PTBZ$X!4_B,\DV1>N*_D7 MO%_](T7'_+^H1SH>B]GGOSRT)I60A?)X/H:A*\QBDA@$BF/@'\.\0OC4[VW M2HMR9?)U?
TYWV\,4?]F'))LYUA6.[!3;HY>!LD* #HNQ<^WPPEY *_2$5' K[MNGE=O3G1WJFIM\73O" *69ISZX]&S]#PFT M7(RY->9 ;(.\/F++AB/K@:[!ZRRN93$?T6^
MBW"]-->9I'G)S]=,+FX.2.^5M/6AC7]L$$+(H/>^$]33#]AP>'3\A7>))HYONQ M4F**MA>|_<";P"H5WM SVH?OZ-HYX$/1_%21BP$=TQ
M8[+!/UP;'CO6IV$UF[A+O:X@['=[9+VK*LQHQJ MO94&UUR'-MXN<4DP"[5/>IJ\\TT$!$P_$U"""$8PVMY1D*(&]AI(8VV\SS+-#0))7_LQ*7#;V M(.$[

*H#W02\]\#)@8[SHHEOA?-!0EPG,*_M0,!Z1_?X /8(.H.;-ID7$3HEQ(O7.(DP#7!L:*(9%X/VE S:!?%"S$5R! H-_M_P(!WX(]GF,.E,9NA*

G@[+$&"XILLD@7VNF&,-5NYI%)\|"N$6;]+F>MRNW8^ M.J[N()\R2+[AY@^(6$!13, ^42[.M@3:T5^"A6^P^DIYO XB$V?FTPYG[SY3V

*MX):%3S398*7_BXM9KA'MQKM"VS!"3;83%QPD22+O-4W@$5R"*T?4K+;?8C9< M ;S!KT%$LLZ06S:B_X+?')# 9"^#W#)V/6+AQF_`?(`?_]ZDW632$CFL_9Z*

*M2)GTI43<*AHY@N3 _;>_)EEO'C?V55-Z3S)G)9*N;6R5O,T[9ELO2R3S>HDE(M9H8B%2[VT7S]!<"=Q$]!0D-652KC(P$0NM%H]-Z@,2&W!LPI8_:(D"&2.8XZ*

MH6;!? ND^=2+1XFV#,M!DU ZA(PC8"XS"9.#C$D 787GX8V..XU.]6!,U1(<-M1Z\I#]JH7#B.+4U)V"S*<-Q9>;+:,$!=- Y](RUYX*L]@L-.\@70!-[66[Z/*

*M,5?;52U^[+IX5L5K%@:AEQY*R@5TF5&*,FDBZ/')4?/660NK$CE#NK,;X)V MY*6/Y9/L69()OUQN*LZQ3%_"[9LH=X$_'A8(0M^,:(99,+(T[X" _]5N'_|#*

M"PD%";9>VE^>/)VK KFW&$GW>@+V@\I=[@DL;UYIX6).(TF'=V^.U)M_7H M?0MWQ8ZIL?IWGS#?:?IAK9]!BNZZ.I.HHCMSLE]V%O\-FXQ\%@-

*WB7QZ@VKH]E]EA7=>AE#18]=-M'GO:2]=]Y+!>+'SD>M_#DBR?"K(IK(LV0OVU%T4HN#K4N*P&.HG0&JO:TWH[-MI/2\[CQ8-M-*

^[%&TK]D#"ML(OX^D)\T;EGTK5,OS/XY[#$ZVWQCS5WG-Z+NR2M?KW>$[N' M@]8"AG<_7/^9&>:?DKR\RV"\DND^)RCSHCX%4[)^C=#??1+7&VE.F[5I

*M[34,PW"[V2"?-CC%+[=PIYR1H*YLEI/-$?[RRUOHOPUO685-@=WSR$6=#;=2 MLY)_ZHBK^=,Q%6R\H#&D%),F-?SVG)DB$ZN[N)"98 D*-*V?H)'!OSH<@VB-*

M@(%1$C20ER(+1]R&D9VTN0)=X@ -HTHT L\<54/+,W,Z"O@D#T[S'(],K* 1 MHL0)] VP_8"3,2DY@A-1EPO32)FW8<69!M3[')DM*I$U\I=^)VT?I;EWG$4

*MJ&M^1_D+' W"E,FG?7\"9""!,9D3%KHZ8:RNOAGE:%/]GQOC6&Y *Y_M0]KQ?C6:RHBFD]OQ)C::R%'PH3Q>PT83(?KN^CGP\W>P^.&% LRBDX&T<)@* M+7*

*FE^\!,X,Y0U<=.0:?*W51X#F=)WJ4)U21?4C7-J.I"O_'I>3C$'B]LWWYB_^LU"!7FABA,:)WK2U08G31?T?A9C05[++W^6'7D[*

MY)+9ZGAF:X,\/VZ3]S\%"PAPG^TP.!__%)9K<+<[^AKTP',4?@01M%A0638 MW=Z+V;F!XK&7!.!+ O!<_*BMFT^O >F[P.-)G*'6-\QE1(+!+F[ZZ*3/<\P1 M+TLB-*

*57V'I*RQ)'@VHEF0 -#*/]}YYP/*',E.S?*+(-8& .LJ_PSW7\=+85E MJQ0UI."./T=%RPY_+BNTB81+WBC3>N'=OYZQJK?S?%3DH>]%;.. >.R)-((*

MM/6B4NYGD"JKA,4]$1GRL#]%M8(;](ZB9$!%Q59]Q (#K?RW3IY12]S@=TE M2P=F1,"4%)8PL;9A.EKN@_]X=-.[WM@QU*UA!-;Q51F&D;IU_TFQ2>)?[%Y M4IZ]*

*[7+O2 ?A>\H^:H'"*T<+HW:SD+_Y+6 '942E5\="")T+Z\R86-M%U)R& MN&;3%E?IWIAG=^E89XX>CQ@&_ ZK]%^/K*=GOS,:NYP@GV+S%YRJ,. M6':$N"7">'L?/Q-*

+]?HCZ1QXU6:401U:"YC&;YA$R7]"_P9EX3:6XU8P_!1X MG8S/N?%(WQB2)1:C5'!FCD>=A!I+9W#8#]+15)<+!O--+D"3X:"CT,?<-2T0 M);YXYH'N$-.:=6MZ(-

:A$$O7E)_7V&)]V+(Y)WAV]5_;^1[7FS#;)YD7_90F MQ?X^]J,BP/>&5(O'I!AB62E8[BL4U7+1+V'^=EW@[>Q0NL@RE%?U\EG F%S> M>!VH%%8)/0US$D+YR(FZ&-

*M47GNB?:*GP? M9=F51V*8*RZVV!%WM\[N!:M88WHW* W?Z48[O=HYW(\]U]):2]4?\HJP;MOM MM^1^DFN'_Q>LO6]<)59_)?O/%.'V;?1%<%,0V: ,IR_?)]*

[C)9]H^KDHB1QK M_.KOA62^1V22$_\'NJ.[K? HC.QU%!]*T?@#*N@$$(.&^E+&48D$>#' ;6XA M-TK748@OA2LOA2M5XGO;^C/\"%5',, JW&<&!6Z4Z?*

*L454R5F(%"2'"7)4CB M51W!AZANI4F$G,-EX$?, CK7#,R #?7#4X9*58Y9[1A0%I3N >ZY*@054I^XP1+2AC'X0 M-V04*

:JRQU=5("-0@<:44L+Z1;X5HNL=1\I<#]$C(Y!8U6Q=X'!>'\Y56]S M2D)7[8WFT;M:/H^B2FE@CG:.$% ^ MZT0Y99"!!G+CF-9"R'@#>>].

*<]].T&5">M]8N8>0805RS?CAK9"1!_*NC1), M(3D#%NFV:G)QI#;BX#C(X%_G_(6+1(F^Q,<,@M>X"0"'OX"#+:M;/_ >:X_Y+9(0(A.*?.1,AYM4Z&LF@/DUE-*

:/"T;5U/V+=K5L(S6J;#]=9@ MLV:6Q9D%JR=BV=+O73)++&@\!%^O[E&HJLR#T#,RJDGHMLZ#M#"QD1]6*F06I M9V#"T:E$,PL.S\#4H%8?9Q;LG8L2K5:*

[9Q84GHL&]%Q2:!8LGHLZPRIS=#[M M=^-\/VW%Q4HV3'%#]N=>)=2;TB+RL2+$;22P]6%'$5Q=6-L/L.YR\9BA] M)WSC/MX7.?

*X:GSZ>Y57X%7;DG>6G+IUY3]B9UQRU71V:/W\,,9_$O//P0%YQ M01\!Q.[./;P=KWH/L[RM*#/5H]4!,V>=%>Q3RGE$5&1 MXP'Z*WHA/^QV5L0VG0:_&?*

*IRMSSRGL>!3UVE6RMG74YZ[^-34 M3,*57S]E(FA^5061[ ]*FD #ZW.E]4ZN6(GXPL&5) ,+4:B9+]B1"8]]U+D@ M6<=8RJ1=EC(&&3E 8B]U!0K(*#WM1:*KB?*

@XXY7U3CI2V?!- .+Y>.#R'I8\ MZ7AM!J=$.HF!RO%T_7,X"AV#ES/Q,R1K 1\^*3.&B+3KYS0\GZWQ\BK2B+1 M'.SE9HW2'1:-[I76T*W.7^\-1!N=_ LH*

*M.2"TPO(5%B1\)/2R\49;VW2'X5,&/RX'/8! ,,&PFW#X2X]>^BO*2;65T_W M'DDO><5<'?]QE:1(\H&)X07?4WX/^,,6A"GGR,O%IX/;[3APUE).NWI,B\ M.%A_8(0>|*

*>CG^8?A!0F -AT'W_&:X# ML9^3C,I[V6T4UA(7S4JI:N6HW)&)*X/BV(*WGSL<% 3GQS[46XCI]4JAC5C MP;&W&Y3Y:4B5L)8U,< Z?CUPH,_,V8\F5^7'&*

*]'15W'H@=5,RWEA1JQ[5]Y! M_D1QQUIC %4!@WC[@+D4;JT!Q/[!X0/"*8:1JT$$)SKNAW"#5GZ(L/*34024 M8CA_7^(),#C_]9N7;KGA<9^+?)6EO8YS-*

H+'3=G6.BB[;9A0D:2@@=':M3L(H-K/G0<"7(E MKRTG>)R=SW%$2:Q[#9:T#&Z.XL2$FM8BC&WV HT:U89H*CZ@<=,,))DL"C0_-*

*MZZ/Q:ALQ+H+&G1(MR08)72@6+HCF!!%C(M!A2-1WOJ.9FC;Y%ZF[AOF+@Z, M&4N;1CZ3WS5'D.BZ6V"PZ$8/R5-I8'QD!LPK30H.Y#U@Q*D[SK?2.8N=8*

M"5)L^(<<$&S%T-/*#Y!18Y#'G)2;G ![^H]Q$X@1R%$5&E=+&I00YH'UN5F) M@(2,OAEIB>_E<[S'FBY"E)R+CO?PFH03F4/3\=Y1DW!RA!/U4R2R]&94V"2Y

*M19LRM^B2WG));[FDM[#!Z=P6<0%#Y2Q0X&C <$DS^KQI1H[DL(,'FSV[&'4' M@BPGQMCQ245QYB5+ZUS"6>=<)O+Z$4EY"*3]1**6B ,U%22.D.HZ'2TBI6\[=*

M2T @#"]9ZGMAL1K0>'$XGLNUX)D3>K5M14%,>&EG]5:>$]+ZV6+N@X0IS) M3[#EWU>[+*=UQYY?.(SC?K/6U[I)TET5LG#QE5U\99<&A6+@/E&#PI:_D NT*

*MV"4%WT\:A**]]@RS24K?J;S9)F. 0C>6S@K6P+SVTO1 Y8 !WBX*2NSK@JJ[MBGURO3ITJA6M_ZK&;YBS/@>1SE7_IPYX)&(5>8MO_UN$^THBZ4>^O83;MWRY*

*M^9JA198A%GVQ'!1&U[=/N71KT_MDT.D:+3Y_]Q,=4VXA\QW7*E.M7_D5ML@-MFN2Y+36H<=O!>'OQ*UD>8KT'B]23&:W6$E X[%62_%K1T^TW'V599_=&6:WP*

MAV9B&<(-"8(AM.9;(JE%\)\BRPGN[Y(4RV/XF?^-\F0.??+'?_KB=$<#4G<4 M6,8K+^]D%!%KTMP1#DB*DPU?DB[],#;#=RS4$[K^&44!)A!,YM16S+H?JE.M M'4>

[P>6FO\6LW2/G--3F7F)?7(U]N70(-6E>U[$.]?P-.GHM9!R=RJW[29K+ M3;!W=+&D;>P"C2Y=3B4R>#%I27AI'4&-8I==5=Q,,9?!1M5,J8AFC7J.8W!N

*MV\[TH*59]#3L7A'ZZIK;?)]MLB"9#8\",GKF%;T;*[.X^ZT M;ZC&),LX*D_.F"$K9B2$'PEG@=6R!&C^29HS.%)CB/VE]G].7GP-B M\4[3UCNWY?MW:(=4@?*

0+$F@_.L!A'._Q"P.(8I9"D:'4(MQ/G9]>[%[F*N3 M:I/",*S!H/D*+)!TVSA'*'Y&*;U9L4]*J^'/,"-1KK.@NHH]NIQZI^JV"O3; M;%'D:YB/_H9X59#,_XYU.A5$;/6&6-

^HQH42A;2ZX;_W]_]PW?E'LV_0QE0% M(Q>3]%AY@\HB"[X6.=8'XS M)#6S,=CB0.K"+(_K8 M%_*A,M-*>0@&*4>I%I*-*

$L,,/;Y83;\H[4@%,;>Z<]21[-2?:DC.,PA/E9A1K M3TYX MTZHBBN.85!(J>\D!8^G&\4@I;10H24N.Q_!H(T51UG(\D$<9+>;$.6=,4&TT MZ]HXS=!_"W(IB+%?

*$(Y&KS+.8(\R.Q)WN#V#4'!'0GL.:Z@*IY;]CGL57X0D3 M1OO^5>3ZX4!'VK+N*84V-Q@P]%_@5P)+!8ILB)*ZB(AQOSQ><)CY"07;'*

MF5P33!=@CH49=QD5Q?,/RR?:HR_R^PO_OT68A1(['W,HF(T++7N,M-\#]\$4!_MECH6!?R/C98^=@[YW;=75X2MX]"7OGC3==

MI@BE)%S"V^(37'Y@]3M[" _=8P44DEO4^'FZ%M5W=)6;'[@)KUBD)#[GV]F'N M1<[>FI-MZ6!" K&R MU7\!N((@9!RH>^@$AB0)JSB+!'V5%W2:X.TX8B9?

$9DT#QDOQ[\-6QR![!XR MC@+..VS0L^%[D5]$WERNC>OET\WMT^KV!O^Q6C[V6H,V"(,6T.%5^0YG8'P(O=

4=Z42X "J,9SK9+>KTDGZA H?P"G\E8 ; MYK4Y@#2!Q#<4Q7Z7WSH%.0O(?G&9>C#6;V-_<$WA@RIEOXMW+XP("]I+4F+Z M7)$]6!0U-^@U;_\UY%#P05=FQ&F!

*L$;"Q]2/B\6UA[KZD? (53C3FT\U;,7 M!O=QI65W>+1#($]ASZQ1+@(\,]4T3+B]{[=.*C=-DI,$>2^Z*W+2FC0Y>!%9 M //]ZAICH6.YN<^R@N33T\!"AU*

BY]Z5&%D:VP@;Q_ .&1A\.-58-}=====@]< M@3U"\]35FR"(_=,"&"+0:!UNGM/#C@2%1=P#\ T@(96(E"6WNC)&<&632%5S2 M^YA8/)/TT-

7VX,.EQH$ZHY;;FS#;)YD7_90FQ?X^]J,BP+R)!M3M0@+E17# M:MXB9^ZJ0* D1%QC^S:#?/X,_9T5!TO>+74$EC2HA8;-/T1LQ^;,C,M6!%-JD MLL7:.^^80_-+

[VSG@(=7"AT[M=%](AD6,@ELOC?&-S3JG?8.VH1^V(/\('F2Y MB$@",6N?M1C5R<,"A?&K]N.6!^>"G./]1A[(<;<.S.,+QX/M)B?P?!L,7?- M&FEMVZHZ_0 &Z30(

,GW#F;XCO)&&BO7(J:8XP)A]I<>^R1X_UB\TGV0)NY M80+_%H<)":98K,"R,.QX($8X\0PH$.)QCL56YW.W#/A;Y1,,)7F;]&#V@S*]O M73Q@>S6$0@)S"I!+-*

O98Z+!YZ\!,\4T'8A/&PL?P03,9 >V0G\#2P28X_MP6)5SZXC@;GMWA (RN4T*YM,$YVTJEWB&WL(^'0W&FOSW=$S^_.>(JU5()R4 MY$4:#[18D55NO&*

*<"H3#1LKG8(/+9)O M7Q;K>_PMA%R3]H*39/+2XE!@G#=XS]!0)DDK1H#O^INO^6IE2X9+ST0#[L M'#/$,_&/1J1 6IRC%&?BF)CV=QT*(L=P0L"7>*

(]MX8BS;9"4HWQTBK MOY+5?F8LYL]H9]8;9KD!&]LTP-TZ9X)5OR!;=>7Z")G#+;^L#,U4\"J.1\-L MB<>]U](Y=AU@ND^=9!+4GGX<:&2S('C5F+U\?'ZY_1F/N?

*_W(<-R!<(+J1.^,#(<>;=8=TKW%9^8O_0 MJ?Z+29^:JX*PN7"C_$CXC@<&[%/QY2#T4*Y M:%KPDP,13S.P-VU4'/%C-K-O9!0_SK[AS@!)*

W]2OO4M99WT_#DB,RV6/U\ MJ[#\!82L1A{5O.SM.4W>0PSWU>%K1JF-_;@!6E#PBZ+A<^ A)VC&U3^MS.+ ME:)3WFPWRV=%'&@S =7]3<+7&ZMD8!9:;

*MAP2S*M))HN1A/Z.HP$3WU:W8CQG8U2^T%4_.UB8<0H(J"^H@X='+*V[SG*)] MQ9MHO8.HRI8;/G-RB&3 \B7F>3F#UB.DK&\'Z=3=Y4]7RE"9[PRY4?*

*AX@Z$-6GNB S:?G'R'$<)D@RS+]KOYLD"#32!'D'W43(*W9]P$_;2QM0"(I@X4IL+C'FVT0T:+++&9! *8 M(Z(4I#!/7WN>A&PI[_A8W)FRC&%*

(%)S8XWW+)X$@1:DS6DIPLA4N>?Y'2@TB MMZ504!!,M ;4+-Y#)A;F^"6;J>%*CD/V,Z\VV3JAJW@!U21C\]SH:'"%;CTF M5*(9@ B1Y9E3)$/&5)N/8N-DX[UY]0![Y:

5W6), !0G R2MQLFE25?U/$ @-M<;U5.IR;,1\0B#WODR)8W3D66,3$@<1AT^)9UHN8,-Q 3$#XX\WK4S+W#%.? MDDRZ5+MLY)1,\)VF^2:(P23:J4\Y7#%

*]=P%YXZ6N2BG\W53LY TZ(J2K$A=RG&?@UX&:[0MVWY*L3KU-4Z1 M%Y%%B7)55@=WHXK8G-J(0TF0-DGF)R^,QR2CGZ=]$:9/*X(=*7C! 5"5V"6 M2I67]M<++I?*

*@A>(MJ,2 11C",HR>E*M/WYW02K2! 25)?]V/;617QH$6KMBL#>T=*6F/B92V ML&!#]RTEG^]Q'(++(>"j.(?8W*KA&XNWS)]H'2G1=Q%)9MH'2W0OQ&)9D)[*

MS%JQ4>]9ZX7&FV\[F$?M^$[QO5Q:]57J8)NG)$=$AWQ(O+@3T46Y%..UA/AZ M6,-A;$QR)FM(+:)"SUV/1(OT%PQ9UH\QQ;%TW MN3PT<7FJ[:=WQ%[GB*

&)S5PRY!@0" IHOS5ZL_'L;8JU.&K<\ H5))]E5>" MN;(N]!WK93<{:\!?\=(4:.BKR.GP.M %1QI(=,\!:U:2B/*]_9X VO%*!>IPG MQ)BL4>3@&@^Q/32"&;;?*

9CTRZ[V[BE/MZ2K&6"9;2:5I.^E>8S242 _7#%)\'_9JY#7^-,3; M7!.717V8[B0P3(9;V,9[A #P)CD5\.O!M[M]E!Q073^"-HR0B#>-MF])-\O?(:2PW]?

F@@&K0WFY%']/T0.CVJET-"'"I M?[PYHD@2(W4+Y/6.EVY-=&F$KP@G*P2GX> 3X!ZPHK.BT2=)=98H&(15H7?F>PM\KG_]I@] MNE$;^K+=0 ?*

*8[HQV"A7>]T8L7GC]L?]6D#39VI9HBNE^&*KD,]9T5;ZS^_3[$+(M\5'T0QTE.5Z":?D8]01'TWOPN#H=%]4#OX M.<$\. ^]:%#Q^:D3AAA[.XS)8U8HSX+03?*

B/71)C+IL>]O'E7^//?_^[K'C- M\C O" 0T)ID>5O.SM.4W>0PSWU>%K1JF-_;@!6E#PBZ+A<^ A)VC&U3^MS.+ ME:)3WFPWRV=%'&@S =7]3<+7&ZMD8!9:;

*MXT7TEM"YKUY$9(=__MY/45"7N6/CZ8D^.3_\^+=\'M'LE9UT"/_JXA"C =$3^ MROX1)#LOC(^_*2C2ZDGF T7_+=@\?@/ID72J)].R\GBQKWM2-1.E?IBU)>9K*

*MZ/3G=0\THRT\9@:]/$\QI.W]3SRP_0/D?@WR(!6]N)=@*0PT?/?4#VMX^0+T M*KY[1Q<2*'%R]#)0N)4485=IF.5)]'A ;;;"\+Y^DB*Y7GSHTIYT&,@IH&IV*

M+F%4'0WE;.4OT5681,E_0O\&9>$V9A^L: C,0R5"$2U\GH5DK:O#8H=_(_-(M$;E]F'M1[07K0ZH_#R3XJ[M_/>/7RQY44Y[C#FYY3=%<0TTTE$/;/F?

*$7WM(BG4,F^T"ME =[2*K_M-FM!WYC'$^_Q9NL> +&7*PJ(!O00^0#Wb; M-[>[.?O\\'@2,[0E<.$9K8@V7!WGK3IYBU:/Z)NW]=>EV:^-_ TTE]13AA5 MZ(=*

[C\CPKSF\1]729HF'YB$7[Q\:"<];A&0B&&53&!9MN6%%%D2S0(+>]G^7 M65[D T$"6+6XB+=KK*IF'LT/R#BZO-I8L$I]Y9CI4V$5FEGYAP?!Y>H30)YM*

M[8VK]_R4O/CD M0V=QR(G1H30),BGX4.,$2IG%(K/(U('TPI<- E=9C9:; M5NUK?!&\Z.O[S?H-GRA5>$F'SX7_%F+,2W!9A<%(Z IN(;]J*"_%:BQA,19*

M19)1A@&>M4H%(XV](Z^SO@1SG/(44_6N5>H)@O,DBLV7(CB.6\37%&D'.PHG MP62-G4#UIX)LM,Q[1!FFYV$ '"NZ76$24%WL(=R@E1^2.A19:8"@"L=0D!$.

*M@GFF1!]:YM\Z)O)Z1A6X7D+24#92&PV29NIK/'[=:ITSS#$DN\6L;C%DH"*MQ?Q'+)3(ACE$G9&,D99%2V@>7;^%]"HG%BP YZ&D1.2HOJ+Z%)"<8D*FRA%)*

M+H#(0;5V5B\RKL[4Y=BH=6: M527@6&WW!&$F_)2;Z@7?.KKW],A[1@.)@ M,*-Z5>+JAZ%, .T3CW"$3EFD6<_\7 MM"4=1)+TH&;-Y4Z!*

(D3)[\+5F[ZAK]E(B:H_!OGXW6XVR"=!:#?X0HYZTQB=F>N,L%48]N U)?O50M(M2.MGGS97RK# MTL3.^[_ !U!+ P04 "'!CCV=9N7"QC>4(#9-0 #P

&YK=(M97@S M,5\Q+FAT;>U;;5/<.!+^OK]"1XHMJ!H/\P(S8)-491.VEB_);395>U[EJ\WH MD"VO),_+_OKKENR981B2X<(&2)&J +9;ZE:K'_73LGP^<85Z\Q.[GP*

*7^)N=M.^D4O+GX3S3L=_OG1^$2!8X.B^4BP6S;]'[5:I$94L8\9KI_\EBTH;QTN7 M5%P(65I%[+2:)TJ6$$U 7DU0I'B>6?DW*4RU$6 BO-(ZS]M61:Y+1R(0*

M]WN52X+506'BG^6\D&H1?Y8%/8!9NR3+GC9"J;..5V@K(.YB[B25V6L(>D M@YI:F83Z2"R%<\@K@Q$,\.K9$/W%]6AKID4;A+GTD492D))2GY^U1_UDO,C

*M:OOF_*C" _^@_[\=_[UG(R.G\C1%G6FD3O^KY?\G=XY^%*4RU M$@_AD(OY1*;2L1"B2[?LZ)#^X&MJ[_9)A@:-V9SX1W+!#NXM/GR]_O7SWIO/E MQP]_?%]';*

(O_7=WP;;.^[++#?]{P;P?[LHF@JRP[+P#B9+YB,%^(J2M%%_$N8+YNO-&:/Y_ M:TMJ6^.\3&0=-R[Q7HI(H8U3;H%6P5O^7 WQM#L8G>T_EH-1^_AL/!J.S@:G MO=

[H>#^9X4(:I0;X=7P-4%-:ND)6?HEW3OD"Q[8>]/OME.QMMP'C?U>,W^C MPT>*)C;A4V &IA)F(#""'I&6_US@ ,&K!/@'E-*9+]JLV!>2WH9]9K@V* <.X*

*MD5HPP%PEV!]0X5RG8-BPUV&#WN"8Z1SU7Z,OV.<)H+E0.YG9U3I.;_AJ)7\) MT\<*T!$S"--?<&X$A6&Q8->EGBD05J)T6I"C J-/97:,.6K%9*

M#DG4"@408QI#UJL+]F3<3EBN],RV #1PA5%NL")CG&YVO!Q:V5G#D6V-N67M M"Y2>&I2.GP&4/M\(O)]?S0>]_EEB&[@T1)V6=IWG$B\/[*$/RTO@ 8$#+

M5(‘G68!#3S')M2"Q K,;)3=Z:]'FREM:VQ'^HU6 0F5T1D(O&W9 0:^ $12 MB.Z+>3;AY16PMYA./M4)?I#'O5/#B!8T3\1X2I<2]KVRH! ZI]1SED#9@-*

MV;\3HORHOSPL+,DE.MX11$BIO%#8_"T.SP[_5X@"'5'I[&C@7",(#P=#$Z& MH]\@Y'0X'C\0"@_XX=.'X7NPZ&\,1L^UOHZ4#M' C-=V!R;$QU+ J&\T!8:G*

M:X,=8/A-I?49"Z6@]/U0=;[=>OY,NSE(8P:BK="0J?)I?108MY#6ZQ64G#G M#4VM%)(;20.0@8CZ!%Y23[4E*4EG%8 MWH@5R<06@;*N,VW*P42Q G#]B*

>/%.^H/3;49H^.Y3NG&UN@77W/+4S9A'G M4RD(BMSJDE-"QD"N#55SA$]N1(L51*_DJ532+8AZ;E-+*X>'E4=, /T-T35R M[?/^O!E059L*$6L]5I] M@><3A&?

*H#W02\]\#)@8[SHHEOA?-!0EPG,*_M0,!Z1_?X /8(.H.;-ID7$3HEQ(O7.(DP#7!L:*(9%X/VE S:!?%"S$5R! H-_M_P(!WX(]GF,.E,9NA*

G@[+$&"XILLD@7VNF&,-5NYI%)\|"N$6;]+F>MRNW8^ M.J[N()\R2+[AY@^(6$!13, ^42[.M@3:T5^"A6^P^DIYO XB$V?FTPYG[SY3V

*MX):%3S398*7_BXM9KA'MQKM"VS!"3;83%QPD22+O-4W@$5R"*T?4K+;?8C9< M ;S!KT%$LLZ06S:B_X+?')# 9"^#W#)V/6+AQF_`?(`?_]ZDW632$CFL_9Z*

*M2)GTI43<*AHY@N3 _;>_)EEO'C?V55-Z3S)G)9*N;6R5O,T[9ELO2R3S>HDE(M9H8B%2[VT7S]!<"=Q$]!0D-652KC(P$0NM%H]-Z@,2&W!LPI8_:(D"&2.8XZ*

MH6;!? ND^=2+1XFV#,M!DU ZA(PC8"XS"9.#C$D 787GX8V..XU.]6!,U1(<-M1Z\I#]JH7#B.+4U)V"S*<-Q9>;+:,$!=- Y](RUYX*L]@L-.\@70!-[66[Z/*

*M,5?;52U^[+IX5L5K%@:AEQY*R@5TF5&*,FDBZ/')4?/660NK$CE#NK,;X)V MY*6/Y9/L69()OUQN*LZQ3%_"[9LH=X$_'A8(0M^,:(99,+(T[X" _]5N'_|#*

M"PD%";9>VE^>/)VK KFW&$GW>@+V@\I=[@DL;UYIX6).(TF'=V^.U)M_7H M?0MWQ8ZIL?IWGS#?:?IAK9]!BNZZ.I.HHCMSLE]V%O\-FXQ\%@-

*WB7QZ@VKH]E]EA7=>AE#18]=-M'GO:2]=]Y+!>+'SD>M_#DBR?"K(IK(LV0OVU%T4HN#K4N*P&.HG0&JO:TWH[-MI/2\[CQ8-M-*

^[%&TK]D#"ML(OX^D)\T;EGTK5,OS/XY[#$ZVWQCS5WG-Z+NR2M?KW>$[N' M@]8"AG<_7/^9&>:?DKR\RV"\DND^)RCSHCX%4[)^C=#?7!1+7&VE.F[5I

*M[34,PW"[V2"?-CC%+[=PIYR1H*YLEI/-$?[RRUOHOPUO685-@=WSR$6=#;=2 MLY)_ZHBK^=,Q%6R\H#&D%),F-?SVG)DB$ZN[N)"98 D*-*V?H)'!OSH<@VB-*

M@(%1$C20ER(+1]R&D9VTN0)=X@ -HTHT L\<54/+,W,Z"O@D#T[S'(],K* 1 MHL0)] VP_8"3,2DY@A-1EPO32)FW8<69!M3[')DM*I$U\I=^)VT?I;EWG$4

*MJ&M^1_D+' W"E,FG?7\"9""!,9D3%KHZ8:RNOAGE:%/]GQOC6&Y *Y_M0]KQ?C6:RHBFD]OQ)C::R%'PH3Q>PT83(?KN^CGP\W>P^.&% LRBDX&T<)@* M+7*

*FE^\!,X,Y0U<=.0:?*W51X#F=)WJ4)U21?4C7-J.I"O_'I>3C$'B]LWWYB_^LU"!7FABA,:)WK2U08G31?T?A9C05[++W^6'7D[*

MY)+9ZGAF:X,\/VZ3]S\%"PAPG^TP.!__%)9K<+<[^AKTP',4?@01M%A0638 MW=Z+V;F!XK&7!.!+ O!<_*BMFT^O >F[P.-)G*'6-\QE1(+!+F[ZZ*3/<\P1 M+TLB-*

*57V'I*RQ)'@VHEF0 -#*/]}YYP/*',E.S?*+(-8& .LJ_PSW7\=+85E MJQ0UI."./T=%RPY_+BNTB81+WBC3>N'=OYZQJK?S?%3DH>]%;.. >.R)-((*

MM/6B4NYGD"JKA,4]$1GRL#]%M8(;](ZB9$!%Q59]Q (#K?RW3IY12]S@=TE M2P=F1,"4%)8PL;9A.EKN@_]X=-.[WM@QU*UA!-;Q51F&D;IU_TFQ2>)?[%Y M4IZ]*

*[7+O2 ?A>\H^:H'"*T<+HW:SD+_Y+6 '942E5\="")T+Z\R86-M%U)R& MN&;3%E?IWIAG=^E89XX>CQ@&_ ZK]%^/K*=GOS,:NYP@GV+S%YRJ,. M6':$N"7">'L?/Q-*

+]?HCZ1QXU6:401U:"YC&;YA$R7]"_P9EX3:6XU8P_!1X MG8S/N?%(WQB2)1:C5'!FCD>=A!I+9W#8#]+15)<+!O--+D"3X:"CT,?<-2T0 M);YXYH'N$-.:=6MZ(-

:A$$O7E)_7V&)]V+(Y)WAV]5_;^1[7FS#;)YD7_90F MQ?X^]J,BP/>&5(O'I!AB62E8[BL4U7+1+V'^=EW@[>Q0NL@RE%?U\EG F%S> M>!VH%%8)/0US$D+YR(FZ&-

*M47GNB?:*GP? M9=F51V*8*RZVV!%WM\[N!:M88WHW* W?Z48[O=HYW(\]U]):2]4?\HJP;MOM MM^1^DFN'_Q>LO6]<)59_)?O/%.'V;?1%<%,0V: ,IR_?)]*

[C)9]H^KDHB1QK M_.KOA62^1V22$_\'NJ.[K? HC.QU%!]*T?@#*N@$$(.&^E+&48D$>#' ;6XA M-TK748@OA2LOA2M5XGO;^C/\"%5',, JW&<&!6Z4Z?*

*L454R5F(%"2'"7)4CB M51W!AZANI4F$G,-EX$?, CK7#,R #?7#4X9*58Y9[1A0%I3N >ZY*@054I^XP1+2AC'X0 M-V04*

:JRQU=5("-0@<:44L+Z1;X5HNL=1\I<#]$C(Y!8U6Q=X'!>'\Y56]S M2D)7[8WFT;M:/H^B2FE@CG:.$% ^ MZT0Y99"!!G+CF-9"R'@#>>].

*<]].T&5">M]8N8>0805RS?CAK9"1!_*NC1), M(3D#%NFV:G)QI#;BX#C(X%_G_(6+1(F^Q,<,@M>X"0"'OX"#+:M;/_ >:X_Y+9(0(A.*?.1,AYM4Z&LF@/DUE-*

:/"T;5U/V+=K5L(S6J;#]=9@ MLV:6Q9D%JR=BV=+O73)++&@\!%^O[E&HJLR#T#,RJDGHMLZ#M#"QD1]6*F06I M9V#"T:E$,PL.S\#4H%8?9Q;LG8L2K5:*

[9Q84GHL&]%Q2:!8LGHLZPRIS=#[M M=^-\/VW%Q4HV3'%#]N=>)=2;TB+RL2+$;22P]6%'$5Q=6-L/L.YR\9BA] M)WSC/MX7.?

*X:GSZ>Y57X%7;DG>6G+IUY3]B9UQRU71V:/W\,,9_$O//P0%YQ M01\!Q.[./;P=KWH/L[RM*#/5H]4!,V>=%>Q3RGE$5&1 MXP'Z*WHA/^QV5L0VG0:_&?*

*IRMSSRGL>!3UVE6RMG74YZ[^-34 M3,*57S]E(FA^5061[ ]*FD #ZW.E]4ZN6(GXPL&5) ,+4:B9+]B1"8]]U+D@ M6<=8RJ1=EC(&&3E 8B]U!0K(*#WM1:*KB?*

@XXY7U3CI2V?!- .+Y>.#R'I8\ MZ7AM!J=$.HF!RO%T_7,X"AV#ES/Q,R1K 1\^*3.&B+3KYS0\GZWQ\BK2B+1 M'.SE9HW2'1:-[I76T*W.7^\-1!N=_ LH*

*M.2"TPO(5%B1\)/2R\49;VW2'X5,&/RX'/8! ,,&PFW#X2X]>^BO*2;65T_W M'DDO><5<'?]QE:1(\H&)X07?4WX/^,,6A"GGR,O%IX/;[3APUE).NWI,B\ M.%A_8(0>|*

*>CG^8?A!0F -AT'W_&:X# ML9^3C,I[V6T4UA(7S4JI:N6HW)&)*X/BV(*WGSL<% 3GQS[46XCI]4JAC5C MP;&W&Y3Y:4B5L)8U,< Z?CUPH,_,V8\F5^7'&*

*]'15W'H@=5,RWEA1JQ[5]Y! M_D1QQUIC %4!@WC[@+D4;JT!Q/[!X0/"*8:1JT$$)SKNAW"#5GZ(L/*34024 M8CA_7^(),#C_]9N7;KGA<9^+?)6EO8YS-*

H+'3=G6.BB[;9A0D:2@@=':M3L(H-K/G0<"7(E MKRTG>)R=SW%$2:Q[#9:T#&Z.XL2$FM8BC&WV HT:U89H*CZ@<=,,))DL"C0_-*

*MZZ/Q:ALQ+H+&G1(MR08)72@6+HCF!!%C(M!A2-1WOJ.9FC;Y%ZF[AOF+@Z, M&4N;1CZ3WS5'D.BZ6V"PZ$8/R5-I8'QD!LPK30H.Y#U@Q*D[SK?2.8N=8*

M"5)L^(<<$&S%T-/*#Y!18Y#'G)2;G ![^H]Q$X@1R%$5&E=+&I00YH'UN5F) M@(2,OAEIB>_E<[S'FBY"E)R+CO?PFH03F4/3\=Y1DW!RA!/U4R2R]&94V"2Y

*M19LRM^B2WG));[FDM[#!Z=P6<0%#Y2Q0X&C <$DS^KQI1H[DL(,'FSV[&'4' M@BPGQMCQ245QYB5+ZUS"6>=<)O+Z$4EY"*3]1**6B ,U%22.D.HZ'2TBI6\[=*

M2T @#"]9ZGMAL1K0>'$XGLNUX)D3>K5M14%,>&EG]5:>$]+ZV6+N@X0IS) M3[#EWU>[+*=UQYY?.(SC?K/6U[I)TET5LG#QE5U\99<&A6+@/E&#PI:_D NT*

*MV"4%WT\:A**]]@RS24K?J;S9)F. 0C>6S@K6P+SVTO1 Y8 !WBX*2NSK@JJ[MBGURO3ITJA6M_ZK&;YBS/@>1SE7_IPYX)&(5>8MO_UN$^THBZ4>^O83;MWRY*

*M^9JA198A%GVQ'!1&U[=/N71KT_MDT.D:+3Y_]Q,=4VXA\QW7*E.M7_D5ML@-MFN2Y+36H<=O!>'OQ*UD>8KT'B]23&:W6$E X[%62_%K1T^TW'V599_=&6:WP*

*MAV9B&<(-"8(AM.9;(JE%\)\BRPGN[Y(4RV/XF?^-\F0.??+'?_KB=$<#4G<4 M6,8K+^]D%!%KTMP1#DB*DPU?DB[],#;

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`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}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}>+*[?"JS7H,F6..!31\8VFOW#_^_D8Y&3/$/O:I=?<"T>]3N MHGNM= <$EI+B? =U88X+F,&M=$'?ZQZ*(QE058:-0@]Y'AN:0;*#KTZV>=K-C MJ_WV\=&3#C%VVT3__CS8&N';A.R*W1G=PS]V)^"NG-D=B3 MNT\XCKM&MR=XPOS4LE^]$L6BMQRL68F?RE,.S '[=G[UY?]<_79^_>7RZN)Z MG2D?P6F_WSXY>BY0?V;7^YEU^T$!MO=4V+S8^>CE,^(/F6KE"/2RS=[JL>]-MU+]DZDCD[/-(0,:^S]NBW_U6PC^HYDL%O8U5W?N/?T&%VMW3<_^Q>(B_]:A[ME2/^/^S[EI66KL1"/"A4"LV8G3NMQM+G0]XQ\=LT](D0KEB5%W>[NR8J-$]I M+X]N?:TMN6!(MU^?S3__FC1E8SF*;]6N&X>78L8TL=AT=';$A_VRVM3]0\ M0_2'7$[XS+RG3Y[^N7LP'VD[C=02P,$% @_8X]G6;_SX;SP!@-M"R4]N:W1R+65X,S)?,2YH=&WM6FU3VS@0_GS]%3HZ=. F=NP$ K%3 M9KB47OE">]#-W;<;Q5IC76W+)RDDN5]_NW]6PF%0MMKC\P0P%H5X^>W;56 M&B0V2X^>L4$"7.!O-K#2IG!T\H?3];C^H%W]BP+M6F(P4F!+&C)VE\'(KX_I* MY@'C8ZM^E%FAM.6Y#0LNA,RO G983,-4YN D(*\2&S __W"JU"'G=C%$+.U85 M@>?NRSS\QY&Y@&G@=,_,YDU?;.MC8Z&,M%+E@8:46WD-X4A-'2/_(84CI05H M!Y^@GD'1J(A5;DD$ M\K;%A972D,R[.89S*=!9G\BH/4H@MZ:#NC9I)(BTXIN 1! (4&9ZY)$:[IOE4=ZH(89.@EM;) M4!)R4O+BN=_SPD&,^AX-V@7^('XECI]SBH@#[>8%"^W#0NK\VXTBE2@?/ MO? (3;I[_I%K"D4K%8P!R,DWD2%I6470.RQT!\3L?4[L9DP@-_+V^\%\)AHN3 MX>7IVS/F=_<]-CPYOSQ?3H\ID<7/WU96&[RAKN"\C ,WHVU&6/.858QFP#3 M\/=8:LB #'+8@Q)"9,Y.Q^G@$AQQ]_;&>TR%9?B%Q"--<83U'4RC1*>?P$[MCBPU^_WN7HMQPS@.)D"P'>KPXOFTX_E1N"Q=/1/A+N.YH"')5:I5P7&&"2^0 M.ZS7I?\N*9XR_[QX+<<<<%.EENT8:@$L!UL_QO',@+=8N\T&"D(C+H%>(16:5)Y1F\MURS MRP00?\!ND5F=UU!E!<]G\RFUJCGAE^;L%]2/T1PUG)(;R*PVX;7,>1Y)GC8F ML)UW6N*3 A]]T#@'Ol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| M (!)+X# &YK=`(M97@S,5\R+FAT;5!+ 0(4 Q0 (&,/9UFO\^&\\ 8 M LE / _ 3W" P!N:W1R+65X,S)?,2YH=&U02P4& / 4 !0 U 0 6LX# end XML 61 nktr-20240930_htm.xml IDEA: XBRL DOCUMENT 0000906709 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000906709 2023-09-30 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyThreeRestructuringPlanMember 2023-06-30 0000906709 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2023-12-31 0000906709 nktr:MeasurementInputMarketParticipantSubtenantBorrowingRateMember 2023-07-01 2023-09-30 0000906709 nktr:PurchaseAndSaleAgreement2012Member 2023-12-31 0000906709 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000906709 nktr:ManufacturingLaboratoryAndOtherEquipmentMember 2024-09-30 0000906709 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-30 0000906709 2024-11-01 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyTwoRestructuringPlanMember 2024-09-30 0000906709 nktr:StockOptionsRSUsAndPSUsMember 2024-01-01 2024-09-30 0000906709 nktr:StockOptionsRSUsAndPSUsMember 2023-07-01 2023-09-30 0000906709 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-09-30 0000906709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000906709 nktr:SubleaseOperatingLeaseRightOfUseAssetsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-09-30 0000906709 nktr:PurchaseAndSaleAgreement2020Member 2024-01-01 2024-09-30 0000906709 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-01-01 2024-03-31 0000906709 nktr:SubleasePropertyPlantAndEquipmentMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0000906709 us-gaap:EmployeeSeveranceMember 2023-04-01 2023-06-30 0000906709 nktr:StockOptionsRSUsAndPSUsMember 2023-01-01 2023-09-30 0000906709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000906709 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000906709 nktr:UcbPharmaManufacturingAgreementMember 2024-07-01 2024-09-30 0000906709 us-gaap:AccumulatedTranslationAdjustmentMember 2023-09-30 0000906709 nktr:ContractTerminationAndOtherCostsMember nktr:RestructuringPlanMember 2023-01-01 2023-03-31 0000906709 nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember 2023-01-01 2023-09-30 0000906709 us-gaap:EmployeeSeveranceMember 2023-06-30 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyThreeRestructuringPlanMember 2024-01-01 2024-03-31 0000906709 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000906709 2024-01-01 2024-09-30 0000906709 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000906709 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 0000906709 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0000906709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000906709 us-gaap:AccumulatedTranslationAdjustmentMember 2024-04-01 2024-06-30 0000906709 nktr:PurchaseAndSaleAgreement2020Member 2020-12-16 2020-12-16 0000906709 us-gaap:RetainedEarningsMember 2023-12-31 0000906709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000906709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000906709 us-gaap:CostOfSalesMember 2024-07-01 2024-09-30 0000906709 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000906709 nktr:OtherPartnerMember 2024-09-30 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyTwoRestructuringPlanMember 2022-12-31 0000906709 us-gaap:RetainedEarningsMember 2024-06-30 0000906709 nktr:UcbPharmaManufacturingAgreementMember 2024-09-30 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyTwoRestructuringPlanMember 2024-01-01 2024-09-30 0000906709 nktr:Nektar0165Member nktr:BiolojicDesignCompanyMember 2023-01-01 2023-12-31 0000906709 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2024-09-30 0000906709 srt:MaximumMember nktr:Nektar0165Member nktr:BiolojicDesignCompanyMember 2023-01-01 2023-12-31 0000906709 2023-01-01 2023-09-30 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyThreeRestructuringPlanMember 2023-03-31 0000906709 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000906709 nktr:SubleasePropertyPlantAndEquipmentMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyThreeRestructuringPlanMember 2023-01-01 2023-12-31 0000906709 us-gaap:EmployeeSeveranceMember 2024-01-01 2024-09-30 0000906709 nktr:SubleaseOperatingLeaseRightOfUseAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-06-30 0000906709 srt:MaximumMember nktr:Nektar358Member nktr:EliLillyAndCompanyMember 2017-07-23 0000906709 us-gaap:RetainedEarningsMember 2024-09-30 0000906709 us-gaap:EmployeeSeveranceMember 2023-07-01 2023-09-30 0000906709 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0000906709 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0000906709 nktr:ContractTerminationAndOtherCostsMember nktr:RestructuringPlanMember 2022-12-31 0000906709 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2024-09-30 0000906709 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000906709 nktr:SharePurchaseAgreementMember nktr:BristolMyersSquibbCompanyMember 2018-04-30 0000906709 us-gaap:CommonStockMember 2024-06-30 0000906709 nktr:SharePurchaseAgreementMember nktr:BristolMyersSquibbCompanyMember 2018-04-01 2018-04-30 0000906709 nktr:SubleasePropertyPlantAndEquipmentMember 2023-01-01 2023-09-30 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyTwoRestructuringPlanMember 2023-09-30 0000906709 nktr:SubleasePropertyPlantAndEquipmentMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-06-30 0000906709 srt:ParentCompanyMember nktr:Nektar214Member nktr:BristolMyersSquibbCollaborationAgreementMember 2018-04-01 2018-04-30 0000906709 us-gaap:ProductMember 2024-01-01 2024-09-30 0000906709 nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember 2024-07-01 2024-09-30 0000906709 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000906709 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000906709 2024-03-31 0000906709 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2024-09-30 0000906709 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000906709 us-gaap:EmployeeSeveranceMember 2023-12-31 0000906709 nktr:TcgCrossoverFundIILPMember nktr:SecuritiesPurchaseAgreementMember 2024-03-04 2024-03-04 0000906709 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000906709 nktr:ContractTerminationAndOtherCostsMember nktr:RestructuringPlanMember 2023-04-01 2023-06-30 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyTwoRestructuringPlanMember 2023-07-01 2023-09-30 0000906709 nktr:SubleaseOperatingLeaseRightOfUseAssetsMember 2023-07-

01 2023-09-30 0000906709 nktr:SubleaseOfLaboratoryAndOfficeSpaceMember 2024-04-01 2024-06-30 0000906709 nktr:SubleaseOperatingLeaseRightOfUseAssetsMember 2024-01-01 2024-09-30 0000906709 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0000906709 nktr:MeasurementInputMarketParticipantSubtenantBorrowingRateMember 2023-04-01 2023-06-30 0000906709 us-gaap:TreasuryStockCommonMember 2024-03-31 0000906709 nktr:TcgCrossoverFundIILPMember nktr:PreFundedWarrantMember nktr:SecuritiesPurchaseAgreementMember 2024-03-04 0000906709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0000906709 nktr:ContractTerminationAndOtherCostsMember nktr:RestructuringPlanMember 2023-09-30 0000906709 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0000906709 nktr:InterestAndOtherNonTradeReceivablesMember 2024-09-30 0000906709 nktr:PrepaidResearchAndDevelopmentExpensesMember 2024-09-30 0000906709 us-gaap:ProductMember 2023-01-01 2023-09-30 0000906709 us-gaap:EmployeeSeveranceMember 2023-01-01 2023-03-31 0000906709 nktr:LaboratoryEquipmentMember 2023-12-31 0000906709 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000906709 us-gaap:RetainedEarningsMember 2023-06-30 0000906709 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2023-12-31 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyThreeRestructuringPlanMember 2023-09-30 0000906709 2024-01-01 2024-03-31 0000906709 us-gaap:CommonStockMember 2023-06-30 0000906709 nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember 2023-07-01 2023-09-30 0000906709 us-gaap:CommonStockMember 2022-12-31 0000906709 nktr:ContractTerminationAndOtherCostsMember nktr:RestructuringPlanMember 2024-07-01 2024-09-30 0000906709 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-07-01 2024-09-30 0000906709 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0000906709 srt:ParentCompanyMember nktr:Nektar214Member nktr:BristolMyersSquibbCollaborationAgreementMember nktr:MilestoneOneMember 2020-12-31 0000906709 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000906709 nktr:BuildingAndLeaseholdImprovementsMember 2024-09-30 0000906709 nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember 2024-01-01 2024-09-30 0000906709 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000906709 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-03-31 0000906709 2024-07-01 2024-09-30 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyTwoRestructuringPlanMember 2023-12-31 0000906709 nktr:Nektar358Member nktr:EliLillyMember 2017-07-23 2017-07-23 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyThreeRestructuringPlanMember 2022-12-31 0000906709 srt:MaximumMember nktr:Nektar0165Member nktr:BiolojicDesignCompanyMember 2023-12-31 0000906709 nktr:MissionBayFacilityMember nktr:TwoThousandTwentyThreeRestructuringPlanMember 2023-01-01 2023-03-31 0000906709 nktr:SubleaseOperatingLeaseRightOfUseAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0000906709 nktr:ContractTerminationAndOtherCostsMember nktr:RestructuringPlanMember 2023-03-31 0000906709 nktr:Nektar0165Member nktr:BiolojicDesignCompanyMember 2024-09-30 0000906709 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0000906709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000906709 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0000906709 nktr:TcgCrossoverFundIILPMember srt:MaximumMember nktr:SecuritiesPurchaseAgreementMember 2024-03-01 2024-03-31 0000906709 2023-03-31 0000906709 2023-04-01 2023-06-30 0000906709 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-09-30 0000906709 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0000906709 nktr:BuildingAndLeaseholdImprovementsMember 2023-12-31 0000906709 us-gaap:FurnitureAndFixturesMember 2023-12-31 0000906709 us-gaap:TreasuryStockCommonMember 2024-09-30 0000906709 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0000906709 nktr:StockOptionsRSUsAndPSUsMember 2024-07-01 2024-09-30 0000906709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0000906709 us-gaap:RetainedEarningsMember 2022-12-31 0000906709 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-03-31 0000906709 nktr:LicenseCollaborationAndOtherRevenueMember 2024-01-01 2024-09-30 0000906709 nktr:PurchaseAndSaleAgreement2020Member 2023-12-31 0000906709 nktr:RestructuringPlanMember 2024-09-30 0000906709 nktr:UcbPharmaManufacturingAgreementMember 2023-12-31 0000906709 nktr:BristolMyersSquibbCollaborationAgreementMember 2024-02-12 2024-02-12 0000906709 us-gaap:EmployeeSeveranceMember 2022-12-31 0000906709 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0000906709 us-gaap:EmployeeSeveranceMember 2023-09-30 0000906709 us-gaap:CommonStockMember 2023-09-30 0000906709 2023-12-31 0000906709 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyTwoRestructuringPlanMember 2023-04-01 2023-06-30 0000906709 us-gaap:CostOfSalesMember 2024-01-01 2024-09-30 0000906709 nktr:TcgCrossoverFundIILPMember srt:MaximumMember srt:AffiliatedEntityMember nktr:SecuritiesPurchaseAgreementMember 2024-03-01 2024-03-31 0000906709 nktr:LicenseCollaborationAndOtherRevenueMember 2023-07-01 2023-09-30 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyThreeRestructuringPlanMember 2024-01-01 2024-09-30 0000906709 nktr:ManufacturingLaboratoryAndOtherEquipmentMember 2023-12-31 0000906709 nktr:ComputerFurnitureAndOtherMember 2023-12-31 0000906709 2024-04-01 2024-06-30 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyThreeRestructuringPlanMember 2023-12-31 0000906709 us-gaap:AccumulatedTranslationAdjustmentMember 2024-09-30 0000906709 nktr:LaboratoryEquipmentMember 2024-09-30 0000906709 nktr:ContractTerminationAndOtherCostsMember nktr:RestructuringPlanMember 2024-09-30 0000906709 nktr:PurchaseAndSaleAgreement2020Member 2024-03-04 2024-03-04 0000906709 us-gaap:TreasuryStockCommonMember 2024-06-30 0000906709 us-gaap:RetainedEarningsMember 2023-09-30 0000906709 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0000906709 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-06-30 0000906709 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2024-09-30 0000906709 srt:ParentCompanyMember nktr:Nektar358Member 2017-07-23 2017-07-23 0000906709 us-gaap:EmployeeSeveranceMember 2023-03-31 0000906709 us-gaap:EmployeeSeveranceMember 2024-09-30 0000906709 nktr:SubleasePropertyPlantAndEquipmentMember 2024-01-01 2024-09-30 0000906709 nktr:PreFundedWarrantMember 2024-03-31 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyThreeRestructuringPlanMember 2023-07-01 2023-09-30 0000906709 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000906709 nktr:ThirdStFacilityMember 2023-04-01 2023-06-30 0000906709 nktr:ThirdStFacilityMember 2024-04-01 2024-06-30 0000906709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0000906709 us-gaap:AccumulatedTranslationAdjustmentMember 2024-07-01 2024-09-30 0000906709 2023-01-01 2023-03-31 0000906709 us-gaap:RetainedEarningsMember 2023-03-31 0000906709 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2023-12-31 0000906709 2022-12-31 0000906709 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000906709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0000906709 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-03-31 0000906709 nktr:SubleaseOperatingLeaseRightOfUseAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0000906709 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0000906709 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0000906709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000906709 nktr:TcgCrossoverFundIILPMember nktr:PreFundedWarrantMember nktr:SecuritiesPurchaseAgreementMember 2024-03-31 0000906709 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000906709 us-gaap:CommonStockMember 2023-12-31 0000906709 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-03-31 0000906709 nktr:MissionBayFacilityMember nktr:TwoThousandTwentyThreeRestructuringPlanMember 2024-04-01 2024-06-30 0000906709 nktr:MissionBayFacilityMember nktr:TwoThousandTwentyTwoRestructuringPlanMember 2023-04-01 2023-06-30 0000906709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000906709 nktr:SubleaseOperatingLeaseRightOfUseAssetsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-12-31 0000906709 nktr:InterestAndOtherNonTradeReceivablesMember 2023-12-31 0000906709 nktr:ContractTerminationAndOtherCostsMember nktr:RestructuringPlanMember 2023-06-30 0000906709 nktr:ContractTerminationAndOtherCostsMember nktr:RestructuringPlanMember 2024-06-30 0000906709 nktr:PrepaidResearchAndDevelopmentExpensesMember 2023-12-31 0000906709 nktr:MissionBayFacilityMember nktr:TwoThousandTwentyTwoRestructuringPlanMember 2023-07-01 2023-09-30 0000906709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000906709 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-12-31 0000906709 nktr:TwoThousandTwentyThreeRestructuringPlanMember 2023-01-01 2023-09-30 0000906709 2024-09-30 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyTwoRestructuringPlanMember 2023-01-01 2023-03-31 0000906709 nktr:ContractTerminationAndOtherCostsMember nktr:RestructuringPlanMember 2024-03-31 0000906709 nktr:PurchaseAndSaleAgreement2012Member 2024-01-01 2024-09-30 0000906709 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2024-09-30 0000906709 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-07-01 2023-09-30 0000906709 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000906709 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-04-01 2023-06-30 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyThreeRestructuringPlanMember 2023-01-01 2023-03-31 0000906709 us-gaap:AccumulatedTranslationAdjustmentMember 2023-07-01 2023-09-30 0000906709 2023-07-01 2023-09-30 0000906709 nktr:ComputerFurnitureAndOtherMember 2024-09-30 0000906709 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-04-01 2024-06-30 0000906709 us-gaap:RetainedEarningsMember 2024-03-31 0000906709 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-12-31 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyThreeRestructuringPlanMember 2023-04-01 2023-06-30 0000906709 2024-06-30 0000906709 nktr:MissionBayFacilityMember nktr:TwoThousandTwentyThreeRestructuringPlanMember 2023-07-01 2023-09-30 0000906709 us-gaap:AccumulatedTranslationAdjustmentMember 2023-04-01 2023-06-30 0000906709 nktr:SubleasePropertyPlantAndEquipmentMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-09-30 0000906709 us-gaap:FurnitureAndFixturesMember 2024-09-30 0000906709 nktr:SubleaseOperatingLeaseRightOfUseAssetsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0000906709 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000906709 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000906709 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000906709 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyThreeRestructuringPlanMember 2023-06-01 2023-06-30 0000906709 nktr:MeasurementInputMarketParticipantSubtenantBorrowingRateMember 2023-01-01 2023-03-31 0000906709 nktr:ContractTerminationAndOtherCostsMember nktr:RestructuringPlanMember 2023-07-01 2023-09-30 0000906709 nktr:TcgCrossoverFundIILPMember nktr:SecuritiesPurchaseAgreementMember 2024-05-28 2024-05-28 0000906709 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000906709 nktr:LicenseCollaborationAndOtherRevenueMember 2024-07-01 2024-09-30 0000906709 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000906709 us-gaap:CommonStockMember 2024-09-30 0000906709 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-06-30 0000906709 nktr:TwoThousandTwentyThreeRestructuringPlanMember 2023-07-01 2023-09-30 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyTwoRestructuringPlanMember 2023-03-31 0000906709 nktr:LicenseCollaborationAndOtherRevenueMember 2023-01-01 2023-09-30 0000906709 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000906709 nktr:SubleasePropertyPlantAndEquipmentMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-09-30 0000906709 nktr:MeasurementInputMarketParticipantSubtenantBorrowingRateMember 2024-04-01 2024-06-30 0000906709 us-gaap:RetainedEarningsMember 2024-04-

01 2024-06-30 0000906709 nktr:ContractTerminationAndOtherCostsMember nktr:RestructuringPlanMember 2024-01-01 2024-03-31 0000906709 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-06-30 0000906709 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0000906709 nktr:BristolMyersSquibbCompanyMember 2024-02-12 2024-02-12 0000906709 nktr:PurchaseAndSaleAgreement2020Member 2024-09-30 0000906709 us-gaap:CommonStockMember 2024-03-31 0000906709 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-31 0000906709 nktr:TcgCrossoverFundIILPMember srt:MaximumMember nktr:PreFundedWarrantMember nktr:SecuritiesPurchaseAgreementMember 2024-05-28 2024-05-28 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyTwoRestructuringPlanMember 2023-06-30 0000906709 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000906709 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2023-12-31 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyThreeRestructuringPlanMember 2024-09-30 0000906709 nktr:ContractTerminationAndOtherCostsMember nktr:RestructuringPlanMember 2024-04-01 2024-06-30 0000906709 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000906709 nktr:SubleaseOperatingLeaseRightOfUseAssetsMember 2023-01-01 2023-09-30 0000906709 2023-06-30 0000906709 nktr:SubleasePropertyPlantAndEquipmentMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-12-31 0000906709 nktr:SubleasePropertyPlantAndEquipmentMember 2023-07-01 2023-09-30 0000906709 us-gaap:EmployeeSeveranceMember nktr:TwoThousandTwentyTwoRestructuringPlanMember 2022-04-01 2022-04-30 0000906709 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000906709 us-gaap:ProductMember 2024-07-01 2024-09-30 0000906709 nktr:RestructuringPlanMember 2023-12-31 0000906709 nktr:AssetAcquisitionByAmpersandCapitalPartnersMember us-gaap:SubsequentEventMember nktr:AssetPurchaseAgreementMember 2024-11-01 0000906709 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000906709 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-09-30 0000906709 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000906709 us-gaap:FairValueInputsLevel2Member 2024-09-30 0000906709 nktr:PurchaseAndSaleAgreement2012Member 2024-09-30 0000906709 nktr:ContractTerminationAndOtherCostsMember nktr:RestructuringPlanMember 2023-12-31 0000906709 nktr:TcgCrossoverFundIILPMember nktr:SecuritiesPurchaseAgreementMember 2024-03-01 2024-03-31 0000906709 us-gaap:CommonStockMember 2023-03-31 0000906709 us-gaap:AccumulatedTranslationAdjustmentMember 2024-06-30 0000906709 us-gaap:ProductMember 2023-07-01 2023-09-30 0000906709 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000906709 nktr:AssetAcquisitionByAmpersandCapitalPartnersMember us-gaap:SubsequentEventMember nktr:AssetPurchaseAgreementMember 2024-11-01 2024-11-01 pure shares iso4217:USD shares iso4217:USD nktr:Milestones --12-31 0000906709 false Q3 10-Q true 2024-09-30 2024 false 0-24006 NEKTAR THERAPEUTICS DE 94-3134940 455 Mission Bay Boulevard South San Francisco CA 94158 415 482-5300 Common Stock, $0.0001 par value NKTR NASDAQ Yes Yes Accelerated Filer true false false 184458284 30109000 35277000 214386000 268339000 0 1205000 0 16101000 8933000 9779000 33053000 0 286481000 330701000 4537000 25825000 3603000 18856000 8826000 18007000 4519000 4644000 307966000 398033000 8577000 9848000 32377000 22162000 21504000 19259000 5125000 0 67583000 51269000 86758000 98517000 97829000 112625000 6912000 4635000 259082000 267046000 0.0001 0.0001 10000000 10000000 0 0 0 0 0 0 0.0001 0.0001 300000000 300000000 192743000 191384000 184458000 191384000 19000 19000 3654981000 3608137000 8285000 0 3000000 0 355000 80000 -3603471000 -3477249000 48884000 130987000 307966000 398033000 8015000 5822000 20689000 15198000 15731000 18167000 48029000 50860000 378000 155000 534000 179000 24124000 24144000 69252000 66237000 4435000 12431000 22709000 26485000 35031000 24070000 92163000 84220000 18957000 21147000 59616000 60097000 46000 11360000 14310000 49107000 0 0 0 76501000 58469000 69008000 188798000 296410000 -34345000 -44864000 -119546000 -230173000 6020000 5910000 17959000 18467000 3437000 5211000 11558000 14392000 -120000 -335000 -255000 100000 -2703000 -1034000 -6656000 -3975000 -37048000 -45898000 -126202000 -234148000 9000 -61000 20000 -171000 -37057000 -45837000 -126222000 -233977000 -0.18 -0.18 -0.24 -0.24 -0.62 -0.62 -1.23 -1.23 209249000 209249000 190406000 190406000 204292000 204292000 189651000 189651000 -37057000 -45837000 -126222000 -233977000 877000 196000 312000 1527000 -28000 -98000 -37000 -972000 849000 98000 275000 555000 -36208000 -45739000 -125947000 -233422000 188560000 19000 3574719000 -6907000 -3201193000 366638000 675000 10019000 10019000 1226000 -137018000 -135792000 189235000 19000 3584738000 -5681000 -3338211000 240865000 884000 18000 18000 7966000 7966000 -769000 -51122000 -51891000 190119000 19000 3592722000 -6450000 -3389333000 196958000 652000 8149000 8149000 98000 -45837000 -45739000 190771000 19000 3600871000 -6352000 -3435170000 159368000 191384000 19000 3608137000 80000 -3477249000 130987000 525000 3000 3000 6000000 6000000 -8285000 8285000 3000000 3000000 30000000 30000000 -483000 -36802000 -37285000 183624000 19000 8285000 -3000000 3644140000 -403000 -3514051000 126705000 437000 19000 19000 5418000 5418000 -91000 -52363000 -52454000 184061000 19000 8285000 -3000000 3649577000 -494000 -3566414000 79688000 397000 13000 13000 5391000 5391000 849000 -37057000 -36208000 184458000 19000 8285000 -3000000 3654981000 355000 -3603471000 48884000 -126222000 -233977000 48029000 50860000 17959000 18467000 16809000 26134000 4059000 6163000 -12000 -1854000 8329000 36628000 0 76501000 20000 4444000 7711000 12137000 841000 -3777000 808000 372000 7620000 6078000 1761000 -4450000 -1023000 -9328000 17329000 -7517000 -129522000 -145559000 191882000 372821000 275247000 494385000 1009000 628000 1245000 82356000 122181000 35000 18000 30000000 0 15000000 0 3000000 0 42035000 18000 -37000 54000 -5168000 -23306000 35277000 88227000 30109000 64921000 2656000 <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Note 1 — Organization and Summary of Significant Accounting Policies</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Organization</p><p style="text-indent:5.84%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Nektar Therapeutics (Nektar, we) is a clinical stage, research-based drug discovery biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware, focused on discovering and developing innovative medicines in the field of immunotherapy. Within this growing field, we direct our efforts toward creating new immunomodulatory agents that selectively induce, amplify, attenuate or prevent immune responses in order to achieve desired therapeutic outcomes. Our pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).</p><p style="text-indent:5.84%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. As of September 30, 2024, we had approximately $249.0 million in cash and investments in marketable securities.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Sale of Manufacturing Facility</p><p style="text-indent:5.84%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On November 1, 2024, we entered into an Asset Purchase Agreement (the APA) with an affiliate (the Purchaser) of Ampersand Management LLC d/b/a Ampersand Capital Partners (Ampersand), for the sale of our manufacturing facility located in Huntsville, Alabama (the Facility) and certain other manufacturing assets related thereto, including the assignment of our existing manufacturing and supply obligations, for consideration of $70 million in cash (subject to customary closing costs and adjustments based on closing net working capital, closing inventory and the amount of any indebtedness assumed by the Purchaser) and an approximate 20% equity ownership at the time of close in the Purchaser. See Note 10 for additional information.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Financing Transactions</p><p style="text-indent:5.84%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">During the nine months ended September 30, 2024, we entered into the following transactions:</p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">•<div style="width:100%;display:inline;">On February 12, 2024, for total cash consideration paid of $3.0 million, we repurchased from Bristol Myers Squibb Company (BMS) 8.3 million shares of Nektar's common stock that were previously sold to BMS, which we report as treasury stock on our Condensed Consolidated Balance Sheets. See Note 6 for additional information.</div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">•<div style="width:100%;display:inline;">On March 4, 2024, we entered into a Securities Purchase Agreement with TCG Crossover Fund II, L.P. (TCG), pursuant to which we issued a pre-funded warrant to TCG to purchase 25,000,000 shares of Nektar's common stock for gross proceeds of $30.0 million (or a purchase price of $<span style="font-size:10pt;font-family:Times New

Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.20 per share of common stock that can be issued upon exercise of the pre-funded warrant). On May 28, 2024, we filed with the SEC a registration statement on Form S-3 (file no. 333-279760) registering for the resale of up to 25,000,000 shares of Nektar's common stock upon exercise of the pre-funded warrant issued to TCG pursuant to the Securities Purchase Agreement. The registration statement became effective on June 5, 2024. See Note 5 for additional information. • On March 4, 2024, for total cash consideration received of $15.0 million, we entered into an amendment (the Amendment) with entities managed by Healthcare Royalty Management, LLC (collectively, HCR) to remove the cap on royalties previously sold to HCR under a Purchase and Sale Agreement (the 2020 Purchase and Sale Agreement). See Note 3 for additional information. Restructuring Plans In April 2022, we announced the termination of the bempegaldesleukin program and a new strategic reorganization and cost restructuring plan (together, the 2022 Restructuring Plan), pursuant to which we completed an approximate 70% reduction of our workforce during 2022. We also decided to seek a sublease for certain of our leased premises in San Francisco, CA, including all of our office space on Third St. and portions of our office and laboratory space on Mission Bay Blvd. South. In April 2023, we announced Eli Lilly and Company's (Lilly) decision to terminate our license agreement (the Lilly Agreement) for the development of rezpegaldesleukin, as well as a new strategic reprioritization and cost restructuring plan (the 2023 Restructuring Plan). Under the 2023 Restructuring Plan, we reduced our San Francisco-based workforce by approximately 60%. In addition, under the 2023 Restructuring Plan, we decided to seek a sublease for our remaining office and laboratory space on Mission Bay Blvd. South which we had not planned to sublease pursuant to the 2022 Restructuring Plan. We have regained full rights to rezpegaldesleukin from Lilly, and we initiated a Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in October 2023 and a Phase 2b study of rezpegaldesleukin in patients with severe-to-very severe alopecia areata in March 2024. We will also explore other auto-immune indications for the development of rezpegaldesleukin. We have incurred significant costs resulting from the 2022 and 2023 Restructuring Plans. See Note 7 for additional information on the effect on our Condensed Consolidated Financial Statements. Basis of Presentation and Principles of Consolidation Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of Nektar Therapeutics and our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation. We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results. Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary's financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive income (loss) in the stockholders' equity section of our Condensed Consolidated Balance Sheets. Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive income (loss) to the statements of operations during the three and nine months ended September 30, 2024 and 2023 except as otherwise disclosed below in Note 3. The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December 31, 2023 was derived from the audited consolidated financial statements which are included in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 5, 2024. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements. Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified. Significant Concentrations Our customers are primarily pharmaceutical companies that are located in the U.S. and Europe and with whom we have multi-year arrangements. Our accounts receivable balances contain billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. We generally do not require collateral from our customers. We perform a regular review of our customers' credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable or contract assets. We have not recorded reserves for credit losses for the three and nine months ended September 30, 2024 and 2023, nor have recorded such an allowance as of September 30, 2024 or December 31, 2023. As of September 30, 2024, all billed and unbilled trade receivables from product sales and contract assets have been classified as held-for-sale and included within assets held for sale on our Condensed Consolidated Balance Sheets. We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations. <p style="text-indent:5.867%;font-size:10pt;margin-top:6pt;font-family:Times

New Roman;margin-bottom:0;text-align:left;">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, various factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer's credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if various factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales. Treasury Stock We record treasury stock activities under the cost method. Treasury stock is included in authorized and issued shares but excluded from outstanding shares. The re-issuance of treasury stock is accounted for on a first in, first-out basis and any differences between the cost of treasury stock and the re-issuance proceeds are charged or credited to additional paid-in capital. Restructuring We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for: • contractual or other employee termination benefits provided that the obligations result from services already rendered based on rights that vest or accumulated when the payment of benefits becomes probable and the amount can be reasonably estimated; • one-time employee termination benefits on the communication date from management to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"> dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn; and • contract termination costs for costs incurred when we cancel the contract in accordance with its terms, or for costs to be incurred over the remaining contract term without economic benefit to us at the cease-use date. For one-time employee terminations benefits, we recognize the liability in full on the communication date when future services are not required or amortize the liability ratably over the service period, if required. The fair value of termination benefits reflects our estimates of expected utilization of certain Company-funded post-employment benefits. See Note 7 for additional information on the severance expense that we recognized for employees terminated in connection with our reductions-in-force. Impairment of Goodwill Goodwill is assessed for impairment on an annual basis and whenever events and circumstances indicate that it may be impaired. Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, current economic, market and geopolitical conditions, including a significant, sustained decline in our stock price and market capitalization compared to the net book value; an adverse change in legal factors, business climate or operational performance of the business; or significant changes in the ability of the reporting unit to generate positive cash flows for our strategic business objectives. If the carrying value of the reporting unit, including goodwill, exceeds the reporting unit's fair value, we will recognize a goodwill impairment loss, and we will write down goodwill such that the carrying value of the reporting unit equals its fair value, provided that we cannot reduce goodwill below zero. See Note 8 for additional information regarding the impairment charges we recorded during the three months ended March 31, 2023 in connection with our goodwill. Long-Lived Asset Impairment We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated net cash flows associated with the asset, discounted at a rate that we believe a market participant would utilize to reflect the risks associated with the cash flows, such as credit risk. See Note 7 for additional information regarding the impairment charges we recorded in connection with our leased facilities and certain property and equipment. Net Loss per Share For all periods presented in the Condensed Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. We calculate basic net loss per share based on the weighted-average number of common shares outstanding, including the pre-funded warrant, during the periods presented. Shares of common stock into which the pre-funded warrant may be exercised are considered outstanding for the purposes of computing basic net loss per share because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date. For the three and nine months ended September 30, 2024 and 2023, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. We excluded shares underlying the weighted average outstanding stock options, restricted stock units (RSUs) and performance stock units (PSUs), as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.9%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.78%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.78%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p

style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Potentially dilutive securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> 25,887 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,476 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26,417 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20,513 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table>   Organization Nektar Therapeutics (Nektar, we) is a clinical stage, research-based drug discovery biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware, focused on discovering and developing innovative medicines in the field of immunotherapy. Within this growing field, we direct our efforts toward creating new immunomodulatory agents that selectively induce, amplify, attenuate or prevent immune responses in order to achieve desired therapeutic outcomes. Our pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255). Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. As of September 30, 2024, we had approximately $249.0 million in cash and investments in marketable securities. 249000000 Sale of Manufacturing Facility On November 1, 2024, we entered into an Asset Purchase Agreement (the APA) with an affiliate (the Purchaser) of Ampersand Management LLC d/b/a Ampersand Capital Partners (Ampersand), for the sale of our manufacturing facility located in Huntsville, Alabama (the Facility) and certain other manufacturing assets related thereto, including the assignment of our existing manufacturing and supply obligations, for consideration of $70 million in cash (subject to customary closing costs and adjustments based on closing net working capital, closing inventory and the amount of any indebtedness assumed by the Purchaser) and an approximate 20% equity ownership at the time of close in the Purchaser. See Note 10 for additional information. 70000000 0.20 Financing Transactions During the nine months ended September 30, 2024, we entered into the following transactions: • On February 12, 2024, for total cash consideration paid of $3.0 million, we repurchased from Bristol Myers Squibb Company (BMS) 8.3 million shares of Nektar's common stock that were previously sold to BMS, which we report as treasury stock on our Condensed Consolidated Balance Sheets. See Note 6 for additional information. <div class="item-list-

element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">• On March 4, 2024, we entered into a Securities Purchase Agreement with TCG Crossover Fund II, L.P. (TCG), pursuant to which we issued a pre-funded warrant to TCG to purchase 25,000,000 shares of Nektar's common stock for gross proceeds of $30.0 million (or a purchase price of $1.20 per share of common stock that can be issued upon exercise of the pre-funded warrant). On May 28, 2024, we filed with the SEC a registration statement on Form S-3 (file no. 333-279760) registering for the resale of up to 25,000,000 shares of Nektar's common stock upon exercise of the pre-funded warrant issued to TCG pursuant to the Securities Purchase Agreement. The registration statement became effective on June 5, 2024. See Note 5 for additional information. • On March 4, 2024, for total cash consideration received of $15.0 million, we entered into an amendment (the Amendment) with entities managed by Healthcare Royalty Management, LLC (collectively, HCR) to remove the cap on royalties previously sold to HCR under a Purchase and Sale Agreement (the 2020 Purchase and Sale Agreement). See Note 3 for additional information. 3000000 8300000 25000000 30000000 1.2 25000000 2024-06-05 15000000 Restructuring Plans In April 2022, we announced the termination of the bempegaldesleukin program and a new strategic reorganization and cost restructuring plan (together, the 2022 Restructuring Plan), pursuant to which we completed an approximate 70% reduction of our workforce during 2022. We also decided to seek a sublease for certain of our leased premises in San Francisco, CA, including all of our office space on Third St. and portions of our office and laboratory space on Mission Bay Blvd. South. In April 2023, we announced Eli Lilly and Company's (Lilly) decision to terminate our license agreement (the Lilly Agreement) for the development of rezpegaldesleukin, as well as a new strategic reprioritization and cost restructuring plan (the 2023 Restructuring Plan). Under the 2023 Restructuring Plan, we reduced our San Francisco-based workforce by approximately 60%. In addition, under the 2023 Restructuring Plan, we decided to seek a sublease for our remaining office and laboratory space on Mission Bay Blvd. South which we had not planned to sublease pursuant to the 2022 Restructuring Plan. We have regained full rights to rezpegaldesleukin from Lilly, and we initiated a Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in October 2023 and a Phase 2b study of rezpegaldesleukin in patients with severe-to-very severe alopecia areata in March 2024. We will also explore other auto-immune indications for the development of rezpegaldesleukin. We have incurred significant costs resulting from the 2022 and 2023 Restructuring Plans. See Note 7 for additional information on the effect on our Condensed Consolidated Financial Statements. 0.70 0.60 Basis of Presentation and Principles of Consolidation Our Condensed Consolidated Financial Statements include the financial position, results of operations and cash flows of Nektar Therapeutics and our wholly-owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation. We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results. Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary's financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive income (loss) in the stockholders' equity section of our Condensed Consolidated Balance Sheets. Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive income (loss) to the statements of operations during the three and nine months ended September 30, 2024 and 2023 except as otherwise disclosed below in Note 3. The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December 31, 2023 was derived from the audited consolidated financial statements which are included in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 5, 2024. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements. Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified. Significant Concentrations Our customers are primarily pharmaceutical companies that are located in the U.S. and Europe and with whom we have multi-year arrangements. Our accounts receivable balances contain billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. We generally do not require collateral from our customers. We perform a regular review of our customers' credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable or contract assets. We have not recorded reserves for credit losses for the <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-

width:fit-content;">three and nine months ended September 30, 2024 and 2023, nor have recorded such an allowance as of September 30, 2024 or December 31, 2023. As of September 30, 2024, all billed and unbilled trade receivables from product sales and contract assets have been classified as held-for-sale and included within assets held for sale on our Condensed Consolidated Balance Sheets. We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations. For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, various factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer's credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if various factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales. 0 0 0 0 Treasury Stock We record treasury stock activities under the cost method. Treasury stock is included in authorized and issued shares but excluded from outstanding shares. The re-issuance of treasury stock is accounted for on a first in, first-out basis and any differences between the cost of treasury stock and the re-issuance proceeds are charged or credited to additional paid-in capital. Restructuring We recognize restructuring charges related to reorganization plans that have been committed to by management when liabilities have been incurred. In connection with these activities, we record restructuring charges at fair value for: • contractual or other employee termination benefits provided that the obligations result from services already rendered based on rights that vest or accumulated when the payment of benefits becomes probable and the amount can be reasonably estimated; • one-time employee termination benefits on the communication date from management to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"> dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn; and • contract termination costs for costs incurred when we cancel the contract in accordance with its terms, or for costs to be incurred over the remaining contract term without economic benefit to us at the cease-use date. For one-time employee terminations benefits, we recognize the liability in full on the communication date when future services are not required or amortize the liability ratably over the service period, if required. The fair value of termination benefits reflects our estimates of expected utilization of certain Company-funded post-employment benefits. See Note 7 for additional information on the severance expense that we recognized for employees terminated in connection with our reductions-in-force. Impairment of Goodwill Goodwill is assessed for impairment on an annual basis and whenever events and circumstances indicate that it may be impaired. Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, current economic, market and geopolitical conditions, including a significant, sustained decline in our stock price and market capitalization compared to the net book value; an adverse change in legal factors, business climate or operational performance of the business; or significant changes in the ability of the reporting unit to generate positive cash flows for our strategic business objectives. If the carrying value of the reporting unit, including goodwill, exceeds the reporting unit's fair value, we will recognize a goodwill impairment loss, and we will write down goodwill such that the carrying value of the reporting unit equals its fair value, provided that we cannot reduce goodwill below zero. See Note 8 for additional information regarding the impairment charges we recorded during the three months ended March 31, 2023 in connection with our goodwill. Long-Lived Asset Impairment We assess the impairment of long-lived assets whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. In the case of property, plant and equipment and right-of-use assets for our leases, we determine whether there has been an impairment by comparing the carrying value of the asset to the anticipated undiscounted net cash flows associated with the asset. If such cash flows are less than the carrying value, we write down the asset to its fair value, which may be measured as anticipated net cash flows associated with the asset, discounted at a rate that we believe a market participant would utilize to reflect the risks associated with the cash flows, such as credit risk. See Note 7 for additional information regarding the impairment charges we recorded in connection with our leased facilities and certain property and equipment. Net Loss per Share For all periods presented in the Condensed Consolidated Statements of Operations, the net loss available to common stockholders is equal to the reported net loss. We calculate basic net loss per share based on the weighted-average number of common shares outstanding, including the pre-funded warrant, during the periods presented. Shares of common stock into which the pre-funded warrant may be exercised are considered outstanding for the purposes of computing basic net loss per share because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date. For the three and nine months ended September 30, 2024 and 2023, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. We excluded shares underlying the weighted average outstanding stock options, restricted stock units (RSUs) and performance stock units (PSUs), as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.9%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.78%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.78%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> <span style="white-

space:pre-wrap;min-width:fit-content;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Potentially dilutive securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25,887 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,476 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26,417 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20,513 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> We excluded shares underlying the weighted average outstanding stock options, restricted stock units (RSUs) and performance stock units (PSUs), as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.88%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.9%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.78%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.78%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.18%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Potentially dilutive securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25,887 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,476 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26,417 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20,513 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> 25887000 17476000 26417000 20513000 Note 2 — Cash and Investments in Marketable Securities Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated Fair Value at </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash and cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">30,109</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,277 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Short-term investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 214,386 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 268,339 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">Long-term investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,537 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 25,825 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total cash, cash equivalents, and investments in marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">249,032</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 329,441 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr></table> Our portfolio of cash and investments in marketable securities includes (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:26.555%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:11.218%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.218999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.978%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.598%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.978%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.458%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> Fair Value Hierarchy Level </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross Unrealized Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Corporate notes and bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">90,589</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 214 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 90,793 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 38,882 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#fffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Corporate commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 125,927 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 163 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (7 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 126,083 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 255,241 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Obligations of U.S. government agencies </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,500 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">

1,502 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Available-for-sale investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">218,016</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 379 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(17</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 218,378 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 294,123 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> 1 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,361 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,359 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Certificates of deposit </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,046 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,116 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td></tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> N/A </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 6,247 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 17,843 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td colspan="6" style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total cash and investments in marketable securities </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">249,032</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 329,441 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> For the three and nine months ended September 30, 2024 and 2023, there were no transfers between Level 1 and Level 2 of the fair value hierarchy. At December 31, 2023, our gross unrealized gains and losses were insignificant. Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Estimated Fair Value at </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:center;">September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash and cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">30,109</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,277 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Short-term investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> 214,386 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:center;"> 268,339 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Long-term investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,537 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 25,825 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total cash, cash equivalents, and investments in marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">249,032</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 329,441 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> 30109000 35277000 214386000 268339000 4537000 25825000 249032000 329441000 Our portfolio of cash and investments in marketable securities includes (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:26.555%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:11.218%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.2189999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.978%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.598%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.978%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.5%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.458%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> <span style="white-space:pre-wrap;min-

width:fit-content;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> Fair Value Hierarchy Level </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross Unrealized Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross Unrealized Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Corporate notes and bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">90,589</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 214 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(10</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 90,793 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 38,882 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Corporate commercial paper </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 125,927 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 163 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (7 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 126,083 </td> <td style="white-

space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 255,241 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Obligations of U.S. government agencies </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,500 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Available-for-sale investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">218,016</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 379 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(17</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 218,378 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 294,123 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> 1 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:right;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,361 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,359 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Certificates of deposit </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,046 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,116 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> N/A </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 6,247 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 17,843 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td colspan="6" style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total cash and investments in marketable securities </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;">

 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">249,032</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 329,441 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr></table> 90589000 214000 10000 90793000 38882000 125927000 163000 7000 126083000 255241000 1500000 2000 0 1502000 0 218016000 379000 17000 218378000 294123000 10361000 2359000 14046000 15116000 6247000 17843000 249032000 329441000 Note 3 — Condensed Consolidated Financial Statement Details Inventory Inventory consists of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:66.993%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.883000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Raw materials </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,861 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Work-in-process </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,880 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Finished goods </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,360 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total inventory, net </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 16,101 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> </tr> </table> We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased. As of September 30, 2024 and December 31, 2023, we recorded aggregate provisions of $0 and $2.0 million, respectively, for the net realizable value of our batches. Our manufacturing agreement with UCB Pharma (UCB) for the reagent used in the manufacture of CIMZIA® provided for a fixed selling price which we had negotiated in exchange for a higher royalty rate. Accordingly, when evaluating the net realizable value of our inventory for UCB, we include the negotiated increase of the royalties in our analysis, and the aggregate revenue has historically been greater than our manufacturing cost. Due to the decreases in the royalty rate for 2024 and 2025 as a result of a settlement agreement with UCB, the aggregate revenue was expected to be less than our manufacturing cost for these years, and therefore we previously recorded a provision for net realizable value. As further disclosed in Note 6, on July 31, 2024, we entered into a long-term supply agreement with UCB that increases the selling price of the reagent used in the manufacture of CIMZIA®, which resulted in the aggregate revenue exceeding our manufacturing costs. As a result, we reduced the provision to $0 during the three months ended September 30, 2024. </p><p style="text-indent:5.84%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of September 30, 2024, all of the inventory balance is classified as held for sale and included within assets held for sale on our Condensed Consolidated Balance Sheets.</p></div><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Other Current Assets</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Other current assets consist of the following (in thousands):</p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Prepaid research and development expenses</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,960 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,325 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Interest and other non-trade receivables </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,123 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,047 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other prepaid expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,850 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-

wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,407 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total other current assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,933</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 9,779 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> Assets Held for Sale We classify assets and liabilities (the “disposal group”) as held for sale in the period in which all of the required criteria under ASC 360 “Property, Plant, and Equipment” are met. We initially measure the disposal group asset that is classified as held for sale at the lower of its carrying value or fair value less any costs to sell. Upon classification of the disposal group, we test the assets for impairment and cease related depreciation and amortization. As of September 30, 2024, we concluded that our manufacturing facility in Huntsville, Alabama meets the requirements for classification as assets held for sale. Accordingly, assets and liabilities associated with the disposal group were reclassified as held for sale. See Note 10 for additional information. The assets and liabilities as of December 31, 2023 on our Condensed Consolidated Balance Sheets were not recast to reflect the held for sale classification. As of September 30, 2024, assets held for sale consist of the following: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:82%;box-sizing:content-box;"></td> <td style="width:1.9%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.100000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accounts receivable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,746</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Inventory, net</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,889</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Property, plant and equipment, net</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,386</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Contract asset</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,032</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total assets held for sale</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 33,053 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> A contract asset is a right to consideration that is conditional upon factors other than the passage of time. The contract asset above relates to the long-term supply agreement with UCB entered into on July 31, 2024 (See Note 6 for additional information). As of September 30, 2024, liabilities related to assets held for sale primarily consists of accrued compensation and other accrued expenses. Property, Plant and Equipment <p style="text-indent:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-

align:left;">Property, plant and equipment consists of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Building and leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,834</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 43,184 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Computer equipment and computer software </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,615 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 22,438 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Manufacturing equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,315 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Laboratory equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 616 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,537 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Furniture, fixtures and other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 59 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 541 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Depreciable property, plant and equipment at cost </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-

space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 19,124 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 105,015 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td></tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: accumulated depreciation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (15,659 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (86,898 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td></tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Depreciable property, plant and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,465 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,117 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Construction in process </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 138 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 739 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Property, plant and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,603</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 18,856 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr></table> Due to the weakening lease markets during the three months ended June 30, 2024, we recorded additional non-cash impairment charges of $1.0 million for property, plant and equipment for the three months ended June 30, 2024, which we report in restructuring, impairment and costs of terminated program in our Condensed Consolidated Statement of Operations. See Note 7 for additional information. As of September 30, 2024, property, plant and equipment associated with our manufacturing facility in Huntsville, Alabama is classified as held for sale and included within assets held for sale on our Condensed Consolidated Balance Sheets. Accrued Expenses Accrued expenses consist of the following (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:center;">September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued compensation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,007</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,553 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued research and development expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,916 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,118 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued contract termination costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,151 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,020 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,303 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,471 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">32,377</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 22,162 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> Liabilities Related to the Sales of Future Royalties In 2012 and 2020, we sold to RPI Finance Trust (RPI) and HCR, respectively, our rights to receive royalties under our license and manufacturing agreements with certain pharmaceutical partners under the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement, respectively. We account for these transactions as debt and recognize non-cash royalty revenue and non-cash interest expense to amortize the proceeds over the lives of the respective arrangements. We periodically update our prospective non-cash interest rate based on our estimates of future royalties. As of September 30, 2024, our imputed interest rates for the arrangements with RPI and HCR were 43% and 24%, respectiv<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New

Roman;min-width:fit-content;">ely. The original 2020 Purchase and Sale Agreement was to expire -- and wherein the right to receive royalties would revert to us -- if HCR received aggregate royalties of $210.0 million on or prior to December 31, 2025 (the 2025 Threshold), or, if the 2025 Threshold was not achieved by December 31, 2025, when HCR received aggregate royalties of $240.0 million. On March 4, 2024, Nektar and HCR amended the original 2020 Purchase and Sale Agreement (the Amendment), pursuant to which the parties agreed to remove our reversionary rights in the royalties in exchange for a $15.0 million payment from HCR. Accordingly, HCR will receive all future royalties of the products, and none of these royalties will return to Nektar. We account for the Amendment as a modification of the existing arrangement, and therefore recorded the $15.0 million proceeds as an increase to the liability. </p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:5.84%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following is a reconciliation of the changes in our liabilities related to the sales of future royalties for the nine months ended September 30, 2024 (in thousands):</p><p style="text-indent:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:57.477%;box-sizing:content-box;"></td><td style="width:1.399%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.776%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.399%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.776%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.399%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.776%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30, 2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2012 Purchase and Sale Agreement</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2020 Purchase and Sale Agreement</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Liabilities related to the sales of future royalties, net – beginning balance</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,217 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">88,408</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 112,625 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Non-cash royalty revenue </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (19,007 </td><td style="white-space:nowrap;vertical-align:bottom;">) </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (29,022 </td><td style="white-space:nowrap;vertical-align:bottom;">) </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (48,029 </td><td style="white-space:nowrap;vertical-align:bottom;">) </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Non-cash interest expense </td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,940 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,019 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,959 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Amortization of transaction costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 274 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 274 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Proceeds from the Amendment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 15,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 15,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Liabilities related to the sales of future royalties, net – ending balance </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,150</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 87,679 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 97,829 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr></table> Accumulated Other Comprehensive Income (Loss) The following table summarizes the changes in accumulated other comprehensive income (loss) by component (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td

style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Foreign currency translation </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left,"> Available-for-sale securities </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left,"> Accumulated Other Comprehensive Income </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left,"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">30</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">80</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Foreign currency translation adjustments</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(8</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(8</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Unrealized gain (loss) on available-for-sale securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(475</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(475</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at March 31, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 22 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-

align:bottom;text-align:center;"> (425 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(403</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Foreign currency translation adjustments</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Unrealized gain (loss) on available-for-sale securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(90</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at June 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(515</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (494 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Foreign currency translation adjustments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (28 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (

28 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Unrealized gain (loss) on available-for-sale securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 877 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 877 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(7</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 362 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">355</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Foreign currency translation</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Available-for-sale securities</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Accumulated Other Comprehensive Income</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at December 31, 2022</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (5,131 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1,776</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (6,907 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-

align:top;"> Foreign currency translation adjustments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 139 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 139 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Unrealized gain (loss) on available-for-sale securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,087 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,087 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at March 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(4,992</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (689 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (5,681 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Foreign currency translation adjustments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Unrealized gain (loss) on available-for-sale securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Unrealized gain (loss) on available-for-sale securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Unrealized gain (loss) on available-for-sale securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">244 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 244 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Reclassification adjustments to income </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,026 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,026 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at June 30, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(6,005</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (445 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (6,450 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Foreign currency translation adjustments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (98 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (98 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Unrealized gain (loss) on available-for-sale securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 196 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">

196 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at September 30, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(6,103</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (249 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(6,352</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The reclassification from accumulated other comprehensive loss relates to the closure of one of our foreign subsidiaries and has been included within other income (expense), net in our Condensed Consolidated Statement of Operations.</p> <p style="text-indent:5.84%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Inventory consists of the following (in thousands):</p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Raw materials</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,861 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Work-in-process </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,880 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Finished goods </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,360 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total inventory, net </td> <td style="white-space:pre-wrap;vertical-

align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 16,101 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> 0 1861000 0 12880000 0 1360000 0 16101000 We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased. As of September 30, 2024 and December 31, 2023, we recorded aggregate provisions of $0 and $2.0 million, respectively, for the net realizable value of our batches. Our manufacturing agreement with UCB Pharma (UCB) for the reagent used in the manufacture of CIMZIA® provided for a fixed selling price which we had negotiated in exchange for a higher royalty rate. Accordingly, when evaluating the net realizable value of our inventory for UCB, we include the negotiated increase of the royalties in our analysis, and the aggregate revenue has historically been greater than our manufacturing cost. Due to the decreases in the royalty rate for 2024 and 2025 as a result of a settlement agreement with UCB, the aggregate revenue was expected to be less than our manufacturing cost for these years, and therefore we previously recorded a provision for net realizable value. As further disclosed in Note 6, on July 31, 2024, we entered into a long-term supply agreement with UCB that increases the selling price of the reagent used in the manufacture of CIMZIA®, which resulted in the aggregate revenue exceeding our manufacturing costs. As a result, we reduced the provision to $0 during the three months ended September 30, 2024. </p><p style="text-indent:5.84%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of September 30, 2024, all of the inventory balance is classified as held for sale and included within assets held for sale on our Condensed Consolidated Balance Sheets.</p> 0 2000000 0 <p style="text-indent:6.667%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Other current assets consist of the following (in thousands):</p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Prepaid research and development expenses</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,960 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,325 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Interest and other non-trade receivables </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,123 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,047 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other prepaid expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,850 </td> <td style="white-space:nowrap;vertical-

align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,407 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total other current assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,933</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 9,779 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> 3960000 4325000 2123000 1047000 2850000 4407000 8933000 9779000 As of September 30, 2024, assets held for sale consist of the following: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:82%;box-sizing:content-box;"></td> <td style="width:1.9%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.100000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accounts receivable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,746</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Inventory, net</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,889</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Property, plant and equipment, net</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,386</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Contract asset</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,032</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total assets held for sale</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 33,053 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> 1746000 16889000 11386000 3032000 33053000 Property, plant and equipment consists of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid

#000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Building and leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,834</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 43,184 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Computer equipment and computer software </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,615 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 22,438 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Manufacturing equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,315 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Laboratory equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 616 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,537 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Furniture, fixtures and other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 59 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 541 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Depreciable property, plant and equipment at cost </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 19,124 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 105,015 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: accumulated depreciation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:right;">(15,659 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (86,898 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Depreciable property, plant and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,465 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,117 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Construction in process </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 138 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 739 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Property, plant and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,603</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 18,856 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> 3834000 43184000 14615000 22438000 0 24315000 616000 14537000 59000 541000 19124000 105015000 15659000 86898000 3465000 18117000 138000 739000 3603000 18856000 1000000 Accrued expenses consist of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued compensation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,007</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,553 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued research and development expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-

space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,916 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"> 10,118 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td></tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued contract termination costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,151 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,020 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td></tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,303 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,471 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">32,377</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 22,162 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr>
</table> 7007000 5553000 17916000 10118000 3151000 3020000 4303000 3471000 32377000 22162000 0.43 0.24 210000000 240000000 15000000 15000000 The following is a reconciliation of the changes in our liabilities related to the sales of future royalties for the nine months ended September 30, 2024 (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2012 Purchase and Sale Agreement </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2020 Purchase and Sale Agreement </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Liabilities related to the sales of future royalties, net – beginning balance </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24,217</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 88,408 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 112,625 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td></tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Non-cash royalty revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (19,007 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (29,022 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (48,029 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Non-cash interest expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,940 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,019 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,959 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Amortization of transaction costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 274 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 274 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Proceeds from the Amendment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 15,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 15,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Liabilities related to the sales of future royalties, net – ending balance </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,150</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 87,679 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">97,829</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table> 24217000 88408000 112625000 19007000 29022000 48029000 4940000 13019000 17959000 0 274000 274000 0 15000000 15000000 10150000 87679000 97829000 <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table summarizes the changes in accumulated other comprehensive income (loss) by component (in thousands):</p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Foreign currency translation</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Available-for-sale securities</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Accumulated Other Comprehensive Income</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at December 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 30 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 80 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Foreign currency translation adjustments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (8 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="color:#000000;white-space:pre-wrap;min-

width:fit-content;">(8 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Unrealized gain (loss) on available-for-sale securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (475 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (475 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at March 31, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">22</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (425 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (403 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Foreign currency translation adjustments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Unrealized gain (loss) on available-for-sale securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (90 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (90 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-

space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">21</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (515 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(494</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Foreign currency translation adjustments</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(28</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(28</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Unrealized gain (loss) on available-for-sale securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">877</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">877</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (7 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">362</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 355 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr></table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;">

</td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Foreign currency translation </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Available-for-sale securities </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Accumulated Other Comprehensive Income </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at December 31, 2022 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(5,131</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,776 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(6,907</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Foreign currency translation adjustments</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">139</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">139</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Unrealized gain (loss) on available-for-sale securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,087</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,087</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at March 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (4,992 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (689 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td

style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(5,681</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Foreign currency translation adjustments</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">13</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">244</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">244</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Reclassification adjustments to income</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1,026</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1,026</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at June 30, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (6,005 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(445</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (6,450 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Foreign currency translation adjustments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (98 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (98 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Unrealized gain (loss) on available-for-sale securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 196 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 196 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at September 30, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(6,103</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (249 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (6,352 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;">) </td> </tr> </table> 30000 50000 80000 -8000 -8000 -475000 -475000 22000 -425000 -403000 -1000 -1000 -90000 -90000 21000 -515000 -494000 -28000 -28000 877000 877000 -7000 362000 355000 -5131000 -1776000 -6907000 139000 139000 1087000 1087000 -4992000 -689000 -5681000 13000 13000 244000 244000 -1026000 -1026000 -6005000 -445000 -6450000 -98000 -98000 196000 196000 -6103000 -249000 -6352000 Note 4 — Commitments and Contingencies Legal Matters From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at each reporting date and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations for that period and on our cash flows and liquidity. On August 7, 2023, we filed a complaint in the United States District Court for the Northern District of California (the Court) against Lilly alleging, among other claims, breach of contract and breach of implied covenant of good faith and fair dealing (the Complaint), in connection with our collaboration with Lilly. Following the denial of its motion to dismiss the Complaint entirely, Lilly filed an answer that included counterclaims against us alleging breach of specified confidentiality provisions and defamation. The case is proceeding. We have recorded no liability for any litigation matters in our Condensed Consolidated Balance Sheets at either September 30, 2024 or December 31, 2023. Indemnifications in Connection with Commercial Agreements As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual commencing after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations. <p style="text-indent:5.867%;font-size:10pt;margin-

top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants. For example, we made certain intellectual property representations in connection with our RPI and HCR transactions, however, the time limitation we have to indemnify RPI with respect to any breach of these intellectual property-based representations and warranties has passed. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements or certain express indemnification provisions are applicable, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims. To date, we have not incurred any costs to defend lawsuits or settle claims related to these indemnification obligations, nor any breaches of representations or warranties or covenants. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. 0 0 Note 5 — Pre-Funded Warrant In March 2024, we issued a pre-funded warrant to purchase an aggregate of 25,000,000 shares of our common stock to TCG at a price of $1.20 per share for gross proceeds of $30.0 million. Transaction costs were immaterial. The pre-funded warrant has an exercise price of $0.0001 per share and may be exercised at any time after the original issuance date. TCG may not exercise the warrant if TCG, together with its affiliates, would beneficially own more than 9.99% of the number of shares of our common stock outstanding immediately after giving effect to such exercise. TCG may increase or decrease this percentage not in excess of 19.99% by providing at least 61 days' prior notice to the Company. On May 28, 2024, we filed with the SEC a registration statement on Form S-3 (file no. 333-279760) registering for resale of up to 25,000,000 shares of our common stock issuable upon exercise of the pre-funded warrant. The registration statement became effective on June 5, 2024. As of September 30, 2024, the warrant has not been exercised. We classified the pre-funded warrant as a component of permanent equity in our Condensed Consolidated Balance Sheets as it is a freestanding financial instrument that was immediately exercisable, does not embody an obligation for the Company to repurchase its own shares and permits the holder to receive a fixed number of shares of common stock upon exercise. All of the shares underlying the pre-funded warrant have been included in the weighted-average number of shares of common stock used to calculate net loss per share attributable to common stockholders because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the pre-funded warrant. 25000000 1.2 30000000 0.0001 0.0999 0.1999 P61D 25000000 2024-06-05 Note 6 — License and Collaboration Agreements We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary polyethylene glycol reagents (PEG reagents) and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808 Collaborative Arrangements, and, if so, we analyze whether we should account for any elements under ASC 606 Revenue from Contracts with Customers. Eli Lilly and Company (Lilly): Rezpegaldesleukin (previously referred to as NKTR-358) On July 23, 2017, we entered into a worldwide license agreement (the Lilly Agreement) with Lilly to co-develop rezpegaldesleukin, a novel immunological drug candidate that we invented, pursuant to which we received an initial payment of $150.0 million and were eligible for up to $250.0 million in additional development and regulatory milestones. The Lilly Agreement provided that, during Phase 1B and Phase 2 development, we shared development costs wherein 75% of the costs were borne by Lilly and 25% of the costs were borne by us. On April 23, 2023, we received from Lilly a notice of at-will termination of the Lilly Agreement. We have regained full rights to rezpegaldesleukin from Lilly, and the Lilly Agreement subsequently terminated. Following the return of our rights to develop rezpegaldesleukin, we bear all costs of development. We initiated a Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in October 2023 and a Phase 2b study of rezpegaldesleukin in patients with severe-to-very severe alopecia areata in March 2024. We will also explore other auto-immune indications for the development of rezpegaldesleukin. Bristol-Myers Squibb Company (BMS): Bempegaldesleukin, also referred to as NKTR-214 Effective April 3, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS. Pursuant to the BMS Collaboration Agreement, we and BMS jointly developed bempegaldesleukin in combination with BMS' Opdivo®. The parties shared the internal and external development costs for bempegaldesleukin in combination regimens based on each party's relative ownership interest in the compounds included in the regimens. Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $<span style="font-size:10pt;font-family:Times New

Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0 billion and purchased 8,284,600 shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $850.0 million. In 2020, we received additional non-refundable milestone payments of $50.0 million.</p><p style="text-indent:5.84%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In April 2022, we announced that BMS and we decided to discontinue all development of bempegaldesleukin in combination with Opdivo®, On September 6, 2023, BMS and we terminated the BMS Collaboration Agreement, and pursuant to the surviving provisions of the BMS Collaboration Agreement, we and BMS continue our efforts to wind down the </p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">bempegaldesleukin program, and the cost sharing provisions continue to remain in effect as the parties wind down the studies. On February 12, 2024, we repurchased the 8.3 million shares previously sold to BMS for total cash consideration of $3.0 million.</p><p style="text-indent:5.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. Based on the cost sharing percentages described above, we recognize the net reimbursement to (from) BMS as an increase (decrease) to the applicable expense. As discussed in Note 7, beginning in the second quarter of 2022, we began reporting clinical trial, other third-party costs and employee costs for the wind down of the bempegaldesleukin program in restructuring, impairment and costs of terminated program. For the three and nine months ended September 30, 2024, such amounts are immaterial and are included in research and development expense.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Biolojic Design (Biolojic): NKTR-0165</p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In 2021, we entered into a research collaboration and license option agreement with Biolojic to discover and develop agonistic antibodies that activate a novel and previously un-drugged target for the treatment of autoimmune diseases. In 2023, we exercised an option to gain an exclusive license to specified agonistic antibodies and other materials that were developed pursuant to a research collaboration and license option agreement in all fields of use (other than in the field of oncology). As a result of exercising the option to gain an exclusive license, we may be required to pay up to $18.0 million based on the achievement of certain development milestones, including the first milestone of $3.0 million payable upon the acceptance of the first investigational new drug application, and up to $35.0 million based on the achievement of certain regulatory approval milestones. Each milestone is payable only once, regardless of the number of indications for which we develop the licensed product. We record a liability when a milestone payment becomes probable. As of September 30, 2024, no milestones have been achieved or are considered probable, and no liability has been recorded. </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Other</p><p style="text-indent:5.84%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">We have other collaboration agreements that have resulted in commercialized products for our collaborations partners. Under these agreements, we may sell our proprietary PEG reagents for use in these products, and we are entitled to receive royalties based on net sales of these products as well as sales milestones. As discussed in Note 3, we have sold our rights to receive royalties from these other collaboration agreements. Our non-cash royalty revenue, which totaled $18.2 million and $50.9 million for the three and nine months ended September 30, 2023, respectively, and $15.7 million and $48.0 million for the three and nine months ended September 30, 2024, respectively, represents revenue for granting licenses which we had satisfied in prior periods.</p><p style="text-indent:5.84%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">We have a collaboration agreement with UCB for dapirolizumab pegol, under which we are entitled to up to a total of $40.0 million of regulatory approval milestones, as well as royalties in the low single digits based on net sales of commercialized products, if any. UCB is developing dapirolizumab pegol, a PEGylated antibody fragment, with Biogen, Inc. for the treatment of systemic lupus erythematosus. However, given the current phase of development of this product and the uncertainty in clinical development, we have excluded these milestones from the transaction price for this agreement. We have not sold our rights to receive these milestones or royalties from dapoirolizumab pegol under the APA with the Purchaser of the sale of the Facility.</p><p style="text-indent:5.84%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On July 31, 2024, and further formalized in an Amended and Restated Manufacturing and Supply Agreement dated October 18, 2024, we entered into a long-term "take or pay" supply agreement with UCB that increases the selling price of the PEG reagent used in the manufacture of CIMZIA® (the UCB Supply Agreement). The UCB Supply Agreement also covers UCB's purchases of the same reagent (at the same price) for use in the manufacture of dapirolizumab pegol. We analyzed the terms of the agreement, including its cancellation provisions, and concluded that it represents a long-term agreement. Since the performance obligations are deliveries of a single reagent, we determined a single sales price for recognition of revenue over the term of the arrangement. Accordingly, because the billed price was less than the single selling price, we recorded a contract asset of $3.0 million as of September 30, 2024, which is included within assets held for sale on our Condensed Consolidated Balance Sheet, as further disclosed in Note 3. Pursuant to a separate APA between the Purchaser and us, the UCB Supply Agreement will be assigned to the Purchaser upon closing of the sale of the Facility. The assignment of the UCB Supply Agreement does not alter the potential milestones and potential royalties payable by UCB to us pursuant to the collaboration agreement for dapirolizumab </p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">pegol nor the non-cash royalties payable under our collaboration agreement for CIMZIA® <span

style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. See Note 10 for additional information on the APA. 150000000 250000000 0.75 0.25 1000000000 8284600 850000000 50000000 8300000 3000000 18000000 3000000 35000000 0 18200000 50900000 15700000 48000000 40000000 3000000 Note 7 — Restructuring, Impairment and Costs of Terminated Program In connection with our 2022 and 2023 Restructuring Plans, we report the following costs in restructuring, impairment and costs of terminated program: • Clinical trial expense, other third-party costs and employee costs for the wind down of the bempegaldesleukin program, net of the reimbursement from BMS, initiated in 2022; • Severance and related benefit costs pursuant to the 2022 and 2023 Restructuring Plans; • Non-cash impairment of right-of-use assets and property, plant and equipment; and • Contract termination and other costs associated with these plans. Restructuring, impairment and costs of terminated program includes the following (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:45.98%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 652 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,606 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr

style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Severance and benefit expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 535 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,961 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Impairment of right-of-use assets and property, plant and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,173 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,329 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 36,628 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Contract termination and other restructuring costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 46 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,981 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 912 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Restructuring, impairment and other costs of terminated program </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">46</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 11,360 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,310</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 49,107 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr></table> Wind Down of the Bempegaldesleukin Program In prior periods through March 31, 2022, we reported the clinical trial costs, other third-party costs and employee costs related to the bempegaldesleukin program primarily in research and development expense. Beginning in the second quarter of 2022, following our announcement to terminate the program, we began reporting clinical trial, other third-party costs and employee costs for the wind down of the bempegaldesleukin program in restructuring, impairment and costs of terminated program. For the three and nine months ended September 30, 2024, such amounts are immaterial and are included in research and development expense. Severance and Benefit Expense Employees affected by the reduction in force under the 2022 and 2023 Restructuring Plans are entitled to receive severance payments and certain Company funded benefits. The restructuring charges are recorded at fair value. For the 2022 Restructuring Plan, we recognized all expense in 2022 and paid the final liability of $3.3 million in the three months ended March 31, 2023. For the 2023 Restructuring Plan, we recognized $7.9 million in total expense in 2023 for the 2023 Restructuring Plan and paid the final liability of $0.2 million in the three months ended March 31, 2024.</p><p style="text-indent:5.84%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">We do not expect to recognize any additional severance and benefits expense for the 2022 and 2023 Restructuring Plans.</p><div><p style="text-indent:5.867%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table provides details regarding the severance and benefit expense for the three and nine months ended September 30, 2024 pursuant to the 2023 Restructuring Plan and a reconciliation of the severance and benefits liability for the </p></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">three and nine months ended September 30, 2023 pursuant to the 2022 and 2023 Restructuring Plans, which we report within accrued expenses on our Condensed Consolidated Balance Sheet (in thousands):</p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023 Restructuring Plan</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2022 Restructuring Plan</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Liability balance as of December 31, 2022</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,299</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:right;">3,299 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Expense recognized during the period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,483 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,483 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Payments during the period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (3,299 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (3,299 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Liability balance as of March 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,483</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,483 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Expense recognized during the period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,943 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,943 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Payments during the period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (6,624 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (6,624 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Liability balance as of June 30, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">802</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">802</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Expense recognized during the period</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">535</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">535</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Payments during the period</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(887</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 802 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Liability balance as of September 30, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">450</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> <span style="white-

space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">450</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023 Restructuring Plan</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2022 Restructuring Plan</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Liability balance as of December 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 196 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 196 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Expense recognized during the period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Payments during the period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (196 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (196 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Liability balance as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr></table> Impairment of Long-Lived Assets As a result of our 2022 and 2023 Restructuring Plans, we decided to seek a sublease for all of our leased spaces on Third Street and Mission Bay Blvd. South (the Third Street Facility and the Mission Bay Facility, respectively). Accordingly, we evaluate each space for impairment when management decides to sublease the respective space and at each reporting date thereafter, as facts and circumstances change. The significant assumptions in our impairment analysis relate to sublease income, including the length of time to enter into a sublease, sublease rental payments, free rent periods, tenant improvement allowances and broker commissions. When available, we use sublease negotiations or agreements, but in the absence of such information, we develop our own subjective estimates based on current real estate trends and market conditions. Accordingly, our estimates are subject to significant risk, and the terms of sublease agreements, if any, and the resulting amount and timing of sublease income, if ever realized, may be materially different than our estimates. As part of our evaluation of each sublease space, we separately compare the estimated undiscounted sublease income, as described above, for each sublease to the net book value of the related long-term assets, which include right-of-use assets and certain property, plant and equipment, primarily for leasehold improvements (collectively, sublease assets). If such sublease income exceeds the net book value of the sublease assets, we do not record an impairment charge. Otherwise, we record an impairment charge by reducing the net book value of the sublease assets to their estimated fair value, which we determined by discounting the estimated sublease income using the estimated borrowing rate of a market participant subtenant. During the three months ended March 31, 2023, we recorded an initial impairment charge of $11.5 million for our remaining office and laboratory leased space in our Mission Bay Facility, when we initially decided to sublease the space under the 2023 Restructuring Plan. We also recorded an additional impairment charge of $1.7 million for certain excess laboratory equipment which we subsequently sold in the three months ended September 30, 2023 and recognized an immaterial gain, resulting in a net impairment of $1.3 million for the nine months ended September 30, 2023. As the life sciences lease market has continued to deteriorate in the San Francisco Bay Area, we recorded additional non-cash impairment charges of $9.1 million in the three months ended September 30, 2023, and $3.9 million in the three months ended June 30, 2024, for this space. During the three months ended June 30, 2023 and September 30, 2023, we recorded additional non-cash impairment charges of $7.1 million and $1.5 million, respectively, for other sublease assets in our Mission Bay Facility that we sought to sublease under the 2022 Restructuring Plan. Due to the worsening office lease market, for the three months ended June 30, 2024 and 2023, we recorded non-cash impairment charges of $4.4 million and $6.2 million, respectively, for our sublease assets at our Third Street Facility. For these impairment charges, we developed our estimates of sublease income based on market participant assumptions as described above, and we discounted the sublease income using the estimated borrowing rate of a market participant subtenant, which we estimated to be 7.9% for the three months ended March 31, 2023, 8.5% for the three months ended June 30, 2023, 8.7% for the three months ended September 30, 2023, and 6.2% for the three months ended June 30, 2024. We recorded <span style="font-

size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no impairment charges for the three months ended March 31, 2024 and the three months ended September 30, 2024. The following is a reconciliation of the impairment charges we recorded for the nine months ended September 30, 2024 and three and nine months ended September 30, 2023, including the net book values of the sublease assets before the impairment and the fair values of the sublease assets (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Property, Plant and Equipment </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Operating Lease Right-of-Use Assets </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net book value of impaired facilities before write-off </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,897</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,506 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,403</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: Fair value of impaired facilities — Level 3 of Fair Value Hierarchy</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(855</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(5,219</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(6,074</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total impairment of right-of-use assets and property, plant and equipment</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,042 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,287 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,329</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="text-indent:5.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended September 30, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Property, Plant and Equipment</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Operating Lease Right-of-Use Assets</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net book value of impaired facilities before write-off</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,050 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,830</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21,880 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: Fair value of impaired facilities — Level 3 of Fair Value Hierarchy </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,650 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (9,663 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (11,313 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Impairment expense for facilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,400 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,167 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,567 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> (Gain) on sale or disposal of property, plant, and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (394 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (394 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total impairment of right-of-use assets and property, plant and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,006</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 9,167 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,173</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr></table><p style="text-indent:5.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Property, Plant and Equipment</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Operating Lease Right-of-Use Assets</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net book value of impaired facilities before write-off</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:right;">7,206 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">46,292</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 53,498 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: Fair value of impaired facilities — Level 3 of Fair Value Hierarchy </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,172 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (14,364 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (16,536 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Book value in excess of fair value </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,034 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 31,928 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 36,962 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: Amounts recorded as amortization between March 31, 2023 and September 30, 2023 for Mission Bay facility </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (263 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,370 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,633 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Impairment expense for facilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,771 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 30,558 </td> <td style="white-

space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">35,329</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Impairment of other property, plant and equipment</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,299</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,299</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total impairment of right-of-use assets and property, plant and equipment</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,070</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">30,558</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">36,628</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="margin-left:2.933%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Contract Termination and Other Costs</p><p style="text-indent:5.84%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;">We have incurred significant contract termination costs in connection with our Restructuring Plans. Because we continue to adjust the liability based on updates to our assumptions at each reporting date, we continue to recognize expense as our estimates change until settlement.</p><div><p style="text-indent:5.867%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;">The following are reconciliations of the contract termination and other costs for three and nine months ended September 30, 2024 and 2023. As of September 30, 2024 and December 31, 2023, we report$3.2 million and $3.0 million, </p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;">respectively, within accrued expenses and the remaining within other long-term liabilities on our Condensed Consolidated Balance Sheets. </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:64.68%;box-sizing:content-box;"></td> <td style="width:1.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">For the Nine Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-

space:pre-wrap;min-width:fit-content;">Liability balances as of December 31, 2023 and 2022, respectively </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,542</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,710 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Expense recognized during the period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 975 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 912 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Payments during the period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (928 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,129 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Liability balances as of March 31, 2024 and 2023, respectively </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,589</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,493 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Expense recognized during the period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,960 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Payments during the period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (887 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,264 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Liability balances as of June 30, 2024 and 2023, respectively </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:right;">9,662 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,229</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Expense recognized during the period</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">46</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Payments during the period</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(886</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(460</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Liability balances as of September 30, 2024 and 2023, respectively</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,822 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,769 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> Restructuring, impairment and costs of terminated program includes the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:45.98%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.02%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Clinical trial expense, other third-party and employee costs for the wind down of the bempegaldesleukin program </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">652</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,606 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Severance and benefit expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 535 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,961 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Impairment of right-of-use assets and property, plant and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,173 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,329 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 36,628 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Contract termination and other restructuring costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 46 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,981 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 912 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Restructuring, impairment and other costs of terminated program </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">46</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 11,360 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,310</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 49,107 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> The following table provides details regarding the severance and benefit expense for the three and nine months ended September 30, 2024 pursuant to the 2023 Restructuring Plan and a reconciliation of the severance and benefits liability for the three and nine months ended September 30, 2023 pursuant to the 2022 and 2023 Restructuring Plans, which we report within accrued expenses on our Condensed Consolidated Balance Sheet (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 Restructuring Plan </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2022 Restructuring Plan </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Liability balance as of December 31, 2022 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-

align:center;"> 3,299 </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,299</p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Expense recognized during the period</p></td> <td style="white-space:pre-wrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,483</p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,483</p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Payments during the period</p></td> <td style="white-space:pre-wrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(3,299</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(3,299</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Liability balance as of March 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content,">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,483 </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,943 </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,943 </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Payments during the period

</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (6,624 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (6,624 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Liability balance as of June 30, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">802</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">802</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Expense recognized during the period</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">535</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">535</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Payments during the period</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(887</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(887</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Liability balance as of September 30, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 450 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">

</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 450 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 Restructuring Plan </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2022 Restructuring Plan </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Liability balance as of December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">196</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Payments during the period

</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (196 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (196 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Liability balance as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr></table><p style="text-indent:5.867%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;">The following is a reconciliation of the impairment charges we recorded for the nine months ended September 30, 2024 and three and nine months ended September 30, 2023, including the net book values of the sublease assets before the impairment and the fair values of the sublease assets (in thousands):</p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Property, Plant and Equipment</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Operating Lease Right-of-Use Assets</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net book value of impaired facilities before write-off</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,897 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12,506</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-

align:bottom;text-align:center;"> 14,403 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: Fair value of impaired facilities — Level 3 of Fair Value Hierarchy </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (855 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (5,219 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (6,074 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total impairment of right-of-use assets and property, plant and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,042</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7,287 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,329</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="text-indent:5.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended September 30, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Property, Plant and Equipment</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Operating Lease Right-of-Use Assets</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net book value of impaired facilities before write-off</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,050 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">18,830 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">21,880</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: Fair value of impaired facilities — Level 3 of Fair Value Hierarchy</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1,650</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(9,663</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(11,313</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Impairment expense for facilities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,400</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,167</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,567</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">(Gain) on sale or disposal of property, plant, and equipment</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(394</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">394</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total impairment of right-of-use assets and property, plant and equipment</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,006 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,167</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,173 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr></table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Property, Plant and Equipment </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Operating Lease Right-of-Use Assets </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net book value of impaired facilities before write-off </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,206</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 46,292 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 53,498 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: Fair value of impaired facilities — Level 3 of Fair Value Hierarchy </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,172 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (14,364 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (16,536 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Book value in excess of fair value </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,034 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 31,928 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span

style="min-width:fit-content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 36,962 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: Amounts recorded as amortization between March 31, 2023 and September 30, 2023 for Mission Bay facility </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (263 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,370 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,633 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Impairment expense for facilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,771 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 30,558 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,329 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Impairment of other property, plant and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,299 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,299 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total impairment of right-of-use assets and property, plant and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,070</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 30,558 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 36,628 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> The following are reconciliations of the contract termination and other costs for three and nine months ended September 30,

2024 and 2023. As of September 30, 2024 and December 31, 2023, we report $3.2 million and $3.0 million, </p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;">respectively, within accrued expenses and the remaining within other long-term liabilities on our Condensed Consolidated Balance Sheets.</p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:64.68%;box-sizing:content-box;"></td> <td style="width:1.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">For the Nine Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Liability balances as of December 31, 2023 and 2022, respectively</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,542 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,710</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Expense recognized during the period</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">975</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">912</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Payments during the period</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(928</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1,129</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Liability balances as of March 31, 2024 and 2023, respectively</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,589 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,493 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">Expense recognized during the period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,960 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Payments during the period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (887 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,264 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Liability balances as of June 30, 2024 and 2023, respectively </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,662</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,229 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Expense recognized during the period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 46 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Payments during the period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (886 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (460 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Liability balances as of September 30, 2024 and 2023, respectively </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,822</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,769 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> 0 652000 0 3606000 0 535000 0 7961000 0 10173000 8329000 36628000 46000 0 5981000 912000 46000 11360000 14310000 49107000 3300000 7900000 200000 0 3299000 3299000 5483000 0 5483000 0 3299000 3299000 5483000 0 5483000 1943000 0 1943000 6624000 0 6624000 802000 0 802000 535000 0 535000 887000 0 887000 450000 0 450000 196000 0 196000 0 0 0 196000 0 196000 0 0 0 11500000 1700000 1300000 9100000 3900000 7100000 1500000 4400000 6200000 0.079 0.085 0.087 0.062 0 0 1897000 12506000 14403000 -855000 -5219000 -6074000 1042000 7287000 8329000 3050000 18830000 21880000 -1650000 -9663000 -11313000 1400000 9167000 10567000 394000 0 394000 1006000 9167000 10173000 7206000 46292000 53498000 -2172000 -14364000 -16536000 5034000 31928000 36962000

263000 1370000 1633000 4771000 30558000 35329000 1299000 1299000 6070000 30558000 36628000 3200000 3000000 5542000 7710000 975000 912000 928000 1129000 5589000 7493000 4960000 0 887000 1264000 9662000 6229000 46000 0 886000 460000 8822000 5769000 Note 8 — Impairment of Goodwill During the three months ended March 31, 2023, our stock price and resulting market capitalization experienced a significant, sustained decline. Accordingly, we assessed our long-lived assets, including our property, plant and equipment, right-of-use assets and goodwill, for impairment. As part of our long-lived asset impairment analysis, we first assessed which long-lived assets have identifiable cash flows that are largely independent of the cash flows of other groups of assets. We concluded that the sublease assets, for which we recognized significant impairment charges during 2022 and 2023, including for the three months ended March 31, 2023, are independent of our entity-wide group. See Note 7 for additional information regarding impairment charges that we have recorded for our sublease assets, as well as certain property, plant and equipment that we subsequently sold. We next evaluated our remaining long-lived assets for impairment and performed a recoverability test using the undiscounted cash flows approach. We did not recognize any additional impairment charges on the remaining long-lived assets. Finally, we measured the fair value of our reporting unit utilizing both income and market approaches for our entity-wide asset impairment analysis. Based on this analysis, we wrote off all of our goodwill, resulting in a non-cash impairment charge of $76.5 million which we reported as impairment of goodwill in our Condensed Consolidated Statements of Operations for the three months ended March 31, 2023. We had previously recognized goodwill primarily from our acquisitions of Shearwater Corp. and Aerogen, Inc. in 2001 and 2005, respectively. </p> 0 76500000 <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Note 9 — Stock-Based Compensation</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:5.84%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.99%;box-sizing:content-box;"></td> <td style="width:2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.002%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.581%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.501999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.501999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.021999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cost of goods sold</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 516 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">841</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,673 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="color:#000000;white-

space:pre-wrap;min-width:fit-content;">2,454 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="text-align:right;">2,010 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,202 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,337 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,107 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,865 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,106 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,799 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,573 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total stock-based compensation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,391</p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,149 </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,809</p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 26,134 </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table> We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.99%;box-sizing:content-box;"></td> <td style="width:2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.002%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.581%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.501999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-

sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.501999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.021999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cost of goods sold </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">516</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 841 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,673</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,454 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,010 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,202 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:center;"> 6,337 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,107 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,865 </td> <td style="white-

space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,106 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,799 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12,573 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total stock-based compensation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,391</p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #fffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,149 </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="border-top:0.5pt solid #fffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,809</p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #fffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 26,134 </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> </tr> </table>   516000 841000 1673000 2454000 2010000 3202000 6337000 11107000 2865000 4106000 8799000 12573000 5391000 8149000 16809000 26134000 Note 10 — Subsequent Event On November 1, 2024, we entered into the APA and certain other agreements (the Transactions) with an affiliate (the Purchaser) of Ampersand Capital Partners. Under the APA, the Purchaser will purchase our manufacturing facility located in Huntsville, Alabama (the Facility), and certain other related assets and will assume certain related liabilities, and we will assign our manufacturing and supply agreements for PEG reagents to the Purchaser. As consideration, we will receive $70 million in cash at closing of the Transactions (subject to customary closing costs and adjustments based on closing net working capital, closing inventory and the amount of any indebtedness assumed by the Purchaser) and an approximate 20% equity ownership at the time of close in the Purchaser. The closing of the Transactions is subject to the satisfaction or waiver of certain customary closing conditions set forth in the APA. The APA contains customary representations and warranties of Nektar and Purchaser. Nektar has agreed to provide certain specific and customary indemnities to Purchaser for certain excluded liabilities not covered by a representation and warranties policy to be obtained by Purchaser in connection with the Transactions. In addition, the APA contains certain restrictive covenants, which will restrict, as of the closing of the Transactions, Nektar's ability to manufacture and sell PEG reagents. In addition, the APA provides that, at the closing of the Transactions, each of Nektar and Purchaser will enter into certain ancillary agreements to effect the Transactions, including a mutual transition services agreement and a manufacturing and supply agreement and for Purchaser to supply to Nektar the PEG reagents for use in the manufacture of rezpegaldesleukin and NKTR-255. 70000000 0.20

"

)_#I?I!:_XXI,G\\[)E(_X:([4>D8Q[T/.^Z&>=>6D_V<%[^A N>'>>W=)V9$O85 MR,^.=/:63_M'Q\>+&#$'\5P33<=OG&NH>(X'/F4\\SF*H6!LYF2"3P8"2*/^ MP%K4<7NV-SWL[_HZE "/8SZ#ZYE/5)_1ZZ=VG!=/ZZ%Z)5T1'S.'&38"AF6?YRDO\Y\@KK_@;E^P MP.D)-*SF7\+$F;Q+7 #E$^C9O;$YBTLVA_F*; Y1-OF"G"&@^;E/K.\#C2T>B5V=$+=G0?-L!DJ)6_R,;EGF! M5*&;:1(G^M00#+;37.X")C?_\0T'TYYSW(^GP+=/[4KOT%L,N#?RX0V7M81S MO7]**B_X21K%::_W(Z5.CG%OSFF/T]1/70%F>0'%+^3ENV%[W*P3[+UW.WL[M/_,H9F,.E9&IL-)3^?-V[/+&(Q'BV6.9SPF@WSK5=ASRQOG[F,;M\<>NS(:@*TY<\].D>#RL<6,OT<-%$BK3=/>FS#]%@J0__ !'7)H MTWQ"S:,=_CGW0<#:T1\%#S_GHH!77N*?F/E'\DP#/A5X6/SRV*G[%2\%G"BV M5YY[$A=[*/V*/V)L #Z!X7J(/]')9&:Y7A!+.1- .1-ON2Q4@RZ\Q0O@<"Y2 M&L?[\Y,!P3;%76/7YW;N]YR[.$Z\"3./0\CH)(2C^G/F.YQOH]<>0:ZUB!$[MS3]&T\73>PD')X(&/4*^A?^->Y,!I,:X[1UB(PP]I#;V;NRY(_$(E-'I S$\U M/[6=OA0D^[M3B6_2KS,YGYJ/RO5XZR "(LXB+[SCQ^\^V M#&LXB\"/F(TD2>^OQ=.JP5-%Y=\!E__@-,9@1'3X]_,Z=2[7V8KR)/VN(.@(6#S,//S8=J,A'N5.3ZL+; %-_\3%?/_>XSY? MYVRW,V0YA8MX$*>V'37>O=Q(PI@A&0"7(L!,$8GZ MC0*D[EUDA2!,V%_.6D;G(7*A"=1K[_[LR=]F'(W^'&>I?.=5\V.#V[^MMN# M[7+]^48 U3O4.,G8_V7O39O;2*YTX;^"T$R_MQV!(^>^2..)D"7V6-=M25=D MSXW[J2-7$38(<+#(DG_]FUD 2) @)0HL@%B.PZ$& 52AL^19B-"46*/4 M3\OAG_](Z;(\;O^V;MY,UCG;NV M^\>;9[?EP\RWRP=9)[DZM4>[Y"&=PV=FZ;IVA"B]+G0;/\PM"92A.9*&B*I M,@4I+0%ENV(/&[?7(=$U#/]Y'&P496' M*J*K*C*7T)_28*8<+(4 +([B^A8B2#(SY#L,8I7]=UAIR18GIIVG1^#L_EP?YW!M.Q_VO,_?P M:"8+B@GS[]G'X%+,W,X-W\Q*:^,I"L%J1[E5R#4E()>+LBJVGSGW(V:<]_< M2;W&D;SZVP4 5W>=GQ1>A5+41XB?FU[BY9M7D!U/IK%H\(@41,HZ2*EP&$XG M-31H/#._EHVXWL7%=-"HY>[RZUW!/'%VSET,SFH1?ET)]BH(&Y1GN+8_E^]8 M#<^9Y^+<58OQRCLQNC'P\;+,_/A7(,508 @ M6 <$Y5XULJ%Q>3?

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

M)QK]4X:=/_EB;Z-,T][‘C6^G!%.2UBDB*’’?&0A?*^M%&2#S)$0TG,40VBA, ML-%VB5QWB=Q@M\2=!4PK5>^0 7=G09$!M\Z C$6AG>0@F58@%?J,,*&37<&1
9,"]7U!DP.TSH(PI!:F 2U'+<’H*UB4*E$CN M:#8FD)4RG.ND>V^4 2E37<;N2ND^=,0@!1[8@B(%;IT"2;9&<9^ %H.Y MA=(I=KW[[’K])J.ZV,PP=C43.X7IJ#?
I)0P#@=KW[>>4:8H& M$N<.A*J^_:1K\V.N)!?:*-Y*’_O&: _!ZV6EP[>=ZM8#B+\/1:0’BZ14.7\5: M,ZO6\BI@?
I_/W)>’^\2^Z0HS!^8&VSP,D,X.8QT/F\XXS<++Q’’’HVD6)V4.^&L2S:]9XC&1\8&BBV58+ ME!T!{)9#M]MWN!) MZDXB=JL)H5AM[^4#$D+QH.%PX(4"<=.’Y’’J9%GF$)@(]6
@@8F,0E!2&:)) MC&SC$=EM1UL+>V12:#L1/VA%X&Y TFQ(DWKK(R]:O_,,1#$!P%M65/]0+ !C M7#*;]*W3)!YTI’SD3.1,[<’F<:P4UT,A?"\Z0HC4R#8\Y "(0YY:F/<:6P M:=L>
[Y8YDVF)I(FDB:2)I+DATE2*,^^-!*4+]PDM5=$Q,P6G8K’7%?4^JDV[MEULF32F1-)\\?’V’?:"/P-"-#8PM6=J"$7O.*H[B<.K[:?4^)@W#,@B?"0LY4><\9,7FEK/_^6L/Y>!-
MC^WNEO-"#39W@Z^]P:?.8#@I%[I1>;L@OGSMT\CU.Y=N M-.D,6E^_UO(9SUXUYU"NOIU[S<(O7+A>%+>J!D9X^>W M9C3V/G=’WXT+4B_=IP2#85’AY@]6IJ)^/)^)?
S45@[Z\ /XR]],7B+U1:@#Z MHLS1]&+P,O;&EWWW]47]].6EB[$,9.F(K#<;_OQ\B3Q7K+Q3,T5Z^>OB%YMK M(0WBR\OAN-?F+*R! .N8’7Y3I’G-9#N6_4-J+L>VNU
MFUO%W."!LC[S?^MBGH]N345OT.\-RE-,RL9YX::3XC*E#^;3(,O]>’>C#9_’.VK_RP’VS1_’,/Y3X\4"VO/]!VZ^6)J=U3CJP\GOYV]?7WZ!(*RT43’!:C_." _C2J/Q[^E_IKW)U]V8 MH]?
OW[TY>7=Z\]937IV^__7MFU=K*N:;>+JS\ERG9Z_.3OYV\N[LM//^E_+7 M^]=__?@JVQNEU>(U%;(MN’TZ)&]KZD M^’+V4Y20Y^2GQ05E%?ONC%/1IHM6?%.V-?=^=CLFZG-
OW/.]?N&V%XOK M[PIV:GZ.\>>"R9^6A?-\H#/I_,=[KJ-;N425A]O.+VWG$OES#K34>>U#CT<\E(7;I?V)7GQ0’=WMPBK$-_-(W8H+-#K0/IT_BR9S?_W^] M+A?
[4>]_=8M..H9Q&O7RTS:&;&LZ’MX8[W]M!]SMH$SVA^>CJLS:H3@OF^G-B%X5J37=#KZBB!$ M$&X)A*WURCZV?A\’+KQ^6"@’/I$X.*/=? (@2/?!;O@Z/SF
M++=EYVTI’/X0A_9@DM@/V[Y-C\CIN1NE[Q:^V.?9VBE/".)HAW9&FSAZ=5%D MS 1QA#A"’*$\0APACE >(8X01_N.H]?NLC=Q_4YO\!^],?_//D2TGC<&>;F
MKP]NU/EOUY\FQ!GB#’’V*’D5PO1BVJ\)KPVTFA*SS:L;]>O-.V_G_9M^?4C_ MIGV>8(0>0F_[T’N3AJX^4DK&-<*XB.)1"!:;!$ M*B \44]35BG[.^IL70P’#=W//-GOIY/QQ UJ@9
;A;;&S:=K-L6@QG2E(ILK ML77(.QS):CCC8!4M9M+B53UPU2UG:X)EBCGA"% *GF)+"-8RTKFOG M,2^]7FD.:9Q5R3@-U$@.0FD*GA)2NR1SHPJ99K?2-
>$QU/>P9@FJ:\D&N]GL M+&A:Z52#1+A3:XI$N/WV,<’Q$’6 ’%DAM:@U6&\59$\YET(E1L)M(LR9ZZ)X M&;!1)!"TZ(T^:07%4406H\C][[PFUA>P:L M4EW%-
]C1>R_,UQ\VS5I48’A@:%;SQ+6ARF!^QW5BM>;3T%2>;VZR?%=RN_K] M#H9RS<)).KWQ>)IBIVF%TYDUZNC4AE-I,&Z:Y’0N^V[PW?Q)%"@[-%P\BGR< M’,E&.YE5 D9CD2-
%5;A68.F5!6QH((/*TJPYE+[)"0842,K++%@-(O ./R%?2LLCES/(7\>^ ME’O/7W@2B[C=G>$B;A&WB%M<2L0M+C;B]H"6$G%[1(N-N#V8I43<’M%B(VX/
M9BD1MT>TV(C;@UE*Q.T^+O;&2\%@O$$3;U!/.\’7$\T; 09(I0>-+J127&S$ M[5,/%W&+N$74!^CT (+;P;S%2A-!["]’T^L.2[C,M#3-/K<"VD6
M<_\QA>&G07.7IO]*6^4*29=@.1(DNR-?RKTG.U12$+>[,US$+>(6<8M+>;BX MO<>X"$)%R3(XR1D(D5TQ,VB +)$T5D0>_(IQP:@1D5@#V0@.@N5BD"A6_K’, MZ^QS$ 2-
BSU&"!:+V$KPQHV>B9W>O%]B_R’]$E$$W3?<[S?ES&UN:.\Q <2 M)FZ(8R+,[;0+HEE+(KT%IFJE=&XTN"!=><6<%]IR1E?ZIB7M%"%9@6-US1:)PIN M]\/<_NSZ;A!2QTTZ?
W.C<-[AM-MAA$,UTO\H.$-C-F"<5"!"S& Y5>"HIBK5!O%4WB% +H:#IB[8 MK.?1^^ED/’&#V!M\;]_1$36VRS@V.T*RVLFEQ.Z?+;%6Y#+Y;"SDE#.(+ 1X M4G1?
3IUS)DGM^&K7MC58:V/=/X\^EP,YZMB7[,US4+1# ".] M7DH$<%L*=%SI9@$*8D$X9@%*W@$’HNZKRV3S*RDCNO$L3>I[V"F@["I##XK_
MMA]V@42X&VN*1+AU(@S:FNRL!AI-C7’@’’S,U>TKI+ \!JO(2EQ$T?6LS@0< MR:Q\4Q% M?D10$9RG’F0DR;JK8C^&Q7-EV>LTU
2.=WG@\3;’LW[*;.ZG9S3=:SW4N^VXP1H%RT)!# M.;(L1[AGW$A*@-)$BA(L’9A8)$KDWM HN=-ZQ1$::4@YFP!99P-’*E=DCQ,0 M%6-)F_["DUC$[>X,%W&+N$7 K"! %6
MA@0B>AJ-,%JKE21@D1VWMGR36Q6+G1\E6*$YZ"ZILCP’D^[.AEBU\YL^%P\P M\Q^1+8&14$A=Q[V4>T]=J’(@;G=GN(A;Q"WB%I?R<’%[3[T@*8*3Q4I@)KL:
M6E),!:4]1!)23%P*SE:.!+,F/#A5&_ Q H)D#HZP!(P2EH,6U-J’’@FBJ;"# M42< 6 T(HTZ;J).ZP:%I"GDCS 2ER4&CZUBE"6J!B-O=&2[B%G&+N,6E1-SB M8B-N#V@I$;=’M-B(VX-
9RKW’[3V!%8HP+2V’)"0!830’9Z,%&ESV7#$:5LM, MKA-8\2K^?3J>7)1’&9\-7\78]_@^A]<+[X=O’:7O8GK-UY3?]MK^K%F.HW+ M0$_3Z’,OI)F;]6,*PT^#YBZ-
Q[4EWZKN6K7!QD6’#!#DNH-9RKWG.M11$+>[M,US$+>(6<8M+>;BXO<^VB-$D38’SK*N=0(MPM1RPE&/TT3GO8AN1&&A;[U ML&#
(5D(W;O0RZ_2:9F:=G_O#\1CK31U64S7L9[B[VB=N&.R(BAL"&00W##((M;@AD$&20’=HPR"’X(9!!<,,@@^"&0 9!!D$&009Y\@UQ* RRG0XH0G%#N8N@ M;) @LI-@O#&0I.-
H<’!@UF18FCHG[6B_5@0]* A-)\Y"YSVY%25XG"&^[MG&SL!IL%[B3R’L’)&Z^7M$Z,W>X’T?W9]=T@I(Z;=/[W=) ZG’0[C#".$70’
M’:**,=PW8K@#29QY"C^=C"=N$’N#3^UUTJ*6="G=H(OED’4Q,FLR)N=V>XJ%L@@!’ >[R4"."6C(.BU-.0BZ)OLW<@O+=@1I2$5 MY][IL.+2L)1:PG0
ZW@Q#K1*X*1/P+7S*:BHDN5;,PYX5UK6U9L\ED2J0$T MJCJXP\#,M%$L4#!$&A"19/"AEN7P//NH"_L9=IOZF’5,6>*,LEII(3;[1,A[W)CNYQS M)$,DPP-84R3#[^<]1.&3]@*$,
[)H<4F"-4)"=$87K4@JQ59.MU1RDGE0.M4 M+E0V%_-7E^>3XUD6SS=4ETKL8T=UD+;0AC7+)RDTVLZ-9;]6W9S)S6[M^497N\YEWPW&*%
.&G(H1VZ$!@LKA&066(X4A"4>C!1%1!1A$"TU5*L5.2*) M#I1R!3J:(D>R++*’: 6)"><\3+S+%YP=V2IT!\P&M4A\5\J4DNDF1OXY[*?>> MO_ D%G&[.\-
%W")N$;>XE(A;7&S$[0$M)>+VB!8;<7LP2XFX/:+%1MP>S%(B M;H]HL1&W![.4B-M]7.R-EX’!>(,FWJ"><D+3:O!&@ %2Z4&C"ZD4%QMQ^]3#
M1=PB;A&WN)2(6UQLQ.T!+27B]H@6&W%[,$NY][B]+P6+&Q>M!I\, 2$< 2=U MA,RD5XEI+RV]’3H?O,K4RUR^22*()#089REP*Y3(VE*[FH+U*OY].IY]B>LW$?
3^=@3]QYKC,BX#/4VCS[V09C’W’U,8 M?AHT=_EOUY^FEA*Z3)<*K%B(7’?<2[GW7(>Y 9VU T"#!9IN 19N(#59$36[;%D)0Q[W.8)F0((AD8(.WD*(D5A(O MC-
5H6^PM0+!4Q%9"-V[TL.KTFB96G9_[P_$8*PW]_^R]:7-;1Y(N_%=.>,8Q M=@2*7?LBW9D(6I*G=<<6-9)\.]Y/’;6*:(, &XLD]J]_L^H<+"1(B2)!$ 3* M$:9(X"RU9#ZY5"
[[U4VK]K’;7>VS$DSMA%D)HB))9B*()4@*H)4!-DA@JD(M4@FB(D@EF(H@E2]@E0$0A2$>31"6)?$.2&6$,5F22$(DQ50#PW(+."QAPW M&"@6*:;
<=^+R>6!.W"4:8^0,LX@’1Y&1*2(OM8;’*!%%N*8%^_+TXW4Y_’@3 MIR?I@_VRH:,\\X EWRMS5+2L!’%(:+F=3D%$))6;HR$:0T+<)=5V?G0T&H]C
MLEJ’J^@;X%HEN$(24P/H:RS29.C HWGY’ MH8K)3X,R*B8_-4Q.B7#GHT74Y,850F-D@H[(RB28#\F*]<85=XF0VRXF* _: M86X[R7GWP.0’+V9TEP"XW8]P^\4.[-#’QDZ;]_%\&L]
<’#<,]QJ**:LQ;IOA M+GI$,WN%T’’ MS75+(@;WE"+;DD.54R[-OYH%.T44VV]8>L X:J20-CJ-)*$.,%$99*14*(’. MKCUE.&"Q"1Q]P*:F%34K:E;4W VBV!>P?-
B@@DHT%4EVERBJ_E4AI4)*A90* M*;L.*=>;=-K*D#2)B.?0(VX]05J;B(@BC$AE/1AV:_W%O4R))X$()PIQ V:@ MYCB@:(FR,I^X:[(UDX[U),8]7?UA%9FK0>%;P?-)GYMY28T-
0*!B#43[M1D;Z M ’\&1XF6$>.X%D7*5<)$,40$T8@SKY#U%B,:M!?1)\ZCW208W^ZH7/:8H >’ MR(\=OU2A^>E31X7FG81F2[5B(DDDC/(S5PBJUE ,GEMN-1*FK4 ?T*)8%9P M)
(B5B),8D14B(*:"PDJG(+C;/C2S’F>B1Q2N\%SAN<)SA>?’<#OX2)R5E"-& M!&BM@1)D,#8HP#-M$@(3OE8_46-&M4P8*6P8XEX*9 ,5*?EE%,?O=’;.TD6 MIL?DUG*E=H9+
[EX7$?ZU,/CRZT..>LDFWP2+$Y__Z@MO.^_’F=XM&’0#D_UP M&AOK<\-,.[SH#S\VP]$4;K1C^!@X&R[[.+:#YMR.I\TH-=/3.(G ;G868#RY
MTV8N,]GVW!R6P&:;/T[]H1WZ/MPXF<(’I=CIT:.OZ)X3S%:G%_]?&C^P$P#6 M<_LQHN$HQ/D],*[\=3>L?Y52I%^>(?8\#>(7%/KC6(#U&5#X[&SX//0GYP-[M\2Q_^_S[J?
M>2]/QU>6HC\<](7_X"5KK]N&Q]&\]O$\SMF1U\MA>3YS_\ M94XDVQ%GMCD=9_’_;Z ;_#T/ZM:L\;DE*P?Z1/M@4 =&XU)N^=D,Z’:<)[P@ MT6[^,@ JR$;0-
XO/C*LOVH\FBUVR*SLUY[=N,G,6*2M7^&.%Q=98Y2X=\1C/UX)ROF(4!LN;2[*]I7B7,#:_#FU?]\-[??/CKN?’;U_]\>’U MB_>/+K-^U?X _WG^ ?
WY_]>;#^^;D5_CK MY,7__/7DMY>OWKTOT1OJ>?/J?_]X_>’_.]1E^^GU$%3 T6QBA^%2<>[#6H4_ MYOKOXR.!5I6^8NU=IS859: 3)GDL6;; X//E".3F: 8J6O]+#,_;5Q&,C_"/
M\QM@%P?V?!*?32*8&6 N7)8;Y=D_7$TZ_-2?]%U_-;_L_G]SZ_))BROH^R(MTQ]7Y5XWSU;P_>6&V\A6;I$[/+8[W"*.C,0K_^WL0.OH M([&K0ZNS.9+$K/[W
&_]2@Z^_FI3FNM4A=OFY=\^!9]L^XQK]?G_\0)N=N/^ M?_1 19V@21SWTST/P>[9!&M3RW’M(L MG=XYX^$K’8S.1L.F’$W=C9Z>QIH]P!GSW8LX519\ZN2T21;\ -)K,AM?5"9\
M+";^^>T+_"U$G M?ZB3KRQPX%2P"[[%_=’G_;4;@T23\. M???%Q,FE&]?SUUHZ;_V<’LU@YKTJPRF?WDF#>S\YF@YR=6UCK9’H:Q^6W2]V6
MFM]&DZHO5FZKW+91;GL94]_WJP)9&:LRUOVB_$:@+!:66Bt#TR5GMAID*0E3 M.>T^1WVUE=^M6OF]C+[KY$=J)[_[E49Z$F6/[KB5>UKORWIFG54:4:L"XM(%
M9!S6N8"73UY[Q=;+C%-GN+(V(HNQA’N"0TY*B301U’F, $ (M(Q$CB1$CJK+";0*TGV>^N M8E3%J">PE4\>FC;="FJ?-[OR;=4M*@,_80;>C^]0Q%(C
MSC%’UL]$,,1XY1\,/*JO1"-2&:3@$58JRY.B6VVFIGN$ MJ6HV5/5C%[>R0M6&H,H0[+V@!F$A ’8(.\@JQI"2+B07O$N)784J)GW$A@ND MA?&(1[A< T A8QG&*C#+;-
P:5.D’[%]3,:IB5,6H+6+4=GIX@6[#@E$6>6X% MJ%HR8QZH9TD%)6UB*5IZ%?-,"L)025$@/B*N:4+:\(0"%X9(;<*_R@]O)3J M4;Y?
[MWM]^>J8+@;>UK!\)O@Y;AR47N,#!4DD)62P=W1\4MX!=H<]L[BV*X9_2A6Y;?’T@U+YIPRT"J,N+< MX6/8/?$ND57=,I1R[>4AJT_%5TO&[V#@51O\T?0GDUD,3>G-
TL1"S4UN7Q6’ MD]*UI3D?V.$W0]BK0-FAZ1Z8*WKC*>* \ARJT5^5D(/>RB>/7%4)J7R[M.].M?%OYMO)MW3 J:!EC7$MD8"HY M’P(B..1D:<.1#LDB%XW7WBHOQ/6)S]52> IA*-
]9SZ>&H90PE$S?R&4BOA1W M4H7)7G/7H0J3J@16OMV=Z5:^K7Q;^;9N9>7;NMF5;_=H*RO?ULVND19U=@\! ME:_WGS)"I>!.(.FD0%QA@PR/ 5E&#
(O6.V;6DO7N$FEQ’XQFTS/8"B3#Z/C M$/IY#’;PUO;#ZV’7+:?X4=U5/^J[G TU@8F^C^-/?1];Q^N[Z$[M(6^K[,&Z’KC’M:HMA[Z53Q[KJMI2^79WIEOYMO)MY=NZE?O+MS?
8%M);#S\0 MEHP@3BA#3ED+OR5IO!*46;R)V(QJ6SP9!JE%1;82S?$NGL_&_A3(O1FE’,]Q M-LJ/’?D_FS0>G36_C/OPUP#]?A\’D^8],(%S533M->’<=JFC:3L$^[YV0/BJD M+’.
(.ZZ1HTDCHH,441/B[’K_E3O4*OD V#>9C2]6^D8=>V#?<0S?59/D=L7[M=(_J_2I/4@OW52P\7"RLYG7EV]V9;N7;^^D<2@F+&?,H2$L1UTKD^N842:U]
M4)8J’=:*!+ND=++6(2’R/5XJY$@BB 5)A"=/ 5(V*5!6I#@ZI MMF-M"1VQH$8CJBE&G)&(+*$226X2)S06JRUA+@W\A57X!SX7HPFT]_C]’04 M-
M;/9M^<@]LWM7:#>RHV5FRLUE?5:>I65KX]N,VN?+LW6UGY]H VN_+MWFSE MD^?;[?@0K+!1:*:0\-9E?P!&6EB&2.T)B5&O>T[L$)U4?PN/X$&K=F*U$
M&N622’;H2YP17)QR Z/0?+;CL1U.JX!Z0KQ6!515+*MB6;>R\FW=[,JW>[25 ME6\/:+,KW^[-5E:^K9M=8Q?J[NX"*]_0Z=U*1XES2IL9[M,]W*MY5O*]_6K=Q?
OKW>)J"$1ZW!"#!6*,2%VL@X:5#@+D;%J3?N7D5?JDU0 MB[7L5PA%+D@TCJ=Q..E_PBU_Z$=GL?EI),I:AV".S.8 XJ+X\50C\3YM)F, M!OW0S/?H2;#@’3?[V[-
_\M)GTUIC)9@;9M]B.F8502I!5 2I!%,1I!)$19"* M(!5!*H)4!*D(\C0(9H$@NT$R%51VD$8JJ%2"J6I))8B*(%M*P78J<$D,"E() MQ(5,2$L:$.6:)
(6I$’*M:+;@R5$:!*)$&\2EM\@$[)%E)C!/C!*87$W!OG3 M\KJ[M!P)]EN^V7>*B _#C@>*1Z’9"%8()3B;"/’G"$G(6:^2M=L9;$25=ZV*P M14!FLJ2\72YE=)>PN]V/J_O%#DIE(CMM?
K=C?]HPTFLHIKQ&U>UUV&J- MQ[[4A#,2)2,G"MJ6>>(FL(0[))HQR)V 5U57Y(E91CQ"#) NCTS%BDJ3CX4J/D)/9=#*UP] ??MQ4>N;F>7,*8%30)$+@;C!
EG"%"+$$TUY8%9N!+4*7IV.!J O3E[<]:? M7FPH@828BE$*M4C0/B4G*9ZV0HXQ]’H:I]URI4[>Q65G5J1YZ@8G9+7^3>Y?G6%M<5"’’L0WN0-XS+$:!0"--
Y M.@%&EE.’@A7!4IS+\FKP*5X,L9+CECD%G&-,=B5(A^N^(!))$30[=F5K"5AC<.@PJC[7# M*2*F-9BA5@ND;6#(R"’9, 1LT;481ZZ4MC9I)(S+,3@9.A/8O (K$XDS 0?S
M&*:K(+R’!:E@6,%P#_:T@N$WP8MXQP,&!4QY&K,I"JJ8$Q818[#R3I,DUL#+ M)VF?@GI"0$U0@X@2V’EM)1=K>L2B5/84/_<"A%M;;2@!@>VS6]">3 M60Q-
KA(Y,F*A9F"1L_,XG-C"6^<#.YQ4@;+7+%?ER"4Y I9_$,DC7!)]8DZ@ M)PC&5(4/@L%M^8+@’L O:E#+G"*. ,5VBJGD.>%_Y[.1OW MAQ_?
QG%_%%K&+#]_L9/<"7?)C9L[VN9,';BO?+L[TZU\ N6_FV\FW=RLJW=;-W9;,K*^_S[FX^LT: N4Z\03H)CW@0 CE.-%)..,:5P\]N
M]6R4WB7#’$7&Q(!XP@H9&A.*S"NNM6*6XEN:_O_/#F;Q%I9_S;RI6DB%KD.% MKJ]%5+[=G>E6OJU\6_FV;N7^\NT-IX2.:^&30(HGF4O[.62P,\AK(]F)CBNB
MKYH*./&H+1@(7AN..#<86:$]S%$P8F4@C(AJ*NP*O3]X9:D:B%("43*!(Y>I M^%+D294F>\U=ARI-JA98^79WIEOYMO)MY=NZE95OZV97OMVCK:Q\6S>[QEK4
MW=T%5K[>@:H]%913@AS)#:YRR(33RB*J<*0,*T/L6JG N\1:’(=_S";3,QC* MY,/H.(1^’H,=O+7]\’KXPI[WIW90’*GNJB/U7?U7?2CC\/RE.*$W9[5?380S;’VF<& MJ6K+WFSED\>ZJK94OMV=Z5:^K7Q;^;9NY?
[R[0TIW(P)&8)"QCN’N-$.V20M MTI[%:##ER:U5(;]+<$:U+9X,@]2R(EN)YKC4)Z_IET9YS4^#T612BU+M5\>^ MVBMS=[7/2C"UVVXEB(H@E6 J@E2"J A2$62’’’*8B2"6(BB"58#:
(+M!,IL$ M%2"__,U__D!_V&,F>V 8KJM4)7B5X(?*-AL_34LT.L&B1D+JB+C%&FG)-6** M.A:E%RZYJZ=I5!C+N%(8::<\HIPE(8S$ MB:P5I0.@-LYZATC <
/D&TC0R9B%PS3(7+S(/![R^9,JH?% Q:@WTG.VW[O MIHK)3X,R*B8-4Q6-!IA&,Y]HAS*X62 KTPC%921%A.+/=E$@-DV,5GV*’[MYE,[R7GWP.0’+P]TE_BQW0\0^\4.[-
#’QDZ;]_%\&L<’#<,]QJ**:\A8IOA M+GI$,WN%T’’S36F(IKWN-B:*]<4*/8;+’UBA’@MD 1E#?’$ M&3(N6)22X"9X!2"8KH)EIL=1.G6/:E’! MLX)G!<^ZJ&DA
D38P[O@E4OH*>TMO=_^6 MY. 0^;&/"&^"YMU@OXK6%:T?4^>ERBEC(T$%8KD-"CD:*2B^*1B,C2’17$57 M+1SS(GH4A+" M(8CZZ1&0GDLB< ZQ; U!P’K2<%
[1C]@+8@=Y9.JZE;PK.#Y MJ.#)’?&6.Q1H"(@;;)’) 11:64NLP$I,B=PH_A(9"8];@Z/&5V5[T$%9Z?#G54>-X(MG#J-@]4N(!,C 0T5.V048TB&((G4QDJ\%C/ K.-*L(023A%Q+01 L&>
(4,(Q M@+.6P6]-J^6ZIS4_. B]>_U(^-?"X,NO#SGJ)9=\$^^NO/VK+[SMO!]G>K?@ MSPU,]L-I;*S/O4;M*(__-@,1U.XT8[A8V!LN.SCV Z:-J/43$_C) *W MV5F
\>02!;D<9]NN=%@BV&W^./6’=NC[<.-D"A^4HK!’5U8T]#\U?F GP)GG M]F-$PU&(\X’!4N2ONY7X5RGZ^>498L_3(’Y!H3^.A36?P1K-SH;/0W]R/K 7 MS_*WS\]MR ?
BR^!ZWF^GWP6DXR,)’^1:M?UT,7]AN17%87A^/IJ4FK//QG%@ MI_U/$=CV2UYD>.:S!0=_N<2HW=Z62J6,Y&C^KU0G)?1;6[6;E$+P)2B _>E^ MYLT\’5]9B_YPT!_",*9 .,_L;#IZ?
OD+6.KVX[+W;>R_33"Y9W;PV5Y,GO_P MESF5; <1;7,ZS@+DWT"Z_#T/ZM9H\[FE*P<2J7TP")31N%0V?C8#PAWG"2]H MM)N_&X 0VP@#9P3.K/FB_6BRV"6[LE-
SANLF,^>1LG)’ OAAA<S=B/=U*$’T(P+-=V=\7#*G5N8 W>O/J?#\?OF@] ???N^.VK M/SZ\?O’^$21ET3B]G9S^/0U&GR>[L30O3MZ\?/7F :N7#?SV_N2WUW=T8CS$ MV%X>?
X!QO?__S^ZLV’]\W)K\V+X_=_;7[]>1OC[&#.[$J/[T>@D8SFDWL M,%RJR7U8J_#’7)W[^3X4>[]!-(^^^M^8F=FD-5’,INNTQZ(2=1(U#R4+6!A[
MOAR!]C":@;;_Q+#_95!.,C_./\!MBI@3V?Q&>3"/HZZ-V7A6=Y]@]7TS0_ M]2=]UQ^ %?UL?O]U^9?E=5+^N"KYNTFVHO\O-
]Q#O_\61$]T@\QI:_DZNJQGZXCC]NF[_[/7FI^FGY2/=Q:HO*@_*’KT_SNXHHS$?] M@ NS.<%ZHP(,UEOS._QY.FE>@[$@E:^^QE>L\M4#](^;E_O9H/C>W7(_
MMR:W%W9RVA0/9I/&H[-F=![SN<’P8Y./GC_UI_TX>;9)T?]DXD]NC5&[$4NQ M-7EU8-.M5+R7V[I7TWWP9JK[6?ON39PVN15J+7-WUW"R1]_O;<13[@94[’XH
MNTFY!#9!#LN(.#8B-QN(R’AI+5%$![H6RFZD5\F$B A7!O$0X6[A’-*&^$0$ M-QROU6MZ.Q[!<’X#OMUT"#NALDX5]6@L_=TPH’PE’,80,@3@@+10&5%+2FI0,Q7%[$$@9
MZQGU@*T =I9=-EQ4^B"\3#>MY7’(LJM%^2$9[I>(#W=:]FNZ#NY[*/’)BP+![XEU\4:OQC>4AJT_% M7\F4V16)^F8T1$58CD<7=C"])GZ*0YGL2GI$" _0:!.3V,S >5ODE,QTFPZ
M&\?N#D M?5Q;PS^GXV? XODP]EW+X.]:_G[7LO>’T7M@[)/T:^]=W.FWES2,:8/6*S\ MT8V7ZO:JJ%A1<=.H&"W&SCB%1/" <)@"N
$8(J:QH"9H!;)KZZ3+IJ2([&E]E07L*64XGXZ*.’%MN :@T:+)&8"03=1);[75PFXB:W"ID4=DC[$+^3X) M.J].XZTHOB\C7.+[A8H;.PR-/1O!C/]5M=_]9[$J2B[UC"& M(^.T0,0+^(*
’IOB)K3?58X[’H;C%7[;5$Q&#U=_;X6I]_*/84I&B3!F@=$ M!?:Y@P\8Z9($I*R1RKLH,5YKOG87C??A80JT7,D.’*:J>W=+6FZ*XW%)%?*C ML]A,[9=Y<$05’GO-

8(!6RL"3FXC81M+OCQ)OXV&'W_K?XKAN'#D7^,@_#H: M_[&Q(U#=8WN655A=V!6P*F"U<6:46VYI0(&I'%TF0#G"'O[TU$2O"3..;$)7
MWB9@,=F35!\X8E5O]B,HR!]'H_"Y/QA4$;+7O%5%R"6=-V(7"$_(L!R@G.,T MG+,$\:@3MD+Z$-9$R%UTWO_NF&O) MK2BS;\>CW,,7& A(LA1VA34;]/]56@Q_LH-9S$IN?
_@)+A^-+ZHPV6NFJ\)D M59C(((E1- $R"X>XU1&YX. '=A93HD$\K&6W?'=-B@4#_CH:OYZSV8F;C 9Q M HOI-Y;5LE_UD*K.6V&JPE3;O45CDI2PR%J6_;F8(),
=Q071K,H%!%K)2Z_ MNP3%MF"*]SC?KXB'ZL?=4=5W-:8^*[EPPUE_=C9I?@K]B8?EG4Y^[A65. 9&WZ=@.)RUUUD)M^\V.ARIMMA.Y9QC'DF"#@DH2<2\Y4T;6REW?
Q5S\T^A':(VR_BL75WF/;5LA?G-KA1WCW MY89BRYCCE2+*M;G85^>Y&^C[+*U3K=2\;YNZUY-M_JPMN/#\JVC*C?JC/U/ M^=2VVF-/2,FL]MANV6-
1)^$,$XA$0Q'GV(,]YAT*C&$6& D^;,0;!388@-LD MOHSMOZ^'7R\,J6JC"XVWM:8?!^L*4 M&*T3DM'H7(LO(LMY1$E@P@)VUK '4L8WCW],U5I\U:.]31W\9"R.\A$/2D1
MF%4>/2$>J_)HM^0134*Z7)M*48(1CY8B(Z1$0GI"0%'WX7Z=%4I^P+HP6C#R M;_GO=WGI3M(?D]A6@'D3X:_+E_RV#._86$RFW+.TIZJ_5[RL>/FP>,FX2=)G
MK9UJA3@S'EG'/<("4Y*8LHZLG0^=S[53N*E[&%5_1W5Y[Y5?;_D5;51GE5L M/2'6JF)KM\26%0FDC4F(4<\0%Q2T]2@2 LT?&^TIX?B!0E<*"R]D4RNO-15T MT%.RAJ]4*-
SM/:U0>$^/N:#<)V41Y=8AKJ5"QF. (9^\IY@Y)>S#>,SO!UVW M"V#A/2[VRPM1P\%W5)E>A(.?VXL:"[[W7'6H4F0["K74.GK)%7(,=&E.A48.
M)X>LQ4I@ASEEFVGL<&-0Y=N6BS??50C3_>K\697J"H<5#A^XS)C%/B5/$$V2 M(IZRDDZ#)V=!"Z8#I@^<(SY \&AZ;$]:QU1O=Y/0%$?SV*8=T&NGN\[LY<#
M,HOCQ5"/Q/FTF8P&_=#,-V:?9=>W9__DI=OUTB@1RD-6M WE&''J) @ M!EM#J=.*/:"WN^/?S1_!$O6PK=X6?6W*66$ZU%PD9 M[R("?#4(5$6+E.:
U,I92L0#NO#O@\>WLQ)43Y '3$/=23;\M0)3EJB3?LU!=!># MY!$QFHN>$(?F*ZIEF1_*)BEO^]RNAQL-PLUUFK.!D@:CSY,FC4=GI3O<Y(J- M4@LT?
W6>NP'BM;1M+=!+KCZ\IQ1/ M4T/1=LNVHU%&YC!&QMB$."82&4T48MHX&2/%*6XDU>VMO2C,^F%T[/\YZX_C M\2?;'^08M%]'X_=@N[V/?
C8N^N[+Z*:,"@$PI*=UK;M447&W][2BXFZAHA*8 MZP2H&*C2B%/%D8G>(:(UTX(1[KW:A,?K<5"1*=K3M.8"USC=;:KOO]MI1\I5 M?W^Z?%8EU3V#;0V)+&B+3+
4<<(P_M.)YW(N=X&%[8P6!RDFZ6.1N2-U2)'N6'WGB@0MJA;^6>0IHR7(N@)9*8 M@;+L]$*6&8E(2,XGI@1W&SD>WB5(\SM@25PX)!6'=_:=WR?CW,0M)KGS%T&&,E#-
!8:G2FHY M-P_B"G_;L?3;S- @Q%[-V7ECE=\P?L#8IJ?E[:EPN*-[6N%PM^!0))Q"9 IA M:3CBVE#D"*-(>N]QR EJD3R(#_RAX5#6$A75];U5!3Z;H%5WKVD.-+(.2XD
M5_[1.AFDA#..,4HQ78LXW& =A-=S'KY+CNW7VW[3'A.R"J2JT5< K0#Z@%73 M''6).HL\QP"&H*LC)ZU$V+'HE5-:Z[76K!LL4O!P $HH[1']@-':>\(PM23! MPY0D2/VA'?I:DJ F<]?
I5BK>WVW=J^G6R,SM1&9V[MU64DY.[1@&TI],[TPM@NK/@J$E 6.< M-X@*QWRDFG*WF2H#*\:TH0(!& D\0$&4LX(M8)+'RP6*W% MBM_W_'@' (WL5^3D-IU,5:^^LU[=
[PB_#:&,*&75.C2?[7AL:]SDGG-\UJ5(ZMRQ)ADM7 ,,>TEXM)' M9)R4R"7NB1-
>8<+OH_(._YR.KXG3_[7PW+LYRVW*@2*JRENAZN"WB1)K[!%JM]8S>*ZOH(:&]JJKS5U_LH*N^[>-[5M\JJKA^= MG8WR8T?
^SU8)_F7+.)XT[_\YZSM7I'4G!"N"1XL&L]RN]3*^O7T7B)$R?I14&)]QDD-N6+?EB]?"?9 MKO9HK8!< ?F1BN9:4/"IXXAY!@"J'49:2YIKZ#HE R9@ VRRNM:F 72KYL*>
M\$@M.K"YH@/79255]^# &:P*H>^L@D,BU2HD1*3H[EQ@@9PV B7!0E;6J<0; MB2:Y(6?VUSD/;SQGEM,>?LC@Z\HO58NO\9%$!U#H;HR(1>>8CXCAK\9X[%+PS MC"1&F-
U(&;&M ^A#!GKO":\\^/ ?FKSKU**?EJB6D9C6*YA${^ 43K\&)NQ MG>8>%\-6V_%<QP/_#;-[NH'IB(K,<%%<4AODI>$(&FT1QR0%AF7--+. M$4:"-!YO))C^47'WJW K^('!;3U?
V.+Y0G_H8>*3V/P$!%=^^QD^JX9(%6!5 M@.VD(4)P$B#6 C*:2,15!'LB>8(TU4$0YT%8;B0 Z5ZB[VT<]T?A=84KRN\'RAO'@[9)((6Y1ES"#R>-
M18)KZ033/%JY";/G::,\93V&#ZW$_BYW/=Q/.^G%3<908Z>-BS"*88['RD5Z M"D=4&VFO&*Y*SX=V\@D?O9'4(X.%!9LF**0YTXA9*S@1B2FU)NVP%2Y91Y"/
MQ:9)"EF0C8C']+@UL#6&;U3:;:PT9H^J0SM!V046JA9))8@#PE1CN<6>&)0\ MSEW,)>"C8QXE103!W&FFUOQE'G4^*($0](GI0#]T-C1+1CP3D'0.QW$5.U M[E%:,;4>DVQ?
_8_P>57\-\GA)(AF%@NCF1O$W;>U__W!Y-7U"[&G$BMHS[0Q M%!%I2"XB0I 6@2('THHRYIS&:[7RF75<"990PBF"E!,":7@,(I1P'*W7,NRD
MQ&*X1[#9EL3:&7YZ)+7ORORK);!31%%!=HL@BS%@(@4[@'MJ$1?6((LU13;& MZ%(*R?.U^OT:,ZIEPDAAP^!&*9 --)]-6$XYSR=LEF- MMPJH_J$)*A91'[:O%:?
1!1Q1E\HA;JY"EWB)FG#=<*^X9VT2@ MZ>NB!'S(.L!;4 S>Q.\(!OUZ#&A/BJV%@.X,C]Q=E85_+0R^_/J0HUXRR3?A M;OEV R__ZOMN.^W'F=UM?4G+L=QELA].8V-];JQNAQ(?
8\#>(7%/KC6#CS M&:S1[&SX//0GYP-[\2Q_^_SCJ^L17\XZ]A&%.@G&=V-AT]O_P%+'7[<=GUJZU M"2;WS X^VXO)\Q_^,B>3[2"B;4['67[\VW3D_YX'=6NT6?7FE@>#/!F-6Z=L
M;K(ZSA->$&DW?S<8^3\WPL$9@3-OOF@_6IK%=F6GYAS736;.)&7E"H>L,-DZ ML]R%)S:U5=W?XVX\FK$?[Z0';V"IKQ&(\[7=7?FP2IT;6(,WK_[GP_&[YL-? M7[T[?
OOJCP^O7[Q_!%%9%,XBJOX^'?U](87^OBJ%_@Y2Z.^3Z8XLV\F'5^^; M#R?-BY,W+U^]>?_J97/'W*^'&!T,ZOW);Z]?'G^ OCW]KWG^
M#WY_]>;#8VSQ3BS,^W@.ZHN+XX;A7D,QY8>Z$C_],5?Z?EY7Y.;VX)O961SW M_;*NHT^$8$2\HXA[3']=1XX,LQ(;;;!-&RES=3+^:(?]?Q6!^V(! /#'\3"\
M'8/".IR6/T_2KW.]]/U"+7VY.%F%J]_#LO<3&&[#Z3$HQ;/A% 3<6WB>[\?) M!QCE+X-2ZSV"=7D.(YB.9UW!F/YP%L/Q]+;3_CNYG:C\I@WS\.?3FP _.J& M-)T?
LEG=KQ(+^WYV!A.YR$K,R@XTRRUHYGNP*GM7U)GO&../U],J5U;8H"32 M,EC$2 MR^HRK6[X8DE6FW.)(\U__(JU]4B+=$^&B7^"W=2 <0X/C+-IWT^:G]H/>\WG
M7%4'3'2PGOO#[&*3*1O;'V&LRU-FQ/T7.9HL\C&\@.5(H_&P;PNWYB.X M\7DV<-JK7X)-\-F.80!IY&?YS<#6_>6W@)P4XB?XF!TGO_L#X>C3\6*:,YB M +8>PIK AS?DZY-B]'
MTSH$FM%LW,0$(YU.FND(AA2:G$5> &0(:]X^\VP49F#$C&!)8-5RY/WTU$Z; M21QDIP*,\@(&$V8>YF//SF'F%_#+%#9F!A-N1N,&-OH3W-<^+N95/P>AT\ZA
MF$+P\L;ZTSY]/.J3I=;">.<9O_EY*@Y@1&?]\]CM@A+8$^WHZCL:%DX M>-N53V^#A6W):?5 3?'HXQ&,_5_G\:,=P"@' MIAB>W^YD@KQ\]&]^50^13[-^S?G
MNE4R+RN_;*G1G-I/F5#^.2NT,%F1<:/AQU'+%)_BI-TQH)YLOY3G93]<_)*W M(-/0:*%JY-^[YUUZW((Q1\UQQ@@8W6PP+5S2/N?J4X";81*3F0/B@D\!%D ;
MRA227S\$XBB,NH@XZWIJC\YCZ^!8_5W/'?SISI1&YIT1,Y%4'.H",AQ!:J14"HX@)-]#ZI%$4URE$>ET-XKX3Q M@G9^_,GV!]G;]>MHG'NVOEX0^\U!OO+2^8_XUOD/-T^#C/V,Y
+I"2A2L.Z2)/C+)55[[C3>J.(NK/9.$8UH-$"= M6*IE%U>-O=I[8UC%]:=V: M^<(=J,8P;-Z 7EQ$$%F10,754_3IK#P.05Q-XK1Y.^_I>SP7OSW^ MN?D,.G&^U*8$"YHUAO+=_)
[QSWGMC\]]$XR\\(N@*)8GO';;R^.\!?W%[OR M]0M[GK>S>0MVP##W"/YI\=W/O1)ZEQ\^Z;8T"_7+8CAUVPKJ@Y];!G\%ZWWR M"2
,=.EC0&Y[9MLQSFF@4RGC>&JS\IR5Y*O2/:_#I"GG#IT:'=@D_3GA:'R M1X\(CS ^(*BYIETLD"_J23$YKDP$)CK)(?T7S<@!$;;J4+NRV6O=#YV*E)^S M[:*87PC;GT ?_\=<69]-
+^R M>RS[*3,I^=&D4W9MR,?8K4!NC?[<]Z.[; @ \GDT_K/EA(])B#-MN>HUXBXG.PFQ94C.@J M&=-OZ:N[1,4_EG(&(%&\P7(-0V*-P*>T+HW1B#+.H-Q045'8)7%IO41XX*'
M^7 Z3P;$T4J"T[8URT "()>E %T!(R[A-YTD0Q8;+H0UDIM[%<#HNZ9G%;S,: M#%I_ZJJ_Y-G5@Y8N4@LF)'@NH?+X=G75'@
MKPW#*D%#S\ORHOS&R;,LW$H4S5ITR&)MX&5,?3,TY*%VAA\I08G2 J4*:ZH M^'$U;^?/&,]A5(.K44!E2;ZR!FWP/I6+H),5A&M?3##^\.OZ6EVE#;FVV$XZ MM@HFC9>S;
[V_OXP!84:#YO>+;(B^!ZW"N>9%=UKUTR^_O_]YY[1,'7D1%N$ M53GT!JO(),<1-59SYRTF3M'8N8&TE5R:65 6SSY_:D=7^E=.>D^NA/)Z".V M@R33M'/*N-
&>B/[')]DGN5O\N*TQWF?0 KV33DPF\P NMIG9#,<;/D7B_#F%ZOAS;_803[;:-Z?1K!(5_17 M>2OU=1DY6T5K%:VW$ZV_ER-&?J/'$&AP[H&_SFM8?(4?7OQW\V(\FDSRP7SS
MZPQL]]>O>\UO1V^/FI_@RY][#>#*9&;;0\@%E_3!_(<7V"OG9CL?= M=?FQ\,\"GX%LS-L?LRD"336>@!W M4B]TT5(;LJPD^&=5 F;G[((7<+)^;COXTY20*@LUEJ M4)
Q6PDR]U'B 4E*+ :198A::R=X%V!I];K7!87?YM4 =:]\=ID0ACDXMP2V M @H=%T^6?9F#)\:3[NJ.3/#WN!C)T4XY&7-QU!93BD-Q3> _S,""W$%FS\U'N MC!W'OC^)7?[:-5+LYZ.FB-
B+ANH5"9OZ@WQ-%IWYOO>O7I2 FH^@HW4&["*[M+2N,O\(R-N\1:W[*-S;#T5'#&$-4&27QS]V-;43<_#@-MK4[4)N=9QFZ M$V>2.X1Q3(@3$9"5N6\Q2PHSDH"0U_!. F&#?
#6(N&S5@ &$7+(1I*]3*4@I MHM"7[.!W91%.THNRF<7 *9CG!O$/V+]7W?8M\.^@!>4M*7K.)UZMJK6%5+^ MFK)XU.3 TYL(W44/6Y?C+-NXP$SY]R3;&_SOU'OC.5;()@-
Z&R,:S&-A4023 M&$/4WBLA/FU7P>+W./UB6)K1)0 M-OI0<:[F&U&P%^@BVC&*PT>Q!OYO#N045[)1KAZ'/!89KQC#HAK#U1C>AC'\ M51_SN#N$W4D-4N;N:T!.*#"=Y2M7R
D-IH*GS&$52=1K?F8">F6.;/6F-2& M8UI'X$=PE,@8-&6,$*#<-*7=3SRZR(GYK)>19"9PJT0]_C;!:ISYKG^W*7:R$5?5 M7-5.5YY'C+?:_[ZXMW/;;!V7O,B?
+T]ST)S/%_ZZ]R4<%M34L=!XUQ(Z)(J ME?7%*]%@P 7X:U?]O +*['M!^?J#]FL_K54='B71\YY5'6BMZE"K.M2J#M=6 M=9BG-G<),W9%=-
\RR_=.R<'TAPV',BDLP/#6.0H3RVP6462BQRAJE;C@A 2' M-]+G.T#YOC\W%_D+4P6O1,.QR"PNW;:/4&9!_< MNHCLSA^Y>'8EZ_)\//HXMF=M.&W)52V>E_@1.'@<1U?SY7,
:3B^DS;NUC;KIF"^G P]B/M_>\8A>GOTXC"> +ZT0STVM;4H! M"69-D#'[T_E:1"_U3..:H#,H=P& RV45$%(K>)@'(B'E<.X6YM'2EQ41)0L@@ M-S_6>]N)T,FK0;]LB ^TQ-P-
1NLPFZ2*W_F#0_ ME0]_+OM?EC+[GSM C.U>ET3?N,SB;4W:]F%+"W9Q8K*:8 V[N); WLO!/)\C M4(2=7 .E,(%1=GS?"DQ;"&770>A1\T>QSK]R31?:EBL)M$G0EVBXJ]&PY!MW
M<8L,Y$=%78,U4SFDC2J+N#$2:8Y!ATR"6&4(CG;-5R5P8!@'@[3FH.T:E^,H MB4#$ AA[P1-S;(=15^X4ZAXUP()SSTVOW+:+XK B9^.5XCCS M5X)H 8:QN>Z&G=I\6WO6D
\:BCKSN9]%2]9IXI=SV)[89:UFIQ?JBJP M?1] M5^[BMG+K0 NHS(FO5"&Y6ANES7-L*YB4J(E,=POLR)M_ _*MAN2JKSB\,ZCE MY[6'V=\
(^EW4CFO>7UO3>!LI:588'9)VB(&XS7X<#I:/)LC+7'I=2^R=W(P? M9Z6*7LU&NY%\?[&3?K$F5LL,%LI\"\3H^V!/3SHG[G(]#U/,G'P?9W7F7>RJ
M@LTOF+NL>QTLM*;UL]JO.C?:2A!3WH#Y 7_-SUCEP,#J^^/H_5%7_JH8T-[GS,TPIZYBCR[!Y*?_/CY^ MVTX)=.Q99HEB^4R*=9"7)1?9ZSPS9RMGTVWE_NL*\R]8+1-
X.\2RH..\OFWM MBI4R UUVS2+* DQL'R>3G/4WUW62[94M$[/PMZWS<86^JQ MY^<@\,KA(VPGR$] LJR9#?VR4L3*2SI]N-6?VL*# (.#Q:Y'"\KS_$$+A+U8
MQ#8N*6*.YR4Z8W4:A:S >@22:87I@H4+3=W0=V).21G(%Z)D96S9UFEQHRMW MEVL?>C\[F[6%9EI^SD@_CJ>Y%%VKI.;>ES$H89D@1X 5)MVTYG40 M)O&2C_1VR61/V?
Y]LEQW>9_S_K;X-IDN?,6YFDKYXGPPF[1H=I4_ODI?^=?9 M$,S* 8PV-.L79#"<%[A#\&Q40L-7"JL5'2:VF8W#T25+*=<(S96(TL+N',W: M4B[?1=*=:V9%-
%S6KL*RX,#T=!Q;3]%M2@\LC36 'O@V.V?+<#[G*.:NN7$6 MA[%M:MS%*AVH'%CKR?.]0F'1GZ?0S*V)Y<>1$$P^I^%-I%#K3O" M6A_8-2D:H[G/I@N1;M=@51];'42I*/R_;?
%CT+[6!_*_S>1T-!MDV@0VLZ'3 M[?\Q&[;@OGCWMY=A46EIO=]2X;S1#0K:@;+!NUQF>19[I7!M+K#FXN9#HZZC(;6E6C-=N M.9%;$MQHM9. M^%Z6RV[ON2;
<;TM(%RS^M$C2F+\5MMJM%/5=*,W9ZUIHO:CV%QUI==1I.5 MFXK%TU)+KYF=%UH%4CIK(SA2SDCK'%7355NX-:667#N_-!L@JP[CQ7LZKV?[M)J#\\02>ES>RG_KQ-
G;*9HO_T\"U!0$H&%:(<\V1]5HCRJCB*003]%K#\3N> MAV=[H$7(=_W)GR&,?2G^;B< 12TPJ,(WL^G "*?N_/JLQPK4\H3-*64PY5C3Y7K]H?-7=W_ -H:XB\KN@), M>CG9%H!BE-
MY_=2YDF$7BD@_;67H13M(ET^:N@Y98='G*(!$7#@7RT#C./<= MO_BY1:FY_WHAKL_M19GR?N=EX4B;71A"5AZZT$2K!;CY.W)4IO M3AV[%E.BH3HH0Q*F&']QSY,"
M0]9H3A,)W*W'%+\=CSZ5 /1?1^.7HYF;IMF@4ZENSGQG7ZTJD_I?8D#_BN/1 MC77G&)-828=PX@ICLQ8PS3FQS*F$#.5@%.*=03$(M; 1V7)LUX?0HDZ-*!1-
S0P@2\RY$"],T'BELG5&>,&_6:E_=1?(^RN2X\\(: M+Q$A*I? %[?L"T(AR1YLEQXO99@Y)A0/A(.6Q7RY'! 6BB,0E32FI0,Q7'+ MDQN.K@E?
O\,'CV4\3(MQ!,A7.Q.2Q>@>YU,:UNJ3/,..IMN&=#5@GB. MBXBAB('QI]C&&%QY0>>7?\3IW^V(M9=C>.8AW=T\)S/?M@K*,57ET,_>T XO MK]W:,=O7NN?EH*&
[J@Q=_LVEG5K1$.9GVOG1\'D->(M#W'^]QV!YT_ M(+<0S=O7UE;[GDJ^AWG0EK/T2BC1>2RSG*]9:5?4+ZKKZCXM^QKEKW+EUPQC
M>;/MYX5QVWE:QK./K3=F:;_F<[G2**]-,9L[6KKPHE%SED^C5*0EO11KO\X M[WJZ&A)8@M_F<7G>3KNVOL(5&PF,"G?QA#-.S&!*C8L>'&60_E]
MCK3(VOAB%D>%7.!-Q:72F^OB;0/8MF]LNTCS:*R!OZ"6]VL<[?/5O_LVKUF_FASXTH#7S"F0B'6-LSP\IUEK19;=:FS5.=S M<)?Z@^:#2;
SUEA.KN8=V/#)]C:!K#29/2]!_4O_ZSRL1U7+N((86:1R9&5=3RJZ=WB*&=Y*-PY7ANYB#M_(@\BKU2:X?6' _;/9V95[5C%]SG!Y/"V;E)C#-JBL M2T3)M'$E;!.&=G7]EG+6B M5A1)?
@O'WS9.EA_G:'*C+LUD;) A 59(Z<&.L 19&1-24@0:1 !;Z?Y=ISYT MW0Y*L=4-Y/=L=.-VQITY7Z6F+-.!"K&_SYD.K M#Y=OZ$\N1=[9&5PU+L&P!8[:@K5=%5PWR\9?
=W%GZTUSA_+B_&HOF@=SH7Y7 M(;TVU=&J\W4G*]1"B,751)(PP MBP%Q(CERS >D751$>8=94CM1[>DFS+D:H'&;"?V='/;9RZ7UO3J6/1%Y.(C^JV):C\:7<
ME,),);"@._0"&;L8B8LY2:6,R!67T)66Q5W/A]:[A=<+.(5PE)/WT2=\&Q; MD2KKG+)S)E5=TC-(?+_,-5F?Q??6>:W;!GF07\)I=4+,+:G;! M@V07W#=-X)KWWMKZK7K-G?
2:'(+1'JD].^T'$*6;T71V7\4IIXJ]KCS9U/8' MDRLJQE+-*3ZLKCYP&XW7SSVFFAD,_\]\RMHV7^LBACM5I^@FI4*$BVV<6A=3 M<>F+;!2'L?T\?)Z?6_7UJJ_?
R*]1+]=_&>)!YJTE6[.;G/%WLQ5;+*K=C!/ MZ6@?T%8"@<4K;MSBL\DLD)\+W#(:KSROS>5=/+7TU6W]P/.2FI>&51Z6GN44_6O&V&0!4PM76NL!S&NY M#"_)%9MRCO7-
%ELABC3+@2TK/HUQ7 W\+2Y\>Y;3<];> *IB\3XLR*![R"(O MHY\6CVD/+U;<>C1T98<6>9AY-HZ= 4'W M]0LZ]]%G>MYR8A+7N"V M\&Y717T"*XU*&>BU8Y]KC.[-
GC<[;3$EA"$AZ5PD8JT[M]ET.B_Y[- I9Y!\/P^OA%/2$/I@[QR5B;_Y5;0&R5G.]!&O-':+S=3K0TYWY M],NA;LE_ZWBNO()*PQ+FVE:561[I9F3/'-P&
[G7QC/VQGYWE,^4N8"K+@HZO M^],2]))E>Q._XS3+F%OE".!%Z56YOFS.88^C[G-XRE[E3T@G^)JE=!Y(?1EHX#% M4$?
N'VTOOQQBVJ7^VO&X5.Y9RNVU5ZYNQ,>.;'NE]E4."%B_?ED/;Z$0%%VF MD/M2H;&+AZW24X[*6A3B+E]^(@,9E>"PY0TE5FMQE'.;2>0R=CF0-VLAJ^.Z
M[+=NE>A60RJ1JXLWMA%I.15A RK&DT2LA8JAOZ9BY,+K)=ROC4%<;NS_/?S M2B3_6@FV2VD!;>&K176L&_2.^0YM.UN7^Q1=D@$QY1WB/CADL 31*Q>_0O6(N
M&$L'CTG73Z2U:XJU7*((IJ4JY2(Z^K*NXRXZU6$.6M<+GO*^N6X!X^O[_KGM MRC+G;CEM_-ZPZ"4+L6T7D6?+(GSE0454%WFW>G7.J&YWT ZO&4HK;Y>"\]*P MKHK
921W]FR64, V26EU[+<=;]]9F6/._2YE>1?2%<1HSI,NV1E%-4E M.0BI9&^T#H"X6NNAB//^Y,_KW[L<5J_+#9NLIA_[8(A3Q)A;N>-^"Y5X0;I MWW57
[5\M2;.W&DT!XK+"+%M3<$S;#WGN1$Z3H@+(G)=#XZ"4,X8*;019A.: MPBL['I9PU#A^GV.*JU)P(X&^ >3YK=0_!LPOBW68-3VR.SKGO'9E]^=U[I=U M.F[(-
'U_J:CRR2(YKK>PITLBT")7+(-Y]E'G-)N5$N/9^5'LLKFT7-27FC^B MI#I[._EM*XX0?Q*]6K8O1(^OXS-RT]IR2<&9+,& >;[L+1::^MCM8-H _-7 MPO!7C=QI6T1L[FO^7&J/9,FV-
%?6%NRH):/)ZDO:H/WAHBWI]<^=2][X)8Y] M/T^C/9]L.Q*49A/+9(%Y(O=J"?FLD\R*H7OS\D1O9Y/6Q=_-?>X2:C,5\G,!
M0*=MOOEPM'C_O+#2>*Z8Y8#'E3HGW:C;2,92N*,$5X("UB]X/T\@*(<_N0[Q M?0IN/YXD[W5KVU9<&<5J_+?tU6W]P/.2FI>&51Z6GN44_6O&V&0!4PM76NL!S&NY M#"_)%9MRCO7-
%ELABC3+@2TK/HUQ7 W\+2Y\>Y;3<];> *IB\3XLR*![R"(O MHY\6CVD/+U;<>C1T98<6>9AY-HZ= 4'W M]0LZ]]%G>MYR8A+7N"V M\&Y717T"*XU*&>BU8Y]KC.[-
GC<[;3$EA"$AZ5PD8JT[M]ET.B_Y[- I9Y!\/P^OA%/2$/I@[QR5B;_Y5;0&R5G.]!&O-':+S=3K0TYWY M],NA;LE_ZWBNO()*PQ+FVE:561[I9F3/'-P&
[G7QC/VQGYWE,^4N8"K+@HZO M^],2]))E>Q._XS3+F%OE".!%Z56YOFS.88^C[G-XRE[E3T@G^)JE=!Y(?1EHX#% M4$?
N'VTOOQQBVJ7^VO&X5.Y9RNVU5ZYNQ,>.;'NE]E4."%B_?ED/;Z$0%%VF MD/M2H;&+AZW24X[*6A3B+E]^(@,9E>"PY0TE5FMQE'.;2>0R=CF0-VLAJ^.Z
M[+=NE>A60RJ1JXLWMA%I.15A RK&DT2LA8JAOZ9BY,+K)=ROC4%<;NS_/?S M2B3_6@FV2VD!;>&K176L&_2.^0YM.UN7^Q1=D@$QY1WB/CADL 31*Q>_0O6(N
M&$L'CTG73Z2U:XJU7*((IJ4JY2(Z^K*NXRXZU6$.6M<+GO*^N6X!X^O[_KGM MRC+G;CEM_-ZPZ"4+L6T7D6?+(GSE0454%WFW>G7.J&YWT ZO&4HK;Y>"\]*P MKHK
921W]FR64, V26EU[+<=;]]9F6/._2YE>1?2%<1HSI,NV1E%-4E M.0BI9&^T#H"X6NNAB//^Y,_KW[L<5J_+#9NLIA_[8(A3QA;N>-^"Y5X0;I MWW57
[5\M2;.W&DT!XK+"+%M3<$S;#WGN1$Z3H@+(G)=#XZ"4,X8*;019A.: MPBL['I9PU#A^GV.*JU)P(X&^ >3YK=0_!LPOBW68-3VR.SKGO'9E]^=U[I=U M.F[(-
'U_J:CRR2(YKK>PITLBT")7+(-Y]E'G-)N5$N/9^5'LLKFT7-27FC^B MI#I[._EM*XX0?Q*]6K8O1(^OXS-RT]IR2<&9+,& >;[L+1::^MCM8-H _-7 MPO!7C=QI6T1L[FO^7&J/9,FV-
%?6%NRH):/)ZDO:H/WAHBWI]<^=2][X)8Y] M/T^C/9]L.Q*49A/+9(%Y(O=J"?FLD\R*H7OS\D1O9Y/6Q=_-?>X2:C,5\G,!
M0*=MOOEPM'C_O+#2>*Z8Y8#'E3HGW:C;2,92N*,$5X("UB]X/T\@*(<_N0[Q M?0IN/YXD[W5KVU9<&<5J_+?tU6W]P/.2FI>&51Z6GN44_6O&V&0!4PM76NL!S&NY M#"_)%9MRCO7-
%ELABC3+@2TK/HUQ7 W\+2Y\>Y;3<];> *IB\3XLR*![R"(O MHY\6CVD/+U;<>C1T98<6>9AY-HZ= 4'W M]0LZ]]%G>MYR8A+7N"V M\&Y717T"*XU*&>BU8Y]KC.[-
GC<[;3$EA"$AZ5PD8JT[M]ET.B_Y[- I9Y!\/P^OA%/2$/I@[QR5B;_Y5;0&R5G.]!&O-':+S=3K0TYWY M],NA;LE_ZWBNO()*PQ+FVE:561[I9F3/'-P&
[G7QC/VQGYWE,^4N8"K+@HZO M^],2]))E>Q._XS3+F%OE".!%Z56YOFS.88^C[G-XRE[E3T@G^)JE=!Y(?1EHX#% M4$?
N'VTOOQQBVJ7^VO&X5.Y9RNVU5ZYNQ,>.;'NE]E4."%B_?ED/;Z$0%%VF MD/M2H;&+AZW24X[*6A3B+E]^(@,9E>"PY0TE5FMQE'.;2>0R=CF0-VLAJ^.Z
M[+=NE>A60RJ1JXLWMA%I.15A RK&DT2LA8JAOZ9BY,+K)=ROC4%<;NS_/?S M2B3_6@FV2VD!;>&K176L&_2.^0YM.UN7^Q1=D@$QY1WB/CADL 31*Q>_0O6(N
M&$L'CTG73Z2U:XJU7*((IJ4JY2(Z^K*NXRXZU6$.6M<+GO*^N6X!X^O[_KGM MRC+G;CEM_-ZPZ"4+L6T7D6?+(GSE0454%WFW>G7.J&YWT ZO&4HK;Y>"\]*P MKHK
921W]FR64, V26EU[+<=;]]9F6/._2YE>1?2%<1HSI,NV1E%-4E M.0BI9&^T#H"X6NNAB//^Y,_KW[L<5J_+#9NLIA_[8(A3QA;N>-^"Y5X0;I MWW57
[5\M2;.W&DT!XK+"+%M3<$S;#WGN1$Z3H@+(G)=#XZ"4,X8*;019A.: MPBL['I9PU#A^GV.*JU)P(X&^ >3YK=0_!LPOBW68-3VR.SKGO'9E]^=U[I=U M.F[(-
'U_J:CRR2(YKK>PITLBT")7+(-Y]E'G-)N5$N/9^5'LLKFT7-27FC^B MI#I[._EM*XX0?Q*]6K8O1(^OXS-RT]IR2<&9+,& >;[L+1::^MCM8-H _-7 MPO!7C=QI6T1L[FO^7&J/9,FV-
%?6%NRH):/)ZDO:H/WAHBWI]<^=2][X)8Y] M/T^C/9]L.Q*49A/+9(%Y(O=J"?FLD\R*H7OS\D1O9Y/6Q=_-?>X2:C,5\G,!
M0*=MOOEPM'C_O+#2>*Z8Y8#'E3HGW:C;2,92N*,$5X("UB]X/T\@*(<_N0[Q M?0IN/YXD[W5KVU9<&<5J_+?tU6W]P/.2FI>&51Z6GN44_6O&V&0!4PM76NL!S&NY M#"_)%9MRCO7-
%ELABC3+@2TK/HUQ7 W\+2Y\>Y;3<];> *IB\3XLR*![R"(O MHY\6CVD/+U;<>C1T98<6>9AY-HZ= 4'W M]0LZ]]%G>MYR8A+7N"V M\&Y717T"*XU*&>BU8Y]KC.[-
GC<[;3$EA"$AZ5PD8JT[M]ET.B_Y[- I9Y!\/P^OA%/2$/I@[QR5B;_Y5;0&R5G.]!&O-':+S=3K0TYWY M],NA;LE_ZWBNO()*PQ+FVE:561[I9F3/'-P&
[G7QC/VQGYWE,^4N8"K+@HZO M^],2]))E>Q._XS3+F%OE".!%Z56YOFS.88^C[G-XRE[E3T@G^)JE=!Y(?1EHX#% M4$?
N'VTOOQBVJ7^VO&X5.Y9RNVU5ZYNQ,>.;'NE]E4."%B_?ED/;Z$0%%VF MD/M2H;&+AZW24X[*6A3B+E]^(@,9E>"PY0TE5FMQE'.;2>0R=CF0-VLAJ^.Z
M[+=NE>A60RJ1JXLWMA%I.15A RK&DT2LA8JAOZ9BY,+K)=ROC4%<;NS_/?S M2B3_6@FV2VD!;>&K176L&_2.^0YM.UN7^Q1=D@$QY1WB/CADL 31*Q>_0O6(N
M&$L'CTG73Z2U:XJU7*((IJ4JY2(Z^K*NXRXZU6$.6M<+GO*^N6X!X^O[_KGM MRC+G;CEM_-ZPZ"4+L6T7D6?+(GSE0454%WFW>G7.J&YWT ZO&4HK;Y>"\]*P MKHK
921W]FR64, V26EU[+<=;]]9F6/._2YE>1?2%<1HSI,NV1E%-4E M.0BI9&^T#H"X6NNAB//^Y,_KW[L<5J_+#9NLIA_[8(A3QA;N>-^"Y5X0;I MWW57
[5\M2;.W&DT!XK+"+%M3<$S;#WGN1$Z3H@+(G)=#XZ"4,X8*;019A.: MPBL['I9PU#A^GV.*JU)P(X&^ >3YK=0_!LPOBW68-3VR.SKGO'9E]^=U[I=U M.F[(-
'U_J:CRR2(YKK>PITLBT")7+(-Y]E'G-)N5$N/9^5'LLKFT7-27FC^B MI#I[._EM*XX0?Q*]6K8O1(^OXS-RT]IR2<&9+,& >;[L+1::^MCM8-H _-7 MPO!7C=QI6T1L[FO^7&J/9,FV-
%?6%NRH):/)ZDO:H/WAHBWI]<^=2][X)8Y] M/T^C/9]L.Q*49A/+9(%Y(O=J"?FLD\R*H7OS\D1O9Y/6Q=_-?>X2:C,5\G,!
M0*=MOOEPM'C_O+#2>*Z8Y8#'E3HGW:C;2,92N*,$5X("UB]X/T\@*(<_N0[Q M?0IN/YXD[W5KVU9<&<5J_+?tU6W]P/.2FI>&51Z6GN44_6O&V&0!4PM76NL!S&NY M#"_)%9MRCO7-
%ELABC3+@2TK/HUQ7 W\+2Y\>Y;3<];> *IB\3XLR*![R"(O MHY\6CVD/+U;<>C1T98<6>9AY-HZ= 4'W M]0LZ]]%G>MYR8A+7N"V M\&Y717T"*XU*&>BU8Y]KC.[-
GC<[;3$EA"$AZ5PD8JT[M]ET.B_Y[- I9Y!\/P^OA%/2$/I@[QR5B;_Y5;0&R5G.]!&O-':+S=3K0TYWY M],NA;LE_ZWBNO()*PQ+FVE:561[I9F3/'-P&
[G7QC/VQGYWE,^4N8"K+@HZO M^],2]))E>Q._XS3+F%OE".!%Z56YOFS.88^C[G-XRE[E3T@G^)JE=!Y(?1EHX#% M4$?
N'VTOOQBVJ7^VO&X5.Y9RNVU5ZYNQ,>.;'NE]E4."%B_?ED/;Z$0%%VF MD/M2H;&+AZW24X[*6A3B+E]^(@,9E>"PY0TE5FMQE'.;2>0R=CF0-VLAJ^.Z
M[+=NE>A60RJ1JXLWMA%I.15A RK&DT2LA8JAOZ9BY,+K)=ROC4%<;NS_/?S M2B3_6@FV2VD!;>&K176L&_2.^0YM.UN7^Q1=D@$QY1WB/CADL 31*Q>_0O6(N
M&

RDY.MB\GXY]5_'S:..>VXN?]\$X8 MG[/*0*AE(+)T8*4F0#VWG"D3N4F/@7>W,8MM;]6K+3\Z6*O>8$6SBF9WK'JS M*]Q/"4PVB&:&2;#91M"):TY=<$)UB*$2<=18YR!EBFAFB)/.
/&N9-":&?= MQCR)V^(C,3UC'ID#ZF#0K/;^V=)V8!B=G:5QZ+M!<^[.T[B:C[H?6/<#GP^0 M5M=AU75@(3*AN03N',%%38Y@M;"@C72*QE3HEZ^[#I%JIS@U(+52N'BBN'@R
ME(.05C'/,S$T["<$I9 6R,9X&2%G8MOL &(KN'DTY)!\5S5D],8HQ*7OLL7L.'(S(UYJ_!VG.6X]7 M=45^)H68_N\G[TZ:#R-\K6$AI6_A!)LHA&,L0JDI,$+IA0Z)?NR
M:]B3Y)&3PZORU';753 JJJZB:K+$6TX%,*)+M"HEL"H%((8Z%K+-U';2.!\! M57=;O%AAML)LA=G]$HPCA]FL24C$0XXV@K Q@,O<@?&..1VHY%D\)S
M;0D' TKC41$>PRA[57&VXFS%V?T2C./&6Y)4K[6B:473/1.,XT93274.D21@BB,RDJC!2'HADN"U59E1 MV0D.B&R5BB%!#-8@FAH*1NO2N]XI087,(;O=HFEU3'>],;Q!!6C[]
(NNV^U5 M-]DM7@Q)V\2ZOM42_M?/,4A$!1@F*-NK#<[K]N&1["$__3 #(T1K'%&2.\9Z](L:D.TS)9"D [/,3]# M$9F#TCQEGHADB>[)_B^CID>HJDEI%=;V?
4HKK&UUC>6#EMZ!9EJ L%P@1'D! M/ =#C6&"=,M''P'6=KH!RW5ER:XXM_=36G%NC^M(G/78N%RUZNS='A6G4'*YQ5.+LC42,;DX+/P'6.(+@(X+CD MD+,UGO&D?
>IPP!%/1#:60"3H[8D@RE(Y.,!UL@!Z;+I]-1P9D6/LEH@OWBY M6EKZ$,WY=31,%PW>[\\T;?*L]I$\GAW !T@%K4)PCS;(!V=A]THQGO4X5(6H M@E#'H2I$%80Z#D>K$$>
[YCQHT=YZF'5;&H51!F(2'H2V&9SR"FA@-NB4@@Z= M>AB?I,"9)$B2R[(]3#+SU=9JC^Y_OC_NL$L_="?A,%H M,ANGK35/['%5:;LJ=-4I?
0;094@6D7@/VE,!0B(,>48T!*YXHLE)8NAUZ#(B M2$]T!46C!)$0Z8S7#I+GQD5*B^OQ%>MYTLE9B+PTF>$Z@]/&@21&2ZJX4:X;&F;1I9@I)&\]"!$;5XMD)7G=)G %T\>.V,-
N!5V:&B2H/5W '1AB;AC;*V M UV)!J.]U4"B("!$\N 28I[/+$JBI2+6/@UTR1ZM=?_+EZL9PP^*#;O):;4* M-1#\VU]>5S&H"_WC=2F>?ARJ0E1!J.-0%:
(*0AV!HG(KUUG'A'S;>6*_LH. M)\$*+P(%'JP#X7@&3?@#QE0AY.&>>'4])L.=%UKBD;A\3R",E&!,X$ 9%22Y M8%3LA)/+$G=+D1?
58^*1&76J0E16_2H8%2G7&ID*'U7)9'::940]%<$(RD!$ M1Q3B(:)E)[&9..FS\Q1"TA:/S'BV4;[MKRZ"FQXA&1DNJ>$8_.:G%$&O'X M&"L^+-Q-"N^QQ,ZM$]#8GB?P=@/
M7=GZ:B](6BI6'1"E<;67L@!'K0*>K15"DL@T>4A<;/CG=-PN]?Y 1W?<#],4 MR]_*OS_^[ZS_$5=[Z/R^'L;K3(@KR4W;*G(5MD?X3OM4[HU>/6'HY-H8U*C:
MW@E'!=U=A]B,]#'!)9Q7?+4-1B1#*1DE&7*2Z<[S0&^)L2V1Z#+F>T)\<3_Q[['U=>:#4,)D^,^&97H; ;E>'JWA9O M?>?=[CU'3_7JT"!:RR9NC(C;3TX3_CE-J8X3#_C
U9WC Z:1)^-ZQ>9?. MI^G,IW'#2:]AA(GV0/S >^7D<6H^E?\,1\UT[(:3G,:3QJ?IIY2&S2_I8QHT MM#UC_ID5FH9RS^SZX^9CR2)O3OMI[,;A].*D>3UM?DAA<3_:WH]OV$)E"^/3
M:T:S/-7(=G2JOV\+(VE@L"= 552)* AF]^F*B#)B@#'A)J#,!_Z&=?@Y6!9TM MFC4J6A.5*![N/1A+0Z926$'T334,P^EH?'%5N/ >K_C]8!3^?-$DM#GG93+&
MLS2_6W\X2_'U]+Z/^$]Z/]S_(E]#E9\FN^X^-$@;F.*?QM-4\.;11?IYLVH MB.\$U0,_M7M5I1%0\U-_Z(:A[P;-NRE^4:P]:O@4/8')C8A[+*,V/[3(\)IBK-!>ILOW^G-
;#S&3^^+8W&;JFUH;Y](^AZF-)<#4X9[TI],)Y?V M<#08C#[UAQ^:;_M#_&8TFZ"%F7SWNNTWI9M/1TD$M#X^7*V_> M=M$>N(O1;-$! M7\V2@A)^2;Y0DX @-W/DDO)^G-
X<7*#K6U[MA-VX+ M255WE+9M:W VKFSK^"&WC5YWK;:YH!S&Z.U4=^Z3OGF,@U(U[M;1NS58417N MD3(#:WW[8G# _<)^:,_32Q[BXKLVP#I$6HC91W":%$Q5:..^
1$]!&$'!,\[M,1&D)ME:THDA;E)S<[F"1_W[=:E^OZ7IV_Q'FJ3QQTW;)[;K+"T8M@V^UI;0[VG$;(OO$RL4/93XX'Z)**,VDG2R8_:I!KFL3"L M6RO3,
(5)R8/"A32I#N_S49QJ()9R:*GVS+,$W+:M M8 +:",L8NKTZ$*J\85YOU<\MBO?S\/>YVE5'=_\$O6+7T4WID6*7%)Q%BZYM M"-
$A=G$!ADD/,2C'D[,A",X:_4'^[:;QJ^O@LIXQI.)7#>@^7&=^Z@_[D].2 M7S@:Q>K@6A5A*%2BNRJ:&)@7J9&9H7PRD(K3EX&B(ZO"X0EWS.OD.*_2 G>:F[M?
RVJ>XA.WN5RTN/5S/?&^]*T3D^RN7O" 8I MN%);F\>CLY;#X=R-IT-\GI/F'X6I(0QF,36QC\=-KR[56WXS<*C.\T>_>N92 MFCM"Y3]-
KG#IK@Q$.2ZF\AZ%/2.,)M/R.*X,R*0(2F_Q:32;EJ?M3\H37GN+ M'Z5RZOHDG32KG!DW%X5+23U15D-DUH#@ M/(*-*8'SRF2FM-)&;I5SX??
1H!\N[LNW<)_:_D6GD0_YKPE*Q(P;6NX!Z-/ M:5Q482X#X[*";^:T(6W%=GO:I4I\&N/SH8WX-$3IR2AW_8]%;9KTN9W6JZM/ M1S=>Z$KR3_L3/+ 8)3SY'"9M?3R9I^D-
.M^]%+22 MNW>"8(QT,CL!)G&&@B 0=9)!6\F"S3E&[ZWOK)*DEH8;!J$<+CP58+T*D#6A M23#%53EGiQ(O\1N>K)7HH!'# 1>L5TG<\-Z>"BUSI+Q2S?:#P1#HNQ\VX:
M3A-Z3&_Q+^O.GD/8FQ,6?>I/3YN_O_F^^?W4X:@TW^+G[RXOCY?^4(Z:%6O< ML.]!XIS<___K___SZZ48(%S-:O)KC=X'T\NC%/_V,GR<)!P]?]QP-,SHE MIWVT_
C_I^CE#M.'T;3?^@;X7NB7G+KAA[0K^[3_X11MQGATX093=*+PL),G ME('KA&NK[L1RL7HK$5NA6PH#-T'9\?)A.$(G=S%Q5^LL3'IJW43/K\$_BH/
MTF>8KQCP'H7Z9G8V?!51VP;NXF7Y]=6YBQ''=F4WL#]_A<46&CE1#+_YG]D$ M/?V+Y1W;H_4?<*CG7[>3/]^N=!E?[J4; M?'(7DP5ES7^L1SP><=&/VC4N&/UOTU'X9WFH>\
<\5DD+V@O'XL:U6O!RAI([M+B]*:2+]_=E0;:-:6EYOEK FW]UE<7H5F9JJ7&+EUDJ23MRK8:L*%E763;1 MB6U-U1HA%CDQG'^S-PR+:V-[VXKJGC2&&[$?
LAKN:$;7$SZBY!>.>1J83A.>*?"Y.HF*\&(P47C"PLL'E7B7'B.FU]J MW<\JP9*3Y@<\?3IJKXN0U3[*9.E-K?H8[;NLTM#*$HQPQ?6;#=HXI$.79CH=
MS%VWKA/7N^79/^%E2FPD+$(A/C6#$H>YXZF7+B".VD5RXZNA0? >M<2XZ%6E MC_W1;#*X6%E07RVDVRO<-(3=5K\1]_GN&EUTL MVD4[N:U);H_#-W#-8%1P-
8W/FLGL_!P/OL&GQ?>;7L[^I!V<=9=P*1#W=7/G MSF9OX4K.YV5^RM.YAS=/>8FTI=@&=F^ JFH/!8 F? M5\;8NX$K\?G^9+[F[.=^,0IH.=-@OC2?H+8L6C:VMCJV:(T
ZDH\Y_J'H[EY M>KIIOX7Z^?O%>[X[3?C0'4;TFQ;H^^O&/3H-]-O6TB_XDILV<#>YMDVRL6?= M9826W%LK./ LXC-#C".5J)3".CTAK5*2)_&"-T^WJ+MYN_W":>L,Q.\ALC$J%?
>34T,_M?2L5]N,ENQ[KZU5BWD]% M7:FP*Q7V7FA,)P8EE:*%ITL$$"9YL(H*R%F+%(30H9RS M'OEI8QKO5\,BZK.M'J\]^@E_ =3IU-A:X^GM,+6-JL/'8W1:@TT20Z"$0*F M5!
(Z*:)EVFD2.[#%19:,6P/*R0)U,8'Q3(.1@A)%K#(F[PRV1(\S66'K =YN M9<*^["%9\M(\1!@V,%0Z84YFHZ+CG9F?&@O5H M"9]48U'1JD[IL:,5-
S2UA/Z2$UURJPE80A/BEO3*,NIS[KJVS%#J3#E2*#Q' M*_").""""IDBE(C++G:$5[1&A*UK50.[#-62>"7.^..?6J&TEI:PDK@\-^&H= MJ.447+$L:%X">!,5:*-\4)Y$S[KF)7I"*-7@T+Z
T$F#H38"B5G;[%A(P>[0 M&3:R-FWB91)V2$!FA((@.I2B&0N+&$1>5B#E>QTW&A;6! M6-",E8@S96!#$J #H]8$XP+K,#D\8L09'[KBYK[%I"O7]177]>B&Q/?J[!\I M%65E;-
WUGBDUT7OM@::(]&&KC->/9L%,S_)'#H/OJ:Y4 MZNL*I!5(]P9(K5$J! ,Q4 (B(2A:JAT8G9EMEE.=KJ);4)]_6A :GM:VPJD MC\I_O7L3R7U.9ORV+T=RB9#RE"?
_0'_C()P7'6%_\C+8D&+I;5Q25U M:-!W;:EJX?CYMM08EV8CC+3D8*,)+L_*6O>_9*^^JY+4+#@@"E\PZ.6WF5.
M^+"+">3!._SOK%SJ:4*B.QWW7M!1DS>MW;QJNR/*&OX]'>)'I1:_Y?>"&TSF+ MSH]X:IN\OWB QHU3?/ZJ"WJ;+U M7*-O M[I?
Z:S<>7Y1ZZP6ETKC)KC]>_&TPY]V^F+/$%/J70IESTOR]4*(O[[0@[EZ, MQ?K#M5PRTY+$U3+3S">E/$_[!QO,ZT(MAE&,)/;:5X49V_S8;3RN! M\^[,H6@7H5C1HR(5V)#BY%\W(
M_%F'H*H57H %-T_#PZ2^^F.)5% MO!>3V<[EZV%\?2E$/\PIT!#J)YV4SY$[HN9$CZ#8VD57ZD".AU#*;DD2G+:F&EU*?NF1Y@@G&M#]UF MEJ-
G7!F%ZQ1;^JXXEL$)RT"&F(DB.A'7(33<9*]S;6US])FJ:=E43S!M<_'&ILUML;]G30M7\^P?8EEI:>EE:6IO//TN]J=9DC3K=H&U@2H&UAH @ MA6W XE^)7^^U;-
C"TQTU=G=35R19TJS25*P(TW^*JQJ26[]3JMDVKVY+*7F<% MPGH#@B:&*YS$@7&IF$V61_Z@>%G;'.HKK-%2M?_1GYZ^F4UP5!:9L-LFCR2< MU9JX?
5L/K76(VD))G#S8BKB;DC>JH3O2Y/1:R+%KJU>V@RQ#DR5E!,$%+L.T M4]4P')@SIY,)ML@R;9\9?RX3[@@'M M[DC+_JYM='M+0NEJBO:R$]%T%[XIS_1\C TQH%?
9IRV5W4AC&>E#&1T5AB] MKNH7YN.T_'G)][4O>=BW=*E;&6P;W2RSX/TF>(M_7%JT;ADL[.AFVYS"VD87Z&Y::?W93M1_8]I-3?TK_W^HYH-F6;9TL_+"_O81-+
M]=K,MDA^.9NGXVMCT1\.^D-\C*D;+U*3UW_H9Y_W4[^?'WC,K[<2S?XY"XF MB]3;_[AOB>"# =,UI^/B-/S;=!3^61[JWA9C-=VQO7 L;7_95FN5%[X4 MTL7[^Y)^OXUI:9N
MJW#YU]=T?^XE9E::MSB999*THY0A]GP 1EP$M"G0GX#[7_ M9'.GN?5H7T_O?1J_WX@?:_WLM;+']:K'1ZL'8D+3E+P!YKD $:(CW8>>' ^
M)XDK(^6W40]TZ_Y2+=_YTE[YFN]T1,U_MP==1U*J5+O_UO>]5ZB]UF?5^JQ: MGU7KLW92GU6[_U:-JJU_:'TDH:2%?3_K#TH\:,XG4@AS3E%2"Y/.>/1Q3II2 MM]
/,,>R%DANE0S64B$8 ^UU!*%, .]T!B*T();X)#F['O9))FGJ8P2BO >A M"07/,EZ"6&5I= Q/74_X6O!3X2K[UO#/7\>CR61KZ5R&BYI;7*%LWZ>T0MDV M:[U-XHX("88G
L(P#5;%#):YX*.A+KI.!#M[X6.B%!P5A825*S#)*Z">6\T8 M2RGX)X4RP7O45"Q[B$-H[BL["BV7Y/+KR2A//[EQ32Q]/AI5 M+\6$@T&&@H@.>*1S!2&$9I! M9Y-
DMIE$]K3.,!4]16N+^0IA=4J? 81II1UEZ,$*[\K:G IPW"?@0,LE256%3XJE-Z_/ 5K.&8>5I_ M5_1X7;+7H.\VU.87YTO9SFA\49W=9Z@]U5JL6HO 0_!<*" ^H+7((H.CVI9> M[MED9]"
(=*(CE*!GS*@!=*K1V;4,+8Q#!YD9=)"I$IJXI[46BE8>M8I?=4J? M 7X)X;5.6@.G+>E(R6[(UH,73 0B?62V0U02$WJUS@L(#E?YPF4#-A(-Z/LJ MSA.10N:GWJ"27%<(J]'=AZO-
3[,QBN1LG'I-1F$K;>&N""6JV:@D=I49]>7FDK *I%4PG@^0*B:(3NB%4Q[1'ZB&PB9^$+G),!1Q2$&D23-
M/#A#'D[^ONOHDNU15@MH*H35*7T&$&:U14"R$G().PB:+!B;TS.6=S7(ASD:EJ..I"M49VOB@WWV[(1/YUQLP)&I-Q"11!.R:8#F M=Q T M2]1(SZCM&+.VE)<@<$/*UB
GP>I[5@^C*_/1CC5_[J[0^"VS)WLJ6<9F+\? M&\1W-4)?<;SB^ 'A>##6V:PH$)\I",41QPM$Q^RM<9D1GNE#%B5[BN-&]8Q] MY*K-
O=32!^)XW1_8S_V!VJK\>04::F1MC1N%)^Z$=!!M*&FDCH%/5((45&1- M C-==JU'V1SX+6VOZZM0-:I6\:M.Z3/ +^&%)1*=\,03.N%&"'2HDP!#(XV!
MRD2SV\G.P/;PBYH>I35QOFX+;$%IWHR&D^EXMM"88?&$0YI4@NSC7*'6.-)N M-J,]"3EF4*'0I$@'T'X8X#9IY9M"53C%V,CTWB=^OZN[/):SS88RJN]4=Z,=F MWZI:4L/P53 J?*
["9[+1$&$(,%-H5G8<]GZ;:MO-)^XS&$=]T&0,R>88P0;* MYBV6#=HK8#$1QZW+RG="4)NL!W82.E>$[]*F[8W6/*'O=VT,ZK)@[X2C0NJN M=R6-$4FG"%$A$ G-
^TG)$G1GQSQ^+#?NGV6U]^ M;.'=?YBE9CIJIJ>I^81+NS0L_.UM6\\&G_?/-)TT<4[J7@Z9GHX3_H!GGTZ: MA,,2F_^>#=-EW^<>7J09IU 4(C8NQG[1-
C=H4'@@N,EIZ1/]^N.V,#BN"\.W--?]*$ 5ZFG_M%22?-*4I:^ZP3E*KV=OUA&,SBXA9X&==*Y+4#1W>. MS_<.'SZDYMUIPE-/;D37O(:C\^/G
M\S)F:SO!:%,W@+Y+!%L8Y\LPKVR%%Z!!+615T MMC$!%:T+ERAXZ3T82T-&)] *HJ\#V+MPFN)LD-[FQ:O]TG>^B%_3=X7Y^$]
M7O_[P2C\^:))"%OGQ:CB<2]N,;+J1"E]=%9V.>UI,>UEX"?]28L=!=GR:# 8 M?2K*^RUJV_1T-)N@&DZ^>_E%I^2+X[5+#^R+;CI9^
M=WD<'+KR].5P&+B+T6S1ON+5_':4D!/RS?($G/.!.Y^DEY-T[A"WTW(8VM75 M_-HO;HJ6?^Q/^JUP7[Q<7N.V=);VMDJ=6,O+?3^7 2H/N7AI'/'/KU[\Y8YS
MZ8EB&YZYX6GLQ!A.KOYL>IWZOMW3OK#_28N[2/.#A7H;"'^F"WC5[7;=Y<4 YC]':J._?)FCG& M0:D:=T<]5U@H'&T5CE>%JTG4NTFF6"Z>2D=U7#U51I5#+4%XFGV\
(]VC8\H(M%[("T]*&<(F?;) @_CQ['PPNDCIC]26P*^$=][,QN/MU;7K M'B&UZJ:BV-
Y/:46Q;68:$&MBC!:8CZ5/KB#@%".@N8V1,,.4[C::W"#38%R3\"D\F#QCH89_++3P]3#^<*6#RVW<[1H1 MJGNV=I^L*%:G]#F@&*5<$BTST$A5H=#(X)--
P*G6F1"AJ']0"_QD*$9ZE#YR M@?/!B'P- 6\!#R<%D&Z3-X>OHIO18X2M& M31G'"%_JZ&81'//)&64 ((SDKZJ/NL/ELZOWN"KX(N[W0XGG)>@T!/TAEWI;^
MZJ6KS%KR>+45E=BETA]M&FV1-*9$2KL73DJ1G@*O3 :51)992X%V:!MI$ZWJ M=DMBMFMJ1(_OEB^BJDJED*N"\=PQU G.);$,4="AUVVC >.4@VQB8#HDF[JI
M9YLD;>P$0WE/Z-IE?>_BV)5'KESG_6CJ!G4!4(F.*M'1XZP&;+#>>PXB%\H. MG0CX$#Q83G6PC+B@.U7R& ;:"?%PCQGID\=@DMN? MQ<9NF(Y65+-95%TLB>;>H4*V[%
<_S::S<<)+7[A!.? ^%'Q'R [T\[!AA+(V MP9\11EH6O0G.3!FP/W[_N?FI/VRYM-Z/9Y-I\RU^]5U[\-_>_-$K]0'G">'I M8QI<]%I&KA;J)^7D<0H)?VC&RQ%&=$3,:8_"R2NKR?
9"ZP1B[L,XM=1FDSG% M6$#X-IT[(:3.3)/"H]93'Y^A\) ^&&(\/*G[((65J/&NL*HM:-;P M6S1-T_E-\UQQ+J?U+CJY9&ZA82A,(Z?CB8P M-?MF#S\1E 5HJARZ.-F"DX^"D3,&#$]Z 9-
PSJF(),#S1C!>RG/V9\16D?T*401OS3)V/IXC_(_08^H6A]$MF MN?GD6K\"[60?[0] >\RG4S0J+6]AFOL>-[L>GT:S06P-\+@]8C8I%^CGUL@L M#H_H?.#-
/A3S=W7F/C($.XKJ[WD&Z01"@8H9+8#P$".W3% 6B>H4G]GL)0_& M M&:@1 9K88Q"6A.,7MF,KDBV&Q!X7=W,><&?G_EZBRCY3R]'L8R2Y>3 M]'-^?
XHZ=8H.Y,^3U^&TCR,>M\0AS"C93Q;A\D]QJOK%I1DUU^F*9//MPNV4 MS>7H?(?.T;A7)+#[6ROIPQ'ZDXL!;/Q%]ZJ%<3@-#U. ?8XB4QF **Y $&; M$QK!:)8$4;E4(NV!
/\VFFY;AL5^RO!)\W;8 -J6>HNE_Y;^G/JQI>N. YL M2WL]_2K0;D7_=3FU_!6E'IV'R:Q02Z.FS"FSVT4.KN>*L+;+OSC\#-<\,S7 ME 6V)X7'>GRQ7& N(?]2S/&+]!D?]<2<^[K_9-
Z3@//PJ&8BXQ2KX@$YU@& M:UQRUIML?"=W@5)+T0-$@+<6O752,IS3]7SCL[)2_7$Q%"CI M?[0#^<:=OQU>^GG;8G67>RG,*$T7<_+V\>BLR"XN44/I"] ??BAQBG9AB8=>
M^@FX/NXL:Y?K:UPKQUF83GK+97M:_#)9\R_FE\-+#(OPSE7GIM#!E2Z4J(%K MSG!]GG&%WHK)XI;IW+L4][L[/QZ)S"_#1$6L2L/O,&X[:2SBGH/ERN[D
M"9]U+8"/0UA^Z@]G;C&&)4+_?YJF):-ONP3\YXMS]R'!D<&3/SH:O8G]R/G 7+\NOK\Y+/X3AAY5DJ/[\81<9 M1.1$,?SF?V:H??EB>!P+%*OGRYH_+YUC0@3DOZ
MU1V+.,HV7\4]C(;S81-;2JU79K;=::FS1J+R9?W6UQ^%69FJI<8N762I) M.W*MAJPH65=9-M&);4W5&G,^.4%7Z)O]V7R[:6R_XD9SR[H*D,NT(465B)) MIHR'<,&
"0K73Y)09P+^0^T_^8LMM_20)FJEI 2I2TN/F#Q8&QT8SJP0)E)J MN@NVKVCIT1KTJWX>EW'(R.7:W09^DVX?1]E2Z_U:0X]^\3"+IS@L77G6?,SY M\F"R;#0T6-
DQ':_OF$Z6.Z8=#WGITCZ=1S%$O%QORM3=A?KJMB9?$HS:U>3I MNII(?2*TWK3+![=VMVT^R(G6:L>M3.I+'N)+UB8MCY=)>JRO=]DR@I+:,^+: M\/U6/(-?YY[!C[=X!K6-
Q+9JKRH\57BJ'6WNCTY?RE6LR%0[2E7]>TS]NWO; MNNI?U;^J?X^G?VUM>56R_:,^.$XNLU\VB&[WFF&:-O_?OQE&Z:O&)WS488FI M^WEO^QDB
MV2]P,Z8G2&V34<%M[Z>T@MLVJV^<2IID#RD1!#>)X.9SV\5!.BV--(&D!_.> M/SFX438:]UQMSK<;IH-^GO1>&P)RQ)8GA&EB/&>44JX[?;?C%98;]&&.1O00:
<$G"06 M=!&&84->NU M=,4FH1+/;10:LE:%K]FS:V9L6\;+'F5+^ONY<=]5E#S N:THN7\HZ3Q#;L M(DFF5!P'L"G2$G[-PE%3L/+!=9A/AY(,49(],E-B1"4*K MF21!!" [9)^
V:AX2IR'W&'B_NKBMJ=#26$0)6U%R2=*J:@!D;6 R'6^RVK% M#E#WJA5[N-6)*@6>E0!+30*AC0*K<@:>;*3&:L]LM__#AA&,GQ=*]^-D0[^8X2 FREGN;"9N
M&F+8+8Q1WB/T^/SFBF,5QRJ.=7 L&6*M,0ZLD I$T+I@4H0D9/8VQTA2)YUU MTR# CG%,]ZRL./:097_-@]A0UU[/.UE<40]=4?&B+DVFM9_D\U&]:F]6[4WF M7
22)&2>"0@E,ABC'61IM"$\OF_4OCT=GACC'FAH&A]KC3S35', MS8Q/2Q$%_TKC49$&PRA[50U/!;0ZI<PJ>)?$6U/7KBDVA9<-.DMHY0"]4'C\EYQ<"0IT"Y2
MS1/7GI,'AP0JHNV/^->*<@)T&!Y8-'.9].M::8U2;L]T.SS=QI!R,6FZE%?H7 M6&*.R6YIYJTJQ7DFL 3",0*64@DD6K184:"SW?'$OSJTL-I]Y5)MUR+9DXXE M^RUM6-RW\
[!"U9[[L'956*V"\7Q@U1(3/>$,9(JJ-""48++UX'QFAFAN:%!; M;6KUZ+!Z0W.K'@Y6A=8*K15:]TLPCAM:C?&.<4Z!T=+;53H*+AH+UFI&+8^1
M:/O@2$N%U@/2H)WE:53&RYL9+U$_*MWEH^DF.V%%.>-H5MHQ/:%V/@VQTGT& MXTA-760T&/3[6U> I$, 4=L)]SE+BZD$9V\CZTD93;($ XC:N(& .N/*B# M1 D7U
>FA=DS\B72HW*GUFYO-.H)/<9K8U 7$WLG'!5N=PRWS ;%F);@B78@ M"$&D]3H M=G(P)B*KD/DJ10)"7$8.#5X3M8>G/ &)..>414YU6& X-;HGM*/ MG.*]IQI5X;;";87;?
8%;J4T0643T5*4'8;,$1WD 163*D4KO0Z<:D#LOM.09 M,LGH$1LIT3<.'"BC@B07C(I[!K=6]\QC,VKLJ48]/)J#GTM3X?]:#M^BT?A_ MS3NF/Z.6S/>9._4T3_A<>
[B[GF9^:+G5R_X4GR+<7A<4PNQL-H]+O9V> MIG'S9G2&SW^5!:AI/^Q]3\/ RCL]1^\MH,OGNQC%;%0]UHI3>%_G8N)EY5T!0 M(6X1D;NN?XG-
"\U:0C.)A#))00=2"K5;EB.60K7 M,[Z;9O;O3Q.:G<%@]*D$7A>-VF=G^*QXV4D;NPVG;O@!/_>'C5O1H%&K06%- M@_H+#1H4#6K\1?OS:
(BW:K[%TZ>GH]G$#>/DNY?/5;V6]F@QTMVDRK9M_<(. ME^G5LD;F\QFU;%^UMI3X16M=&ZO4EC^PE:_IQUO8'^OKU9Z;MX[> M3Z,Q'C5L0KL4#A?S6OQ!6YI?6W'NN-
]MU;0]DY!M:MKKCZX_:+W$/$+/L726 MGB14NS8=HZI:5;6J:EM3M7O%D:K.[5\)Y''FW7T_3Y=KW+3Y(85TYE$B.>TU MC#!><^@.L)"X-A[<9NZ;-
^QD;X%D*T$0YL'5]D[&L928-R$FTCL*?IV@WTGCRX__.^M+=+6W\4IK7#%K M[Z>T8M8V&UEJXA7+/C# P&?>5&?B0)#"5HF:4)N.[C>8,3$FG!#I[A><8 S:X M"
(KZ[#67,62_,\QZ[#3CL] E MJY->]7BO7KGJ\?[Y/5ZK$(D.$%A9H4>IP--4R-(-$98G9[I=TZK?LS\Z59L/ M']*R_N]#'*=!H=!N/KC^<%D44=;T#TW5JM;NF1!254JW77J^57
J2605C.>* M*+OQP8G4BG*5@&OF0$AIP2K*@#A*P.A'(U%/A"5&^NW!01B:>A0.I"1HLYR(8*1,D%0-3WC!MR,[2ZQ@[MNH!\W;>LF%4Q:W<.>,@R4L4S&*T)>M0*/Q&-
_Z%),F.#9JK38RXY4QAU#<0@ M#0C%%%A3?'BI$KKSVCL5MXF!]W2NV2,[UWNK.C4MZWCGML+BD\ B4U)EIW'M MF$]@02B"$)'24'9/DQ)I-6\5+P]F;BM>/G5*VK%/>M7C
MHYO2@]?CW?@]7!BI7:F^R)F#H$Z!BQ'7XSYPP;D.R?']]^RO3AU*HD!=UM=B MC)I^5]/O#LWSKL8)3$WJK8#Q71-E1[-$[354RH*UG($P@X$W6(!-+FCMEI'/7 M?
7"AI0@V&CQ(RD)9EL$Y;X%S*RW3-&?6H5G<#Q_<[K0U^IXH9JW%J-!=H?OX MH)NP;'R@#I*BI8Y.:; Q>,A4&1TYCU)T:C$J=!^48AY*XL31EV+\]VR8&DYJ M)
<:1!RMK^MZ]3$\R(B5F&*X52NH3O.E48DC#LLW< %-<@&#&@?1+/'BZQ$B7=0Y=Z(2CG'%6G@
MDZWFW%KC^%-48EA18;&F;-1*C&K%#GZ)5HW7O8R7TUHG;C00GVEI>JG!R6@@ M*YZD2L);UVG@Q"B)5&4)-BD-PDL"5NB$BP&E. F>F-AAF-B/D#JK_- 5,]G
M;BM@/G5"VK%/>M7CHYO2@]?C'?$GF!AYYAF]%H*.#^'H^%"E@&6:./XA+-OJ M^.RQ4AU*ID!=V-=:C)I^5]/O#LWUK8)3$WJK8#Q71+G9:39>2Q94@D@9 Y&U M!B]\@"
,5=$D))D[T<(DM8>+LO"E21M0K&,T16RT46Z,.!]8&#,#R#1]1 3L(IH@73S%1D?48*5)M* M;*N2X5TZGZ8SG\:UG.&1%(V=L*)I<31#S-C_ZJ%MY\G=9S .WFSMJ,)/2"FL MR$!

<<""X4V!XR$ M82KC=U1VS" EBE(I.=!0".(S%6"LMU 2DET@@@D>=I]+ MMU-+=V *^+B5U]<&HRXH#E1**DQO#5:Y2"1ZF\K"PH"(//($U0@(+5I"0G$[$ M7X?
5;)W5W%'0G'D05BJPRC!(0F<3(M>X8-E9]1I7C]Q(:$\UY0D7WQ5&]UTX M*HSN&$:CT4Z6J(QTI=*#*@Z&V0 Z<&>B\93H#G60H]EX%BD8CX KLBOI(C9# M9([E
KRFG+,K&)4[;>^Y-YKR\! ,?BX!L3W!OFOWOO-V]WWUY8NV[WE3WHF; M34?+"2[/TQ]^*(_?IFX,W,5H-L5;?$[QU?QVE) 3\LWR!-3%@3N?I)>3=.[&
M;IJ6X]!J[OS:+VZ*=WWL3_J^/T =>+F\QFV!K/:V4I\(K&D< M\L^O7OSECG/I";=VPU,W//(V<:*UV>\OZD@?YDE\(")L[X\$W@8U?Z="U]_LT5PF/'M1&E8:; MB\QAC.-.M6CSO?
ZJ:4>A::\?FN![R -95:VJV@Y5+839V0R-6(K-V^EI&C=O M1F=SF=,TG/0_IN;G81B=I:ISCYR%04?DDNUD8/Z2P2,*@;1(&JTD81UMT58F(MGB1YPABKB:,*N&81!&
<4/'$*E&$TV.BM-)WD"2NS8$HKT#$A.51P,)DG""J2 MF(GAHI1![IR?K4?Y\?%55JJ&"HP5&)\ &!-SFID<@#E/H>12%Y## _T05(^-6 M!=K9MTO*)G3C$A ;)
(A@#3B5\!,3&A]%&>W-[H&1]K16%1@K,![9W%9@?!KJ MRBAL%%R!)$Z T&T]'RVE)X)RIB@)M,-J;IQ5R3@-U$@.0FGT,BDA>+;D1DD:
MLTN[!T;5L^214V[W5GDJ>>5^1#LJ>>41V[*X;2%_+F<@]2*00C.H^DH 8HL M'=*0D\J.V5PJ-=;-C0^>)>$X>$<,^N&)H(E* A*3U@LC]&=)AI/6N1(N3TZ
M.U0YZ2J>/6L\J]R258_KE!Z^'M_LEX2 "U=.%#"%*V 1#'H;PC%(SEL>N!>6 MTNJ7'(WP5^K'2OWX'*S1$;&A5#JA2OVX)X3)"V&K8!PUHMSB(VM&I%$:M0'#"M1(HY "%
<@9!1H[=L!5 GO2!&X[>=/?2G]9%[M^%25HJQB:\76_1*,X\96:VT,(BHH+%<@4 ' V>0@!YHR43IXVFFL6['UJ%6H MTC]NJ_#@5S<.I\NJ
UZC"@<8YJLY9'N<0^:B(\P+"E$R#L(&"\:I",G*1++R M*N1.#IFUAB92",BT$"!B-N"RMKBV8(8H08WT3] 57O2L?62:L;U5GII<>[QS
M6X'Q28*16D)2B@Q"Y@B,TD4P6@0(2GNCH49LC*Z$-(&M2"@U.4 '/:.EXV,W,GMBYL8M&BB4I&2Q N
M*;!>$;#))>.BM9[G_8JM\Z,S0S55N<+9LX:S6G)0];A.Z>'K\6U<38)$SQB0 M-IW*: ;6D%)#0+UA.F=K;75+CD7V:R%^K3BHQFB/%/*Y&J/J5%8]KE-Z^'I\
MLU,IA>9),0LB^@!"60'>$@LR1L&9TM)PT7$JF7/9$ I:"0V")P\V" 8NBJ!# M4LKISM;*DSJ53(CJ558\JU/Z#/#,*>UH(B!DP2:)>.:X06S25M!H+(U$53P[M&N&O6\<[725?
%_;5[>)F.FKZ]VX648W/,ZE*J85=3YQK;V4@F1N0.3$TB,J" MX5("2YRXI)SW5F\C:GP=&GX:C\Y>CT>_39ME,OT]C?NCN!W;>%_>:\(>F?=Z M+]7T:;)4:X7NX4A(!?
+]CY!6P:F(4@7CN2+*;EQ#;TDPT3+T!9D!H94$1S(% M)4W";YP.:2MYCM4UW!,U/93> $=/,/#?LV%J.*G\ @<;KJSU8GMLV)3C(>>H M(4LJ2LPC@LTB00XB5;'B2'C6$
MR*.+]=="V@J,%1B?(ABC08C3 :9+&/49R&Z[5Z5L$$06_@% M3 +AK00?)85H2EEN($*2)P!&(2HL5E@\MKFML/@DL!A,U*'LD1'+T?=C7H'3
M'B$N,F4R<\K03I,I9AU35C,@M#1S8"2!29Z7[E2:1V445^XI_6XPJ,-4FD M\@M4.W;PD?YJON[9DE>ZJ"R!(*0"$1D%JVQ$>V0"D=E$QF(GCL]#5%YP4-9E
M$"IJ/,='R%9)0SWV.V<" A^)LZ::M\J8![,W%; ?.I4BF.?]*K'1S>E!Z_' MNW%\A!6..\5!YK)GXTD 6]C^4N*".4:E8]WBM>KX[(]2'4I"0EW85XZ$FO-7 M<_X.S?
6M@E.SB*M@/%=$N27KUU/BJ)9@(BW5SM:#LS:"2I)'80S-(7><9N*4 MM-2@TQS1:18IXCG<01;$.QV"5[2SV?6T-&+V.>;W[HL"562M@O$,D94E1WGR
M"JQ5"41BB)+""@A<:&F(ID9WVA149#UB!=I9XL'1%TR\2^?3=.;3N%9-/)*B ML1-6-"V.9H@9^U^DM.U,N?L,QL&;K1UUZY$^*&8#^)PH".HX^+*>X$88+Z6U
MGG7*"BV32M#H(1OB0<229*RE@R2*V50JTM")RN\BFXZ21^8C/F@E?%P2B6N# M41<5!RHE%:KW%JHI(4$$(8!GQD!DX'%A8$HPZL MUQIDB-;P9 5SZ3I09Z$SH9H#E=2
X$&#"XX BR;(%+(0Z4DJ5+A\Y([I!ZV$ M]TIVP<\EM/=?RW'\;7:6QOV ?X_]CWN"NM?N?>?M[@W0EV^VFCNC3I32W^Q1 M
LT67OW]:6K&U]E6\WATUK@09F>S@9NFV(RFIVF,:G^&MSY-PTG_8VI*4@Z> M6@YH.5GQD";@E[-Q:D:Y&0WG_YN-BYZVA3J3F9_T8]^-^WB&&\;FU$T:G]*P
M\+D.9A%O]*D_/>T/%_>;L[PVWZ;/YWC/]%VO&:9I4W[&B[X9E4F9X#GXJ8W; MMD_Z;HK_*V4_Y>9OS]-X'K ^69-V%.8R OWAS"U0H8@SROSQ2G1Y.7S)IIWI M_WQQ[CXD&
(YB6IZ#SU5^7CS6OUJ1__P2^*L\2)\A]E%&RE#AN UF9\-7L3\Y M'[B+E^775^?HO_>''U9"Z?WYDRWBS^1$,?RF%&3U\\7RCNVYD(;QU?EHTF\O
MWDH3RA8BZ^/NL77D+NU=.:M?$ML7< M2U$]'5\;B_YPT!_B8TS=>/K2S::C5^L_X%#/OVXG?Q[K=QE?[J4;?'(7DU_QLZ_\L#W5OY?2T%RR/#L3\PFCV1W-5?SE#R1V7%[X4
MTL7[^P'Z'%O!S&(3"[Z\F7]UE7GH5F9JJ7&+EUDJ23MRK8:L*%E763;1B6U- MU>+OX\7S&,Z_V1L!S$" LS^ UXZ E"\QG M%:WLT/E;%72V"*%4Z-
+7)%'RT[6PGH9,I;"""Z.M^[YO1V5E_7I;Z>AC?M$;H M0QH&M(@_]"<+_D>[_%]$=8734(G^+RX(>-9NM]4V\VA[B%>R*I&;F'>?QM- M4R.:1:YBLS)LK>.P-G
W^FW',D#S0\NM7O:G^!3AUB']7UP@^97-T5$OWE, M5GU9>6+$7:[L$XW2PZ2F$#XV4SRX]4?Q_[WF4VH<.J3]XG"P^Q5URC_AG^'X]-Z*E\F'_?RMOY>!12*OA=CL-O^Y,B?
\& M]/'F@P%Z1S,X//9BS0,O9?2Q?<+R#.YL M-)M[T>5OK;,?<#Y]62ZXR6B(U[MH_A][;][$Z[Z/+\;Y_?XT,4H>_A^GL]G\[IRJ*W7=_6) M^G -;!EH [B2]8WC,R"/^OXN+Q:37J>?
YC>SQ7BU8?] K/@AMA6993H&H86S6>3T<_%G@L?EK\ M.]!2<"/ZX0%USBNMSL#6PG'4Z[KS'-$6PP&,9^D$EP,NRW_"[+JZ-J <=.-A M!V%B'HD)KL652.\R4LQJ]7IZFN=N.8%
[!WMLMC:+*N54HNC?U2]*;V#!'-^. MRF3VOF>!R?A_EF"\+2Y./T]L>3T=O5R^ 5(=F3XPI&)+&4^0O*MI#/ Q7:Q8 M^_&_3\=H<[4;?
(6$"/8#@6LX7PZKGT5^!&6!OIYOO4:F$F<(%T[$??847U5N^ M'GE,A8&W_S2> (5Y@!Q8HSS9_X/]+QX,\'HQ_#8?)^J$PFMDC2ZRD_]$>^Y
M^VA)Z8L2$K1Z*@*1.63B'0#7[BTV5%% MBLJ*2,,,\4H)DAFCCKI0O-YSU%.OX// 2,S58"EPC]6X)ME([\#2&;/^"L?WBBWM*0$*M1*D\VPGY0W3[@B5Q%%?[V-F]&- M$E3-T7:_8
MU2$A=/TAQI.40B^[JIZO--Q=/<2O5V>CJ>#54V3B_@0CK4XP8%.0ET\ R][E MR>P<;SL!CI\N"Z 2GFV@-M MS\\G5?=.\^6;7D/XY?O_O)BL :*JXV!;><2% M0:-&ZW
^S@NT[!8YOIW"TKQ9G87@@]#"2A4^NJI=OLDP1%_U/9Q"59!RR=.$ M"EA/(!?]00H0(HCA^=D$3,3=^?5G.6@@#8K0XNUXGNKW%SM&(UJ@U:9=KJV^ M]<*=#-H5?
@^S2$O0*#<0^55=53 RSJOQ-JL#0 Q_5Y_\=7T]&%ES=-FLSF:N MM)M7NP DA9=5._#*ZT#S&C8(EC=<5.VN&BFQ1^)A$*M5Z'4VV)2S86K5UMYA ML=$L3-8V/SQ^L_;PQO-
<7U^-^FG$5:B.']X4G=2#^] M'AKT4X2&JYU"]50'B6LVV$[580$,6LZ[)=I3\-C>KS/XG_8V;9YACJ)+;:\3._]"!ZV6"%"W=<%7@PW M 1&B.H7RNMJ:%SV4Q=Y'L3;D@-
)_F"%=>KBFG^F93WE]W=7<=!DP!ZR[7W_Y ML0[LOU[]NC/M$\"?]\"-\^JJZ-=ZB\[?#Q9"[=NY0BU\UF780#5K8YJM"/]* M 9,>5C^PANC;.O==A)ZI'WM>JYZ=P3.6,N+!>
(J;@O8C#+-_.1J#PW(-7/V! M%]4]&=:_7^X>D5;^GI&Z+"RX?GYS_QP=T>VU[RHWF0-O!5&':TAX+JL:MG MZ@O?X\?EIVRC>\KG(#7 MR1 N.4"%IZ-
O<_3++@]""8CO376X[FSP1O(<'@MR"L[:P\K7\?>/Z.G03_&K M*_S!O1?[715[P!%_CL^69U=1UU7BZ9&-CBLCG=;'XE>='6;+1>8\$"J4)U+K
M2$*BA3B9&&/"AI38IYP=3O]8S%_\,L_H$!(?^]W_- 9X6@(;,GIY>*F@_L' M^^R.%M7Z:!$6EO0K.QJ6]O/TXX&$_-G/@2?1+5#9>]QUR^K42*HD&O*D: MR1*N1B\H^F'7"
/UGBOUQTJORL\JA_QWZ.Z8=\/5@S^6;E,/_U"V M_2D_*JHY1XL,IU/]KV_F>/P\'+5T1TDEU%&N+::3ZE*(],X3GT4BGIG$O!$^ MN;U68";*F)T,Q/,$LIEB309L!29+","9DGCE34
%=/^I.WC=4YJ-[U!'U\MO*X]8Z>*P06&H,>#2[TF';Y MB/%&@4;HJ'?$V(2TP"104I$D6EEL-E0ZOM<[B3G-HN8@XI)7< \69=>Y #$& MSYP261M](W'U_; ^%8
V=+624>PNL$A^@/J ^"AEQT1_&S1"*_G,7Z ?;D5* M-;H%+9KJ]^C]@GT0SQBT/#2N!C:MMN1I%7GX"#2=UN2(-ZQ(=5SPFA,0CV]R M=4U5/PD:E;X4L.<']_#@#YSF4H-
@'T!W]?CHZF\UKF,_TZ-0PJ[ECS(,(-:$V M/A3$9L:(T44')[.7T>V=6=,;@M 9<3%)F(J-RQ'(%?SJ7J?0J)I9VS2183S20 MWP#QKE6O*EA_F,T':E[1>-HA9E!G-_1*^,<0K#MUAY-
"'YY1G0#(-7C MPO6_+]Z.:Q35L".#]P3NCO64X@@MA4"U<\806F'4PP\?)"">FZ,QBY I4NKWL M-VU]DM&O+06+'G0]SP&$AN=52#5QR=1=G0T&H80FTIX@* 3()G%IU+$
MH>AN9TW.E&,!0NRA)2B(5,Y!/%HC0N'4IOWT\X]0SNJ^7MXZ$*&S^5]GBUZ3 M_2?D!$6LZ3OW@4BCXFK(I*O/:W[U^!53G/;X:0T(IWZ]2P*9Z2G(U^(V+T
M%=X(+SH=84$";IS1.OAQHPGEM4" >[T?<['\AR'OA?=(2%@GX1,%E"\9EP&TO)6JNL[Z%_UH7X75Y M5>5'3>&M)DB8Y+^=SZ8KRE^KC<_;H_%X([A"C#\!YWE+/7Q*J8?
H#FJIARWU ML*4>WG'JX7;B^4<<(![Y&=VG+?5XT"(>4:8N08'9N&,& WK?C]C[%P^HE2%' M4)8&8QF3D&:?[(4Y8-!XG2)8)(4("G0B^7\WC.YC@EE*WK;*A2XN %K)XBS<2T.#)
M1?9S4@/'7WX7_WLYS2/56P5'9]^6LOX['$ M1WP^)^)_SZ-5792<#N !!@?VV5^SZ1#8>IZ!/>H?N18V^L@T@6X(3_.C,L]Y M[9H; @YKK Y S_*LCX_%N#6\9W8GE4>VF!8
M]RF8ZW/]&L;T?KJR=VH>+$;,#4F(??6F_IZ8$>Y@R.,_84I7^1UW?(X[8 ML M,9FL$'>XH5>D+E;98E>>Y\ +=VO'#)EWO8*&[AJ,/WISM1MT=SA#Q'#TDU@+
MWM0Z,S7E=ASB=.0 MCGE2@_W*$GWY&&\Z9./Z>=[X@=>;,5PCO6Y8!>=@J%/D(FO4.Z8($&&1$]L MR((8RE(*W!5C/RG4:5,F81V__RZ_Q+'W@>,?KI%P.?
[I)B,^AO6\D"E^:P8;-N730R_,RAR5;YRJIUF'OPCD6)ZB1X@??,50_.ZGG M9N?]@/I'XF^K;)Q^ 8>TE]V-7:<"K3,25J,;]U$4J^SO#OM?I#H3#U+EXE_] M^+?
(K@8Z#V'S6&6B/YY&85=/HWVLN=?K;;I$L(. [N+LO JIE[^]&EEJ'\#J MNWGBW8[D&6V)GN[Q]._*!"<8%]#->LX<=N?Z'4"-+D^&]>^3A'#%-=5'M>*_ M8E+&,O>):NC60A?
_@'"OE@ '9UOU;![!:CLVN^OHI.R])\-^/QFOREY4):4W M5KZJ'WU]3*3\8O1K_MO-70V]50.E-1C((=J"$2W0"& _V(R)MORRSPQ&96XW+7B=J88UJF!P(!6N M3#D<5+(V4\'=<#
M1;3>QIL%U7[X-)NIXPRK[=,9:XDI8,(QNAA0?>@#'8Z.5(P*UBK.,!"PNK&! M5&(,Q(GL;$S%@@ITF52"-\IJQ8A+B1$I*)**$"0Z*6+*QHIP*=MJE1GWW481 M![KY-;]!_]!L?
K&FH!N&7-\DUN%(J0.S6%.)X*(1Y>LU/EZ23;6VY!N?PD- MAW"O(=T6[-UEC:[YI?H:V;=]#87Z!]\MOO!^<*;MFD5#^^#XK7*J;1A)^F%*-.B(R70>[;J4#@/DVK3G8&Z7Q
MV.@C!A6<#8$DC?01LR2!"T-*4B(S&551>Y&F'RWP'HD^^).AC^719!U_5HKV MR_/Y>#)HVD,=Q;7"6KT]^NPC\Q8QS,3/APU/N>_';)E4MBIKJOAHIT6/$& MG[F$.VM(2=?
[,2_;:)N7GJSKGUZ67EAH(?_/,M<"GZMA8&F)W<*&\[Q8SJ:58N?+FH-T]'KN)CA<1EN37_\=+OW]>_ MM\%_+T:K5V+%GCCVZ%SV"X^W;;*.ZT3K-@/2S-#Q.<%LEMZ#C.%CI-
I&M73" MNC#6RM>XK1M<-<*CX_3#?/U(M3+NW8_S[7P_^N&$_'R!WNC?_FL]'3CU M[%TZ0)6'+OAZ@,>:O#/Z914VL7E Q4%XP"E^N7;2?."I@X_.U6O^.1M7>;-5
MZ^PR3?:'.&=A)157+UTE4KP^3^-WLUO2YJ6^5]WR/,^W]DF?FML'5QKYS6/& M8M4\8:SH#=K#& M;E5K[PW[M,Q0&JM&"[_&4[NWXO!\$V-
*KD)8:7[2F@%"+STW(]3K20(BN>4 ,K#DM>(F]49=RV)?5.H,C]%(}#-D M(K'H23!@5G*OE7?>I1+VS,JHJ4]&HC=,%*"ICL0'D8BET7I'34DA?:P?%:L3
M7':C'O:4N8_THQZ7GRQL>5%7L7/YW!(PH7,K2 YT41DT(IXJS2)C/F2?')& M[J5 1J"%1+4C5'M/I"V%6 4D)97U5"DE^'X5[.TJ)I^<_V5/N)4G^BC3OZ[*
MI3Z_).8/:@;5:)DM:L.&M6NUHLM.0.!18DQF27+C-$G>.ZP\[HA+5! K=<)6 MH P08X^2.!56 OUPF1G68+U@S&\UT;"F&+[:7I$5P-Q1 MH1-[I$[W6K
23&*ZZQS9(I9+$FH_WMS]>K]L-&Q8]NO"0_5"+!?9O/> M4_Q^C &@F'@!3SL2IV7+ZWXV>=UL9U];7G?+ZVYYW9?SGJ[(T;YA'M&MTH_X MS5;\22IF^RK4XXDTD-
5OYOYL<\9;?Q-Q/ZU0@06=?.)?, MAKV0FVB"BP4$CA'8E=I33IR2%KW9,2>18&A[N5F/*$O4J6F,U&3)019@CEE! M2R"V%) +TBL2, E514F!ED.,?"\],6/1(R[A2F$3.DL$2*
(,\H<%18444:5T M/"P@C_.(YZG)$GE9ELSS.1ZVH@$W7U42KBWC?:TXOO*[;E6_?NL3V%V+<502?^D;79_R%3L8P#^]NK;NKS)GX_G,S#1EV<^P-*]F4VN M]L
^4/>F:ONO=_BRG=X?#_DAG/(8CQYY85)Q"RJ S(%(C*(,P0BBBXO:Z""O M2(ST)DC#.06X-'BF)"P8EIX2;QEWWN/0[",D1LKC3(SLBT)==Q)TLNV8V?A2 MAJB+R>S]"
,J)AA[\@:;X%SMZSG@OZKEVVOS6F2A<;0B]7,[G>.]YS97?+8'6.]'&W;K=P2J'"S,\ZRE? MWV=I'=IXN8!HW\CCSR'@K_>,;9TKK/QE, 4_[0;.!+$0\S Y;,BT7V$.&RM=
MXX_;>PVVDMCUT<'6SR[O_5"K'X?S\I>7FY;&JSH"\OS=M%5^K\MV"K;0$I)"RG%?O9\6KGA_[*>79[UZ@1?]FFL'OS3Z>=U4I+8DAZ]^
MZ]N*;,*)^Y9=JQ)Y;+O_]*4HN\D,$[/R_&STQ<+_4=L]G?N++U:=2JX0J]4= MO@H/[H:@7H"NFIHRWL1&;/FL^\Y5 T!M]T3!1+(??_[_?GS99P'WI:SP)9=G
M]'5?".FJK_I:9S7*K\,+5@6+'A'*5_'^W88#SO)Z,;X:XL'KAW7)OK[DT[^\ M1E< [W;WDQYBN#[OP+)'5)D.-O;L;9+Q5N6V
M(1FE$G4W>HNQO,B"O3"_>:O([JVN!%SJ^^)MGQCN%AT$SL_G'BL>5ITBY,7[M/.A=&[6B1M)U?3/2*R5"KFS+9Z58/*UU]L-*U5.%>XZ 7M#(N\72[I<,CLW;-VCR1B
MY/KVC:THPY,JRL!;4896E*$593A4E.$6JMX7GU3(X885&9ZDJ=S[&!Y/BDT' M;]&EH*-M0=T[0/8[6>Y*Y6T+]S'K7('>EWNEB]&^\>*F3-]XVBO2U;":KGPZ
MG]R'68E,A7*'"%!D5D:$XX@(+1'@ 2!524/M-D&[3A_G7[]400# +OBY8[6>QLZ:C7\"X)%%59GV5('UJ@XO>Z0]%:<2T(DY)A6C6CCSY3>8E=!KL2_^R/DMF '5+"Y.1C#R M00G
B@GUM/D;_+-18J/$VTG_U9'7=I^[30620>1WW2SVDG@5&X#918B!IX\:F_>7OKUMD6Y5B=9W25SZ:MZQCY;=G:]_]_6+&UBA M!J'F.!)>
[\YQ^;]&=]=__651/UA5X7EWS@V<7QX..7A@^7DX ?V9+ *_QGSE] ML\:F4T"GX8;J#SOO\HO5<=ZN$[<^^XO5&& 0Z[,#C$?HDZ!?K)ZQ=2%Z4WN<+_\]?%O.KV'PX M7+*
9L''/][,L6T<&21*J?^NEBA;>E9_8H@?'$"(2STK>@@^<$)E'QK3/^*$ M:9$^J^D!%>"W-=CGVJFNCQU7Q_SG-2*D=_CXGS:T?RVE_[@26]- M0?EY5C-/OM_//+D]V3R-
M7Q03KIF27J$HN)9+DKCO\,>&$S\:NQW!Y36%(.F M&-P:F'@#ILN1>5M%[1KZ-.'?>.Q>>$PT'FL\UGBLR;%C(J?&8XW'FAQ[+$NU
MGLCMFZH1.*O$C[)*;])W&9;J7E(L/OVH]],#!>\D1/ FA'V3A;[6:'[X$^!/ M%P_;CYW.CFO*N^3UP6)@=[2W5X+(?4Z]GGW?(6L=:(R9"U-1.9)2QM8Q6I*@
MG"0INR"8SCM8E[O,@=MB&".26_@A(]P#F$:\LY(7EF0(>XTQOUUVXVGNNN__ M'"]JD L[F+4M=K*VQ6[6=@TB(/_*\UD? ,4P8/= TO93)?"
[9=^&64MR,GL=C:1D7@13B,/:BI(J3EP,CN2D MJ%,T2.OVHO7N"K/V*DUH=;@&]5.E\ 9:#;0::!T&+2H9P)9CQ.@,2I.0B=@
M&!:#+@7+ZP2I[R+$N"E:#;,:9C7,NI/ZU39:RS,GF7GL]&<=L9I'$K@2)FI% M;=PK!!:$,C$S"9I50LRB@'/*4%!^C/:N%,=I?C!%2YQHJAML?8)GS:U=9G8.#LHF*SX:-
FH38EA#2A$BQOP?VYB#2@ZX:C.9$JT)#LIZ%L.[" M?;CFOJ;2'A%1-YQZ=EOZ3''K BN =RX$P4P0>"4_L=NX1J0-6 JFWI\P\CM3?226" MIE =(5$WG'IV6_I,<4H['X2-V)JQ $[QDHA-
W),LDXHQLD)UN@O7X/TH5.;$ M:=:@ZA/\@BUB<56A\].K:S4A\MDP6Q,B.U:Y2Z"A9D.TB(%()25QV5OB*8@0 M*Z+P?$^(W,9[N.'1U^6GV?3-3^-
W.=4.,MU_Y4GZ83;_6Y>;"GP4I-[0Z]EM MZ3-%KZ2H]0F 2TLGB+0E$@MV-S%:!2H]\T[O%0V\C4_Q'M%KOZ4Y/6%&- 1K M"-:V]/DCF(J).Z<$()C71'H*:,0C)326)#BE/'EZ%\
[&AT0P>R*X:P#6 *QM MZ?,', NF5Q,,$ P&Z4T"8Q!SDGPHHB@7*%V+ZCZ-E[(AP0PH4\TMPW!/L$Y MV8(6;U9Y?:<%4)]$W43)I_+6ATL>/!GNN^6F?U31A^8^<8B-
RFTT["S$<;G M@YU1E%A"5$0SJ8E4UA+/U#O&S@<__VDLTK"S$4;#SIV" M&#P;P40@KF0\1\^:!%XJP[(:ES3X;(31
MX'/'B^R48M8:HK.D1)9,P027D4AG<^9)VACD77B1[QL^';OGLD+/B$<>+.JU MCGYH#EB?>AM/\[DM=->?D05\=(:-.OAZ(BCP>N#!Z1D M8SE51+$$IH2*AH1B _$Y2IE2HC[?
26G2AX=7QDZ$IQ@UB&\0VB&T0^YA!%D*D MHD!Y31(SC[42)-AL21"VN,*]*KG5.\." M% 2T5H!+3@%=I<@D69J+$YC8.\4=P$K@31DV#V%OYR>%W#Y/XOZOE M^^OR+,_'$?
Y.XWL5VW;GJU,KO[S&I>\>9POMF('JV1@RZWQ;#X2'XJ9 MI0[6:#Y;OGD[^MG/X]N18"&L!P0 ?]C,IL,IF]QPMGRSD\;SI;3F.N#\,QK"'L5 M:.+0;#%V9LIO Y6^/,NO^CRN0?
MS+O,7I_]Q54Y5^_&W;C7@EZLGG$@F:I_K3*GTI@OMU%KV+,>MOYRS;WL5#AW MRUMO>1L]-48_["O;))_D)#^0E&BO+79W%09^3*+BQZ3*V:<7!/=,?
G']7#\JOWLU]'M4VC_W4OO[U+[]K3S--;S#NFM MP5.#IUO#$V_H=-D#<[55T #I#AGH)L5NGN.B-+:[CNVNBM!I;-?8KK'=_;'= M[QB2T9CL^ H4/<_*]S^M#U;#X!SU-

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{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{K}CML8S/V'XF?:@VTY_@[55 MSU#4=&6DSU<=LY9=`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

=D6@HYIPR_<#(V#12H$<(TQ"YGF8Q3L!+<[@'/2Y "Q T^+%,FODN$]\W>K>0)FJ M2_DHKL%:2G10#H^JQ?R29P6=PE>2XV@X2 F,!8'!PL2<)!/=BK XY(2!0>ZZ
M(#5,!H+B&/7;F1.PE"SS-XH'LVGD;C'H#*Q'=UUTZ\A 5F'$]6*IH]L\ P MS">N>7SHY*X0[."V]$ 1;.)%AIN N6[&5 0%<(DES-'=P&5F$KJ3D*T403%\
M[OE18.N3B0D(9G%#9['EZ+[MN;YK.38S7C:>8H\L0]WTK!!,;>D1(%AL.EYD MF;%N.;&E.PFJ7Q88[48$MG<$B#1QDA4=+.)&8GJ1[IJFISM.$.BAR[B.]GHT ML;ACA\:+
(I@WLNV)0C"%8&I+#Q_!N!,XB9^8^H29Z$+T3#VT?4./D\C BX1- MSU_1P:Q)Z(=)XNJ!;P'JF8&E@U:6Z!X+@LB81%YB.2\;03%'IJ$@[#%^1Y4(M*1?W=Y[SDF7D=F0Q/)56-
19ZN>1*9AP-#RF9,909EFFZ/ACB.N,31W>\(-19 M:'/0>B/F1/!5L%HHS0H"Q_%YHO.(F[HS =6780;2)' ,#]XS+#M\8<^C[]U< MG%"1NT*P'9FR0K!MW _)'".(SWR
KQ8RTITWS<\W8_LB1T$/+1B>Z627Q2% M-FB\NNUB]3_BO0P-$S=C_V)X7B.89@KU52?%<$<4'I5+K=",+6E1X!@)O-9 MQ&)?MSW?UITX,G3?\ET] M,XR0><:ZNW:>-85[-
F>^(:K0R=WA6 'MZ4'BF"6&X>6D8)&",:<A+YH>=P[AOFZN6FEAE./);H@8E)DJ&)^9$.UV/7#3S7=CR?K]S1_;R>1VOD
MJN3M1WD>'Y#Q.*Q>3:T^Q!4IEX1*%/>7<,A6C5OJ8>^*I_+;K46ME9RY8=*R M$@(-=TT9A'V_.W.+2?KW6"EU$>W-24\34-LC3P^\D.N.8SEZZ/H3$&&,Q5'$ MG8FY)X!T
3IT%/M[J$F/F_\L>(A_9P<-.7QXX]ST= M/'5E?;;%=@=X2_B!$Y>"]MV"=L<.[#C"7 IN.+KC8JV/.(ST))XX9FQ%1ABL M9.0[CLGL< (6C>7@I4-
XK#X"VX;'KA&X1NCXP4O[9$SG83Z9 ^<^!>T*VA6T M'PFT6U;,_4G(](GMAP#3QD3WD]C1O1@4W\#C(7-7$GT?=+7]LSJKO)%O*&Q7 MV*ZP76'[\6*[:?CN' V>_QL0SX'2\KW!&\
[?O> MVA6.ZR_YJ+>GN$#8 M-/H;A+NEU6AMUU[/.@P#;O=JW#[*^/B5>MS"_)%W]VT_?^>?BDMQO96X =T9 MX4WLI%_P6$OSNJ"+T\\^G]$9C AD#<.+>>'#4F,7)9=W\)
[@4]]*!N*49%WU M1KM*:ZP7H[$D2;,41*]XZ'-31E,0O^4;K'!]!B*XQ/MYM?=LGF((]3,KZQP^ M&VM_AVTOV^Y'VL++FKB&7?Y)%P7#+)L$>F_*-+_0X#>Z;U:38A_FL@_WJ4<9
MJT##F+,+KN<%8)5LY-7";=I_$DO\.-7MMTG&?^AQ6G):=KQ=MYGE;^.TFF?L M^A2_?3MG<0Q+,B@WGXJARE0 8^Q9\,F_FJI.D^NV1WI7YWG\=EZ(:^U/2[PC
M/;WDP[L^.SWCQXWQ?-M$1>86QC6MAP/_%1U>T2 M&^Q4RW%R,BV32,4;^&' 9*O,\A">V-96R;]+.1[?ME_4F=[\%*O45[7K.T] M.A)FHE2FV- 'N$6%:E\5A;\V0,R7(/CXZ
4UAK.,A6S&A#3_38K9-Z,U^@'Q M!HA>$&D<= 1\@,0V_ W"KWNX?0R4!+HC/N65: TTD?9Y6/@U0AX?JIKY/+L> MZB)@FFN??_T=V@7,P@^D$M,I#V/MK$*%O4J!38G(1EU?
($@YL+/VT[H%OL?J M;=]1$MN6DT0>,$ 2ZHZ-44LC\(+F!58AA&9JQ;/)'$MYH<3/>(&, VS)GK M)Z'NQ2&/8B\R?+Y2[>)S6427&GL!#0V>SFBQAB /)
92!)EK7;%V2_DZH)_P7:'E)U M!"H;/%Q>=V.-BDIR&HM1H1,<(1(287;M8SFOM:NB_$ZO",5[U'V9YFB.%= J MMH-39[,"H
<7@N77&HK%$!@VYU4E>3G6PFMM2;M_N26BZ8/A,9^7Q0\@-C] M=HV;/0*#='W="2>8 MO)8$NNE9$\MAGN?[7<'9_'M=GG[F):K'@()_']=?!,#%YSEQ\UGT M[R85NLP"7X-
IQ3O&UJTA9UMW>3]WB;%?:QPF"'9@T2X LC:2:@TM($DCV7/D M^T49<;3NB&^P#+=!7UII PC"KJ&%7B62OD'X7C$@L)+65HKX=4"5QZEH$*@0 M":J>MIL YOYQ+S^Z6_
36+IJL'8EAXXJY&BQ<*0CL1(V!W4F7.]/_#N8E_3% M0-N1G\)?0DV*<>, &R]!_^FVJ)H#_R9I)/2XKD]<[5E.2AF^U3M@4,MJW^4_ MHJR)%U4X+2]
A!:7Y$@"Z<"6AK\\^GF1I=$U]A$"6X;8KGBQ[Q()JH0 M_J5EZAQKY]!R+$AKU/FN^L7L=,ZJ+E-2:FB0.8P"M$[8U&C:*H+B"5!%JY8/ M;F&+D5QE\FY.WL)*A\+_!!/JE58N5%8.
[0\UU..E]K6(}4D3"&[*? M,]BW&QA ["?YB81'LR4"EH/QDB&5#ZP'^)XG":';2B]ICG1.EH"I[[]+=O7T#M<,?+3LFAU:W:-=8^LAP8!B5.IZ?\DE:@[56M1G:V8*KA5&"(MLW]:_YS%
[-6C[+@M3REGV765DFKV6YJC* =I_+ZU*F@N7WC59#4]\L=<>OJJ MI0R#F[0M;[(]=6MK$?G'6Q9)D67%%:HA<;_OG78,Z@1HY+&>%06YAD HU*U:
M!*H8>H:*##3F,JV^"_.CR:4RA3K\6/NC =TK(L6HE(L?%4T60V^@4Z'[%@0' M;!1H-4E9S*!5M+WE4$#=GX*U,$:G43:#9;S] BO2CGM,GYG+N2Q;#TSH
M%_.K%UB.9YV_>!2[.D5_:AK=N")?L88EOP!;^Y=60R:, N9YUX"-PZLC1BEI MZ@!808.\J=.(7$X,;) TQSQ'1*4+X/!2WDDDC]O'92- #5T.UUJ8%O,I*V